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Preface 
Systemic lupus erythematosus (SLE) is a multi-systemic disease characterized by a
wide variety of autoantibodies leading to highly heterogeneous clinical manifestations.
SLE, or lupus, the Latin name for wolf is a unique, complex disease that comes with its
own challenges; a challenge in diagnosis as lupus has a broad scope of symptoms,
various clinical presentations & often does not follow a predictable course. 
Another challenge is the management of Lupus; a healthcare professional maybe able to
control the symptoms and disease activity with treatment, but it is not uncommon for 
health care professionals to encounter a lupus patient with numerous severe symptoms
that are difficult to control. These challenges drove our efforts to write this book. 
SLE book provides an overview of lupus and the elements involved in caring for 
patients with this disease. It addresses primarily healthcare professionals who deal
with lupus patients. Each chapter of this book deals with a specific aspect of the
disease. We addressed new advances in the pathogenesis of SLE. At the same time, we
provided a comprehensive clinical guide for dealing with this disease.
Today, the prognosis for people with lupus is better than it was two decades ago;
advances in research, improved treatments and the evolution in information resources 
helped many lupus patients to remain active and involved with life, family, and work.
We hope that this book can provide healthcare professionals with a solid grounding in
this important disease so that they can provide the care to make an active and 
involved life a reality for women and men with lupus.
At the end, we would like to express our gratitude by thanking the team of 
internationally recognized authors who participated with us in the process of writing 
this book.
Dr. Hani Almoallim
MBBS, ABIM, FRCPC, DipMedEd
Head Department of Medicine, Medical College, Umm Alqura University(UQU) 
Associate Professor, Medical College, UQU
Consultant Rheumatologist, King Faisal Specialist Hospital and Research Center  
Saudi Arabia
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Systemic lupus erythematosus (SLE) (OMIM #152700) is the prototype of a multiorgan 
autoimmune disease and still considered as a disease with an ambiguous etiology. The 
disease predominantly affects women during the reproductive years at a ratio of eight 
women per one man (Lopez, 2003). Its pathogenesis is multifactorial lying on genetic and 
environmental factors in which it occurs in genetically-predisposed individuals who have 
experienced certain environmental triggers resulting in an irreversible loss of immunologic 
self-tolerance. The nature of these environmental triggers is largely unknown. It is most 
likely that it requires a number of environmental triggers occurring together or sequentially 
over a limited period of time. The concept has therefore emerged of ‘threshold liability’ in 
which disease develops when a threshold of genetic and environmental susceptibility effects 
is reached (Jönsen,2007). Epigenetics, the control of gene packaging and expression 
independent of alterations in the DNA sequence, is providing new directions linking 
genetics and environmental factors. It has become clear that besides genetics, epigenetics 
plays a major role in complex diseases with complex immunological pathogenesis like 
lupus. Convincing evidence indicates that epigenetic mechanisms, and in particular 
impaired T cell DNA methylation, provide an additional factor. Interpreting the precise 
contribution of epigenetic factors to autoimmunity, and in particular to SLE, has become an 
active research area. 
Herein, we will discuss our current understanding of SLE as an autoimmune disease and as 
a complex genetic disorder. Through the review of the current list of best validated SLE 
disease susceptibility candidate genes, in particular considering how the known and 
potential function of these genes may allow us to articulate the genetic of SLE pathogenesis. 
In addition we will review the effect of epigenetics on SLE pathology. 
1.1 SLE, the disease  
This complex autoimmune disease results on defects of multiple immunologic components 
of both the innate immune system and the adaptive immune system including altered 
immune tolerance mechanism, hyperactivation of T and B cells, decreased ability to clear 
immune complexes and apoptotic cells, and failure of multiple regulatory networks 
(Firestein, 2008). Moreover it is likely that immunological dysfunction precedes the onset of 
clinical disease by many years, making it a particularly challenging disease to study 
(Arbuckle, 2003). 
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SLE is a heterogeneous disease that has a diverse range of clinical symptoms, resulting from 
a widespread immune-mediated damage and it is presented differently from patient to 
patient (Arnett, 1988). The most common clinical manifestations of this disease include an 
are erythematous rash, oral ulcers, polyarthralgia, polyserositis, nonerosive arthritis, renal, 
hematologic, neurologic, pulmonary and cardiac abnormalities. Eleven criteria were 
identified for SLE clinical presentation, at least four of the 11 coded criteria need to be 
present for a clinical diagnosis of SLE (Arnett, 1988; Hochberg, 1997; Tan, 1982). Ethnic and 
genetic heterogeneity contributes to the complexity in SLE clinical presentation. Differently 
from Multiple sclerosis and although the disease is progressive in nature, no severity criteria 
have been developed to subgroup SLE patients (with the exception of kidney disease) (Tsao, 
1998). A more detailed classification of SLE this heterogeneous disease would significantly 
help in its genetic analysis. Analyses conditioned on specific disease traits suggest that 
genetic effects arising from particular linkage regions may contribute to specific clinical or 
immunological features of SLE (i.e. the presence of haemolytic anaemia or the production of 
dsDNA antibodies) (Ramos, 2006; Hunnangkul, 2008). A similar picture has arisen from the 
study of mouse models. However, now it is widely accepted that SLE occurs in phases 
during a period of time that can be also of years. Therefore, the following steps in the 
development process of SLE have been suggested: i) genetic predisposition, ii) gender as an 
additional predisposing factor, iii) environmental stimuli which start immune responses, iv) 
appearance of autoantibodies, v) regulation of the autoantibodies, T and B cell fails with the 
development of the clinical disease, vi) chronic inflammation and oxidative damage as 
causes of tissue damage influencing morbidity (Gualtierotti, 2010). 
1.2 Genetic contribution in the pathology of lupus 
A genetic contribution to human lupus is well established. The strong genetic contribution 
to the development of SLE is supported by the high heritability of the disease (>66%), a 
higher concordance rate for SLE in monozygotic twins than in dizygotic twins or siblings 
(24–56% versus 2–5%, respectively) which was observed over 30 years ago, and the high 
sibling recurrence risk ratio of patients with SLE (between eightfold and 29-fold higher than 
in the general population) and up to 10% of SLE patients have a relative with lupus 
(Deapen, 1992). Clustering of SLE is fairly rare occurring only in 1/1000-2000 cases. Except 
in the rare cases of complement deficiency, the inheritance pattern of SLE does not follow 
simple Mendelian rules as we would expect for a single major gene effect, instead a 
polygenic model of susceptibility provides the best explanation for the familial clustering. 
Suggesting that genetic risk in most lupus patients arises from the combination of a number 
of relatively common variations in several different genes, each of these variations have a 
modest effect size, contribute to disease genesis. Despite this knowledge, however, it is a 
challenge to fully understand the genetic pathogenesis of the disease. This is essentially 
because SLE features a polygenic genetic model, which according to today’s evidence may 
involve as many as 100 genes, and every gene only has a moderate effect size. Genetic 
studies can enhance our understanding of disease pathogenesis better. During the past few 
years, progress in biomedical science, bioinformatics, and experimental technology has 
given us new tools rapidly advanced our understanding of the genetic basis of systemic 
lupus erythematosus (SLE) and allowed a deeper investigation of SLE genetics and 
genomics. High throughput genotyping/sequencing platforms, high-throughput 
expression-level study technologies, etc., have brought forth many new insights. In 
particular, the genome-wide association study (GWAS) approach, with its ability to screen 
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hundreds of thousands of SNPs across the genome without previous knowledge of 
candidate regions or genes, has not only supported some findings from previous candidate 
gene studies, but also discovered convincing evidence for novel genetic loci that may be 
implicated in SLE (Hardy, 2009; Hirschhorn, 2009). Although the number of genes involved 
in susceptibility to SLE is increasing in number with the advances in research and 
technology, however, the complete list of genes that fully account for disease susceptibility 
is not completed yet. Table1 represents the top SLE candidate genes categorized by 
chromosomal location.  
Most of the genes proven to be associated with susceptibility to SLE are involved in three 
types of biological process: 1) immune complex processing, 2) toll-like receptor function and 
type I interferon production, and 3) immune signal transduction in lymphocytes. Several 
genes without an obvious immunologic function in SLE have been discovered from recent 
GWA studies  such as: KIAA1542, PXK, XKR6, ATG5, etc. (Harley, 2008). These novel gene 
(loci) discoveries, which are assumed the most powerful and interesting results from GWA 
studies, can lead us to new pathways or mechanisms that we previously didn’t know. The 
genetic heterogeneity between ethnic populations has been suggested to be important in 
SLE risk (Yang, 2009), showing the need for further GWAS in the various populations. 
Genetic loci for SLE in an ethnic group are not always replicated in the other ethnic groups, 
especially between Whites and Asians (Kim, 2009). However, some loci have been shown 
consistent associations across ethnicities such as; HLA-DRB1, FCGRs (FCGR2A and 
FCGR3A), STAT4, and IRF5, BLK, TNFAIP3, BANK1, and MECP2, providing common 
mechanisms in the development of SLE across ethnic groups. For example: In a large 
collection of different ethnic groups including European American, Korean, African 
American, and Hispanic American, relatively high-density genotyping across STAT1 and 
STAT4 genes has confirmed the association of multiple STAT4 SNPs and common risk 
haplotypes with SLE in multiple racial groups (Namjou, 2009). 
The ethnical diversity in gene association with SLE can be explained due to various reasons: 
First, different genetic backgrounds in the various populations from different ancestries 
result in the different genetic risk factors for the same disease (Namjou, 2009; Kochi 2009; 
Tian , 2008). Second, SLE as most of the complex traits in human are developed by combined 
genetic factors and environmental factors for a long period of time. Third, the other 
explanation of inconsistency in genetic association among populations is that disease-
associated SNP is unlikely to be the causal variant and rather is more likely to be in strong 
LD with the biologically relevant variant (Hardy, 2009; Graham, 2009). To date, since it is 
not feasible to test all variants of human genome even in a GWA study, the aforementioned 
reasons as reasonable explanation of non-reproducible genetic studies between populations. 
1.3 SLE and Copy Number Variation (CNV) and Mendelian forms of SLE 
1.3.1 Copy Number Variation (CNV) 
CNV is exhibited in up to 12% of the human genome (Ku, 2010). Therefore, it is 
increasingly believed that large-scale deletion or duplication of DNA segments is a major 
source of human genetic variation (Ku, 2010). CNVs appear to play an important role in 
several common diseases (International Schizophrenia Consortium, 2008; Sebat, 2007). 
The relative contribution of CNVs, to the genetic component of SLE is unclear. 
Comprehensive studies of CNVs in SLE are expected in the coming years. Although 
evidences of the involvement of CNVs in SLE susceptibility are accumulating, for 
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example; CNV was found in various genes involved in the pathology of SLE such as: the 
Fc receptor region (Fanciulli, 2007), Complement Factor 4 in the HLA class III region 
(Yang,2007), the histamine H4 receptor (HRH4) (Yu, 2010), however, a definitive role for 
the CNV has not been convincingly disentangled from nearby, linked risk variants 
(Fanciulli, 2007; Yang,2007).  
1.3.2 Mendelian manner of SLE 
A number of rare variants that cause SLE in a Mendelian manner have been identified 
throughout the years, including disruption of several complement pathway components 
(Harley, 1998). The Mendelian forms of SLE shed light onto pathways critical in 
pathogenesis, but account for only a small portion of the overall disease incidence (Harley, 
1998). 
2. Genes involved in the susceptibility to SLE 
Herein we will describe the involvement of the key genes involved in the susceptibility to 
SLE. The genes will be introduced according to their location on the chromosomes.  
2.1 Chromosome 1 
There is considerable evidence supporting that multiple genes on this chromosome 
contribute to the development and expression of SLE (Tsao, 2000).   
2.1.1 Fcγ receptors: FCGR2A, FCGR3A, FCGR2B and FCGR3B, (1q23-24)  
The Fragment crystallizable receptors (FcRs) Fcγ receptor family (FCGRs: FCGR2A 
(CD32a); FCGR2B (CD32b); FCGR3A (CD16a) and FCGR3B (CD16b)) are a heterogeneous 
group of hematopoeitic cell surface glycoproteins that bind to the Fc region of 
immunoglobulins and facilitate the efficiency of antibody-antigen interactions with 
effector cells of the immune system. These receptors regulate a variety of cellular and 
humoral immune responses including phagocytosis, immune complex clearance, 
degranulation, antibody-dependent cellular cytotoxicity, transcriptional regulation of 
cytokine and chemokine expression, and B cell activation. The cellular distribution and Ig 
isotype (IgA, IgD, IgE, IgG and IgM) specificity influence the regulatory roles of Fc 
receptors. In broad terms, FcγRs can be classified into high or low affinity receptors based 
on their affinity for IgG or into activating (FcγRI, FcγRIIA/C, FcγRIII) or inhibitory 
(FcγRIIB) receptors based on their signaling activity and associated functions as they 
stimulate or inhibit immune functions such as phagocytosis, cytotoxicity, degranulation, 
antigen presentation and cytokine production via immune tyrosine activating or 
inhibitory motifs (ITAM or ITIM). In humans, three major classes of IgG-receptor have 
been described; FcRI (CD64), FccRII (CD 32), and FcγRIII (CD16). These classes can be 
further sub-divided into discrete isoforms such as FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA 
and FcγRIIIB that exhibit significant differences in their affinity for individual IgG sub-
classes and tissue distribution. One of the difficulties of studying the Fc-receptor region 
on chromosome (1q23-24) is the high level of sequence similarity between each of the Fc-
receptor genes suggests that the whole Fc-receptor gene cluster arose from the 
duplication of a single ancestral gene. Another complicating factor at this locus is the 
presence of copy number variation (CNV).  
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In human patients as well as in experimental animal models, FcγRs have been implicated in 
immune dysfunction and the development of autoimmunity. The best correlation between 
impaired FcγRs function and autoimmune pathogenesis is seen in systemic lupus. Various 
functional variants in FCγR2A, FCγR2B, and FCγR3A have been identified as risk factors for 
SLE (Nimmerjahn, 2008). These variants might lead to the defective clearance of immune 
complexes from the circulation therefore will contribute to the deposition in tissues such as 
the kidney and blood vessels (Lehrnbecher, 1999a; Tsokos, 2001).   
FcγRIIA receptor contains ITAM on cell membranes of neutrophils, monocytes, 
macrophages, dendritic cells and platelets. It is the major receptor for the IgG2 subclass, 
which is a poor activator of classical complement pathway. It is the only FcR for clearing 
IgG2-bound immune complexes. The association of FCGR2A alleles with SLE has been 
studied intensively in several populations (Brown, 2007). Mutations in FCGRs have been 
shown to alter the function of monocytic cells and B-lymphocytes. For example; the 
nonsynonymous SNP which result in the substitution of Arginine at amino acid position 131 
(R131) of FCGR2A (R131; rs1801274) to Histidine within the ligand binding domain of 
FcγRIIa diminishes binding to IgG2 results in impaired IgG2-mediated phagocytosis 
(Parren, 1992a,b; Warmerdam, 1991a,b; Clark, 1991; Salmon, 1996). FcγRIIA R131, might 
contribute to the risk of proliferative lupus nephritis by activating phagocytes, releasing 
proinflammatory cytokines and reduced clearance of immune complexes (ICs) (Bredius, 
1993; Karassa, 2002). Karassa et al. conducted a meta-analysis regarding this polymorphism 
which included 17 studies, involving a total of 3114 SLE patients and 2580 non-SLE controls 
of European, African, and Asian descent, demonstrating that the R131 allele was associated 
with SLE (Karassa, 2002). In other studies conducted in Asians, it has been shown that the 
FCGRIIA-R131 allele was correlated with certain disease phenotypes. Kobayashi et al. 
studied Japanese SLE patients with or without periodontitis, and found that the R allele was 
significantly correlated (Kobayashi, 2007). Siriboonrit et al. also found in a Japanese cohort that 
the R allele was significantly increased in patients with lupus nephritis (Siriboonrit, 2003). In 
various ethnic groups (Europeans, African Americans and Koreans), R131 (rs1801274) showed 
inconsistent association with susceptibility to SLE, lupus nephritis, or both (Duits, 1995; Yap, 
1999; Chen, 2004; Salmon, 1996; Song, 1998). Ethnic differences, disease heterogeneity, 
genotyping error due to extensive sequence homology among FCGR genes and random 
fluctuations in small samples might explain these inconsistent associations. 
FcγR3IIIA receptor contains ITAM on cell surfaces of natural killer (NK) cells, monocytes, 
and macrophages. FcγR3A alleles with differential affinity for IgG1 and IgG3 have also been 
shown to be associated with SLE patients from ethnically diverse groups (Yap, 1999).  The 
nonsynonymous SNP, where valine (V158) of FcγRIIIA changes to phenylalanine (F158) 
(rs396991) was shown to reduce the IgG1-, IgG3-, and IgG4-binding capacity of the receptor 
compared to V/V homozygotes. This polymorphism, normally termed FcγRIIIA-176 F/V or 
FcγRIIIA-158 F/V when excluding the leader sequence, was first reported to be of 
significant correlation with SLE in the Asian population (Japanese) by Kyogoku et al 
(Tsuchiya, 2005). Studies in human cohorts have shown that SLE is significantly associated 
with both alleles, R131 and F158, that encode lower affinity isoforms of FcγRIIA and 
FcγRIIIA respectively (Lehrnbecher, 1999b). F158 homozygotes bind IgG1- and IgG3-
containing ICs less efficiently than V 158 homozygotes, and confers less efficient clearance of 
ICs than other alleles was associated with SLE susceptibility(Koene, 1998). However, the 
association between FcγR3A-V/F158 polymorphism and susceptibility to SLE and/or lupus 
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nephritis has been variable in several studies (Tsao, 2004). A meta-analysis of more than 
1,000 subjects in each of the three categories (SLE without or without renal involvement, and 
non-SLE controls) has concluded that the F158 allele confers a 1.2-fold risk for developing 
lupus nephritis in patients of European, African, and Asian descent but not for SLE 
susceptibility without renal involvement (Karassa, 2003). 
The FcγRIIA-R131 and FcγRIIIA-F158 are often inherited together on the same chromosome 
as a single-risk haplotype for SLE (Magnusson, 2004). The presence of multiple risk alleles 
might interact to enhance the risk for SLE (Sullivan, 2003). The relative importance of 
FcγR2A-H/R131 and FcγR3A-V/F158 to disease progression might depend on the IgG 
subclass of pathogenic auto antibodies in an individual patient.  
A novel polymorphism in FCGR3A, the rs403016 located in the Exon 3 which causes a 
non-synonymous substitution, the FCGR3A-72R/S, has been found to be associated with 
SLE in a Chinese SLE cohort, where the R allele contributes to disease susceptibility (Ye, 
2006; Pan, 2008). 
In a meta-analysis carried out by Lehrnbecher et. al., the development of SLE was 
significantly associated with the alleles encoding the low affinity isoforms of both 
FcγRIIA (FcγRIIA–R/R131) and FcγRIIIA (FcγRIIIA–F/F158) (Lehrnbecher, 1999b). More 
recently, a similar meta-analysis study carried out by Karassa and colleagues found that 
an FcγRIIA–R/H131 polymorphism represents a significant risk factor for the 
development of SLE but had no clear effect on susceptibility for lupus nephritis in a large 
patient cohort (Karassa, 2002). 
Lower level evidence exists for a non-synonymous mutation in FcγRIIIA proposed to alter 
IgG binding affinity, a promoter SNP in FCGR2B that alters transcription factor binding and 
receptor expression and, in Asian populations, a non-synonymous SNP in exon 6 of 
FCGR2B suggested to influence B-cell activation (Brown, 2007).  
FcγRIIB: FCGR2B receptor is expressed on B cells, dendritic cells, monocytes/macrophages, 
and mast cells. It contains an ITIM that regulates B-cell survival and proliferation by down-
modulating B-cell receptor signaling, and by decreasing antibody-mediated phagocytosis in 
macrophages (Daeron, 1997).  
A nonsynonymous SNP in the transmembrane domain of FcγRIIB (Ile187Thr) that alters the 
inhibitory function of FcγRIIB on B cells is associated with SLE in Asian populations,( 
Kyogoku, 2002; Siriboonrit, 2003; Chu, 2004) but not in other populations partly owing to 
their low allele frequencies (Li, 2003; Kyogoku, 2004; Magnusson, 2004). The FcγR2B 
encoded by the Thr187 allele results in impaired inhibition of B-cell activation and promotes 
autoimmunity (Floto, 2005). A functional promoter haplotype (–386G/–120T) of FcγRIIB 
that confers increased transcription of FcγRIIB has been associated with 1.6-fold risk for SLE 
in Caucasian Americans (Su, 2004). This haplotype is not in LD with FcγRIIA and FcγRIIIA 
polymorphisms and is likely to have an independent association with SLE (Kyogoku, 2002). 
FcγRIIIB: FCGR3B is expressed solely on neutrophils. It lacks an ITAM domain, so the 
transmission of intracellular signals is likely to involve cooperation with other 
transmembrane proteins. Of particular interest are data suggesting that this is achieved 
through an interaction with complement receptor 3/integrin M (Krauss, 1994; Poo, 1995; 
Stockl, 1995). It is considered low affinity receptor for the Fc region of immunoglobulins 
gamma. It binds to complexed or aggregated IgG and also monomeric IgG. Contrary to 
FCγR3A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. It 
may serve as a trap for immune complexes in the peripheral circulation which does not 
activate neutrophils. 
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Six SNPS exist in FCGR3B, underlying three different allotypic variants of FCGR3B (NA1, 
NA2 and SH). The association reported by Hatta et a.l.( Hatta, 1999) between the NA2 
allotype and SLE in a Japanese population has not been replicated, suggesting that the 
association between SLE and this genomic region might be influenced by other genetic 
variations. Both duplication and deficiency of FCGR3B were reported in normal individuals 
(Clark, 1990; Koene, 1998). The inheritance pattern of FCGR3B in some families affected by 
SLE has suggested that the copy number variation might be the underlying condition.  
The number of copies of FCGR3B in a cell can vary from none to four, with a gene-dose 
effect that reduced FcγRIIIB copy number being a risk factor for glomerulonephritis in SLE 
patients. In addition, FCGR3B copy number varies significantly with non-Mendelian 
inheritance, suggesting that the association of FCGR3B copy number with lupus nephritis is 
an independent risk factor (Aitman, 2006). Since human FCGR3B is expressed mainly in 
neutrophils, and it is postulated that SLE patients with low FCGR3B copy number have 
reduced neutrophil expression, which leads to reduced glomerular clearance of immune 
complexes, and brings forth susceptibility to SLE and other autoimmune disorders. This 
observation supports that copy number polymorphism at orthologous regions of diverse 
genomes is associated with immunologically related disease. It also suggests that genome 
plasticity, manifested by gene duplication/deletion and copy number polymorphism, is a 
common cause of genetically complex phenotypes. Fc receptor-like genes (FCRLs): FCLs 
clustered at 1q21–22 encode proteins that are structurally homologous classical FCGRs. To 
enhance our understanding of the functional roles of Fcγ receptors in SLE, an integrated 
approach to simultaneously assess CNVs, allotypic variants, SNPs and the functional 
diversity of these receptors in large-scale case–control studies including multiple ethnic 
populations is needed to dissect the relative contribution of various variants in this complex 
FCGR locus to SLE. 
2.2 Protein tyrosine phosphatase non-receptor 22 (PTPN22) (1p13)  
PTPN22 is a negative regulator for T-cell signal transduction in cellular immunity.  It is 
considered to be the strongest common genetic risk factor for human autoimmunity besides 
the major histocompatibility complex (MHC) and as an important candidate gene in SLE. A 
number of candidate gene studies found (SNP rs2476601) R620W polymorphism in the 
proximal protein-rich SH3-binding domain (+1858T/C), to be associated with the increased 
risk of SLE (Orozco, 2005). This has been confirmed in a meta-analysis (Lea, 2011) and SLE 
GWA analysis. This polymorphism was found to be associated with several autoimmune 
diseases in Caucasians, including T1D, autoimmune thyroid disease, RA and SLE, but not 
with multiple sclerosis (MS). SNP rs2476601 is not polymorphic in Koreans and Japanese 
and almost absent in African populations (Gregersen, 2006) while it is more common in 
northern Europeans (8–15%) compared with southern Europeans (2–10%) (Gregersen, 2009). 
Suggesting the presence of genetic heterogeneity across various ethnicities. 
The lymphoid tyrosine phosphatase protein (LYP), which is encoded by PTPN22, is known 
to regulate immunological synapse formation. LYP is involved in the down-regulation of  
T-cell activation through its interaction with a negative regulator of TCR signaling C-
terminal Src tyrosine kinase (Csk); this interaction is prevented by the arginine to 
tryptophan amino acid substitution consequent upon the associated mutation rs2476601 
R620W (C1858T) (Begovich, 2004; Bottini, 2004).  
One would expect this R620W substitution to result in increased T-cell signaling and 
activation; however, experimental evidence suggests the opposite with TCR signaling 
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actually reduced in cells carrying the tryptophan variant protein (Vang, 2005). A number of 
explanations have been proposed including an effect of the mutation on the tyrosine 
phosphatase activity of LYP, or an effect on the binding of other ligands or the conformation 
of LYP in response to these ligands (Vang, 2008). At a cellular level the mechanism by which 
reduced T-cell activation may actually increase the potential for autoimmunity remains a 
matter for speculation, although the suppression of regulatory T-cells is a possibility (Vang, 
2008). A connection between PtPn22 and the type I IFN pathway has been suggested on the 
basis of elevated serum IFN-α activity and decreased tumor necrosis factor (TNF) levels in 
patients with SLE carrying the rs2476601 risk allele (Kariuki, 2008). By contrast, another 
PTPN22 polymorphism, the loss-of-function mutation Arg263Gln in the catalytic domain 
(R263Q), leads to reduced phosphatase activity of PtPn22, and, therefore, increases the 
threshold for TCR signaling has been associated with protection against SLE in European-
derived populations (Orru, 2009). 
2.3 Interleukin 10 (IL 10) 1q32.1 
IL-10 is an important immunoregulatory cytokine in man with both immunosuppressive 
and immunostimulatory properties (Mosmann, 1994).  It is characterized with anti-
inflammatory and stimulatory activities, and plays a critical role in the regulation of cellular 
and humoral immune responses. IL-10 is also involved in the pathology of human 
autoimmune disease (Llorente, 1994; Cash, 1995; Perez, 1995), particularly in the 
dysregulation of B-cell function in systemic lupus erythematosus leading to autoantibody 
production (Itoh, 1995; Llorente, 1995). In addition, its ability to induce T-cell anergy 
(Luscher, 1994) and inhibit major histocompatibility complex class-I expression (Matsuda, 
1994) may be important in its apparent contribution to tumor-related immunosuppression 
(Kim, 1995; Suzuki, 1995; Fortis, 1996). 
It has been known that IL10 production is under strong genetic influence (Westendorp, 
1997). Two CA-repeat microsatellites, IL10R (-4 kb) (GeneBank accession number AF295024) 
and IL10G (-1.1 kb) (GeneBank accession number X78437), and single nucleotide 
polymorphisms (SNPs) were reported in IL10 promoter that has potential association with 
IL10 production. These SNPs are located at positions -A3575T, -A2849G, -A2763C, -A1082G, 
-C819T, and -A592C from the transcription start site. It has been known that -A1082G,  
-C819T, and -A592C combined to form three haplotypes; GCC, ACC, and ATA linked with 
different IL10 expression level (Crawley, 1999). 
IL-10 has been associated in the pathogenesis of SLE; Increased IL10 production by 
peripheral blood B cells and monocytes from patients with SLE is known to correlate with 
disease activity (Hagiwara, 1996), increased IL-10 productions promotes B-cell hyperactivity 
and autoantibody production (Llorente, 1995). The association between IL10 promoter 
haplotypes (defined by three SNPs in the IL10 promoter region -627CA, -854CT and  
-1117GA. These single base-pair substitutions produce three different haplotypes, GCC, 
ACC and ATA,) (Turner, 1997; Eskdale, 1997a) and SLE has been have been reported in 
European, Hispanic American and Asian populations (Eskdale, 1997b; Mehrian, 1998; 
Chong, 2004). A large-scale replication study in populations from the USA and Sweden has 
confirmed IL10 as a SLE susceptibility locus (Gateva, 2009). However, they were found to 
have significant association with lupus nephritis.  
Levels of IL-10 secretion have been correlated to specific IL10 promoter polymorphisms; a 
study has shown that the SNP haplotypes in the distal promoter of IL-10 correlate with 
different IL-10 production phenotype in normal individuals, and high IL-10 haplotype is 
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associated with SLE in African-Americans, which may be a part of their genetic 
susceptibility to SLE. A meta-analysis of 15 IL-10 studies has shown that the G11 allele is 
associated with SLE in whole studied populations, and among the promoter SNPs, −A1082G 
polymorphism, which is found in Asian population only, was also associated with SLE 
(Nath, 2005). Based on these analyses, IL-10 polymorphisms confer SLE risk in an ethnicity-
specific manner (Gateva, 2009; Eskdale, 1997; Mehrian, 1998; Chong, 2004). 
2.4 Complement receptor 1 (CR1, CD35), (1q32)  
Genome scans have shown linkage (lod score >1.0) at chromosome 1q32, which contains 
complement components, like complement receptor 1 (CR1), complement receptor 2 (CR2), 
and C4b-binding protein (C4BP) genes and IL10 family members; IL10, IL19, IL20, and IL24, 
which play a significant role in the pathogenesis of SLE (Johanneson, 2002; Tsao, 1999). The 
C3b/C4b complement receptor (Gene ID: 1378) (CR1, CD35) is a polymorphic 
transmembrane single chain glycoprotein expressed on red cell surface binds to C3b and 
C4b and clears circulating C3- and C4-bearing immune complexes containing (Dykman, 
1984). 
Functional and structural polymorphisms of CR1 have been reported. The functional 
polymorphism determines the quantitative expression of CR1 on erythrocytes, i.e. HH, HL, 
and LL (H = allele correlated with high expression, L = low) (Wilson, 1986). The structural 
polymorphism exists in its molecular size (Dykman, 1983). The extracellular portion of the 
CR1 molecule consists of three to five groups of seven short consensus repeats termed long 
homologous repeats (LHR). The most frequent type of CR1 (F or A) is comprised of four 
extracellular LHRs and expresses one binding site for C4b and two binding sites for C3b 
(Wong, 1983). The S (or B) variant of CR1 is characterized by additional C3b binding site on 
a fifth LHR (Wong, 1989). A meta-analysis for the CR1 functional polymorphisms in SLE 
shows no significant association of CR1 L allele, L/L genotype, and L/L+L/H genotypes 
with SLE. However, the same meta-analysis of CR1 structural polymorphisms suggested an 
association of CR1 S (structural variant of CR1) to be associated with SLE in Caucasians 
(Nath, 2005). 
2.5 Tumor necrosis factor (ligand) SuperFamily, member 4(TNFSF4), 1q25 
TNFSF4 (also known as OX40L; 1q25) encodes a cytokine that is expressed on CD40-
stimulated B cells, activated antigen-presenting cells (APCs) and vascular endothelial cells. 
Also its unique receptor, TNFRSF4 (also known as OX40; 1p36), is primarily expressed on 
activated CD4+ T cells. Their interaction induces the production of CD28-independent  
co-stimulatory signals to activate CD4+ T cells (Baum, 1994). OX40L-mediated signaling 
inhibits the generation and function of IL-10-producing CD4+ type 1 regulatory T cells, but 
induces B-cell activation and differentiation, as well as IL-17 production in vitro (Ito, 2006a; 
Li, 2008).   
These two tumor necrosis factor (TNF) superfamily members (OX40L and OX40) located 
within proximal intervals showing genetic linkage with SLE (Cunninghame, 2008; Chang, 
2009; delGado-Vega, 2009).TNFSF4 has been identified as a susceptibility gene for SLE in 
multiple studies. Protective and risk haplotypes at TNFSF4 were identified in a study of two 
cohorts from Minnesota and UK, a haplotype in the upstream region of TNFSF4, marked by 
SNPs rs844644 and rs2205960, has been shown to correlate with increased cell surface 
TNFSF4 expression and TNFSF4 transcript and to be associated with SLE (Graham, 2008). 
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Associations between some TNFSF4-tagging SNPs and an increased risk for SLE have been 
confirmed in GWAS in Chinese populations and in a European replication study; these 
results were also replicated in four independent SLE datasets from Germany, Italy, Spain 
and argentine. It has not been fully established how TNFRSF4/ TNFSF4 interactions 
influence T-cell subset profiles. Most evidence suggests a bias towards a Th2 pattern of 
cytokine release, although there is also evidence for a down-regulation of regulatory T-cell 
subsets (Ito, 2006b; Lane, 2000). There is also good evidence that signaling through TNFSF4 
can induce B-cell activation and differentiation (Stuber, 1995&1996). TNFRSF4/ TNFSF4 
signaling is therefore bi-directional, and the precise immunological consequences of this 
complex pathway are yet to be clarified. Further studies are needed to localize causal 
variants and to understand how these polymorphisms affect the pathogenesis of SLE. 
2.6 C-reactive protein (CRP), 1q23.2 
CRP is a sensitive marker of inflammation. The genes for CRP (CRP) map to 1q23.2 within 
an interval linked with SLE in multiple populations. It is hypothesized that polymorphism 
of CRP gene contributes to susceptibility to systemic lupus erythematosus (SLE).  
Basal levels of CRP were influenced independently by two polymorphisms at the CRP locus, 
CRP 2 and CRP 4. Furthermore, the latter polymorphism was linked/associated with SLE 
and antinuclear autoantibody production. Thus, the polymorphism associated with reduced 
basal CRP was also associated with the development of SLE. 
CRP is normally involved in phagocytosis of apoptotic debris and immune complexes in 
innate immune response. Defective clearance of products of apoptosis may be the source of 
autoantigens in SLE, and such phenomenon may also be enhanced by FcγR2A 
polymorphisms, with FcγR2 receptor being the main receptor for CRP (Bharadwaj, 1999).  
During the active phase of SLE, despite the presence of marked tissue inflammation, CRP 
levels are abnormally low due to reduced synthesis (Russell, 2004). Family-based studies of 
association and linkage have identified the minor allele of rs1205 in the 3’UTR SNP of CRP 
to be associated with SLE and antinuclear antibody production (Russell, 2004), and the 
number of CA repeats correlated with disease risk in a Spanish cohort (Russell, 2004). Also, 
a single dose of CRP has recently shown to reverse lupus nephritis and nephrotoxic 
nephritis in mice, suggesting the acute-phase response of CRP may hinder tissue 
inflammation and damage (Rodriguez, 2005). These results are promising, and future 
investigation of this gene will not only allow better understanding of the genetic influence of 
CRP but also its pathophysiology and possible therapeutic options. 
Two of several polymorphisms in the CRP gene, designated CRP2 (G/C) and CRP4 (G/A) 
have been demonstrated to have an impact on baseline serum concentration of CRP, with 
the C- and A-alleles being associated with lower concentrations (Russell, 2004). 
Furthermore, the CRP4 A-allele was shown to confer increased susceptibility to SLE in 586 
families (P=0.006) (Russell, 2004). The A allele at CRP 4 had a relatively high frequency in 
European and Asian-Indian populations (∼0.3) and was present in Afro-Caribbean families 
too, but at a lower frequency (0.14). 
2.7 Poly(ADP-ribose) polymerase (PARP), (1q41–42) 
PARP is an enzyme (PARP-1 EC 2.4.2.30) is induced by DNA strand breaks caused by 
several agents and utilizes NAD to form polyADPR, bound to acceptor proteins. It is 
responsible for DNA repair, proliferation, stress response, apoptosis, and genomic stability 
(Oliver, 1999). The involvement of PARP-1 in autoimmune diseases has been suggested 
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especially in systemic lupus erythematosus (SLE) due to the decreased levels of activity and 
mRNA in SLE patients (Haug 1994). Autoantibodies to PARP are frequently found in 
patients affected with autoimmune diseases, some of which may prevent caspase-3-
mediated PARP cleavage during apoptosis, resulting in the accumulation of autoimmune 
cells (Decker, 2000). On chromosome 1q41–q42 a 15-cM region has been linked with 
susceptibility to SLE (Tsao, 1997), this linkage has been confirmed in several independent 
studies. In a family-based TDT analysis, PARP alleles had skewed transmission to affected 
offspring, but this finding is not consistent in other multi-ethnic studies (Tsao, 1999).  
A polymorphic CA tandem repeat within the PARP promoter region suggested to affect 
transcription activity has been associated with SLE in some but not other similar studies 
(Oei, 2001). A study investigated the association of PARP promoter CA tandem repeats 
polymorphisms with SLE susceptibility in Taiwan. Nine alleles ranging from 12 to 20 
repeats were disclosed. No statistically significant association with SLE susceptibility was 
found in this population however; PARP microsatellite polymorphisms demonstrate 
associations with clinical subphenotypes such as discoid rash and arthritis, anti-cardiolipin 
IgG and anti-ds-DNA antibody production. These indicate that PARP CA repeats may play 
a key role in lupus pathogenesis involving DNA repair of cell damage and consequent 
autoantibody production. Tsao et al demonstrated a skewed transmission of PARP alleles in 
a family study with the PARP CA8 allele as susceptible and the PARP CA14 allele as a 
protector of lupus transmission (Tsao, 1999). 
In a Korean study, PARP polymorphisms could not prove any statistically significant 
association with the risk of SLE was observed, however, they found that two single-
nucleotide polymorphisms (SNPs -1963A/G and +28077G/A) were significantly associated 
with an increased risk of nephritis, and one non-synonymous variant [+40329T/C (V762A)] 
was also significantly associated with an increased risk of arthritis, while the -1963A/G 
polymorphism showed a protective effect on arthritis in Korean SLE patients (Hur, 2006). 
2.8 Toll-like receptor 5 (TLR5), 1q41–q42 
At least 10 different TLR have been cloned from the human genome to date. Toll-like 
receptors (TLR) are type I transmembrane proteins contain an extracellular leucine-rich 
region involved in pathogen recognition and a conserved intracellular Toll/IL-1 receptor 
domain that activates a signaling pathway. Stimulation of the TLR pathway ends in NF-B 
activation and transcription of immune response genes, such as cytokines and chemokines. 
TLRs play an important role in the activation and regulation of both adaptive and innate 
immunity. They are considered as excellent candidate genes for genetic susceptibility 
studies for autoimmune diseases. TLR5 is a critical regulator of inflammatory pathways and 
maps to chromosome 1q41. Activation of TLR5 triggers production of proinflammatory 
cytokines, such as IL-6, which, in turn, can stimulate B cells to proliferate, differentiate, and 
secrete antibodies. Dysregulation of this process may lead to excessive production of 
cytokines as well as autoantibodies (Dean, 2000). 
It was hypothesized that the stop codon variant C1174T (rs5744168) (Arginine to a stop 
codon at position 392 (R392X) in TLR5, is associated with susceptibility to SLE. This 
hypothesis was tested by using a TDT in a Caucasian SLE cohort and found that the TLR5 
stop codon polymorphism, but not other TLR5 alleles, is associated with protection from 
developing SLE as subjects with 1174T produced less proinflammatory cytokines (IL-6, 
TNF-α, and IL-1β) (Hawn, 2003; Hawn, 2005). In addition the same group found that this 
association was most pronounced in individuals who are seronegative for anti-dsDNA 
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domain that activates a signaling pathway. Stimulation of the TLR pathway ends in NF-B 
activation and transcription of immune response genes, such as cytokines and chemokines. 
TLRs play an important role in the activation and regulation of both adaptive and innate 
immunity. They are considered as excellent candidate genes for genetic susceptibility 
studies for autoimmune diseases. TLR5 is a critical regulator of inflammatory pathways and 
maps to chromosome 1q41. Activation of TLR5 triggers production of proinflammatory 
cytokines, such as IL-6, which, in turn, can stimulate B cells to proliferate, differentiate, and 
secrete antibodies. Dysregulation of this process may lead to excessive production of 
cytokines as well as autoantibodies (Dean, 2000). 
It was hypothesized that the stop codon variant C1174T (rs5744168) (Arginine to a stop 
codon at position 392 (R392X) in TLR5, is associated with susceptibility to SLE. This 
hypothesis was tested by using a TDT in a Caucasian SLE cohort and found that the TLR5 
stop codon polymorphism, but not other TLR5 alleles, is associated with protection from 
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TNF-α, and IL-1β) (Hawn, 2003; Hawn, 2005). In addition the same group found that this 
association was most pronounced in individuals who are seronegative for anti-dsDNA 
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autoantibodies (Tsao, 1999; Hawn, 2005). TLR5R392X may provide protection from SLE by 
decreasing production of proinflammatory cytokines during infection with flagellated 
bacteria, which may influence formation of the adaptive immune response. These results 
suggest a role for the innate immune response in the development of SLE that involves 
flagellated bacterial infections. 
3. Chromosome 2 
Locus 2q32- q37 encodes the Programmed cell death 1 gene (PDCD1), Cytotoxic T-
lymphocyte associated protein 4 (CTLA4) and STAT4 transcription factor. All were proven 
to be associated to susceptibility to SLE.  
3.1 Programmed cell death 1 gene (PDCD1/ CD279) (2q37)  
PDCD1 codes for an immunoreceptor, PD-1, member of the CD28/CTLA4/ICOS co-
stimulatory receptor family that bears an inhibitory immunoreceptor tyrosine-based motif 
(ITIM). It is expressed on activated T- and B-cell surfaces to regulate their peripheral 
tolerance (Agata 1996; Finger, 1997). PDCD1 is upregulated in T cells following activation, 
and inhibits TCR signaling and T/B cell survival. It is considered a strong candidate for SLE 
association. 
The human PDCD1 has an intron enhancer which contains binding sites for other 
transcription factors that are involved in lymphocyte development and T cell differentiation. 
PDCD single nucleotide polymorphism (SNP) (PD1.3A, the minor A allele of 7146 G/A) in 
this intron enhancer alters a binding site for the runt-related transcription factor (RUNX1). 
The PDCD1 enhancer has a very high GC content (from 50 to 75%). The A allele of the 
PDCD1 enhancer SNP changes a potential methylation site from CpG to CpA that is 
surrounded by many other potential methylation sites. Methylation is a known mechanism 
of regulation of gene activity (Avni, 2000). Whether methylation is involved in the 
regulation of PDCD1 is under investigation. Changes in methylation can condition the 
developmental stage of PDCD1 expression. 
SNP 7146 G/A was shown to be association with SLE susceptibility and its contribution to 
SLE development was confirmed in Europeans and Mexicans by inducing lymphocytic 
hyperactivity in these patients (Prokunina, 2002). PDCD-1 polymorphisms may be a shared 
genetic factor for multiple autoimmune diseases in humans, and the cellular function 
leading to disease onset awaits further investigation. PDCD1 7209 CT or 7209 TT genotype 
exhibited 3.28-fold increased risk of SLE in the Polish and Taiwanese populations 
(Mostowska, 2008). 
The most logical explanation of the mechanism of disease susceptibility for PDCD1 was 
suggested by Alarcón-Riquelme M et al (Alarcón-Riquelme, 2003); The stated: “So what 
effects could the aberrant function or expression of PDCD1 have in early lymphocyte 
differentiation that may lead to autoimmune disease, in particular SLE? It mainly depends 
on at what stage of differentiation does the RUNX1–PDCD1 interaction take place whether 
it occurs before clonal receptor rearrangements or after. As PDCD1 seems to act during 
positive selection in the thymus, at least in the mouse, this leads us to suggest that the 
human mutation may be promoting positive selection of early autoreactive progenitors, 
leading to an increased “susceptibility” to expand autoreactive T or B cells after antigenic 
stimuli, however the amount of information to date on PDCD1 in lymphocyte development 
and its regulation is still an open question”. 
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3.2 Cytotoxic T-lymphocyteassociated protein 4 (CTLA4), (2q33) 
CTLA4 is a structural homologue of CD28. It is a negative costimulatory molecule that 
inhibits T cell activation, and may help to limit T cell responses under conditions of 
inflammation and prevents autoimmune diseases by promoting anergy. It competes with 
the binding of CD28 on antigen presenting cells (APCs), and transduces inhibitory signals 
by activation of serine/threonine phosphatases. Genetic variability in CTLA4 has been 
implicated in the development of several autoimmune diseases including SLE (Matsushita, 
1999). SLE patients have increased levels of soluble CTLA-4. A single nuclear polymorphism 
(SNP) CT60A/G within the 3’UTR of CTLA4 decreased the production of a spliced variant 
with inhibitory activity, which indicates the importance of CTLA-4 in providing protection 
against autoimmunity (Ueda, 2003). 
SLE in Caucasians, CTLA-4 polymorphisms of its promoter and exon-1 regions was found 
to be associated to SLE. Later, in a Chinese cohort, the CTLA-4 promoter (-1722 T/C) 
polymorphism showed positive evidence (Liu, 2001 & Xu, 2004). However, several genetic 
studies investigating CTLA-4 polymorphisms and SLE have been negative. Among the 
positive studies, different mutations were identified within the CTLA4 promoter 
(−1722T/C, −1661A/G, −319C/T) and exon 1 (+49G/A) in various ethnic groups (Lee, 
2005). More work is needed to delineate the genetic relationship between CTLA-4 and SLE.  
3.3 Signal transducer and activator of transcription 4 protein (STAT4), (2q32) 
STAT4 play key roles in the interferon and Th1 signaling pathway through mediating 
responses to IL-12 in lymphocytes, and regulates T helper cell differentiation. STAT4 also is 
known to mediate signals induced by immunologically relevant cytokines including, like 
IRF5, the Type 1 IFNs (Darnell, 1994 & Watford, 2004). In response to these cytokines, 
STAT4 activation plays an important role in directing a Th1 T-cell response, and mediates 
the production of Th1-type cytokines such as IFN-( Morinobu, 2002; Nguyen, 2002; 
Nishikomori, 2002). In addition, STAT4 signaling also mediates type 1 IFN signaling in 
antigen-presenting cells, and may be necessary for the production of IFN- by these cells 
(Frucht, 2003 & Fukao, 2001). 
STAT4 variation and SLE risk was initially reported in 2007 from a case–control association 
study (Remmers, 2007). This was subsequently confirmed in both GWA studies. Three SNPs 
in STAT4, rs7574865, rs11889341, and rs10168266, were then shown to be in significant 
association with SLE in a Japanese population, with the rs7574865 T allele, in the third intron 
of STAT4, showing the strongest significance. Interestingly, this rs7574865 risk variant is 
associated with a more severe SLE phenotype that is characterized by disease onset at a 
young age (<30 years), a high frequency of nephritis, the presence of antibodies towards 
double stranded DNA, (Taylor, 2008; Kawasaki, 2008; Sigurdsson, 2008) and an increased 
sensitivity to IFN-α signaling in peripheral blood mononuclear cells (Kariuki, 2009). In a 
meta-analysis including Europeans and Asian patients of SLE and RA, the rs7574865 T allele 
was found to be consistently associated with both diseases (Ji, 2010). Possible functional 
relevance of risk STAT4 variant has recently strongly suggested by in vivo experiment in 
SLE patients, in which risk variant of STAT4 (T allele; rs7574865) was simultaneously 
associated with both lower serum IFN-a activity and greater IFN- induced gene expression 
in PBMC in SLE patients. 
A risk haplotype (spanning 73 kb from the third intron to the seventeenth exon of STAT4) 
common to European, Americans, Koreans and Hispanic Americans was also identified 
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(ITIM). It is expressed on activated T- and B-cell surfaces to regulate their peripheral 
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and inhibits TCR signaling and T/B cell survival. It is considered a strong candidate for SLE 
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The human PDCD1 has an intron enhancer which contains binding sites for other 
transcription factors that are involved in lymphocyte development and T cell differentiation. 
PDCD single nucleotide polymorphism (SNP) (PD1.3A, the minor A allele of 7146 G/A) in 
this intron enhancer alters a binding site for the runt-related transcription factor (RUNX1). 
The PDCD1 enhancer has a very high GC content (from 50 to 75%). The A allele of the 
PDCD1 enhancer SNP changes a potential methylation site from CpG to CpA that is 
surrounded by many other potential methylation sites. Methylation is a known mechanism 
of regulation of gene activity (Avni, 2000). Whether methylation is involved in the 
regulation of PDCD1 is under investigation. Changes in methylation can condition the 
developmental stage of PDCD1 expression. 
SNP 7146 G/A was shown to be association with SLE susceptibility and its contribution to 
SLE development was confirmed in Europeans and Mexicans by inducing lymphocytic 
hyperactivity in these patients (Prokunina, 2002). PDCD-1 polymorphisms may be a shared 
genetic factor for multiple autoimmune diseases in humans, and the cellular function 
leading to disease onset awaits further investigation. PDCD1 7209 CT or 7209 TT genotype 
exhibited 3.28-fold increased risk of SLE in the Polish and Taiwanese populations 
(Mostowska, 2008). 
The most logical explanation of the mechanism of disease susceptibility for PDCD1 was 
suggested by Alarcón-Riquelme M et al (Alarcón-Riquelme, 2003); The stated: “So what 
effects could the aberrant function or expression of PDCD1 have in early lymphocyte 
differentiation that may lead to autoimmune disease, in particular SLE? It mainly depends 
on at what stage of differentiation does the RUNX1–PDCD1 interaction take place whether 
it occurs before clonal receptor rearrangements or after. As PDCD1 seems to act during 
positive selection in the thymus, at least in the mouse, this leads us to suggest that the 
human mutation may be promoting positive selection of early autoreactive progenitors, 
leading to an increased “susceptibility” to expand autoreactive T or B cells after antigenic 
stimuli, however the amount of information to date on PDCD1 in lymphocyte development 
and its regulation is still an open question”. 
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3.2 Cytotoxic T-lymphocyteassociated protein 4 (CTLA4), (2q33) 
CTLA4 is a structural homologue of CD28. It is a negative costimulatory molecule that 
inhibits T cell activation, and may help to limit T cell responses under conditions of 
inflammation and prevents autoimmune diseases by promoting anergy. It competes with 
the binding of CD28 on antigen presenting cells (APCs), and transduces inhibitory signals 
by activation of serine/threonine phosphatases. Genetic variability in CTLA4 has been 
implicated in the development of several autoimmune diseases including SLE (Matsushita, 
1999). SLE patients have increased levels of soluble CTLA-4. A single nuclear polymorphism 
(SNP) CT60A/G within the 3’UTR of CTLA4 decreased the production of a spliced variant 
with inhibitory activity, which indicates the importance of CTLA-4 in providing protection 
against autoimmunity (Ueda, 2003). 
SLE in Caucasians, CTLA-4 polymorphisms of its promoter and exon-1 regions was found 
to be associated to SLE. Later, in a Chinese cohort, the CTLA-4 promoter (-1722 T/C) 
polymorphism showed positive evidence (Liu, 2001 & Xu, 2004). However, several genetic 
studies investigating CTLA-4 polymorphisms and SLE have been negative. Among the 
positive studies, different mutations were identified within the CTLA4 promoter 
(−1722T/C, −1661A/G, −319C/T) and exon 1 (+49G/A) in various ethnic groups (Lee, 
2005). More work is needed to delineate the genetic relationship between CTLA-4 and SLE.  
3.3 Signal transducer and activator of transcription 4 protein (STAT4), (2q32) 
STAT4 play key roles in the interferon and Th1 signaling pathway through mediating 
responses to IL-12 in lymphocytes, and regulates T helper cell differentiation. STAT4 also is 
known to mediate signals induced by immunologically relevant cytokines including, like 
IRF5, the Type 1 IFNs (Darnell, 1994 & Watford, 2004). In response to these cytokines, 
STAT4 activation plays an important role in directing a Th1 T-cell response, and mediates 
the production of Th1-type cytokines such as IFN-( Morinobu, 2002; Nguyen, 2002; 
Nishikomori, 2002). In addition, STAT4 signaling also mediates type 1 IFN signaling in 
antigen-presenting cells, and may be necessary for the production of IFN- by these cells 
(Frucht, 2003 & Fukao, 2001). 
STAT4 variation and SLE risk was initially reported in 2007 from a case–control association 
study (Remmers, 2007). This was subsequently confirmed in both GWA studies. Three SNPs 
in STAT4, rs7574865, rs11889341, and rs10168266, were then shown to be in significant 
association with SLE in a Japanese population, with the rs7574865 T allele, in the third intron 
of STAT4, showing the strongest significance. Interestingly, this rs7574865 risk variant is 
associated with a more severe SLE phenotype that is characterized by disease onset at a 
young age (<30 years), a high frequency of nephritis, the presence of antibodies towards 
double stranded DNA, (Taylor, 2008; Kawasaki, 2008; Sigurdsson, 2008) and an increased 
sensitivity to IFN-α signaling in peripheral blood mononuclear cells (Kariuki, 2009). In a 
meta-analysis including Europeans and Asian patients of SLE and RA, the rs7574865 T allele 
was found to be consistently associated with both diseases (Ji, 2010). Possible functional 
relevance of risk STAT4 variant has recently strongly suggested by in vivo experiment in 
SLE patients, in which risk variant of STAT4 (T allele; rs7574865) was simultaneously 
associated with both lower serum IFN-a activity and greater IFN- induced gene expression 
in PBMC in SLE patients. 
A risk haplotype (spanning 73 kb from the third intron to the seventeenth exon of STAT4) 
common to European, Americans, Koreans and Hispanic Americans was also identified 
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(Namjou, 2009). Functionally, either type I IFN or interleukin (IL)-12 induces 
phosphorylation of STAT4, which has a signal transduction role in these pathways. 
Individuals carrying one or more risk alleles of both IRF5 and STAT4 have an increased risk 
for SLE, suggesting a genetic interaction between these two genes (Sigurdsson, 2008).  
The important roles of STAT4 in both innate immunity and Th1 immune response, recent 
enormous body of evidence of consistent association of STAT4 with SLE in multiple racial 
groups indicates that a risk variant or a certain risk haplotype of STAT4 has a crucial role in 
SLE pathogenesis that has yet to be completely determined and could provide new 
therapeutic targets for SLE and the other autoimmune diseases in future. 
4. Chromosome 3 
4.1 Phox homology (PX) domain Kinase (PXK), (3p14.3)  
PXK is of unknown function. PXK domain containing serine/threonine kinase and act as 
modulator of Na, K-ATPase enzymatic and ion pump activities (Mao, 2005). It was 
identified as a novel candidate gene for systemic lupus erythematosus (SLE) from genome-
wide association studies (GWAS) in Caucasians (Suarez-Gestal, 2009). The association of 
PXK rs6445975 with SLE observed in Caucasians was not replication study in Hong Kong 
Chinese and Koreans (Kim, 2011; Yu, 2011; Yang, 2009). It is possible that PXK has different 
genetic contribution on SLE between Caucasians and Asians and that the gene is associated 
with disease subphenotypes rather than with overall susceptibility. 
5. Chromosome 4 
5.1 BANK, BLK and LYN 
All three of these genes play a critical role in controlling the activation of B cells following 
signaling through the B-Cell Receptor (BCR). Following ligand binding and BCR 
aggregation, an early intracellular event is the recruitment and activation of Src-family 
protein tyrosine kinases, including BLK and LYN, which mediate further intracellular 
signaling. The exact role of these kinases in determining cellular events has yet to be 
determined with certainty. 
5.2 B-cell scaffold protein with ankyrin repeats (BANK1), (4q24) 
BANK1 is a B-cell scaffold protein that is tyrosine phosphorylated through the B-cell 
receptor (BCR) upon B-cell activation, which in turn associates with the tyrosine kinase Lyn 
(Src family of tyrosine kinase) and the calcium channel IP3R which results in calcium ion 
release from the stores of the endoplasmic reticulum (Yokoyama, 2002 & Kozyrev, 2008). 
BANK1 is thought to alter B cell activation to increase SLE risk. Polymorphisms in BANK1 
may cause B-cell hyper-responsiveness.  
GWAS in European-derived populations have identified associations of BANK1 and LYN 
with susceptibility to SLE (Kozyrev, 2008 & Guo, 2009). For BANK1 three functional 
variants with either a non-synonymous SNP (rs10516487; Arg61His), a branch point-site 
SNP (rs17266594; located in an intron) or a SNP in the ankyrin domain (rs3733197; 
Ala383Thr) might contribute to the sustained activation of B-cell receptors and the 
subsequent B-cell hyperactivity that is commonly observed in SLE (Kozyrev, 2008). 
However, the best functional evidence was found for rs17266594, which altered a branch 
point upstream of exon 2, resulting in the generation of a novel short isoform, but little 
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quantitative difference in BANK1 expression overall. With the exception of the rs10516487 
SNP of BANK1, which showed a weak association with SLE in an Asian GWAS, the 
remaining SNPS of BANK1 have not been confirmed in either Chinese or Asian GWAS, 
partly owing to the low frequencies of the SNPS in these populations (Chang, 2009). 
6. Chromosome 5 
6.1 TNIP1 (Tumor necrosis factor -induced protein 3 (TNFAIP3) interacting protein 1), 
also known as ABIN (A20-binding inhibitor of NF-B)-1, (5q32-q33.1) 
TNIP1 expression is induced by NF-B, and in turn, overexpression of TNIP1 inhibits NF-
B activation by TNF (Verstrepen, 2009). TNIP1 was shown to inhibit TNF-induced 
apoptosis independently of A20 (Oshima, 2009). Two recent GWAS revealed association of 
TNIP1 intronic SNPs rs7708392 and rs10036748, which are in strong linkage disequilibrium 
(LD) with SLE in the Caucasian (European-American and Swedish) and Chinese Han 
populations, respectively (Han, 2009 & Gateva, 2009). Association of TNIP1 with SLE was 
also confirmed in a Japanese population.  
To date, at least 11 splice variants of TNIP1have been identified (Verstrepen, 2009). Presence 
of alternative exon 1A and 1B, as well as splice variants lacking exon 2, has been described. 
Because rs7708392 is located between exon 1B and exon 2, it is possible that this SNP may 
influence the usage of the splicing isoform. It is also possible that other causative SNPs in 
tight LD with rs7708392 may exist. Such a possibility would be addressed by resequencing 
the entire TNIP1 gene. TNIP1 is a shared SLE susceptibility gene in the Caucasian and Asian 
populations, but the genetic contribution appeared to be greater in the Asians because of the 
higher risk allele frequency in the population. 
7. Chromosome 6 
7.1 Major Histocompatibility Complex (MHC), (6p21.31) 
A body of evidence has been collected to establish the pivotal role of major 
histocompatibility complex (MHC) in immune tolerance. The classical MHC locus (6p21.3) 
3.6Mb contains at least 250 expressed genes. This locus is divided into the Class I and II 
regions that encode the antigen-presenting HLA proteins and Class III MHC that contains 
58 genes, located between Class I and II regions, only some its genes are of potential 
immunological interest (e.g. TNF-α and TNF-β, C4A, C4B and C2) and others which have 
poorly defined function. There is particularly strong linkage disequilibrium between genetic 
markers in this region which is strongly association with SLE in all GWA studies. It is 
therefore difficult to establish whether any associated variant is functional or simply 
observed due to linkage disequilibrium with functional polymorphisms elsewhere. It was as 
early as 1971 that Grumet et al. reported possible relationship between the HLA genes and 
SLE (Grumet, 1971). MHC alleles on 6p11–21 have shown the most significant association. 
Although the genetic structure of the MHC makes it a particularly challenging region to 
study, significant progress has been made over the last year. 
The Class II HLA genes are of particular importance, which encode antigen-presenting 
molecules that play a pivotal role in T-cell immunity. Most evidence has highlighted the DR 
loci, which are one of the Class II HLA gene complexes. The HLA-DRB1 gene is of particular 
importance in SLE. For the HLA-DRB1 gene, the serotype of DR2 holds the strongest 
evidence of disease association. Three class-II-containing-SLE-risk haplotypes (DRB1*1501 
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(Namjou, 2009). Functionally, either type I IFN or interleukin (IL)-12 induces 
phosphorylation of STAT4, which has a signal transduction role in these pathways. 
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therapeutic targets for SLE and the other autoimmune diseases in future. 
4. Chromosome 3 
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5. Chromosome 4 
5.1 BANK, BLK and LYN 
All three of these genes play a critical role in controlling the activation of B cells following 
signaling through the B-Cell Receptor (BCR). Following ligand binding and BCR 
aggregation, an early intracellular event is the recruitment and activation of Src-family 
protein tyrosine kinases, including BLK and LYN, which mediate further intracellular 
signaling. The exact role of these kinases in determining cellular events has yet to be 
determined with certainty. 
5.2 B-cell scaffold protein with ankyrin repeats (BANK1), (4q24) 
BANK1 is a B-cell scaffold protein that is tyrosine phosphorylated through the B-cell 
receptor (BCR) upon B-cell activation, which in turn associates with the tyrosine kinase Lyn 
(Src family of tyrosine kinase) and the calcium channel IP3R which results in calcium ion 
release from the stores of the endoplasmic reticulum (Yokoyama, 2002 & Kozyrev, 2008). 
BANK1 is thought to alter B cell activation to increase SLE risk. Polymorphisms in BANK1 
may cause B-cell hyper-responsiveness.  
GWAS in European-derived populations have identified associations of BANK1 and LYN 
with susceptibility to SLE (Kozyrev, 2008 & Guo, 2009). For BANK1 three functional 
variants with either a non-synonymous SNP (rs10516487; Arg61His), a branch point-site 
SNP (rs17266594; located in an intron) or a SNP in the ankyrin domain (rs3733197; 
Ala383Thr) might contribute to the sustained activation of B-cell receptors and the 
subsequent B-cell hyperactivity that is commonly observed in SLE (Kozyrev, 2008). 
However, the best functional evidence was found for rs17266594, which altered a branch 
point upstream of exon 2, resulting in the generation of a novel short isoform, but little 
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quantitative difference in BANK1 expression overall. With the exception of the rs10516487 
SNP of BANK1, which showed a weak association with SLE in an Asian GWAS, the 
remaining SNPS of BANK1 have not been confirmed in either Chinese or Asian GWAS, 
partly owing to the low frequencies of the SNPS in these populations (Chang, 2009). 
6. Chromosome 5 
6.1 TNIP1 (Tumor necrosis factor -induced protein 3 (TNFAIP3) interacting protein 1), 
also known as ABIN (A20-binding inhibitor of NF-B)-1, (5q32-q33.1) 
TNIP1 expression is induced by NF-B, and in turn, overexpression of TNIP1 inhibits NF-
B activation by TNF (Verstrepen, 2009). TNIP1 was shown to inhibit TNF-induced 
apoptosis independently of A20 (Oshima, 2009). Two recent GWAS revealed association of 
TNIP1 intronic SNPs rs7708392 and rs10036748, which are in strong linkage disequilibrium 
(LD) with SLE in the Caucasian (European-American and Swedish) and Chinese Han 
populations, respectively (Han, 2009 & Gateva, 2009). Association of TNIP1 with SLE was 
also confirmed in a Japanese population.  
To date, at least 11 splice variants of TNIP1have been identified (Verstrepen, 2009). Presence 
of alternative exon 1A and 1B, as well as splice variants lacking exon 2, has been described. 
Because rs7708392 is located between exon 1B and exon 2, it is possible that this SNP may 
influence the usage of the splicing isoform. It is also possible that other causative SNPs in 
tight LD with rs7708392 may exist. Such a possibility would be addressed by resequencing 
the entire TNIP1 gene. TNIP1 is a shared SLE susceptibility gene in the Caucasian and Asian 
populations, but the genetic contribution appeared to be greater in the Asians because of the 
higher risk allele frequency in the population. 
7. Chromosome 6 
7.1 Major Histocompatibility Complex (MHC), (6p21.31) 
A body of evidence has been collected to establish the pivotal role of major 
histocompatibility complex (MHC) in immune tolerance. The classical MHC locus (6p21.3) 
3.6Mb contains at least 250 expressed genes. This locus is divided into the Class I and II 
regions that encode the antigen-presenting HLA proteins and Class III MHC that contains 
58 genes, located between Class I and II regions, only some its genes are of potential 
immunological interest (e.g. TNF-α and TNF-β, C4A, C4B and C2) and others which have 
poorly defined function. There is particularly strong linkage disequilibrium between genetic 
markers in this region which is strongly association with SLE in all GWA studies. It is 
therefore difficult to establish whether any associated variant is functional or simply 
observed due to linkage disequilibrium with functional polymorphisms elsewhere. It was as 
early as 1971 that Grumet et al. reported possible relationship between the HLA genes and 
SLE (Grumet, 1971). MHC alleles on 6p11–21 have shown the most significant association. 
Although the genetic structure of the MHC makes it a particularly challenging region to 
study, significant progress has been made over the last year. 
The Class II HLA genes are of particular importance, which encode antigen-presenting 
molecules that play a pivotal role in T-cell immunity. Most evidence has highlighted the DR 
loci, which are one of the Class II HLA gene complexes. The HLA-DRB1 gene is of particular 
importance in SLE. For the HLA-DRB1 gene, the serotype of DR2 holds the strongest 
evidence of disease association. Three class-II-containing-SLE-risk haplotypes (DRB1*1501 
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(DR2)/DQB1*0602, DRB1*0301) (DR3)/DQB1*0201, and DRB1*0801 (DR8)/DQB1*0402) are 
consistently associated with SLE in Caucasian populations by family-based TDT (van der 
Linden, 2001). 
Within the MHC class III region, there are genes that encode TNF-α and -β, lymphotoxin-β, 
complement components C2 and C4, and heat shock protein 70 (Hsp70). In particular, TNFs, 
C2, and C4 have been implicated in SLE susceptibility. TNF-α is a multifunctional 
proinflammatory cytokine involved in regulating a wide spectrum of biological processes 
including cell proliferation, differentiation, and apoptosis, while TNF-β mediates a variety 
of inflammatory, immunostimulatory, and antiviral responses. Polymorphisms in these 
genes have been implicated in SLE susceptibility (Pan 2011 & Bettinotti, 1993). 
Complement component genes within the MHC class III region include C2, C4A, C4B, and 
factor B. These genes are closely linked and are usually inherited as a group known as 
complotype. Deficiencies in complement pathway genes C2, C4, C1q and C3 appear to cause 
SLE in some people (Kallel-Sellami, 2008). Polymorphisms in C2, C4A and C4B are in 
linkage disequilibrium with HLA-B and HLA-DR alleles (Alper, 2007) and may predispose 
to SLE. Also the complete deficiencies of the early components are highly associated with 
human SLE (Yu, 2007). A homozygous deficiency in one of the early complement 
components, including C1q, C1r, C1s and C4 in the classical activation pathway, alone can 
be strong enough to cause the disease, a situation similar to a single gene defect in an 
autosomal recessive disease. Respectively, 93% and 78% of patients with complete C1q and 
C4 deficiencies eventually develop SLE or a lupus-like disease (Yu, 2007 & Botto, 2002). In 
addition, the concordance rates for siblings with homozygous deficiency of C1q or C4 to 
develop SLE are 90% and 80%, respectively, which are even higher than the rate in 
monozygotic twins (26–60%) with other genetic defects (Tsao, 2008). Complete deficiency of 
complement C4 is among the strongest genetic risk factors for human systemic lupus 
erythematosus (SLE). Further work will be required to determine the effect arising from 
C4A. C4 is the most polymorphic protein of the complement system. It is encoded by two 
genes, C4A and C4B, which have minor sequence differences. The resulting proteins have 
different functional characteristics, with C4A better able to bind immune complexes 
(Schifferli, 1986). The C4 genes are inherited in a discrete ‘RCCX module’, which contains 
one C4 gene (either C4A or C4B) along with three neighboring genes (RP, CYP21 and TNX) 
(Yang, 1999). The Class III MHC carries between one and four copies of this module; hence 
each diploid genome has between two and eight C4 genes, which may be either C4A or C4B 
(Yang, 2007). Carrying less than two copies of C4A has been identified as a risk factor for 
SLE (Yang, 2007). 
The common European haplotype AH8.1 carries multiple variants that have been associated 
with SLE including DRB1*0301 (DR3), the TNF -308A allele and the C4A complement null 
allele. Many studies were unable to break down this haplotype below a 1Mb interval 
covering most of the Class II and II regions (Alper, 2007).  
7.2 PR domain containing 1, with ZNF domain - APG5 autophagy 5-like (PRDM1-ATG5 
region), (6q21) 
PRDM1 acts as a repressor of beta-interferon gene expression. The protein binds specifically 
to the PRDI (positive regulatory domain I element) of the beta-IFN gene promoter. While, 
the ATG5 candidate gene function is still obscure and needed to be determined however, 
both known to play important roles in immunity. Genome-wide association studies 
suggested the PRDM1-ATG5 gene region as a systemic lupus erythematosus (SLE)-
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associated locus both in Caucasian and Asian populations, presumably through 
upregulating gene expression (Zhou, 2011; Harley, 2008; Gateva, 2009; Han, 2009). 
Significant positive correlations with ATG5 expression were identified, suggesting ATG5 as 
a candidate gene in the region (Harley, 2008). Later GWAS from a Chinese population 
denied the association between polymorphisms in ATG5 and SLE, but replicated the 
association between the intergenic region of PRDM1-ATG5 (rs548234 and rs6568431) and 
SLE ((Han, 2009). At the same time, from Caucasian replication data, both PRDM1 
(rs6568431) and ATG5 (rs2245214) were suggested as candidate genes, because rs6568431 
was more close to PRDM1 and rs6568431 has an r2 of less than 0.1 with rs2245214. Meta-
analysis consolidated the association between rs548234 and SLE (p=1.28×10-16).  
7.3 Tumor necrotic factor α-induced protein 3 (TNFAIP3), 6q23 
The gene product of TNFAIP3 is a zinc-finger A20 protein, a ubiquitin-modifying enzyme, 
which is essential for proteasome degradation and termination of proinflammatory 
responses mediated by nuclear factor kappa B, thereby preventing inflammation. In 
humans, genetic surveys have suggested a role for TNFAIP3 in susceptibility to complex 
genetic autoimmune disorders, including systemic lupus erythematosus (SLE) (Graham, 
2008; Musone, 2008; Bates, 2005; Han, 2009). 
Genetic association between variants in TNFAIP3 and SLE suggest that alterations in activity 
and/or expression of TNFAIP3 influence SLE pathophysiology (Graham, 2008; Musone, 
2008; Bates, 2005; Han, 2009). Independent genetic associations of SLE and TNFAIP3 in 
European-ancestry (EA) subjects have been localized to a region 185 kb upstream of 
TNFAIP3 that was first identified with rheumatoid arthritis (Plenge, 2007; Thomson, 2007; 
Plenge, 2007), a region 249 kb downstream of TNFAIP3 and a 109 kb haplotype spans the 
TNFAIP3 coding region (Musone, 2008; Bates, 2005; Han, 2009) that includes a suggested 
causal coding variant in exon 3 (rs2230926 T>G; F127C) that reduces the ability of A20 to 
attenuate NF-κB signaling (Musone, 2008). 
Evidence for association with SLE was observed also for a variant within TNFAIP3 
(rs5029939, GWAS P value = 2.55×10−8) and two flanking SNPs (rs10499197, GWAS P  
value = 2.11×10−6; rs7749323, GWAS P value = 9.63×10−7) in strong LD with rs5029939 
(r2>0.95). A SNP located ∼185 kb upstream of TNFAIP3 reported to be associated with risk 
for RA (204,206) (rs6920220) demonstrated modest association in the SLE GWAS dataset 
(GWAS P value = 0.01) 
By fine mapping and genomic resequencing in ethnically diverse populations Adrianto I et 
al, fully characterized the TNFAIP3 risk haplotype and isolated a novel TT>A polymorphic 
dinucleotide (deletion T followed by a T to A transversion) associated with SLE in subjects 
of European (P = 1.58 × 10−8) and Korean (P = 8.33 ×10−10) ancestry (Adrianto, 2011). This 
variant, located in a region of high conservation and regulatory potential, bound a nuclear 
protein complex comprised of NF-κB subunits with reduced avidity. Furthermore, 
compared with the non-risk haplotype, the haplotype carrying this variant resulted in 
reduced TNFAIP3 mRNA and A20 protein expression. These results establish this TT>A 
variant as the most likely functional polymorphism responsible for the association between 
TNFAIP3 and SLE (Adrianto, 2011). 
One hundred and twenty seven (127) SNPs in the region of TNFAIP3 on 6q23 and 347 
ancestry informative markers (AIMs) in five diverse ethnic populations were analyzed by 
Adrianto I et al, They discovered a peak associations in European and Asian populations 
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were seen at markers rs6932056 and rs4896303 in 38 kb and 30 kb downstream of TNFAIP3, 
respectively (Adrianto, 2011). 
8. Chromosome 7 
8.1 Interferon regulatory factor 5 gene (IRF5), 7q32 
IRF5 is one of the key genes of the interferon (IFN)-α pathway. IRF5 is a transcription factor 
that is responsible for the innate immune response during viral infection. IRF5 is important 
for trans-activation of type 1 IFN and IFN-responsive genes and for the production of pro-
inflammatory cytokines interleukins such as; IL-6, IL-12, and tumor necrosis factor- (TNF)] 
after toll like receptor (TLR) signaling induced by immune complexes containing self-
antigens and nucleic acids (Takaoka, 2005). IRF5 is one of the most strongly and consistently 
SLE-associated loci outside the MHC region in various ethnic groups and was detected 
using both candidate gene and GWAS approaches (Lee, 2009). Interest in type 1 (IFN- and -
) IFN pathways was stimulated by the discovery that there is a general up-regulation IFN-
inducible genes in SLE (Baechler, 2003 & Bennett, 2003). The best current genetic model 
proposes an SLE risk haplotype carrying multiple functional SNPs. Several SNPs in IRF5 
(rs2004640, rs752637, rs729302, rs10954213etc.) were first found to be associated with SLE in 
Caucasians (Niewold, 2008; Kim, 2009). 
In vitro functional evidence exists for at least two of these polymorphisms at SNP 
(rs2004640) creates a novel splice site in exon1B allowing the expression of a novel IRF5 
isoform (Graham, 2006 & Sigurdsson, 2005) while the second polymorphism (rs10954213) 
located in the 3’ UTR creates a functional polyadenylation site and hence a shorter and 
more stable gene transcript (Cunninghame, 2007). To our knowledge, the most consistent 
evidence of association for this gene with SLE, across different populations including, was 
observed in the rs2004640 T allele. A meta-analysis has been conducted to study the 
association of the rs2004640 T allele with SLE; it included 12 studies in Europeans and 
Asians, it has been concluded that this polymorphism is associated with SLE 
susceptibility across different ethnic groups (Lee, 2009). In addition, the gene has a 
polymorphic 30 bp indel (insertion/deletion) in exon 6, which contributes to the diversity 
in the isoform pattern of IRF5, and a 5 bp indel near the 5'UTR upstream of exon 1A 
(Sigurdsson, 2008 & Dideberg, 2007). 
To understand how IRF5 variants may predispose to SLE we need to understand the 
physiological role of the Type 1 IFN pathways. The majority of cells produce Type 1 IFNs as 
part of their early response to viral infection. Particularly large amounts are produced by 
plasmacytoid dendritic cells, perhaps stimulated by the recognition of viral RNA and DNA 
through TLR7 and TLR9. In SLE, it is possible that this is also triggered in response to 
inadequately cleared nucleic acid antigens released from apoptotic cells (Ronnblom, 2002). 
Type 1 IFNs exert a multitude of downstream effects on the immune system. Perhaps 
critically, they stimulate Th1 pathways and sustain activated T cells, while also lowering the 
threshold for B-cell activation through the B-cell receptor (BCR) and promoting B-cell 
survival and differentiation (Ronnblom, 2002; Braun, 2002; Le Bon, 2001; Marrack, 1999). It 
can therefore be seen that genetic variants that prolong or alter the actions of IRF5 could 
result in a prolonged proinflammatory response, and potentially break immunological 
tolerance. Interestingly, IRF5 signaling has also been shown to play a role in the regulation 
of cell cycle and apoptosis raising the possibility that susceptibility variants of IRF5 exert 
their effects at multiple levels (Barnes, 2003). 
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8.2 Ikaros zinc finger 1(IKZF), 7p12.2 
IKZF1 encodes a lymphoid restricted zinc finger transcription factor named Ikaros, which is 
critically important for the normal development of all lymphoid cells. It regulates 
lymphocyte differentiation and proliferation (Georgopoulos, 1994), as well as self-tolerance 
through regulation of B-cell receptor signaling (Wojcik, 2007). Data derived from both 
GWAS and large replication studies identified IKZF1 as a novel SLE susceptibility locus in 
Chinese and European-derived populations (Han, 2009). Yap et al. reported that IKZF1 was 
involved in the regulation of STAT4 in human T cells, which suggested that STAT4 and 
IKZF1 might cooperate with each other and play roles in the development of SLE (Yap, 
2005). Hu W. et al, demonstrated that IKZF1 mRNA expression levels in PBMCs from 
patients with SLE were significantly lower than those in healthy controls (Hu, 2011). 
Association of SLE and disease phenotype with IKZF1 was studied in Chinese Han origin 
SLE patients were the allele frequency of rs4917014 (IKZF1) was significantly different in 
two subphenotypes: renal nephritis (p=0.02) and malar rash (p=0.00038) (He, 2010). 
9. Chromosome 8 
Several studies have revealed association of SLE susceptibility to different genes within a 
700 kb region of locus 8p23.1 (Hom, 2008; Graham, 2008; Harley, 2008). This region contains 
several candidate genes, including BLK, XKR6, FAM167A/C8orf13 and C8orf12, these genes 
were in significant linkage disequilibrium (LD), making it difficult to determine whether the 
different reports are detecting the same association signal. Budarf ML et al. found significant 
association to both the BLK (rs2618476) and XKR6 (rs6985109) genes (Budarf, 2011). 
Although these two SNPS are separated by 620 kb, there is relatively strong correlation 
between them (r2=0.39), allowing the possibility that they may represent the same signal. 
Here in we will review the evidence of association of both genes BLK, XKR6 with 
susceptibility to SLE (Budarf, 2011).   
9.1 B lymphoid tyrosine kinase (BLK), 8p23.1 
BLK encodes a nonreceptor tyrosine-kinase of the src family of proto-oncogenes, which 
mediates intracellular signaling and influences cell proliferation and differentiation. The 
human BLK gene was mapped to chromosome 8 at p23.1, and is expressed only in B 
lymphocytes (Drebin, 1995). The protein has a role in B-cell receptor signaling, B-cell 
development and tolerance of B cells (Reth, 1997). B cell receptor (BCR) signaling requires a 
tight regulation of several protein tyrosine kinases and phosphatases, and associated co-
receptors. Break of the balance between positive and negative signaling molecules likely 
modifies the BCR signaling thresholds. Such alterations, together with other factors, may 
contribute to the disruption of selftolerance in SLE. 
BLK has apparently become one of the most important and consistent non-MHC gene for 
SLE and the other autoimmune diseases across multiple ethnic groups and is one of three 
key genes (BLK, LYN and BANK) involved in BCR signaling found to be strongly associated 
with SLE proves the importance of this pathway in disease pathogenesis. B-lymphoid 
tyrosine kinase (BLK) was one of the top hit in more than one GWA analyses, while LYN 
was associated with high significance in the International Consortium for Systemic Lupus 
Erythematosus (SLEGEN) study only. BLK has been implicated in the pathogenesis of SLE 
and has been investigated in numerous ethnically diverse studies. 
GWAS in European-derived populations identified a SNP (rs13277113; located in the 
promoter region of BLK, maps to the intergenic region between FAM167A/C8orf13 and 
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BLK), of which allele A is associated with reduced expression of BLK but increased 
expression of FAM167A (previously referred to as C8orf13) in patients with SLE (Ito, 2010). 
Another BLK SNP (rs2248932), located 43 kb downstream of rs13277113, is also associated 
with SLE where the risk C allele of rs2248932 was associated with the lower levels of BLK 
mRNA expression (Zhang, 2010).  
Both SNPs have subsequently been confirmed as SLE-associated in Asian populations 
(Zhang, 2010 & Ito, 2009). Genotyping SNP rs2248932 in SLE patients of Chinese Han 
confirmed that SNP rs2248932 in BLK gene was significantly associated with SLE (P = 1.41 
x 10-8). The association of BLK in Chinese SLE patients was consistent with a dominant 
model. In contrast to the Caucasian, this risk allele was the major allele in the Chinese 
Han; the risk allele frequency was higher in Chinese Han than in Caucasian. No 
association was found between this SNP and any subphenotype of SLE.  Fan et al 
performed a meta-analysis to test the association of two SNPs rs13277113 and rs2248932. 
A significant associations of rs13277113 and SLE were observed for dominant model 
(AA + AG vs. GG, OR: 1.518), and recessive model (AA vs. AG + GG, OR: 1.553); so were 
rs2248932 and SLE for dominant model (TT + TC vs. CC, OR: 1.34), and recessive model 
(TT vs. TC + CC, OR: 1.34) (Fan, 2010).   
9.2 X Kell blood group precursor-related family, member 6 (XKR6), 8p23.1 
XKR6, a member of a novel family of PDZCBM containing proteins sharing homology 
with the C. elegans gene ced-8, which has been implicated in regulating the timing of 
apoptosis (Giallourakis, 2006). XKR6 contains an intronic microRNA, hsa-miR-598,  
which is highly expressed in human peripheral blood mononuclear cells, especially 
activated B-cells (Lawrie, 2008). Dissecting the relative contribution of XKR6 to SLE risk  
is likely to be a complicated undertaking, especially given that a polymorphic inversion 
under apparent selection pressure on 8p23 encompasses the XKR6, C8orf12, C8orf13,  
and BLK genes, all of which have been implicated in SLE risk in GWAS studies  
(Deng, 2008). 
9.3 Yamaguchi sarcoma viral (v-yes-1) related oncogene homolog, LYN, 8q12.1 
LYN is a Src-tyosine kinase involved in B cell activation by phosphorylating the ITAM 
domain of the BCR-associated Ig α/β signaling molecules, in turn recruiting and activating 
the tyrosine kinase SYK, which initiates multiple activating signals. LYN also mediates 
inhibitory signals by phosphorylating inhibitory receptors such as CD22 and FcRIIb and 
may therefore have a critical role as a modulator of B-cell activation thresholds. In the 
Genome wide association studies (GWAS) of SLE, three B cell signaling molecules BLK, LYN 
and BANK1 (Hom, 2008; Kozyrev, 2008) were found to be associated with SLE. The best 
characterized functionally is LYN among the other two kinases (BANK, BLK) shown to be 
associated with SLE. These data suggest that aberrant regulation of B cell signaling may be 
one mechanism for generating hyper-responsive B cells, which might lead to aberrant B cell 
development, selection and ultimately influence the production of autoantibodies. 
Expression of Lyn is significantly decreased in both resting and BCR stimulated 
peripheral blood B cells from two-thirds of SLE patients compared to controls (Liossis, 
2001). Further, statistically significant alterations at the transcriptional level were 
confirmed by a 2.5-fold decrease in Lyn mRNA in SLE patients compared to healthy 
individuals. Another group analyzed the level and subcellular distribution of Lyn in SLE 
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B cells and found that slightly more than half of the SLE patients analyzed had reduced 
levels of Lyn protein, which was subsequently determined to be due to increased 
ubiquitination of the protein. Functional differences in LYN ubiquitination have been also 
associated with SLE risk (Flores-Borja, 2005). 
Two SNPs, rs7829816 and rs2667978, showed significant association in some of the cohorts 
tested, but failed to consistently replicate in all cohorts (Harley, 2008). Lu R. et al has 
performed one of the largest studies to examine the possible genetic association of LYN with 
SLE in multiple large populations of different ancestries (European-derived, African 
American and Korean). Their study has replicated a previously observed association with 
rs7829816 (Harley, 2008), however, data from Lu R. et al study suggested that this 
association is not a dominant lupus effect. The strongest and most consistent association 
found in this study was at rs6983130, which is within the first intron at the 5′ end near the 
primary transcription initiation site. This SNP showed the strongest association in the 
European-American female population. A strong gender influence was found with this SNP 
when analyzing only female subjects. Rs6983130 also showed associations with 
autoantibodies which is strongly associated with the development of SLE, specifically anti-
dsDNA, anti-chromatin, anti-52 kDa Ro and anti-Sm. 
10. Chromosome 10 
10.1 Mannose-Binding Lectin (MBL), (10q11.2-21) 
MBL is very similar to C1q in its structure and function. It is an important element of the 
innate immune system. MBL comprises a trimer of three identical polypeptides, and 
several trimmers further combine to form a bouquet-like structure (Holmskov, 1994). MBL 
recognizes carbohydrate patterns, found on the surface of a large number of pathogenic 
micro-organisms, including bacteria, viruses, protozoa and fungi and initiates the lectin 
pathway for opsonization and clearance of pathogens in an antibody-independent 
manner.  
MBL gene comprising four exons and there is only one single functional gene. The normal 
structural MBL alleles is named A, while the common designation for the 3 variant 
structural allele B (Gly54Asp), C (Gly57Glu) and D (Arg52Cys) are O. MBL expression is 
influenced by polymorphic sites in the upstream part of the MBL gene nucleotides 
substitutions at positions -550, -221 and +4. Absent or low levels of serum MBL is a result of 
these polymorphisms and might be associated with the development of SLE (Takahashi, 
2005 & Pradhan, 2010). Case-control genetic studies of MBL polymorphism were performed 
in various Ethnic groups. MBL genotyping in SLE confirmed that the MBL functional 
variants are associated with SLE (Ramasawmy, 2008). Serum MBL levels fluctuate during 
the course of SLE disease activity and MBL genotypes have been found to be useful in 
assessing the risk of infection during immunosuppressive treatment the majority of the SLE 
patients receive. 
Two possible explanations for associations between MBL deficiency and occurrence of SLE 
were proposed (Korb, 1997): (a) MBL can bind to and initiate uptake of apoptotic cells into 
macrophages (Ogden, 2001 & Okada, 2002), and abnormal clearance of apoptotic cells 
caused by MBL deficiency may result in overexpression of autoantigens; (b) viral infection is 
believed to be one of the causes of SLE (Okada, 2002), and MBL deficiency may lead to more 
frequent infections. 
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11. Chromosome 11 
11.1 Interferon regulatory factor 5 /PHD and RING-finger domains 1(IRF7/ PHRF1) 
locus, 11p15.5 
IRF7 is a transcription factor that can induce transcription of IFNα and in turn IFNα-induced 
genes downstream of endosomal TLRs, similar to IRF5 (Barnes, 2004). A SNP near IRF7 was 
found to be associated with SLE susceptibility in the International Consortium for SLE 
Genetics (SLEGEN) genome-wide association study (Harley, 2008). The associated SNP 
(rs4963128) was located 23 kb telomeric to IRF7 in a gene of unknown function named PHD 
and RING-finger domains 1 (PHRF1; also known as KIAA1542 or CTD-binding SR-like 
protein rA9). This SNP was in high linkage disequilibrium (r2 = 0.94) with the rs702966 SNP 
in IRF7 (Harley, 2008). The PHRF1 gene contains PHD-finger and RING-finger domains, 
and has not been functionally characterized to date. PHD and RING-finger domains both 
chelate zinc ions, and PHD domains are frequently found in proteins which mediate 
protein–protein interactions in the cell nucleus (Bienz, 2006). 
There is a hypothesizes that the SLE-associated variant discovered in the IRF7/PHRF1 locus 
in the SLEGEN study (International Consortium for Systemic Lupus Erythematosus 
Genetics, 2008) could be due to a polymorphism in IRF7 that predisposes to increased IFNα 
production. Then, Salloum R. et al have proven this hypothesis by analyzing serum IFNα in 
SLE patients as a quantitative trait to determine associations with haplotype-tagging SNPs 
in the IRF7/PHRF1 locus (Salloum, 2009). In a joint analysis of European American and 
Hispanic American subjects, the rs702966 C allele was associated with the presence of anti–
double-stranded DNA (anti-dsDNA) antibodies (P=0.0069). The rs702966 CC genotype was 
only associated with higher serum levels of IFNα in European American and Hispanic 
American patients with anti-dsDNA antibodies (joint analysis P = 4.1 × 10−5) (International 
Consortium for Systemic Lupus Erythematosus Genetics, 2008). However, the rs702966 C 
allele was not associated with anti-dsDNA in the African American subjects, and no other 
significant associations were seen in this group. In African American patients, the rs4963128 
T allele downstream of IRF7 was associated with the presence of anti-Sm antibodies  
(P = 0.0017), where subjects with the rs4963128 CT and TT genotypes had higher IFNα levels 
than those with the CC genotype (P = 0.0012). The striking differences observed within the 
African American cohort separated by the presence or absence of anti-Sm antibodies suggest 
2 independent patterns of association with IRF7/PHRF1 variants, which cannot be 
explained by European admixture at the locus. It is possible that the rs4963128 T allele 
marks a particular element in African-derived chromosomes that associates with anti-Sm 
antibodies and is not present in the other ancestral backgrounds (Salloum, 2009). Salloum R. 
et al hypothesized that the rs702966 C allele and elements in linkage with it may function 
similarly across all ancestral backgrounds, although the effect of the anti-Sm–rs4963128 T 
allele interaction on serum levels of IFNα in African Americans is independent of the effect 
at the rs702966 C allele (Salloum, 2009). 
12. Chromosome 16 
12.1 Integrin αM (ITGAM), 16p11.2 
ITGAM is a single-pass type I membrane protein predominantly expressed primarily on 
neutrophils, macrophages and dendritic cells that is involved in various adhesive 
interactions to stimulated endothelium, and also in the phagocytosis of complement coated 
particles. Together with integrin chain β2, ITGAM forms a functionally active heterodimer, 
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the integrin αMβ2 molecule to form the cell surface receptor, known as complement 
receptor 3 (CR3) or Mac-1, can bind a variety of ligands including intercellular adhesion 
molecule 1 (ICAM-1), the C3bi fragment of activated complement C3, fibrinogen, and factor 
X. ITGAM is perhaps more familiarly known as CD11b or CR3, and it thereby takes part in 
the uptake of complement-coated particles and the clearance of immune complexes. 
The identification of ITGAM as a major susceptibility gene was perhaps the greatest surprise 
of the GWA analyses because it has been subject to expression studies in the past with little 
convincing evidence for a role in SLE (Harley, 2008 & Hom, 2008). A non-synonymous SNP 
in ITGAM, rs1143679, functional mutation results in an Arg77His (R77H), was first 
associated in European and African descendants SLE patients, where the G allele 
contributes to disease susceptibility (Nath, 2008 & Han, 2009). This amino acid does not lie 
within any known ligand binding site, but may alter the confirmation of the  I/A domain to 
which many ligands do bind. This variant could therefore influence leucocyte trafficking 
mediated via ICAM-1, or equally it could influence the CR3-mediated uptake of apoptotic 
cells or immune complexes. Functional data is awaited with interest. However, the 
consistent association of rs1143679 was not replicated in Asian population (Korean and 
Japanese) because this SNP was monomorphic for ‘G’ allele (Han, 2009). This result suggests 
that the genetic association of ITGAM with SLE is unlikely in Asians. However, another 
group studied Chinese SLE patients living in Hong Kong and found that rs1143679 was 
associated with SLE, and another related SNP in the gene, rs1143683, was also identified 
(Yang, 2009). Therefore, it needs to be confirmed in larger number of SLE case–controls in 
Korean and Japanese populations. 
12.2 Deoxyribonuclease DNase I, 16p13.3 
DNase I may be the most important nuclease for the removal of DNA from nuclear 
antigens. Several lines of evidence suggest that defects in DNase I activity play a role in SLE 
pathogenesis. Studies in SLE patients and in mouse models support the involvement of 
DNase I among the genes involved in the clearance of apoptotic cells. The first evidence was 
reported by Chitrabamrung et al. (Chitrabamrung, 1981) more than two decades ago. These 
authors found decreased DNaseI activity in patients with SLE. It has been shown that a 
DNaseI knockout mouse develops a lupus-like syndrome (Napirei, 2000) and a nonsense 
mutation on the DNASEI gene leading to a non-functional protein has been identified in two 
Japanese girls with SLE. These girls had very low DNaseI activity and high titers of anti-
nucleosome and anti-double-stranded DNA (dsDNA) antibodies. Subsequent analysis of 
several series of SLE patients from different populations showed that this mutation is 
extremely rare. Bodan˜o A et al., have described two Spanish SLE patients with very low 
serum DNase I activity harboring three new mutations in the DNASEI coding sequence that 
account for the reduced enzymatic activity (Bodan˜ o, 2004). The frequency of these new 
mutations was below 1% both in SLE patients and in the population. Bodan˜o A. et al. also 
found other DNASEI single-nucleotide polymorphisms (SNPs) but there was no evidence 
suggesting a functional role for them. These studies support the involvement of DNase I in 
the pathogenesis of SLE. 
In a Korean SLE population, 16 SNPs from the DNaseI were studied using a case–control 
approach. In parallel, common autoantibodies were also examined for the same population. 
None of the SNPs were in significant association with SLE, however, a non-synonymous 
SNP in exon 8, namely rs1053874 (which was also known as +2373A/G, and which causes 
Gln244Arg substitution), was significantly associated with an increased risk of the 
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production of anti-RNP and anti-dsDNA (Shin, 2004). However, the same SNP (+2373A/G) 
has shown association between the GG allele and SLE susceptibility in Spanish population, 
but no association with the majority of antinuclear antibodies (anti-dsDNA, anti-ssDNA and 
anti-RNP) and no effect on DNase I activity (Bodaño , 2006). This discrepancy could be 
related to heterogeneity between the populations. 
13. Chromosome 17 
13.1 Monocyte chemo-attractant protein 1 (MCP1), 17q11.2-12 
MCP-1, currently also designated CCL2, encodes a β-chemokine that recruits monocyte, 
eosinophils, and memory T cells to inflammatory sites, to regulate adhesion molecule 
expression and T-cell functions in acute and possibly chronic inflammation (Charo, 2004). 
Evidence in human and animal studies suggests a significant role of MCP-1 in the 
progression of glomerular and tubulointerstitial injuries and glomerulonephriti in patients 
with SLE (Stahl, 1993; Rovin, 1996; Saitoh, 1998; Rovin 1998). In particular, MCP-1 has been 
shown to be pathogenic for kidney injury in murine lupus nephritis (Shimizu, 2004), and 
reported to be involved in glomerulonephritis in SLE patients, in which elevation of serum 
MCP-1 correlates with disease activity (Tesar, 1998). An increased urine MCP-1 (uMCP-1) 
level was detected in SLE patients during active renal disease (Rovin, 2005). 
SNP (rs1024611) -2518A/G and G/G in MCP1 promoter region may modulate the levels of 
MCP-1 expression and increased susceptibility to SLE and lupus nephritis in patients from 
North America (Tucci, 2004). However, the Involvement of the MCP-1 –2518 A>G promoter 
polymorphism in SLE development and its contribution to some clinical manifestations of 
SLE remains controversial (Tucci, 2004; Aguilar, 2001; Hwang, 2002; Kim, 2002; Brown, 2007; 
Liao, 2004; Ye, 2005). In a Spanish study for example, −2518G polymorphism is noted to be 
associated with cutaneous vasculitis but not SLE or lupus nephritis as genotyping of 
−2518A/G polymorphism shows no difference in allelic or genotype frequencies in SLE 
patient and healthy controls (Aguilar, 2001). Further investigation is needed to delineate if 
ethnic heterogeneity contributes to this gene polymorphism and SLE susceptibility. 
14. Chromosome 19 
14.1 Tyrosine kinase 2 (TYK2), 19p13.2 
TYK2 is part of the Janus kinase that binds to the interferon (IFN)- receptor (IFNAR),  
on the cell surface of IFN-producing cells. Binding of IFN- to its receptor, leads to  
the phosphorylation and therefore activation of TYK2 (Richter, 1998). Active TYK2  
then phosphorylates IFNAR to allow binding of STAT3 and STAT5 (David, 2002) which 
leads to expression of IFN-α. Deficiency of TYK2 leads to defects of multiple cytokine 
pathways, including type I interferon, IL-6, IL-10, IL-12, and IL-23, and to impaired T-
helper type 1 differentiation and accelerated T helper type 2 differentiation (Minegishi, 
2006). More research needed to clarify which of these pathways is critically affected by the 
TYK2 risk allele.  
TYK2 gene has been linked to the formation of anti-dsDNA antibodies of Caucasian SLE 
patients (Namjou, 2002). TYK2 rs2304256 was associated with increased risk of discoid lupus 
erythematosus (P=0.012). In a joint linkage and association study of 44 SNPs in 13 genes 
from type I IFN pathway in the Scandinavian population, TYK2 and interferon regulatory 
factor 5 (IRF5) genes displayed strong association with SLE susceptibility (Sigurdsson, 2005). 
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The most remarkable result from this study has probably been the association signal 
observed with the rs2304256 nonsynonymous SNP of TYK2 (OR = 0.79) because this has 
been a controversial SLE genetic factor. The rs2304256 SNP introduces a valine to 
phenylalanine change in the Janus homology domain 4 of TYK2 whose functional relevance 
has not yet been tested. This nonsynonymous SNP showed the strongest association among 
the 11 TYK2 SNPs studied in Scandinavian families (Sigurdsson, 2005), but was not 
associated in a study of UK families (Cunninghame, 2007). This latter study, however, found 
association with another TYK2 SNP (rs12720270) that was not associated in the 
Scandinavian study. Finally, the International Consortium for Systemic Lupus 
Erythematosus Genetics (SLEGEN) GWA study excluded association with the rs12720270 
SNP (the rs2304256 SNP was not included in the GWA panels)( International Consortium 
for Systemic Lupus Erythematosus Genetics, 2008).  
TYK2 single nucleotide polymorphisms (SNPs), rs2304256, rs12720270 and rs280519, were 
genotyped in the Japanese population by Kyogoku C et. al. in a case-control association 
study. Linkage disequilibrium (LD) among TYK2 SNPs was examined and no association 
was revealed with SLE therefore it was concluded that TYK2 is not a genetic risk factor for 
SLE in a Japanese population (Kyogoku, 2009). 
15. Chromosome X 
15.1 Interleukin-1 receptor-associated kinase 1/Methyl-CpG-binding Protein 2 locus 
(IRAK1/MECP2), Xq28 
IRAK1, a serine–threonine protein kinase, regulates multiple pathways in both innate and 
adaptive immune responses by linking several immune-receptor- complexes to TNF 
receptor-associated factor 6 in mouse models of lupus, Irak1 is shown to regulate nuclear 
factor κB (NFκB) in TCR signaling and Toll/interleukin-1 receptor (TLR) activation, as well 
as the induction of IFN-α and IFN-γ, (Jacob, 2009) implicating IRAK1 in SLE. In a study of 
four different ethnic groups, multiple SNPs within IRAK1 were associated with both adult-
onset and childhood-onset SLE (Jacob, 2009). The identified polymorphism C203S in IRAK1 
is not in any known functional domain, therefore it was suggested that the association may 
actually be with its neighbor, methyl-CpG-binding protein 2 (MECP2). 
MECP2 is an X-linked gene located in a region of LD with IRAK1, encoding a protein that 
represses transcription from methylated promoters, has also been associated with lupus. 
Polymorphisms in MECP2 may have relevance to the epigenetic DNA methylation changes 
found in lupus and discussed below. There is evidence for altered methylation in SLE, 
(Webb, 2009) as well as differential expression of potentially methylated genes, (Pan, 2009) 
although, as with IRAK1, a contributing causative SNP is not immediately obvious. Indeed, 
it is possible that both of these strong candidates contribute to the effect. 
A large replication study in a European-derived population confirmed the importance of 
this region (IRAK1–MECP2) to SLE. The location of IRAK1 and MECP2 on the X 
chromosome raises the possibility that gender bias of SLE might, in part, be attributed to sex 
chromosome genes. Further work is required to identify the causal variants (Sestak, 2011). 
15.2 Toll-like receptor (TLR7), Xp22.2 
TLR7, the protein encoded by this gene is a member of the Toll-like receptor (TLR) family 
which is single transmembrane cell-surface receptors expressed on many types of cells 
including macrophages and dendritic cells, plays a fundamental role in pathogen 
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production of anti-RNP and anti-dsDNA (Shin, 2004). However, the same SNP (+2373A/G) 
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MCP-1 correlates with disease activity (Tesar, 1998). An increased urine MCP-1 (uMCP-1) 
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the phosphorylation and therefore activation of TYK2 (Richter, 1998). Active TYK2  
then phosphorylates IFNAR to allow binding of STAT3 and STAT5 (David, 2002) which 
leads to expression of IFN-α. Deficiency of TYK2 leads to defects of multiple cytokine 
pathways, including type I interferon, IL-6, IL-10, IL-12, and IL-23, and to impaired T-
helper type 1 differentiation and accelerated T helper type 2 differentiation (Minegishi, 
2006). More research needed to clarify which of these pathways is critically affected by the 
TYK2 risk allele.  
TYK2 gene has been linked to the formation of anti-dsDNA antibodies of Caucasian SLE 
patients (Namjou, 2002). TYK2 rs2304256 was associated with increased risk of discoid lupus 
erythematosus (P=0.012). In a joint linkage and association study of 44 SNPs in 13 genes 
from type I IFN pathway in the Scandinavian population, TYK2 and interferon regulatory 
factor 5 (IRF5) genes displayed strong association with SLE susceptibility (Sigurdsson, 2005). 
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recognition and activation of innate immunity. TLRs generally exist as homodimers. They 
are highly conserved from Drosophila to humans and share structural and functional 
similarities. TLR are activated by molecules associated with biological threat and are highly 
specific towards evolutionary conserved entities on microbes, such as bacterial cell-surface 
lipopolysaccharides, flagella and unmethylated CpG islands.  
Activation of toll-like receptors initiates downstream signaling cascades, initially via the 
adapter molecules MyD88, Trap, Trif and Tram, leading to NF-kappa-B activation, cytokine 
secretion and the inflammatory response, regulate intracellular kinases and gene expression. 
The signaling cascade coupled to toll-like receptor activation is very similar to that of 
interleukin-1 receptor (IL-1R) activation. It has been suggested that some toll-like receptors 
may have endogenous ligands, such as Hsp60 and fibrinogen, and this has promoted 
speculation that endogenous toll-like receptor activators may have a pathological role in 
autoimmune disease. TLRs play an important role in the pathogenesis of SLE (Vollmer, 2005 
& Christensen, 2006). The role of nucleic acid binding TLR7 has become quite apparent in 
both SLE animal models and human patients. This receptor promotes autoantibodies and 
cytokines responsible for chronic inflammation (Christensen, 2007 & Savarese, 2008). A 
recent fine mapping of the 23-kb TLR7 region using 11 SNPs in 1434 SLE cases of Eastern 
Asian descent versus 1591 controls showed the association of two TLR7 SNPs with SLE 
(rs5935436 in the promoter, p=1.8x10-3; rs3853839 in the 3’-UTR, p=6.7x10-4) (in press). 
16. Epigenetics involvement in the pathology of SLE  
The controversy, we came cross in the previous section, in the association of 
immunologically related genes with susceptibility to SLE and the incomplete concordance in 
monozygotic twins affected with SLE, while they carry the same SLE susceptibility genes, 
are clear indications that genetics is not the only factor that influences susceptibility to SLE. 
This means that some non-genetic factors can modify gene expression through epigenetic 
mechanisms, potentially contributing to SLE. The field of epigenetics is rapidly growing 
especially in studying autoimmune diseases. Epigenetics is the study of heritable 
modifications in gene function that alter the phenotype without modifying the genetic 
sequence, these modifications result in the activation or complete/partial gene silencing 
(Hirst, 2009). It is becoming clear that epigenetic modifications contribute to a variety of 
pathogenetic processes in which environmental and genetic factors are involved. Much of 
the variability in severity, organ involvement, and response to therapy among patients with 
systemic lupus erythematosus (SLE) is blamed on differences in gene expression. That, in 
turn, is due to epigenetic mechanisms, one of the "master regulators" of gene expression. 
Accumulating epidemiological, clinical, and experimental evidence supports the conclusion 
of the critical role of epigenetic factors in immune programming. Compelling evidence has 
been gathered supports a role for epigenetic alterations in the pathogenesis of SLE. For 
example, inhibiting DNA methylation in normal CD4+ T cells induces autoreactivity, and 
these autoreactive cells promote autoantibody production. Furthermore, transferring 
hypomethylated T cells into syngeneic mice causes a lupus-like disease (Richardson, 1990 & 
Yung 1997). Understanding this mechanism provides the basis for clarifying how the 
complex interactions of the genome and epigenome shape immune responses and maintain 
immune tolerance to self-antigens.  
In this section we will discus, in brief, some of the epigenetics mechanisms that are involved 
in the SLE pathogenesis. These mechanisms play an essential role in gene regulation  
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Gene  locus function P-values ORs 
PTPN22  1p13 T-cell signaling <1x10-5 - 
5.2x10-6 
1.49-1.53 
FCGR2A  1q21-23 Immune complex clearance  Fc Receptor 0.0016 -
6.78x10-7  
1.30-1.35 
FCGR3B  1q23.3  Immune complex clearance  Fc Receptor 2.7x10-8 2.21c 
FcGR3A 1q23.3  Immune complex clearance  Fc Receptor  1.6 
CRP 1q23.2 sensitive marker of inflammation 6.4x10-7  
TNFSF4  
 
1q25.1 T-cell signaling over: 1.91x10-6 over: 1.63 
(T/U) and 
1.28b 
NMNAT2  1q25.3 Catalyzes the formation of NAD(+)from 
nicotinamide mononucleotide (NMN) and 
ATP. 
1x10-10 1.18 
IL10* 1q31–q32 1q24 4.0×10 −8  1.2 
TLR5 1q41-q42 innate immunity    





2q37 pro-B-cells differentiation  1.2 
CTLA4 
(CD152) 
2q33.2 transmits an inhibitory signal to T cells   
PXK  3p14.3 Bind and modulates both Na, 
K-ATPase enzymatic and ion pump 
activities  
7.10x10-9 1.25  
BANK1  4q24 B-cell signaling 3.7x10-7 1.38 
TNIP1 5q33 TNF–NFκB signaling  1.3 
The MHC  6p21.3 T-cell signaling 2.71x10-21-
1.7x10-52 
2.01-2.36 
ATG5  6q21  1.36x10-7 1.19 
PRDM1 6q21 B-cell signaling 1.74×10 −8  1.3 
TNFAIP3 6q23 TNF–NFκB signaling 2.9x10-12 1.7 
IRF5  7q32 TLR–IFN signaling 1.65x10-11 -
3.61x10-19 
1.54-1.72 
ICA1  7p21.3  1.90x10-7 1.32 
IKZF1 7p12 B-cell signaling  1.4 
BLK  8p23.1 T-cell signaling 1x10-10 -7x10-10 1.22-1.39 
XKR6  8p23.1  2.51x10-11 1.23 
LYN  8q12.1  5.4x10-9 1.30 





8p23.1 B-cell signaling 1.7x10-8 1.2-1.6 
MBL 10q11.2-
21 
element of the innate immune system   
KIAA1542 
(near IRF7)  
11p15.5 Interferon and TLR7  9 Signaling 3.00x10-10 1.28 
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recognition and activation of innate immunity. TLRs generally exist as homodimers. They 
are highly conserved from Drosophila to humans and share structural and functional 
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specific towards evolutionary conserved entities on microbes, such as bacterial cell-surface 
lipopolysaccharides, flagella and unmethylated CpG islands.  
Activation of toll-like receptors initiates downstream signaling cascades, initially via the 
adapter molecules MyD88, Trap, Trif and Tram, leading to NF-kappa-B activation, cytokine 
secretion and the inflammatory response, regulate intracellular kinases and gene expression. 
The signaling cascade coupled to toll-like receptor activation is very similar to that of 
interleukin-1 receptor (IL-1R) activation. It has been suggested that some toll-like receptors 
may have endogenous ligands, such as Hsp60 and fibrinogen, and this has promoted 
speculation that endogenous toll-like receptor activators may have a pathological role in 
autoimmune disease. TLRs play an important role in the pathogenesis of SLE (Vollmer, 2005 
& Christensen, 2006). The role of nucleic acid binding TLR7 has become quite apparent in 
both SLE animal models and human patients. This receptor promotes autoantibodies and 
cytokines responsible for chronic inflammation (Christensen, 2007 & Savarese, 2008). A 
recent fine mapping of the 23-kb TLR7 region using 11 SNPs in 1434 SLE cases of Eastern 
Asian descent versus 1591 controls showed the association of two TLR7 SNPs with SLE 
(rs5935436 in the promoter, p=1.8x10-3; rs3853839 in the 3’-UTR, p=6.7x10-4) (in press). 
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The controversy, we came cross in the previous section, in the association of 
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monozygotic twins affected with SLE, while they carry the same SLE susceptibility genes, 
are clear indications that genetics is not the only factor that influences susceptibility to SLE. 
This means that some non-genetic factors can modify gene expression through epigenetic 
mechanisms, potentially contributing to SLE. The field of epigenetics is rapidly growing 
especially in studying autoimmune diseases. Epigenetics is the study of heritable 
modifications in gene function that alter the phenotype without modifying the genetic 
sequence, these modifications result in the activation or complete/partial gene silencing 
(Hirst, 2009). It is becoming clear that epigenetic modifications contribute to a variety of 
pathogenetic processes in which environmental and genetic factors are involved. Much of 
the variability in severity, organ involvement, and response to therapy among patients with 
systemic lupus erythematosus (SLE) is blamed on differences in gene expression. That, in 
turn, is due to epigenetic mechanisms, one of the "master regulators" of gene expression. 
Accumulating epidemiological, clinical, and experimental evidence supports the conclusion 
of the critical role of epigenetic factors in immune programming. Compelling evidence has 
been gathered supports a role for epigenetic alterations in the pathogenesis of SLE. For 
example, inhibiting DNA methylation in normal CD4+ T cells induces autoreactivity, and 
these autoreactive cells promote autoantibody production. Furthermore, transferring 
hypomethylated T cells into syngeneic mice causes a lupus-like disease (Richardson, 1990 & 
Yung 1997). Understanding this mechanism provides the basis for clarifying how the 
complex interactions of the genome and epigenome shape immune responses and maintain 
immune tolerance to self-antigens.  
In this section we will discus, in brief, some of the epigenetics mechanisms that are involved 
in the SLE pathogenesis. These mechanisms play an essential role in gene regulation  
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CD226 18q22.3 member of the Ig-superfamily    
TYK2 19p13.2 Janus kinases (JAKs) protein 
interferon signaling pathway 
  
UBE2L3  22q11.2 encodes a member of the E2 ubiquitin-
conjugating enzyme 
7.53x10-8 1.22 
SCUBE1  22q13.2 adhesive molecule 1.21x10-7 1.28 
MECP2  Xq28  Chromosomal protein that binds to 
methylated DNA 
1.2x10-8 1.39 
IRAK1 Xq28 responsible for IL1-induced upregulation 
of the transcription factor NF-kappa B 
  
TLR7 Xp22.2 innate immunity   
Table 1. Top SLE candidate genes categorized by chromosomal location. 
through covalent modifications of DNA and histones, and determine regional chromatin 
structure with consequences on gene expression. We will also discuss the involvement of 
MicroRNAs (miRNAs) as an epigenetic factor involved in the pathology of SLE. 
16.1 Histone covalent modification 
The basic chromatin subunit is the nucleosome, which consists of DNA wrapped twice 
around a histone core. Nucleosomes are then organized into higher order structures forming 
chromatin fibers (Felsenfeld 2003). Chromatin in its native form is tightly compacted and 
inaccessible to transcription factors and the transcription initiation machinery. However, 
histone “tails” protrude from the nucleosome, and are covalently modified by acetylation, 
methylation, phosphorylation, ubiquitination, and SUMOylation (SUMO (small ubiquitin-related 
modifier) (Felsenfeld 2003). These modifications serve as signals, referred to as the “histone 
code”, that initiate a number of processes including the localized remodeling of chromatin 
from a compact, transcriptionally silent configuration to a more open structure accessible to 
the transcription initiation machinery. 
16.2 DNA methylation and autoimmunity 
DNA methylation refers to the methylation of cytosines in CpG pairs (cytosine and guanine 
residues separated by a phosphate, which links the two nucleosides together in DNA). Most 
CpG pairs in the mammalian genome are methylated, with some unmethylated pairs found 
in the regulatory elements of active genes. Most unmethylated CpGs are found in GC-rich 
sequences, termed CpG islands. CpG islands contain multiple binding sites for transcription 
factors, and serve as promoters for the associated gene. Methylation of these promoters can 
lead to gene silencing where transcriptionally active chromatin is characterized by 
unmethylated DNA. Convincing evidence indicates that DNA can be actively demethylated 
and therefore affect gene expresssion. For example, several CpG pairs in the IL-2 promoter 
demethylate within 20 minutes of T-cell stimulation, prior to initiation of DNA synthesis 
(Bruniquel, 2003).  
DNA methylation is catalyzed by the enzyme DNA methyltransferases (DNMTs) while and 
histone acetylation is controlled by histone acetylases (HATs) and deacetylases (HDACs). It 
is hypothesized that the processes of DNA methylation and histone deacetylation work 
together through the formation of DNMT/HDAC transcriptional repressor complexes that 
work in silencing gene expression through establishing a repressive chromatin environment 
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(Cameron, 1999). However, DNMTs and HDACs lack DNA-binding domains, and are 
therefore dependent on transcription factors (TFs) for their recruitment to DNA. Zhao M et 
al. set out a study to uncover mechanisms underlying the hypomethylation and 
hyperacetylation of genes involved in lupus autoimmunity by investigating the involvement 
of specific TFs. They assessed the activities of 225 TFs in CD4+ T cells from SLE patients 
relative to healthy controls using a newly developed screening method (Qiao, 2008), and 
found that the activity of regulatory factor X 1 (RFX1) is significantly downregulated in SLE 
CD4+ T cells (Zhao, 2010). Follow-up analyses confirmed the result of Zhao M et al. study 
and further revealed that both the expression and activity of RFX1 protein are reduced in 
SLE CD4+ T cells. Zhao M et al (Zhao, 2010) also provided evidence indicating that RFX1 
recruits the co-repressors HDAC1 and DNMT1 to the promoter region of CD11a and CD70, 
thus regulating their expression in CD4+ T cells. Taken together, our findings indicate that 
reduction of RFX1 plays an important role in inducing autoreactivity and autoantibody 
overstimulation in SLE. 
In addition, DNA hypomethylation appears to induce CD4+ T cell autoreactivity and the 
inhibition of DNA methylation with 5-azacytidine caused CD4+ T-cell autoreactivity. This 
lupus-like autoimmunity correlated with overexpression of ITGAL (CD11a) and TNFSF7 
(CD70) (Lu, 2002 & 2005). CD11a and CD70 overexpression in these CD4+ T cells is 
associated with hypomethylation of their respective promoters (Lu, 2002 & 2005). CD11a is 
the alpha chain of the heterodimeric integrin lymphocyte function-associated antigen-1 
(LFA-1) (CD11a/CD18) (ITGAL/Integrin beta-2). Overexpressing LFA-1 by transfection 
caused an identical autoreactivity (Yung, 1996).LFA-1 plays a central role in adhesive 
interactions between T cells and other immune system cells including macrophages, 
dendritic cells and B cells. This protein is also essential for the recruitment of leukocytes into 
sites of inflammation, antigen-specific T cell activation, helping B cell, as well as alloreactive, 
cytotoxic T cell and natural killer responses (Shimaoka & Springer, 2003). LFA-1 deficient 
lupus mice have significantly increased survival, decreased anti-DNA autoantibody 
formation, and reduced glomerulonephritis (Kevil, 2004). CD70 is expressed on activated T 
cells and increases pokeweed mitogen (PWM)-stimulated immunoglobulin (Ig) G synthesis, 
indicating B cell costimulatory functions (Kobata, 1995). Demethylated, autoreactive CD4+ T 
cells overstimulate antibody production by B cells and kill macrophages (Richardson, 2007), 
relaeasing apoptotic nuclear material that stimulates lupus-like autoantibodies (Denny, 
2006). T-cell hypomethylation correlates with disease activity in SLE, suggesting that DNA 
hypomethylation may be a key player in the pathogenesis of the disease (Corvetta, 1991). 
Furthermore, CD4+ lymphocytes undergo global histone H3 and H4 deacetylation and 
consequent skewed gene expression. Although multiple lines of evidence highlight the 
contribution of epigenetic alterations to the pathogenesis of lupus in genetically predisposed 
individuals, many questions remain to be answered. Attaining a deeper understanding of 
these matters will create opportunities in the promising area of epigenetic treatments. 
16.3 MicroRNAs (miRNAs) and autoimmunity 
MicroRNAs (miRNAs) are newly discovered, small (about 23-nucleotide),  noncoding 
ribonucleic acids (RNAs) that function in the posttranscriptional regulation of about 30% of 
mRNAs by binding to their 3′-untranslated region (3′-UTR), thus targeting them for 
degradation or translational repression. miRNA are known to regulate cellular processes 
such as apoptosis, cell cycle, differentiation, and immune functions. The powerful gene 
regulatory role of miRNAs is now well recognized, where the recent discovery of the gene-
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CD226 18q22.3 member of the Ig-superfamily    
TYK2 19p13.2 Janus kinases (JAKs) protein 
interferon signaling pathway 
  
UBE2L3  22q11.2 encodes a member of the E2 ubiquitin-
conjugating enzyme 
7.53x10-8 1.22 
SCUBE1  22q13.2 adhesive molecule 1.21x10-7 1.28 
MECP2  Xq28  Chromosomal protein that binds to 
methylated DNA 
1.2x10-8 1.39 
IRAK1 Xq28 responsible for IL1-induced upregulation 
of the transcription factor NF-kappa B 
  
TLR7 Xp22.2 innate immunity   
Table 1. Top SLE candidate genes categorized by chromosomal location. 
through covalent modifications of DNA and histones, and determine regional chromatin 
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DNA methylation is catalyzed by the enzyme DNA methyltransferases (DNMTs) while and 
histone acetylation is controlled by histone acetylases (HATs) and deacetylases (HDACs). It 
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together through the formation of DNMT/HDAC transcriptional repressor complexes that 
work in silencing gene expression through establishing a repressive chromatin environment 
 
Genetics and Epigenetic in Systemic Lupus Erythematosus 
 
31 
(Cameron, 1999). However, DNMTs and HDACs lack DNA-binding domains, and are 
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hyperacetylation of genes involved in lupus autoimmunity by investigating the involvement 
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indicating B cell costimulatory functions (Kobata, 1995). Demethylated, autoreactive CD4+ T 
cells overstimulate antibody production by B cells and kill macrophages (Richardson, 2007), 
relaeasing apoptotic nuclear material that stimulates lupus-like autoantibodies (Denny, 
2006). T-cell hypomethylation correlates with disease activity in SLE, suggesting that DNA 
hypomethylation may be a key player in the pathogenesis of the disease (Corvetta, 1991). 
Furthermore, CD4+ lymphocytes undergo global histone H3 and H4 deacetylation and 
consequent skewed gene expression. Although multiple lines of evidence highlight the 
contribution of epigenetic alterations to the pathogenesis of lupus in genetically predisposed 
individuals, many questions remain to be answered. Attaining a deeper understanding of 
these matters will create opportunities in the promising area of epigenetic treatments. 
16.3 MicroRNAs (miRNAs) and autoimmunity 
MicroRNAs (miRNAs) are newly discovered, small (about 23-nucleotide),  noncoding 
ribonucleic acids (RNAs) that function in the posttranscriptional regulation of about 30% of 
mRNAs by binding to their 3′-untranslated region (3′-UTR), thus targeting them for 
degradation or translational repression. miRNA are known to regulate cellular processes 
such as apoptosis, cell cycle, differentiation, and immune functions. The powerful gene 
regulatory role of miRNAs is now well recognized, where the recent discovery of the gene-
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regulatory role of miRNAs has led to a paradigm shift in the understanding of expression 
and function of the mammalian genome. The field of miRNA research gained widespread 
attention with the recognition of aberrant expression and/or function of miRNAs in a broad 
range of human diseases including autoimmune diseases (Pauley, 2009). 
Recent research evidence has emerged showing the critical role of miRNAs not only for the 
development of the immune system but also for the function of both innate and adaptive 
arms of the immune system (Taganov, 2007; Xiao, 2009; Gantier, 2007; O’Connell, 2010; 
Lodish, 2008; Sonkoly, 2008; Baltimore, 2008). Using state of the art quantitative mass 
spectrometry two investigators measured the response of thousands of proteins after 
introducing microRNAs into cultured cells and after knockdown mir-223 in mouse 
neutrophils. Their results are consistent with each other and demonstrate that changes in the 
level of a single miRNA may have a significant impact on the levels of hundreds to 
thousands of proteins (Baek, 2008). These important studies are the first to show the impact 
of microRNAs on the proteome which indicated that for most interactions microRNAs act as 
rheostats to make fine-scale adjustments to protein output (Baek, 2008 & Selbach, 2008). 
Tang et al have shown that miR-146 regulates the level of at least TRAF6, IRAK1, STAT-1, 
and IFN regulatory factor 5 (IRF-5), all of which are important for the IFN pathway (Tang, 
2009). The reported reduction of miR-146 in PBMCs from SLE patients (Tang, 2009) will 
likely affect the levels of these factors significantly and contribute to overexpression of type I 
IFN and, thus, disease activity. 
It is intriguing that independent studies have demonstrated an increased level of miR-146 in 
RA patients, but a decreased level in SLE patients, as compared with healthy controls. Given 
that RA and SLE are both systemic rheumatic diseases, one may be surprised by the finding 
that miR-146 levels are contradictory in these diseases, and yet, it should not be surprising, 
since this may simply be reflecting a difference in the overall cytokine profiles between the 
two diseases, with type I IFN playing a dominant role in SLE, whereas TNFα, interleukin-1 
(IL-1), and IL-6 are the principle cytokines in RA. In the coming years, one can expect 
research reports on miRNA expression in many other autoimmune diseases, as well as 
more-complete profiling data, with disease activity correlations or a lack thereof. 
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1. Introduction 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease  characterized by 
the production of numerous autoantibodies that typically involves multiple organ systems. 
As opposed to lupus in animal models, SLE in humans is heterogeneous and affects 
different individuals with a wide range of disease courses and manifestations. The 
pathogenesis is still unclear, a myriad of innate and adaptative immune system aberrations 
in SLE have been identified as major contributors of the disease. 
Cytokines are a diverse group of soluble proteins and peptides, produced and released by 
immune system cells , that act as humoral regulators and modulate the functional activities 
of individual cells and tissues, playing a pivotal role in the differentiation, maturation, and 
activation of various immune and no immune cells. Cytokine dysregulation is likely to play 
a role in the loss of immune tolerance that leads to SLE, and in the damage resulting from 
the disease. Many of the genes that are associated with risk for lupus are cytokines, 
regulators of cytokines, or downstream members of cytokine pathways. 
Multiple cytokines have been implicated in the disease activity or organ involvement in 
SLE. Among these, IL-6, Interferon (IFN), B-lymphocyte stimulator (BlyS), IL-10, IL-17 is 
thought to play an important role in the creation of the characteristic milieu in SLE,  which 
promotes B-cell survival and autoantibody production. On the other hand, also cytokines 
like IL-10, IL1, TNF-α , IFN,  are important in development of the autoimmune injury in 
renal and central nervous system, the most frequently observed causes of death in patients 
with SLE. Moreover, recent studies strongly suggest  that the cytokines, at least in part, 
would be implicated in the pathogenesis of accelerated atherosclerosis associated with SLE.  
The  knowledge of cytokines not only provides new insight into pathogenesis of SLE, but 
also it has allowed the development of clinical applications such as monitoring of disease 
and as potential therapeutic targets with the use  of several biologic agents, targeting 
different cytokines or their receptors. Consequently, many trials of anticytokine therapies 
for SLE are underway.  
The focus of the present chapter is to summarize the cytokines which have significant 
implications in the pathogenesis of SLE, the potential clinical and therapeutic use will be 
reviewed.  
2. SLE gender susceptibility and cytokines 
One feature of lupus, which also occurs with other autoimmune diseases, is the influence of 
gender on disease susceptibility. In fact 90% of people affected by lupus are women (Masi & 
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Kaslow 1978). Immunological, epidemiological and clinical evidence suggest that female sex 
hormones play an important role in the etiology and pathophysiology of chronic immune 
diseases.  Abundant studies have suggested that gender differences in susceptibility to SLE 
are mediated by sex hormones (Rider & Abdou 2001, Cohen-Solal et al  2006, Zandman et al 
2007) .The  high female prevalence is most marked after puberty: while the pre-puberty 
female to male ratio is 3 : 1, this increases to 10 : 1 during the childbearing years and 
decreases again to 8 : 1 after menopause (Lahita et al 1999a). Pregnancy is frequently 
associated with activity and flares of the disease in SLE patients (Lahita 1999a). Also there is 
an increased risk of developing SLE in postmenopausal women who received estrogen 
hormone replacement therapy (Buyon et al 2007) and increased the risk  of flares in 
postmenopausal patients (Straub 2007). Together these considerations indicate that estrogen 
may be proposed as candidates to explain the sexual dimorphism of SLE. Cytokines are 
intimately involved with sex hormones, as they regulate the level of sex hormones both 
systemically and locally, especially in the reproductive organs. The interactions between 
cytokines and estrogens affect important cellular activities as proliferation and apoptosis 
(Lahita  1999b).  
Estrogens exert their effects by activation of intracellular receptors,  the estrogen receptor 
alpha (ERα) and beta (ERβ) (Green et al 1986). In addition to its intracellular receptors have 
also been reported  membrane receptors that correspond to full-length isoforms of both ERα 
and  ERβ with extracellular functionality (Pedram et al 2006). Both receptors have been 
identified in the membrane of thymocytes and have a great importance in the proper 
development of the thymus (Stimson & Hunter 1980). Thus it seems that estrogen receptors 
influence the adequate development of T lymphocytes. It is well known that low doses of 
estrogen promote enhanced Th1 responses and increased cell-mediated immunity, while 
high doses of estrogen lead instead to increased Th2 responses and antibodies production 
(Maret et al 2003, Bao et al 2002). This effect of estrogens seems to be achieved through 
direct alteration in the Th cytokine profile from a proinflammatory (IL-2, IFN-γ) to an 
humoral direction ( IL-4, IL-5, IL-9, IL-13).  Besides the effect of estrogen on the profile of 
cytokines released by T cells, estrogen also increases the release of IL-1, IL-6 and TNF by 
monocytes/macrophages (Kramer et al 2004). SLE patients  show immune-related  disorders 
mediated through estrogens. In vitro peripheral blood mononuclear cells in SLE patients 
show an increase in anti-dsDNA and IL-10 in response to estrogen, and in vivo there are 
clear differences in hormonal and cytokine levels in SLE vs control pregnancies (Doria et al 
2004). Although there is much indirect evidence for estrogen involvement in the lupus 
disease process, the direct role of estrogen/estrogen-receptor mediated pathways in 
regulating cytokine production in SLE patients has not as yet been clearly defined. The first 
evidence for a molecular marker of estrogen action in SLE was the estrogen dependent 
changes  in lupus T-cells calcineurin that could alter  cytokine regulation (Rider et al 1998). 
Calcineurin is the target of a class of drugs called calcineurin inhibitors, which includes 
cyclosporine, pimecrolimus and tacrolimus. Calcineurin induces different transcription 
factors as NFATs that are important in the transcription of cytokine genes. A recent study 
demonstrate that blocking estrogens receptor in vivo in SLE pre- menopausal women they 
reduced the expression of calcineurin in peripheral T cells (Abdou et al  2008). Another 
possible mechanism of the role of estrogen in gender susceptibility in lupus is the altered 
expression of its receptors. Peripheral cells of SLE patients showed increased expression of 
ERα  mRNA and decreased expression of ERβ (Iinui et al 2007).  ERs are  overexpressed in 
CD4+ and CD8+ cells while  is decreased in B cells. The decline in ERβ  expression inversely 
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correlated with SLEDAI score. In conclusion, estrogen and its ability to influence on the  
profiles of cytokines release and immune system regulation is a very powerful  factor in the 
gender susceptibility described in lupus.  
3. Cytokines involved in SLE 
3.1 Th1/Th2 balance in SLE 
The Th1/Th2 balance hypothesis emerge from observations in mice of two subtypes of CD4 
T-helper cells differing in cytokine secretion patterns and other functions (Mosmann et al 
1986). The concept subsequently was applied to human immunity (Mosmann et al 1989). 
Th1 cells release significantly INFγ and IL2, and through these mediators Th1- polarized 
responses are highly protective against infections  especially the intracellular pathogens, 
because of the ability of Th1-type cytokines to activate phagocytes and enhance the cellular 
response.  In contrast Th2 cells release mainly IL4, IL5  IL9 and IL13 and induce  the in situ 
survival of eosinophils (through IL-5), promote the production by B lymphocytes of high 
amounts of antibodies, including IgE (through IL-4 and IL-13), as well as the growth and 
degranulation of mast cells and basophiles (through IL-4 and IL- 9). (figure 1)  
 
 
Fig. 1. Diagrammatic representation of the differentiation into Th1 or Th2 cells from  
naive cells.  
Antigen-presenting cells interact with undifferentiated cells secreting specific cytokines that 
induce differentiation toward Th1 or Th2 cells. INFγ released by Th1 cells and IL4 produced 
by Th2 cells act as their own growth factors and cross-regulate  the other   differentiation. 
Two features define the Th1/Th2 balance, first each cell subset produced cytokines  that 
served as their own growth factor (autocrine effect) and second the two subsets released 
cytokines to cross regulate each other's development. Polarization to a subtype or another 
depends largely on the APC and experience on the antigen. This process is directed by the 
microenvironment of cytokines resulting in the antigen presentation of APC to T naive cells. 
A Th1/Th2 imbalance with excess of Th1 predominance appears in organ specific 
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inflammatory diseases as arthritis, multiple sclerosis and type 1 diabetes,  and  instead a 
predominance of Th2 response has been described in allergy and systemic autoimmune 
diseases (Abbas et al  1996).   
The roles of Th1 and Th2 cytokines in the pathogenesis of SLE are controversial. In patients 
with SLE, Th2 cytokines are increased (Ogawa et al 1992), whereas Th1 cytokines are 
decreased (Klinman & Steinberg 1995 ). Thus, SLE was initially considered to be a Th2 
predominant disease. However different results contradict this hypothesis like that IFNγ 
levels in the sera of patients with SLE are significantly elevated and that there is a 
correlation between the severity of SLE and the amount of IFNγ secreted  (Al-Janadi et al 
1993). All these findings suggest that the Th1 and Th2 responses are both important in the 
pathogenesis of lupus associated tissue injury. SLE is a disease involving a wide spectrum of 
cytokines. SLE patients with arthritis have higher IFNγ  levels than  the other patients, and 
conversely, patients with serositis or CNS involvement have higher IL-4 levels (Chang et al 
2002). Furthermore SLE patients with nephritis have higher Th1 cytokines in serum and 
urine than non-nephritis patients (Chang et al 2006). Still more  a significant difference in the 
Th1/Th2 balance in peripheral blood exists between WHO class IV and V lupus nephritis.  
Th1 cells are predominant in class IV but not in class V (Akahoshi et al 1999). In class V, the 
number of infiltrating cells was reduced, with a large percentage of CD4 T cells producing 
IL4 in the peripheral blood (Masutani et al 2001).  
SLE is known to be a heterogeneous disease in which a wide range of cytokines are 
involved, it seems the most likely that Th1 or Th2 dominance depends on the stage of the 
disease and involvement. The Th2 response would be related to the development and 
production of autoantibodies, and Th1 with immune-mediated inflammatory activity.  
3.2 B-lymphocytic Stimulator (BLyS) 
BlyS a member of theTNF family, is also known as the B cell–activating factor(BAFF) and 
appears to play an important role in the differentiation  and survival of B cells (Mackay et al  
2002).  BlyS can be released in a soluble form or can be expressed as a transmembrane 
protein on a wide variety of cell types, including monocytes, activated neutrophils, T cells, 
and DCs and its release is upregulated by IFN-γ, IL-10, G-CSF and CD40L (Nardelli et al  
2001, Moore et al 1999,  Litinskiy et al 2002, Harigay et al 2008). 
BLyS binds to 3 receptors, BAFF-R (BAFF receptor), TACI (transmembrane activator and 
calcium modulator and cyclophylin ligand anteractor), and BCMA (B-cell maturation 
antigen), that are differentially expressed during B cell ontogeny (Bossen  & Schneider 2006, 
Bossen et al 2008). The stimulation of all three receptors promotes B-cell differentiation and 
proliferation. BLyS is the sole ligand for BAFF-R, whereas TACI and BCMA each can bind 
either BLyS or another TNF family ligand known as a proliferation-inducing ligand (APRIL) 
(Bossen et al 2008).  
After maturation in the bone marrow, newly formed B cells migrate to the secondary 
lymphoid organs (spleen and lymph nodes). These B cells do not possess all the 
characteristics of fully mature B cells, and they are referred to as transitional B cells. This 
transitional stage is an elastic checkpoint where thresholds for negative selection are 
homeostatically adjusted by free BLyS concentration.  At this point an upregulation of  BLyS 
expression can result in the rescue of self-reactive B cells from elimination. This effect 
explains, at least in part, the greatly increased levels of autoantibody production and 
associated autoimmune manifestations observed in transgenic mice that overexpress BlyS 
(Cancro et al  2009, MacKay et al 2007, Zheng et al  2005,  Miller et al 2006, Thien et al 2004) 
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Elevated BLyS serum levels are often observed in SLE patients and correlate with disease 
activity (Petri et al 2008). Experiments in mice, have been  demonstrated causality between 
BLyS over expression and development of SLE , on the other hand, also had been  
documented the amelioration of clinical disease in SLE mice following  treatment with  BlyS 
antagonist (Mackay et al 1999, Petri et al 2008, Jacob et al 2006) 
The primary source of BlyS secretion in SLE remains speculative, a secretion by DCs 
(dendritic cells), a profoundly dysregulated IFNs in SLE  or an increased levels of BLyS 
resulting from the presentation of self antigens (derived of an defective clearance of 
apoptotic bodies) to innate immune cells (which express BLyS upon antigenic stimulation) 
are potentially mechanisms implicated (Cancro et al 2009).  
Because BLyS may figure prominently in the development of SLE and it  could be a valid 
target for SLE, therapy with BLyS antagonists have been developed.  Belimumab, a fully 
human monoclonal Ab (IgG1) that binds soluble BLyS and inhibits its binding to TACI, 
BCMA, and BR3, and  Atacicept (TACI-Ig)  a soluble, recombinant fusion protein of the 
human IgG1 Fc and the extracellular domain of the TACI receptor that binds BLyS and 
APRIL, have been tested in clinical trials. Results from phase III trials have demonstrated 
the safety profile and efficacy of belimumab in controlling SLE in a broad range of patients 
(Navarra et al 2011).  
3.3 Interferon-α 
Interferon alpha (INF-α) is  produced mainly by  plasmocytoid dendritic cells (PDC) in 
response to viral infection. INF-α is not one protein, but rather a family of highly related 
proteins encoded on the short arm of chromosome 9,  and  called type I INFs. Studies in 
which cellular mRNAs are screened against thousands of gene sequences have 
demonstrated that in SLE patients the INF-α induced genes are the most overexpresed  of all 
those assayed (Baechler et al 2003). Evidence of the effect of INF-α in SLE comes from 
observations on the therapeutic administration of IFN-α in various types of malignancies  
and hepatitis C infection. Case reports emerged describing the development of lupus 
associated autoantibodies and even clinical lupus (Niewold & Swedler 2005).  
Discontinuation of IFN-α typically resulted in remission of SLE symptoms, supporting a 
causal relationship with IFN-α. Only a minority of patients treated with IFN-α develop  
SLE (<1% of patients) , these data support the idea that IFN-α can be sufficient to induce  
SLE in some genetically designed individuals. In addition,  SLE patients commonly harbor 
anti INF-α  autoantibodies. Anti INF-α antibodies-positive patients have lower levels of 
serum type I IFN bioactivity and evidence for reduced downstream IFN-pathway and 
disease activity. 
A very strong correlation is consistently observed between the presence of SLE-associated 
autoantibodies that recognize nucleic acid structures or RNA-containing protein, such as 
anti-Ro, anti-La, anti-Sm, anti-RNP, and anti-dsDNA and high production of INF-α (Kirou 
et al 2005). Also lupus patients with high serum IFNα had a significantly higher prevalence 
of cutaneous and renal disease in most studies (Dall'era  et al 2005). It is interesting that both 
of these clinical manifestations share an association with a particular serology (rash with 
anti-Ro and nephritis with anti-dsDNA).  
The principal mechanism through which INF-α is produced in SLE is through Toll-like 
receptors (TLR). TLR receptors is a family of receptors present in a variety of cells and that 
recognize characteristics ligand present in pathogens. Some TLR recognize RNA and DNA 
sequences of single or double chain. A quality of many cases of lupus is the production of 
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autoantibodies against RNA or DNA containing protein complexes such as Sm, RNP, Ro, 
and La. Autoantibodies specific for these lupus-associated riboproteins can bind with 
antigens derived from apoptotic cells. The RNA/DNA found in these complexes are capable 
of promoting the production of IFN-α through the stimulation of TLR. Because some TLR is 
located in the endosomes, RNA  or DNA containing complexes must access the interior of 
the cell before they are able to act as activators. The Fc portions of the immune complexes 
are recognized and internalized by cells with Fc receptors in their surface, providing a route 
of entry for RNA or DNA  to reach TLR, resulting in interferon alpha production (Figure 2). 
This process is especially well established in PDCs  on TLR7 and  TLR9 (Båve et al 2003).  
 
 
Fig. 2. Induction of INF-α in lupus. RNA/DNA containing immunecomplexes access  the 
interior of the cell through recognition of Fc portion by Fc receptors in PDC membrane. 
Inside cell the RNA/DNA  specific ligand are recognized by Toll-like receptors (TLR).   
TLR depending signals reach to the cell nucleus and induces transcription of IFN genes. 
INF-α generate an effective antigen-presenting cells state by mediating maturation of  
dendritic cells. Thus INF-α  prime the immune system for augmented sensitivity to 
subsequent stimuli. The activate antigen presenting cell state may also be characterized by 
an augmented capacity to generate a peripheral T-cell repertoire enriched in autoreactive 
cells. Dendritic cells  are primary activators of T-cells and affect both tolerance and 
activation, depending of the  state of dendritic cells. Dendritic cells from lupus patients  are 
able to present self-antigens to T-cells in  a stimulatory rather than regulatory manner, a 
process which is INF-α dependent (Blanco et al 2001). Moreover PDCs significantly enhance 
autoreactive B cell proliferation, autoantibody production, and survival in response to TLR 
activation (Ding et al 2009). Recently it has been reported that activation of the IFN signaling 
pathway may be linked to the risk of atherosclerosis by affecting plaque formation in 
patients with SLE (Li et al 2011). 
In conclusion, in SLE patients, some autoantibodies are able to induce the production of 
INF-α. INF-α enhances the  autoimmunity and immune response.  
3.4 Tumor necrosis factor-α (TNF-α) 
TNF-α is a pleiotropic cytokine produced by a variety of cell types including monocytes, 
lymphocytes and non immunological cell types in response to inflammation, infection and 
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other environmental challenges. There are controversial results about the role of TNF in 
mice lupus strains. In NZB/W stain diminished production of TNF-α has been reported 
demonstrating the protective effect of TNF-α (Jacob  & McDevitt 1988). In other strains of 
murine lupus an increased production of TNF-α has been described.  In addition, TNF-α 
concentration correlates with the severity of the illness and anti-TNF therapy is profitable 
(Boswell et al 1988). Overall, these results show a duality in the role of TNF in lupus, one 
beneficial and one detrimental.  
TNF-α contributes to avoiding the development of autoimmunity and autoantibody 
production. When introducing inhibitory TNF-α therapies in patients with diseases such as 
arthritis, spondyloarthropathies or Crohn disease shows the appearance of antinuclear 
antibodies and anti-ds DNA antibodies (De Ricke et al 2003, Garcia-Planella et al 2003). 
Normally these antibodies are not pathological, but in a few patients autoantibodies are 
associated with a SLE-like activity. TNF-α blocker induced lupus is usually benign and the 
symptoms resolve after TNF blockade stopped (Ramos-Casal et al 2007). It should be noted 
that these patients do not have the genetic background that makes them susceptible to SLE 
developing. When using anti-TNF therapy in SLE patients it has been found an elevation of 
antinuclear and anticardiolipin antibodies in most patients (Aringer et al 2007). This 
elevation was transient and did not produce complement consumption or lupus flare. 
On the other hand numerous studies have shown that TNF blockade in SLE patients 
suffering from arthritis, nephritis and skin lesions were clinically effective in open clinic 
trials (Aringer et al 2004, Hayat el al 2007). It has found expression of TNF-α in inflamed 
tissue biopsies in patients with lupus, which does not occur in healthy individuals (Herrera-
Esparza et al 1998), and TNF-α expression is associated with high histological disease 
activity (Zha et al 2009).  
TNF-α performs two major functions: one as an immunoregulatory cytokine and the other 
as a potent mediator of inflammation. Among the immunoregulatory functions TNF-α 
induces the release of antiapoptotic molecules, TNF blockade may lead to increased 
apoptosis (Aringer et al 2007). The resulting increase in apoptotic material could explain 
why the emerging antibodies appear to exclusively target nuclear antigens and 
phospholipids, both of which are expressed on apoptotic bodies (Utz et al 1997). In addition, 
TNF blockade hampers the elimination of autoimmune B lymphocytes by cytotoxic T cells 
(Via et al 2001). All together could explain the pathways to increased lupus autoantibodies 
under TNF-α blockade.  
The immunecomplexes generated by autoantibodies are deposited in tissues and organs. 
The deposit of immunecomplexes mediated inflammatory process triggered largely by  
TNF-α. The expression of TNF-α activates the local inflammation and tissue damage. TNF-α 
is the most important proinflammatory cytokine and a harbinger of tissue destruction, and it 
is at the top of a pro-inflammatory “cascade” leading to tissue damage. In contrast to the 
complex role of TNF-α in apoptosis and in immune regulation, its powerful 
proinflammatory effects are unequivocal. At the tissue level, TNF blockade induces 
remission of inflammation and hence tissue recovery. Anyway in the use of anti-TNF 
therapy is important to note the dual activity of this cytokine. 
3.5 IL-6 
IL6 is a pleiotropic cytokine, structurally, it shares homology with other cytokines: 
oncostatin M, IL11, leukaemia inhibitory factor, ciliary neurotrophic factor and 
cardiotrophin (Hirano, 1998). It was known initially as B-cell stimulatory factor 2 because it 
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autoantibodies against RNA or DNA containing protein complexes such as Sm, RNP, Ro, 
and La. Autoantibodies specific for these lupus-associated riboproteins can bind with 
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located in the endosomes, RNA  or DNA containing complexes must access the interior of 
the cell before they are able to act as activators. The Fc portions of the immune complexes 
are recognized and internalized by cells with Fc receptors in their surface, providing a route 
of entry for RNA or DNA  to reach TLR, resulting in interferon alpha production (Figure 2). 
This process is especially well established in PDCs  on TLR7 and  TLR9 (Båve et al 2003).  
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other environmental challenges. There are controversial results about the role of TNF in 
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stimulates B cell growth and maturation to antibody-producing plasma cells. It is produced 
by a wide range of cell types including, monocytes, T cells, fibroblasts, synoviocytes and 
endothelial cells. IL-6 beyond his capacity of B cell activation and promotion of  
Ig production, play an important role in governing inflammation process (Ishihara et al., 
2002).   
IL-6 responses are transmitted through gp130, which serves as the universal signal-
transducing receptor subunit for all IL-6-related cytokines. Although this classically occurs 
through IL-6 binding to its membrane-bound receptor (IL-6R), it is clear that a soluble form 
of the cognate IL-6 receptor (sIL-6R) affords IL-6 with an alternative mechanism of gp130 
activation. This additional mode of cell activation is termed IL-6 trans-signaling and results 
from formation of a sIL-6R_IL-6 complex, which can directly bind cellular gp130. Because 
gp130 is ubiquitously expressed within tissue, trans-signaling provides IL-6 with the 
capacity to activate cells that would not intrinsically respond to IL-6 itself (Hibi et al., 1990; 
Hirano et al., 1994; McLoughlin  et al., 2005). Therefore, IL-6 and gp130 signaling plays a 
critical role in the inflammatory process and tissue injury (Nechemia-Arbely et al., 2008). 
An association between IL-6 and progression of lupus has been published for several 
murine models of SLE. The direct role of IL-6 in controlling autoantibody production has 
been demonstrated  in the pristane induced model of lupus (Richards  et al., 1998). On the 
other hand the administration of recombinant IL-6 to female NZB/W mice exacerbates the 
progression of glomerulonephritis (Ryffel  et al., 1994). Anti IL-6 monoclonal antibody given 
in MRL lpr lupus prone mice, has been shown to cause a decrease in renal damage and a 
temporary reduction in levels of anti-dsDNA antibody production (Kiberd  1993).  
Elevated levels of IL-6 have been found in the serum and in the urine of active SLE patients 
(Chun  et al., 2007; Grondal  et al., 2000; Horii  et al., 1993). Raised expression of gp130, has 
been found in patients with active SLE, while an important reduction in the gp130 
expression on B lymphocytes was observed when the activity of the disease had 
disappeared after readjusting its  immunosuppressive treatment (De La Torre et al., 2009). 
Therefore, monitoring the frequency of gp130, could provide a useful tool in the diagnosis 
and monitoring of disease activity in patients with lupus. 
Beyond  the ability of IL-6 to stimulate B-lymphocyte differentiation into immunoglobulin 
secreting cells, IL-6  in concert with TGF-B  is a critical cofactor for Th17 development, 
whereas the absence of IL-6  induces Foxp3, thereby specifying Treg development (Weaver 
et al., 2006). The two T-cell subsets play prominent roles in immune functions: Th17 cell is  
a key player in the pathogenesis of autoimmune diseases and protection against bacterial 
infections, while Treg functions to restrain excessive effector T-cell responses (Kimura et  
al., 2010). 
Factors leading to the constitutive expression of IL-6 in SLE have not been elucidated yet, 
they may involve other regulator cytokines, like IL-10, or may be due, at least in part, to 
genetic differences (Linker et al., 1999; Tackey  et al., 2004). 
Recently, tocilizumab, a humanized monoclonal antibody against the α-chain of the IL-6 
receptor, which prevents the binding of IL-6 to membrane bound and soluble IL-6 receptor, 
has been tested in SLE patients, with promising results (Illei  et al., 2010). 
3.6 IL-2  
The cytokine IL-2 is a multifactorial cytokine. It was initially identified as a potent T cell 
growth factor, however, more recent data strongly indicate that IL-2 is essential for immune 
tolerance (Humrich  et al., 2010). IL-2 constitutes a key element in the maintenance of the 
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homeostasis between a proliferative immune response and the induction of tolerance, which 
supports the involvement of this cytokine in diverse autoimmunity disorders, such as SLE  
(Sharma  et al., 2011). Predominantly produced by activated CD4+ and CD8+ T cells, IL-2 
exerts its functions trough the interaction with its receptor (IL-2R) (Kammer, 2005).  
It has been reported that production of IL-2 is decreased in patients with SLE (Sharma  et al., 
2011). Transcriptional regulators responsible for the transcription or suppression of IL-2 
production are imbalanced in SLE T cells and this explains the reduced IL-2 levels found in 
SLE patients (Solomou  et al., 2001). The decreased production of IL-2 in SLE patients most 
likely contributes to various immune defects such as decreased Treg production, decreased 
activation-induced cell death (AICD), and potentially decreased cytotoxic T lymphocytes 
(Lieberman & Tsokos 2010). 
 IL-2 signals are critical for the outcome of a CD8+ T cell response.  Recently it was 
discovered that a strong IL-2 signal promotes the progressive acquisition of effector T cell 
functions (such as perforin and granzyme B expression, the hallmarks of CD8+ T cell 
cytotoxicity) but decreases the capacity to generate cells with memory features. By contrast, 
in conditions of weak IL-2 signaling, T cells fail to acquire the full program of effectors 
differentiation.( Pipkin et al., 2010) 
IL-2 module activation-induced cell death (AICD). The activation of AICD is a mechanism 
of self tolerance in which apoptosis of autoreactive lymphocytes is induced after repeated 
stimulation. The deficiency in activation induced cell death might be related to the 
persistence of autoreactive T cell clones that eventually may lead to the activation of B cell 
subsets, with the subsequent production of autoantibodies and the development of 
autoimmune disorders (Gómez-Martín  et al., 2009).  
IL-2  is also required for the expansion and conversion of CD4+foxp3-T cells into CD4+ 
foxp3+ cells or regulatory T cells (Treg) (Setoguchi  et al., 2005; Zheng  et al., 2007;). Tregs 
cells, are necessary for maintaining tolerance to self antigens and they are able to do is by 
suppressing self-reactive T cells (Buckner , 2010). It has been well recognized that a decline 
in Tregs as a critical event in the development of systemic autoimmunity both mice and SLE 
patients (Valencia et al., 2007; Suzuki et al., 1995). On the other hand, recently IL-2 signaling 
has been shown to play a role in inhibiting the development of Th17 cells (Tato et al., 2007; 
Ma et al., 2010). Thus, the effects of IL-2 on Treg and Th17 cells may serve to promote auto-
reactivity while at the same time inhibiting a counter regulatory response (discussed later). 
3.7 IL-17 
Interleukin 17 (IL-17) is a proinflammatory cytokine that is involved in defending the host 
against extracellular, some intracellular pathogens and fungi (Bettelli et al., 2008; Khader  
et al., 2010). IL-17 promote inflammation on several levels, as their receptors are expressed 
on both hematopoietic cells and non hematopoietic cells. Il-17 exerts its effects through  
the recruitment of monocytes and neutrophils by increasing the local production of 
chemokines. IL-17 can also stimulate B-cell antibody production (Hsu et al., 2008; 
Mitsdoerffer et al., 2010). 
Recent studies have reported that production of IL-17 is abnormally high in patients with 
SLE. Its levels are increased in SLE sera and correlate with SLE disease activity. Moreover, 
the frequency of IL-17-producing T cells is increased in the peripheral blood of patients with 
SLE (Crispín  & Toscos, 2010; Shah et al., 2010).  Recent evidence indicates that a significant 
fraction of the IL-17 produced in SLE derives from Th17 cells and CD3+CD4-CD8- (double 
negative or DN) T cells (Nalbandian  et al., 2009).  
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The identification of Th17-lineage-specific transcription factors, established Th17 cells as an 
independent T-cell subset. Differentiation of naïve T cells into Th17 cells depends on TGF-β 
and IL-6, being IL-23 essential for expansion and maintenance of pathogenic Th17 cells 
(Jäger & Kuchroo, 2010). Interestingly, the participation of TGF-β in the differentiation of 
Th17 cells places the Th17 lineage in close relationship with CD4+CD25+Foxp3+ regulatory T 
cells (Tregs), as TGF-β also induces differentiation of naive T cells into Foxp3+ Tregs in the 
peripheral immune compartment (Korn  et al., 2009).  
In light of this knowledge, now is the general notion that there is a reciprocal relationship 
between pro-inflammatory IL-17-producing Th17 cells and protective Foxp3+ Tregs. The 
presence of pro-inflammatory cytokines like IL-6, which is induced during infection, 
inflammation or injury, inhibited the induction of Foxp3+ Tregs and simultaneously 
promoted Th17-cell differentiation (Bettelli et al., 2006). On the other hand, tolerance 
induction was associated with decreased IL-6 production and increased TGF-β production 
that paralleled a reduction in the fraction of IL-17-producing T cells and a reciprocal 
increase in regulatory T cells (Kang  et al., 2007). Therefore, some authors support the notion 
that therapeutic intervention in SLE should focus on therapeutic agents that can regulate the 
immune balance between Th17 and Treg cells rather than on those that exclusively regulate 
Th17 cells or a specific cytokine (Yang et al., 2011). 
3.8 IL-10 
Interleukin (IL)-10 is one of the most important cytokine with anti-inflammatory properties. 
Today it its known that the ability to synthesize IL-10 is not limited to certain T cells subsets, 
but is characteristic of almost all leukocytes. Very important sources in vivo appear to be 
mainly monocytes and macrophages as well as Th cells (Sabat et al., 2010). 
IL-10 is a potent inhibitor of antigen presentation. The other profound effect of IL-10 is to 
inhibit the production of proinflammatory cytokines and mediators from macrophages and 
DCs. The major inflammatory cytokines, IL-1, IL-6, IL-12, and tumor necrosis factor (TNF), 
are all dramatically repressed following exposure to IL-10. On the other hand, IL-10 can 
costimulate B-cell activation, prolong B-cell survival, and contribute to class switching in B 
cells (Mosser & Zhang, 2008). 
Multiple studies have reported high levels of IL-10 in SLE patients and in murine models of 
lupus, and this increase correlated with disease activity (Capper et al., 2004; Hagiwara et al., 
1996; Houssiau et al., 1995; Park et al., 1998). However, the specificity of these findings is 
unclear. A recent study  that investigated the role of IL-10 in a novel congenic model of 
lupus, B6.Sle1.Sle2.Sle3 (B6.TC) showed, that  although B6.TC mice produced higher IL-10 
levels that nonautoimmune control mice, an overexpression of IL-10 decreased T-cell 
activation, auto-antibody production and autoimmune pathogenesis (Blenman et al., 2006).  
Interestingly, other study has recently been shown that the presence of immune complexes  
and IFNα a cytokine implicated in the pathogenesis of SLE, decreases the capacity of IL-10 
to suppress inflammation, limiting therefore the anti-inflammatory effect of this cytokine 
(Yuan et al., 2011). These results reinforce the notion that IL-10 exerts multiple functions and 
we must be cautious in equating high levels of IL-10 and increased pathogenesis in systemic 
autoimmunity (Blenman et al., 2006).  
4. Cytokines in organ damage  
4.1 Cutaneous lupus and cytokines 
Cutaneous lupus erythematosus represents an autoimmune disease characterized by 
photosensitivity, apoptosis of keratinocytes and an inflammatory infiltrate in superficial 
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and/or deep compartments of the skin. Skin disease is the second most common 
manifestation in SLE patients. Although clearly there is a link between the skin and systemic 
manifestations of SLE, often the skin may flare independently or patients may have SLE 
without skin disease. Treatments also may improve the skin, systemic disease, or both, 
suggesting that there are differences pathogenetically between skin and systemic findings in 
cutaneous lupus.  
UV-irradiation is a well-known trigger of apoptosis in keratinocytes and there is 
accumulating evidence that abnormalities in the generation and clearance of apoptotic 
material is an important source of antigens in autoimmune diseases (Caricchio et al 2003). 
Phototesting studies suggest that both UVB and UVA are potentially pathogenic  
wavelengths, although it is clear that UVA induction requires higher doses of light relative 
to UVB. UV light can  induce the binding of autoantibodies  to selected nuclear antigens 
located on blebs or apoptotic bodies of skin. It has been suggested that these bleb-associated 
antigens may then be phagocyted, packaged, and presented to lymphocytes, thereby 
stimulating autoimmune responses (Casciola-Rosen  & Rosen   1997). The high presence of 
anti-Ro antibodies in cutaneous involvement in lupus might be explained because anti-Ro 
antibodies might interfere with protection from UV damage as genetic knock-out of 60kD 
Ro resulted in an SLE-like illness in multiple strains of mice that were susceptible to UV 
damage (Xue et al 2003).  
Exposure of keratinocytes to UVB results in the synthesis of many pro-inflammatory 
cytokines, including tumor necrosis factor-a (TNF-α) interleukin-1α (IL-1α), IL-6, IL-8, and 
IL-10 (Brink et al 2000). TNF-α is not only involved in the mediation of local inflammatory 
reactions within the epidermis, but may also enter the circulation and cause systemic effects. 
There is an association of subacute cutaneous LE  with the extended HLA haplotype   
DRB1*03-B*08. Contained within this haplotype is the TNF2 allele, a TNFα promoter 
polymorphism, associated with increased TNFα production (Werth et al 2000). 
UV induced injury trigger  the initial chemokine  production and release results in a first wave 
of skin-homing memory T cells and plasmacytoid dendritic cells (PDCs) via chemokine driven 
pathways. DNA, RNA, and immune complexes, present in skin containing apoptotic material, 
can serve as IFN-alpha inducers  in PDCs . There is a higher frequency of PDCs in skin 
compared to the blood of patients with SLE, suggesting that PDCs migrate from the circulation 
into the skin. Under normal conditions PDCs are not able to respond to self nucleic acids,  but 
in lupus PDCs became activated to produce INF-α by self nucleic acids in complex with 
autoantibodies to DNA or nucleoproteins. These immuno-complexes trigger innate activation 
of PDC through TLR7 and 9 and lead to sustained production of INF-α (show Figure 2) that 
may induce  an unabated maturation of dendritic cells  and the activation of autoreactive  T 
cells.    Enhanced type I IFN signaling promotes Th1-biased inflammation in cutaneous lupus. 
IFN-α can amplify cutaneous inflammation via the induction of chemokines that recruit  
potentially auto-reactive T cells into the skin. For example, IFN-α induces the production of 
chemokines, CXCL9, CXCL10, and CXCL11, which recruit chemokine receptor CXCR3 
expressing lymphocytes, including Th1 cells and CD8+ T cells, from peripheral blood into 
inflamed skin (Wenzel et al 2005). Large numbers of CXCR3+ lymphocytes are detected  in 
cutaneous lupus skin lesions. The majority of these infiltrating cells are memory T CD4+ 
lymphocytes. Among memory T cell subsets, CXCR3 is predominantly expressed on the 
surface of IFN-γ-producing Th1 cells, generating a proinflammatory effector response (Meller 
et al 2005). Hence, UV-irradiation may induce chemokine production and release, 
subsequently recruiting a first wave of skin-homing memory T cells and PDCs to sites of UV-
injury which produce cytokine-mediated inflammation and tissue damage. 
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4. Cytokines in organ damage  
4.1 Cutaneous lupus and cytokines 
Cutaneous lupus erythematosus represents an autoimmune disease characterized by 
photosensitivity, apoptosis of keratinocytes and an inflammatory infiltrate in superficial 
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and/or deep compartments of the skin. Skin disease is the second most common 
manifestation in SLE patients. Although clearly there is a link between the skin and systemic 
manifestations of SLE, often the skin may flare independently or patients may have SLE 
without skin disease. Treatments also may improve the skin, systemic disease, or both, 
suggesting that there are differences pathogenetically between skin and systemic findings in 
cutaneous lupus.  
UV-irradiation is a well-known trigger of apoptosis in keratinocytes and there is 
accumulating evidence that abnormalities in the generation and clearance of apoptotic 
material is an important source of antigens in autoimmune diseases (Caricchio et al 2003). 
Phototesting studies suggest that both UVB and UVA are potentially pathogenic  
wavelengths, although it is clear that UVA induction requires higher doses of light relative 
to UVB. UV light can  induce the binding of autoantibodies  to selected nuclear antigens 
located on blebs or apoptotic bodies of skin. It has been suggested that these bleb-associated 
antigens may then be phagocyted, packaged, and presented to lymphocytes, thereby 
stimulating autoimmune responses (Casciola-Rosen  & Rosen   1997). The high presence of 
anti-Ro antibodies in cutaneous involvement in lupus might be explained because anti-Ro 
antibodies might interfere with protection from UV damage as genetic knock-out of 60kD 
Ro resulted in an SLE-like illness in multiple strains of mice that were susceptible to UV 
damage (Xue et al 2003).  
Exposure of keratinocytes to UVB results in the synthesis of many pro-inflammatory 
cytokines, including tumor necrosis factor-a (TNF-α) interleukin-1α (IL-1α), IL-6, IL-8, and 
IL-10 (Brink et al 2000). TNF-α is not only involved in the mediation of local inflammatory 
reactions within the epidermis, but may also enter the circulation and cause systemic effects. 
There is an association of subacute cutaneous LE  with the extended HLA haplotype   
DRB1*03-B*08. Contained within this haplotype is the TNF2 allele, a TNFα promoter 
polymorphism, associated with increased TNFα production (Werth et al 2000). 
UV induced injury trigger  the initial chemokine  production and release results in a first wave 
of skin-homing memory T cells and plasmacytoid dendritic cells (PDCs) via chemokine driven 
pathways. DNA, RNA, and immune complexes, present in skin containing apoptotic material, 
can serve as IFN-alpha inducers  in PDCs . There is a higher frequency of PDCs in skin 
compared to the blood of patients with SLE, suggesting that PDCs migrate from the circulation 
into the skin. Under normal conditions PDCs are not able to respond to self nucleic acids,  but 
in lupus PDCs became activated to produce INF-α by self nucleic acids in complex with 
autoantibodies to DNA or nucleoproteins. These immuno-complexes trigger innate activation 
of PDC through TLR7 and 9 and lead to sustained production of INF-α (show Figure 2) that 
may induce  an unabated maturation of dendritic cells  and the activation of autoreactive  T 
cells.    Enhanced type I IFN signaling promotes Th1-biased inflammation in cutaneous lupus. 
IFN-α can amplify cutaneous inflammation via the induction of chemokines that recruit  
potentially auto-reactive T cells into the skin. For example, IFN-α induces the production of 
chemokines, CXCL9, CXCL10, and CXCL11, which recruit chemokine receptor CXCR3 
expressing lymphocytes, including Th1 cells and CD8+ T cells, from peripheral blood into 
inflamed skin (Wenzel et al 2005). Large numbers of CXCR3+ lymphocytes are detected  in 
cutaneous lupus skin lesions. The majority of these infiltrating cells are memory T CD4+ 
lymphocytes. Among memory T cell subsets, CXCR3 is predominantly expressed on the 
surface of IFN-γ-producing Th1 cells, generating a proinflammatory effector response (Meller 
et al 2005). Hence, UV-irradiation may induce chemokine production and release, 
subsequently recruiting a first wave of skin-homing memory T cells and PDCs to sites of UV-
injury which produce cytokine-mediated inflammation and tissue damage. 
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4.2 Neuropsychiatric SLE 
Neuropsychiatric systemic lupus erythematosus (NPSLE) involves neurological 
manifestations seen in the central, peripheral, and autonomic nervous systems as well as 
psychiatric disorders in patients with SLE in which other causes have been excluded. 
NPSLE may occur at any time during the course of the disease, and symptoms are extremely 
diverse, ranging from depression, psychosis, and seizures to stroke (Committee on 
Neuropsychiatric Lupus Nomenclature 1999).  Though the pathophysiology of NPSLE has 
not yet been elucidated, two mechanisms of damage, specifically those produced by 
autoantibodies, and inflammatory mediators, are implicated in NPSLE. The most common 
neuropathologic features are multifocal microinfarcts  many of them due to the effect of 
anti-cardiolipin antibodies (Hanlyet al 1992).  
Cytokines and chemokines have  been implicated in the pathophysiology of NPSLE. Of the 
different cytokines studied, interleukin-6 (IL-6) has been shown to have the strongest 
positive association with NPSLE (Fragoso-Loyo et al 2007). IL-6 is a cytokine with high 
proinflammatory activity. IL-6 level in the CSF of NPSLE was reported to be elevated 
without damage of the blood-brain barrier, demonstrating an intrathecal synthesis of IL-6. 
In addition, the expression of IL-6 mRNA was elevated in the hippocampus and cerebral 
cortex, suggesting that IL-6 expression was increased within the entire CNS of NPSLE 
(Hirohata & Hayakawa 1999). Furthermore, when IL-6 activity was followed throughout 
symptom remission, they noted a decrease in CSF IL-6 activity measured indirectly, but not 
in serum IL-6 activity (Hirohata &  Miyamoto 1990). A recent study has shown that the 
sensitivity and specificity of CSF IL-6 for diagnosis of lupus psychosis was 87.5% and 92.3%, 
respectively, indicating that CSF IL-6 might be an effective marker for the diagnosis of lupus 
psychosis (Hirohata et al 2009). Although some cytokines are important biomarkers of 
NPSLE, the mechanism for the elevated levels of cytokines is thus far unknown.  Immune 
complexes in SLE can stimulate IFN-α and there is strong evidence in humans and in mice 
that IFN-α can cause neuropsychiatric manifestations. It has recently described using a 
bioassay containing plasmacytoid dendritic cells,  that NPSLE CSF induced significantly 
higher IFN-α compared with CSF from patients with multiple sclerosis or other autoimmune 
disease controls.  NPSLE CSF was 800-fold more potent at inducing IFN-α compared with 
paired serum, due to inhibitors present in serum (Santer et al 2009). Further immunological 
studies are expected to show how autoantibodies in SLE patients work to promote the 
cytokine storm associated with the pathophysiology of NPSLE. 
4.3 Cytokines role in lupus nephropathy 
Renal involvement in SLE  is present in over 50% of patient with active SLE and remains a 
major cause of end-stage renal disease and it is associated with a greater than four-fold 
increase in mortality in recent series (Bernatsky  et al., 2006; Boumpas et al., 1995). The 
pathologic manifestations of lupus nephritis (LN) are extremely diverse and may affect any 
or all renal compartments. The complexity of renal manifestations can be most easily 
approached using the World Health Organization Classification revised and updated in 
2004 (Weening  et al., 2004). 
The picture of cytokines present in LN is already complex and no single-cell population or 
cytokine has been decisively identified as a key mediator. Elevated circulating levels and/or 
tissue mRNA transcripts for several cytokines are reported in lupus patients and mice. On 
the other hand, the data regarding the relative importance of Th1-type versus Th2-type 
cytokines are inconsistent (Foster, 2005; Theofilopoulos et al., 2001).  
 
Cytokines and Systemic Lupus Erythematosus 
 
65 
The development of laser-manipulated micro dissection (LMD) from clinical biopsy 
specimens, together with  messenger RNA (mRNA) expression analysis in the targeted 
glomeruli or specific regions of interest, using real-time quantitative PCR,  has allowed to 
explore the single-cell cytokine profile of the samples from the LN patients. Interestingly a 
recent study, using LMD and PCR analysis of renal biopsy samples from LN patients has 
showed a negative correlation between the level of IL-2 and renal damage while a positive 
correlation between IL-17 and renal damage was evidenced. Indicating that IL-2 and IL-17 
play opposite roles in SLE development, suggesting that IL-2 may play a role in protecting 
against SLE development, while IL-17 might have a reverse effect (Wang et al., 2010). On the 
other hand, recent studies have highlighted the potential importance of the Th17 immune 
response in renal inflammatory disease. These include the identification and 
characterization of IL-17-producing T cells in nephritic kidneys of mice and humans, as well 
as evidence for the contribution of IL-17 and the IL-23/Th17 axis to renal tissue injury in LN 
(Turner et al., 2010; Zhang et al., 2009). 
5. Conclusions 
This chapter has focused in the  new insights about the role of cytokine  in the pathogenesis 
of Systemic Lupus Erythematosus. The imbalance in the levels of cytokines and their 
receptors found in SLE is clearly crucial to the development of the pathology of the disease. 
The cytokines are actively involved in both favoring the production of auto-antibodies as 
generating inflammation in affected tissues. Interactions between the cytokine milieus are 
complex and the attenuation of one cytokine  would need to be approached  with caution, 
considering effects on the cytokine network as a whole. There are still many facets of 
immunopathology of SLE elicited by  cytokines to be elucidated. A more in-depth 
understanding of these cytokines may be of clinical significance in the context of devising 
biomarkers or therapeutic agents. Cytokine therapy, is highly probable that, in the future 
will take a relevant place in the therapeutic armamentarium of autoimmune disorders. 
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1. Introduction 
Systemic lupus erythematosus (SLE) is generally diagnosed long after the disease begins.  
This means that the cause of the disease is hard to find, buried in the past.  In the search for 
the elusive causal agents for SLE, one candidate is the immune signaling molecule, 
interferon (IFN). Interferon is a secreted signaling protein, or cytokine, which is expressed at 
higher levels in SLE patients and has been associated with incidence and severity of the 
disease. 
A combination of environmental triggers and genetic susceptibility combine to initiate SLE.  
Although there are many etiological components, they usually converge on a heightened 
state of activation for the immune system, with resultant increases in interferon production 
and interferon signaling.  That is to say that interferon could be thought of as either a 
causative agent, a result of the disease, or both. 
This chapter will discuss the basics of interferon function and how de-regulation of 
apoptosis can lead to interferon production due to immune complexes.  We will then 
discuss how the functioning of the immune system changes in someone with SLE, the genes 
which are associated with risk for SLE, and clinical manifestations of interferon in SLE.   
2. How interferon works in the context of SLE 
Interferon is a signaling protein which is secreted to activate neighboring cells in response to 
viruses or other infections.  It is a cytokine, or immune signaling molecule which allows 
communication between cells.  When a cell is infected with a virus, interferon is produced 
and secreted as a warning to other cells to prepare for an infection.  Interferons alpha (IFNα) 
and beta (IFNβ) are the type I interferons, and interferon gamma (IFNγ) is the type II 
interferon.  Most of the cells in the human body have receptors for type I IFN, whereas 
certain immune cells express the receptor for type II IFN (Su, et al., 2004).  The proteins are 
made by many different cells, but generally speaking, IFNα is of leukocyte origin, IFNβ is of 
fibroblast origin, and IFNγ is made by lymphocytes (Lucero, et al., 1982).  Other less studied 
interferons also exist, and interferons are conserved among many species.  This chapter will 
talk mostly about type I interferons, which are IFNα and IFNβ.   
The main purpose of interferon is to shut down a cell before a virus can take it over, 
although it has many other jobs (Niewold, et al., 2010).  Interferon signaling leads to 
increased apoptosis, which is a normal response to control viral spread or to decrease the 
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size of a tumor (Takaoka, et al., 2003).  If one cell can undergo apoptosis before a virus can 
replicate and infect other cells, the infection is halted (Luker, et al., 2005). 
 
 
Fig. 1. Interferon protein structures.  Interferons alpha and beta, the type I interferons, have 
a common structure composed mainly of five alpha helices (shown are IFNα2a and IFNβ1 
based on PDB files 1itf and 1au1, respectively).  Although the monomers of each are very 
similar in structure, the functional form of both is a dimer, and the two dimerize differently, 
IFNα2a along homologous surfaces and IFNβ1 on opposing sides of the protein (Karpusas, 
et al., 1997).  IFNγ is show in its dimerized form, with the two colors representing two 
intertwined monomers (based on PDB file 1hig).  Not shown to scale; figures drawn with 
Jmol (Jmol, 2011). 
Interferon can be produced in response to infection, other cytokines, mitogens and several 
signaling pathways.  Once produced it is secreted where it can be recognized by other cells, 
which is called paracrine signaling, or by the cell which produced it, called autocrine 
signaling.  One type of cell, the plasmacytoid dendritic cell (pDC) is a natural IFN producer, 
and is able to make very large amounts of IFNα (Ronnblom & Alm, 2001). 
When interferon ligates an interferon receptor, signaling pathways are activated.  Interferon 
causes an increase in the expression of both major histocompatibility complexes (MHCI and 
MHCII) for presentation of viral peptides to T cells, which can then lead to activation of 
other cells in order to kill infected cells, and remove them (Fruh & Yang, 1999).  Interferon 
also increases intracellular levels of protein kinase R (PKR) which recognizes viral nucleic 
acids and activates RNase L to degrade viral RNAs.  PKR also slows protein synthesis by 
inactivating translational initiation factors, so that viral proteins synthesis is slowed (Pindel 
& Sadler, 2011).  p53 is also activated, which is pro-apoptotic (Takaoka, 2003).  Interferons 
activate immune cells, especially natural killer cells and macrophages (Murray, 1988).  This 
activation cascade is normally “turned off” after an infection is cleared to prevent damage to 
uninfected cells.  However this activation state is not reduced to the normal levels in 
individuals with SLE, where a higher level of interferon is present (T. Kim, et al., 1987; 
Ytterberg & Schnitzer, 1982).  This higher amount of interferon is also measurable by an 
increase in the expression of interferon-stimulated genes seen in lupus patients, called the 
interferon response signature (Baechler, et al., 2003; Bennett, et al., 2003; Feng, et al., 2006). 
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Fig. 2. Cell to cell IFN signaling and its effects.  One cell produces interferon and either 
another cell (paracrine signaling) or the same cell (autocrine signaling) receives the signal.  
↑: an increase, ↓: a decrease, MHC: major histocompatibility complex, PKR: protein kinase R, 
NK: natural killer cell, MΦ: macrophage 
As a general feature of autoimmune diseases such as SLE, the immune system is in  
an “always on” state, which can lead to a breach in the body’s natural tolerance to self.  
Once this self tolerance is lost, autoimmune disease can result.  In addressing why the 
immune system generates an attack against one’s own body, the over activation of the 
immune system, including the overproduction of interferon in SLE patients is a part of this 
picture. 
3. Interferon leads to apoptosis, and the SLE-apoptosis connection 
One effect of interferon production is the release of autoantigens due to increased cell death.  
This release is normally controlled by a process called efferocytosis, or apoptotic cell 
removal, where cell debris are processed by immune cells or neighboring cells which 
remove them by phagocytosis.  Defects in apoptotic pathways have been noted  
in individuals with SLE (Gaipl, et al., 2006).  Examples of why this occurs have been studied.  
For example, in SLE patients there is an overexpression of both soluble and membrane-
bound Fas.  Fas is a receptor which when ligated signals to a cell to undergo apoptosis.   
The levels of Fas also correlate with the amount of apoptotic lymphocytes and disease 
activity of SLE (Li, et al., 2009; Sahebari, et al., 2010).  Mouse models of lupus commonly 
have genetic variations in apoptotic pathways such the Fas/Fas L pathway and interferon 
pathways. 
Mouse as well as human SLE patients make antibodies to self antigens.  This is likely 
because of over-exposure of potential autoantigens to the immune system.  This could be 
due to an increased amount of apoptosis, or a decrease in the rate of clearance of apoptotic 
debris. Apoptosis, which can be induced by interferon, is also part of the natural cycle of 
cellular growth and death.  Cells undergoing apoptosis are recognized as dead by other 
cells, so that they are cleared (Munoz, et al., 2010). 
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size of a tumor (Takaoka, et al., 2003).  If one cell can undergo apoptosis before a virus can 
replicate and infect other cells, the infection is halted (Luker, et al., 2005). 
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Jmol (Jmol, 2011). 
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Fig. 3. Production of interferon can begin with defects in apoptosis.  This can be due to 
either an increase in apoptosis or a decrease in clearance of apoptotic debris.  If contents are 
released, they can form immune complexes with autoantibodies.  These immune complexes 
can cause cells to produce interferon.  Manipulating this pathway is also a common 
characteristic of mouse models of lupus. 
3.1 Mouse models allow the study of IFN and apoptosis pathways 
Mouse models have been very useful in understanding the etiology and pathogenesis of 
lupus.  Two approaches to experimental mice have been used to generate information about 
the role of interferon in lupus.  In the first approach, interferon-related genes are knocked 
out and the resulting effects on lupus are studied.  For the second, established lupus mouse 
models are studied on a molecular level for differences in interferon pathways or interferon-
related effects. These two approaches often overlap, as in cases where interferon-related 
genes are knocked out in lupus-prone mice.  Several established lupus mouse models 
include the MRL/lpr mice, NZW/NZB, and others.  These are mice that spontaneously 
develop lupus, and several of them have been investigated to understand the role of 
interferon in their pathogenesis.  Although a complete description of the mouse models for 
lupus is beyond the scope of this or any one publication, a few illustrative examples 
represent the power of these model systems. 
One mouse model that is especially relevant for the study of interferon in lupus is the 
BXSB/MpJ (BXSB) or Yaa mouse.  These mice spontaneously develop lupus-like disease in a 
sex-linked fashion because of a duplication of the Toll-like receptor 7 (TLR7) gene on the 
Y chromosome (Izui, et al., 1994).  TLR7 is responsible for inducing interferon in response to 
viral infection or autoantibody production. 
Another interesting mouse for the study of interferon is the NZB/NZW mouse.  These mice 
spontaneously develop a lupus-like autoimmune disease.  They have been used to 
investigate the role of several interferon-related molecules and cells.  For example, treating 
these mice with interferon accelerates disease in a T-cell like manner (Z. Liu, et al., 2010; 
Mathian, et al., 2005), while knocking out or inhibiting interferon-related genes slows or 
eliminates the development of lupus-like symptoms  (Jorgensen, et al., 2007; Sharma, et al., 
2005).  These mice have been used to clarify the interactions between sex hormones and 
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interferon in lupus etiology (Bynote, et al., 2008; Panchanathan, et al., 2009; Panchanathan, et 
al., 2010), and they serve as an excellent all-around model for spontaneous development of 
lupus. 
The role of several interferon-related molecules has been examined using a combination of 
mouse models.  As an example, consider the gene interferon regulatory factor five (IRF5).  
This gene is an interferon-regulating gene which will be described in section 5.2 below.  It 
was discovered that knockout of IRF5 prevents or inhibits the development of lupus in 
MRL/lpr mice, Fcγ-/- Yaa mice, and pristine-injected mice (Richez, et al., 2010; Savitsky, et 
al., 2010; Tada, et al., 2011). 
Mouse models for lupus represent a powerful and flexible mechanism for investigating the 
role of multiple aspects of lupus.  However, it must be remembered that the mutations or 
disease manifestations in these mice are not necessarily related to those seen in human 
lupus, and therefore the results observed must be interpreted with caution. 
4. A cycle of autoantibody production 
When it comes to SLE we may think of interferon production as a cycle, which begins when 
an environmental trigger, such as a viral infection, UV light damage or medical treatment 
activates the immune system to produce interferon. 
Normally B cells which produce antibodies to self-antigens undergo negative selection, 
where they receive signals to die off or become inactivated if they make antibody against a 
self-antigen.  This self-tolerance is breached in SLE (Cancro, et al., 2009), and the self-
antigens released from damaged or apoptotic cells during or after initial triggering events 
become the targets of autoantibodies.  When autoantibodies are produced, they are made by 
B cells as well as plasma cells, which are a mature differentiated form of B cells. 
 
 
Fig. 4. The altered immune response in SLE generates a cycle.  In blue is a cycle which exists 
in SLE, amplifying the amount of IFN present.  This cycle needs a trigger, but once it begins, 
it can leave the immune system in an “always on” state. 
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Autoantibodies lead to the production of interferon by forming immune complexes which 
are immunostimulatory (Ronnblom, et al., 2011).  Immune complexes are composed of 
aggregates of antibody and antigen molecules which are processed by the body.  These 
immune complexes are a main source of SLE pathology, as they obstruct small passages in 
areas of the body such as the kidneys and joints (Crispin, et al., 2010). 
Immune complexes may include the common SLE autoantigens such as RNA-containing 
protein complexes like Sm, RNPs, Ro, and La.  Having a combination of both nucleic acids 
and protein complexed with antibody means many pathways can be turned on.  For 
example, antibody can stimulate an immune cell through an Fc receptor, nucleic acids can 
stimulate cells through Toll-like receptors (TLRs), and proteins can be recognized by other 
antibodies. 
Immune cells are activated by immune complexes and the cycle continues.  Interferon 
production is instigated by immune cells which recognize part of the complex, be it the 
antibody, the antigen, or other associated molecules. 
5. SLE genetic risk screens identify genes in interferon signaling pathways 
We have looked at the disease state of SLE, and how the immune system functions 
improperly to instigate disease.  Things begin when an environmental trigger works on the 
genetic background of varying degrees of susceptibility.  Genetic susceptibility is thought to 
account for at least 20% of the risk for SLE (Deapen, et al., 1992).  To find the actual genes 
involved, studies are performed to determine the linkage or association of a variation in the 
genome to a particular disease. 
One important method is called a genome wide association study (GWAS).  These GWA 
studies genotype thousands of individuals, grouped into SLE patients and non-patients 
comparing them at thousands of single nucleotide polymorphisms (SNPs).  These studies 
reveal the genomic regions which contain disease-associated genes, because the variations 
are more common in people with the disease.  Individual genes or gene pathways are 
pinpointed, and can ultimately lead to treatment strategies.  Many genes have been 
identified that contain SNPs which confer risk to SLE. 
These studies are especially useful for diseases with unknown or complex genetic 
components.  The genome is examined for sets of single nucleotide polymorphisms (SNPs).  
When sets of SNPs are usually inherited together in a group it is called a haplotype.  When a 
haplotype is more common in the disease group than in the unaffected group, it can be 
assumed that it is associated with the disease.  Although specific genes are sometimes found 
which may predict a disease, it is more likely that the information will reveal molecular 
pathways associated with the disease.  Association of genes or pathways to diseases such as 
heart disease, asthma, diabetes and others have been found using this method (Stranger, et 
al., 2011).  The amount of effect is measured as an odds ratio (OR), which is a measure of the 
strength of association of the disease with a haplotype.  A median OR value is around 1.3, 
with some genes having much higher association ORs.  For example, one of the lupus-
associated haplotypes TREX1, has a published OR of 25 (Lee-Kirsch, et al., 2007).  In such 
cases, the genetic risk is almost certainly associated with the disease. 
An important caveat to these tests is that they answer the question, “What?” but not the 
question, “How?”  That is, they identify genetic loci which confer risk to SLE, but then 
further studies are needed to show what functional changes affect people with a risk 
haplotype.  For most of the genes, we do not know what functional role they play.  However 
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it is promising to note that the genes are within certain pathways, some of which are already 
associated with lupus. 
 
 
Fig. 5. Genome wide association studies (GWAS).  Genome-wide association studies aim to 
discover the genetic risk component of a disease by finding differences in a group with the 
disease compared to a group of unaffected control individuals. 
Several review articles have reviewed the findings of many lupus GWAS with varying 
degrees of certainty (R.R. Graham, et al., 2009; I.T.W. Harley, et al., 2009; Moser, et al., 2009; 
Rhodes & Vyse, 2008; Sebastiani & Galeazzi, 2009).  In some cases the indicated 
susceptibility genes are common in many ethnicities and populations, while others are 
specific to certain groups. The statistical significance of many of these genes is well 
established, while others are novel and need to be replicated by other groups.  An important 
finding is that most of the genes that have been identified in GWA studies can be grouped 
into several functional pathways.  We will focus on the genes in the IFN pathway and the 
pathways involving clearing of apoptotic cells and immune complexes.   
5.1 Interferon production pathways 
Intracellular signaling pathways which control interferon production include the production 
of type I interferons by interferon regulatory factors (IRFs), and the production of type II 
interferon by STAT4.  IRFs are activated by TLRs, which are extracellular or endosomal 
pattern recognition molecules. TLRs 7, 8, and 9 recognize nucleic acids and are endosomal.  
Maintaining these TLRs in the endosome instead of the cell surface is an important barrier to 
too frequent TLR activation.  Once the nucleic acids are brought into the cells through 
endocytosis, the TLRs become activated to turn on IRFs.  TLR 8 and TLR 9 have both been 
identified as lupus risk genes (Armstrong, et al., 2009; Xu, et al., 2009). 
TLRs begin a signaling cascade through a MyD88 signaling complex.  MyD88 activates 
another confirmed locus of SLE risk, the gene which encodes IL1 receptor-associated kinase 1 
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(IRAK1).  In Sle1 and Sle3 mouse models of lupus, IRAK deficiency eliminated most lupus 
symptoms (Jacob, et al., 2009), which highlights the importance of IRAK1.  Since this gene is on 
the X chromosome, it could help explain why lupus is more common among women.  The 
MyD88 complex can be affected by osteopontin (OPN). It regulates IFNα production in 
plasmacytoid dendritic cells, which are the body’s main IFNα producer cell (Cao & Liu, 2006).  
The lupus-risk variant of OPN was tied to high IFNα levels in certain lupus patients (Kariuki, 
et al., 2009b). 
Two interacting proteins involved in inflammation, TNFα-induced protein 3 (TNFAIP3) and 
TNFAIP3-interacting protein 1 (TNIP1), are also lupus risk loci (Gateva, et al., 2009; Musone, 
et al., 2008). TNFAIP3 encodes the protein A20, which abrogates NF B after an 
inflammatory response, and lupus-risk variants of this gene are associated with blood and 
kidney manifestations (Bates, et al., 2009). TNIP1 interacts with TNFAIP3 as well as affecting 
several other signal transduction pathways. 
Interferon regulatory factors are activated next, downstream of TLRs; they are transcription 
factors which travel to the nucleus to bind DNA to initiate transcription.  IRF5 binds to a 
sequence-specific region of DNA to induce IFN production.  It has been confirmed as a risk 
factor for SLE in among several ethnicities (Kawasaki, et al., 2008; Kelly, et al., 2008; Lee & 
Song, 2009; Reddy, et al., 2007; Shimane, et al., 2009).  There are three main genetic variants 
within IRF5, one copy number variant with either two or four copies of a 30-bp sequence, 
and two SNPs (R.R. Graham, et al., 2007b).  The rs2004640 SNP changes the first exon, 
although this exon does not encode protein.  The other SNP, rs10954213, creates an early 
polyadenylation sequence, which yields shorter more stable mRNA (D.S.C. Graham, et al., 
2007a).  Work has shown that these variants increase the amount of IFN in the presence of 
SLE autoantibodies (Niewold, et al., 2008; Salloum, et al., 2009). 
 
 
Fig. 6. Interferon production pathways are affected by lupus-risk genes.  The * represents 
genes which have been identified as having risk for lupus.  The endosomal TLRs (7, 8, and 9) 
can bind to autoantigenic nucleic acids and signal through a MyD88 complex which can be 
affected by association with osteopontin (OPN).  If it is not blocked by TNFAIP3, this 
activates an IRAK signaling complex to phosphorylate the IRF5 and IRF7 transcription 
factors to produce type I IFN.  IL-12 or IL-23 signal through Tyk2/Jak2 to activate the 
STAT4 transcription factor to produce type II IFN, commonly in T helper cells (Watford, et 
al., 2004). 
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IRF7 is associated with SLE risk by its proximity to SNPs in the IRF7/KIAA1542 locus (J.B. 
Harley, et al., 2008; Suarez-Gestal, et al., 2009).  IRF7 SNPs have been shown to lead to 
increased IFNα levels and alter of which autoantibodies are made (Salloum, et al., 2009). 
Signal transducer and activator of transcription 4 (STAT4) is also associated with risk for 
SLE.  It is a transcription factor which activates genes in proliferation, differentiation and 
apoptosis pathways.  Two STAT4 SNPs have been examined, rs7574865 increases sensitivity 
to IFNα (Kariuki, et al., 2009a), and rs3821236 causes STAT4 to be transcribed at higher 
levels and is additive with IRF5 risk loci so that when both are present, the risk to SLE is 
multiplied (Abelson, et al., 2009; Sigurdsson, et al., 2008). 
5.2 Genes associated with apoptosis and immune complexes 
Another set of risk genes can be placed into a functional group of apoptosis-associated 
genes.  As we read earlier in the chapter, defects in apoptosis can lead to the presence of 
potential autoantigens.  For example, a cell undergoes apoptosis and instead of being 
cleared by other cells, its contents are released.  The cellular contents can contain things like 
nucleic acids, RNA binding proteins, and others which are common lupus autoantigens.  If 
antibodies bind to these antigens, a complex of multiple antibodies and multiple antigens 
can aggregate.  The resultant immune complexes can be broken down through reactions 
with complement components, which are commonly found at low levels in SLE patients 
(C.C. Liu & Ahearn, 2009).  If they are not broken down, they reach areas such as the 
kidneys or joints, which can be damaged by these immune complexes.  This is how organ 
damage usually occurs in lupus patients. 
 
 
Fig. 7. Genes associated with risk for lupus in the apoptosis pathway.  The * represents 
genes which have been identified as having risk for lupus.  TNFα, CASP10 and IRF5 are 
pro-apoptotic whereas OPN and p21 are anti-apoptotic.  These genes all have a role in how 
much apoptosis is occurring.  Once apoptosis has transpired, the cell must be cleared.  Parts 
of apoptotic cells or immune complexes can be recognized by other cells to facilitate their 
removal.  This is aided by recognition molecules such as the complement components 
shown here. 
The problem of creating autoantibodies could stem from too much apoptosis or too little 
clearance of apoptotic debris.  Genes identified in GWA studies that could alter the amount 
of apoptosis include TNFα, caspase 10, IRF5, osteopontin and p21. 
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other cells and is found at high levels in the serum of lupus patients (Davas, et al., 1999; 
Emilie, et al., 1996; Sabry, et al., 2006).  Part of its function is to induce apoptosis—when a 
cell binds TNFα, it activates the caspase cascade.  Caspases are proteases which are 
activated under certain conditions and are a hallmark of apoptosis.  They cleave other 
caspases as well, and the combined proteolytic activity of several different activated 
caspases breaks down cellular components as the cell prepares to die.  Caspase 10 is part 
of this cascade and is another lupus susceptibility gene (Armstrong, et al., 2009).  Caspase 
8, is activated by TNF signaling, and cleaves caspase 10, which then cleaves caspases 3 
and 7.  IRF5, as well as being a transcription factor which helps produce IFN, is also a 
tumor suppressor gene which is commonly inactivated in cancers.  This is because of 
IRF5’s pro-apoptotic function. 
Osteopontin (OPN) and p21 are also lupus risk genes, both anti-apoptotic.  OPN promotes 
proliferation, as well as prevention of death under apoptotic stimuli (Standal, et al., 2004).  A 
mimic of p21 was used in the treatment of murine lupus in the NZB/NZW mouse, and it 
was found to dramatically reduce the disease (Goulvestre, et al., 2005). 
So, there are genes which dysregulate the amount of apoptosis, and they are associated with 
risk for lupus. But this is only half of the picture; the other part is the clearance of apoptotic 
cells or immune complexes.  Several SLE susceptibility genes in this pathway have been 
identified as well.  Active SLE can be assessed when low levels of complement proteins are 
found in circulation.  Complement can function against microbes during an infection, but 
can also help to degrade immune complexes. Once attached, they can help cells recognize 
and degrade them. Other proteins function to bind apoptotic cells or immune complexes to 
facilitate their uptake by other cells. 
Integrin αM (ITGAM) has been convincingly associated to SLE (Nath, et al., 2008).  Risk 
variants of ITGAM have been associated with certain clinical manifestations of lupus (Kim-
Howard, et al., 2010).  It is a cell receptor which binds to OPN or to complement C3b.  C3b 
binds to apoptotic cells or immune complexes. 
SLE association with complement components C1q, C2, C4a and C4b have large OR 
values, meaning that the risk haplotypes of these genes are causing a large effect. When 
C1q is expressed at low levels it can lead to lupus, and it was shown to increase the amount 
the of IFN produced due to immune complexes (Lood, et al., 2009). Complement 
components function by binding immune complexes by the Fc region of antibody or by 
binding to other parts of apoptotic cells, which can opsonize them for easier uptake by 
other cells.  Cells can then remove the immune complex or apoptotic debris by 
endocytosis.  Receptors for the Fc region of antibody have also been implicated in SLE risk 
(Lee-Kirsch, et al., 2007).  These receptors can bind to antibody within an immune 
complex. 
Other proteins such as milk fat globule EGF factor 8 (MFG-E8) and C-reactive  
protein (CRP) can bind to apoptotic cells by recognizing phospholipids on their 
membranes.  MFG-E8 binds to phosphatidylserine, an “eat me” signal which is expressed 
on apoptotic cells.  The MFG-E8 knockout mouse gets SLE because of failure to remove 
apoptotic cells (Yamaguchi, et al., 2010).  CRP binds to phosphocholine, which is present 
on dying or damaged cells.  Both MFG-E8 and CRP are lupus risk genes (Batuca &  
Alves, 2009; Hu, et al., 2009; H.A. Kim, et al., 2009).  Low mannose-binding lectin (MBL) 
levels can lead to higher levels of apoptosis is this lupus-risk associated gene (Pradhan,  
et al., 2010). 
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The number of genes associated with risk for SLE will likely increase, though we have an 
interesting pool of genes already that point to certain pathways associated with the disease.  
The interferon and apoptosis pathways are certainly important in SLE etiopathogenesis. 
6. Clinical component of interferon and SLE 
Many researchers have sought to determine if higher levels of IFN, which is common in 
lupus patients, is a cause of lupus or an effect of lupus.  An interesting occurrence can 
happen when someone undergoes treatment with IFNα.  The presence of increased levels of 
IFN leads to lupus or a lupus-like syndrome (Gota & Calabrese, 2003; Ioannou & Isenberg, 
2000; Niewold & Swedler, 2005).  Because the lupus symptoms usually disappear after IFN 
treatment ends, this connection suggests that IFN may be more of a cause than an effect.  In 
a small number of cases, some patients also develop SLE as a result of these IFN treatments.  
Furthermore, within a family, the levels of interferon among all members correlate, 
suggesting that this is a heritable trait (Niewold, et al., 2007).  That is, even the siblings of a 
lupus patient with high IFN levels are more likely to have higher IFN levels.  This also 
supports a causal role for IFN. 
Clinically, disease activity can be measured and correlated to other observations to 
determine the cause of the different levels of activity.  One item linked to SLE activity is 
interferon, where higher levels of IFN in the serum correlated with more severe disease in 
most cases (Bauer, et al., 2009; Dall'Era, et al., 2005; Feng, et al., 2006; Landolt-Marticorena, et 
al., 2009; Petri, et al., 2009; Zhuang, et al., 2005). 
Common autoantibodies also correlate with IFN levels.  A very strong correlation is 
consistently observed between IFNα levels and the presence of antibodies to common SLE 
autoantigens like Ro, La, Sm, RNP, and dsDNA (Kirou, et al., 2005). 
Another set of findings has to do with properties of main producer of IFNα, the 
plasmacytoid dendritic cells (pDCs).  High numbers of IFN-producing pDCs have been 
observed in lupus skin lesions (Blomberg, et al., 2001; Farkas, et al., 2001).  Since the cells are 
present at the scene of the crime, the increased interferon could have to do with the 
pathology in these cases. 
At the time of writing, two clinical drug trials for SLE are being conducted, Sifalimumab is 
in Phase II, and Rontalizumab is in Phase I.  Both are antibodies, designed to block 
interferon alpha signaling by binding it to prevent its recognition by neighboring cells 
(Clinical Trials, 2011).  If these drugs are found to be effective, it will show that IFN plays a 
critical role in the pathogenesis of lupus.  In addition, the United States Food and Drug 
Administration recently approved an antibody to B lymphocyte stimulator (BLyS) to treat 
SLE called Belimumab (Sanz, et al., 2011).  This should help control the selective apoptosis 
and autoantibody production to some degree.  
7. Conclusions 
Several themes have been examined in this chapter.  Specifically that the production of 
interferon is tied to lupus and that apoptosis, clearance of apoptotic cells, and the 
formation of immune complexes are events that can augment the production of interferon.  
Exciting findings about the actual genetic causes of SLE are being examined which will 
lead to better treatments for this complex disease.  Although most of the data discussed in 
this chapter are inferential, there is a large body of evidence in support of the hypothesis 
that increased interferon signaling promotes an autoimmune state in those genetically 
prone to SLE. 
 
Systemic Lupus Erythematosus 
 
86
other cells and is found at high levels in the serum of lupus patients (Davas, et al., 1999; 
Emilie, et al., 1996; Sabry, et al., 2006).  Part of its function is to induce apoptosis—when a 
cell binds TNFα, it activates the caspase cascade.  Caspases are proteases which are 
activated under certain conditions and are a hallmark of apoptosis.  They cleave other 
caspases as well, and the combined proteolytic activity of several different activated 
caspases breaks down cellular components as the cell prepares to die.  Caspase 10 is part 
of this cascade and is another lupus susceptibility gene (Armstrong, et al., 2009).  Caspase 
8, is activated by TNF signaling, and cleaves caspase 10, which then cleaves caspases 3 
and 7.  IRF5, as well as being a transcription factor which helps produce IFN, is also a 
tumor suppressor gene which is commonly inactivated in cancers.  This is because of 
IRF5’s pro-apoptotic function. 
Osteopontin (OPN) and p21 are also lupus risk genes, both anti-apoptotic.  OPN promotes 
proliferation, as well as prevention of death under apoptotic stimuli (Standal, et al., 2004).  A 
mimic of p21 was used in the treatment of murine lupus in the NZB/NZW mouse, and it 
was found to dramatically reduce the disease (Goulvestre, et al., 2005). 
So, there are genes which dysregulate the amount of apoptosis, and they are associated with 
risk for lupus. But this is only half of the picture; the other part is the clearance of apoptotic 
cells or immune complexes.  Several SLE susceptibility genes in this pathway have been 
identified as well.  Active SLE can be assessed when low levels of complement proteins are 
found in circulation.  Complement can function against microbes during an infection, but 
can also help to degrade immune complexes. Once attached, they can help cells recognize 
and degrade them. Other proteins function to bind apoptotic cells or immune complexes to 
facilitate their uptake by other cells. 
Integrin αM (ITGAM) has been convincingly associated to SLE (Nath, et al., 2008).  Risk 
variants of ITGAM have been associated with certain clinical manifestations of lupus (Kim-
Howard, et al., 2010).  It is a cell receptor which binds to OPN or to complement C3b.  C3b 
binds to apoptotic cells or immune complexes. 
SLE association with complement components C1q, C2, C4a and C4b have large OR 
values, meaning that the risk haplotypes of these genes are causing a large effect. When 
C1q is expressed at low levels it can lead to lupus, and it was shown to increase the amount 
the of IFN produced due to immune complexes (Lood, et al., 2009). Complement 
components function by binding immune complexes by the Fc region of antibody or by 
binding to other parts of apoptotic cells, which can opsonize them for easier uptake by 
other cells.  Cells can then remove the immune complex or apoptotic debris by 
endocytosis.  Receptors for the Fc region of antibody have also been implicated in SLE risk 
(Lee-Kirsch, et al., 2007).  These receptors can bind to antibody within an immune 
complex. 
Other proteins such as milk fat globule EGF factor 8 (MFG-E8) and C-reactive  
protein (CRP) can bind to apoptotic cells by recognizing phospholipids on their 
membranes.  MFG-E8 binds to phosphatidylserine, an “eat me” signal which is expressed 
on apoptotic cells.  The MFG-E8 knockout mouse gets SLE because of failure to remove 
apoptotic cells (Yamaguchi, et al., 2010).  CRP binds to phosphocholine, which is present 
on dying or damaged cells.  Both MFG-E8 and CRP are lupus risk genes (Batuca &  
Alves, 2009; Hu, et al., 2009; H.A. Kim, et al., 2009).  Low mannose-binding lectin (MBL) 
levels can lead to higher levels of apoptosis is this lupus-risk associated gene (Pradhan,  
et al., 2010). 
 
Interferon and Apoptosis in Systemic Lupus Erythematosus 
 
87 
The number of genes associated with risk for SLE will likely increase, though we have an 
interesting pool of genes already that point to certain pathways associated with the disease.  
The interferon and apoptosis pathways are certainly important in SLE etiopathogenesis. 
6. Clinical component of interferon and SLE 
Many researchers have sought to determine if higher levels of IFN, which is common in 
lupus patients, is a cause of lupus or an effect of lupus.  An interesting occurrence can 
happen when someone undergoes treatment with IFNα.  The presence of increased levels of 
IFN leads to lupus or a lupus-like syndrome (Gota & Calabrese, 2003; Ioannou & Isenberg, 
2000; Niewold & Swedler, 2005).  Because the lupus symptoms usually disappear after IFN 
treatment ends, this connection suggests that IFN may be more of a cause than an effect.  In 
a small number of cases, some patients also develop SLE as a result of these IFN treatments.  
Furthermore, within a family, the levels of interferon among all members correlate, 
suggesting that this is a heritable trait (Niewold, et al., 2007).  That is, even the siblings of a 
lupus patient with high IFN levels are more likely to have higher IFN levels.  This also 
supports a causal role for IFN. 
Clinically, disease activity can be measured and correlated to other observations to 
determine the cause of the different levels of activity.  One item linked to SLE activity is 
interferon, where higher levels of IFN in the serum correlated with more severe disease in 
most cases (Bauer, et al., 2009; Dall'Era, et al., 2005; Feng, et al., 2006; Landolt-Marticorena, et 
al., 2009; Petri, et al., 2009; Zhuang, et al., 2005). 
Common autoantibodies also correlate with IFN levels.  A very strong correlation is 
consistently observed between IFNα levels and the presence of antibodies to common SLE 
autoantigens like Ro, La, Sm, RNP, and dsDNA (Kirou, et al., 2005). 
Another set of findings has to do with properties of main producer of IFNα, the 
plasmacytoid dendritic cells (pDCs).  High numbers of IFN-producing pDCs have been 
observed in lupus skin lesions (Blomberg, et al., 2001; Farkas, et al., 2001).  Since the cells are 
present at the scene of the crime, the increased interferon could have to do with the 
pathology in these cases. 
At the time of writing, two clinical drug trials for SLE are being conducted, Sifalimumab is 
in Phase II, and Rontalizumab is in Phase I.  Both are antibodies, designed to block 
interferon alpha signaling by binding it to prevent its recognition by neighboring cells 
(Clinical Trials, 2011).  If these drugs are found to be effective, it will show that IFN plays a 
critical role in the pathogenesis of lupus.  In addition, the United States Food and Drug 
Administration recently approved an antibody to B lymphocyte stimulator (BLyS) to treat 
SLE called Belimumab (Sanz, et al., 2011).  This should help control the selective apoptosis 
and autoantibody production to some degree.  
7. Conclusions 
Several themes have been examined in this chapter.  Specifically that the production of 
interferon is tied to lupus and that apoptosis, clearance of apoptotic cells, and the 
formation of immune complexes are events that can augment the production of interferon.  
Exciting findings about the actual genetic causes of SLE are being examined which will 
lead to better treatments for this complex disease.  Although most of the data discussed in 
this chapter are inferential, there is a large body of evidence in support of the hypothesis 
that increased interferon signaling promotes an autoimmune state in those genetically 
prone to SLE. 
 




Abelson, A.K.; Delgado-Vega, A.M.; Kozyrev, S.V.; Sanchez, E.; Velazquez-Cruz, R.; 
Eriksson, N.; Wojcik, J.; Reddy, M.; Lima, G.; D'Alfonso, S.; Migliaresi, S.; Baca, V.; 
Orozco, L.; Witte, T.; Ortego-Centeno, N.; Abderrahim, H.; Pons-Estel, B.A.; 
Gutierrez, C.; Suarez, A.; Gonzalez-Escribano, M.F.; Martin, J.; Alarcon-Riquelme, 
M.E. & Grp, A. (2009). STAT4 associates with systemic lupus erythematosus 
through two independent effects that correlate with gene expression and act 
additively with IRF5 to increase risk. Annals of the Rheumatic Diseases, 68 pp. 1746-
1753 
Armstrong, D.L.; Reiff, A.; Myones, B.L.; Quismorio, F.P.; Klein-Gitelman, M.; McCurdy, D.; 
Wagner-Weiner, L.; Silverman, E.; Ojwang, J.O.; Kaufman, K.M.; Kelly, J.A.; Merrill, 
J.T.; Harley, J.B.; Bae, S.C.; Vyse, T.J.; Gilkeson, G.S.; Gaffney, P.M.; Moser, K.L.; 
Putterman, C.; Edberg, J.C.; Brown, E.E.; Ziegler, J.; Langefeld, C.D.; Zidovetzki, R. 
& Jacob, C.O. (2009). Identification of new SLE-associated genes with a two-step 
Bayesian study design. Genes and Immunity, 10 pp. 446-456 
Baechler, E.C.; Batliwalla, F.M.; Karypis, G.; Gaffney, P.M.; Ortmann, W.A.; Espe, K.J.; 
Shark, K.B.; Grande, W.J.; Hughes, K.M.; Kapur, V.; Gregersen, P.K. & Behrens, 
T.W. (2003). Interferon-inducible gene expression signature in peripheral blood 
cells of patients with severe lupus. Proceedings of the National Academy of Sciences of 
the United States of America, 100 pp. 2610-2615 
Bates, J.S.; Lessard, C.J.; Leon, J.M.; Nguyen, T.; Battiest, L.J.; Rodgers, J.; Kaufman, K.M.; 
James, J.A.; Gilkeson, G.S.; Kelly, J.A.; Humphrey, M.B.; Harley, J.B.;  
Gray-McGuire, C.; Moser, K.L. & Gaffney, P.M. (2009). Meta-analysis and 
imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with 
lupus nephritis and hematologic manifestations. Genes and Immunity, 10 pp. 470-
477 
Batuca, J. & Alves, J.D. (2009). C-reactive protein in systemic lupus erythematosus. 
Autoimmunity, 42 pp. 282-285 
Bauer, J.W.; Petri, M.; Batliwalla, F.M.; Koeuth, T.; Wilson, J.; Slattery, C.; Panoskaltsis-
Mortari, A.; Gregersen, P.K.; Behrens, T.W. & Baechler, E.C. (2009). Interferon-
Regulated Chemokines as Biomarkers of Systemic Lupus Erythematosus Disease 
Activity A Validation Study. Arthritis and Rheumatism, 60 pp. 3098-3107 
Bennett, L.; Palucka, A.K.; Arce, E.; Cantrell, V.; Borvak, J.; Banchereau, J. & Pascual, V. 
(2003). Interferon and granulopoiesis signatures in systemic lupus erythematosus 
blood. Journal of Experimental Medicine, 197 pp. 711-723 
Blomberg, S.; Eloranta, M.L.; Cederblad, B.; Nordlind, K.; Alm, G.V. & Ronnblom, L. (2001). 
Presence of cutaneous interferon-alpha producing cells in patients with systemic 
lupus erythematosus. Lupus, 10 pp. 484-490 
Bynote, K.K.; Hackenberg, J.M.; Korach, K.S.; Lubahn, D.B.; Lane, P.H. & Gould, K.A. (2008). 
Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x 
NZW)F1 mice. Genes Immun, 9 pp. 137-152 
Cancro, M.P.; D'Cruz, D.P. & Khamashta, M.A. (2009). The role of B lymphocyte stimulator 
(BLyS) in systemic lupus erythematosus. Journal of Clinical Investigation, 119 pp. 
1066-1073 
 
Interferon and Apoptosis in Systemic Lupus Erythematosus 
 
89 
Cao, W. & Liu, Y.J. (2006). Opn: key regulator of pDC interferon production. Nature 
Immunology, 7 pp. 441-443 
ClinicalTrials.gov. (2011) http://www.clinicaltrials.gov 
Crispin, J.C.; Liossis, S.N.C.; Kis-Toth, K.; Lieberman, L.A.; Kyttaris, V.C.; Juang, Y.T. & 
Tsokos, G.C. Pathogenesis of human systemic lupus erythematosus: recent 
advances. Trends in Molecular Medicine, 16 pp. 47-57 
Dall'Era, M.C.; Cardarelli, P.M.; Preston, B.T.; Witte, A. & Davis, J.C. (2005). Type I 
interferon correlates with serological and clinical manifestations of SLE. Annals of 
the Rheumatic Diseases, 64 pp. 1692-1697 
Davas, E.M.; Tsirogianni, A.; Kappou, I.; Karamitsos, D.; Economidou, I. & Dantis, P.C. 
(1999). Serum IL-6, TNF alpha, p55 srTNF alpha, p75 srTNF alpha, srIL-2 alpha 
levels and disease acitivity in systemic lupus erythematosus. Clinical Rheumatology, 
18 pp. 17-22 
Deapen, D.; Escalante, A.; Weinrib, L.; Horwitz, D.; Bachman, B.; Royburman, P.; Walker, A. 
& Mack, T.M. (1992). A revised estimate of twin concordance in systemic lupus 
erythematosus. Arthritis and Rheumatism, 35 pp. 311-318 
Emilie, D.; Llorente, L. & Galanaud, P. (1996). Cytokines and systemic lupus erythematosus. 
Annales De Medecine Interne, 147 pp. 480-484 
Farkas, L.; Beiske, K.; Lund-Johansen, F.; Brandtzaeg, P. & Jahnsen, F.L. (2001). Plasmacytoid 
dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in 
cutaneous lupus erythematosus lesions. American Journal of Pathology, 159 pp. 237-
243 
Feng, X.B.; Wu, H.; Grossman, J.M.; Hanvivadhanakul, P.; FitzGerald, J.D.; Park, G.S.; Dong, 
X.; Chen, W.L.; Kim, M.H.; Weng, H.H.; Furst, D.E.; Gorn, A.; McMahon, M.; 
Taylor, M.; Brahn, E.; Hahn, B.H. & Tsao, B.P. (2006). Association of increased 
interferon-inducible gene expression with disease activity and lupus nephritis in 
patients with systemic lupus erythematosus. Arthritis and Rheumatism, 54 pp. 2951-
2962 
Fruh, K. & Yang, Y. (1999). Antigen presentation by MHC class I and its regulation by 
interferon gamma. Current Opinion in Immunology, 11 pp. 76-81 
Gaipl, U.S.; Sheriff, A.; Franz, S.; Munoz, L.E.; Voll, R.E.; Kalden, J.R. & Herrmann, M. 
(2006). Inefficient clearance of dying cells and autoreactivity. Current Concepts in 
Autoimmunity and Chronic Inflamation, 305 pp. 161-176 
Gateva, V.; Sandling, J.K.; Hom, G.; Taylor, K.E.; Chung, S.A.; Sun, X.; Ortmann, W.; Kosoy, 
R.; Ferreira, R.C.; Nordmark, G.; Gunnarsson, I.; Svenungsson, E.; Padyukov, L.; 
Sturfelt, G.; Jonsen, A.; Bengtsson, A.A.; Rantapaa-Dahlqvist, S.; Baechler, E.C.; 
Brown, E.E.; Alarcon, G.S.; Edberg, J.C.; Ramsey-Goldman, R.; McGwin, G.; 
Reveille, J.D.; Vila, L.M.; Kimberly, R.P.; Manzi, S.; Petri, M.A.; Lee, A.; Gregersen, 
P.K.; Seldin, M.F.; Ronnblom, L.; Criswell, L.A.; Syvanen, A.C.; Behrens, T.W. & 
Graham, R.R. (2009). A large-scale replication study identifies TNIP1, PRDM1, 
JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nature 
Genetics, 41 pp. 1228-U1293 
Gota, C. & Calabrese, L. (2003). Induction of clinical autoimmune disease by therapeutic 
interferon-alpha. Autoimmunity, 36 pp. 511-518 
 




Abelson, A.K.; Delgado-Vega, A.M.; Kozyrev, S.V.; Sanchez, E.; Velazquez-Cruz, R.; 
Eriksson, N.; Wojcik, J.; Reddy, M.; Lima, G.; D'Alfonso, S.; Migliaresi, S.; Baca, V.; 
Orozco, L.; Witte, T.; Ortego-Centeno, N.; Abderrahim, H.; Pons-Estel, B.A.; 
Gutierrez, C.; Suarez, A.; Gonzalez-Escribano, M.F.; Martin, J.; Alarcon-Riquelme, 
M.E. & Grp, A. (2009). STAT4 associates with systemic lupus erythematosus 
through two independent effects that correlate with gene expression and act 
additively with IRF5 to increase risk. Annals of the Rheumatic Diseases, 68 pp. 1746-
1753 
Armstrong, D.L.; Reiff, A.; Myones, B.L.; Quismorio, F.P.; Klein-Gitelman, M.; McCurdy, D.; 
Wagner-Weiner, L.; Silverman, E.; Ojwang, J.O.; Kaufman, K.M.; Kelly, J.A.; Merrill, 
J.T.; Harley, J.B.; Bae, S.C.; Vyse, T.J.; Gilkeson, G.S.; Gaffney, P.M.; Moser, K.L.; 
Putterman, C.; Edberg, J.C.; Brown, E.E.; Ziegler, J.; Langefeld, C.D.; Zidovetzki, R. 
& Jacob, C.O. (2009). Identification of new SLE-associated genes with a two-step 
Bayesian study design. Genes and Immunity, 10 pp. 446-456 
Baechler, E.C.; Batliwalla, F.M.; Karypis, G.; Gaffney, P.M.; Ortmann, W.A.; Espe, K.J.; 
Shark, K.B.; Grande, W.J.; Hughes, K.M.; Kapur, V.; Gregersen, P.K. & Behrens, 
T.W. (2003). Interferon-inducible gene expression signature in peripheral blood 
cells of patients with severe lupus. Proceedings of the National Academy of Sciences of 
the United States of America, 100 pp. 2610-2615 
Bates, J.S.; Lessard, C.J.; Leon, J.M.; Nguyen, T.; Battiest, L.J.; Rodgers, J.; Kaufman, K.M.; 
James, J.A.; Gilkeson, G.S.; Kelly, J.A.; Humphrey, M.B.; Harley, J.B.;  
Gray-McGuire, C.; Moser, K.L. & Gaffney, P.M. (2009). Meta-analysis and 
imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with 
lupus nephritis and hematologic manifestations. Genes and Immunity, 10 pp. 470-
477 
Batuca, J. & Alves, J.D. (2009). C-reactive protein in systemic lupus erythematosus. 
Autoimmunity, 42 pp. 282-285 
Bauer, J.W.; Petri, M.; Batliwalla, F.M.; Koeuth, T.; Wilson, J.; Slattery, C.; Panoskaltsis-
Mortari, A.; Gregersen, P.K.; Behrens, T.W. & Baechler, E.C. (2009). Interferon-
Regulated Chemokines as Biomarkers of Systemic Lupus Erythematosus Disease 
Activity A Validation Study. Arthritis and Rheumatism, 60 pp. 3098-3107 
Bennett, L.; Palucka, A.K.; Arce, E.; Cantrell, V.; Borvak, J.; Banchereau, J. & Pascual, V. 
(2003). Interferon and granulopoiesis signatures in systemic lupus erythematosus 
blood. Journal of Experimental Medicine, 197 pp. 711-723 
Blomberg, S.; Eloranta, M.L.; Cederblad, B.; Nordlind, K.; Alm, G.V. & Ronnblom, L. (2001). 
Presence of cutaneous interferon-alpha producing cells in patients with systemic 
lupus erythematosus. Lupus, 10 pp. 484-490 
Bynote, K.K.; Hackenberg, J.M.; Korach, K.S.; Lubahn, D.B.; Lane, P.H. & Gould, K.A. (2008). 
Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x 
NZW)F1 mice. Genes Immun, 9 pp. 137-152 
Cancro, M.P.; D'Cruz, D.P. & Khamashta, M.A. (2009). The role of B lymphocyte stimulator 
(BLyS) in systemic lupus erythematosus. Journal of Clinical Investigation, 119 pp. 
1066-1073 
 
Interferon and Apoptosis in Systemic Lupus Erythematosus 
 
89 
Cao, W. & Liu, Y.J. (2006). Opn: key regulator of pDC interferon production. Nature 
Immunology, 7 pp. 441-443 
ClinicalTrials.gov. (2011) http://www.clinicaltrials.gov 
Crispin, J.C.; Liossis, S.N.C.; Kis-Toth, K.; Lieberman, L.A.; Kyttaris, V.C.; Juang, Y.T. & 
Tsokos, G.C. Pathogenesis of human systemic lupus erythematosus: recent 
advances. Trends in Molecular Medicine, 16 pp. 47-57 
Dall'Era, M.C.; Cardarelli, P.M.; Preston, B.T.; Witte, A. & Davis, J.C. (2005). Type I 
interferon correlates with serological and clinical manifestations of SLE. Annals of 
the Rheumatic Diseases, 64 pp. 1692-1697 
Davas, E.M.; Tsirogianni, A.; Kappou, I.; Karamitsos, D.; Economidou, I. & Dantis, P.C. 
(1999). Serum IL-6, TNF alpha, p55 srTNF alpha, p75 srTNF alpha, srIL-2 alpha 
levels and disease acitivity in systemic lupus erythematosus. Clinical Rheumatology, 
18 pp. 17-22 
Deapen, D.; Escalante, A.; Weinrib, L.; Horwitz, D.; Bachman, B.; Royburman, P.; Walker, A. 
& Mack, T.M. (1992). A revised estimate of twin concordance in systemic lupus 
erythematosus. Arthritis and Rheumatism, 35 pp. 311-318 
Emilie, D.; Llorente, L. & Galanaud, P. (1996). Cytokines and systemic lupus erythematosus. 
Annales De Medecine Interne, 147 pp. 480-484 
Farkas, L.; Beiske, K.; Lund-Johansen, F.; Brandtzaeg, P. & Jahnsen, F.L. (2001). Plasmacytoid 
dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in 
cutaneous lupus erythematosus lesions. American Journal of Pathology, 159 pp. 237-
243 
Feng, X.B.; Wu, H.; Grossman, J.M.; Hanvivadhanakul, P.; FitzGerald, J.D.; Park, G.S.; Dong, 
X.; Chen, W.L.; Kim, M.H.; Weng, H.H.; Furst, D.E.; Gorn, A.; McMahon, M.; 
Taylor, M.; Brahn, E.; Hahn, B.H. & Tsao, B.P. (2006). Association of increased 
interferon-inducible gene expression with disease activity and lupus nephritis in 
patients with systemic lupus erythematosus. Arthritis and Rheumatism, 54 pp. 2951-
2962 
Fruh, K. & Yang, Y. (1999). Antigen presentation by MHC class I and its regulation by 
interferon gamma. Current Opinion in Immunology, 11 pp. 76-81 
Gaipl, U.S.; Sheriff, A.; Franz, S.; Munoz, L.E.; Voll, R.E.; Kalden, J.R. & Herrmann, M. 
(2006). Inefficient clearance of dying cells and autoreactivity. Current Concepts in 
Autoimmunity and Chronic Inflamation, 305 pp. 161-176 
Gateva, V.; Sandling, J.K.; Hom, G.; Taylor, K.E.; Chung, S.A.; Sun, X.; Ortmann, W.; Kosoy, 
R.; Ferreira, R.C.; Nordmark, G.; Gunnarsson, I.; Svenungsson, E.; Padyukov, L.; 
Sturfelt, G.; Jonsen, A.; Bengtsson, A.A.; Rantapaa-Dahlqvist, S.; Baechler, E.C.; 
Brown, E.E.; Alarcon, G.S.; Edberg, J.C.; Ramsey-Goldman, R.; McGwin, G.; 
Reveille, J.D.; Vila, L.M.; Kimberly, R.P.; Manzi, S.; Petri, M.A.; Lee, A.; Gregersen, 
P.K.; Seldin, M.F.; Ronnblom, L.; Criswell, L.A.; Syvanen, A.C.; Behrens, T.W. & 
Graham, R.R. (2009). A large-scale replication study identifies TNIP1, PRDM1, 
JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nature 
Genetics, 41 pp. 1228-U1293 
Gota, C. & Calabrese, L. (2003). Induction of clinical autoimmune disease by therapeutic 
interferon-alpha. Autoimmunity, 36 pp. 511-518 
 
Systemic Lupus Erythematosus 
 
90
Goulvestre, C.; Chereau, C.; Nicco, C.; Mouthon, L.; Weill, B. & Batteux, F. (2005). A mimic 
of p21(WAF1)/(CIP1) ameliorates murine lupus. Journal of Immunology, 175 pp. 
6959-6967 
Graham, D.S.C.; Manku, H.; Wagner, S.; Reid, J.; Timms, K.; Gutin, A.; Lanchbury,  
J.S. & Vyse, T.J. (2007a). Association of IRF5 in UK SLE families identifies a  
variant involved in polyadenylation. Human Molecular Genetics, 16 pp. 579- 
591 
Graham, R.R.; Hom, G.; Ortmann, W. & Behrens, T.W. (2009). Review of recent  
genome-wide association scans in lupus. Journal of Internal Medicine, 265 pp. 680- 
688 
Graham, R.R.; Kyogoku, C.; Sigurdsson, S.; Vlasova, I.A.; Davies, L.R.; Baechler, E.C.; 
Plenge, R.M.; Koeuth, T.; Ortmann, W.A.; Hom, G.; Bauer, J.W.; Gillett, C.; Burtt, 
N.; Cunninghame Graham, D.S.; Onofrio, R.; Petri, M.; Gunnarsson, I.; 
Svenungsson, E.; Ronnblom, L.; Nordmark, G.; Gregersen, P.K.; Moser, K.; Gaffney, 
P.M.; Criswell, L.A.; Vyse, T.J.; Syvanen, A.C.; Bohjanen, P.R.; Daly, M.J.; Behrens, 
T.W. & Altshuler, D. (2007b). Three functional variants of IFN regulatory factor 5 
(IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U 
S A, 104 pp. 6758-6763 
Harley, I.T.W.; Kaufman, K.M.; Langefeld, C.D.; Harley, J.B. & Kelly, J.A. (2009). Genetic 
susceptibility to SLE: new insights from fine mapping and genome-wide 
association studies. Nature Reviews Genetics, 10 pp. 285-290 
Harley, J.B.; Alarcon-Riquelme, M.E.; Criswell, L.A.; Jacob, C.O.; Kimberly, R.P.; Moser, 
K.L.; Tsao, B.P.; Vyse, T.J.; Langefeld, C.D. & Int Consortium Systemic Lupus, E. 
(2008). Genome-wide association scan in women with systemic lupus 
erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and 
other loci. Nature Genetics, 40 pp. 204-210 
Hu, C.Y.; Wu, C.S.; Tsai, H.F.; Chang, S.K.; Tsai, W.I. & Hsu, P.N. (2009). Genetic 
polymorphism in milk fat globule-EGF factor 8 (MFG-E8) is associated with 
systemic lupus erythematosus in human. Lupus, 18 pp. 676-681 
Ioannou, Y. & Isenberg, D.A. (2000). Current evidence for the induction of autoimmune 
rheumatic manifestations by cytokine therapy. Arthritis and Rheumatism, 43 pp. 
1431-1442 
Izui, S.; Merino, R.; Fossati, L. & Iwamoto, M. (1994). The role of the Yaa gene in lupus 
syndrome. Int Rev Immunol, 11 pp. 211-230 
Jacob, C.O.; Zhu, J.K.; Armstrong, D.L.; Yan, M.; Han, J.; Zhou, X.J.; Thomas, J.A.; Reiff, A.; 
Myones, B.L.; Ojwang, J.O.; Kaufman, K.M.; Klein-Gitelman, M.; McCurdy, D.; 
Wagner-Weiner, L.; Silverman, E.; Ziegler, J.; Kelly, J.A.; Merrill, J.T.; Harley, J.B.; 
Ramsey-Goldman, R.; Vila, L.M.; Bae, S.C.; Vyse, T.J.; Gilkeson, G.S.; Gaffney, P.M.; 
Moser, K.L.; Langefeld, C.D.; Zidovetzki, R. & Mohan, C. (2009). Identification of 
IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus 
erythematosus. Proceedings of the National Academy of Sciences of the United States of 
America, 106 pp. 6256-6261 
Jimenez-Morales, S.; Velazquez-Cruz, R.; Ramirez-Bello, J.; Bonilla-Gonzalez, E.; Romero-
Hidalgo, S.; Escamilla-Guerrero, G.; Cuevas, F.; Espinosa-Rosales, F.; Martinez-
Aguilar, N.E.; Gomez-Vera, J.; Baca, V. & Orozco, L. (2009). Tumor necrosis factor-
 
Interferon and Apoptosis in Systemic Lupus Erythematosus 
 
91 
alpha is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and 
systemic lupus erythematosus in a Mexican pediatric population. Human 
Immunology, 70 pp. 251-256 
Jmol: an open-source Java viewer for chemical structures in 3D.  http://www.jmol.org 
Jorgensen, T.N.; Roper, E.; Thurman, J.M.; Marrack, P. & Kotzin, B.L. (2007). Type I 
interferon signaling is involved in the spontaneous development of lupus- 
like disease in B6.Nba2 and (B6.Nba2 x NZW)F(1) mice. Genes Immun, 8 pp. 653- 
662 
Kariuki, S.N.; Kirou, K.A.; MacDermott, E.J.; Barillas-Arias, L.; Crow, M.K. & Niewold, T.B. 
(2009a). Cutting Edge: Autoimmune Disease Risk Variant of STAT4 Confers 
increased Sensitivity to IFN-alpha in Lupus Patients In Vivo. Journal of Immunology, 
182 pp. 34-38 
Kariuki, S.N.; Moore, J.G.; Kirou, K.A.; Crow, M.K.; Utset, T.O. & Niewold, T.B. (2009b). 
Age- and gender-specific modulation of serum osteopontin and interferon-alpha by 
osteopontin genotype in systemic lupus erythematosus. Genes and Immunity, 10 pp. 
487-494 
Karpusas, M.; Nolte, M.; Benton, C.B.; Meier, W.; Lipscomb, W.N. & Goelz, S. (1997).  
The crystal structure of human interferon beta at 2.2-angstrom resolution. 
Proceedings of the National Academy of Sciences of the United States of America, 94  
pp. 11813-11818 
Kawasaki, A.; Kyogoku, C.; Ohashi, J.; Miyashita, R.; Hikami, K.; Kusaoi, M.; Tokunaga, K.; 
Takasaki, Y.; Hashimoto, H.; Behrens, T.W. & Tsuchiya, N. (2008). Association of 
IRF5 polymorphisms with systemic lupus erythematosus in a Japanese population: 
support for a crucial role of intron 1 polymorphisms. Arthritis Rheum, 58 pp. 826-
834 
Kelly, J.A.; Kelley, J.M.; Kaufman, K.M.; Kilpatrick, J.; Bruner, G.R.; Merrill, J.T.;  
James, J.A.; Frank, S.G.; Reams, E.; Brown, E.E.; Gibson, A.W.; Marion, M.C.; 
Langefeld, C.D.; Li, Q.Z.; Karp, D.R.; Wakeland, E.K.; Petri, M.; Ramsey-
Goldman, R.; Reveille, J.D.; Vila, L.M.; Alarcon, G.S.; Kimberly, R.P.; Harley,  
J.B. & Edberg, J.C. (2008). Interferon regulatory factor-5 is genetically associated 
with systemic lupus erythematosus in African Americans. Genes Immun, 9 pp. 
187-194 
Kim-Howard, X.; Maiti, A.K.; Anaya, J.M.; Bruner, G.R.; Brown, E.; Merrill, J.T.; Edberg, 
J.C.; Petri, M.A.; Reveille, J.D.; Ramsey-Goldman, R.; Alarcon, G.S.; Vyse, T.J.; 
Gilkeson, G.; Kimberly, R.P.; James, J.A.; Guthridge, J.M.; Harley, J.B. & Nath, 
S.K. ITGAM coding variant (rs1143679) influences the risk of renal disease, 
discoid rash and immunological manifestations in patients with systemic lupus 
erythematosus with European ancestry. Annals of the Rheumatic Diseases, 69 pp. 
1329-1332 
Kim, H.A.; Chun, H.Y.; Kim, S.H.; Park, H.S. & Suh, C.H. (2009). C-Reactive Protein  
Gene Polymorphisms in Disease Susceptibility and Clinical Manifestations  
of Korean Systemic Lupus Erythematosus. Journal of Rheumatology, 36 pp. 2238- 
2243 
 
Systemic Lupus Erythematosus 
 
90
Goulvestre, C.; Chereau, C.; Nicco, C.; Mouthon, L.; Weill, B. & Batteux, F. (2005). A mimic 
of p21(WAF1)/(CIP1) ameliorates murine lupus. Journal of Immunology, 175 pp. 
6959-6967 
Graham, D.S.C.; Manku, H.; Wagner, S.; Reid, J.; Timms, K.; Gutin, A.; Lanchbury,  
J.S. & Vyse, T.J. (2007a). Association of IRF5 in UK SLE families identifies a  
variant involved in polyadenylation. Human Molecular Genetics, 16 pp. 579- 
591 
Graham, R.R.; Hom, G.; Ortmann, W. & Behrens, T.W. (2009). Review of recent  
genome-wide association scans in lupus. Journal of Internal Medicine, 265 pp. 680- 
688 
Graham, R.R.; Kyogoku, C.; Sigurdsson, S.; Vlasova, I.A.; Davies, L.R.; Baechler, E.C.; 
Plenge, R.M.; Koeuth, T.; Ortmann, W.A.; Hom, G.; Bauer, J.W.; Gillett, C.; Burtt, 
N.; Cunninghame Graham, D.S.; Onofrio, R.; Petri, M.; Gunnarsson, I.; 
Svenungsson, E.; Ronnblom, L.; Nordmark, G.; Gregersen, P.K.; Moser, K.; Gaffney, 
P.M.; Criswell, L.A.; Vyse, T.J.; Syvanen, A.C.; Bohjanen, P.R.; Daly, M.J.; Behrens, 
T.W. & Altshuler, D. (2007b). Three functional variants of IFN regulatory factor 5 
(IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U 
S A, 104 pp. 6758-6763 
Harley, I.T.W.; Kaufman, K.M.; Langefeld, C.D.; Harley, J.B. & Kelly, J.A. (2009). Genetic 
susceptibility to SLE: new insights from fine mapping and genome-wide 
association studies. Nature Reviews Genetics, 10 pp. 285-290 
Harley, J.B.; Alarcon-Riquelme, M.E.; Criswell, L.A.; Jacob, C.O.; Kimberly, R.P.; Moser, 
K.L.; Tsao, B.P.; Vyse, T.J.; Langefeld, C.D. & Int Consortium Systemic Lupus, E. 
(2008). Genome-wide association scan in women with systemic lupus 
erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and 
other loci. Nature Genetics, 40 pp. 204-210 
Hu, C.Y.; Wu, C.S.; Tsai, H.F.; Chang, S.K.; Tsai, W.I. & Hsu, P.N. (2009). Genetic 
polymorphism in milk fat globule-EGF factor 8 (MFG-E8) is associated with 
systemic lupus erythematosus in human. Lupus, 18 pp. 676-681 
Ioannou, Y. & Isenberg, D.A. (2000). Current evidence for the induction of autoimmune 
rheumatic manifestations by cytokine therapy. Arthritis and Rheumatism, 43 pp. 
1431-1442 
Izui, S.; Merino, R.; Fossati, L. & Iwamoto, M. (1994). The role of the Yaa gene in lupus 
syndrome. Int Rev Immunol, 11 pp. 211-230 
Jacob, C.O.; Zhu, J.K.; Armstrong, D.L.; Yan, M.; Han, J.; Zhou, X.J.; Thomas, J.A.; Reiff, A.; 
Myones, B.L.; Ojwang, J.O.; Kaufman, K.M.; Klein-Gitelman, M.; McCurdy, D.; 
Wagner-Weiner, L.; Silverman, E.; Ziegler, J.; Kelly, J.A.; Merrill, J.T.; Harley, J.B.; 
Ramsey-Goldman, R.; Vila, L.M.; Bae, S.C.; Vyse, T.J.; Gilkeson, G.S.; Gaffney, P.M.; 
Moser, K.L.; Langefeld, C.D.; Zidovetzki, R. & Mohan, C. (2009). Identification of 
IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus 
erythematosus. Proceedings of the National Academy of Sciences of the United States of 
America, 106 pp. 6256-6261 
Jimenez-Morales, S.; Velazquez-Cruz, R.; Ramirez-Bello, J.; Bonilla-Gonzalez, E.; Romero-
Hidalgo, S.; Escamilla-Guerrero, G.; Cuevas, F.; Espinosa-Rosales, F.; Martinez-
Aguilar, N.E.; Gomez-Vera, J.; Baca, V. & Orozco, L. (2009). Tumor necrosis factor-
 
Interferon and Apoptosis in Systemic Lupus Erythematosus 
 
91 
alpha is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and 
systemic lupus erythematosus in a Mexican pediatric population. Human 
Immunology, 70 pp. 251-256 
Jmol: an open-source Java viewer for chemical structures in 3D.  http://www.jmol.org 
Jorgensen, T.N.; Roper, E.; Thurman, J.M.; Marrack, P. & Kotzin, B.L. (2007). Type I 
interferon signaling is involved in the spontaneous development of lupus- 
like disease in B6.Nba2 and (B6.Nba2 x NZW)F(1) mice. Genes Immun, 8 pp. 653- 
662 
Kariuki, S.N.; Kirou, K.A.; MacDermott, E.J.; Barillas-Arias, L.; Crow, M.K. & Niewold, T.B. 
(2009a). Cutting Edge: Autoimmune Disease Risk Variant of STAT4 Confers 
increased Sensitivity to IFN-alpha in Lupus Patients In Vivo. Journal of Immunology, 
182 pp. 34-38 
Kariuki, S.N.; Moore, J.G.; Kirou, K.A.; Crow, M.K.; Utset, T.O. & Niewold, T.B. (2009b). 
Age- and gender-specific modulation of serum osteopontin and interferon-alpha by 
osteopontin genotype in systemic lupus erythematosus. Genes and Immunity, 10 pp. 
487-494 
Karpusas, M.; Nolte, M.; Benton, C.B.; Meier, W.; Lipscomb, W.N. & Goelz, S. (1997).  
The crystal structure of human interferon beta at 2.2-angstrom resolution. 
Proceedings of the National Academy of Sciences of the United States of America, 94  
pp. 11813-11818 
Kawasaki, A.; Kyogoku, C.; Ohashi, J.; Miyashita, R.; Hikami, K.; Kusaoi, M.; Tokunaga, K.; 
Takasaki, Y.; Hashimoto, H.; Behrens, T.W. & Tsuchiya, N. (2008). Association of 
IRF5 polymorphisms with systemic lupus erythematosus in a Japanese population: 
support for a crucial role of intron 1 polymorphisms. Arthritis Rheum, 58 pp. 826-
834 
Kelly, J.A.; Kelley, J.M.; Kaufman, K.M.; Kilpatrick, J.; Bruner, G.R.; Merrill, J.T.;  
James, J.A.; Frank, S.G.; Reams, E.; Brown, E.E.; Gibson, A.W.; Marion, M.C.; 
Langefeld, C.D.; Li, Q.Z.; Karp, D.R.; Wakeland, E.K.; Petri, M.; Ramsey-
Goldman, R.; Reveille, J.D.; Vila, L.M.; Alarcon, G.S.; Kimberly, R.P.; Harley,  
J.B. & Edberg, J.C. (2008). Interferon regulatory factor-5 is genetically associated 
with systemic lupus erythematosus in African Americans. Genes Immun, 9 pp. 
187-194 
Kim-Howard, X.; Maiti, A.K.; Anaya, J.M.; Bruner, G.R.; Brown, E.; Merrill, J.T.; Edberg, 
J.C.; Petri, M.A.; Reveille, J.D.; Ramsey-Goldman, R.; Alarcon, G.S.; Vyse, T.J.; 
Gilkeson, G.; Kimberly, R.P.; James, J.A.; Guthridge, J.M.; Harley, J.B. & Nath, 
S.K. ITGAM coding variant (rs1143679) influences the risk of renal disease, 
discoid rash and immunological manifestations in patients with systemic lupus 
erythematosus with European ancestry. Annals of the Rheumatic Diseases, 69 pp. 
1329-1332 
Kim, H.A.; Chun, H.Y.; Kim, S.H.; Park, H.S. & Suh, C.H. (2009). C-Reactive Protein  
Gene Polymorphisms in Disease Susceptibility and Clinical Manifestations  
of Korean Systemic Lupus Erythematosus. Journal of Rheumatology, 36 pp. 2238- 
2243 
 
Systemic Lupus Erythematosus 
 
92
Kim, T.; Kanayama, Y.; Negoro, N.; Okamura, M.; Takeda, T. & Inoue, T. (1987). Serum 
levels of interferons in patients with systemic lupus-erythematosus. Clinical and 
Experimental Immunology, 70 pp. 562-569 
Kirou, K.A.; Lee, C.; George, S.; Louca, K.; Peterson, M.G.E. & Crow, M.K. (2005). Activation 
of the interferon-alpha pathway identifies a subgroup of systemic lupus 
erythematosus patients with distinct serologic features and active disease. Arthritis 
and Rheumatism, 52 pp. 1491-1503 
Landolt-Marticorena, C.; Bonventi, G.; Lubovich, A.; Ferguson, C.; Unnithan, T.; Su,  
J.; Gladman, D.D.; Urowitz, M.; Fortin, P.R. & Wither, J. (2009). Lack of association 
between the interferon-alpha signature and longitudinal changes in disease activity 
in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 68 pp. 1440- 
1446 
Lee-Kirsch, M.A.; Gong, M.; Chowdhury, D.; Senenko, L.; Engel, K.; Lee, Y.A.; de Silva, U.; 
Bailey, S.L.; Witte, T.; Vyse, T.J.; Kere, J.; Pfeiffer, C.; Harvey, S.; Wong, A.; 
Koskenmies, S.; Hummel, O.; Rohde, K.; Schmidt, R.E.; Dominiczak, A.F.; Gahr, M.; 
Hollis, T.; Perrino, F.W.; Lieberman, J. & Hubner, N. (2007). Mutations in the gene 
encoding the 3 '-5 ' DNA exonuclease TREX1 are associated with systemic lupus 
erythematosus. Nature Genetics, 39 pp. 1065-1067 
Lee, Y.H. & Song, G.G. (2009). Association between the rs2004640 functional polymorphism 
of interferon regulatory factor 5 and systemic lupus erythematosus: a meta-
analysis. Rheumatology International, 29 pp. 1137-1142 
Li, L.H.; Li, W.X.; Wu, O.; Zhang, G.Q.; Pan, H.F.; Li, X.P.; Xu, J.H.; Dai, H. & Ye, D.Q. 
(2009). Fas expression on peripheral blood lymphocytes in systemic lupus 
erythematosus: relation to the organ damage and lymphocytes apoptosis. Molecular 
Biology Reports, 36 pp. 2047-2052 
Lin, Y.J.; Chen, R.H.; Wan, L.; Sheu, J.J.C.; Huang, C.M.; Lin, C.W.; Chen, S.Y.; Lai, C.H.; Lan, 
Y.C.; Hsueh, K.C.; Tsai, C.H.; Lin, T.H.; Huang, Y.M.; Chao, K.; Chen, D.Y. & Tsai, 
F.J. (2009). Association of TNF-alpha gene polymorphisms with systemic lupus 
erythematosus in Taiwanese patients. Lupus, 18 pp. 974-979 
Liu, C.C. & Ahearn, J.M. (2009). The search for lupus biomarkers. Best Practice & Research in 
Clinical Rheumatology, 23 pp. 507-523 
Liu, Z.; Bethunaickan, R.; Huang, W.; Lodhi, U.; Solano, I.; Madaio, M.P. & Davidson, A. 
(2011). Interferon-alpha accelerates murine systemic lupus erythematosus in a T 
cell-dependent manner. Arthritis Rheum, 63 pp. 219-229 
Lood, C.; Gullstrand, B.; Truedsson, L.; Olin, A.I.; Alm, G.V.; Ronnblom, L.; Sturfelt, G.; 
Eloranta, M.L. & Bengtsson, A.A. (2009). C1q Inhibits Immune Complex-Induced 
Interferon-alpha Production in Plasmacytoid Dendritic Cells A Novel Link 
Between C1q Deficiency and Systemic Lupus Erythematosus Pathogenesis. Arthritis 
and Rheumatism, 60 pp. 3081-3090 
Lucero, M.A.; Magdelenat, H.; Fridman, W.H.; Pouillart, P.; Billardon, C.; Billiau, A.; Cantell, 
K. & Falcoff, E. (1982). Comparison of effects of leukocyte and fibroblast interferon 
on immunological parameters in cancer-patients. European Journal of Cancer & 
Clinical Oncology, 18 pp. 243-251 
 
Interferon and Apoptosis in Systemic Lupus Erythematosus 
 
93 
Luker, K.E.; Hutchens, M.; Schultz, T.; Pekosz, A. & Luker, G.D. (2005). Bioluminescence 
imaging of vaccinia virus: Effects of interferon on viral replication and spread. 
Virology, 341 pp. 284-300 
Mathian, A.; Weinberg, A.; Gallegos, M.; Banchereau, J. & Koutouzov, S. (2005). IFN- 
alpha induces early lethal lupus in preautoimmune (New Zealand Black x  
New Zealand White) F1 but not in BALB/c mice. J Immunol, 174 pp. 2499- 
2506 
Moser, K.L.; Kelly, J.A.; Lessard, C.J. & Harley, J.B. (2009). Recent insights into the  
genetic basis of systemic lupus erythematosus. Genes and Immunity, 10 pp. 373- 
379 
Munoz, L.E.; Lauber, K.; Schiller, M.; Manfredi, A.A. & Herrmann, M. (2010). The role of 
defective clearance of apoptotic cells in systemic autoimmunity. Nature Reviews 
Rheumatology, 6 pp. 280-289 
Murray, H.W. (1988). Interferon-gamma, the activated macrophage, and host defense 
against microbial challenge. Annals of Internal Medicine, 108 pp. 595-608 
Musone, S.L.; Taylor, K.E.; Lu, T.T.; Nititham, J.; Ferreira, R.C.; Ortmann, W.; Shifrin, N.; 
Petri, M.A.; Kamboh, M.I.; Manzi, S.; Seldin, M.F.; Gregersen, P.K.; Behrens, T.W.; 
Ma, A.; Kwok, P.Y. & Criswell, L.A. (2008). Multiple polymorphisms in the 
TNFAIP3 region are independently associated with systemic lupus erythematosus. 
Nature Genetics, 40 pp. 1062-1064 
Nath, S.K.; Han, S.Z.; Kim-Howard, X.; Kelly, J.A.; Viswanathan, P.; Gilkeson, G.S.; Chen, 
W.; Zhu, C.; McEver, R.P.; Kimberly, R.P.; Alarcon-Riquelme, M.E.; Vyse, T.J.; Li, 
Q.Z.; Wakeland, E.K.; Merrill, J.T.; James, J.A.; Kaufman, K.M.; Guthridge, J.M. & 
Harley, J.B. (2008). A nonsynonymous functional variant in integrin-alpha M 
(encoded by ITGAM) is associated with systemic lupus erythematosus. Nature 
Genetics, 40 pp. 152-154 
Niewold, T.B.; Clark, D.N.; Salloum, R. & Poole, B.D. Interferon Alpha in Systemic Lupus 
Erythematosus. Journal of Biomedicine and Biotechnology, pp. 8 
Niewold, T.B.; Hua, J.; Lehman, T.J.A.; Harley, J.B. & Crow, M.K. (2007). High serum IFN-
alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes and 
Immunity, 8 pp. 492-502 
Niewold, T.B.; Kelly, J.A.; Flesch, M.H.; Espinoza, L.R.; Harley, J.B. & Crow, M.K. (2008). 
Association of the IRF5 risk haplotype with high serum interferon-alpha activity in 
systemic lupus erythematosus patients. Arthritis and Rheumatism, 58 pp. 2481- 
2487 
Niewold, T.B. & Swedler, W.I. (2005). Systemic lupus erythematosus arising during 
interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis 
C. Clinical Rheumatology, 24 pp. 178-181 
Panchanathan, R.; Shen, H.; Bupp, M.G.; Gould, K.A. & Choubey, D. (2009). Female and 
male sex hormones differentially regulate expression of Ifi202, an interferon-
inducible lupus susceptibility gene within the Nba2 interval. J Immunol, 183 pp. 
7031-7038 
Panchanathan, R.; Shen, H.; Zhang, X.; Ho, S.M. & Choubey, D. (2010). Mutually  
positive regulatory feedback loop between interferons and estrogen receptor-
 
Systemic Lupus Erythematosus 
 
92
Kim, T.; Kanayama, Y.; Negoro, N.; Okamura, M.; Takeda, T. & Inoue, T. (1987). Serum 
levels of interferons in patients with systemic lupus-erythematosus. Clinical and 
Experimental Immunology, 70 pp. 562-569 
Kirou, K.A.; Lee, C.; George, S.; Louca, K.; Peterson, M.G.E. & Crow, M.K. (2005). Activation 
of the interferon-alpha pathway identifies a subgroup of systemic lupus 
erythematosus patients with distinct serologic features and active disease. Arthritis 
and Rheumatism, 52 pp. 1491-1503 
Landolt-Marticorena, C.; Bonventi, G.; Lubovich, A.; Ferguson, C.; Unnithan, T.; Su,  
J.; Gladman, D.D.; Urowitz, M.; Fortin, P.R. & Wither, J. (2009). Lack of association 
between the interferon-alpha signature and longitudinal changes in disease activity 
in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 68 pp. 1440- 
1446 
Lee-Kirsch, M.A.; Gong, M.; Chowdhury, D.; Senenko, L.; Engel, K.; Lee, Y.A.; de Silva, U.; 
Bailey, S.L.; Witte, T.; Vyse, T.J.; Kere, J.; Pfeiffer, C.; Harvey, S.; Wong, A.; 
Koskenmies, S.; Hummel, O.; Rohde, K.; Schmidt, R.E.; Dominiczak, A.F.; Gahr, M.; 
Hollis, T.; Perrino, F.W.; Lieberman, J. & Hubner, N. (2007). Mutations in the gene 
encoding the 3 '-5 ' DNA exonuclease TREX1 are associated with systemic lupus 
erythematosus. Nature Genetics, 39 pp. 1065-1067 
Lee, Y.H. & Song, G.G. (2009). Association between the rs2004640 functional polymorphism 
of interferon regulatory factor 5 and systemic lupus erythematosus: a meta-
analysis. Rheumatology International, 29 pp. 1137-1142 
Li, L.H.; Li, W.X.; Wu, O.; Zhang, G.Q.; Pan, H.F.; Li, X.P.; Xu, J.H.; Dai, H. & Ye, D.Q. 
(2009). Fas expression on peripheral blood lymphocytes in systemic lupus 
erythematosus: relation to the organ damage and lymphocytes apoptosis. Molecular 
Biology Reports, 36 pp. 2047-2052 
Lin, Y.J.; Chen, R.H.; Wan, L.; Sheu, J.J.C.; Huang, C.M.; Lin, C.W.; Chen, S.Y.; Lai, C.H.; Lan, 
Y.C.; Hsueh, K.C.; Tsai, C.H.; Lin, T.H.; Huang, Y.M.; Chao, K.; Chen, D.Y. & Tsai, 
F.J. (2009). Association of TNF-alpha gene polymorphisms with systemic lupus 
erythematosus in Taiwanese patients. Lupus, 18 pp. 974-979 
Liu, C.C. & Ahearn, J.M. (2009). The search for lupus biomarkers. Best Practice & Research in 
Clinical Rheumatology, 23 pp. 507-523 
Liu, Z.; Bethunaickan, R.; Huang, W.; Lodhi, U.; Solano, I.; Madaio, M.P. & Davidson, A. 
(2011). Interferon-alpha accelerates murine systemic lupus erythematosus in a T 
cell-dependent manner. Arthritis Rheum, 63 pp. 219-229 
Lood, C.; Gullstrand, B.; Truedsson, L.; Olin, A.I.; Alm, G.V.; Ronnblom, L.; Sturfelt, G.; 
Eloranta, M.L. & Bengtsson, A.A. (2009). C1q Inhibits Immune Complex-Induced 
Interferon-alpha Production in Plasmacytoid Dendritic Cells A Novel Link 
Between C1q Deficiency and Systemic Lupus Erythematosus Pathogenesis. Arthritis 
and Rheumatism, 60 pp. 3081-3090 
Lucero, M.A.; Magdelenat, H.; Fridman, W.H.; Pouillart, P.; Billardon, C.; Billiau, A.; Cantell, 
K. & Falcoff, E. (1982). Comparison of effects of leukocyte and fibroblast interferon 
on immunological parameters in cancer-patients. European Journal of Cancer & 
Clinical Oncology, 18 pp. 243-251 
 
Interferon and Apoptosis in Systemic Lupus Erythematosus 
 
93 
Luker, K.E.; Hutchens, M.; Schultz, T.; Pekosz, A. & Luker, G.D. (2005). Bioluminescence 
imaging of vaccinia virus: Effects of interferon on viral replication and spread. 
Virology, 341 pp. 284-300 
Mathian, A.; Weinberg, A.; Gallegos, M.; Banchereau, J. & Koutouzov, S. (2005). IFN- 
alpha induces early lethal lupus in preautoimmune (New Zealand Black x  
New Zealand White) F1 but not in BALB/c mice. J Immunol, 174 pp. 2499- 
2506 
Moser, K.L.; Kelly, J.A.; Lessard, C.J. & Harley, J.B. (2009). Recent insights into the  
genetic basis of systemic lupus erythematosus. Genes and Immunity, 10 pp. 373- 
379 
Munoz, L.E.; Lauber, K.; Schiller, M.; Manfredi, A.A. & Herrmann, M. (2010). The role of 
defective clearance of apoptotic cells in systemic autoimmunity. Nature Reviews 
Rheumatology, 6 pp. 280-289 
Murray, H.W. (1988). Interferon-gamma, the activated macrophage, and host defense 
against microbial challenge. Annals of Internal Medicine, 108 pp. 595-608 
Musone, S.L.; Taylor, K.E.; Lu, T.T.; Nititham, J.; Ferreira, R.C.; Ortmann, W.; Shifrin, N.; 
Petri, M.A.; Kamboh, M.I.; Manzi, S.; Seldin, M.F.; Gregersen, P.K.; Behrens, T.W.; 
Ma, A.; Kwok, P.Y. & Criswell, L.A. (2008). Multiple polymorphisms in the 
TNFAIP3 region are independently associated with systemic lupus erythematosus. 
Nature Genetics, 40 pp. 1062-1064 
Nath, S.K.; Han, S.Z.; Kim-Howard, X.; Kelly, J.A.; Viswanathan, P.; Gilkeson, G.S.; Chen, 
W.; Zhu, C.; McEver, R.P.; Kimberly, R.P.; Alarcon-Riquelme, M.E.; Vyse, T.J.; Li, 
Q.Z.; Wakeland, E.K.; Merrill, J.T.; James, J.A.; Kaufman, K.M.; Guthridge, J.M. & 
Harley, J.B. (2008). A nonsynonymous functional variant in integrin-alpha M 
(encoded by ITGAM) is associated with systemic lupus erythematosus. Nature 
Genetics, 40 pp. 152-154 
Niewold, T.B.; Clark, D.N.; Salloum, R. & Poole, B.D. Interferon Alpha in Systemic Lupus 
Erythematosus. Journal of Biomedicine and Biotechnology, pp. 8 
Niewold, T.B.; Hua, J.; Lehman, T.J.A.; Harley, J.B. & Crow, M.K. (2007). High serum IFN-
alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes and 
Immunity, 8 pp. 492-502 
Niewold, T.B.; Kelly, J.A.; Flesch, M.H.; Espinoza, L.R.; Harley, J.B. & Crow, M.K. (2008). 
Association of the IRF5 risk haplotype with high serum interferon-alpha activity in 
systemic lupus erythematosus patients. Arthritis and Rheumatism, 58 pp. 2481- 
2487 
Niewold, T.B. & Swedler, W.I. (2005). Systemic lupus erythematosus arising during 
interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis 
C. Clinical Rheumatology, 24 pp. 178-181 
Panchanathan, R.; Shen, H.; Bupp, M.G.; Gould, K.A. & Choubey, D. (2009). Female and 
male sex hormones differentially regulate expression of Ifi202, an interferon-
inducible lupus susceptibility gene within the Nba2 interval. J Immunol, 183 pp. 
7031-7038 
Panchanathan, R.; Shen, H.; Zhang, X.; Ho, S.M. & Choubey, D. (2010). Mutually  
positive regulatory feedback loop between interferons and estrogen receptor-
 
Systemic Lupus Erythematosus 
 
94
alpha in mice: implications for sex bias in autoimmunity. PLoS ONE, 5 pp.  
e10868 
Petri, M.; Singh, S.; Tesfasyone, H.; Dedrick, R.; Fry, K.; Lal, P.G.; Williams, G.; Bauer, J.W.; 
Gregersen, P.K.; Behrens, T.W. & Baechler, E.C. (2009). Longitudinal expression of 
type I interferon responsive genes in systemic lupus erythematosus. Lupus, 18 pp. 
980-989 
Pindel, A. & Sadler, A. The Role of Protein Kinase R in the Interferon Response. Journal of 
Interferon and Cytokine Research, 31 pp. 59-70 
Pradhan, V.; Surve, P. & Ghosh, K. Mannose binding lectin (MBL) in autoimmunity and  
its role in systemic lupus erythematosus (SLE). J Assoc Physicians India, 58 pp. 688-
690 
Reddy, M.V.; Velazquez-Cruz, R.; Baca, V.; Lima, G.; Granados, J.; Orozco, L. & Alarcon-
Riquelme, M.E. (2007). Genetic association of IRF5 with SLE in Mexicans: higher 
frequency of the risk haplotype and its homozygozity than Europeans. Hum Genet, 
121 pp. 721-727 
Rhodes, B. & Vyse, T.J. (2008). The genetics of SLE: an update in the light of genome-wide 
association studies. Rheumatology, 47 pp. 1603-1611 
Richez, C.; Yasuda, K.; Bonegio, R.G.; Watkins, A.A.; Aprahamian, T.; Busto, P.; Richards, 
R.J.; Liu, C.L.; Cheung, R.; Utz, P.J.; Marshak-Rothstein, A. & Rifkin, I.R., (2010) IFN 
regulatory factor 5 is required for disease development in the FcγRIIB-/- Yaa and 
FcγRIIB-/- mouse models of systemic lupus erythematosus. J Immunol, 184 pp. 796-
806 
Ronnblom, L. & Alm, G.V. (2001). A pivotal role for the natural interferon alpha-producing 
cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. Journal of 
Experimental Medicine, 194 pp. F59-F63 
Ronnblom, L.; Alm, G.V. & Eloranta, M.L. The type I interferon system in the development 
of lupus. Seminars in Immunology, 23 pp. 113-121 
Sabry, A.; Sheashaa, H.; El-husseini, A.; Mahmoud, K.; Eldahshan, K.F.; George, S.K.; Abdel-
Khalek, E.; El-Shafey, E.M. & Abo-Zenah, H. (2006). Proinflammatory cytokines 
(TNF-alpha and IL-6) in Egyptian patients with SLE: Its correlation with disease 
activity. Cytokine, 35 pp. 148-153 
Sahebari, M.; Hatef, M.R.; Rezaieyazdi, Z.; Abbasi, M.; Abbasi, B. & Mahmoudi, M. 
Correlation between Serum Levels of Soluble Fas (CD95/Apo-1) with Disease 
Activity in Systemic Lupus Erythematosus Patients in Khorasan, Iran. Archives of 
Iranian Medicine, 13 pp. 135-142 
Salloum, R.; Franek, B.; Kariuki, S.; Utset, T. & Niewold, T. (2009). T.16. Genetic Variation  
at the IRF7/KIAA1542 Locus is Associated with Autoantibody Profile and  
Serum Interferon Alpha Levels in Lupus Patients. Clinical Immunology, 131 pp. S54-
S54 
Sanz, I.; Yasothan, U. & Kirkpatrick, P. Belimumab. Nature Reviews Drug Discovery, 10 pp. 
335-336 
Savitsky, D.A.; Yanai, H.; Tamura, T.; Taniguchi, T. & Honda, K. (2010). Contribution of 
IRF5 in B cells to the development of murine SLE-like disease through its 
transcriptional control of the IgG2a locus. Proc Natl Acad Sci U S A, 107 pp. 10154-
10159 
 
Interferon and Apoptosis in Systemic Lupus Erythematosus 
 
95 
Sebastiani, G.D. & Galeazzi, M. (2009). Immunogenetic studies on systemic lupus 
erythematosus. Lupus, 18 pp. 878-883 
Sharma, R.P.; He, Q. & Riley, R.T. (2005). Lupus-prone NZBWF1/J mice, defective in 
cytokine signaling, are resistant to fumonisin hepatotoxicity despite accumulation 
of liver sphinganine. Toxicology, 216 pp. 59-71 
Shimane, K.; Kochi, Y.; Yamada, R.; Okada, Y.; Suzuki, A.; Miyatake, A.; Kubo, M.; 
Nakamura, Y. & Yamamoto, K. (2009). A single nucleotide polymorphism in the 
IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the 
Japanese population. Annals of the Rheumatic Diseases, 68 pp. 377-383 
Sigurdsson, S.; Nordmark, G.; Garnier, S.; Grundberg, E.; Kwan, T.; Nilsson, O.; Eloranta, 
M.L.; Gunnarsson, I.; Svenungsson, E.; Sturfelt, G.; Bengtsson, A.A.; Jonsen, A.; 
Truedsson, L.; Rantapaa-Dahlqvist, S.; Eriksson, C.; Alm, G.; Goring, H.H.H.; 
Pastinen, T.; Syvanen, A.C. & Ronnblom, L. (2008). A risk haplotype of STAT4 for 
systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and 
shows additive effects with two risk alleles of IRF5. Human Molecular Genetics, 17 
pp. 2868-2876 
Standal, T.; Borset, M. & Sundan, A. (2004). Role of osteopontin in adhesion, migration, cell 
survival and bone remodeling. Experimental Oncology, 26 pp. 179-184 
Stranger, B.E.; Stahl, E.A. & Raj, T. Progress and Promise of Genome-Wide Association 
Studies for Human Complex Trait Genetics. Genetics, 187 pp. 367-383 
Su, A.I.; Wiltshire, T.; Batalov, S.; Lapp, H.; Ching, K.A.; Block, D.; Zhang, J.; Soden, R.; 
Hayakawa, M.; Kreiman, G.; Cooke, M.P.; Walker, J.R. & Hogenesch, J.B. (2004). A 
gene atlas of the mouse and human protein-encoding transcriptomes. Proceedings of 
the National Academy of Sciences of the United States of America, 101 pp. 6062-6067 
Suarez-Gestal, M.; Calaza, M.; Endreffy, E.; Pullmann, R.; Ordi-Ros, J.; Sebastiani, G.D.; 
Ruzickova, S.; Santos, M.J.; Papasteriades, C.; Marchini, M.; Skopouli, F.N.; Suarez, 
A.; Blanco, F.J.; D'Alfonso, S.; Bijl, M.; Carreira, P.; Witte, T.; Migliaresi, S.; Gomez-
Reino, J.J.; Gonzalez, A. & European Consortium, S.D. (2009). Replication of 
recently identified systemic lupus erythematosus genetic associations: a case-
control study. Arthritis Research & Therapy, 11 pp.  
Tada, Y.; Kondo, S.; Aoki, S.; Koarada, S.; Inoue, H.; Suematsu, R.; Ohta, A.; Mak, T.W. & 
Nagasawa, K. (2011). Interferon regulatory factor 5 is critical for the development 
of lupus in MRL/lpr mice. Arthritis Rheum, 63 pp. 738-748 
Takaoka, A.; Hayakawa, S.; Yanai, H.; Stoiber, D.; Negishi, H.; Kikuchi, H.; Sasaki, S.; Imai, 
K.; Shibue, T.; Honda, K. & Taniguchi, T. (2003). Integration of interferon-
alpha/beta signalling to p53 responses in tumour suppression and antiviral 
defence. Nature, 424 pp. 516-523 
Watford, W.T.; Hissong, B.D.; Bream, J.H.; Kanno, Y.; Muul, L. & O'Shea, J.J. (2004). 
Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. 
Immunological Reviews, 202 pp. 139-156 
Xu, C.J.; Zhang, W.H.; Pan, H.F.; Li, X.P.; Xu, J.H. & Ye, D.Q. (2009). Association study of a 
single nucleotide polymorphism in the exon 2 region of toll-like receptor 9 (TLR9) 
gene with susceptibility to systemic lupus erythematosus among Chinese. 
Molecular Biology Reports, 36 pp. 2245-2248 
 
Systemic Lupus Erythematosus 
 
94
alpha in mice: implications for sex bias in autoimmunity. PLoS ONE, 5 pp.  
e10868 
Petri, M.; Singh, S.; Tesfasyone, H.; Dedrick, R.; Fry, K.; Lal, P.G.; Williams, G.; Bauer, J.W.; 
Gregersen, P.K.; Behrens, T.W. & Baechler, E.C. (2009). Longitudinal expression of 
type I interferon responsive genes in systemic lupus erythematosus. Lupus, 18 pp. 
980-989 
Pindel, A. & Sadler, A. The Role of Protein Kinase R in the Interferon Response. Journal of 
Interferon and Cytokine Research, 31 pp. 59-70 
Pradhan, V.; Surve, P. & Ghosh, K. Mannose binding lectin (MBL) in autoimmunity and  
its role in systemic lupus erythematosus (SLE). J Assoc Physicians India, 58 pp. 688-
690 
Reddy, M.V.; Velazquez-Cruz, R.; Baca, V.; Lima, G.; Granados, J.; Orozco, L. & Alarcon-
Riquelme, M.E. (2007). Genetic association of IRF5 with SLE in Mexicans: higher 
frequency of the risk haplotype and its homozygozity than Europeans. Hum Genet, 
121 pp. 721-727 
Rhodes, B. & Vyse, T.J. (2008). The genetics of SLE: an update in the light of genome-wide 
association studies. Rheumatology, 47 pp. 1603-1611 
Richez, C.; Yasuda, K.; Bonegio, R.G.; Watkins, A.A.; Aprahamian, T.; Busto, P.; Richards, 
R.J.; Liu, C.L.; Cheung, R.; Utz, P.J.; Marshak-Rothstein, A. & Rifkin, I.R., (2010) IFN 
regulatory factor 5 is required for disease development in the FcγRIIB-/- Yaa and 
FcγRIIB-/- mouse models of systemic lupus erythematosus. J Immunol, 184 pp. 796-
806 
Ronnblom, L. & Alm, G.V. (2001). A pivotal role for the natural interferon alpha-producing 
cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. Journal of 
Experimental Medicine, 194 pp. F59-F63 
Ronnblom, L.; Alm, G.V. & Eloranta, M.L. The type I interferon system in the development 
of lupus. Seminars in Immunology, 23 pp. 113-121 
Sabry, A.; Sheashaa, H.; El-husseini, A.; Mahmoud, K.; Eldahshan, K.F.; George, S.K.; Abdel-
Khalek, E.; El-Shafey, E.M. & Abo-Zenah, H. (2006). Proinflammatory cytokines 
(TNF-alpha and IL-6) in Egyptian patients with SLE: Its correlation with disease 
activity. Cytokine, 35 pp. 148-153 
Sahebari, M.; Hatef, M.R.; Rezaieyazdi, Z.; Abbasi, M.; Abbasi, B. & Mahmoudi, M. 
Correlation between Serum Levels of Soluble Fas (CD95/Apo-1) with Disease 
Activity in Systemic Lupus Erythematosus Patients in Khorasan, Iran. Archives of 
Iranian Medicine, 13 pp. 135-142 
Salloum, R.; Franek, B.; Kariuki, S.; Utset, T. & Niewold, T. (2009). T.16. Genetic Variation  
at the IRF7/KIAA1542 Locus is Associated with Autoantibody Profile and  
Serum Interferon Alpha Levels in Lupus Patients. Clinical Immunology, 131 pp. S54-
S54 
Sanz, I.; Yasothan, U. & Kirkpatrick, P. Belimumab. Nature Reviews Drug Discovery, 10 pp. 
335-336 
Savitsky, D.A.; Yanai, H.; Tamura, T.; Taniguchi, T. & Honda, K. (2010). Contribution of 
IRF5 in B cells to the development of murine SLE-like disease through its 
transcriptional control of the IgG2a locus. Proc Natl Acad Sci U S A, 107 pp. 10154-
10159 
 
Interferon and Apoptosis in Systemic Lupus Erythematosus 
 
95 
Sebastiani, G.D. & Galeazzi, M. (2009). Immunogenetic studies on systemic lupus 
erythematosus. Lupus, 18 pp. 878-883 
Sharma, R.P.; He, Q. & Riley, R.T. (2005). Lupus-prone NZBWF1/J mice, defective in 
cytokine signaling, are resistant to fumonisin hepatotoxicity despite accumulation 
of liver sphinganine. Toxicology, 216 pp. 59-71 
Shimane, K.; Kochi, Y.; Yamada, R.; Okada, Y.; Suzuki, A.; Miyatake, A.; Kubo, M.; 
Nakamura, Y. & Yamamoto, K. (2009). A single nucleotide polymorphism in the 
IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the 
Japanese population. Annals of the Rheumatic Diseases, 68 pp. 377-383 
Sigurdsson, S.; Nordmark, G.; Garnier, S.; Grundberg, E.; Kwan, T.; Nilsson, O.; Eloranta, 
M.L.; Gunnarsson, I.; Svenungsson, E.; Sturfelt, G.; Bengtsson, A.A.; Jonsen, A.; 
Truedsson, L.; Rantapaa-Dahlqvist, S.; Eriksson, C.; Alm, G.; Goring, H.H.H.; 
Pastinen, T.; Syvanen, A.C. & Ronnblom, L. (2008). A risk haplotype of STAT4 for 
systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and 
shows additive effects with two risk alleles of IRF5. Human Molecular Genetics, 17 
pp. 2868-2876 
Standal, T.; Borset, M. & Sundan, A. (2004). Role of osteopontin in adhesion, migration, cell 
survival and bone remodeling. Experimental Oncology, 26 pp. 179-184 
Stranger, B.E.; Stahl, E.A. & Raj, T. Progress and Promise of Genome-Wide Association 
Studies for Human Complex Trait Genetics. Genetics, 187 pp. 367-383 
Su, A.I.; Wiltshire, T.; Batalov, S.; Lapp, H.; Ching, K.A.; Block, D.; Zhang, J.; Soden, R.; 
Hayakawa, M.; Kreiman, G.; Cooke, M.P.; Walker, J.R. & Hogenesch, J.B. (2004). A 
gene atlas of the mouse and human protein-encoding transcriptomes. Proceedings of 
the National Academy of Sciences of the United States of America, 101 pp. 6062-6067 
Suarez-Gestal, M.; Calaza, M.; Endreffy, E.; Pullmann, R.; Ordi-Ros, J.; Sebastiani, G.D.; 
Ruzickova, S.; Santos, M.J.; Papasteriades, C.; Marchini, M.; Skopouli, F.N.; Suarez, 
A.; Blanco, F.J.; D'Alfonso, S.; Bijl, M.; Carreira, P.; Witte, T.; Migliaresi, S.; Gomez-
Reino, J.J.; Gonzalez, A. & European Consortium, S.D. (2009). Replication of 
recently identified systemic lupus erythematosus genetic associations: a case-
control study. Arthritis Research & Therapy, 11 pp.  
Tada, Y.; Kondo, S.; Aoki, S.; Koarada, S.; Inoue, H.; Suematsu, R.; Ohta, A.; Mak, T.W. & 
Nagasawa, K. (2011). Interferon regulatory factor 5 is critical for the development 
of lupus in MRL/lpr mice. Arthritis Rheum, 63 pp. 738-748 
Takaoka, A.; Hayakawa, S.; Yanai, H.; Stoiber, D.; Negishi, H.; Kikuchi, H.; Sasaki, S.; Imai, 
K.; Shibue, T.; Honda, K. & Taniguchi, T. (2003). Integration of interferon-
alpha/beta signalling to p53 responses in tumour suppression and antiviral 
defence. Nature, 424 pp. 516-523 
Watford, W.T.; Hissong, B.D.; Bream, J.H.; Kanno, Y.; Muul, L. & O'Shea, J.J. (2004). 
Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. 
Immunological Reviews, 202 pp. 139-156 
Xu, C.J.; Zhang, W.H.; Pan, H.F.; Li, X.P.; Xu, J.H. & Ye, D.Q. (2009). Association study of a 
single nucleotide polymorphism in the exon 2 region of toll-like receptor 9 (TLR9) 
gene with susceptibility to systemic lupus erythematosus among Chinese. 
Molecular Biology Reports, 36 pp. 2245-2248 
 
Systemic Lupus Erythematosus 
 
96
Yamaguchi, H.; Fujimoto, T.; Nakamura, S.; Ohmura, K.; Mimori, T.; Matsuda, F. & Nagata, 
S. Aberrant splicing of the milk fat globule-EGF factor 8 (MFG-E8) gene in human 
systemic lupus erythematosus. European Journal of Immunology, 40 pp. 1778-1785 
Ytterberg, S.R. & Schnitzer, T.J. (1982). Serum interferon levels in patients with systemic 
lupus-erythematosus. Arthritis and Rheumatism, 25 pp. 401-406 
Zhuang, H.Y.; Narain, S.; Sobel, E.; Lee, P.Y.; Naconales, D.C.; Kelly, K.M.; Richards, H.B.; 
Segal, M.; Stewart, C.; Satoh, M. & Reeves, W.H. (2005). Association of anti-
nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene 
transcripts and dendritic cell maturation in systemic lupus erythematosus. Clinical 
Immunology, 117 pp. 238-250 
4 
Fas Pathway of Cell Death and  
B Cell Dysregulation in SLE 
Roberto Paganelli, Alessia Paganelli and Maria C. Turi  
Department of Medicine and Sciences of Aging 
University “G. d’Annunzio” of Chieti-Pescara 
 and Ce.S.I.- U.d’A. Foundation, Chieti scalo (CH) 
 Italy 
1. Introduction 
Systemic lupus erythematosus (SLE) is a generalized autoimmune disease affecting several 
organ systems, characterized by the presence of a vast array of autoantibodies, 
characteristically directed to nuclear antigens (ANA) (Arbuckle et al, 2003, Hahn, 1998, 
Rothman and Isenberg, 2008).  Systemic lupus erythematosus (SLE) is the second most 
common human autoimmune disease affecting between 400 and 1000 per million people 
worldwide (Craft, 2011). 
SLE is caused by the breakdown of tolerance to nuclear self-antigens, which leads to 
activation of autoreactive B cells that produce autoantibodies against self-nucleic acids 
and associated proteins (Lande et al, 2011). These autoantibodies bind self-nucleic acids 
released by dying cells, and form immune complexes that are deposited in different parts 
of the body, leading to detrimental inflammation and tissue damage. A key early event 
that triggers autoimmunity in SLE is the chronic innate activation of plasmacytoid 
dendritic cells (pDCs) to secrete type I interferons (IFNs) (Theofilopoulos et al, 2005; 
Ronnblom et al, 2006; Banchereau and Pascual, 2006). The high levels of type I IFNs 
induce an unabated differentiation of monocytes into dendritic cells that stimulate 
autoreactive B and T cells (Blanco et al, 2001), licensing T cells recognize autoantigens and 
lower the activation threshold of autoreactive B cells (LeBon et al, 2006), thereby 
promoting autoimmunity in SLE. 
Analysis of genes encoding components of the interferon pathway has led to extensive 
support for an association of polymorphic variants of interferon regulatory factor 5 (IRF5) 
with SLE (Bennett et al, 2003; Crow, 2008; Niewold et al,2007;). Recent genomewide 
association studies confirm associations of HLA and STAT4 variants with SLE and also the 
role of PTPN22 (International Consortium, 2008; Rieck et al, 2007; Remmers et al, 2007).  
New reports of genetic SNPs associations include the B-cell-receptor–signaling pathway and 
the mechanisms of adhesion of inflammatory cells to the vasculature (Hom et al, 2008; 
Kozyrev et al, 2008). 
The heterogeneity of clinical manifestations and the disease's unpredictable course (Tan et 
al, 1982) characterized by flares and remissions are very likely a reflection of heterogeneity 
at the origin of disease, with a final common pathway leading to loss of tolerance to nuclear 
antigens. Impaired clearance of immune complexes and apoptotic material and production 
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of autoantibodies have long been recognized as major pathogenic events (Arbuckle et al, 
2003; Rothman and Isenberg, 2008). Apoptotic defects underlie some models of autoimmune 
diseases, and they have been proposed in the pathogenesis of SLE, a prototypic autoimmune 
disorder. 
SLE disease activity can be difficult to monitor, and flares are unpredictable in both 
frequency and severity. Certain clinical laboratory tests, including anti-double-stranded 
DNA antibodies (anti-dsDNA), complement factor levels, and the erythrocyte sedimentation 
rate (ESR) are often measured as potential indicators of disease activity (Ippolito et al, 2011). 
Neutrophils are part of the innate immune response and they have long been suspected  
to play a role in SLE pathogenesis. Nevertheless, their role has not been elucidated  
until very recently. 
In 1948, Hargraves et al. described mature bone marrow neutrophils containing 
intracytoplasmic nuclear material in 25 SLE patients at the Mayo Clinic (Hargraves, 1948). 
This phenomenon, which they called the “LE cell,” helped develop the first diagnostic test 
for this disease (Haserick and Bortz, 1949a).  In 1949, Haserick and Bortz found that plasma 
from 50 to 75% of patients with SLE reproduced the LE cell phenomenon in vitro, with the 
formation of clumps of neutrophils around amorphous masses of nuclear material (Haserick 
and Borts, 1949b). Subsequent reports described the LE factor binding to nuclear 
components, including RNPs and histones. The identification of anti-nuclear antibodies 
(Baugh et al, 1960; Hahn, 1998) later replaced the LE cell as a diagnostic test, and switched 
the focus of lupus research from neutrophils to B cells, which now seems to switch back 
again (see below, NETosis). 
2. Types of cell death 
In human adults, billions of cells die every day as part of the body’s natural processes. Cells 
that become damaged by microbial infection or mechanical stress also die. The cell death 
that occurs in the physiological setting is programmed (Nagata et al, 2010). 
Four different cell-death processes (apoptosis, cornification, necrosis, and autophagy) have 
been officially proposed (Kroemer et al., 2009). In apoptosis, the cell and nuclei condense 
and become fragmented and are engulfed by phagocytes (Kerr et al., 1972). Apoptosis is the 
major death process, but necrosis and autophagic cell death have also been proposed to play 
roles in programmed cell death (Kroemer et al., 2009). Dying cells secrete a “find me” signal, 
and they expose an “eat me” signal on their surface. In response to the “find me” signal, 
macrophages approach the dead cells; they then recognize the “eat me” signal 
(Ravichandran and Lorenz, 2007). 
The machinery used for the engulfment and degradation of the extruded nuclei appears 
similar to that used for the removal of apoptotic cells. Mice deficient in the engulfment of 
apoptotic cells develop SLE-type autoimmune diseases (Hanayama et al., 2004). A defect in the 
degradation of the chromosomal DNA from engulfed cells in mice activates macrophages, 
leading to lethal anemia in embryos and chronic arthritis in adults (Kawane et al., 2001; 
Kawane et al., 2006). These observations indicate that dead cells and the nuclei expelled from 
erythroid precursor cells need to be swiftly cleared for animals to maintain homeostasis. 
2.1 High mobility group box 1 (HMGB1) 
In 1999, K.J. Tracey and colleagues discovered that the abundant chromatin-associated 
protein HMGB1 is secreted by activated macrophages during inflammation, and plays a 
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critical role as a late mediator of lethal endotoxemia and sepsis (Wang et al, 1999). Since this 
initial report, the cytokine activity of HMGB1 has been confirmed by many groups and 
HMGB1 has now been proposed to be a crucial mediator in the pathogenesis of many  
diseases including sepsis, arthritis, and cancer (Erlandsson Harris and Andersson, 2004; 
Dumitriu et al, 2005; Ulloa and Messmer, 2006).   
HMGB1 is an intracellular protein that when present in the extracellular milieu acts as a 
‘‘necrotic marker’’ for the immune system. Recent studies indicate that damaged or necrotic 
cells can release HMGB1 into the extracellular milieu, where it triggers inflammatory 
responses. In contrast to necrosis, cells undergoing programmed cell death or apoptosis 
induce negligible inflammation in the surrounding tissue (Yang et al, 2004), which is 
attributed in part, to the retention of HMGB1 within the apoptotic cells (Kokkola, 2003). 
Indeed, there are two mechanisms for cells to liberate HMGB1 into the  extracellular milieu . 
The first mechanism is a ‘‘passive release’’ of HMGB1 from damaged or necrotic cells: 
extracellular HMGB1 acts as an immune-stimulatory signal that indicates the extent of tissue 
injury (Wang et al, 2004; Yang, 2004), promotes the recruitment of mononuclear cells to clear 
cellular debris and protects against possible infection that often follows trauma (Carriere et 
al, 2007). The second mechanism is an ‘‘active secretion’’ of HMGB1 from immune cells to 
act as a pro-inflammatory cytokine during an immunological challenge. 
IL-33, the most recent addition to the IL-1 family, is a potent proinflammatory cytokine  
that induces production of Th2-associated cytokines IL-4, IL-5, and IL-13, both in vitro and 
in vivo (Schmitz, 2005). Surprisingly, IL-33 has also been described as an abundant 
chromatin associated nuclear factor, which associates with mitotic chromosomes in living 
cells and with interphase chromatin in the nucleus of endothelial cells in vivo (Baekkevold, 
2003). IL-33 therefore constitutes a second example of a chromatin associated cytokine 
(Yamada, 2007). 
2.2 NETosis 
Neutrophils in circulation are directed by cytokines into infected tissues, where they 
encounter invading microbes. This encounter leads to the activation of neutrophils and the 
engulfment of the pathogen into a phagosome. In the phagosome, two events are required 
for antimicrobial activity. First, the presynthesized subunits of the NADPH oxidase 
assemble at the phagosomal membrane and transfer electrons to oxygen to form superoxide 
anions. Second, the granules fuse with the phagosome, discharging antimicrobial peptides 
and enzymes. Together, they are responsible for microbial killing (Klebanoff, 1999). Patients 
with mutations in the NADPH oxidase suffer from chronic granulomatous disease (CGD; 
Heyworth et al., 2003). 
Upon activation, neutrophils release extra cellular traps (neutrophil extracellular traps 
[NETs]; Brinkmann et al., 2004). NETs are composed of chromatin decorated with granular 
proteins, including LL-37, antibiotic peptides, neutrophil peptides and nuclear proteins, e.g. 
histones and HMGB1. These structures bind Gram-positive and -negative bacteria. 
Activated neutrophils initiate a process where first the classical lobulated nuclear 
morphology and the distinction between eu- and hetero-chromatin are lost. Later, all the 
internal membranes disappear, allowing NET components to mix. Finally, NETs emerge 
from the cell as the cytoplasmic membrane is ruptured by a process that is distinct from 
necrosis or apoptosis. This active process is dependent on the generation of ROS by NADPH 
oxidase (Fuchs et al., 2007). With the loss of nuclear and granular membranes, the 
decondensed chromatin comes into direct contact with cytoplasmic and granular 
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components. 120 min after activation the granular marker neutrophil elastase colocalizes 
with chromatin. NETs were detected after PMA activation, but not after incubation with Fas 
antibody (inducing apoptosis) or treatment with S. aureus toxins (inducing necrosis). 
Together, these data indicate that neither apoptosis nor necrosis lead to NET formation, and 
that NET-inducing cell death is different from both apoptosis and necrosis by morphological 
and molecular criteria. A hitherto unknown form of active cell death apparently evolved to 
allow neutrophils to kill microbes post mortem. In this form of cell death, the potent cationic 
antimicrobial peptides and proteins of neutrophils are mixed with chromatin and released 
to form NETs. Interestingly, the generation of ROS by NADPH oxidase is required for 
efficient phagocytic killing, and ROS act as a second messenger to trigger NET formation 
(Lande et al, 2011). 
Importantly, in this form of cell death DNA fragmentation is not activated, allowing the 
chromatin to unfold in the extracellular space. NETs can bind and kill microbes by 
providing a high local concentration of antimicrobial peptides and, at the same time, 
minimize tissue damage by sequestering the noxious granule enzymes (Fuchs et al, 2007). 
Therefore, intact nucleosomes decorated with antimicrobial peptides and nuclear proteins 
may be released in NETosis, whose dysregulation has been postulated to represent a critical 
event in SLE pathogenesis (Craft, 2011). 
3. Cell death as driving force for autoantibodies production 
Phagocytes engulf dead cells, which are recognized as dead by virtue of a characteristic "eat 
me" signal exposed on their surface. Inefficient engulfment of dead cells activates the 
immune system, causing disease (such as SLE). The molecular details of these processes 
have been recently superbly reviewed in Cell  (Nagata, 2010).  
During apoptosis, the asymmetric distribution of phospholipids of the plasma membrane 
gets lost and phosphatidylserine (PS) is translocated to the outer leaflet of the plasma 
membrane. There, PS acts as one major "eat me" signal that ensures efficient recognition and 
uptake of apoptotic cells by phagocytes. PS recognition of activated phagocytes induces the 
secretion of anti-inflammatory cytokines like interleukin-10 (Fadok, 2001). Accumulation of 
dead cells containing nuclear autoantigens in sites of immune selection may provide 
survival signals for autoreactive B-cells.  
The production of antibodies against nuclear structures determines the initiation of chronic 
autoimmunity in systemic lupus erythematosus. Various soluble molecules and biophysical 
properties of the surface of apoptotic cells play significant roles in the appropriate 
recognition and further processing of dying and dead cells. High mobility group box 1 
(HMGB1), C-reactive protein (CRP), and anti-nuclear autoantibodies may  contribute to the 
etiopathogenesis of the disease (Craft, 2011). 
3.1 Autoantibodies in SLE 
Patients with SLE have autoantibodies in their sera against nuclear components (anti-
ribonucleoprotein and anti-DNA antibodies) and sometimes exhibit circulating DNA or 
nucleosomes (Rumore and Steinman, 1990). As unengulfed apoptotic cells are present in the 
germinal centers of the lymph nodes of some SLE patients and macrophages from these 
patients often show a reduced ability to engulf apoptotic cells, a deficiency in the clearance 
of apoptotic cells is proposed to be one of the causes of SLE (Gaipl et al., 2006). Apoptotic 
corps are disposed by phagocytes (Savill, 1994) and show immunosuppressive activity (Voll, 
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1997) and recently are reported to be conducive to generation of B regulatory cells (see 
below) (Gray 2007). 
There is increasing evidence that in systemic lupus erythematosus, nucleosomes, the basic 
chromatin component, represent both a driving immunogen and a major in vivo target for 
antibodies (Casciola-Rosen, 1994; Huggins et al, 1999). Either a disturbed apoptosis or a 
reduced clearance of apoptotic cells by phagocytes may lead to an increased exposure of 
apoptotic nucleosomes protected by HMGB1, to the immune system (Urbonaviciute et al., 
2008). One possible new source of HMGB1-nucleosome complexes is thought to derive from 
NETosis (Lande, 2011; Garcia-Romo, 2011).   
3.2 The Fas/FasL pathway of apoptosis in SLE 
Apoptosis is activated by two pathways, the intrinsic and extrinsic pathways (Ow et al., 
2008). Fas ligand (FasL), tumor necrosis factor (TNF), and TRAIL (TNF-related apoptosis-
inducing ligand) are type II membrane proteins that can activate the extrinsic death 
pathway (Krammer, 2000; Nagata, 1997; Strasser et al., 2009). The binding of FasL to its 
receptor (Fas) induces the formation of the death inducing signaling complex (DISC), 
consisting of Fas, an adaptor protein (FADD), and procaspase 8. Formation of the DISC 
leads to the processing and activation of caspase 8. In both the intrinsic and extrinsic 
pathways, apoptosis is completed by the cleavage of a set of cellular proteins (more than 500 
substrates) by effector caspases (caspases 3 and 7) (Lüthi and Martin, 2007; Timmer and 
Salvesen, 2007). 
Fas is a 43 kDa glycoprotein molecule which is involved in inducing apoptosis in both B and 
T lymphocytes (Singh, 1995). In the murine MRL/lpr/lpr model of systemic lupus 
erythematosus (SLE), the lymphoproliferation (lpr) mutation results in defective 
transcription of the gene that codes for the Fas protein. MRL mice which carry the 
homozygous recessive lpr mutation develop a severe early-onset genetically predetermined 
autoimmune syndrome. Susceptibility to SLE is found to be associated with many genes  
(see Table 1), one of which is APO-1/Fas gene, which is present on chromosome 10 in 
humans (Singh et al, 2009). The APO-1/Fas promoter contains consensus sequences for 
binding of several transcription factors that affect the intensity of Fas expression in cells. The 
mutations in the APO-1/Fas promoter are associated with risk and severity in various 
autoimmune diseases. A decreased rate of apoptosis may possibly be related also to 
elevated levels of soluble Fas (sFas) which can inhibit Fas mediated apoptosis of 
lymphocytes (Kruse et al, 2010).  
 
GENETIC TYPE I IFN (Irf-5, etc) TLRs  (7 to 9) 




FACTORS Complement factors (classical/alternate) 
NETs 
control CD4 activation 
ITGAM 
FcGRII 
Table 1. Possible genetic loci controlling SLE predisposition; they include antigen 
presentation, IFN type-I production by pDCs, activation of autoreactive T and B cells and 
neutrophils, complement cascade and nucleic acid sensing and antibody signalling. 
In overwhelming majority of situations alterations in Fas and FasL expression are viewed in 
frames of Fas-mediated apoptosis (Tinazzi et al, 2009; Nozawa, 1997). Telegina et al. (2008) 
tested a possible involvement of Fas-ligand-mediated "reverse signaling" in the 
pathogenesis of autoimmune diseases such as rheumatoid arthritis (RA) and SLE. The 
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1997) and recently are reported to be conducive to generation of B regulatory cells (see 
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receptor (Fas) induces the formation of the death inducing signaling complex (DISC), 
consisting of Fas, an adaptor protein (FADD), and procaspase 8. Formation of the DISC 
leads to the processing and activation of caspase 8. In both the intrinsic and extrinsic 
pathways, apoptosis is completed by the cleavage of a set of cellular proteins (more than 500 
substrates) by effector caspases (caspases 3 and 7) (Lüthi and Martin, 2007; Timmer and 
Salvesen, 2007). 
Fas is a 43 kDa glycoprotein molecule which is involved in inducing apoptosis in both B and 
T lymphocytes (Singh, 1995). In the murine MRL/lpr/lpr model of systemic lupus 
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elevated levels of soluble Fas (sFas) which can inhibit Fas mediated apoptosis of 
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GENETIC TYPE I IFN (Irf-5, etc) TLRs  (7 to 9) 




FACTORS Complement factors (classical/alternate) 
NETs 
control CD4 activation 
ITGAM 
FcGRII 
Table 1. Possible genetic loci controlling SLE predisposition; they include antigen 
presentation, IFN type-I production by pDCs, activation of autoreactive T and B cells and 
neutrophils, complement cascade and nucleic acid sensing and antibody signalling. 
In overwhelming majority of situations alterations in Fas and FasL expression are viewed in 
frames of Fas-mediated apoptosis (Tinazzi et al, 2009; Nozawa, 1997). Telegina et al. (2008) 
tested a possible involvement of Fas-ligand-mediated "reverse signaling" in the 
pathogenesis of autoimmune diseases such as rheumatoid arthritis (RA) and SLE. The 
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results indicated that high level of sFas in RA patient blood correlates with a high activity of 
disease; in SLE patients with elevated sFas level there was a correlation between sFas 
concentration and tissue and organ damage. In serum sFas is present in oligomeric form 
(Tokano, 1996). Oligomeric sFas demonstrated cytotoxicity in lymphocyte primary culture 
and in transformed cells, while non-toxic recombinant Fas-ligand partially blocked this 
effect (Telegina, 2008). Levels of sFas correlated with the percentages of activated B cells 
defined as CD20(+)CD38(+) cells. Serum levels of sFas correlate with percentages of 
activated B cells but not with that of activated T cells (Bijl, 1998). There is a significant 
correlation between serum concentrations of sFas and serum IL-18 in SLE patients (Sahebari, 
2010). sFas and TNF serum levels are increased in SLE patients (Miret et al, 2001). sFas 
levels seems to be secondary to TNF action, which is enhanced in inflammatory conditions 
such as SLE. Bcl-2 antigen expression and IL-10 serum levels are related to the maintenance 
of SLE activity. These alterations may interfere with the apoptotic process. 
3.2.1 Role of Fas/FasL in SLE 
Fas ligand (FasL), an apoptosis-inducing member of the TNF cytokine family, and its 
receptor Fas are critical for the shutdown of chronic immune responses and prevention of 
autoimmunity. Accordingly, mutations in their genes cause severe lymphadenopathy and 
autoimmune disease in mice and humans. FasL function is regulated by deposition in the 
plasma membrane and metalloprotease-mediated shedding. mFasL is essential for cytotoxic 
activity and constitutes the guardian against lymphadenopathy, autoimmunity and cancer, 
whereas excess sFasL appears to promote autoimmunity (O’Reilly et al., 2009). Lymphocytes 
from aged autoimmune MRL/lpr mice overexpress Fas ligand (FasL), and are cytotoxic 
against Fas+ target cells. This cytotoxic potential is only partly due to FasL, as wild-type 
MRL+/+ lymphocytes are not able to kill Fas+ targets after induction of FasL (Hadj-Slimane 
et al, 2004). IFN alpha, which is increased in SLE, induces overexpression of Fas on 
lymphocyte surface of lpr mice.  
In healthy subjects, more memory than naive T lymphocytes undergo TNF alpha-induced 
apoptosis. By contrast, in patients with SLE, more naive T cells undergo apoptosis with 
TNFalpha (Habib et al, 2009). Enhanced apoptosis of T cells in SLE seems to be independent 
of disease activity or medication. Finally, inhibition experiments showed that apoptosis in 
the presence of TNFalpha was only partly blocked by anti-FasL antibody (Habib, 2009). 
Another study showed that mFas expression levels were significantly higher among SLE 
patients than in healthy controls, and the expression levels had a positive correlation with 
the early apoptosis rate of mononuclear cells in SLE patients (Li et al, 2009).  
Data from several studies demonstrate increasing serum concentrations of the soluble 
molecules sFas and sFasL starting the first days after birth, indicating possibly a gradual 
decrease of apoptosis in early neonatal life (Telegina, 2009). In our study (Turi et al., 2009) 
SLE patients with lower ratios of sFas/sFasL in their sera were of younger age, and had a 
shorter disease duration (as calculated by the time from diagnosis) and also shorter duration 
of therapy and/or less organ damage. This pointed to the association of the index with age, 
which resulted to be strongly correlated with this parameter. Therefore the main variable 
associated with changes of the sFas/sFasL ratio is the age of the subjects.  
Neutrophil apoptosis was significantly increased in patients with juvenile-onset SLE  
as compared with the noninflamed controls (Midgley et al, 2009). Concentrations of 
TRAIL and FasL were significantly increased in sera from patients with juvenile-onset 
SLE, but formation of NETs was not assessed in this study. Finally, it has been reported 
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that SLE serum is capable of inducing apoptosis independent of Fas or TNF-R (Bengtsson 
et al, 2008). 
3.3 Type I Interferons and apoptosis 
Type I IFN (IFN-I) was firstly described in 1957 as a soluble factor responsible for viral 
resistance in vitro. IFN-I can be considered a "director" of protective immune responses 
(Sozzani et al, 2010). The recent finding of the so-called interferon signature in patients 
suffering from different autoimmune diseases has underlined its possible role in the 
pathogenesis of these diseases (Obermoser and Pascual, 2010). Type I IFN has 
immunoregulatory functions by affecting cell proliferation and by inducing 
antiinflammatory responses (Cantaert et al, 2010).  
pDCs, specialized type I IFN producers, significantly enhance autoreactive B cell proliferation, 
autoantibody production, and survival in response to TLR and BCR stimulation (Thibault, 
2009). IFNAR2-/- B cells fail to upregulate nucleic acid-sensing Toll-like receptors TLR7 as 
well as TLR9 expression in response to IFN-I (Ding et al, 2009). In addition, serum levels of 
IFN-alpha increase in parallel with the Fas-dependent cytotoxic potential of lymphocytes from 
MRL/lpr mice as they age (Hadj-Slimane, 2004). MRL/lpr lymphocytes overexpressed mRNA 
for the IFN-alpha receptor (IFNAR-1 and IFNAR-2) chains of the IFN-I receptor and exhibited 
high endogenous levels of phosphorylated Stat1. These data suggest that IFN-alpha plays an 
important role in the SLE-like syndrome occurring in MRL/lpr mice, and link aberrant 
apoptosis caused by FasL to high levels of IFN-I. 
It has been found that type 1 IFNs protect human B cells in culture from spontaneous 
apoptosis and from apoptosis mediated by anti-CD95 agonist, in a dose- and time-
dependant manner (Badr et al, 2010). Such effect on human B cells was totally abrogated by 
blockade of IFNR1 chain. PI3Kδ, Rho-A, NFκB and Bcl-2/BclXL are active downstream of 
IFN receptors and are the major effectors of IFN-I-rescued B cells from apoptosis. 
Furthermore, marked reduction in numbers of CD20 positive B cell in both spleen and 
Peyer’s patches was seen in mice treated with anti-IFNR1. Type I IFNs can stimulate B-cell 
proliferation and differentiation into antibody-secreting plasma cells, and differentiation of 
immature monocytes into antigen presenting dendritic cells. These dendritic cells can 
activate autoreactive lymphocytes and promote autoantibody production (Ding, 2009). 
These functions of type I IFN, coupled with impaired clearance of apoptotic debris in SLE 
patients, promote formation of immune complexes, which are potent inducers of type I IFN 
(Craft, 2011). Inappropriate IFN production and/or an inability to dampen IFN responses 
thus may initiate a positive feedback loop, resulting in perpetuation of the autoimmune 
response. 
4. B cell phenotypes in SLE 
4.1 B lymphocytes development 
Cells that have recently emerged from the bone marrow and have yet to acquire follicular 
markers such as IgD and CD23, but that express very low levels of CD21 and invariably 
express high levels of CD24 and AA4.1, are called T1 or newly formed (NF) B cells (Carsetti, 
2004a). These cells do not require BAFF (B cell–activating factor of the TNF family) for their 
survival (Schneider, 2001), but like all B cells they depend on signals from the BCR for 
survival (Kraus, 2004; Hardy and Hayakawa, 2001). These cells, after emerging from the 
marginal sinus, mature and are drawn into follicles following a CXCL13 gradient (Pillai, 
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that SLE serum is capable of inducing apoptosis independent of Fas or TNF-R (Bengtsson 
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2009). IFNAR2-/- B cells fail to upregulate nucleic acid-sensing Toll-like receptors TLR7 as 
well as TLR9 expression in response to IFN-I (Ding et al, 2009). In addition, serum levels of 
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for the IFN-alpha receptor (IFNAR-1 and IFNAR-2) chains of the IFN-I receptor and exhibited 
high endogenous levels of phosphorylated Stat1. These data suggest that IFN-alpha plays an 
important role in the SLE-like syndrome occurring in MRL/lpr mice, and link aberrant 
apoptosis caused by FasL to high levels of IFN-I. 
It has been found that type 1 IFNs protect human B cells in culture from spontaneous 
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dependant manner (Badr et al, 2010). Such effect on human B cells was totally abrogated by 
blockade of IFNR1 chain. PI3Kδ, Rho-A, NFκB and Bcl-2/BclXL are active downstream of 
IFN receptors and are the major effectors of IFN-I-rescued B cells from apoptosis. 
Furthermore, marked reduction in numbers of CD20 positive B cell in both spleen and 
Peyer’s patches was seen in mice treated with anti-IFNR1. Type I IFNs can stimulate B-cell 
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immature monocytes into antigen presenting dendritic cells. These dendritic cells can 
activate autoreactive lymphocytes and promote autoantibody production (Ding, 2009). 
These functions of type I IFN, coupled with impaired clearance of apoptotic debris in SLE 
patients, promote formation of immune complexes, which are potent inducers of type I IFN 
(Craft, 2011). Inappropriate IFN production and/or an inability to dampen IFN responses 
thus may initiate a positive feedback loop, resulting in perpetuation of the autoimmune 
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survival (Kraus, 2004; Hardy and Hayakawa, 2001). These cells, after emerging from the 
marginal sinus, mature and are drawn into follicles following a CXCL13 gradient (Pillai, 
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2008), initially become transitional follicular B cells, and eventually give rise to at least two 
lineages of B cells, mature FO B cells and MZ B cells. Transitional follicular B cells can be 
subdivided into two distinct categories. NF (newly formed)/T1 (transitional stage 1) B cells 
are believed to differentiate into T2-FP (transitional stage 2-follicular precursors), which 
may either differentiate into mature FO B cells or sequentially into T2-MZP (transitional 
stage 2-MZ B cell precursors) or MZ (marginal zone) B cells (Cariappa and Pillai, 2002).  
Although MZ B cells are defined primarily on the basis of their anatomical localization 
(Martin and Kearney, 2002), the surface expression of a number of markers can also be used 
to characterize these cells. In rodents the only secondary lymphoid organ in which cells 
bearing surface markers characteristic of MZ B cells are normally found is the spleen. Unlike 
follicular B cells that express high levels of IgD and CD23, with either high or low levels of 
IgM, MZ B cells express high levels of IgM and very low levels of IgD and CD23 (Oliver, 
1999). They also express higher levels of CD21 (complement receptor type II), CD1d (an 
MHC class Ib protein linked to the presentation of lipid antigens), CD38 (an ADP-ribosyl 
cyclase), CD9 (a scavenger receptor family protein), and CD25 (the  chain of the IL-2 
receptor) than those on follicular B cells. MZ B cells also express higher levels of B7 proteins 
than do follicular B cells and overall are described as having an “activated” phenotype 
(Oliver, 1997). 
4.1.1 Transitional B cells 
To identify human transitional B cells, two developmentally regulated markers, CD24 and 
CD38, are used in combination with the B-lineage marker CD19. In the peripheral blood, all 
cells of the B lineage (CD19pos) coexpress CD24 and CD38, and, conversely, all non-B cells 
(CD19neg) lack CD24. (Carsetti, 2004b) Three populations of B cells can be discriminated 
based on the relative distribution of CD24 and CD38. The CD24brightCD38neg population 
includes 60% of all B cells and only 2% expressed high levels of both CD24 and CD38 
(CD24brightCD38bright). To distinguish mature from memory B cells, the expression of 
CD27 (a marker of memory cells) can be studied in the three populations. Essentially all 
CD24brightCD38neg cells are memory B cells, and mature B cells correspond to the 
CD24dullCD38pos population. CD24brightCD38bright cells lack CD27 (Carsetti 2004 a, b). 
The analysis of IgM and IgD in the CD24brightCD38bright population shows that 
transitional B cells coexpress IgM and IgD. IL-10 produced by B cells can downregulate 
autoimmune disease in EAE (Fillatreau et al., 2002), collagen-induced arthritis (Mauri et al., 
2003), and inflammatory bowel disease (Mizoguchi et al., 2002). IL-10-deficient (Il10-/-) mice 
also have enhanced hypersensitivity responses (Berg et al., 1995). Neutralizing IL-10 by 
monoclonal antibody (mAb) treatment also enhances these responses, whereas systemic IL-
10 administration reduces them (Ferguson et al., 1994; Schwarz et al., 1994). IL-10 is secreted 
by multiple cell types, including T cells, monocytes, macrophages, mast cells, eosinophils, 
and keratinocytes, and can suppress both Th1 and Th2 polarization (Yanaba, 2008) and 
inhibit macrophage antigen presentation and  proinflammatory cytokine production 
(Asadullah et al., 2003). Thus, B cells and IL-10 play important inhibitory roles during T cell-
mediated inflammatory responses.  
4.1.2 Negative regulation by B cells 
B cells have been recently shown to negatively regulate autoimmunity and inflammation in 
numerous mouse models (Bouaziz, 2008). Mizoguchi and Bhan (2006) were the first to use 
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the term ‘regulatory B cells’ to designate B cells with regulatory properties. 
Suppressor/regulatory B-cell populations have predominantly been identified using diverse 
mouse models of autoimmune diseases, suggesting that autoimmunity itself promotes the 
expansion of these cells as a compensatory mechanism to limit self-directed inflammation. 
Immunological tolerance exemplifies the capacity of the immune system to downmodulate 
host immune responses (Shevach, 2000). Several regulatory T-cell subsets have been 
identified that contribute to immunological tolerance, including naturally arising 
CD4+CD25+Forkhead box protein 3 (FoxP3)+ regulatory T cells (Sakaguchi, 2004) and T-
regulatory type 1 cells that produce high amounts of interleukin-10 (Groux, 1997). B cells are 
generally considered to be positive regulators of immune responses. 
Whether negative regulation is a general property of B cells induced as a consequence of 
normal B-cell activation or whether only a specific subset of B cells posses this property has 
also been unknown. However, it has been recently shown that regulatory B cells are a 
phenotypically unique (CD1dhi CD5+) and rare subset of B cells in the spleens of na¨ve 
wildtype mice that can significantly influence T-cell activation and some inflammatory 
responses (Yanaba, 2008). This specific subset of regulatory B cells only produces IL-10 and 
is responsible for most IL-10 production by B cells. Other regulatory B-cell subsets that may 
also exist (Mauri and Ehrestein, 2008, Bouaziz, 2008). 
Stimulation of arthritogenic B cells with an agonistic anti-CD40 and collagen generated a 
subset of B cells producing IL-10 (Mauri, 2007).  Transfer of collagen and anti-CD40-
stimulated Bcells to syngeneic immunized mice prevented the induction of arthritis and 
ameliorated established disease. This suppressive effect was associated with a 
downregulation of Th1 cytokines and was dependent upon the release of IL-10 because B 
cells isolated from IL-10- deficient mice stimulated with collagen and anti-CD40 failed to 
suppress disease (Mauri et al, 2007). The engagement of CD40 on B cells is also a principal 
requirement for the generation of Bregs in EAE. Additional in vivo results have shown that 
MZ B cells participate in the suppression of systemic lupus erythematosus (Lenert et al, 
2005). After anti-CD40 treatment an increase of IL-10 production and a decrease of IFN-
gamma release was observed (Mauri, 2000) so it was suggested that the therapeutic effect 
observed after administration of anti-CD40, could have been achieved by redirecting 
pathogenic Th1 type response toward the “protective” Th2 type (Harris et al, 2000). These 
data show that the dialogue between B and T cells during an (auto)-immune response is not 
one sided and demonstrate that B cells have a strong impact in conditioning T cell 
differentiation. 
4.2 Breg phenotype(s) 
Further phenotypical identification showed that the majority of CD19+CD38hiCD24hi B 
cells were also IgMhiIgDhiCD5+CD10+CD20+CD27-CD1dhi (Blair et al, 2010). Interestingly, 
the majority of the CD19+CD5+CD1dhiB cells (71%), previously reported to be regulatory in 
experimental models of inflammation (Matsushita et al., 2008; Yanaba et al., 2008a), are 
contained within the CD24hiCD38hi B cell subset. Co-culture of CD4+ T cells with 
CD19+CD24hiCD38hi B cells significantly suppressed the frequencies of CD4+IFN-+ and 
CD4+TNF-+ T cells. 
The group of Mauri evaluated whether there was a numerical deficit in 
CD19+CD38hiCD24hi B cells in patients with SLE (Blair et al, 2010). The absolute cell 
numbers were not statistically different from controls. In contrast, the numbers of both 
CD19+CD38intCD24int and CD19+CD24hiCD38- B cells were both significantly reduced in 
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SLE patients. These results suggest that the inability of SLE CD19+CD38hiCD24hi B cells to 
suppress the expression of proinflammatory cytokines by CD4+ T cells is unlikely to be due 
to a numerical deficiency. Depleting CD19+ CD38hiCD24hi B cells from PBMCs of healthy 
donors and SLE patients leads to an increased production of inflammatory cytokines such as 
IFN gamma and TNF alpha in healthy donors, suggesting an immunoregulatory effect, but 
this was not observed in SLE patients.  
4.3 Other novel B cell subsets 
A novel subset of  circulating memory B cells with >2-fold higher levels of CD19 [CD19(hi) B 
cells] correlates with long-term adverse outcomes in SLE (Nicholas et al, 2008). These B cells 
do not appear anergic, as they exhibit high basal levels of phosphorylated Syk and ERK1/2, 
signal transduce in response to BCR crosslinking, and can become plasma cells in vitro. 
Autoreactive anti-Smith (Sm) B cells are enriched within this subset.  Quantitative genetic 
variation in CD19 expression correlates with autoimmunity (Sato et al, 2000). CD19(hi) B 
cells have elevated CXCR3 levels and chemotax in response to its ligand CXCL9. Thus, 
CD19(hi) B cells are precursors to anti-self PCs, and identify an SLE patient subset likely to 
experience poor clinical outcomes (Nicholas, 2008). CD19(hi)CD21(lo/neg) B cells of 
uncertain origin are expanded also in common variable immunodeficiency patients with 
autoimmune features (Warnatz et al, 2002).  
B cell functions are under the regulation of B cell antigen receptor (BCR)-induced signals 
and by specialized cell surface coreceptors, or "response regulators", which inform B cells of 
their microenvironment. These response regulators include CD19 and CD22 (Fujimoto and 
Sato, 2007). Importantly, this “CD19/CD22 loop" is significantly related to an autoimmune 
phenotype in mice. Thus, the CD19/CD22 loop may be a potential therapeutic target. 
Regulatory B cells that produce IL-10 are now recognized as an important component of the 
immune system .  
4.4 Role of TLR 7 and 9 
A previously uncharacterized population of B cells has been recently described in aged 
mice, called Age-associated B cells (ABCs), which express integrin αX chain CD11c (Rubtsov 
et al, 2011). This subset is present also in young lupus-prone mice. Upon stimulation, 
CD11c+ B cells secrete autoantibodies and depletion of these cells in vivo leads to reduction 
of autoreactive antibodies. Toll-like receptor 7 (TLR7) is crucial for development of this B 
cell population. A similar population of B cells was observed in elderly women with 
autoimmune disease (Rubtsov et al, 2011). Age-associated mature B cells have been 
described also by Hao et al (2011): they are refractory to BCR and CD40 stimulation but 
respond to TLR9 or TLR7 stimulation and divide maximally upon combined BCR and TLR 
ligation, leading to Ig production and preferential secretion of IL-10. They derive from 
normal mature B cells but have lost the need of BLyS for survival. Finally, they present 
antigen effectively and favor polarization to a TH17 profile. It has been reported four years 
ago (Treml, 2007) that TLR9 stimulates TACI expression in all follicular and marginal zone B 
cells, but only BLyS enhances survival in TLR stimulated B cells. Following the exit from the 
bone marrow, peripheral B cells develop through transitional type 1 (T1) and transitional 
type 2 (T2) B-cell stages. Emerging data suggest that the T2 subset  is the immediate 
precursor of the mature B-cell populations. T2 cells uniquely activate a proliferative, pro-
survival, and differentiation program in response to B-cell antigen receptor (BCR) 
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engagement. The type of signal(s) encountered by T2 cells lead to their differential 
maturation toward the follicular mature versus marginal zone mature B-cell populations (Su 
et al, 2004).  
Among the principal targets of autoantibodies produced in murine SLE are nucleic acid–
protein complexes, such as chromatin and ribonucleoproteins, and the envelope 
glycoprotein gp70 of endogenous retroviruses. The preferential production of these 
autoantibodies is apparently promoted by the presence of genetic abnormalities leading to 
defects in the elimination of apoptotic cells and to an enhanced expression of endogenous 
retroviruses. Moreover, recent studies revealed that the innate receptors TLR7 and TLR9 are 
critically involved in the activation of dendritic cells and autoreactive B cells through the 
recognition of endogenous DNA- or RNA-containing antigens and subsequent development 
of autoimmune responses against nuclear autoantigens (Santiago-Raber et al, 2009). 
Furthermore, the regulation of autoimmune responses against endogenous retroviral gp70 
by TLR7 suggested the implication of endogenous retroviruses in this autoimmune 
response. Clearly, further elucidation of the precise molecular role of TLR7 and TLR9 in the 
development of autoimmune responses will help to develop novel therapeutic strategies 
and targets for SLE (Goeken et al, 2010). 
4.5 Relationship of B1 to Breg cells 
B1 cells constitute a specialized B cell lineage with remarkable properties that include 
spontaneous secretion of immunoglobulin, autoreactive repertoire skewing, focused 
memory characteristics, abnormal receptor signaling, induction of Th17 cell differentiation, 
and production of immunomodulatory IL-10. A particularly exciting issue is the relationship 
of B1 cells to regulatory B cells and the extent to which these cell types may be one and the 
same (Cancro, 2009).   
Colonna-Romano et al (2009) describe the IgD−CD27− double-negative B cell population 
which is increased in the elderly. Most of these cells are IgG+. Evaluation of the telomere 
length and expression of the ABCB1 transporter and anti-apoptotic molecule, Bcl2, shows 
that they have the markers of memory B cells. These cells do not act as antigen presenting 
cells, as indicated by the low levels of CD80 and DR, nor do they express significant levels of 
the CD40 molecule necessary to interact with T lymphocytes through the ligand, CD154 
(Duffau et al, 2010). The authors  hypothesize that these expanded cells are late memory or 
exhausted cells that have down-modulated the expression of CD27.  
It is interesting to note that platelets are the main source of circulating CD154, and they can 
stimulate IFN typeI production from pDCs as well as ligate CD40 on autoreactive B cells 
(Duffau et al, 2010; Craft, 2011).  
5. SLE as the result of defects both in apoptosis control and B cell regulation 
Recent data have emerged to support the role of IFN alpha in both control of cell death and 
regulation of B lymphocyte functions. Two papers (Lande, 2011; Garcia-Romo, 2011) have 
reported the induction of neutrophil changes due to autoantibodies to DNA or RNA in 
immune complexes interacting with FcRIIa as well as TLRs in the presence of inflammatory 
cytokines and IFN type I, resulting in the formation of NETs which represent a type of cell 
death with DNA extrusion and release of antimicrobial peptides and cytolytic enzymes that 
is very effective in defence against bacteria.  
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5.1 Neutrophils, NETosis and B cells 
SLE neutrophils undergo accelerated spontaneous apoptosis in vitro, and SLE sera induce 
the apoptosis of healthy neutrophils, and nuclear material such as DNA and histones, which 
comprises the major structural components of NETs, is released in immunogenic form. The 
inappropriate amplification of this phenomenon in SLE perpetuates B cell stimulation to 
produce anti-DNA and –RNA antibodies, as well as autoantibodies to antibiotic peptides, 
and also, via TLR 7 and 9 interactions, IFN alpha production by pDC (Craft, 2011). IFN in 
turn primes neutrophils for death with NET formation, which makes more immunogenic 
DNA and RNA available to the immune system. Both IFN- and SLE serum up-regulate 
neutrophil TLR7 expression. In addition, sera from ~40% of SLE patients contain TLR7 
ligands in the form of ICs derived from antibodies recognizing small nuclear RNA/RNA 
binding protein complexes. These ICs have been shown to activate pDCs and induce type I 
IFN secretion. Anti-RNP antibodies are not efficient activators of pDCs in vitro, however, 
unless combined with dying cells, which provide the substrate to form ICs that might be 
internalized via FcRIIa. 
Anti-RNP Ig–induced SLE NETosis requires FcRIIa and endosomal TLR7 signaling and 
depends on the formation of ROS. Furthermore, anti-RNP antibodies induce SLE but not 
healthy neutrophils to secrete high levels of LL37 and HMGB1, two endogenous proteins 
that contribute to increase the immunogenicity and uptake of mammalian DNA by pDCs. 
Therefore other sources of immunogenic nuclear material has to be present, and this is 
provided by increased apoptosis, mostly due to Fas/FasL dysregulation, and inefficient 
disposal of IC due to complement and reticulo-endothelial defects.  
5.2 Fas/FasL dysregulation in SLE 
The Fas(CD95) antigen and its ligand (FasL, CD95L) are members of the TNF/TNFR 
families, expressed on the surface of immune and other cell types. They regulate one 
important extrinsic apoptotic pathway, by higher or lower expression and by their splice or 
cleaved soluble variants, sFas and sFasL (Sheriff et al., 2004; Tinazzi et al., 2009). Peripheral 
T cell apoptosis is upregulated in active SLE, in parallel with high expression of both 
membrane-bound and soluble Fas (Silvestris et al., 2003; Hao et al., 2006).  Previous studies 
postulated that sFas down-regulates apoptosis in vitro through its blockade of the FasL of 
cytotoxic cells. This paradox has been examined by Silvestris et al. (2003) and Hao et al. 
(2006), but it is still unresolved. The situation is even more complex since autoantibodies to 
FasL have been detected in sera of SLE patients which contribute to inhibit apoptotic cell 
death of lymphocytes (Suzuki et al., 1998). In our study (Turi et al, 2009) we confirmed that 
though slightly increased values of both sFas and sFasL are found in SLE patients compared 
to normal subjects, a very scattered distribution is observed. No definitive answer to the 
importance of these differences may derive from examining one factor when many 
contribute to the final effect, so we decided to derive and index from the ratio of the values 
of sFas to sFasL, which is about 50 in normal controls. This ratio has been found to be lower 
in younger subjects, being related to age, both in SLE patients and healthy controls. 
Apoptosis resistance is modulated during aging, and the changes in the sFas/sFasL ratio 
may be involved in this phenomenon. As clarified by the study by O’Reilly (2009), sFasL 
does not efficiently mediate Fas-induced apoptosis, therefore its increase in serum equals to 
an additive anti-apoptotic mechanism in conjunction with elevated sFas circulating levels 
and autoantibodies to FasL.  
 




Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the 
production of high-titer IgG autoantibodies directed against nuclear autoantigens. Type I 
interferon (IFN-I) has been shown to play an important pathogenic role in this disease. 
Common hypotheses about SLE pathogenesis suggest that environmental triggers, such as 
infectious agents, operate in the context of both susceptibility genes and epigenetic 
modifications, resulting in alterations in antigen presentation, lymphoid signaling, 
apoptosis, and antigen/IC clearance. Decreased numbers of neutrophils, dendritic cells, and 
lymphocytes are common features of SLE. pDCs accumulate at sites of inflammation such as 
the skin and the kidney, where they secrete type I interferon (IFN). Upon exposure to SLE 
serum, healthy monocytes differentiate into mature DCs in an IFN-I–dependent fashion. 
SLE display a type I IFN signature as measured by peripheral blood mononuclear cell 
(PBMC) gene expression profiling. The second most prevalent PBMC transcriptional 
signature corresponds to neutrophil-specific genes, and differential expression of these 
genes correlates with disease activity. Indeed, polymorphisms in genes expressed by 
neutrophils, such as ITGAM/CD11b, rank among the highest in the scale of SLE 
susceptibility. Polymorphisms in genes along the IFN and TLR signaling pathways (that is, 
IRF5, TLR7, IRAK1, STAT4, etc.) could amplify the response of SLE neutrophils to TLR7 
triggering. Polymorphisms affecting thresholds of B cell activation and/or deficient removal 
of ICs might contribute to prolonged neutrophil exposure to activating ICs. Polymorphisms 
in FcgRIIa could affect the internalization and/or endosomal trafficking of SLE-specific ICs 
in neutrophils and pDCs. 
Our review has highlighted some recent aspects of the main points relating to these issues, 
both at the cellular and molecular level, with discussion of the role of NETs formation, TLR 
7/9 signaling, apoptosis increased proneness, and the induction both of autoantibodies and 
IFN-I overproduction. The consequences of these pathogenetic changes are then defined in 
terms of autoantigens presentation, B lymphocyte dysregulation and IC formation with 
organ damage. We mainly studied the alterations occurring at quantitative and functional 
level in the Fas/FasL apoptotic pathway, but also touched upon several other issues such as 
the relationship of newly identified B cell subsets to autoimmunity,  and the role of nuclear 
cytokines in autoantibody stimulation. We believe that the key aspects of SLE pathogenesis 
have now been uncovered, and await the composition of their temporal sequence in a 
unified view of this multifaceted systemic autoimmune disorder. 
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terms of autoantigens presentation, B lymphocyte dysregulation and IC formation with 
organ damage. We mainly studied the alterations occurring at quantitative and functional 
level in the Fas/FasL apoptotic pathway, but also touched upon several other issues such as 
the relationship of newly identified B cell subsets to autoimmunity,  and the role of nuclear 
cytokines in autoantibody stimulation. We believe that the key aspects of SLE pathogenesis 
have now been uncovered, and await the composition of their temporal sequence in a 
unified view of this multifaceted systemic autoimmune disorder. 
7. Acknowledgments 
Studies reported here have been supported by grants of the Faculty of Medicine of Chieti 
(60%) for 2009-11 and PRIN 2009 from the Italian Ministry of University (MIUR) to R.P.  
Studies on B reg have been carried out by M.C.T. as part of a PhD Fellowship at the 
University of Chieti.  
8. Note added in proof 
Since completion of this chapter, a review was published in the section of Clinical 
implications of Basic research of the N Engl J Med (Bosch X (2011). Systemic lupus 
erythematosus and the neutrophil. N Engl J Med 365;8 (Aug.25) 758-60) discussing the work 
 
Systemic Lupus Erythematosus 
 
110 
of Lande and Garcia-Romo reviewed here. No mention of HMGB1 is to be found in the 
review, however much emphasis was put on antimicrobial peptides (LL-37, which is also 
implicated in psoriasis) and antagonistic molecules for TLR signalling; the main message 
was on the new therapeutic aspects and the generalization of these findings (of neutrophil 
NETosis as pathogenetic mechanism) to vasculitis with ANCA antibodies.  
9. References 
Arbuckle MR, Mc Clain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB 
(2003). Development of autoantibodies before the clinical onset of systemic lupus 
erythematosus. N Engl J Med 349:1526-33. 
Asadullah, K., Sterry, W., and Volk, H.D. (2003). Interleukin-10 therapy-review of a new 
approach. Pharmacol. Rev. 55, 241–269. 
Badr G, Saad H, Waly H, Hassan K, Abdel-Tawab H, Alhazza IM, Ahmed EA. (2010). Type I 
interferon (IFN-alpha/beta) rescues B-lymphocytes from apoptosis via 
PI3Kdelta/Akt, Rho-A, NFkappaB and Bcl-2/Bcl(XL). Cell Immunol. 263:31-40.  
Baekkevold, E.S. et al. (2003) Molecular characterization of NF-HEV, a nuclear factor 
preferentially expressed in human high endothelial venules. Am. J. Pathol. 163, 69–
79 
Banchereau J., V. Pascual (2006). Type I interferon in systemic lupus erythematosus and 
other  autoimmune diseases. Immunity 25, 383–392  
Baugh C. W., P. M. Kirol, M. V. Sachs, (1960). Demonstration and titration of anti-nuclear 
antibodies in systemic lupus erythematosus. Can. Med. Assoc. J. 83, 571–580.  
Bengtsson AA, Gullstrand B, Truedsson L, Sturfelt G. (2008). SLE serum induces classical 
caspase-dependent apoptosis independent of death receptors. Clin Immunol. 
126:57-66.  
Bennett L., A. K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, V. Pascual, (2003). 
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. 
Exp. Med. 197, 711–723  
Berg, D.J., Leach, M.W., Kuhn, R., Rajewsky, K., Muller, W., Davidson, N.J., and Rennick, D. 
(1995). Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous 
inflammatory responses. J. Exp. Med. 182, 99–108. 
Bijl M, van Lopik T, Limburg PC, Spronk PE, Jaegers SM, Aarden LA, Smeenk RJ, 
Kallenberg GG. (1998). Do elevated levels of serum-soluble fas contribute to the 
persistence of activated lymphocytes in systemic lupus erythematosus? J 
Autoimmun. 11:457-63. 
Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C. 
(2010). CD19(+) CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy 
individuals but are functionally impaired in systemic Lupus Erythematosus 
patients. Immunity. 32:129-40. 
Blanco P., A. K. Palucka, M. Gill, V. Pascual, J. Banchereau, (2001). Induction of dendritic cell 
differentiation by IFN-a in systemic lupus erythematosus. Science 294, 1540–1543  
Bouaziz JD, Yanaba K, Tedder TF. (2008)  Regulatory B cells as inhibitors of immune 
responses and inflammation. Immunol Rev. 224:201-14. 
Brinkmann, V., U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D.S. Weiss, Y. 
Weinrauch, and A. Zychlinsky. (2004). Neutrophil extracellular traps kill bacteria. 
Science. 303:1532–1535. 
 
Fas Pathway of Cell Death and B Cell Dysregulation in SLE 
 
111 
Cancro MP, Y Hao, JL. Scholz, RL. Riley, D Frasca, DK. Dunn-Walters, BB. Blomberg (2009) 
B cells and aging: molecules and mechanisms. Trends Immunol. 30: 313–318. 
Cantaert T, Baeten D, Tak PP and van Baarsen LGM. (2010). Type I IFN and TNFα cross-
regulation in immune-mediated infl ammatory disease: basic concepts and clinical 
relevance. Arthr Res Ther 12:219. 
Cariappa A, Pillai S. (2002). Antigen dependent B-cell development. Curr Opin Immunol 
14:241–9.  
Carriere, V. et al. (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-
associated nuclear factor in vivo. Proc. Natl. Acad. Sci. U. S. A. 104, 282–287. 
Carsetti R. (2004a) Characterization of B-cell maturation in the peripheral immune system. 
Methods Mol Biol. 271:25-35. 
Carsetti R, Rosado MM, Wardmann H. (2004b) Peripheral development of B cells in mouse 
and man. Immunol Rev. 197:179-91. 
Casciola-Rosen, L. A., G. Anhalt, and A. Rosen. (1994). Autoantigens targeted in systemic 
lupus erythematosus are clustered in two populations of surface structures on 
apoptotic keratinocytes. J. Exp. Med. 179: 1317–1330. 
Colonna-Romano G, M Bulati, A Aquino, M Pellicanò, S Vitello, D Lio, G Candore and C 
Caruso (2009). A double-negative (IgD−CD27−) B cell population is increased in 
the peripheral blood of elderly people.  Mech Ageing Dev 130: 681-90. 
Craft J (2011). Dissecting the immune cell mayhem that drives lupus pathogenesis. Sci 
Transl Med 3, 73ps9. 
Crow M.K. (2008). Collaboration, Genetic Associations, and Lupus Erythematosus. N Engl J 
Med 358: 956-61.  
Ding C, Cai Y, Marroquin J, Ildstad ST, Yan J. (2009). Plasmacytoid dendritic cells regulate 
autoreactive B cell activation via soluble factors and in a cell-to-cell contact manner. 
J Immunol. 183:7140-9.  
Duffau P., J. Seneschal, C. Nicco, C. Richez, E. Lazaro, I. Douchet, C. Bordes, J.-F. Viallard, C. 
Goulvestre, J.-L. Pellegrin, B. Weil, J.-F. Moreau, F. Batteux, P. Blanco (2010). 
Platelet CD154 potentiates interferon-a secretion by plasmacytoid dendritic cells in 
systemic lupus erythematosus. Sci. Transl. Med. 2, 47ra63. 
Dumitriu, I. E., P. Baruah, A. A. Manfredi, M. E. Bianchi, and P. Rovere-Querini. (2005). 
HMGB1: guiding immunity from within. Trends Immunol. 26: 381–387.  
Erlandsson Harris, H., and U. Andersson. (2004). Mini-review: the nuclear protein HMGB1 
as a proinflammatory mediator. Eur. J. Immunol. 34: 1503–1512. 
Fadok, V.A., Bratton, D.L., Guthrie, L., and Henson, P.M. (2001). Differential effects of 
apoptotic versus lysed cells on macrophage production of cytokines: role of 
proteases. J. Immunol. 166, 6847–6854. 
Ferguson, T.A., Dube, P., and Griffith, T.S. (1994). Regulation of contact hypersensitivity by 
interleukin 10. J. Exp. Med. 179, 1597–1604. 
Fillatreau, S., Sweenie, C.H., McGeachy, M.J., Gray, D., and Anderton, S.M. (2002). B cells 
regulate autoimmunity by provision of IL-10. Nat. Immunol. 3, 944–950. 
Fuchs TA,U Abed, C Goosmann, R Hurwitz, I Schulze, V Wahn, Y Weinrauch, V 
Brinkmann, A Zychlinsky (2007) Novel cell death program leads to neutrophil 
extracellular traps. J Cell Biol 176, 231–241. 
 
Systemic Lupus Erythematosus 
 
110 
of Lande and Garcia-Romo reviewed here. No mention of HMGB1 is to be found in the 
review, however much emphasis was put on antimicrobial peptides (LL-37, which is also 
implicated in psoriasis) and antagonistic molecules for TLR signalling; the main message 
was on the new therapeutic aspects and the generalization of these findings (of neutrophil 
NETosis as pathogenetic mechanism) to vasculitis with ANCA antibodies.  
9. References 
Arbuckle MR, Mc Clain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB 
(2003). Development of autoantibodies before the clinical onset of systemic lupus 
erythematosus. N Engl J Med 349:1526-33. 
Asadullah, K., Sterry, W., and Volk, H.D. (2003). Interleukin-10 therapy-review of a new 
approach. Pharmacol. Rev. 55, 241–269. 
Badr G, Saad H, Waly H, Hassan K, Abdel-Tawab H, Alhazza IM, Ahmed EA. (2010). Type I 
interferon (IFN-alpha/beta) rescues B-lymphocytes from apoptosis via 
PI3Kdelta/Akt, Rho-A, NFkappaB and Bcl-2/Bcl(XL). Cell Immunol. 263:31-40.  
Baekkevold, E.S. et al. (2003) Molecular characterization of NF-HEV, a nuclear factor 
preferentially expressed in human high endothelial venules. Am. J. Pathol. 163, 69–
79 
Banchereau J., V. Pascual (2006). Type I interferon in systemic lupus erythematosus and 
other  autoimmune diseases. Immunity 25, 383–392  
Baugh C. W., P. M. Kirol, M. V. Sachs, (1960). Demonstration and titration of anti-nuclear 
antibodies in systemic lupus erythematosus. Can. Med. Assoc. J. 83, 571–580.  
Bengtsson AA, Gullstrand B, Truedsson L, Sturfelt G. (2008). SLE serum induces classical 
caspase-dependent apoptosis independent of death receptors. Clin Immunol. 
126:57-66.  
Bennett L., A. K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, V. Pascual, (2003). 
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. 
Exp. Med. 197, 711–723  
Berg, D.J., Leach, M.W., Kuhn, R., Rajewsky, K., Muller, W., Davidson, N.J., and Rennick, D. 
(1995). Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous 
inflammatory responses. J. Exp. Med. 182, 99–108. 
Bijl M, van Lopik T, Limburg PC, Spronk PE, Jaegers SM, Aarden LA, Smeenk RJ, 
Kallenberg GG. (1998). Do elevated levels of serum-soluble fas contribute to the 
persistence of activated lymphocytes in systemic lupus erythematosus? J 
Autoimmun. 11:457-63. 
Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C. 
(2010). CD19(+) CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy 
individuals but are functionally impaired in systemic Lupus Erythematosus 
patients. Immunity. 32:129-40. 
Blanco P., A. K. Palucka, M. Gill, V. Pascual, J. Banchereau, (2001). Induction of dendritic cell 
differentiation by IFN-a in systemic lupus erythematosus. Science 294, 1540–1543  
Bouaziz JD, Yanaba K, Tedder TF. (2008)  Regulatory B cells as inhibitors of immune 
responses and inflammation. Immunol Rev. 224:201-14. 
Brinkmann, V., U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D.S. Weiss, Y. 
Weinrauch, and A. Zychlinsky. (2004). Neutrophil extracellular traps kill bacteria. 
Science. 303:1532–1535. 
 
Fas Pathway of Cell Death and B Cell Dysregulation in SLE 
 
111 
Cancro MP, Y Hao, JL. Scholz, RL. Riley, D Frasca, DK. Dunn-Walters, BB. Blomberg (2009) 
B cells and aging: molecules and mechanisms. Trends Immunol. 30: 313–318. 
Cantaert T, Baeten D, Tak PP and van Baarsen LGM. (2010). Type I IFN and TNFα cross-
regulation in immune-mediated infl ammatory disease: basic concepts and clinical 
relevance. Arthr Res Ther 12:219. 
Cariappa A, Pillai S. (2002). Antigen dependent B-cell development. Curr Opin Immunol 
14:241–9.  
Carriere, V. et al. (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-
associated nuclear factor in vivo. Proc. Natl. Acad. Sci. U. S. A. 104, 282–287. 
Carsetti R. (2004a) Characterization of B-cell maturation in the peripheral immune system. 
Methods Mol Biol. 271:25-35. 
Carsetti R, Rosado MM, Wardmann H. (2004b) Peripheral development of B cells in mouse 
and man. Immunol Rev. 197:179-91. 
Casciola-Rosen, L. A., G. Anhalt, and A. Rosen. (1994). Autoantigens targeted in systemic 
lupus erythematosus are clustered in two populations of surface structures on 
apoptotic keratinocytes. J. Exp. Med. 179: 1317–1330. 
Colonna-Romano G, M Bulati, A Aquino, M Pellicanò, S Vitello, D Lio, G Candore and C 
Caruso (2009). A double-negative (IgD−CD27−) B cell population is increased in 
the peripheral blood of elderly people.  Mech Ageing Dev 130: 681-90. 
Craft J (2011). Dissecting the immune cell mayhem that drives lupus pathogenesis. Sci 
Transl Med 3, 73ps9. 
Crow M.K. (2008). Collaboration, Genetic Associations, and Lupus Erythematosus. N Engl J 
Med 358: 956-61.  
Ding C, Cai Y, Marroquin J, Ildstad ST, Yan J. (2009). Plasmacytoid dendritic cells regulate 
autoreactive B cell activation via soluble factors and in a cell-to-cell contact manner. 
J Immunol. 183:7140-9.  
Duffau P., J. Seneschal, C. Nicco, C. Richez, E. Lazaro, I. Douchet, C. Bordes, J.-F. Viallard, C. 
Goulvestre, J.-L. Pellegrin, B. Weil, J.-F. Moreau, F. Batteux, P. Blanco (2010). 
Platelet CD154 potentiates interferon-a secretion by plasmacytoid dendritic cells in 
systemic lupus erythematosus. Sci. Transl. Med. 2, 47ra63. 
Dumitriu, I. E., P. Baruah, A. A. Manfredi, M. E. Bianchi, and P. Rovere-Querini. (2005). 
HMGB1: guiding immunity from within. Trends Immunol. 26: 381–387.  
Erlandsson Harris, H., and U. Andersson. (2004). Mini-review: the nuclear protein HMGB1 
as a proinflammatory mediator. Eur. J. Immunol. 34: 1503–1512. 
Fadok, V.A., Bratton, D.L., Guthrie, L., and Henson, P.M. (2001). Differential effects of 
apoptotic versus lysed cells on macrophage production of cytokines: role of 
proteases. J. Immunol. 166, 6847–6854. 
Ferguson, T.A., Dube, P., and Griffith, T.S. (1994). Regulation of contact hypersensitivity by 
interleukin 10. J. Exp. Med. 179, 1597–1604. 
Fillatreau, S., Sweenie, C.H., McGeachy, M.J., Gray, D., and Anderton, S.M. (2002). B cells 
regulate autoimmunity by provision of IL-10. Nat. Immunol. 3, 944–950. 
Fuchs TA,U Abed, C Goosmann, R Hurwitz, I Schulze, V Wahn, Y Weinrauch, V 
Brinkmann, A Zychlinsky (2007) Novel cell death program leads to neutrophil 
extracellular traps. J Cell Biol 176, 231–241. 
 
Systemic Lupus Erythematosus 
 
112 
Fujimoto M, Sato S. (2007). B cell signaling and autoimmune diseases: CD19/CD22 loop as a 
B cell signalling device to regulate the balance of autoimmunity. J Dermatol Sci. 
46:1-9.  
Gaipl, U.S., Kuhn, A., Sheriff, A., Munoz, L.E., Franz, S., Voll, R.E., Kalden, J.R., and 
Herrmann, M. (2006). Clearance of apoptotic cells in human SLE. Curr. Dir. 
Autoimmun. 9, 173–187. 
Garcia-Romo G.S., S. Caielli, B. Vega, J. Connolly, F. Allantaz, Z. Xu, M. Punaro, J. Baisch, 
C.Guiducci, R. L.Coffman, F. J.Barrat, J. Banchereau,V. Pascual, (2011). Netting 
neutrophils are major inducers of type I IFN production in pediatric systemic lupus 
erythematosus. Sci. Transl. Med. 3, 73ra20  
Goeken JA, T Layer, S Fleenor, M Laccheo and P Lenert (2010) B-cell receptor for antigen 
modulates B-cell responses to complex TLR9 agonists and antagonists: implications 
for systemic lupus erythematosus. Lupus 19, 1290–1301. 
Gray M, Miles K, Salter D, Gray D, Savill J. (2007). Apoptotic cells protect mice from 
autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad 
Sci USA 104:14080–5 
Groux, H., A. O’Garra, M. Bigler, M. Rouleau, S. Antonenko, J. E. de Vries, and M. G. 
Roncarolo. (1997). A CD4+ T cell subset inhibits antigen-specific T cell responses 
and prevents colitis. Nature 389: 737–742. 
Habib HM, Taher TE, Isenberg DA, Mageed RA. (2009). Enhanced propensity of T 
lymphocytes in patients with systemic lupus erythematosus to apoptosis in the 
presence of tumour necrosis factor alpha. Scand J Rheumatol. 38:112-20. 
Hadj-Slimane R, Chelbi-Alix MK, Tovey MG, Bobé P. (2004). An essential role for IFN-alpha 
in the overexpression of Fas ligand on MRL/lpr lymphocytes and on their 
spontaneous Fas-mediated cytotoxic potential. J Interferon Cytokine Res. 24:717-28. 
Hahn BH (1998). Antibodies to DNA. N Engl J Med 338:1359-68.  
Hanayama, R., Tanaka, M., Miyasaka, K., Aozasa, K., Koike, M., Uchiyama, Y., and Nagata, 
S. (2004). Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-
deficient mice. Science 304, 1147–1150. 
Hao, J.H., Ye, D.Q., Zhang, G.Q., Liu, H.H., Dai, H., Huang, F., Pan, F.M., Su, H., Dong, 
M.X., Chen, H., Wang, Q., Zhang, X.J. (2006): Elevated levels of serum soluble Fas 
are associated with organ and tissue damage in systemic lupus erythematosus 
among Chinese. Arch. Dermatol. Res. 297, 329-332.  
Hao Y, O'Neill PJ, Naradikian MS, Scholz JL, Cancro MP. (2011). A B-cell subset uniquely 
responsive to innate stimuli accumulates in aged mice. Blood. 118:1294-304 
Hardy RR, Hayakawa K. (2001). B cell development pathways. Annu. Rev. Immunol. 19:595–
621 
Hargraves M.M., H. Richmond, R. Morton, (1948). Presentation of two bone marrow 
elements; the tart cell and the L.E. cell. Mayo Clin. Proc. 23, 25–28  
Harris, D.P., L. Haynes, P.C. Sayles, D.K. Duso, S.M. Eaton, N.M. Lepak, L.L. Johnson, S.L. 
Swain, and F.E. Lund. (2000). Reciprocal regulation of polarized cytokine 
production by effector B and T cells. Nat. Immunol. 1:475–482. 
Haserick J.R., D. W. Bortz (1949a). A new diagnostic test for acute disseminated lupus 
erythematosus. Cleve. Clin. Q. 16, 158–161  
Haserick J.R., D. W. Bortz, (1949b). Normal bone marrow inclusion phenomena induced by 
lupus erythematosus plasma. J. Invest. Dermatol. 13, 47–49.  
 
Fas Pathway of Cell Death and B Cell Dysregulation in SLE 
 
113 
Heyworth, P.G., A.R. Cross, and J.T. Curnutte. (2003). Chronic granulomatous disease. Curr. 
Opin. Immunol. 15:578–584. 
Hom G, Graham RR, Modrek B, et al. (2008) Association of systemic lupus erythematosus 
with C8orf13–BLK and ITGAM–ITGAX. N Engl J Med 358: 900–909. 
Huggins, M. L., I. Todd, M. A. Cavers, S. R. Pavuluri, P. J. Tighe, and R. J. Powell. (1999). 
Antibodies from systemic lupus erythematosus (SLE) sera define differential 
release of autoantigens from cell lines undergoing apoptosis. Clin. Exp. 
Immunol.118: 322–328. 
International Consortium for Systemic Lupus Erythematosus Genetics, Harley JB, Alarcon-
Riquelme ME, et al. (2008). A genomewide association scan in women with 
systemic lupus erythematosus identifies risk variants in ITGAM, PXK, KIAA1542 
and other loci and confirms multiple loci contributing to disease susceptibility. Nat 
Genet 40, 204–210  
Ippolito A., DJ Wallace, D Gladman, PR Fortin, M Urowitz, V Werth, M Costner, C Gordon, 
GS Alarcón, R et al. (2011) Autoantibodies in systemic lupus erythematosus: 
comparison of historical and current assessment of seropositivity. Lupus 20, 250–
255. 
Kawane, K., Fukuyama, H., Kondoh, G., Takeda, J., Ohsawa, Y., Uchiyama, Y., and Nagata, 
S. (2001). Requirement of DNase II for definitive erythropoiesis in the mouse fetal 
liver. Science 292, 1546–1549. 
Kawane, K., Ohtani, M., Miwa, K., Kizawa, T., Kanbara, Y., Yoshioka, Y., Yoshikawa, H., 
and Nagata, S. (2006). Chronic polyarthritis caused by mammalian DNA that 
escapes from degradation in macrophages. Nature 443,998–1002. 
Kerr, J.F., Wyllie, A.H., and Currie, A.R. (1972). Apoptosis: a basic biological phenomenon 
with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239–257. 
Klebanoff, S.J. (1999). Oxygen metabolites from phagocytes. In J.I. Gallin and R. Snyderman, 
editors. Infl ammation: Basic Principles and Clinical Correlates. Lippincott 
Williams & Wilkins, Philadelphia. 721–768 
Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, et al. (2003) Successful 
treatment of collagen-induced arthritis in mice and rats by targeting extracellular 
high mobility group box chromosomal protein 1 activity. Arthritis Rheum 48:2052–
8. 
Kozyrev SV, Abelson A-K, Wojcik J, et al. (2008) Functional variants in the B cell gene 
BANK1 are associated with systemic lupus erythematosus. Nat Genet 40: 211–216.. 
Krammer, P.H. (2000). CD95’s deadly mission in the immune system. Nature 407, 789–795. 
Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. (2004). Survival of resting mature B 
lymphocytes depends on BCR signaling via the Igα/β heterodimer. Cell 117:787–800 
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E.S., Baehrecke, E.H., 
Blagosklonny, M.V., El-Deiry, W.S., Golstein, P., Green, D.R., et al; Nomenclature 
Committee on Cell Death 2009. (2009). Classification of cell death: 
recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death 
Differ. 16, 3–11. 
Kruse K, Janko C, Urbonaviciute V, Mierke CT, Winkler TH, Voll RE, Schett G, Muñoz LE, 
Herrmann M. (2010). Inefficient clearance of dying cells in patients with SLE: anti-
dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis. 15:1098-
113. 
 
Systemic Lupus Erythematosus 
 
112 
Fujimoto M, Sato S. (2007). B cell signaling and autoimmune diseases: CD19/CD22 loop as a 
B cell signalling device to regulate the balance of autoimmunity. J Dermatol Sci. 
46:1-9.  
Gaipl, U.S., Kuhn, A., Sheriff, A., Munoz, L.E., Franz, S., Voll, R.E., Kalden, J.R., and 
Herrmann, M. (2006). Clearance of apoptotic cells in human SLE. Curr. Dir. 
Autoimmun. 9, 173–187. 
Garcia-Romo G.S., S. Caielli, B. Vega, J. Connolly, F. Allantaz, Z. Xu, M. Punaro, J. Baisch, 
C.Guiducci, R. L.Coffman, F. J.Barrat, J. Banchereau,V. Pascual, (2011). Netting 
neutrophils are major inducers of type I IFN production in pediatric systemic lupus 
erythematosus. Sci. Transl. Med. 3, 73ra20  
Goeken JA, T Layer, S Fleenor, M Laccheo and P Lenert (2010) B-cell receptor for antigen 
modulates B-cell responses to complex TLR9 agonists and antagonists: implications 
for systemic lupus erythematosus. Lupus 19, 1290–1301. 
Gray M, Miles K, Salter D, Gray D, Savill J. (2007). Apoptotic cells protect mice from 
autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad 
Sci USA 104:14080–5 
Groux, H., A. O’Garra, M. Bigler, M. Rouleau, S. Antonenko, J. E. de Vries, and M. G. 
Roncarolo. (1997). A CD4+ T cell subset inhibits antigen-specific T cell responses 
and prevents colitis. Nature 389: 737–742. 
Habib HM, Taher TE, Isenberg DA, Mageed RA. (2009). Enhanced propensity of T 
lymphocytes in patients with systemic lupus erythematosus to apoptosis in the 
presence of tumour necrosis factor alpha. Scand J Rheumatol. 38:112-20. 
Hadj-Slimane R, Chelbi-Alix MK, Tovey MG, Bobé P. (2004). An essential role for IFN-alpha 
in the overexpression of Fas ligand on MRL/lpr lymphocytes and on their 
spontaneous Fas-mediated cytotoxic potential. J Interferon Cytokine Res. 24:717-28. 
Hahn BH (1998). Antibodies to DNA. N Engl J Med 338:1359-68.  
Hanayama, R., Tanaka, M., Miyasaka, K., Aozasa, K., Koike, M., Uchiyama, Y., and Nagata, 
S. (2004). Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-
deficient mice. Science 304, 1147–1150. 
Hao, J.H., Ye, D.Q., Zhang, G.Q., Liu, H.H., Dai, H., Huang, F., Pan, F.M., Su, H., Dong, 
M.X., Chen, H., Wang, Q., Zhang, X.J. (2006): Elevated levels of serum soluble Fas 
are associated with organ and tissue damage in systemic lupus erythematosus 
among Chinese. Arch. Dermatol. Res. 297, 329-332.  
Hao Y, O'Neill PJ, Naradikian MS, Scholz JL, Cancro MP. (2011). A B-cell subset uniquely 
responsive to innate stimuli accumulates in aged mice. Blood. 118:1294-304 
Hardy RR, Hayakawa K. (2001). B cell development pathways. Annu. Rev. Immunol. 19:595–
621 
Hargraves M.M., H. Richmond, R. Morton, (1948). Presentation of two bone marrow 
elements; the tart cell and the L.E. cell. Mayo Clin. Proc. 23, 25–28  
Harris, D.P., L. Haynes, P.C. Sayles, D.K. Duso, S.M. Eaton, N.M. Lepak, L.L. Johnson, S.L. 
Swain, and F.E. Lund. (2000). Reciprocal regulation of polarized cytokine 
production by effector B and T cells. Nat. Immunol. 1:475–482. 
Haserick J.R., D. W. Bortz (1949a). A new diagnostic test for acute disseminated lupus 
erythematosus. Cleve. Clin. Q. 16, 158–161  
Haserick J.R., D. W. Bortz, (1949b). Normal bone marrow inclusion phenomena induced by 
lupus erythematosus plasma. J. Invest. Dermatol. 13, 47–49.  
 
Fas Pathway of Cell Death and B Cell Dysregulation in SLE 
 
113 
Heyworth, P.G., A.R. Cross, and J.T. Curnutte. (2003). Chronic granulomatous disease. Curr. 
Opin. Immunol. 15:578–584. 
Hom G, Graham RR, Modrek B, et al. (2008) Association of systemic lupus erythematosus 
with C8orf13–BLK and ITGAM–ITGAX. N Engl J Med 358: 900–909. 
Huggins, M. L., I. Todd, M. A. Cavers, S. R. Pavuluri, P. J. Tighe, and R. J. Powell. (1999). 
Antibodies from systemic lupus erythematosus (SLE) sera define differential 
release of autoantigens from cell lines undergoing apoptosis. Clin. Exp. 
Immunol.118: 322–328. 
International Consortium for Systemic Lupus Erythematosus Genetics, Harley JB, Alarcon-
Riquelme ME, et al. (2008). A genomewide association scan in women with 
systemic lupus erythematosus identifies risk variants in ITGAM, PXK, KIAA1542 
and other loci and confirms multiple loci contributing to disease susceptibility. Nat 
Genet 40, 204–210  
Ippolito A., DJ Wallace, D Gladman, PR Fortin, M Urowitz, V Werth, M Costner, C Gordon, 
GS Alarcón, R et al. (2011) Autoantibodies in systemic lupus erythematosus: 
comparison of historical and current assessment of seropositivity. Lupus 20, 250–
255. 
Kawane, K., Fukuyama, H., Kondoh, G., Takeda, J., Ohsawa, Y., Uchiyama, Y., and Nagata, 
S. (2001). Requirement of DNase II for definitive erythropoiesis in the mouse fetal 
liver. Science 292, 1546–1549. 
Kawane, K., Ohtani, M., Miwa, K., Kizawa, T., Kanbara, Y., Yoshioka, Y., Yoshikawa, H., 
and Nagata, S. (2006). Chronic polyarthritis caused by mammalian DNA that 
escapes from degradation in macrophages. Nature 443,998–1002. 
Kerr, J.F., Wyllie, A.H., and Currie, A.R. (1972). Apoptosis: a basic biological phenomenon 
with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239–257. 
Klebanoff, S.J. (1999). Oxygen metabolites from phagocytes. In J.I. Gallin and R. Snyderman, 
editors. Infl ammation: Basic Principles and Clinical Correlates. Lippincott 
Williams & Wilkins, Philadelphia. 721–768 
Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, et al. (2003) Successful 
treatment of collagen-induced arthritis in mice and rats by targeting extracellular 
high mobility group box chromosomal protein 1 activity. Arthritis Rheum 48:2052–
8. 
Kozyrev SV, Abelson A-K, Wojcik J, et al. (2008) Functional variants in the B cell gene 
BANK1 are associated with systemic lupus erythematosus. Nat Genet 40: 211–216.. 
Krammer, P.H. (2000). CD95’s deadly mission in the immune system. Nature 407, 789–795. 
Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. (2004). Survival of resting mature B 
lymphocytes depends on BCR signaling via the Igα/β heterodimer. Cell 117:787–800 
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E.S., Baehrecke, E.H., 
Blagosklonny, M.V., El-Deiry, W.S., Golstein, P., Green, D.R., et al; Nomenclature 
Committee on Cell Death 2009. (2009). Classification of cell death: 
recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death 
Differ. 16, 3–11. 
Kruse K, Janko C, Urbonaviciute V, Mierke CT, Winkler TH, Voll RE, Schett G, Muñoz LE, 
Herrmann M. (2010). Inefficient clearance of dying cells in patients with SLE: anti-
dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis. 15:1098-
113. 
 
Systemic Lupus Erythematosus 
 
114 
Lande R, D. Ganguly, V. Facchinetti, L. Frasca, C. Conrad, J. Gregorio, S. Meller, G. 
Chamilos, R. Sebasigari, V. Riccieri, R. Bassett, H. Amuro, S. Fukuhara, T. Ito, Y.-J. 
Liu, M. Gilliet, (2011). Neutrophils activate plasmacytoid dendritic cells by 
releasing self-DNA–peptide complexes in systemic lupus erythematosus. Sci. 
Transl. Med. 3, 73ra19  
Le Bon A., C. Thompson, E. Kamphuis, V. Durand, C. Rossmann, U. Kalinke, D. F. Tough 
(2006). Cutting edge: Enhancement of antibody responses through direct 
stimulation of B and T cells by type I IFN. J. Immunol. 176, 2074–2078.  
Lenert, P., R. Brummel, E. H. Field, and R. F. Ashman. (2005). TLR-9 activation of marginal 
zone B cells in lupus mice regulates immunity through increased IL-10 production. 
J. Clin. Immunol. 25: 29–40. 
Li LH, Li WX, Wu O, Zhang GQ, Pan HF, Li XP, Xu JH, Dai H, Ye DQ. (2009). Fas expression 
on peripheral blood lymphocytes in systemic lupus erythematosus: relation to the 
organ damage and lymphocytes apoptosis. Mol Biol Rep. 36:2047-52. 
Loken MR, Shah VO, Hollander Z, Civin CI. (1988). Flow cytometric analysis of normal B 
lymphoid development. Pathol Immunopathol Res. 7:357-70. 
Lüthi, A.U., and Martin, S.J. (2007). The CASBAH: a searchable database of caspase 
substrates. Cell Death Differ. 14, 641–650. 
Martin F, Kearney JF. (2002). Marginal zone B cells. Nat. Rev. Immunol. 2:323– 35 
Mauri, C., L.T. Mars, and M. Londei. (2000). Therapeutic activity of agonistic monoclonal 
antibodies against CD40 in a chronic autoimmune inflammatory process. Nat. Med. 
6:673–679. 
Mauri, C., Gray, D., Mushtaq, N., and Londei, M. (2003). Prevention of arthritis by 
interleukin 10-producing B cells. J. Exp. Med. 197, 489–501. 
Mauri, C. and Ehrenstein, M.R. (2007) Cells of the synovium in rheumatoid arthritis. B cells. 
Arthritis Res. Ther. 9, 205-10. 
Mauri C, Ehrenstein MR. (2008). The ‘short’ history of regulatory B cells. Trends Immunol 
29:34–40. 
Midgley A, McLaren Z, Moots RJ, Edwards SW, Beresford MW. (2009). The role of 
neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. Arthritis 
Rheum. 60:2390-401. 
Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M, Cervera R, Ballesta A, 
Ingelmo M. (2001).  Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, 
alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res. 
21(4B):3053-9. 
Mizoguchi, A., Mizoguchi, E., Takedatsu, H., Blumberg, R.S., and Bhan, A.K. (2002). Chronic 
intestinal inflammatory condition generates IL-10-producing regulatory B cell 
subset characterized by CD1d upregulation. Immunity 16,219–230. 
Mizoguchi A, Bhan AK. (2006). A case for regulatory B cells. J Immunol. 176:705-10. 
Moschese V, Orlandi P, Di Matteo G, Chini L, Carsetti R, Di Cesare S, Rossi P. (2004). Insight 
into B cell development and differentiation. Acta Paediatr Suppl. 93(445):48-51. 
Nagata, S. (1997). Apoptosis by death factor. Cell 88, 355–365. 
Nagata S, Hanayama R, Kawane K (2010). Autoimmunity and the clearance of dead cells. 
Cell 140: 619-630. 
 
Fas Pathway of Cell Death and B Cell Dysregulation in SLE 
 
115 
Nicholas MW, Dooley MA, Hogan SL, Anolik J, Looney J, Sanz I, Clarke SH. (2008). A novel 
subset of memory B cells is enriched in autoreactivity and correlates with adverse 
outcomes in SLE. Clin Immunol. 126:189-201. 
Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. (2007). High serum IFN-alpha activity 
is a heritable risk factor for systemic lupus erythematosus. Genes Immun 8:492-502. 
Nozawa, K., Kayagaki, N., Tokano, Y., Yagita, H., Okumura, K., Hasimoto, H. (1997): 
Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis 
Rheum. 40, 1126-1129.  
Obermoser G, Pascual V. (2010). The interferon-alpha signature of systemic lupus 
erythematosus. Lupus. 19:1012-9. 
Oliver AM, Martin F, Gartland GL, Carter RH, Kearney JF. (1997). Marginal zone B cells 
exhibit unique activation, proliferative and immunoglobulin secretory responses. 
Eur. J. Immunol. 27:2366–74 
Oliver AM, Martin F, Kearney JF. (1999). IgMhighCD21high lymphocytes enriched in the 
splenic marginal zone generate effector cells more rapidly than the bulk of 
follicular B cells. J. Immunol. 162:7198–207 
O' Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, 
Zhang JG, Belz GT, Smyth MJ, Bouillet P, Robb L, Strasser A. (2009). Membrane-
bound Fas ligand only is essential for Fas-induced apoptosis. Nature. 
461(7264):659-63. 
Ow, Y.P., Green, D.R., Hao, Z., and Mak, T.W. (2008). Cytochrome c: functions beyond 
respiration. Nat. Rev. Mol. Cell Biol. 9, 532–542. 
Pillai, S., A. Cariappa, and S. T. Moran. (2005). Marginal zone B cells. Annu. Rev.Immunol. 23: 
161–196. 
Ravichandran, K.S., and Lorenz, U. (2007). Engulfment of apoptotic cells: signals for a good 
meal. Nat. Rev. Immunol. 7, 964–974. 
Remmers EF, Plenge RM, Lee AT, et al. (2007). STAT4 and the risk of rheumatoid arthritis 
and systemic lupus erythematosus. N Engl J Med 357:977-86. 
Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH. 
(2007). Genetic variation in PTPN22 corresponds to altered function of T and B 
lymphocytes. J Immunol 179:4704-10. 
Rönnblom L, Eloranta ML, Alm GV. (2006). The type I interferon system in systemic lupus 
erythematosus. Arthritis Rheum 54:408-20. 
Rothman A, Isenberg DA (2008). Systemic lupus erythematosus. N Engl J Med 358:929-39.  
Rubtsov A.V. , K Rubtsova, A Fischer, R T. Meehan, J Z. Gillis, JW. Kappler, and P Marrack 
(2011) TLR7-driven accumulation of a novel CD11c+ B-cell population is important 
for the development of autoimmunity. Blood. 118(5):1305-15 
Rumore, P.M., and Steinman, C.R. (1990). Endogenous circulating DNA in systemic lupus 
erythematosus. Occurrence as multimeric complexes bound to histone. J. Clin. 
Invest. 86, 69–74. 
Sahebari M, Rezaieyazdi Z, Nakhjavani MJ, Hatef M, Mahmoudi M, Akhlaghi S. (2010). 
Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 
in patients with systemic lupus erythematosus. Rheumatol Int. DOI: 
10.1007/s00296-010-1633-9  
 
Systemic Lupus Erythematosus 
 
114 
Lande R, D. Ganguly, V. Facchinetti, L. Frasca, C. Conrad, J. Gregorio, S. Meller, G. 
Chamilos, R. Sebasigari, V. Riccieri, R. Bassett, H. Amuro, S. Fukuhara, T. Ito, Y.-J. 
Liu, M. Gilliet, (2011). Neutrophils activate plasmacytoid dendritic cells by 
releasing self-DNA–peptide complexes in systemic lupus erythematosus. Sci. 
Transl. Med. 3, 73ra19  
Le Bon A., C. Thompson, E. Kamphuis, V. Durand, C. Rossmann, U. Kalinke, D. F. Tough 
(2006). Cutting edge: Enhancement of antibody responses through direct 
stimulation of B and T cells by type I IFN. J. Immunol. 176, 2074–2078.  
Lenert, P., R. Brummel, E. H. Field, and R. F. Ashman. (2005). TLR-9 activation of marginal 
zone B cells in lupus mice regulates immunity through increased IL-10 production. 
J. Clin. Immunol. 25: 29–40. 
Li LH, Li WX, Wu O, Zhang GQ, Pan HF, Li XP, Xu JH, Dai H, Ye DQ. (2009). Fas expression 
on peripheral blood lymphocytes in systemic lupus erythematosus: relation to the 
organ damage and lymphocytes apoptosis. Mol Biol Rep. 36:2047-52. 
Loken MR, Shah VO, Hollander Z, Civin CI. (1988). Flow cytometric analysis of normal B 
lymphoid development. Pathol Immunopathol Res. 7:357-70. 
Lüthi, A.U., and Martin, S.J. (2007). The CASBAH: a searchable database of caspase 
substrates. Cell Death Differ. 14, 641–650. 
Martin F, Kearney JF. (2002). Marginal zone B cells. Nat. Rev. Immunol. 2:323– 35 
Mauri, C., L.T. Mars, and M. Londei. (2000). Therapeutic activity of agonistic monoclonal 
antibodies against CD40 in a chronic autoimmune inflammatory process. Nat. Med. 
6:673–679. 
Mauri, C., Gray, D., Mushtaq, N., and Londei, M. (2003). Prevention of arthritis by 
interleukin 10-producing B cells. J. Exp. Med. 197, 489–501. 
Mauri, C. and Ehrenstein, M.R. (2007) Cells of the synovium in rheumatoid arthritis. B cells. 
Arthritis Res. Ther. 9, 205-10. 
Mauri C, Ehrenstein MR. (2008). The ‘short’ history of regulatory B cells. Trends Immunol 
29:34–40. 
Midgley A, McLaren Z, Moots RJ, Edwards SW, Beresford MW. (2009). The role of 
neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. Arthritis 
Rheum. 60:2390-401. 
Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M, Cervera R, Ballesta A, 
Ingelmo M. (2001).  Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, 
alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res. 
21(4B):3053-9. 
Mizoguchi, A., Mizoguchi, E., Takedatsu, H., Blumberg, R.S., and Bhan, A.K. (2002). Chronic 
intestinal inflammatory condition generates IL-10-producing regulatory B cell 
subset characterized by CD1d upregulation. Immunity 16,219–230. 
Mizoguchi A, Bhan AK. (2006). A case for regulatory B cells. J Immunol. 176:705-10. 
Moschese V, Orlandi P, Di Matteo G, Chini L, Carsetti R, Di Cesare S, Rossi P. (2004). Insight 
into B cell development and differentiation. Acta Paediatr Suppl. 93(445):48-51. 
Nagata, S. (1997). Apoptosis by death factor. Cell 88, 355–365. 
Nagata S, Hanayama R, Kawane K (2010). Autoimmunity and the clearance of dead cells. 
Cell 140: 619-630. 
 
Fas Pathway of Cell Death and B Cell Dysregulation in SLE 
 
115 
Nicholas MW, Dooley MA, Hogan SL, Anolik J, Looney J, Sanz I, Clarke SH. (2008). A novel 
subset of memory B cells is enriched in autoreactivity and correlates with adverse 
outcomes in SLE. Clin Immunol. 126:189-201. 
Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. (2007). High serum IFN-alpha activity 
is a heritable risk factor for systemic lupus erythematosus. Genes Immun 8:492-502. 
Nozawa, K., Kayagaki, N., Tokano, Y., Yagita, H., Okumura, K., Hasimoto, H. (1997): 
Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis 
Rheum. 40, 1126-1129.  
Obermoser G, Pascual V. (2010). The interferon-alpha signature of systemic lupus 
erythematosus. Lupus. 19:1012-9. 
Oliver AM, Martin F, Gartland GL, Carter RH, Kearney JF. (1997). Marginal zone B cells 
exhibit unique activation, proliferative and immunoglobulin secretory responses. 
Eur. J. Immunol. 27:2366–74 
Oliver AM, Martin F, Kearney JF. (1999). IgMhighCD21high lymphocytes enriched in the 
splenic marginal zone generate effector cells more rapidly than the bulk of 
follicular B cells. J. Immunol. 162:7198–207 
O' Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, 
Zhang JG, Belz GT, Smyth MJ, Bouillet P, Robb L, Strasser A. (2009). Membrane-
bound Fas ligand only is essential for Fas-induced apoptosis. Nature. 
461(7264):659-63. 
Ow, Y.P., Green, D.R., Hao, Z., and Mak, T.W. (2008). Cytochrome c: functions beyond 
respiration. Nat. Rev. Mol. Cell Biol. 9, 532–542. 
Pillai, S., A. Cariappa, and S. T. Moran. (2005). Marginal zone B cells. Annu. Rev.Immunol. 23: 
161–196. 
Ravichandran, K.S., and Lorenz, U. (2007). Engulfment of apoptotic cells: signals for a good 
meal. Nat. Rev. Immunol. 7, 964–974. 
Remmers EF, Plenge RM, Lee AT, et al. (2007). STAT4 and the risk of rheumatoid arthritis 
and systemic lupus erythematosus. N Engl J Med 357:977-86. 
Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH. 
(2007). Genetic variation in PTPN22 corresponds to altered function of T and B 
lymphocytes. J Immunol 179:4704-10. 
Rönnblom L, Eloranta ML, Alm GV. (2006). The type I interferon system in systemic lupus 
erythematosus. Arthritis Rheum 54:408-20. 
Rothman A, Isenberg DA (2008). Systemic lupus erythematosus. N Engl J Med 358:929-39.  
Rubtsov A.V. , K Rubtsova, A Fischer, R T. Meehan, J Z. Gillis, JW. Kappler, and P Marrack 
(2011) TLR7-driven accumulation of a novel CD11c+ B-cell population is important 
for the development of autoimmunity. Blood. 118(5):1305-15 
Rumore, P.M., and Steinman, C.R. (1990). Endogenous circulating DNA in systemic lupus 
erythematosus. Occurrence as multimeric complexes bound to histone. J. Clin. 
Invest. 86, 69–74. 
Sahebari M, Rezaieyazdi Z, Nakhjavani MJ, Hatef M, Mahmoudi M, Akhlaghi S. (2010). 
Correlation between serum concentrations of soluble Fas (CD95/Apo-1) and IL-18 
in patients with systemic lupus erythematosus. Rheumatol Int. DOI: 
10.1007/s00296-010-1633-9  
 
Systemic Lupus Erythematosus 
 
116 
Sakaguchi, S. (2004). Naturally arising CD4_ regulatory T cells for immunologic self 
tolerance and negative control of immune responses. Ann. Rev. Immunol. 22:531–
562. 
Salmon JE, Millard S, Schacter LA, et al. (1996). Fc gamma RIIA alleles are heritable risk 
factors for lupus nephritis in African Americans. J Clin Invest 97:1348-54. 
Santiago-Raber M-L, L Baudino and S Izui (2009). Emerging roles of TLR7 and TLR9 in 
murine SLE. J Autoimmunity 33:231-8. 
Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. (2000).  Quantitative genetic 
variation in CD19 expression correlates with autoimmunity. J Immunol. 165:6635-
43. 
Savill, J., V. Fadok, P. Henson, and C. Haslett. (1993). Phagocyte recognition of cells 
undergoing apoptosis. Immunol. Today 14: 131–136. 
Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, 
Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA.  (2005) IL-33, an 
interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and 
induces T helper type 2-associated cytokines. Immunity 23, 479–490 
Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, et al. (2001). Maturation of 
marginal zone and follicular B cells requires B cell activating factor of the tumor 
necrosis factor family and is independent of B cell maturation antigen. J.Exp. Med. 
194:1691–97 
Sheriff, A., Gaipl, U.S., Voll, R.E., Kalden, J.R., Herrmann, M. (2004): Apoptosis and systemic 
lupus erythematosus. Rheum. Dis. Clin. North Am. 30, 505-527. 
Shevach, E. M. (2000). Regulatory T cells in autoimmunity. Ann. Rev. Immunol. 18:423–449. 
Sigurdsson S, Göring HH, Kristjansdottir G, et al. (2008). Comprehensive evaluation of the 
genetic variants of interferon regulatory factor 5 reveals a novel 5bp length 
polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol 
Genet 17:872-81. 
Silvestris, F., Grinello, D., Tucci, M., Cafforio, P., Dammacco, F. (2003): Enhancement of T 
cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-
1)in active lupus. Lupus 12, 8-14.  
Singh AK. (1995). Lupus in the Fas lane? J R Coll Physicians Lond. 29:475-8. 
Singh R, Pradhan V, Patwardhan M, Ghosh K. (2009). APO-1/Fas gene: Structural and 
functional characteristics in systemic lupus erythematosus and other autoimmune 
diseases. Indian J Hum Genet. 15:98-102. 
Sozzani S, Bosisio D, Scarsi M, Tincani A. (2010). Type I interferons in systemic 
autoimmunity. Autoimmunity. 43:196-203. 
Strasser, A., Jost, P.J., and Nagata, S. (2009). The many roles of FAS receptor signaling in the 
immune system. Immunity 30, 180–192. 
Su TT, Guo B, Wei B, Braun J, Rawlings DJ. (2004). Signaling in transitional type 2 B cells is 
critical for peripheral B-cell development. Immunol Rev. 197:161-78. 
Suzuki, N., Ichino, M., Mihara, S., Kaneko, S., Sakane, T. (1998): Inhibition of Fas/Fas 
ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas 
ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis 
Rheum. 41, 344-353. 
Tan EM, Cohen AS, Fries JF, et al. (1982). The 1982 revised criteria for the classification of 
systemic lupus erythematosus. Arthritis Rheum 25:1271-7 
 
Fas Pathway of Cell Death and B Cell Dysregulation in SLE 
 
117 
Telegina E, Reshetnyak T, Moshnikova A, Proussakova O, Zhukova A, Kuznetsova A, 
Ivanov A, Paltsev M, Beletsky I. (2009). A possible role of Fas-ligand-mediated 
"reverse signaling" in pathogenesis of rheumatoid arthritis and systemic lupus 
erythematosus. Immunol Lett. 122:12-7. 
Theofilopoulos A,N., R. Baccala, B. Beutler, D. H. Kono (2005). Type I interferons (a/b) in 
immunity and autoimmunity. Annu. Rev. Immunol. 23, 307–336  
Thibault DL, Graham KL, Lee LY, Balboni I, Hertzog PJ, Utz PJ. (2009). Type I interferon 
receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and 
autoantibody production in a murine model of lupus. Arthritis Res Ther. 11:R112.  
Timmer, J.C., and Salvesen, G.S. (2007). Caspase substrates. Cell Death Differ. 14, 66–72. 
Tinazzi, E., Puccetti, A., Gerli, R., Rigo, A., Migliorini, P., Simeoni, S., Beri, R., Dolcino, M., 
Martinelli, N., Corrocher, R., Lunardi, C. (2009): Serum DNase I, soluble Fas/FasL 
levels and cell surface Fas expression in patients with SLE: a possibile explanation 
for the lack of efficacy of hrDNase I treatment. Int. Immunol. 21, 237-243. 
Tokano, Y., Miyake, S., Kayagaki, N., Nozawa, K., Morimoto, S., Azuma, M., Yagita, H., 
Takasaki, Y., Okumura, K., Hashimoto, H. (1996): Soluble Fas molecule in the 
serum of patients with systemic lupus erythematosus. J. Clin. Immunol. 16, 261-265. 
Treml LS, Carlesso G, Hoek KL, Stadanlick JE, Kambayashi T, Bram RJ, Cancro MP, Khan 
WN. (2007). TLR stimulation modifies BLyS receptor expression in follicular and 
marginal zone B cells. J Immunol. 178:7531-9. 
Turi MC, D’Urbano M, Celletti E, Alessandri C, Valesini G, Paganelli R. (2009). Serum 
Fas/FasL ratio in sistemi lupus erythematosus (SLE) is a function of age. Arch 
Gerontol Geriatr S1:221-6. 
Ulloa L, D Messmer (2006). High-mobility group box 1 (HMGB1) protein: Friend and foe. 
Cytokine & Growth Factor Reviews 17:189–201 
Urbonaviciute V, et al. (2008) Induction of infl amatory and immune responses by HMGB1 
nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 
205:3007-3018 
Voll , R.E. , M. Herrmann , E.A. Roth , C. Stach , J.R. Kalden , and I. Girkontaite . (1997). 
Immunosuppressive eff ects of apoptotic cells. Nature . 390 : 350 – 351 . 
Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J.M.,Ombrellino, M.,Che, J., Frazier, A., 
Yang, H., Ivanova, S., Borovikova, L., Abraham E, Andersson J, Andersson U, 
Molina PE, Abumrad NN, Sama A, Tracey KJ (1999). HMG-1 as a late mediator of 
endotoxin lethality in mice. Science 285:248 –251.  
Wang H., H. Yang & K Tracey (2004). Extracellular role of HMGB1 in inflammation and 
sepsis. Journal of Internal Medicine 255: 320–331 
Warnatz K, Wehr C, Dräger R, Schmidt S, Eibel H, Schlesier M, Peter HH. (2002). Expansion 
of CD19(hi)CD21(lo/neg) B cells in common variable immunodeficiency (CVID) 
patients with autoimmune cytopenia. Immunobiology. 206:502-13. 
Yamada S, Maruyama I (2007). HMGB1, a novel inflammatory cytokine. Clin Chim Acta 
375:36–42 
Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. (2008). A regulatory B cell 
subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent 
inflammatory responses. Immunity. 28:639-50. 
 
Systemic Lupus Erythematosus 
 
116 
Sakaguchi, S. (2004). Naturally arising CD4_ regulatory T cells for immunologic self 
tolerance and negative control of immune responses. Ann. Rev. Immunol. 22:531–
562. 
Salmon JE, Millard S, Schacter LA, et al. (1996). Fc gamma RIIA alleles are heritable risk 
factors for lupus nephritis in African Americans. J Clin Invest 97:1348-54. 
Santiago-Raber M-L, L Baudino and S Izui (2009). Emerging roles of TLR7 and TLR9 in 
murine SLE. J Autoimmunity 33:231-8. 
Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. (2000).  Quantitative genetic 
variation in CD19 expression correlates with autoimmunity. J Immunol. 165:6635-
43. 
Savill, J., V. Fadok, P. Henson, and C. Haslett. (1993). Phagocyte recognition of cells 
undergoing apoptosis. Immunol. Today 14: 131–136. 
Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, 
Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA.  (2005) IL-33, an 
interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and 
induces T helper type 2-associated cytokines. Immunity 23, 479–490 
Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, et al. (2001). Maturation of 
marginal zone and follicular B cells requires B cell activating factor of the tumor 
necrosis factor family and is independent of B cell maturation antigen. J.Exp. Med. 
194:1691–97 
Sheriff, A., Gaipl, U.S., Voll, R.E., Kalden, J.R., Herrmann, M. (2004): Apoptosis and systemic 
lupus erythematosus. Rheum. Dis. Clin. North Am. 30, 505-527. 
Shevach, E. M. (2000). Regulatory T cells in autoimmunity. Ann. Rev. Immunol. 18:423–449. 
Sigurdsson S, Göring HH, Kristjansdottir G, et al. (2008). Comprehensive evaluation of the 
genetic variants of interferon regulatory factor 5 reveals a novel 5bp length 
polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol 
Genet 17:872-81. 
Silvestris, F., Grinello, D., Tucci, M., Cafforio, P., Dammacco, F. (2003): Enhancement of T 
cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-
1)in active lupus. Lupus 12, 8-14.  
Singh AK. (1995). Lupus in the Fas lane? J R Coll Physicians Lond. 29:475-8. 
Singh R, Pradhan V, Patwardhan M, Ghosh K. (2009). APO-1/Fas gene: Structural and 
functional characteristics in systemic lupus erythematosus and other autoimmune 
diseases. Indian J Hum Genet. 15:98-102. 
Sozzani S, Bosisio D, Scarsi M, Tincani A. (2010). Type I interferons in systemic 
autoimmunity. Autoimmunity. 43:196-203. 
Strasser, A., Jost, P.J., and Nagata, S. (2009). The many roles of FAS receptor signaling in the 
immune system. Immunity 30, 180–192. 
Su TT, Guo B, Wei B, Braun J, Rawlings DJ. (2004). Signaling in transitional type 2 B cells is 
critical for peripheral B-cell development. Immunol Rev. 197:161-78. 
Suzuki, N., Ichino, M., Mihara, S., Kaneko, S., Sakane, T. (1998): Inhibition of Fas/Fas 
ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas 
ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis 
Rheum. 41, 344-353. 
Tan EM, Cohen AS, Fries JF, et al. (1982). The 1982 revised criteria for the classification of 
systemic lupus erythematosus. Arthritis Rheum 25:1271-7 
 
Fas Pathway of Cell Death and B Cell Dysregulation in SLE 
 
117 
Telegina E, Reshetnyak T, Moshnikova A, Proussakova O, Zhukova A, Kuznetsova A, 
Ivanov A, Paltsev M, Beletsky I. (2009). A possible role of Fas-ligand-mediated 
"reverse signaling" in pathogenesis of rheumatoid arthritis and systemic lupus 
erythematosus. Immunol Lett. 122:12-7. 
Theofilopoulos A,N., R. Baccala, B. Beutler, D. H. Kono (2005). Type I interferons (a/b) in 
immunity and autoimmunity. Annu. Rev. Immunol. 23, 307–336  
Thibault DL, Graham KL, Lee LY, Balboni I, Hertzog PJ, Utz PJ. (2009). Type I interferon 
receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and 
autoantibody production in a murine model of lupus. Arthritis Res Ther. 11:R112.  
Timmer, J.C., and Salvesen, G.S. (2007). Caspase substrates. Cell Death Differ. 14, 66–72. 
Tinazzi, E., Puccetti, A., Gerli, R., Rigo, A., Migliorini, P., Simeoni, S., Beri, R., Dolcino, M., 
Martinelli, N., Corrocher, R., Lunardi, C. (2009): Serum DNase I, soluble Fas/FasL 
levels and cell surface Fas expression in patients with SLE: a possibile explanation 
for the lack of efficacy of hrDNase I treatment. Int. Immunol. 21, 237-243. 
Tokano, Y., Miyake, S., Kayagaki, N., Nozawa, K., Morimoto, S., Azuma, M., Yagita, H., 
Takasaki, Y., Okumura, K., Hashimoto, H. (1996): Soluble Fas molecule in the 
serum of patients with systemic lupus erythematosus. J. Clin. Immunol. 16, 261-265. 
Treml LS, Carlesso G, Hoek KL, Stadanlick JE, Kambayashi T, Bram RJ, Cancro MP, Khan 
WN. (2007). TLR stimulation modifies BLyS receptor expression in follicular and 
marginal zone B cells. J Immunol. 178:7531-9. 
Turi MC, D’Urbano M, Celletti E, Alessandri C, Valesini G, Paganelli R. (2009). Serum 
Fas/FasL ratio in sistemi lupus erythematosus (SLE) is a function of age. Arch 
Gerontol Geriatr S1:221-6. 
Ulloa L, D Messmer (2006). High-mobility group box 1 (HMGB1) protein: Friend and foe. 
Cytokine & Growth Factor Reviews 17:189–201 
Urbonaviciute V, et al. (2008) Induction of infl amatory and immune responses by HMGB1 
nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 
205:3007-3018 
Voll , R.E. , M. Herrmann , E.A. Roth , C. Stach , J.R. Kalden , and I. Girkontaite . (1997). 
Immunosuppressive eff ects of apoptotic cells. Nature . 390 : 350 – 351 . 
Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J.M.,Ombrellino, M.,Che, J., Frazier, A., 
Yang, H., Ivanova, S., Borovikova, L., Abraham E, Andersson J, Andersson U, 
Molina PE, Abumrad NN, Sama A, Tracey KJ (1999). HMG-1 as a late mediator of 
endotoxin lethality in mice. Science 285:248 –251.  
Wang H., H. Yang & K Tracey (2004). Extracellular role of HMGB1 in inflammation and 
sepsis. Journal of Internal Medicine 255: 320–331 
Warnatz K, Wehr C, Dräger R, Schmidt S, Eibel H, Schlesier M, Peter HH. (2002). Expansion 
of CD19(hi)CD21(lo/neg) B cells in common variable immunodeficiency (CVID) 
patients with autoimmune cytopenia. Immunobiology. 206:502-13. 
Yamada S, Maruyama I (2007). HMGB1, a novel inflammatory cytokine. Clin Chim Acta 
375:36–42 
Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. (2008). A regulatory B cell 
subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent 
inflammatory responses. Immunity. 28:639-50. 
 
Systemic Lupus Erythematosus 
 
118 
Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, et al. (2004). Reversing established 
sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad 
Sci USA 101:296–301. 
5 
Regulation of Nucleic Acid Sensing Toll-Like 
Receptors in Systemic Lupus Erythematosus 
Cynthia A. Leifer and James C. Brooks 
College of Veterinary Medicine, Cornell University 
USA 
1. Introduction  
Autoimmune disease is an aberrant response of the immune system to self. Unlike the 
adaptive immune system, the innate immune system is not selected during development 
and was originally thought to inherently discriminate between host and foreign molecular 
structures (Janeway, 1989). This is true for many innate immune receptor ligands including 
lipopolysaccharide, which is only synthesized by Gram-negative bacteria. However, some 
innate immune receptors detect nucleic acids that are shared between microbes and the host. 
Immune complexes containing nucleic acids are a hallmark of Systemic Lupus 
Erythematosus (SLE), and the nucleic acid sensing Toll-like receptors (TLRs) respond to the 
DNA and RNA within these complexes thereby contributing to disease. Defects in 
regulation of this class of innate immune receptors likely play a key role in precipitation of 
disease. Here we review nucleic acid sensing TLRs in SLE and recent advances in our 
understanding of the regulatory mechanisms governing TLR activity. Since breakdown of 
regulatory mechanisms controlling response of nucleic acid-sensing TLRs likely contributes 
to development of SLE, targeting specific proteins in these regulatory pathways has the 
potential to block nucleic acid-driven autoimmune inflammation. 
2. Nucleic acid sensing toll-like receptors in SLE 
2.1 Toll-like receptors 
Toll-like receptors (TLRs) are a family of innate immune receptors that directly detect 
molecular structures and initiate signaling. Engagement of TLRs initiates innate immune 
responses that promote microbial killing and antigen presentation to educate T cells and B 
cells. At least 10 different TLRs recognize various microbial structures such as lipopeptides 
(TLR1, TLR2, and TLR6), lipopolysaccharide (TLR4), bacterial flagellin (TLR5), double 
stranded RNA (dsRNA, TLR3), single stranded RNA (ssRNA, TLR7, TLR8), and single 
stranded DNA (ssDNA, TLR9) (Takeda, et al. 2003).  
TLRs are type 1 transmembrane receptors with C-termini facing the cytoplasm of the cell 
and ectodomains either at the cell surface or in the lumen of intracellular compartments. The 
cytoplasmic domain has homology with the IL-1 and IL-18 receptors and has been called the 
Toll/IL-1-like receptor domain (TIR). The three-dimensional structures of two TLR 
cytoplasmic TIR domains have been solved and are globular with many surfaces for protein-
protein interactions (Xu, et al. 2000). The TIR domain associates with several adapter 
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proteins that initiate signal transduction. These adapters include myeloid differentiation 
factor 88 (MyD88), and TIR-domain-containing adapter-inducing interferon-β (TRIF, also 
known as MyD88 adapter-like, MAL), which promote production of proinflammatory 
cytokines and type I interferons. The ectodomain is composed of a series of leucine rich 
repeats that form a curved solenoid. Alignment studies predicted a model structure for the 
ectodomains of TLRs (Bell, et al. 2003), which was supported by crystallographic studies 
(Bell, et al. 2005; Choe, et al. 2005). TLRs are expressed on a wide variety of cell types 
including B cells, T cells, dendritic cells, macrophages, and intestinal epithelial cells, 
although different cell types have unique repertoires of TLR expression (Takeda, et al. 2003). 
For example, human plasmacytoid dendritic cells express the nucleic acid-sensing TLRs, 
TLR7 and TLR9. TLR7- and TLR9-dependent responses by both B cells and plasmacytoid 
dendritic cells have been proposed to contribute to SLE (Marshak-Rothstein, 2006).  
2.2 Nucleic acids as TLR ligands 
Multiple nucleic acids, including ssRNA, dsRNA, and DNA, induce inflammatory 
responses. For DNA, the response is dependent on a 5’- cytosine-guanosine-3’ dinucleotide 
(CpG). The central cytosine must be unmethylated, and is active when surrounded by 
specific bases, which together form the CpG motif (Krieg, 2002). These CpG motifs are rare 
in vertebrate DNA due to reduced frequency of the CG dinucleotide (CpG suppression) and 
increased frequency of cytosine methylation (Cardon, et al. 1994; Klinman, et al. 1996; Krieg, 
et al. 1995).  However, CpG motifs are present and functional in bacterial DNA, in plasmid 
DNA produced in bacteria, and in synthetic DNA. Variation of sequence and physical 
structure of synthetic DNAs have resulted in characterization of at least four types of CpG 
oligodeoxynucleotides each with different activity on cells. Three are stimulatory, and one is 
inhibitory (Gursel, et al. 2003; Verthelyi, et al. 2001). Inhibitory DNAs do not require a CpG 
motif and the mechanism of inhibition has not been clearly defined (Gursel, et al. 2003; 
Krieg, et al. 1998; Lenert, et al. 2003). Type A CpG DNAs (also called D) induce robust type I 
interferon production, while type B CpG DNAs (also called K) induce B cell proliferation 
and proinflammatory cytokine production (Verthelyi, et al. 2001). The last class type C CpG 
DNAs have properties of both type A and type B CpG DNAs and thus induces both types of 
cellular responses (Vollmer, et al. 2004).  
Regardless of their class, CpG DNAs require endocytosis and acidification of endosomes for 
activity (Figure 1). Blockade of uptake by immobilization of the CpG DNA on beads inhibits 
the B cell proliferative activity of synthetic CpG DNAs (Manzel & Macfarlane, 1999). 
Inhibition of endosomal acidification blocks CpG DNA-induced cytokine release by 
macrophages (Hacker, et al. 1998). Furthermore, cellular activation by CpG DNA initiates on 
endosomes (Ahmad-Nejad, et al. 2002). Vertebrate DNAs are poorly internalized, which 
contributes to their poor stimulatory activity. However, vertebrate DNA is stimulatory 
when in complex with proteins such as high mobility group box 1 (HMGB1), the 
antimicrobial peptide LL37, or anti-DNA antibodies (Lande, et al. 2007; Leadbetter, et al. 
2002; Tian, et al. 2007). Whether the CpG DNA induces proinflammatory cytokines or type I 
interferon also depends on the endosomal compartment where the DNA is retained (Honda, 
et al. 2005). Honda and colleagues demonstrated that different types of DNA were trafficked 
to and retained within different endosomal compartments. For example, the type I 
interferon inducing CpG DNAs (type A) rapidly co-localized with FITC-dextran, a marker 
for early endosomes, but failed to co-localize with lysosomal markers. In contrast, rapid 
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localization with lysosomal markers correlated with proinflammatory cytokine production 
induced by type B CpG DNAs. In another study the outcome of cellular responses to the 
DNA types could be swapped by changing the physical and chemical properties of the DNA 
(Guiducci, et al. 2006). Multimerization of type B CpG DNAs, so that their physical structure 
resembled type A CpG DNAs, caused them to be retained in early endosomes and induce 
A-type responses. Response of B cells was also dependent on CpG DNA type and delivery 
mechanism (Avalos, et al. 2009). These studies strongly correlated location of DNA detection 
with cellular outcome and suggested that manipulation of localization and receptor 












endosomal activation of TLR9
 
Fig. 1. DNA uptake into the cell. Host DNA is degraded in the extracellular space by DNase 
and does not normally induce inflammatory responses. However, several host proteins 
including LL37, HMGB1, and anti-nuclear antibodies stabilize host DNA and facilitate 
uptake into the endosomal compartment. Endocytosed host DNA activates TLR9. Unlike 
host DNA, synthetic CpG DNAs, or bacterial DNA, are efficeintly endocytosed and  
activate TLR9.  
At concentrations of CpG DNA used by many investigators, uptake occurs by fluid phase 
endocytosis. Uptake of CpG DNA reached a plateau at 2 hours, was slowed at low 
temperature and was inhibited by known endocytosis inhibitors such as sodium azide and 
cytochalasin B (Yakubov, et al. 1989). Yet, at lower concentrations, uptake was significantly 
more efficient, which indicated that the CpG DNA was internalized by receptor-mediated 
endocytosis. Using radiolabeled cells, multiple groups demonstrated specific DNA binding 
proteins that likely assisted in internalization and trafficking of CpG DNA to the correct 
endosomal compartment where it encountered TLR9 (Beltinger, et al. 1995; Yakubov, et al. 
1989). However, the identity of these receptors remains unknown. During the 
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internalization process, CpG DNA transits though both early and late endosomes, which is 
important because, as mentioned above, CpG DNAs trigger different cellular outcomes 
depending on the compartment where signaling initiates.  
A hallmark of SLE is elevated serum antibodies to nuclear components, which enhance 
response to DNA (Leadbetter, et al. 2002). Immune complexes from SLE patient serum were 
enriched in CG content within the DNA, consistent with increased presence of potential 
stimulatory motifs (Sano & Morimoto, 1982). Complexes with DNA bound to anti-idiotype 
B cell receptors (rheumatoid factor) and to Fc receptors to mediate internalization (Boule, et 
al. 2004; Leadbetter, et al. 2002). By either mechanism the uptake was very efficient and 
delivered the complexes to the endosomal compartment. Synergistic cytokine production 
and autoantibody induction by enhanced uptake of DNA-containing immune complexes 
likely contributes to the induction and propagation of anti-nucleic acid antibody production 
so frequently observed in SLE.  
Internalization of CpG DNA and host DNA is also facilitated by several other host proteins 
including high mobility group protein 1 (HMGB-1), and the antimicrobial peptide LL37. The 
cationic antimicrobial peptide LL37 was highly elevated in the skin of patients with 
psoriases (Lande, et al. 2007). LL37 formed a stable complex with host DNA, and induced a 
TLR9-dependent, DNase-sensitive, type I interferon response from human plasmacytoid 
dendritic cells. The nuclear factor HMGB1 is retained within cells under normal conditions, 
but cell death and inflammation releases HMGB1, which formed a stable complex with host 
DNA. Association of CpG DNA-A with HMGB1 dramatically enhanced production of type I 
interferon (Tian, et al. 2007). In fact, HMGB1 was found in immune complexes with host 
DNA. Altogether, these studies demonstrate that while host DNA alone is not very 
immunostimulatory, association with a variety of different proteins, present in disease 
states, promote endosomal uptake where the DNA can associate with TLRs and induce 
pathologic interferon responses.  
2.3 The role of TLRs in B cells and DC in SLE models 
Mouse models have provided significant experimental evidence for the importance of TLRs 
in SLE. Deficiency in UNC93B1, a chaperone-like protein required for endocytic trafficking 
of nucleic acid-sensing TLRs, results in less severe disease in induced models of SLE in mice 
(Kono, et al. 2009). Furthermore, UNC93B1 protein is upregulated in SLE (Nakano, et al. 
2010), underscoring the importance of TLRs in disease manifestations. The Y-linked 
autoimmune accelerator (Yaa) mutation, which accelerates and enhances spontaneous 
disease on the B6/FcRIIB -/- background, is due to TLR7 gene duplication (Pisitkun, et al. 
2006), and disease in Fas-deficient MRL/lpr mice is dependent on TLR7 expression 
(Christensen, et al. 2006). Together these studies show that nucleic acid-sensing TLRs 
contribute to SLE. 
The role for TLR9 in SLE-like disease in mice is less clear. TLR9 deficient mice have reduced 
anti-DNA antibodies, but enhanced disease (Christensen, et al. 2005). Despite these 
limitations, much is known about the regulation of TLR9, and TLR9 remains a good model 
to study the regulation of nucleic acid-sensing TLRs. A specific role for TLR9 in B cell 
responses to DNA containing immune complexes was supported by studies using a mouse 
expressing a transgenic “rheumatoid factor” receptor. In vitro stimulation with immune 
complexes that included DNA, such as anti-nucleosome complexes, induced proliferation of 
the transgenic B cells, but non-nucleic acid complexes, such as BSA-anti-BSA complexes did 
not. The response was DNase sensitive and dependent on MyD88 and uptake of the 
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immune complexes into the endosomal compartment (Leadbetter, et al. 2002). Therefore, 
while TLR9 may not be a major contributor to disease in patients, defects in TLR9 regulation 
may have very specific functional consequences and a better understanding of the 
regulatory mechanisms may provide necessary information to therapeutically target TLR9 
and other nucleic acid-sensing TLRs.  
Patients with SLE have high levels of type I interferons in the blood and their peripheral 
blood mononuclear cells have a characteristic upregulation of interferon regulated genes 
(Bennett, et al. 2003). Plasmacytoid dendritic cells circulating in the blood are a major source 
of type I interferons and were originally called natural interferon producing cells (NIPCs). 
In humans, this subset of dendritic cells expresses predominantly TLR7 and TLR9 
(Hornung, et al. 2002; Krug, et al. 2004). Production of type I interferons by plasmacytoid 
dendritic cells can be induced by immune complexes produced in abundance in patients 
with SLE (Ronnblom & Alm, 2001). Dendritic cells have Fc receptors on their cell surface 
that capture and internalize immune complexes, which induces interferon in a CpG motif- 
and TLR9-dependent manner (Boule, et al. 2004; Yasuda, et al. 2009). High circulating type I 
interferon correlates with immune pathology and disease severity in SLE. Therefore, TLR9 
contributes to interferon production, and interferon can in turn augment TLR9-dependent 
responses.  
2.4 Nucleic acid-sensing TLRs detection of self-ligands 
When the stimulatory activity of CpG DNA was first described, it was thought to represent 
microbial DNA and that self-DNA was non-stimulatory. This was due to the requirement 
for the central CG dinucleotide, unmethylation of the C, and for selectivity for surrounding 
bases. These arguments held for many years, but it was known, even then, that the 
mammalian genome had the potential to induce TLR9-mediated responses (Ishii, et al. 2001; 
Yasuda, et al. 2005). Many studies, including the ones reviewed below, have been focussed 
on understanding what regulates TLR9 mediated responses and why self-DNA is not 
normally detected. However, recent studies suggest that TLR9 signaling is important for 
normal responses like wound repair. 
Cells go to great lengths to assure DNA is not released into the extracellular milieu when 
they die by condensing and digesting their DNA during apoptosis. However, necrosis 
and neutrophil extracellular trap (NET) formation intentionally releases DNA that can 
induce inflammatory responses (Garcia-Romo, et al. 2011; Lande, et al. 2011; Villanueva, 
et al. 2011). Interestingly, SLE neutrophils were primed by high type I interferon levels in 
vivo, and in response to immune complexes, the neutrophils from SLE patients generated 
NETs that had a high content of DNA, LL37 and HMGB1. These proteins protected the 
DNA from degradation and facilitated internalization, and thereby increased the 
inflammatory potential of the host DNA. Therefore, since it is purposefully released 
under certain conditions, there must be other regulatory mechanisms to avoid response to 
host DNA. DNase is present in serum and in the extracellular environment and degrades 
potentially stimulatory host DNA. DNase deficient mice were born healthy but develop 
lupus like disease around six months of age (Napirei, et al. 2000). Heterozygous mice had 
increased serum concentrations of anti-nuclear antibodies, and more glomerulonephritis. 
However, in homozygous DNase deficient mice these SLE parameters were even higher. 
Mutations in DNase have been identified in SLE patients (Yasutomo, et al. 2001), and 
together these studies suggest that DNase is an important mechanism to prevent response 
to host DNA.  
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internalization process, CpG DNA transits though both early and late endosomes, which is 
important because, as mentioned above, CpG DNAs trigger different cellular outcomes 
depending on the compartment where signaling initiates.  
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immune complexes into the endosomal compartment (Leadbetter, et al. 2002). Therefore, 
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lupus like disease around six months of age (Napirei, et al. 2000). Heterozygous mice had 
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Interestingly, recent studies have shown that detection of self-DNA may be a normal 
biological process, and is, in fact, critical for wound healing (Gregorio, et al. 2010; Sato, et 
al. 2010). In the absence of TLR9, full thickness biopsy wound healing was delayed, and 
application of CpG DNA enhanced healing in a TLR9 dependent manner (Sato, et al. 
2010). These data suggest that TLR9 plays an important role in wound healing. In a 
different model, tape stripping-induced epidermal injury induced plasmacytoid dendritic 
cell and neutrophil infiltration (Guiducci, et al. 2010). This response was accompanied by 
production of type I interferon, and was dependent on the signaling adapter molecule 
MyD88. Treatment of wild-type mice with a TLR7-TLR9 inhibitor inhibited the response, 
implicating these TLRs in the process. In lupus-prone mice, the same tape-stripping 
procedure led to chronic wounds with a type I interferon signature that resembled SLE 
skin lesions. Therefore, detection of DNA and RNA by TLR9 and TLR7 is important for 
normal wound healing. Dysregulation of this pathway in SLE likely contributes to 
autoimmune inflammation, especially in the skin, and is a potential target for therapeutic 
intervention.  
3. Regulation of TLR9  
3.1 Compartmentalization of TLR9 
Infectious agents replicate in various locations outside and inside cells. Bacteria and 
viruses are internalized into endosomes, and some can escape into the cytoplasm. 
Therefore, positioning of TLRs is important for detecting components of microbes in the 
varied locations where they can reside. Some TLRs, such as TLR2, TLR4, and TLR5, are 
expressed at the cell surface to detect ligands expressed on the surface of bacteria 
(lipopolysaccharide, TLR4; lipopeptides, TLR2; and flagellin, TLR5). However, nucleic 
acids, such as DNA and RNA, are encapsulated within bacteria and viruses, and are only 
released upon internalization into endosomes. To accommodate this, nucleic acid sensing 
TLRs are localized intracellularly. For example, TLR9 is primarily found in the 
endoplasmic reticulum (ER) of resting cells (Latz, et al. 2004; Leifer, et al. 2004) where it 
colocalizes with ER, and not endosomal, markers. Since detection of DNA occurs in 
endosomes, these data suggest that that there is an induced trafficking event that leads to 
TLR9 entry into this compartment (Leifer, et al. 2004). The unique compartmentalization 
of nucleic acid-sensing TLRs has been proposed as a major regulatory mechanism to 
prevent response to host DNA (Barton, et al. 2006). Fusion of the ectodomain of TLR9 
with the transmembrane domain and cytoplasmic tail of TLR4 created a protein that 
localized to the cell surface. This change in localization endowed the TLR9 ectodomain 
with the ability to respond to host DNA (Barton, et al. 2006). These data support a model 
where TLR9 is specifically trafficked intracellularly to avoid access to the extracellular 
milieu, thereby preventing recognition of host DNA.   
3.2 Trafficking of TLR9 through the Golgi to localize in the endolysosomes 
While TLR9 predominantly resides in the ER it must traffic to the endosomal compartment 
where it encounters endocytosed CpG DNA (Latz, et al. 2004; Leifer, et al. 2004) (Figure 2). 
Normally, transmembrane or secreted proteins synthesized in the ER traffic through the 
Golgi to access the cell surface or intracellular endosomes. However, TLR9 was sensitive to 
endoglycosidase H (endo H) treatment, which indicated that TLR9 had not reached the 
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Golgi (Latz, et al. 2004). In 2009 Chockalingam et al., showed that Brefeldin A inhibited 
TLR9 response to CpG DNA (Chockalingam, et al. 2009). Since Brefeldin A is a small 
molecule that inhibits transport of proteins from ER to Golgi, TLR9 signaling appeared to be 
dependent on Golgi trafficking.  
When proteins traffic through the Golgi, the high mannose glycans are processed to 
hybrid forms that are still cleaved by Endo H; therefore, highly specific lectins were used 
to determine whether TLR9 had glycan modifications indicative of Golgi transit 
(Chockalingam, et al. 2009). Lectins are plant proteins that selectively recognize 
carbohydrate structures. For example, Datura stramonium (DS) lectin specifically 
recognizes “Galβ1→4GlcNac” structures present only on proteins that have been 
processed by Golgi resident enzymes. DS lectin bound to TLR9, which confirmed that 
TLR9 trafficked through the Golgi during synthesis (Chockalingam, et al. 2009). TLR9 
immunoprecipitated from the lysosomal compartment of HEK293 cells also bound DS 
lectin, and co-immunoprecipitated with the signaling adapter MyD88 (Chockalingam, et 
al. 2009). These data indicated that lysosomal TLR9 had transited through the Golgi and 














Fig. 2. Regulation of TLR9 trafficking. After synthesis in the ER TLR9 associates with gp96. 
TLR9 traffics out of the ER to the Golgi in a manner dependent on gp96, PRAT4A, and 
UNC93B1. TLR9 traffics from the Golgi to a sorting vesicle in an AP3 dependent manner 
where it is then sorted to the endosomal compartment via a cytoplasmic tyrosine motif. In 
the endosomal compartment TLR9 is proteolytically processed either active or negative 
regulatory forms that modulate TLR9 signaling. Lack of gp96 prevents TLR9 proteolytic 
processing. 
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Golgi (Latz, et al. 2004). In 2009 Chockalingam et al., showed that Brefeldin A inhibited 
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Fig. 2. Regulation of TLR9 trafficking. After synthesis in the ER TLR9 associates with gp96. 
TLR9 traffics out of the ER to the Golgi in a manner dependent on gp96, PRAT4A, and 
UNC93B1. TLR9 traffics from the Golgi to a sorting vesicle in an AP3 dependent manner 
where it is then sorted to the endosomal compartment via a cytoplasmic tyrosine motif. In 
the endosomal compartment TLR9 is proteolytically processed either active or negative 
regulatory forms that modulate TLR9 signaling. Lack of gp96 prevents TLR9 proteolytic 
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3.3 Proteins that regulate intracellular localization and trafficking 
Several proteins are critical for TLR9 trafficking both out of the ER and to the endosomal 
compartment (Figure 2): UNC93B1, adapter protein 3 (AP3), a protein associated with TLR4 
(PRAT4A), Slc15a4, and glycoprotein 96 (gp96, also known as glucose regulated protein 94 
(gp94). Recessive N-ethyl-N-nitrosourea-induced mutagenesis revealed a mouse line that 
lacked response to TLR3, TLR7, and TLR9 ligands. These mice had a single point mutation 
(H412R) in UNC93B1 (Tabeta, et al. 2006). In dendritic cells from these mice, TLR7 and TLR9 
did not localize to the endosomal compartment (Kim, et al. 2008). Interestingly, UNC93B1 
seems to play opposing roles in regulation of TLR7 and TLR9 (Fukui, et al. 2009). 
Reconstitution of UNC93B1 deficient cells with UNC93B1 containing a single point mutation 
(D34A) resulted in hyperresponsivenss to TLR7, yet hyporesponsiveness to TLR9, ligands. 
Therefore, the role of UNC93B1 in regulation of nucleic acid sensing TLRs is clearly 
important and interfering with UNC93B1 function has different effects on signaling by 
different TLRs. 
Two ER luminal proteins, gp96 and PRAT4A, are essential for TLR9 exit from the ER. 
PRAT4A, also known as CNPY3, bound to TLR9, which depended on methionine 145 of 
PRAT4A (Kiyokawa, et al. 2008). In the absence of PRAT4A, TLR9 did not access 
endosomes, and PRAT4A deficient cells lacked response through all TLRs, except TLR3 
(Takahashi, et al. 2007). The heat shock protein gp96 also bound to TLR9 and was required 
for B cell and macrophage response to CpG DNA (Randow & Seed, 2001; Yang, et al. 2007). 
A pre-B cell line with a frame-shift mutation in gp96 was 10,000 times less sensitive to LPS 
then the non-mutant line, which was due to a lack of TLR4 on the cell surface (Randow & 
Seed, 2001). This study suggested that gp96 regulated trafficking of TLRs. Further studies 
using a mouse with macrophage specific knockout of gp96 showed that gp96 is essential for 
TLR9 trafficking and signaling, and was in fact a chaperone for all TLRs except TLR3 (Liu, et 
al. 2010; Yang, et al. 2007). In 2011 Liu et al., demonstrated that gp96 and PRAT4A directly 
interacted to form a multimeric complex with TLR9 (Liu, et al. 2010). Very recent studies 
using gp96 specific inhibitors have examined the role of gp96 after TLR9 synthesis and 
trafficking is complete. These studies show that gp96 remains associated with TLR9 in the 
endosomal compartment and that specific inhibitors block CpG DNA signaling and cause a 
loss of TLR9 protein (JC Brooks and CA Leifer unpublished observations). This suggests that 
gp96 has an additional function in regulating the conformational stability of TLR9 in the 
endosomal compartment.   
Cytoplasmic proteins are also important for TLR9 trafficking. Plasmacytoid DCs from 
adapter protein 3 (AP3) deficient mice failed to induce a type I interferon response after 
CpG DNA stimulation despite normal IL-12 production (Sasai, et al. 2010). AP3 is a 
cytosolic protein that associates with endosomes and sorts transmembrane proteins from 
the endosomal compartment to lysosome-related organelles (Bonifacino & Traub, 2003).  
In the absence of AP3, TLR9 did not colocalize with markers for lysosome-related 
organelles (Sasai, et al. 2010). This group suggested that it was these lysosome-related 
organelles that were critical for induction of type I interferons (Sasai, et al. 2010). 
However, this conclusion contradicts previously published studies showing that initiation 
of signaling that results in type I interferon production occurs on early endosomes 
(Guiducci, et al. 2006; Honda, et al. 2005). In a separate study using the same AP3 
deficient mice, both proinflammatory and type I interferon production were lost. 
Therefore, AP3 is important for TLR9-induced cytokine production, but its exact role in 
TLR9 biology remains unclear. 
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Recent data have shown that TLR9 signaling also depends on Slc15a4, a twelve-spanning 
transmembrane oligopeptide transporter that localizes to the endolysosomal compartment 
(Blasius, et al. 2010; Yamashita, et al. 1997). Cells from Slc15a4 deficient mice lack response 
to nucleic acid sensing TLRs (Blasius, et al. 2010). Again, the specific role of Slc15a4 remains 
unknown, but may involve endolysosomal transport of TLR9 or a TLR9-associated protein 
required for TLR9 function.  
3.4 Specific motifs in TLR9 that regulate localization and trafficking 
Localization of TLRs is regulated by sequences in their transmembrane domains and 
cytoplasmic tails. Fusion of TLR4 to the transmembrane and cytoplasmic tail of various 
TLRs resulted in distinct localizations of the chimeric proteins (Nishiya & DeFranco, 2004). 
For example, TLR4 by itself localized to the cell surface, and fusion of TLR4’s ectodomain 
with the transmembrane and cytoplasmic tail of TLR1, TLR2, TLR5, or TLR6 resulted in 
similar localization. In contrast, when TLR4 was fused to the transmembrane and 
cytoplasmic tail of any of the nucleic acid-sensing TLRs, the resulting chimeric receptor was 
not detected at the cell surface. Further studies using different approaches identified 
different motifs in TLR9 responsible for this localization (Barton, et al. 2006; Leifer, et al. 
2006). TLR9’s ectodomain fused to TLR4’s transmembrane and cytoplasmic domains 
localized to the cell surface (Barton, et al. 2006). The chimera retained the ability to respond 
to CpG DNA, yet was resistant to endosomal acidification inhibitors. Interestingly, TLR9 
associates with UNC93B1 via the transmembrane domain and this may explain, in part, the 
requirement for this association in TLR9 signaling.  
The cytoplasmic tail of TLR9 also contains a specific localization motif (Leifer, et al. 2006). In 
this study, the ectodomain of the IL-2 receptor alpha chain, which normally localized to cell 
surface, was fused to the transmembrane and cytoplasmic tail of different TLRs (Leifer, et al. 
2006). A fusion with the TLR4 transmembrane and cytoplasmic tail localized to the cell 
surface; however, a fusion with the same regions of TLR9 was not. Truncation analysis 
revealed that deletion of all but four amino acids of the cytoplasmic tail generated a protein 
that was robustly expressed at the cell surface, ruling out a contribution of the 
transmembrane domain to intracellular localization. It is unclear why these two studies 
showed opposite requirements for TLR9 transmembrane domain. Regardless, additional 
truncations and mapping identified a 14 amino acid motif that was important for TLR9 
intracellular localization. Follow-up studies showed that mutation of a critical tyrosine (888) 
within this motif abolished proinflammatory cytokine production. Interestingly, this mutant 
maintained normal interferon responses suggesting that this motif was required for 
trafficking TLR9 to the compartment selectively required for induction of proinflammatory 
cytokines (A Chockalingam and CA Leifer unpublished observations). It remains to be 
determined if this motif is necessary for association with AP3 or other regulatory proteins. 
3.5 Proteolytic regulation of TLR9 
In addition to trafficking to specific endocytic compartments, several recent studies have 
demonstrated that TLR9 is proteolytically processed in endosomes and that this processing 
regulates TLR9 function (Chockalingam, et al. 2011; Ewald, et al. 2011; Ewald, et al. 2008; 
Park, et al. 2008; Sepulveda, et al. 2009). The ectodomain of TLR9 contains 25 leucine rich 
repeats. The first 14 and the second 15 leucine-rich repeats are interrupted by a region 
predicted to have very little secondary structure, often referred to as the hinge (Bell, et al. 
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Recent data have shown that TLR9 signaling also depends on Slc15a4, a twelve-spanning 
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trafficking TLR9 to the compartment selectively required for induction of proinflammatory 
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3.5 Proteolytic regulation of TLR9 
In addition to trafficking to specific endocytic compartments, several recent studies have 
demonstrated that TLR9 is proteolytically processed in endosomes and that this processing 
regulates TLR9 function (Chockalingam, et al. 2011; Ewald, et al. 2011; Ewald, et al. 2008; 
Park, et al. 2008; Sepulveda, et al. 2009). The ectodomain of TLR9 contains 25 leucine rich 
repeats. The first 14 and the second 15 leucine-rich repeats are interrupted by a region 
predicted to have very little secondary structure, often referred to as the hinge (Bell, et al. 
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2003). The first described proteolytic event was mapped to this hinge region through a mass 
spectrometric approach (Park, et al. 2008). The form of TLR9 generated encompasses one-
half of the ectodomain and all of the transmembrane and cytoplasmic tail (Figure 3). This 
proteolytic event is inhibited by endosomal acidification inhibitors and by broad-spectrum 
cathepsin inhibitors (Ewald, et al. 2008; Park, et al. 2008). Additional studies with specific 
cathepsin inhibitors, and in cathepsin deficient mice, did not reveal a unique cathepsin 
responsible for the cleavage. An independent study, showed an additional proteolytic event 
(Sepulveda, et al. 2009). While this study did not reveal the precise location of the 
proteolysis, a specific enzyme, asaparagine endopeptidase was shown to be important. A 
more recent study suggested that stepwise processing of TLR9 is required to attain fully 
functional proteolytically processed TLR9 (Ewald, et al. 2011). Interestingly, knockdown of 
either PRAT4A (CNPY3) or gp96 by shRNA targeting resulted in a loss of proteolytic 
processing of TLR9, and suggested that these chaperones were required for TLR9 to access 
endosomes (Liu, et al. 2010).  
 
 
Fig. 3. Proteolytic processing of TLR9. The ectomain of TLR9 is proteolytically processed 
into two forms. The first form is active and consists of one half of the ectodomain of TLR9 
and the transmembrane and cytoplasmic tail (amino acids 471-1032) The second form is a 
negative regulator of TLR9 signaling and consists of almost the entire ectodomain with no 
transmembrane or cytoplasmic tail. This form, called soluble TLR9, is released into 
endosomes, but is not secreted. By binding to internalized DNA, and to full-length TLR9, 
this form blocks signaling. The relative ratio of these two fragments likely determines the 
cellular response upon exposure to DNA.  
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TLR9 is also proteolytically processed at a completely different position to generate a 
negative regulator of TLR9 signaling (Chockalingam, et al. 2011). This proteolytic event 
resulted in generation of an intact ectodomain separated from the transmembrane domain 
and cytoplasmic tail (Figure 2). This soluble form of TLR9 bound to CpG DNA, associated 
with full length TLR9, and dominant negatively inhibited responses by the full-length 
receptor (Chockalingam, et al. 2011). In contrast to the other proteolytic cleavage events, 
generation of soluble TLR9 occurred in cells expressing endogenous TLR9 (Chockalingam, 
et al. 2011). Soluble TLR9 is likely important in regulating TLR9 responses since intestinal 
epithelial cells poorly responded to CpG DNA, and abundantly generated soluble TLR9 
(Chockalingam, et al. 2011). Therefore, correlative studies on TLR9 in different 
pathological conditions must account for the complexity of TLR9 post-translational 
modification.  
4. Conclusion  
In this review we have highlighted recent studies describing regulatory mechanisms 
governing nucleic acid-sensing TLRs. While TLRs are critical for host defence against 
infection, some TLRs recognize ligands shared between infectious agents and the host 
(Marshak-Rothstein & Rifkin, 2007). Despite complex regulatory mechanisms, these TLRs do 
contribute to autoimmune disease (Marshak-Rothstein, 2006). Recent studies have revealed 
multiple post-translational mechanisms that regulate this family of TLRs, and if 
dysregulated could also contribute to the development of autoimmune disease. By 
exploiting mechanisms that control nucleic acid sensing TLRs we will relieve TLR-mediate 
autoimmune inflammation.  
Host DNA and RNA are not typically inflammatory since there are several regulatory 
mechanisms to prevent availability of host DNA. These include preventing its release 
(apoptosis), and degrading it once it is released (DNase). Association with various host 
proteins such as HMGB1, LL37, and autoantibodies stabilize host DNA and enhance its 
uptake where it gains access to intracellular nucleic acid sensing TLRs (Lande, et al. 2007; 
Leadbetter, et al. 2002; Tian, et al. 2007). When this occurs, especially by anti-nuclear 
antibodies, host DNA and RNA enhance type I interferon production from dendritic cells 
and promote proliferation and antibody production from B cells. Defects in expression of 
the nucleic acid stabilizing proteins changes susceptibility to autoimmunity in mouse 
models. Development of drugs that block stabilization of DNA by these host proteins, and 
thereby block proinflammatory or interferon responses, will reduce autoinflammation and 
offer new ways to treat SLE.  
The nucleic acid-sensing TLRs are also carefully regulated to avoid response to host DNA. 
To avoid detection of host DNAs and RNAs, nucleic acid-sensing TLRs are excluded from 
the cell surface (Latz, et al. 2004; Leifer, et al. 2004). Several proteins including UNC93B1, 
and gp96 regulate nucleic acid-sensing TLR access to endosomes (Kim, et al. 2008; Yang, et 
al. 2007). Specific parts of TLR9 have been found to be important for this regulation and may 
interact with some of the localization regulators (Barton, et al. 2006; Leifer, et al. 2006). 
Development of drugs that affect the activity of these proteins would change the 
intracellular distribution of TLRs, thereby affecting the ability of these receptors to detect 
and respond to nucleic acids. 
Once nucleic acid-sensing TLRs do reach endosomes, they are proteolytically processed 
(Chockalingam, et al. 2011; Ewald, et al. 2008; Park, et al. 2008), which modifies their 
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al. 2007). Specific parts of TLR9 have been found to be important for this regulation and may 
interact with some of the localization regulators (Barton, et al. 2006; Leifer, et al. 2006). 
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Once nucleic acid-sensing TLRs do reach endosomes, they are proteolytically processed 
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function. Cleavage at two different locations within the ectodomain leads to either activation 
(Ewald, et al. 2008; Park, et al. 2008), or inhibition (Chockalingam, et al. 2011), of TLR9 
activity. Specific identification of the enzymes responsible for these proteolytic events will 
provide new targets for drug development to interfere with TLR signaling and response to 
host DNA.   
When host DNA, or RNA, does activate a TLR, it induces robust inflammation and 
production of pathologic levels of cytokines such as type I interferon. While several 
contributing factors to the development of SLE have been found, new data on post-
translational regulation of nucleic acid-sensing TLRs show that we still have much to learn. 
Dysregulation in any of these regulatory proteins will change the intracellular localization of 
TLR9 and could potentially lead to aberrant response to host nucleic acids. Identifying these 
regulatory pathways is the first step to understanding how defects in these pathways lead to 
disease. Specifically targeting these regulatory proteins within these pathways will reduce, 
or restore, function as necessary to return the regulatory networks to the non-disease state. 
Therefore, future studies should be focused on improving our understanding of the basic 
regulatory networks for nucleic acid-sensing TLRs so that we may determine which are 
defective in SLE. Our hope is that these studies will lead to novel drug development, and 
improve our repertoire of options to treat autoimmune disease.   
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1. Introduction  
SLE is the classical model of a chronic multi-systemic immune-mediated inflammatory 
disease. It affects mainly young women, a subgroup of the general population usually free 
of cardiovascular risk.  Although survival rates have improved dramatically, mainly due to 
early diagnosis, improved treatment, and better management of complications, death rates 
for patients with SLE remain 3 to 5 times higher than in the general population (Haque & 
Bruce, 2009). Nevertheless, whilst the 5-year survival of SLE was below 50% in the 1950s, it 
is nowadays above 90% (Nikpour et al., 2005).  
Atherosclerosis in SLE is a highly complex process with autoimmunity, local and systemic 
inflammation, and endothelial dysfunction playing critical roles in its initiation and 
propagation. In the particular case of SLE, the extremely intricate immune system 
deregulation involving all types of immune cells up to an increased autoantibody 
production seems to play a major role for the accelerated atheroma formation found in these 
patients.  
Cardiovascular events are now the major cause of morbidity and mortality in SLE. The 
acceptance of the importance of vascular risk in this context came from the description of a 
bimodal mortality pattern (Urowitz et al., 1976), with the early peak (within 1 year of 
diagnosis) as a consequence of active lupus and its complications, and the later peak (more 
than 5 years after diagnosis) mainly attributable to atherosclerosis. SLE is now considered to 
be a coronary heart disease-risk equivalent, mainly due to accelerated atherosclerosis 
(Aranow & Ginzler, 2000; Bjornadal et al., 2004; Manzi et al., 1997; Esdaile et al., 2001; 
Fischer et al. 2004; Roman et al., 2003; Ward, 1999).  This can be especially relevant in young 
women, where up to a 50-fold increase in cardiovascular risk over age and gender-matched 
controls has been reported (Manzi et al., 1997). In fact, the majority of those women were 
aged less than 55 years at the time of their first cardiac event.  
Framingham risk factors do not explain entirely the atherosclerotic burden found in  
patients with SLE. Furthermore, traditional cardiovascular risk factors seem to be less 
important predictors of cardiovascular events than the activity of lupus (Esdaile et al., 2001). 
(see table 1). 
The direct relation between conventional and SLE-related risk factors and the actual 
incidence of events has not been easy to establish for different reasons: most patients with 
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SLE are young or middle-age women, for whom the background rate of cardiovascular 
disease is low, SLE cohorts are small, the number of observed coronary heart disease events 
is also reduced, and may not provide statistical power for testing their associations with 
hypothetical SLE-specific risk factors ( Karp et al., 2008). This is the main reason why recent 
studies are considering surrogate markers of cardiovascular risk, such as the presence of 
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Increased oxidative stress 
Table 1. Proposed cardiovascular risk factors in SLE 
Both SLE-specific and non-specific mechanisms have been proposed to play a prominent 
role in the induction of premature vascular damage, but the exact etiology remains unclear. 
Chronic inflammation is a very appellative contributor for atherosclerosis, since the 
pathogenesis of the latter is, in part, mediated by inflammation (Ross, 1999). 
A potential confounding factor is that clinically active lupus may also manifest itself with 
vascular inflammation and thrombosis in any vascular territory. However, when a 
significant large population is considered, premature vascular disease in SLE is not, as 
previously thought, just attributable to vasculitis. Actually, it presents mostly as premature 
atherosclerosis (Bacon et al., 2002; Ward, 1999), both clinically and histologically. Many 
authors believe that the rapid and progressive nature of vascular injury in patients with SLE 
makes this population ideal for the identification of mechanisms involved in general 
atherosclerosis and vascular damage.  
This chapter aims at elucidating why patients with SLE are at high risk for cardiovascular 
events, what different types of vascular conditions may be more commonly found, and what 
treatments are more likely to help overcome such burden. 
2. Burden of disease   
Despite the fact that the overall survival of patients with SLE has reached over 90% in recent 
decades, the long term survival rate has not changed since the 1980s (Petri, 2002). SLE patients 
have mortality rates of 5-10% at 5 years and 15-30% at 10 years (Abu-Shakra et al., 1995; 
Jacobsen et al., 1998; Ståhl-Hallengren et al., 2000; Uramoto et al., 1999). This is particularly 
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overwhelming in patients aged less than 55 years (Abu-Shakra et al., 1995). After the 
identification of the bimodal pattern of mortality in SLE, a more recent uptade from the 
Toronto group (Nikpour, 2005) showed that sudden death, congestive heart failure and 
vascular events are responsible for nearly 30% of late deaths in their SLE cohort. Currently, 
cardiovascular disease alone accounts for 20 to 30 % of deaths in patients with SLE (Rubin et 
al., 1985). Even with all-cause mortality declining during the last 20 years the risk of 
cardiovascular death remains unchanged. With the advent of more potent 
immunosuppressive and anti-inflammatory treatments, it is likely that the contribution of 
cardiovascular disease to morbidity and mortality in these patients will increase even further. 
Using myocardial perfusion scintigraphy, subclinical coronary atherosclerosis can be 
present in 28-38% of patients with SLE (Manger et al., 2003; Sella et al., 2003) and the 
prevalence of symptomatic coronary heart disease (as defined by angina and myocardial 
infarction) ranges from 6,6% to 20% (Gladman & Urowitz, 1987; Jonsson et al., 1989; Manzi 
et al., 1997) . Women with SLE in the 35-44 year age group are over 50 times more likely to 
have a myocardial infarction than women of similar age in the Framingham Offspring Study 
(Manzi et al., 1997). The mean age at a first coronary event is 49 years in patients with SLE 
compared with 65-74 years in the general population, as the risk of development of coronary 
heart disease in the first decade after diagnosis is approximately 12% (Bruce et al., 1999).  
There are significant racial disparities regarding age at the time of first hospital admission 
for a cardiovascular event and cardiovascular-related hospitalization resulting in death in 
patients with SLE (Scalzi et al., 2010). African-origin, in particular, is associated in an 
independent fashion with a worsened probability of survival.  
The outcomes of hospitalization for acute myocardial infarction were thought to be identical 
between patients with and without SLE, despite women with SLE being less likely to 
undergo coronary artery bypass grafting (Ward, 2004).  Whether this is due to a decreased 
need for the procedure or whether reflects a decreased referral or reduced access to the 
surgery, is not established. More recently it has been recognized that, like diabetes mellitus, 
SLE increases the risk of poor outcomes after acute myocardial infarction, and these patients 
should be considered for aggressive treatment. In fact, the risk for prolonged hospitalization 
is even higher for patients with SLE (OR 1.48, 95% CI 1.32-1.79) compared to those with 
diabetes mellitus (OR 1.30, 95% CI 1.28-1.32) (Shah et al., 2009). 
Cerebrovascular disease has been identified in 2-15% of patients with SLE (Hermosillo-
Romo & Brey, 2002; Manzi et al., 1999; Mok et al., 2001; Sanna et al., 2003), with a reported  
2-10 times higher risk for stroke SLE (Jonsson et al., 1989; Manzi et al., 1997; Ward, 1999). A 
recent prospective study showed that the cumulative incidence of arterial thromboembolism 
in new-onset Caucasian SLE patients is 5,1%, with ischemic stroke and transient ischemic 
attack comprising 65% of them (Mok et al., 2005) . Cardiovascular risk is even higher in 
lupus patients who also have secondary antiphospholipid syndrome (APS), due to the 
additive effects of SLE- and APS-related risk factors. In fact, as APS is also related to 
accelerated atherosclerosis, it may be difficult to differentiate between SLE- and APS-
associated risk factors in these patients. 
3. Vascular disease in systemic lupus erythematosus 
3.1 Atherosclerosis  
3.1.1 Epidemiology 
In cross-sectional studies, approximately one-third of patients with SLE has evidence of 
subclinical atheroma plaques in the carotid or coronary arteries (Asunuma et al., 2003) and 
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autopsy findings have showed an even higher prevalence of subclinical atherosclerosis 
(Bulkley & Roberts, 1975). More than 20% of SLE patients who had been on steroids for 
more than one year before death had a 50% occlusion of at least one major coronary artery. 
In a cohort of women with SLE, in whom 15% had already a cardiovascular event, 40% had 
at least one focal carotid artery plaque, a higher frequency than would be expected among 
healthy women (Manzi et al., 1999). Not surprinsingly, the common carotid intima-media 
thickness (IMT) of patients with a history of cardiovascular disease is greater than that of 
SLE patients who had no such history and of healthy volunteers controls (Svenungsson et 
al., 2001). Using photon emission computed tomography (SPECT) and dual isotope 
myocardial perfusion imaging (DIMPI), 40% of all women with SLE and 35% of women 
with SLE and no history of coronary artery disease had abnormalities in myocardial 
perfusion, reinforcing the idea of a high prevalence of early coronary artery disease (Bruce 
et al., 2000).  Also, coronary-artery calcification, as detected by electron-beam computed 
tomography (Roman et al., 2003), occurs more frequently and at a younger age in patients 
with SLE than in healthy controls. Aortic stiffness overall and at any level of the aortic artery 
was higher in patients with SLE than in controls, even after adjusting for age (Roldan et al., 
2010). Furthermore, increased aortic stiffness seems to be an early manifestation of lupus 
vasculopathy that seems to precede the development of hypertension and atherosclerosis. 
Whether we consider the SLE context or not, better biomarkers for measuring disease 
burden are needed. They should be non-invasive, have a good sensitivity and specificity, 
predict disease in asymptomatic individuals and be available for widespread application.  
In clinical practice, diagnosis of atherosclerosis is usually made after the presence of 
symptoms. Pre-symptomatic screening could identify subclinical disease, allowing for a 
more aggressive treatment of the different atherothrombotic risk factors.  
3.1.2 Atheroma formation  
Atherosclerosis is not an age-related process with passive accumulation of lipids in the 
vessel wall. It must be understood as a dynamic and complex biochemical and anatomical 
process. It is characterized by changes in lipoprotein metabolism, activation of the 
immune system and consequent proliferation of smooth-muscle cells, atheroma formation 
and arterial narrowing. In atheroma formation, inflammation and autoimmunity are at 
the forefront of the initiation, progression, and rupture of the plaque (Libby et al., 2010; 
van Leuven et al., 2008). Patients suffering from chronic inflammatory diseases have 
accelerated atherosclerosis, and the high level of inflammation to which patients with 
auto-immune diseases are exposed may induce and accelerate endothelial cell injury. 
Furthermore, biomechanic shear forces enhanced by classic cardiovascular risk factors, 
such as hypertension, hypercholesterolemia, diabetes and smoking are known to 
contribute to endothelium dysfunction (Ando & Yamamoto, 2011). In fact, the earliest 
manifestation of atherothrombosis can be the result of a single disturbance on the 
physiologic pattern of blood flow at an arterial bending on bifurcation site. 
Endothelium regulates anti-inflammatory, mitogenic and contractility activities of the 
vessel wall; also, it has a role in the the hemostatic process within the vessel lumen. A 
dysfunctional endothelium is characterized by an increase in oxidative stress. It facilitates 
oxidation, the uptake of circulating lipoproteins by monocytes, and the migration of these 
cells to the vessel wall, resulting in the proliferation of smooth muscle cells. The 
expression of adhesion molecules (such as ICAM and VCAM) induces the binding of 
monocytes to the endothelial wall (Lusis, 2000). This, when submitted to shear stress 
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forces is also susceptible to permeation and subendothelial accumulation of 
apolipoprotein-B-containing lipoproteins, such as low density lipoproteins (LDL) and 
remnant lipoproteins,  that become targets for oxidative and enzymatic attack. After 
monocyte-endothelial binding takes place, the blood cells are internalized and 
differentiated into macrophages. Retained pro-atherogenic LDL leads to an enhanced 
selective leukocyte recruitment and attachment to the endothelial layer, further 
contributing to their transmigration across the endothelium into the intima. Lipoprotein 
uptake promotes the accumulation of lipid droplets in the cytoplasm of the macrophages, 
transforming them into foam cells. The consequent inflammatory response leads to the 
recruitment of more monocytes, T cells, mast cells and neutrophiles. A fibrous cap is 
produced by collagen secreting myofibroblasts that populate the intima, and the 
developing lesion is contained, most of the times, by a fibrous cap. At the beginning, the 
atherosclerotic lesions are asymptomatic and not at risk for rupture and induction of 
thrombosis. Atheroma lesions submitted to a chronic inflammatory state will become 
unstable and may result in an acute vascular event (Virmani et al., 2002). Within those 
plaques, apoptotic macrophages will suffer necrosis and perpetuate inflammation, with 
the formation of necrotic cores. These vulnerable or unstable plaques may rupture, 
exposing pro-coagulant and pro-thrombogenic molecules into the intima and initiating 
platelet activation and aggregation. This, in turn, will lead to thrombosis and to the 
clinical manifestation of atherothrombotic disease.  
Inflammation plays a major role during all stages of atherosclerosis: endothelial 
dysfunction, endothelial and cytokine activation, recruitment of inflammatory cells, 
macrophage uptake of oxidized low-density lipoprotein (oxLDL), development of fatty 
streaks and fibrous plaque, and finally plaque rupture. Being so, it becomes obvious why 
SLE and atherosclerosis are so closely related. 
3.1.3 Lipids and humoral response towards lipoproteins 
Lipid abnormalities are one of the major contributors for atherosclerosis in SLE and different 
patterns of dyslipoproteinemia have been reported in this disease (Ilowite et al., 1988; 
Svenungsson et al., 2003). Dyslipoproteinemia in active lupus is characterized by depressed 
high density lipoprotein cholesterol and apolipoprotein A1 (ApoA1) with elevated very low 
density lipoprotein cholesterol (VLDL) and triglyceride; on the other hand, the 
dyslipoproteinemia associated with corticosteroid treatment is characterized by increased 
total cholesterol, VLDL, and triglycerides. The pattern of dyslipoproteinemia typical of SLE 
is closely related to disease activity. An enhanced activity in the TNFalpha/soluble TNF-
receptor system seems to be an important underlying factor (Svenungsson et al., 2003). 
Oxidative stress is also a key factor in atherogenesis, and it is increased in patients with SLE. 
Interactions between anticardiolipin (aCL) antibodies and anti-oxidant endothelial cells 
antibodies with the production of pro-oxidant substances suggestes that the interactive 
mechanisms linking plasma lipoproteins, the immune system, and the endothelium are one 
of the missing links that can unveil atheroma plaque formation in SLE. Oxidation profile in 
SLE is reflection of a pro-oxidant status and the presence of aCL antibodies is just one of the 
potential contributors. A direct effect of aCL antibodies with endothelial cells (inducing 
inducible nitric oxide synthase expression) leads to an enhanced peroxynitrite synthesis, a 
pro-oxidant substance, associated with vascular dysfunction and atherogenesis (Delgado 
Alves et al., 2005). 
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forces is also susceptible to permeation and subendothelial accumulation of 
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The primary lipid components involved in atherosclerosis are lipoproteins. Among these, 
low-density lipoprotein (LDL) and high-density lipoprotein (HDL) assume a central role. 
HDL are thought to have an anti-atherothrombogenic effect by stimulating endothelial nitric 
oxide and inhibiting oxidative stress and inflammation (Yuhanna et al., 2001), thus 
preventing LDL oxidation. LDL is the most pro-atherogenic lipoprotein, due to its ability to 
capture free radicals becoming itself a powerful pro-oxidant. HDL-associated ApoA1 has 
known anti-inflammatory properties (Ashby et al., 1998; Hyka et al., 2001) by promoting 
reverse cholesterol transport from macrophages in vivo as well as by blocking contact 
mediated activation of monocytes by T lymphocytes. Its anti-atherosclerotic actions is also 
associated with the stabilization of  paraoxonase  (James & Deakin, 2000). Paraoxonase is an 
anti-oxidant enzyme that prevents the formation of lipid peroxidation products, such as 
oxLDL. Higher paraoxonase activity is associated with a lower incidence of cardiovascular 
events (Soran et al., 2009).  
HDL has several other antiatherogenic properties, including the transport of cholesterol 
from peripheral tissues to the liver. The concept that macrophage-cholesterol efflux has a 
significant role in cardiovascular disease prevention was recently suggested by the finding 
of a strong inverse association between HDL-mediated cholesterol efflux from macrophages, 
carotid intima media thickness (IMT) and the likelihood of coronary heart disease (Khera et 
al., 2011). These effects were shown to be independent of HDL-cholesterol level. 
Nevertheless, low levels of HDL increase the cholesterol burden and macrophage-driven 
inflammation, being strongly associated with the risk of coronary artery disease. Another  
condition that increases that risk involves the conversion of HDL to a dysfunctional form 
that is no longer cardioprotective (Barter et al., 2004), but instead acquire a pro-
inflammatory and pro-oxidant phenotype promoting atherosclerosis (Delgado Alves et al., 
2002, 2009). Regardless of all these data, the underlying mechanisms are still unclear, and no 
widely accepted methods for determining HDL function have been recognized. Other 
possible mechanisms for HDL dysfunction may be the increased glycation with the 
consequent ApoA1 multimerization and decreased phospholipid content (Parker & Cho, 
2011). This proinflammatory form of HDL (piHDL) has been described in SLE (Navab et al., 
2001) High levels of piHDL increases the risk of developing subclinical atherosclerosis in 
SLE (MacMahon et al., 2009).  
A new concept has merged recently that might account for the higher risk of atherosclerosis 
in SLE: the humoral response towards HDL. It has been confirmed the presence of IgG 
antibodies towards HDL and its main protein component ApoA1 in patients with SLE. By 
interfering with the anti-atherogenic properties of HDL, anti-HDL and ApoA1 antibodies 
enhance oxidative stress and the consequent SLE-related atherosclerotic lesions. Anti-HDL 
antibodies are associated with decreased paraoxonase activity, increased biomarkers of 
endothelial dysfunction (nitric oxide, adhesion molecules VCAM-1 and ICAM-1), reduced 
total antioxidant capacity, and also increased disease-related damage and activity (Batuca et 
al., 2009). Both anti-HDL and anti-apolipoprotein A1 antibodies cross react with aCL. 
Theoretically, anti-HDL and anti-ApoA1 antibodies that cross react with aCL antibodies 
may contribute to endothelial dysfunction by favouring the oxidation of LDL. 
Anti-ApoA1 antibodies have also been described in acute coronary syndromes (Vuilleumier 
et al., 2008), and they be potential markers of plaque instability (Montecucco et al., 2011).   
LDL is the major cholesterol carrying lipoprotein in plasma and may exist in different forms. 
OxLDL injures cells in artery walls, and promotes atheroma formation (Colles et al., 2001; 
Hessler et al., 1979). Small dense LDL, when compared with its larger, normal-size 
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counterpart, is more easily oxidized, has a higher affinity for extracellular matrix, and is 
subject to a higher degree of retention in the arterial wall (Berneis & Krauss, 2002; Hurt-
Camejo et al., 2001; Packard & Sheperd, 1997). Also, smaller LDL has reduced binding to 
LDL receptors (Chapman et al., 1998) and a longer “half-life”. These facts may lead to a 
greater degree of structural modification, which further increases its atherogenic profile. 
In SLE, antibodies to oxidized LDL (anti-oxLDL) have been demonstrated in up to one half 
of patients with SLE (Romero et al., 1998). Also, anti-oxLDL antibody levels correlate with 
complement activation, disease activity scores, anti-double-stranded DNA antibody titres 
(Gómez-Zumaquero et al., 2004)  and were found to facilitate the formation of foam cells( 
Matsuura et al., 2006) 
3.1.4 Inflammation and acute response 
It is already established that inflammation plays a pivotal role in the pathogenesis of 
atherosclerosis. It mediates several of the stages of atheroma development from initial 
leukocyte recruitment to eventual rupture of the unstable atherosclerotic plaque. SLE is 
characterized by a low-grade persistent pro-inflammatory state, present not only during 
flares but also during stable disease. The chronic burden of activated inflammatory 
mediators may have a considerable impact on endothelial cell function and blood 
coagulation. Several inflammatory circulating intermediates in SLE have been identified as 
highly atherogenic, such as IL-1, IL-6, IL-18, monocyte chemotatic protein 1, interferon γ and 
TNFα, among others (Asanuma et al., 2006; Blake &Ridker, 2001; Aringer & Smolen, 2004). 
C-Reactive protein (CRP) is an acute phase protein that plays a major role in the regulation 
of the inflammatory response. It has been implicated in the promotion of both leukocyte 
adhesion and migration and also in vascular endothelial dysfunction by inducing adhesion 
molecules, chemokines and cytokines(Pasceri et al., 2000, 2001). Levels of C-reactive protein 
(CRP) have been shown to be predictive of cardiovascular disease in the general population 
(Ridker et al., 2002). High-sensitivity CRP and ICAM-1 have been associated with increased 
coronary artery calcification in SLE patients (Kao et al., 2008). The interaction of anti-
monomeric CRP with monomeric CRP in blood vessel walls may also contribute to 
development of cardiovascular disease in SLE (O’Neill et al., 2007). 
As compared with other auto-immune diseases, such as rheumatoid arthritis, the magnitude 
of CRP elevation is less important. It has been proposed that the relatively low CRP levels in 
SLE patients can be explained by increased clearance or decreased production of this 
protein. Autoantibodies to CRP in SLE patients support its increased clearance (Bell et al, 
1998; Sjowall et al, 2004); however, the plasma clearance rate of CRP is the same in patients 
with active lupus and normal individuals, which makes this hypothesis less likely (Vigushin 
et al, 1993).  
3.1.5 Insulin resistance and the metabolic syndrome  
The metabolic syndrome is a new defined cluster of risk factors associated with increased 
insulin resistance, higher risk of developing type II diabetes mellitus and cardio and 
cerebrovascular events. It is an independent predictor of cardiovascular morbidity and 
mortality. These risk factors include abdominal obesity, pro-atherogenic dyslipidemia and 
elevated blood pressure. Even though individually these abnormalities may contribute little, 
as a risk-factor cluster it is very important and aggressive treatment should be considered in 
these patients. It is estimated that this syndrome may affect 20-25% of the overall population 
in the United States and the prevalence increases with age (Ford et al., 2002).  
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Insulin resistance is characterized by an impaired response to insulin in several insulin-
sensitive tissue, such as muscle, liver, fat and endothelium (Simonson et al., 2005). Insulin has 
anti-inflammatory properties, mainly due to its ability to suppress several proinflammatory 
transcription factors, such as nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) , early growth response protein 1 (Egr-1) and activator protein 1 (AP-1) (Aliada et al., 
2002). Insulin resistance is a main contributor to the increased cardiovascular risk attributed to 
the metabolic syndrome (Hanley et al., 2002). There is a link between high levels of 
proinflammatory cytokines and cardiovascular disease through metabolic pathways. The exact 
mechanisms linking insulin resistance and inflammation are not fully established. A possible 
candidate is TNF- α. It is over-expressed in the adipose tissues of animal models of obesity 
(Hotamisligi et al., 1993). Adipose tissue act as an endocrine secretory gland, producing 
several inflammatory mediators, responsible for a pro-inflammatory state and thus to an 
increased cardiovascular risk (Després & Lemieux, 2006).   
Tumor necrosis factor-α (TNF-α), IL-1β, IL-4, IL-6, IL-11, Interferon-γ (INF-γ), acting on 
sensitive adipocytes, can lead to the activation of inflammatory signaling cascades (Rajala & 
Sherer, 2003). As a response to fat activation, there is enhanced expression and secretion of 
several acute phase reactants and also mediators of inflammation, such as TNF-α, IL-1β, IL-
6, IL-8, IL- 10, prostaglandin E2 (PGE2). Leptin, adiponectin, and resistin (Fain et al., 2004) 
can  perpetuate in the highly pro-inflammatory state.  
SLE is associated with an increased prevalence of the metabolic syndrome (El-Magdami et 
al., 2006). The frequency of metabolic syndrome amongst patients with SLE varies from 
16,7% in Mexico(Zonana-Nacah e tal., 2008), 28,6 % in Argentina to 29,4 % in USA (Chung et 
al., 2007) and 32,1 % in Brazil (Telles et al., 2010), with other cohorts showing similar results. 
Other metabolic-associated changes such as insulin resistance, premature menopause, renal 
impairment and high triglyceridemia also occur more frequently in SLE. Controversy still 
remains regarding the exact role of metabolic syndrome in predicting long-term risk for 
coronary heart disease in SLE. The major benefit in recognising this syndrome in the context 
of SLE is related to the identification of patients more in need for lifestyle interventions and 
specific therapeutic approach.  
There is no clear association between treatment with steroids and the development of 
metabolic syndrome (Telles et al., 2007. However, prednisone in dosages higher than 10 
mg/ day and high dosages of intravenous methylprednisone has been previously associated 
with this condition (Négron et al., 2008). These findings are still not definitive as they can be 
a reflection of lupus activity and severity. In fact, low-dose steroids may still be of value, 
due to its anti-inflammatory effects. 
3.1.6 Traditional risk factors for cardiovascular disease in SLE  
A patient with SLE and cardiovascular disease has on average one less traditional risk factor 
than people in the general population with a similar cardiovascular condition (Bruce, 2005; 
Urowitz et al., 2007) and the baseline 10-year coronary heart disease and stroke risk (after 
adjusting for Framingham score) for all patients with SLE is 7.5–17-fold higher (Esdaile et 
al., 2001). This is one of the reasons why the relative importance of the individual traditional 
risk factors differs between patients with SLE and the general population. 
Hypertension 
Hypertension is a predictor of mortality and vascular events in SLE (Petri et al., 1992; 
Rahman et al., 2000). It is more common than in the general population with a relative risk 
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of 2.59 (95% CI 1.79–3.75) (Bruce et al., 2003), independently of whatever treatment for SLE 
is being administred. 
Smoking 
Smoking, a well known risk factor for atherosclerosis, is not more frequent in patients with 
SLE than in the general population (RR 0.86, 95% CI 0.59–1.24) (Boyer et al., 2011), but in the 
Systemic Lupus International Collaborating Clinics registry (SLICC) (Urowitz et al., 2008) 
the prevalence of smokers increased from 13.7% at baseline to 18.7%. 
Dyslipidemia  
Hpercholesterolemia in lupus patients is associated with an 18-fold increased risk of 
myocardial infarction as compared with the general population (Fischer et al., 2004).   
Body composition and low physical exercise 
Patients with lupus are more likely to have a sedentary lifestyle, with consequent obesity 
and hypercholesterolemia (Petri et al., 1992). Low physical activity is associated with 
increased subclinical atherosclerosis and proinflammatory HDL levels in patients with SLE. 
Despite the common presence of fatigue as a symptom of the disease, there is reason to 
believe that exercise should be included in the rehabilitation of patients with mild to 
moderate SLE (Yuen et al., 2011). Exercise, if well tolerated, may reduce the risk of 
atherosclerosis in SLE (Volkmann et al., 2010). 
3.1.7 Other risk factors 
Treatment of SLE and its most common co-morbidities has become more and more complex 
with drug interactions and side effects becoming a very important issue. Apart from the 
classical complications of steroid and immunosuppressive treatment, new associations 
between drugs and clinical adverse effects have been identified. Azathioprine, as an 
example, was associated with arterial events (hazard ratio of 1.45 (95% CI 1.21–10.4) (Toloza 
et al., 2004) and with the presence of carotid plaques (Ahmad et al., 2004). Although we 
should keep these results in mind, the fact is that azathioprine is used in more active disease 
and it may be just a surrogate for more severe inflammation.  
Hyperhomocysteinemia is a well known risk factor for cardiovascular disease and it is a 
possible marker of atherosclerosis progression and more-active lupus (Bultink et al., 2005; 
Kianai et al., 2007; Roman et al., 2007). It decreases the availability of endothelial cell-
derived nitric oxide, impairs endothelial-dependent vasodilatation, induces oxidative stress, 
and increases the risk of thrombosis (Maron & Loscalzo, 2009). Homocystein actions on 
endothelial cells are partly mediated by asymmetric dimethylarginine (ADMA), an intrinsic 
inhibitor of nitric oxide synthase (Stuhlinger et al., 2003).  High levels of ADMA have been 
described in patients with renal and heart failure, diabetes mellitus, hypertension, and acute 
coronary events and may predict stroke, coronary artery disease, and also cardiovascular-
related death (Laier et al. 2008; Wilson et al., 2008). Among patients with SLE, higher ADMA 
levels are linked to a higher prevalence of cardiovascular disease.  
Hyperuricemia correlates with arterial stiffness and inflammation markers in patients with 
SLE without symptomatic atherosclerotic disease. It has been showed that women with SLE 
and hyperuricemia have a high risk cardiovascular profile with metabolic syndrome and 
renal failure. 
 
Systemic Lupus Erythematosus 
 
144 
Insulin resistance is characterized by an impaired response to insulin in several insulin-
sensitive tissue, such as muscle, liver, fat and endothelium (Simonson et al., 2005). Insulin has 
anti-inflammatory properties, mainly due to its ability to suppress several proinflammatory 
transcription factors, such as nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) , early growth response protein 1 (Egr-1) and activator protein 1 (AP-1) (Aliada et al., 
2002). Insulin resistance is a main contributor to the increased cardiovascular risk attributed to 
the metabolic syndrome (Hanley et al., 2002). There is a link between high levels of 
proinflammatory cytokines and cardiovascular disease through metabolic pathways. The exact 
mechanisms linking insulin resistance and inflammation are not fully established. A possible 
candidate is TNF- α. It is over-expressed in the adipose tissues of animal models of obesity 
(Hotamisligi et al., 1993). Adipose tissue act as an endocrine secretory gland, producing 
several inflammatory mediators, responsible for a pro-inflammatory state and thus to an 
increased cardiovascular risk (Després & Lemieux, 2006).   
Tumor necrosis factor-α (TNF-α), IL-1β, IL-4, IL-6, IL-11, Interferon-γ (INF-γ), acting on 
sensitive adipocytes, can lead to the activation of inflammatory signaling cascades (Rajala & 
Sherer, 2003). As a response to fat activation, there is enhanced expression and secretion of 
several acute phase reactants and also mediators of inflammation, such as TNF-α, IL-1β, IL-
6, IL-8, IL- 10, prostaglandin E2 (PGE2). Leptin, adiponectin, and resistin (Fain et al., 2004) 
can  perpetuate in the highly pro-inflammatory state.  
SLE is associated with an increased prevalence of the metabolic syndrome (El-Magdami et 
al., 2006). The frequency of metabolic syndrome amongst patients with SLE varies from 
16,7% in Mexico(Zonana-Nacah e tal., 2008), 28,6 % in Argentina to 29,4 % in USA (Chung et 
al., 2007) and 32,1 % in Brazil (Telles et al., 2010), with other cohorts showing similar results. 
Other metabolic-associated changes such as insulin resistance, premature menopause, renal 
impairment and high triglyceridemia also occur more frequently in SLE. Controversy still 
remains regarding the exact role of metabolic syndrome in predicting long-term risk for 
coronary heart disease in SLE. The major benefit in recognising this syndrome in the context 
of SLE is related to the identification of patients more in need for lifestyle interventions and 
specific therapeutic approach.  
There is no clear association between treatment with steroids and the development of 
metabolic syndrome (Telles et al., 2007. However, prednisone in dosages higher than 10 
mg/ day and high dosages of intravenous methylprednisone has been previously associated 
with this condition (Négron et al., 2008). These findings are still not definitive as they can be 
a reflection of lupus activity and severity. In fact, low-dose steroids may still be of value, 
due to its anti-inflammatory effects. 
3.1.6 Traditional risk factors for cardiovascular disease in SLE  
A patient with SLE and cardiovascular disease has on average one less traditional risk factor 
than people in the general population with a similar cardiovascular condition (Bruce, 2005; 
Urowitz et al., 2007) and the baseline 10-year coronary heart disease and stroke risk (after 
adjusting for Framingham score) for all patients with SLE is 7.5–17-fold higher (Esdaile et 
al., 2001). This is one of the reasons why the relative importance of the individual traditional 
risk factors differs between patients with SLE and the general population. 
Hypertension 
Hypertension is a predictor of mortality and vascular events in SLE (Petri et al., 1992; 
Rahman et al., 2000). It is more common than in the general population with a relative risk 
 
Atherogenesis and Vascular Disease in SLE 
 
145 
of 2.59 (95% CI 1.79–3.75) (Bruce et al., 2003), independently of whatever treatment for SLE 
is being administred. 
Smoking 
Smoking, a well known risk factor for atherosclerosis, is not more frequent in patients with 
SLE than in the general population (RR 0.86, 95% CI 0.59–1.24) (Boyer et al., 2011), but in the 
Systemic Lupus International Collaborating Clinics registry (SLICC) (Urowitz et al., 2008) 
the prevalence of smokers increased from 13.7% at baseline to 18.7%. 
Dyslipidemia  
Hpercholesterolemia in lupus patients is associated with an 18-fold increased risk of 
myocardial infarction as compared with the general population (Fischer et al., 2004).   
Body composition and low physical exercise 
Patients with lupus are more likely to have a sedentary lifestyle, with consequent obesity 
and hypercholesterolemia (Petri et al., 1992). Low physical activity is associated with 
increased subclinical atherosclerosis and proinflammatory HDL levels in patients with SLE. 
Despite the common presence of fatigue as a symptom of the disease, there is reason to 
believe that exercise should be included in the rehabilitation of patients with mild to 
moderate SLE (Yuen et al., 2011). Exercise, if well tolerated, may reduce the risk of 
atherosclerosis in SLE (Volkmann et al., 2010). 
3.1.7 Other risk factors 
Treatment of SLE and its most common co-morbidities has become more and more complex 
with drug interactions and side effects becoming a very important issue. Apart from the 
classical complications of steroid and immunosuppressive treatment, new associations 
between drugs and clinical adverse effects have been identified. Azathioprine, as an 
example, was associated with arterial events (hazard ratio of 1.45 (95% CI 1.21–10.4) (Toloza 
et al., 2004) and with the presence of carotid plaques (Ahmad et al., 2004). Although we 
should keep these results in mind, the fact is that azathioprine is used in more active disease 
and it may be just a surrogate for more severe inflammation.  
Hyperhomocysteinemia is a well known risk factor for cardiovascular disease and it is a 
possible marker of atherosclerosis progression and more-active lupus (Bultink et al., 2005; 
Kianai et al., 2007; Roman et al., 2007). It decreases the availability of endothelial cell-
derived nitric oxide, impairs endothelial-dependent vasodilatation, induces oxidative stress, 
and increases the risk of thrombosis (Maron & Loscalzo, 2009). Homocystein actions on 
endothelial cells are partly mediated by asymmetric dimethylarginine (ADMA), an intrinsic 
inhibitor of nitric oxide synthase (Stuhlinger et al., 2003).  High levels of ADMA have been 
described in patients with renal and heart failure, diabetes mellitus, hypertension, and acute 
coronary events and may predict stroke, coronary artery disease, and also cardiovascular-
related death (Laier et al. 2008; Wilson et al., 2008). Among patients with SLE, higher ADMA 
levels are linked to a higher prevalence of cardiovascular disease.  
Hyperuricemia correlates with arterial stiffness and inflammation markers in patients with 
SLE without symptomatic atherosclerotic disease. It has been showed that women with SLE 
and hyperuricemia have a high risk cardiovascular profile with metabolic syndrome and 
renal failure. 
 




In the absence of clinically significant coronary atherosclerosis, two other major mechanisms 
of vascular damage may occur: vasculitis and thrombosis. 
The prevalence of vasculitis in SLE patients ranges from 11% to 20% (Cardinali et al., 2000; 
Wisnieki, 2000). Small vessels (both arteries and venules) of the skin are the most commoly 
involved (Gonzalez-Gay et al., 2005); medium-sized vessel involvement is less frequent 
(D’Cruz et al., 1993), and large vessel involvement is rare (Goldberger et al., 1992). Although 
vasculitis presents mainly as cutaneous lesions, the clinical spectrum is wide, and 
lifethreatening ischemic injury may result from vasculitis of medium-sized vessels in the 
gastrointestinal, cardiac, pulmonary, or cerebrovascular regions (D’Cruz, 1998). 
Coronary vascular damage may be related to coronary arteritis, affecting preferentially 
small-size coronary arteries (Bulkley & Roberts, 1975) or, rarely, the medium-size coronary 
arteries (Bonfiglio et al., 1992); and/ or coronary artery thrombosis. Acute myocardial 
infarction due to coronary arteritis is reported in SLE, although the incidence is very low.  
Immune complex deposition and complement activation play important roles in the 
pathogenesis of vasculitis in general and coronary arteritis in particular. In patients with both 
SLE and antiphospholipid syndrome, microvascular thrombi of the coronary circulation, with 
discrete atherosclerosis and vasculitis, have been observed (Brown et al., 1988).  
The distinction between atherosclerosis and arteritis is a difficult task, because coronary 
vasculitis often occurs in the absence of a clinical SLE flare and also with minimal serologic 
evidence of disease activity (Wilson et al., 1992).  
Central nervous system (CNS) vasculitis in the context of SLE is rare, although it has been 
found in autopsies in SLE in 7-12% of cases (Johnson & Richardson, 1968; Ellis & Verity,  
1979).  
Stroke (both ischaemic and haemorrhagic) and SLE cerebral vasculopathy are far more 
frequent. While ischaemic stroke in SLE is strongly associated to antiphospholipid 
syndrome, atherosclerosis (Bruce, 2005) and Libman-Sacks endocarditis (Moyassaki et al., 
2007), factors that contribute to hemorrhagic stroke are less clear. 
The predominant pathology finding in CNS vessels in SLE patients is a noninflammatory 
small vessel vasculopathy involving small arterioles and capillaries. At autopsy, 50% of the 
patients have cerebral vasculopathy, characterized by hyaline thickening and eosinophilia of 
the vessel wall, fibrinoid degeneration without vasculitis, and endothelial proliferation, 
sometimes accompanied by microhemorrhages (Devinsky et al., 1988; Ellison et al. 1993; 
Hanly et al., 1992).  
3.3 Thrombosis 
Thrombotic events are reported in 7-12% of patients with SLE (Somers et al., 1999). During 
the first year of disease, the incidence of both arterial and venous thrombotic events 
increases. Several reasons have been pointed out, and include  aPL antibodies, circulating 
immune complexes, high levels of disease activity, and chronic inflammation (Manger et al., 
2002). When associated with SLE, antiphospholipid syndrome is a relevant predictor of 
organ damage and death in patients (Ruiz-Irastorza et al., 2004). Anti-cardiolipin (aCL) 
antibodies, lupus anticoagulant (LAC) and anti-beta2-glycoprotein 1 antibodies (anti-B2GPI) 
are detected in approximately one-third of patients with SLE (Love & Santoro, 1990), 
especially in the context of the antiphospholipid syndrome. The best predictors for 
thrombotic events in SLE are persistent aPL antibodies, the presence of LAC (Somers et al., 
2002), and high titers of aCL antibodies (Ginsburg et al., 1992).   
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Not all thrombotic phenomena are associated with the presence of aPL antibodies and some 
patients may develop venous and arterial thrombosis without aCL positivity.  The relevance 
of traditional and SLE-related thrombotic risk factors in aPL positive patients is still under 
investigation. Most of the patients with SLE and aPL antibodies who developed thrombosis 
had other thrombotic risk factors (Erkan et al., 2007). Interestingly, after adjusting for other 
risk factors, SLE itself remains independently associated with thrombotic events (Bruce, 
2005). Thrombosis is frequent in early SLE and is associated with a significant mortality; 
therefore, the identification of possible modifiable risk factors and the establishment of 
efficacious strategies of prevention and treatment are vital. 
4. Treatment 
The impact of cardiovascular disease has been under-recognized in the context of SLE, with 
limited attention on aggressive management of possible modifiable risk factors. Despite a 
general awareness of coronary vascular disease in SLE patients, physicians do not address 
risk factors in a comprehensive fashion. Also, the management of conventional 
cardiovascular risk factors such as diabetes mellitus, smoking, hypercholesterolemia and 
hypertension is not at the same level of non-SLE patients. This is reinforced by the fact that 
recruiting and retaining patients with SLE for clinical trials regarding preventive measures 
has been proven to be extremely difficult.  
It is therefore of great importance to identify in each patient the modifiable risk factors and 
introduce in clinical practice guidelines to help clinicians reducing long-term cardiovascular 
morbidity and mortality. In this chapter, we analyze the potential impact of some of the 
most commonly used drugs in SLE and their effects in the cardiovascular system.  
The general approach suggested in the overall population for primary and secondary 
prophylaxis of vascular disease should be proposed to every patient and should include 
(table 2): 
4.1 Corticosteroids: Are they good or bad for lupus? 
Corticosteroids still remain a first line treatment for lupus, despite having numerous 
detrimental side effects on blood pressure, blood glucose and lipid profile (Manzi et al., 
2000).  Corticosteroids have a particular deleterious effect on the heart (Bulkley et al., 1975). 
Prednisone dosage superior to 7,5 mg/d increases insulin levels, a risk factor for 
cardiovascular disease (Karp et al., 2008) and total cholesterol, triglycerides and 
apolipoprotein B levels increase significantly with a daily prednisone dose higher than 10 
mg (Petri et al., 1992). The estimated 2-year coronary risk for a patient treated with anved an 
average dosage of 30 mg/day of prednisone for 1 year, is approximately 60% higher than it 
would be for a patient with the same levels of SLE activity and similar risk factors who 
received no corticosteroids (Karp et al., 2008).   
When compared to a baseline chronic inflammatory status, low dose corticosteroids may 
exert an anti-inflammatory action which might be beneficial. In fact, such exposure may 
improve the lipid profile and increase insulin levels, whithout having a negative effect on 
blood pressure and atherosclerosis. A weak association between low-dose corticosteroids 
and cardiovascular risk factors has been established, and identified a dose-related trend for 
increasing major cardiovascular events (Ruyssen-Witrand et al., 2010). Furthermore, 
subclinical atherosclerosis is correlated with lower mean dose of corticosteroids and lesser 
immunossupressants (Roman et al., 2003).  
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 1. Screening: fasting lipid profile every year; 
2. For LDL cholesterol <2.6 mmol/l: no treatment; 
3. For LDL cholesterol 2.6–3.4 mmol/l: therapeutic lifestyle changes.   
4. Consider statins when LDL is >3.4 mmol/l with or without other risk 









1. Blood pressure assessments at every visit to the outpatients clinic; 
2. Ideal target is defined as blood pressure at <130 mmHg systolic and 
<80 mmHg diastolic.  
3. If elevated blood pressure (>140 mmHg systolic or >90 mmHg diastolic): 
lifestyle modification.;  
4. If, despite previous measures, the blood pressure is persistently found to be 










 1. Regular testing for diabetes (1-2 /year); 
2. In patients with a fasting glucose ≥6.1 mmol/l:  glucose tolerance test and 
lifestyle changes;  









1. Screening for obesity;  
2. Lifestyle changes, exercise programmes and behavioral support;  
3. If, despite efforts, obesity remains, refer to drug/ bariatric surgery by a 
multidisciplinary team. 
Table 2. Summary of some therapeutic interventions. 
There are some important limitations in addressing the role of steroids in cardiovascular 
risk. Corticosteroid use is more common in patients with moderate to severe disease (Bruce, 
2006) and the duration of exposure to this drug may function as a surrogate for disease 
duration. Further work is needed to assess if there are doses or regimes of corticosteroid 
therapy that can optimise their anti-inflammatory effects whilst minimizing their multiple 
adverse effects.  
4.2 Statins 
Pleotropic actions of hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors 
(statins) have been thourougly reported and is now accepted that their benefits go beyond 
cholesterol lowering and include immunomodulatory and immunossupressive properties. 
Statins inhibit HMG-CoA reductase, an enzyme that converts HMG-CoA to mevalonate, a 
fundamental step in cholesterol synthesis. The mevalonate pathway is involved in 
posttranslational modification of cell-signaling proteins during cell division and maturation, 
with inhibition of proinflammatory effects. It then promotes anti-inflammatory activities 
through the direct inhibition/activation of chemokyne, cytokine-, and acute-phase reactant-
driven intracellular pathways in several cell types involved in inflammation. Statins 
modulate the activity of cells involved in both innate and adaptative immune responses, 
affecting the production of cytokines and cellular adhesion molecules (e.g. ICAM-a, IL-6, 
TNF-α, IL-1 and selectin levels (Mira & Mañes, 2009) and have an antithrombotic effect by 
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inhibiting platelet activation (Ferroni et al., 2006). In the general population, statins have 
shown efficacy in primary and secondary prevention of acute myocardial infarction and 
stroke (Amarenco et al., 2006; Ridker et al., 2008).  
Following the identification of their mechanisms of action, statins became a potential drug 
for treating SLE patients despite cardiovascular involvement. Low dose rosuvastatin 
induced a significant reduction in LDL and CRP after 12 months treatment (Mok et al., 
2011). In patients with low disease activity, rosuvastatin decreased plasma levels of 
endothelial activation markers such as P-selectin and VCAM-1. Unexpectedly, in 2011, the 
results from the Lupus Atherosclerosis Prevention Study (Petri et al., 2011) offered no 
evidence that atorvastatin could reduce markers of subclinical atherosclerosis or disease 
activity over 2 years and the anti-inflammatory effects of statins observed in the general 
population were not replicated in this SLE clinical trial. However, comments were raised 
regarding the homogeneity of both treatment arms which may limit the final interpretation. 
Importantly, there was no information about the treatments received by patients during the 
2 years follow-up, regarding the use of prednisone, immunosupresive agents and 
hydroxychloroquine, all of them having a direct effect on inflammation and disease activity 
and potentially on subclinical atherosclerosis. Hence, the negative results in this clinical trial 
could be caused by an imbalance in the use of these drugs in both arms, rather than by the 
lack of efficacy of atorvastatin. 
4.3 Low dose salicylic acid  
Most of SLE patients with aPL, but without a history of thrombosis, do not receive any 
preventive therapeutic, while some receive low dose salicylic acid (ASA) (Kamashta, 2000). 
Prophylactic treatment with ASA in SLE patients may prevent both arterial and venous 
thrombotic manifestations, especially in patients with positive aPL (Wahl et al., 2000). In 
fact, ASA decreases the probability of thrombosis in asymptomatic individuals with aPL 
(Erkan et al., 2002). The use of low-dose ASA has been recommended by the expert 
committee in the recent European League Against Rheumatism guidelines for the 
management of SLE (Bertsias et al., 2008).  
4.4 Hydroxychloroquine 
Hydroxychloroquine is an anti-malarial drug also used to treat SLE,  Sjögren's syndrome 
and other immune mediate diseases. Several mechanisms have been proposed to explain its 
beneficial effect, which is not fully established. Hydroxychloroquine can inhibit the binding 
of antiphospholipid antibody–β2-glycoprotein I complexes to phospholipid bilayers (Rand 
et al., 2008), reverse platelet activation induced by human IgG aPL antibodies (Espinola et 
al., 2002), and reduce of aPL antibody–induced thrombosis (Edwards et al., 1996). There is 
no consistent data regarding whether this antithrombotic effect is present both for arterial 
and venous events. 
A beneficial effect on serum lipid levels, including patients taking corticosteroid therapy 
(Borba et al., 2001; Hodis et al., 1993; Sachet et al., 2007; Tam et al., 2000), was shown by a 
few observational studies. However, the strenght of evidence supporting a clinically 
meaningful beneficial effect was rated as low. Also, there is no data supporting any 
protective effect of this drug on the development of metabolic syndrome (Ruiz-Irastorza et 
al., 2010). 
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Regarding the effect of hydroxychloroquine on atherosclerosis, most studies are limited by 
the low consistency and lack of specific design (Ahmad et al., 2007; Maksimowicz-
McKinnon et al, 2006). The effect was not quantified in most cases and the exposure to 
hydroxychloroquine has been heterogeneously defined, without taking into account the 
time of exposure or a possible dose effect. 
Because of its beneficial effects on reducing SLE activity and mortality, most of the authors 
recommend hydroxychloroquine for most patients with SLE, starting as soon as the 
diagnosis is made. Its application for the specific prevention of thrombosis and treatment of 
atherosclerosis requires validation in future clinical trials. 
4.5 B-cell depletion therapy 
Rituximab, a drug that had no previously documented lipid-lowering effect, was recently 
investigated in patients with SLE who had failed standard immunosuppressive therapy 
(Pego-Reigosa et al., 2010). An increase in HDL cholesterol and a fall in the total 
cholesterol/HDL ratio and triglyceride levels was documented in a significant proportion of 
the 12 patients studied. Furthermore, this improvement in lipid profile mirrored a decrease 
in disease activity; this suggests a positive effect of rituximab related to a reduction in the 
overall high inflammatory status. Still, larger prospective studies should aim to evaluate if 
this observed favorable effect contributes to a lower incidence of cardiovascular events. 
5. Conclusion 
Patients with SLE are at increased risk for cardiovascular complications. Atherosclerosis 
occurs prematurely in patients with systemic lupus erythematosus and is independent of 
the traditional risk factors for cardiovascular disease. Premature atherosclerosis has 
emerged as a leading cause of morbidity and mortality in SLE. Traditional risk factors, such 
as hypertension, smoking, diabetes, obesity and dyslipidemia are common in SLE but they 
fail to explain entirely the atherosclerotic burden found in these patients. Increased 
understanding of the mechanisms underlying vascular damage, plaque formation and 
stability, and thrombosis, will greatly facilitate the long-term care of patients with lupus. 
The clinical profile of patients with lupus and atherosclerosis suggests a role for disease-
related factors in atherogenesis and underscores the need better trials targeting 
atherosclerosis in a specific fashion. 
An early identification of subclinical atherosclerosis in SLE is warranted to help to identify 
patients with higher risk to undergo major vascular complications, who might benefit from 
more aggressive treatment and lifestyle modifications.  
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Regarding the effect of hydroxychloroquine on atherosclerosis, most studies are limited by 
the low consistency and lack of specific design (Ahmad et al., 2007; Maksimowicz-
McKinnon et al, 2006). The effect was not quantified in most cases and the exposure to 
hydroxychloroquine has been heterogeneously defined, without taking into account the 
time of exposure or a possible dose effect. 
Because of its beneficial effects on reducing SLE activity and mortality, most of the authors 
recommend hydroxychloroquine for most patients with SLE, starting as soon as the 
diagnosis is made. Its application for the specific prevention of thrombosis and treatment of 
atherosclerosis requires validation in future clinical trials. 
4.5 B-cell depletion therapy 
Rituximab, a drug that had no previously documented lipid-lowering effect, was recently 
investigated in patients with SLE who had failed standard immunosuppressive therapy 
(Pego-Reigosa et al., 2010). An increase in HDL cholesterol and a fall in the total 
cholesterol/HDL ratio and triglyceride levels was documented in a significant proportion of 
the 12 patients studied. Furthermore, this improvement in lipid profile mirrored a decrease 
in disease activity; this suggests a positive effect of rituximab related to a reduction in the 
overall high inflammatory status. Still, larger prospective studies should aim to evaluate if 
this observed favorable effect contributes to a lower incidence of cardiovascular events. 
5. Conclusion 
Patients with SLE are at increased risk for cardiovascular complications. Atherosclerosis 
occurs prematurely in patients with systemic lupus erythematosus and is independent of 
the traditional risk factors for cardiovascular disease. Premature atherosclerosis has 
emerged as a leading cause of morbidity and mortality in SLE. Traditional risk factors, such 
as hypertension, smoking, diabetes, obesity and dyslipidemia are common in SLE but they 
fail to explain entirely the atherosclerotic burden found in these patients. Increased 
understanding of the mechanisms underlying vascular damage, plaque formation and 
stability, and thrombosis, will greatly facilitate the long-term care of patients with lupus. 
The clinical profile of patients with lupus and atherosclerosis suggests a role for disease-
related factors in atherogenesis and underscores the need better trials targeting 
atherosclerosis in a specific fashion. 
An early identification of subclinical atherosclerosis in SLE is warranted to help to identify 
patients with higher risk to undergo major vascular complications, who might benefit from 
more aggressive treatment and lifestyle modifications.  
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1. Introduction 
The present chapter considers only one aspect of glucocorticoid therapy of patients with 
systemic lupus erythematosus (SLE): a possibility of using blood level of tyrosine for 
monitoring glucocorticoid therapy. Thus, problems of SLE etiology and pathogenesis, as 
well as numerous schemes of SLE therapy are beyond the limits of this chapter. In the 
сhapter normal catabolism of tyrosine and some congenital disturbances in catabolism of 
this amino acid are considered. But in the great majority of cases, specific features of 
tyrosine catabolism allow us to admit that tyrosine content in blood should be determined 
by the liver functional competence, in particular, its ability to synthesize an adaptive 
enzyme tyrosine aminotransferase and by entrance into the liver of glucocorticoids, natural 
hormones or glucocorticoid preparations. This сhapter also presents experimental data 
obtained on adrenalectomized rats and observations on children with adrenogenital 
syndrome which clearly demonstrate blood tyrosine dependence on glucocorticoids and 
support the idea of using blood tyrosine content as a promising laboratory parameter for 
monitoring glucocorticoid therapy, similar to blood glucose for insulin. Some observations 
on glucocorticoid therapy in patients with SLE compared with changes in their blood 
tyrosine level which were earlier published only in Russian are presented, as well as the 
imaginary tyrosine-based monitoring of these cases.  
2. Approaches to treatment of systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) seems to be the most striking example of using 
corticosteroid, or glucocorticoid, preparations in non-endocrine diseases as the most 
powerful anti-inflammatory, immunosuppressive, anti-allergic, antitoxic, etc. agents. Sixty 
years ago glucocorticoids allowed clinicians to radically change the fate of patients with SLE 
– this collagen disease stopped to be virtually lethal (Dubois, 1974; Schroeder & Euler, 1997; 
Ioannou & Isenberg, 2002; Goldblatt & Isenberg, 2005; Nived et al., 2008). In modern 
schemes of SLE treatment glucocorticoids are usually combined with various other 
preparations: cyclophosphamide, mycophenolate mofettil, rituximab, cyclosporine, 
azathioprine, etc. (Ntali et al., 2009; Ponticelli et al., 2010). In addition to their specific effects, 
all these preparations are given, in particular, in order to lower the dose of steroids, 
however, up to now glucocorticoids remain the cornerstone in the schemes of SLE 
treatment. Therefore, in SLE all problems associated with using glucocorticoid preparations 
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in non-endocrine diseases are clearly pronounced and still urgent: the unpredictability of 
efficiency of glucocorticoids and nearly inevitable serious side effects, difficulties and 
sometimes even the impossibility to abolish glucocorticoids, and glucocorticoid resistance of 
some patients – such was the situation at the beginning of the “steroid era” and it is nearly 
the same nowadays, and the same problems are still urgent. 
Since 1966, life-threatening exacerbations of SLE are sometimes treated by pulse-therapy – 
intravenous injection of very high doses of glucocorticoid preparations – up to 1 mg 
methylprednisolone daily for three days. However, the rapid immunosuppressive effect is 
often accompanied by various infections. But this regimen of pulse-therapy has been formed 
historically, although it is not excluded that lower doses of glucocorticoids would be 
similarly effective (Badscha & Edwards, 2003; Franchin & Diamond, 2006). 
It is obvious that the existent schemes of using glucocorticoids in SLE are far from optimal, and 
to specify and refine therapeutical approaches there are some attempts to compare the 
glucocorticoid efficiency in SLE with different individual characteristics of the patients, such as 
the number and type of glucocorticoid receptors (Li et al., 2010; Deng & Tsao, 2010; Oakley & 
Cidlowski, 2011), titers of antibodies to double-stranded DNA (Rahman & Isenberg, 2008), 
specific features of T- and B-cells, etc. It seems clear that responsiveness to glucocorticoids 
should be associated with some individual specific features of the patients. Moreover, 
glucocorticoid sensitivity is not steady in the same patient, but can vary from time to time and 
can be much more changeable than it has been believed earlier (De Rijk & Sternberg, 1997). 
It is rather strange but a very essential aspect of action of glucocorticoid preparations has been 
neglected during the whole period of using glucocorticoids in clinical medicine. It is extremely 
important that glucocorticoid preparations, as discriminated from all other pharmaceuticals 
used in the treatment of SLE, are synthetic copies of natural products of the organism – of 
glucocorticoid hormones synthesized in the adrenal cortex. Glucocorticoid preparations 
possessing the unique combination of therapeutic properties also inevitably retain the features 
of their natural prototypes, i.e. they are directly or indirectly involved in regulation of many if 
not all physiological processes and metabolic reactions and their using interferes the negative 
feedback regulation in the hypothalamus–pituitary–adrenocortical system. Therefore, it 
should be noted and emphasized that the inevitable complications of glucocorticoid therapy 
really are not “side effects”, on the contrary, they are natural manifestations of just hormonal 
properties of glucocorticoid preparations, either of their excess or of induced disorders in the 
feedback regulation of the hypothalamus–pituitary–adrenocortical system. Possibly, this 
neglecting was reasoned by a surprising and somewhat discouraging discovery in the 
beginning of “the glucocorticoid era” that the therapeutical effect of glucocorticoid 
preparations did not depend on the level of a patient’s own hormones?  
However, not the level of glucocorticoid hormones should be important, but the tissue 
provision with these hormones, especially on taking into account that glucocorticoids are 
hormones of virtually total action. Nevertheless, for glucocorticoids there is no parameter to 
characterize the tissue provision with these hormones (or with glucocorticoid preparations) 
and to determine the real need in them of a subject under various circumstances, in 
particular, under stress situations or in disease. This is especially important because 
glucocorticoids play a determinative role in stress situations. For glucocorticoids an indirect 
parameter is required which would be similar to blood glucose for insulin.  
Naturally, this parameter must be easily determinable in blood, have rather narrow normal 
limits in healthy persons, and clearly depend on glucocorticoids, natural hormones or 
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preparations. In particular, the glucocorticoid-dependent hepatic enzyme tyrosine 
aminotransferase and the resulting tyrosine level in blood which is directly determined by 
the activity of this enzyme deserve a special attention. 
3. Blood tyrosine levels in some non-endocrine diseases 
In the late 1950s Japanese researchers of the Nishimura group found increased levels of 
tyrosine in blood and urine of patients with collagen diseases (Nishimura et al., 1958; 
Nishimura et al., 1961) and supposed that disorders in tyrosine catabolism could be a 
biochemical basis of these diseases. These reports stimulated intensive studies on tyrosine 
catabolism in collagenoses and some other diseases, especially in Russia. As it was 
reasonably to expect, tyrosine catabolism was disturbed in patients with liver disorders, 
such as infectious hepatitis, chronic hepatitis, and liver cirrhosis, and blood tyrosine level 
was two-threefold increased in them (Levine & Kohn, 1967; Powell & Axelsen, 1972; 
Nordlinger et al., 1979). 
The hypothesis about the role of tyrosine catabolism disorders in pathogenesis of collagen 
diseases was not confirmed, but very interesting observations were described, in particular, 
by A.S. Kainova (Kainova, 1974): tyrosine levels in blood of patients with rheumatism 
decreased to normal values on successful hormonal and/or medicamentous therapy, and 
abolishment of glucocorticoid preparations in some cases was accompanied by an increase 
in the blood tyrosine level. 
4. Observations on blood tyrosine levels and glucocorticoid treatment in 
patients with SLE 
Systemic Lupus Erythematosus (SLE) was a problem for the Clinics of Therapy and 
Occupational Diseases, I Moscow Medical Institute, where I entered as a biochemist in 1968 
and had been working until 1978. Naturally, the disorders in tyrosine metabolism observed 
by Nishimura et al. in patients with collagen diseases and observations by Kainova on blood 
tyrosine changes in patients with rheumatism seemed to me a possible biochemical 
approach to start my study on SLE. 
Sixteen healthy donors (14 women and 2 men in the age from 20 to 40 years old) were used 
for determination the normal level of blood tyrosine, and it was found to be 16.2 ± 0.9 
µg/ml. Note, that the repeated measurements of blood tyrosine levels in the same donors 
gave virtually the same values, i.e. it occurred to be rather a stable parameter. 
Altogether 80 patients with SLE, 70 women and 10 men in the age range from 16 to 53 years 
old, were observed at 134 hospitalizations over the period of 19731976. Some patients were 
under observation repeatedly. The patients were not selected previously basing on their case 
history and severity and character of the disease. Tyrosine was determined in the serum 
from blood samples taken from patients with SLE at 8.00–8.30 a.m. on the empty stomach, 
usually once during 7-14 days over the period of hospitalization. The work was not a part of 
a previously approved plan of investigations, therefore, no blood samples were taken 
specially to determine the tyrosine content. Initially, levels of tyrosine and of its 
transamination product p-oxyphenylpyruvic acid were determined in parallel samples of 
blood and 24-h urine. The determination of tyrosine was performed spectrophotometrically 
by the method of Udenfriend & Cooper (1952), p-oxyphenylpyruvic acid was determined as 
described in the work (Knox & Pitt , 1957). It was shown that the increase in blood tyrosine 
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level was caused by disturbance in transamination (Rass, 1976), whereas the further stages 
of tyrosine oxidation in the patients under study were virtually unaffected.  
Changes in blood tyrosine in every patient were compared with the clinical and laboratory 
data recorded in their case histories after the patients’ discharge from the hospital, with a 
special attention to using glucocorticoid preparations, i.e. a kind of the retrospective 
experiment was performed. The results were published in Russian in the work (Rass et al., 
1977). Thirty-six patients were observed in the state of clinical remission; blood tyrosine was 
in normal limits in 23 of them and was steadily elevated in three patients (two of them had 
the affected liver); 28 patients obtained a supporting dose of glucocorticoids (not more than 
15 mg prednisolone per day).  
In 44 patients with SLE short-term “splashes” in blood tyrosine level were observed, and the 
retrospective analysis revealed that these “splashes” occurred simultaneously with some 
extraordinary events, such as a concurrent infection, aggravation of symptoms, or on the 
other day of a severe diagnostic procedure (e.g. the kidney biopsy), during the reaction to a 
new preparation, etc. Thus, these “splashes” were associated with a “stress-situation” when 
the need in glucocorticoid hormones was increased and in healthy subjects the synthesis of 
glucocorticoid hormones should increase. Thus, in a patient with chronic SLE who obtained 
5 mg/day prednisolone as a supporting dose over the period of 50 days of hospitalization 
blood tyrosine values were 25, 20, 22 µg/ml, and a “splash” to 53 µg/ml was recorded on 
the day after the diagnostic intravenous urography. At the other hospitalization two years 
later this patient obtained the daily dose of 10 mg prednisolone and had blood tyrosine level 
of 8 µg/ml (possibly, the supporting dose of 10 mg prednisolone/day was too high – the 
previous supporting dose of 5 mg/day seemed sufficient to maintain the level of blood 
tyrosine in normal limits of 20-25 µg/ml). Similar “splashes” in blood tyrosine level were 
also observed in patients with glomerulonephritis under similar situations. 
A very demonstrative was an attempt to even slightly lower the dose of glucocorticoid 
preparations in a clinically steroid-dependent patient with subacute SLE (Fig. 1). This 
“splash” in blood tyrosine was observed concurrently with the aggravation of her condition. 
In this patient the high background content of tyrosine was thought to be associated with 
the liver affection.  
 
 
Fig. 1. Changes in the blood tyrosine content in a clinically steroid-dependent 40-year-old 
patient with subacute SLE. The attempt to decrease the dose of prednisolone was associated 
with an aggravation of the patient’s condition. Dotted lines here and in the further Figures 
show normal limits of blood tyrosine contents.  
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“Splashes” in blood tyrosine were also observed in some patients with SLE at the  
alternate-day scheme of hormonal treatment on the next morning after glucocorticoid-free 
day. 
But comparing results of glucocorticoid therapy with the initial level and behavior of 
blood tyrosine in patients with SLE seems to be the most interesting and informative. 
Changes in blood tyrosine upon prescribing or increasing the dose of glucocorticoids (40-
60 mg/day calculated per prednisolone) because of SLE exacerbation were followed in 32 
patients. Glucocorticoid preparations were prescribed according to the conventional 
schemes. The post-discharge analysis of the case histories revealed that to 20 patients 
glucocorticoids were prescribed at the significantly increased level of blood tyrosine (49.1 
± 0.8 µg/ml as compared to 16.2 ± 0.9 µg/ml in 16 healthy donors) and an essential 
improvement of clinical and laboratory parameters was recorded in 17 of them. In 13 
patients this improvement was accompanied by a decrease in blood tyrosine, and this 
decrease was recorded before appearance of signs of Cushing’s syndrome; in four patients 
with markedly affected liver functions the level of blood tyrosine remained elevated 
although their general condition became somewhat better. It should be noted that the 
“improvement” in all cases concerned only parameters of SLE activity, and side effects 
were considered as inevitable. 
Twelve patients were given glucocorticoids on the background of normal blood tyrosine ( 
26.5 µg/ml); glucocorticoids were inefficient in nine of them, and in four patients signs of 
Cushing’s syndrome appeared very rapidly. Some improvement was recorded in three 
patients but this improvement could be due to other preparations given to them 
concurrently with glucocorticoids: azathioprine, heparin, cyclophosphamide, etc.  
Let us consider some real cases.  
Patient M., 27 years old, suffering from SLE for nine years was hospitalized because of 
aggravation of chronic SLE. Blood tyrosine at the first determination was 47.5 µg/ml.  
She was given prednisolone (30 mg/day) and antibiotics because of catarrhal  
state, however, 20 days later the immunologic activity was still present, as well as 
arthralgia and myalgia, blood tyrosine remains increased - 40 µg/ml; because of a 
continued aggravation of her condition 15 days later the prednisolone dose was increased 
to 40 mg/day, and in a week a pronounced clinical improvement was recorded, together with a 
decrease in the blood tyrosine level to normal (25 µg/ml). She received 40 mg/day 
prednisolone for 20 days, and then the lowering prednisolone dose was started – and 
blood tyrosine slightly increased. The patient was discharged with the improved clinical 
and laboratory data (Fig. 2).  
The following case (Fig. 3) presents a 21-year-old patient Zh., suffering of SLE during  
five years. She received long-term courses of prednisolone earlier in the maximal dose  
of 30 mg/day. A progressing osteonecrosis was observed. This time she was hospitalized 
because of an acute flare. At the first determination blood tyrosine level was somewhat 
increased (34.0 µg/ml), on the next day she was prescribed with prednisolone –  
45 mg/day, and this dose was maintained during 20 days. Five days after the beginning of 
glucocorticoid therapy blood tyrosine decreased to 20.0 µg/ml, and two days later a moon-
like face appeared and elevations of arterial pressure up to 170/100 mm Hg were recorded.  
GG therapy for 1.5 months was considered to be unfavorable; moreover, pains in  
femoral joints increased. Clinical improvement in this patient was obtained on  
prescribing heparin.  
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level was caused by disturbance in transamination (Rass, 1976), whereas the further stages 
of tyrosine oxidation in the patients under study were virtually unaffected.  
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the liver affection.  
 
 
Fig. 1. Changes in the blood tyrosine content in a clinically steroid-dependent 40-year-old 
patient with subacute SLE. The attempt to decrease the dose of prednisolone was associated 
with an aggravation of the patient’s condition. Dotted lines here and in the further Figures 
show normal limits of blood tyrosine contents.  
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Fig. 2. Changes in the blood tyrosine content and regimen of glucocorticoid therapy 




Fig. 3. Changes in the blood tyrosine content and regimen of glucocorticoid therapy 
(hatched) in a 21-year-old patient with chronic SLE.  
Figure 4 shows changes in blood tyrosine level observed at withdrawal syndrome in a 22-
year-old patient P. with subacute SLE (Fig. 4). The patient was in the state of a relative 
clinical and laboratory remission at the supporting dose of prednisolone (15 mg/day) for 
rather a long time. Such a rapid abolishment of prednisolone at the hospitalization in 1974 
was forced by development of a pronounced aseptic osteonecrosis of femoral heads, and 
this abolishment was associated with a sharp aggravation of SLE symptoms associated with 
a sharp increase in blood tyrosine level. 
 




Fig. 4. Blood tyrosine levels and regimen of glucocorticoid therapy in a patient with 
subacute SLE during two hospitalizations, at the state of relative remission in 1973, and at 
withdrawal syndrome in 1974. 
Thus, a certain association obviously occurred between the therapeutic effect of 
glucocorticoid preparations and their regulatory effect manifested by changes in the blood 
level of tyrosine. Moreover, such association cannot be occasional, exclusive, or SLE-specific, 
because the dependence of tyrosine catabolism on glucocorticoids is fundamentally the 
same in humans and in other mammals. Such an association must be significantly most 
common. In particular, blood tyrosine level was also increased in patients with bronchial 
asthma (not receiving glucocorticoids) during the period of attacks and was normal during 
the state of remission (Rass et al., 1978). 
If so, may be blood tyrosine content can be used as a representative index of action of 
glucocorticoid hormones on metabolism, as an index of tissue provision with these 
hormones, and of real need of a subject in these hormones? May be blood tyrosine level can 
be used as a parameter (index) of glucocorticoid action, similarly to blood glucose which is a 
parameter of insulin action? 
5. Tyrosine catabolism and blood tyrosine level as an index of glucocorticoid 
hormone action  
This idea induced by observations on changes in blood tyrosine levels and regimens of 
glucocorticoid therapy in patients with SLE was for the first time published in the above-
mentioned work (Rass et al., 1977) and was theoretically considered in the paper (Rass, 
1978); then this idea was confirmed by experimental studies on adrenalectomized rats (Rass, 
1980; Rass, 1983) and by observations on children with adrenogenital syndrome receiving 
long-life substitutive glucocorticoid therapy (Rass et al., 1979). In 1991 the hazard of 
glucocorticoid hormone application in non-endocrine diseases was considered to be mainly 
due to the absence of a test for sufficiency and real need in these hormones, and 
introduction of blood tyrosine as such a test was proposed as a safety basis for the 
individualized strategy of glucocorticoid therapy (Piruzian & Rass, 1991). However, all 
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these works were published only in Russian, and this apparently promising idea remained 
virtually not called for until the review (Rass, 2010) was published in English. 
Let us consider some specific features of tyrosine catabolism, especially those which allow 
us to consider the blood level of this amino acid as a promising laboratory parameter for 
monitoring glucocorticoid therapy. 
Tyrosine is produced in the organism as a result of hydrolysis of food protein immediately 
or after hydrolysis of phenylalanine. About 30% of produced tyrosine is used for synthesis 
of catecholamines, melanin, and thyroid hormones, a portion is used for renewal of tissue 
proteins, and more than 60% is oxidized in the liver (Knox, 1955). And the first reaction in 
the major oxidation pathway of tyrosine is its transamination with alpha-ketoglutaric acid 
under the influence of tyrosine aminotransferase with production of p-oxyphenylpyruvic 
acid. Then p-oxyphenylpyruvic acid is oxidized under the influence of the appropriate 
oxidase in the presence of ascorbic acid with production of 2,5-dioxyphenylpyruvic, or 
homogentisic acid. The terminal products of the major pathway of tyrosine oxidation are 
acetoacetic and fumaric acids (Fig. 5). 
Most frequently, tyrosine content in blood is determined using its reaction with  
alpha-nitroso-beta-naphthol with a subsequent recording by spectrophotometry 
(Udenfriend & Cooper, 1952) or by fluorimetry (Grenier & Laberge, 1974; Gavrilov et al., 
1998). In some works HPLC (Kand’ar & Zakova, 2009), ion-exchange chromatography 
(Allard et al., 2004), and gas chromatography – mass-spectrometry (Deng et al., 2002) are 
also used. In some of the above-listed works tyrosine was determined in blood samples 
dried on filter paper discs.  
The interest for determination of tyrosine level in blood is caused by necessity of early 
diagnosis of congenital disturbances of phenylalaninetyrosine catabolism which result in 
severe disorders in the mental and physical development of the affected children. 
Phenylketonuria is caused by deficiency of the enzyme phenylalanine hydroxylase and is 
characterized by an extremely low level of blood tyrosine (< 0.05 µg/ml), tyrosinosis which 
is caused by an insufficient elimination of p-oxyphenylpyruvate acid due to deficiency of the 
appropriate oxidase (Scriver, 1967; Cerone at al., 1997) is manifested by a stable 
hypertyrosinemia up to 100 µg/ml, and in Richner–Hanhart syndrome caused by an inborn 
insufficiency of tyrosine aminotransferase blood tyrosine level can reach 600 µg/ml 
(Goldsmith, 1978; Natt et al., 1992). Incidence of phenylketonuria throughout the world is, 
on average, 1 : 15’000, and of the two other disorders in tyrosine catabolism are, 
respectively, 1 : 100’000 and 1 : 250’000, but in Canada they are recorded more frequently.  
Tyrosine aminotransferase is an adaptive enzyme synthesized by the liver cells in response 
to entrance of the substrate – tyrosine, but for the substrate induction of this enzyme the 
entrance of glucocorticoids in the liver is necessary (Rosen and Nichol, 1963; Gelehrter, 1973; 
Thompson, 1979). Synthesis of hepatic tyrosine aminotransferase is a well-known example 
of the so-called gene-mediated action of glucocorticoids, and this enzyme is the most 
demonstrative and beloved object for studies of such effects of glucocorticoids (Sun at al., 
1998; Grange et al., 2001; Hazra et al., 2007). Tyrosine aminotransferase is also used for 
testing on cell cultures and on intact and adrenalectomized animals of newly synthesized 
preparations which are expected to have less adverse effects than “classic” glucocorticoid 
preparations (Schacke et al., 2004; Zimmermann et al., 2009). The synthesis of tyrosine 
aminotransferase quantitatively depends on glucocorticoids, but being a hepatic enzyme, it 
cannot be determined in blood. However, tyrosine aminotransferase is a key enzyme in the 
major pathway of tyrosine catabolism and its activity determines the level of free tyrosine in 
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blood. As a result, blood tyrosine level also depends on glucocorticoids (and, naturally, also 
on the functional competence of the liver cells). 
 
 
Fig. 5. Tyrosine catabolism (Scheme).  
Due to substrate induction of tyrosine aminotransferase, even on tenfold increase in protein 
amount in the diet the blood content of tyrosine increases no more than by 50% above the 
basal level (Scriver et al., 1971), whereas circadian variations in blood tyrosine level mainly 
depending on circadian variations in production of natural glucocorticoids are in the limit  
of ± 25% (Wurtman et al., 1968).  
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But in the majority of cases and under real conditions an increase in blood tyrosine can be 
mainly determined by two factors: 1) a functional inferiority of the liver leading to a 
disturbed reception of glucocorticoids and inability of the liver cells to synthesize some 
enzymes including tyrosine aminotransferase, and 2) an insufficient entrance of 
glucocorticoids in the liver. As a result, under conditions of physiological rest, in the 
absence of extreme fluctuations in the diet, and on determination on the empty stomach in 
the morning the levels of free tyrosine in blood are similar in healthy animals and humans 
and do not depend on age and sex (Table 1).  
 
Subjects under study The number of subjects g/ml 
Men 91 13.0 ± 2.7 
Women 103 12.3 ± 2.4 
Boys 6-18 yr 75 12.3 ± 1.8 
Girls 6-18 yr 65 11.4 ± 2.0 
Table 1. Blood tyrosine levels in humans, after (Armstrong & Stave, 1973a) 
Moreover, it should be noted that blood samples taken from the same subjects (35 boys and 
26 girls) four times over the period of 33½ years displayed characteristic individual 
patterns for the most of plasma amino acids, in particular, the content of blood tyrosine was 
virtually constant in the same subject (Armstrong & Stave, 1973b). We have also observed 
virtually the same values of blood tyrosine level in the samples taken repeatedly from the 
same healthy donors, as well as in blood samples from patients with SLE on supporting 
dose of glucocorticoids in the state of remission.  
Injection of glucocorticoid preparations induced a 2040% dose-dependent decrease in 
blood tyrosine in both animals and humans (Rivlin & Melmon, 1965; Betheil et al., 1965), 
and this decrease was the most pronounced 4-5 h after the injection, i.e. at the maximum of 
the glucocorticoid-induced synthesis of tyrosine aminotransferase. A decrease in the content 
of blood tyrosine was also recorded under stress conditions (Nemeth, 1978), obviously, due 
to a well-known increase in the glucocorticoid production by the adrenal cortex. Effects of 
hydrocortisone injection to healthy volunteers recorded by changes in the blood tyrosine 
levels and in the peripheral lymphocyte counts were considered as manifestations of 
genomic and nongenomic effects of glucocorticoids, respectively (Derks et al., 1999). 
It is interesting to note that injections of hepatotoxins caused in rats an increase in the level 
of blood tyrosine, and the more pronounced was the liver necrosis the higher was this 
increase (Clayton et al., 2007).  
6. Blood tyrosine content is an index of tissue provision with 
glucocorticoids: Confirmation on the experimental and clinical models 
The dependence of blood tyrosine content on glucocorticoids was demonstrated 
experimentally on adrenalectomized rats (Rass, 1980; Rass, 2010). In intact rats blood 
tyrosine level was 15.0 ± 1.4 µg/ml. After bilateral adrenalectomy the blood level of tyrosine 
began to increase and reached, on average, 37.9 ± 6.4 µg/ml on the 5th day concurrently with 
the worst condition of the animals; then blood tyrosine level began to decrease most likely 
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due to synthesis of corticosterone in the brown fat tissue in response to the increased 
synthesis of ACTH after adrenalectomy; on the 10th day blood tyrosine level was the same 
as initially (under conditions of physiological rest!). Thus, the tyrosine level in blood 
manifested a pronounced dependence on production of natural glucocorticoids. 
Starting from the 7th day after the operation, adrenalectomized rats were injected daily 
intraperitoneously with hydrocortisone in the dose of 2 mg per kg body weight (this  
dose approximately corresponded to the supporting dose 15 mg/day of prednisolone). 
Daily injections of hydrocortisone during 20 days resulted in a decrease in the tyrosine level 
in blood to undeterminable level, the abolishment of the injections and their absence during 
5 days caused an increase in blood tyrosine, and the recommencement of hydrocortisone 




Fig. 6. Changes in tyrosine content in blood of adrenalectomized rats subjected to daily 
injections of hydrocortisone (hatched), upon abolishment of the injections, and on their 
recommencement.  
And it seems that the only clinical situation exists (the model was recommended by Prof. 
M.A. Zhukovsky) which allows a physician (endocrinologist) to control the entrance of 
glucocorticoids in the organism and to some degree assess the adequacy of tissue 
provision with glucocorticoids to real needs of just this patient. This unique situation is 
presented by adrenogenital syndrome (synonyms: congenital adrenal hyperplasia, 
congenital virilizing adrenal cortex dysfunction) in children. The disease is caused by a 
genetically determined deficiency of glucocorticoid biosynthesis enzymes in the adrenal 
cortex, most frequently of 21-beta-hydroxylase, and a resulting shift to synthesis of 
androgens, mainly of dehydroepiandrosterone. The decreased production of 
glucocorticoids induces an increased synthesis of ACTH in the adenohypophysis that 
permanently stimulates the adrenal cortex with a resulting surplus synthesis of androgens 
(Brooks, 1979). The excess of androgens is displayed by a characteristic clinical picture: an 
abnormal structure of external sex organs, an accelerated body growth with an 
overdevelopment of masculine type muscles during the first years of life, the early 
arresting of growth because of premature ossification of tubular bones, etc. In the affected 
girls a picture of pseudohermaphroditism is developed. 
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due to synthesis of corticosterone in the brown fat tissue in response to the increased 
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Fig. 6. Changes in tyrosine content in blood of adrenalectomized rats subjected to daily 
injections of hydrocortisone (hatched), upon abolishment of the injections, and on their 
recommencement.  
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The lifelong substitutive glucocorticoid therapy is the only pathogenetically reasonable 
treatment of this disease (Lo et al., 1999; Stikkelbroeck et al., 2003; Hughes, 2007). 
Glucocorticoid preparations break the vicious circle: recompensing the shortage of 
endogenous glucocorticoids they inhibit synthesis of ACTH responsible for overproduction 
of androgens. Glucocorticoid therapy started as early as possible after the birth and the 
appropriate dose can provide the normal physical and sexual maturation of the affected 
children according to their genetic sex, with a possibility of normal pregnancy and labor in 
females. The dose of glucocorticoids must be strictly individualized, and it can vary from 2.5 
to 15 mg prednisolone per day.    
On the other hand, changes in the clinical picture observed in children with adrenogenital 
syndrome – the rate of growth, ossification, and sexual maturation – allow a physician to 
relatively objectively and faultlessly estimate the correctness of the dose. In adult patients 
with this syndrome and in other conditions which obviously require the substitutive 
glucocorticoid therapy, after bilateral adrenalectomy or in chronic hypocorticism of 
various etiology, the dose of glucocorticoids can be prescribed only “according to the 
patient’s self-feeling”. According to B. Lukert (Lukert, 2006), “The problem for the 
clinician is the lack of objective criteria for determining adequate, but not excessive doses 
of glucocorticoids… In current practice, the clinician must rely on surrogate markers of 
glucocorticoid excess (early changes of Cushing’s syndrome) rather than definitive end 
points”.  
Our study was performed with participation of 38 children with virilizing adrenogenital 
syndrome (33 girls and five boys of 318 years old hospitalized in the Pediatric Department 
of the Institute of Experimental Endocrinology and Chemistry of Hormones, the USSR 
Academy of Medical Sciences). Tyrosine levels were determined in blood samples taken in 
the morning on empty stomach and compared with clinical picture which characterized the 
degree of compensation of the genetic defect. The results were published in Russian (Rass et 
al., 1979) and republished in English in the review (Rass, 2010). The main results are 
presented in Fig. 7. 
Figure 7 shows that in 17 children with adrenogenital syndrome at the complete clinical 
compensation blood contents of tyrosine were the same as in healthy donors (16 adults and 
seven children of 713 years old). In a girl with signs of Cushing’s syndrome blood tyrosine 
was below the normal level. In untreated patients and in non-compensated patients because 
of irregular treatment blood tyrosine was significantly increased. In three non-compensated 
patients a pronounced melanodermia was observed along with the normal level of blood 
tyrosine, i.e. a part of excessive tyrosine was not oxidized through the major pathway but 
was converted into melanin (compare with the Scheme in Fig. 5!). Prescribing 
glucocorticoids resulted in “whitening” of such patients. Normalization of skin color in 
patients with hypocorticism upon taking glucocorticoids was also described in the literature 
(Snell, 1967).  
In two compensated patients who initially displayed normal levels of blood tyrosine, 
transient increases to 29.0 and 45.0 µg/ml were recorded in association with a concurrent 
acute respiratory disease. Obviously, these increases are very alike “splashes” observed in 
patients with SLE, and can be explained by increased requirements for glucocorticoid 
hormones under conditions of stress or concurrent disease. Such observations justify the 
empirical recommendation to increase the dose of glucocorticoid preparations in the case of 
stress situations. 
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Two previously untreated girls were prescribed with glucocorticoids, and the 
determinations of blood tyrosine levels were helpful for choosing the optimal dose. Note 
that in patients with hypocorticism an acute withdrawal of the substitutive hydrocortisone 
injections resulted on the next day in a 25-30% increase in the level of blood tyrosine, 
whereas the levels of other amino acids remained virtually unchanged (Christiansen et  
al., 2007). The data presented in this section show that the normal level of blood tyrosine 
seems to indicate a sufficient provision of tissues and glucocorticoid-dependent reactions 
and processes with these hormones, whereas an increased level of blood tyrosine seems  




Fig. 7. Tyrosine contents in blood of healthy donors and children with adrenogenital 
syndrome. The columns present arithmetic means for the corresponding groups; the circles 
show individual values: I) healthy adults; II) healthy children; III) patients with the 
complete clinical compensation; IV) a girl patient with overdosed glucocorticoids; V) 
irregularly treated non-compensated patients; VI) untreated patients. Hatched circles in the 
columns V and VI show patients with a pronounced melanodermia. 
However, it is also reasonable to expect that blood content of tyrosine could be a promising 
candidate for the role of an indirect marker for prescribing the correct dose in non-endocrine 
diseases. Unfortunately, for non-endocrine diseases there are no similar data, nevertheless, 
let us admit that blood tyrosine level could be used as an index of tissue provision and real 
need in glucocorticoid hormones (or glucocorticoid preparations) – in our patients with SLE 
described in the Section 4.      
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7. The imaginary tyrosine-based monitoring of glucocorticoid therapy in  
the above-presented cases of SLE (reconsideration of cases presented  
in Figs. 24)  
Thus, keeping in mind the blood tyrosine as an index of the real need in glucocorticoids, let 
us look again at Figs. 24 and imagine the tyrosine-based monitoring of glucocorticoid 
treatment in these patients with SLE.  
Fig. 2  the imaginary monitoring. The patient M. was prescribed with 30 mg prednisolone 
daily on the background of a rather high initial level of blood tyrosine (47.5 µg/ml);  
she received this dose during 35 days without a pronounced clinical effect and on 
retention of the increased blood tyrosine (40.0 µg/ml). The improvement was achieved as 
soon as a week after increasing the prednisolone dose to 40 mg/day and this 
improvement was accompanied by normalization of blood tyrosine. The patient 
continued to receive 40 mg prednisolone for the following 15 days. Thus, in total,  
the patient M. received 30-40 mg prednisolone daily within two months. But, taking into 
account the initial high level of blood tyrosine, as well as its retention at the second 
determination 20 days later, it would have been reasonable to give her 40 mg prednisolone 
earlier and to start lowering the dose on normalization of blood tyrosine, i.e. the course of hormonal 
therapy could be much shorter. 
Fig. 3  the imaginary monitoring. The increased level of blood tyrosine (34 µg/ml) at the first 
determination on the next day after the hospitalization could be a kind of “splash” – the 
reaction to hospitalization-associated procedure. The patient was prescribed 45 mg 
prednisolone per day and obtained this dose for 20 days. Blood tyrosine became normal 
very rapidly – on the 5th day after the hospitalization (even earlier than the recorded in the case 
history appearance of the moon-like face and elevations in blood pressure!) and continued to 
decrease to very low level during the treatment with glucocorticoids. After 1.5 months, 
glucocorticoid therapy was qualified as unfavorable. Was it a case of steroid-resistance or 
simply a manifestation of a sufficient provision with own hormones? In any case, this patient 
did not need such a prolonged and rather intensive glucocorticoid therapy. 
Fig. 4  the imaginary monitoring. Withdrawal syndrome in a 22-year-old patient with 
subacute SLE. The normal blood tyrosine level during the hospitalization the year before at 
the supporting dose of prednisolone 15 mg/day made it possible to think about at least of 
decreasing the supporting dose of glucocorticoids, or even of trying to abolish hormonal preparations 
the year earlier! 
8. And the real successful course of glucocorticoid therapy  
without side effects  
The next case (Fig. 8) exemplifies a successful course of glucocorticoid therapy performed by 
Dr. I.A. Borisov (described in detail in the work (Rass et al., 1977)) in a 48-year-old patient E. 
who had been suffering of SLE for 12 years. This hospitalization was because of a serious 
flare of SLE after an acute respiratory disease. All previous courses of glucocorticoids in this 
patient resulted in a rapid development of Cushing’s syndrome. On the entrance blood tyrosine 
was 45–79 µg/ml. She was given prednisolone (40 mg/day) within a week and then 
transferred to alternate-day scheme of the dose lowering (the increase in blood tyrosine to 
100 µg/ml was recorded in the morning two days after the abolishment of daily 
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prednisolone). The alternate-day scheme was started from daily dose of 75 mg with a 
stepwise decreasing to 25 mg/day (combined with methindol on prednisolone-free days). 
Blood tyrosine decreased to the normal level (16 µg/ml) alongside with a general 
improvement of all clinical and laboratory data. The increase in the blood tyrosine level to 
35 µg/ml concurrently with the SLE activation was recorded when prednisolone was 
replaced by decortilene; then a respiratory disease was associated with blood tyrosine 
increases to 30–45 µg/ml; and prednisolone was prescribed again in the daily dose of 30 mg 
during a week followed by the alternate-day lowering the prednisolone dose starting from 




Fig. 8. Changes in the blood tyrosine content and regimen of glucocorticoid therapy 
(hatched) in a 48-year-old patient with SLE. 
It should be underlined that in this case two specific hormonal features of the glucocorticoid 
preparations were taken into account: the organism’s provision with glucocorticoids 
characterized by blood tyrosine level and using the alternate-day scheme for lowering the 
dose of hormonal preparation dose to promote the recovery of the negative feedback 
regulation in the hypothalamus-pituitary-adrenocortical system.  
9. Conclusion 
Preparations of glucocorticoid hormones for more than 60 years remain one of cornerstones 
of modern medicine as the most effective anti-inflammatory drugs also possessing anti-
allergic, immunosuppressive, antitoxic, and anti-shock properties. Glucocorticoid 
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preparations are widely used in all fields of clinical medicine and are virtually 
indispensable, although very serious complications are associated with their application. 
The number of works concerning glucocorticoid treatment of various diseases is 
innumerable. However, despite the extreme importance and indispensability of 
glucocorticoid preparations, up to now there is no objective laboratory parameter, similar to 
blood glucose for insulin, which would allow a clinician to foresee the effect of hormonal 
therapy in a given patient and realize a reasonable monitoring of the dose of glucocorticoid 
preparations.  
The problem of safety of glucocorticoid therapy arose concurrently with the first usage of 
glucocorticoids by Dr. P. Hench and colleagues in 1948 (Hench et al, 1949) and difficulties 
which should be inevitable on using glucocorticoids were predicted and described in their 
large publication (Hench et al., 1950). Unfortunately, multiple refined studies on 
glucocorticoids by biochemists, geneticists, endocrinologists, physiologists, although very 
informative, are not frequently intersected with real need of clinical medicine.  
Just the permanent critical state of glucocorticoid therapy made me reconsider my old 
works published in Russian in 19761983 which remained unnoticed and unknown. And 
only the publication in English (Rass, 2010) has attracted the attention to the still urgent 
problem of absence of a laboratory parameter extremely required for glucocorticoid therapy 
of both endocrine and non-endocrine diseases.  
I hope that rather an easy determination of blood tyrosine level will be at last used as a 
suitable laboratory parameter for many situations in clinical medicine, endocrinology, and 
physiology of the hypothalamus–pituitary–adrenal cortex system. In physiology blood 
tyrosine determination can supplement measurements of levels of the hormonal participants 
of this system by data on adequacy of this system functioning to the organism’s needs under 
different situations. 
And finally some speculations.  
The comparison of therapeutic effect of glucocorticoid preparations in SLE with their 
regulatory influence on the blood tyrosine level suggests that the therapeutic action of these 
preparations cannot be conditioned by an exclusive combination of pharmacological 
properties; on the contrary, the unique combination of therapeutic properties of these 
preparations is caused by retention of specific hormonal properties.  
Glucocorticoid hormones are essentially responsible for supporting homeostasis – they 
directly or indirectly participate in regulation of the majority (if not all) biochemical 
reactions and physiological processes. They are hormones of total action and of vital 
importance. But in addition to supporting homeostasis under conditions of health and 
physiological rest, glucocorticoid hormones play a very important and sometimes a decisive 
role under conditions of stress or disease when, as a rule, their secretion increases. Under 
stress situations or in disease glucocorticoid hormones can realize their effects acting via the 
evolutionary selected best pathways, and, no doubt, a certain optimum of the adrenal cortex 
activity must exist for every subject (a human or animal) under extraordinary conditions. 
However, it seems that the optimum of this individual adrenocortical response can be 
revealed not by determination of functions of the hypothalamus-pituitary-adrenocortical 
system links, but only using a result of this system activity - an indirect glucocorticoid-
dependent parameter, which can indicate whether this response is sufficient or not just for 
the concrete subject in a specific situation.  
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Glucocorticoid preparations retain the fundamental features of their natural prototypes, 
including their physiological and regulatory functions and can act via the same pathways. 
Therefore, it seems very likely that glucocorticoid therapy in non-endocrine diseases must 
imitate the optimal hormonal response of a given patient under conditions of disease – as if 
his adrenals could realize such a response. Glucocorticoid therapy must compensate an 
insufficient response of the patient’s own adrenals, it can be life-saving within these limits 
and dangerous beyond them. The determination of blood tyrosine level which is a 
manifestation of the regulatory effect of glucocorticoid can allow a clinician to assess the 
correspondence of the hormonal provision to real needs of the patient.  
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stress situations or in disease glucocorticoid hormones can realize their effects acting via the 
evolutionary selected best pathways, and, no doubt, a certain optimum of the adrenal cortex 
activity must exist for every subject (a human or animal) under extraordinary conditions. 
However, it seems that the optimum of this individual adrenocortical response can be 
revealed not by determination of functions of the hypothalamus-pituitary-adrenocortical 
system links, but only using a result of this system activity - an indirect glucocorticoid-
dependent parameter, which can indicate whether this response is sufficient or not just for 
the concrete subject in a specific situation.  
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Glucocorticoid preparations retain the fundamental features of their natural prototypes, 
including their physiological and regulatory functions and can act via the same pathways. 
Therefore, it seems very likely that glucocorticoid therapy in non-endocrine diseases must 
imitate the optimal hormonal response of a given patient under conditions of disease – as if 
his adrenals could realize such a response. Glucocorticoid therapy must compensate an 
insufficient response of the patient’s own adrenals, it can be life-saving within these limits 
and dangerous beyond them. The determination of blood tyrosine level which is a 
manifestation of the regulatory effect of glucocorticoid can allow a clinician to assess the 
correspondence of the hormonal provision to real needs of the patient.  
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1. Introduction 
Autoimmune diseases may have an adverse effect on reproduction and pregnancy 
outcome. Systemic Lupus Erythematosus (SLE) is associated with a wide variety of 
antibodies to different cell body components, mostly antiphospholipid antibodies. These 
are a heterogeneous group of antibodies that bind to negatively charged phospholipids 
and/or serum phospholipid binding proteins. Antiphospholipid syndrome (APLs) may 
occur as primary APLs or in association with autoimmune diseases. During normal 
pregnancy maternal immunity and hormones allow fetal survival, but when these 
mechanisms are impaired it may have a detrimental effect on the fetus. Pregnancies in 
women with APLs can be complicated by a high rate of pregnancy loss, pre-eclampsia, 
fetal growth restriction, prematurity and fetal distress. Disease flare during pregnancy 
predicts adverse fetal outcome (Kwok et al., 2011). The mechanisms underlying the 
recurrent abortions and fetal loss among women suffering from SLE are not completely 
elucidated. Thrombotic placental events may explain only some of the miscarriages. In 
vitro cell culture of placental trophoblast cell lines with IgG from patients suffering from 
APLs showed that APLs/ anti-β2-glycoprotein I antibodies / anti-β 2 globulin antibodies 
might disrupt the annexin coverage of thrombogenic anionic surfaces on the trophoblast 
and endothelial cell monolayers and lead to Factor X and prothrombin activation (Rand et 
al., 1997). However histopathological findings suggestive of thrombosis cannot be 
detected in the majority of the placentas from women suffering from APLs (Levy et al., 
1998, Meroni et al., 2008). It has been suggested that antiphosholipids may be responsible 
for a local acute inflammatory response mediated by complement activation and 
neutrophil infiltration that eventually leads to fetal loss. Circulating antiphospholipid 
antibodies occurring at about 40% of SLE patients are associated with fetal loss. Some 
investigators regard APLs as a marker for recurrent abortions and not necessarily as their 
primary cause. Lupus anticoagulants, anticardiolipin and anti-β2-glycoprotein I 
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antibodies are typically found among the patients. Complement activation was shown to 
play a role in antiphospholipid antibody - mediated fetal loss associated with 
inflammatory process, when C4d, a degradation product of C4 was demonstrated in 
human placenta of SLE patients (Cohen et al., 2011), as well as diminished number of T 
regulatory cells, associated with pregnancy loss and pre-eclampsia (Tower et al., 2011). 
Circulating microparticles that expose phospholipids in the outer membrane and induce 
coagulation via tissue factor have been associated with lupus anticoagulants and poor 
obstetric outcome (Alijotas-Reig et al., 2009). Other reports indicate that enhanced 
oxidative stress could be linked to autoimmune diseases; however, there is lack of data 
about anti oxidant status of the placenta and embryos during pregnancy in women 
suffering from autoimmune diseases. 
2. The role of experimental animal studies in evaluation of pregnancy 
complications among women suffering from autoimmune diseases 
As more than one mechanism of pathogenesis exists for fetal damage in autoimmune 
diseases, experimental animal models can be used to isolate the different causative effects. 
Evaluation of the role of different antibodies and molecules can be obtained by direct 
injection or induction of antibodies production in the pregnant animals and evaluation of 
the resultant effect on the embryos and fetuses. In such case the effect is evaluated in normal 
animals rather than being secondary to an autoimmune disease.  
Previous published studies revealed fetal damage induced by various antibodies. A smaller 
litter size was demonstrated after the injection to pregnant BALB/C mice with a human 
cytomegalovirus -peptide-induced monoclonal antiphospholipid (Gharavi et al., 2004). Fetal 
heart block and bradycardia were evidenced in a murine model as a result of maternal 
autoantibodies to Ro and La antigen induced by maternal immunization (Suzuki et al., 
2005). In addition maternal immunization with DNA memitope in mice led to the induction 
of autoantibodies that bind DNA and the N-methyl-D-aspartate receptor in the maternal 
circulation leading to increased neocortical cell death in the fetal brain and subsequent 
delayed acquisition of neonatal reflexes and cognitive impairments in the adult offspring. In 
this model the antibodies that were detected in the fetal neocortex outside of blood vessels 
evidenced their transport through fetal circulation until binding to the fetal brain (Lee et al., 
2009). We previously found that the immunization of BALB /C mice with mouse laminin-1 
was followed by the development of anti-laminin-1 antibodies. A double fetal resorption 
rate and lower fetal and placental weight was found in the laminin-1 immunized group 
compared with controls. Resorption rate was highest in the subgroup of animals with very 
high levels of anti-laminin-1 (Matalon et al., 2003). Other molecules were also found to have 
direct embryotoxic effects. The injection of a low-molecular weight fraction of boiled human 
serum containing antiphospholipid antibodies that had been obtained from women with 
antiphospholipid syndrome to pregnant rats at day 5 - 6 of pregnancy resulted in increased 
embryonic apoptosis 2 to 4 hours after the injection  (Halperin et al., 2008). 
3. In vitro systems to evaluate sera toxicity in autoimmune diseases 
To try to evaluate the different mechanisms that lead to poor obstetric outcome we practiced 
three in vitro systems that use sera obtained from patients suffering from autoimmune 
diseases and recurrent abortions as culture media. 
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3.1 In vitro development of pre-implantation mice embryos in culture 
Mouse blastocysts obtained from the uterine horns before implantation at 3.5 days of 
gestation can be cultured for up to 10 days and reach the developmental stage equivalent of 
9.5 to 10 days of gestation in utero, or one-half of the total gestational period. At that early 
somite stage, the blood circulation in the yolk sac is not yet established and the anterior 
neuropore is open. The limb buds and the primordia of the lung, liver, and pancreas are not 
yet present (Chen & Hsu, 1982). 
The technology in brief: Female mice are treated with gonadotropins followed 48 h later 
by Human Chorionic Gonadotropin in order to cause super-ovulation. The mice are 
mated with males and insemination is verified the following morning by the finding of a 
copulation plug in the vagina (day 0). Late morula-early blastocyst stages are obtained by 
flushing the uterine horns with culture medium 3 days after mating. Embryos are 
removed from several mice, pooled in an embryological watchglass, washed and 
transferred to fresh medium. A group of 8-10 embryos are placed in drops with Eagle's 
medium supplemented with 50% or 80% human serum. L Glutamine is added to the 
medium in a concentration of 2 mM/cc. Embryos are cultured in a humidified 
atmosphere in unaerobic conditions under paraffin drops. They are checked before 
incubation, after 24 and 72 hours or other incubation times under an inverted microscope 
to determine the developmental stage. The parameters used as criteria for assessing the 
rate of development and differentiation of embryos are namely, hatching of blastocysts 
from the zona pellucida, their adhesion to the substratum, and outgrowth and spreading 
on the surface (Abir et al., 1990). 
Using this method, one can examine direct effects of the sera from women with recurrent 
abortions on early pre-implantation embryos. 
3.2 In vitro development of early somite stage rat embryos in culture 
The early somite rat embryo culture allows the investigation of the embryotoxicity of 
various teratogens in face of the difficulty to perform studies on mammalian embryos while 
in utero (New et al., 1976). It is an in vitro method to evaluate teratogenicity of various 
chemicals (i.e. different drugs and chemicals) as the tested compounds are added to the 
culture medium and the embryos cultured during organogenesis (New et al., 1976). The 
various agents can be evaluated either individually or in combination. Adverse embryonic 
outcomes (malformations or embryolethality) were shown to be directly related to the 
serum concentration of the compound being tested and can be compared to the serum 
concentration in the human. Moreover, as embryos can also be cultured directly on human 
serum, it may serve as a tool to investigate the direct effects of sera from women with 
different diseases on embryonic development. Additionally, the early somite rat embryo 
culture model can allow the evaluation of success of various treatment modalities and thus 
may be an important tool to predict the outcome of the pregnancy. This can be achieved due 
to the yolk sac (the chorioallantoic placental equivalent at this stage in rat pregnancy) which 
provides a large surface area for nutritional and respiratory exchange between the embryo 
and the culture medium. Previous studies proved that rat conceptuses explanted at 9.5-12.5 
days, when the embryo develops from the early neurula to the late tail bud stage, can be 
maintained in vitro for 48 hours with almost 100% survival and growth that is 
indistinguishable from that occurring in vivo.  
The technology in brief: Pregnant female rats are euthanized on day 9.5 to 12.5 of pregnancy 
when sperm finding is considered to be day 0. The embryos are cultured for 28-48 hours at 
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37°C in rotating bottles, and supplemented with gas mixtures: day-1: 20% Oxygen, 75% N2, 
5% CO2, and day-2: 40% oxygen, 55% N2, and 5% CO2. After 28-48 hours of culture the 
embryos are examined under a dissecting microscope and scored according to the method 
described by Brown et al (Brown & Fabro, 1981) and us (Abir & Ornoy, 1996, Abir et al., 1994). 
Only embryos with a beating heart are examined for yolk sac size and circulation, axial 
rotation, neural tube closure, presence of telencephalic vesicles, optic and otic vesicles, number 
of somites, body size, and presence of gross anomalies. The use of morphological scoring 
system provides an index for embryonic development proportional to the embryonic age and 
aids in the detection of anomalies induced by the different teratogens. The embryos and yolk 
sacs are kept for different morphological, biochemical and molecular studies.  
The possible direct effects of the sera from women with autoimmune diseases can be 
examined on cultured rat embryos using sera or IgG obtained from women with SLE/APLs 
as the culture medium, and analyzing the effects these sera has on embryonic growth, rate 
of anomalies, and ultrastructural yolk sac damage compared to sera from control healthy 
women and control rats. 
3.3 Human placental explants in culture 
The use of first trimester chorionic villi explants cultures has the advantage over cell culture 
of being the in vivo source of extravillous trophoblast and the preservation of topological 
and functional villous-extravillous trophoblast inter-relationships. It was demonstrated that 
first trimester villous explants maintained on Matrigel or rat tail collagen support the villous 
explants differentiation, migration and hormone production in 98 per cent of cultures 
(Genbacev et al., 1992). The study of placental explants in culture, where no blood 
circulation exists, enabled the evaluation of the direct effects of different sera on the 
placenta, thus exposing the mechanisms of placental damage other than placental infarcts, 
thrombosis and vasculopathy. 
The technique in brief: Placental tissue of 5.5–7.5 weeks of gestation are transferred on sterile 
gauze in an ice-cold phosphate-buffered saline and then removed to a Petri dish and rinsed 
in phosphate buffered saline. Placental tissue is dissected from deciduas and fetal 
membranes for inspection under a dissecting microscope. Explants of approximately 10 mg 
wet weight are transferred into Millicell-CM culture dish insert (Millipore, Bedford, MA), 
which has been previously layered with polymerized Matrigel® (Collaborative Research, 
Bedford, MA). The inserts are then placed in 24-well culture dishes. Explants are placed in 
incubator (5% CO2) for 60 min at 39°C to evaporate phosphate buffered saline droplets to 
assist in villi adherence to the thin layer of Matrigel®. Cultures are incubated overnight in 
an incubator with 5% CO2. Twelve hours from the initiation of culture 400 µl of different 
types of different sera enriched with 1 mg glucose/ml are added directly to the inserts. Both 
the media from the insert (top) and the well (bottom) are changed every 48 hr, collected, and 
stored at -20°C until assayed. Villous explants are inspected daily using an inverted phase-
contrast microscope for general cellular integrity, cellular proliferation, and outgrowth. The 
explants remain in culture for 4 days. At the end of the experiment, villi with supporting 
Matrigel® are dissected out using surgical blades and kept for morphological, 
immunohistochemical biochemical and molecular studies, and the media is removed for the 
analysis of major hormones secreted by the placental tissue. 
To evaluate the possibility that in SLE/APLs at least some of the antibodies may directly 
damage placental trophoblastic cells, consequently causing fetal damage that may lead to 
Embryonic and Placental Damage Induced by Maternal  
Autoimmune Diseases - What Can We Learn from Experimental Models 
 
189 
intrauterine growth restriction or fetal death and to evaluate therapeutic interventions we 
used human placental explants in culture. 
4. In vitro studies of embryotoxicity of sera from women with recurrent 
abortions on pre-implantation mice in culture 
4.1 The embryotoxicity of sera from women with recurrent abortions on pre-
implantation mice in culture 
Mouse blastocysts 3.5-day-old at late morula stage and inside the zona pellucida,  
were cultured for 72 h in 50% or 80% sera from women with recurrent abortions. In 
embryos cultured in sera from women with recurrent abortions, 53.2% did not reach 
blastocystic development, compared to 33.6% of the embryos grown on sera from women 
after only one miscarriage and 8.2% and 12% on control sera from women following 
delivery of a normal infant or on sera obtained from women in the second trimester of a 
normal pregnancy respectively. When sera from women with miscarriages were divided 
into “high risk'”(50% or more embryotoxicity) and “low risk”(less than 50% 
embryotoxicity) sera, the “high risk” sera from two or more miscarriages caused an 
average of 72.1% undevelopment (i.e. not reaching the blastocystic stage), while the  
“low risk” sera from the same group caused 33.6% undevelopment. The “high risk” sera 
from one miscarriage were embryotoxic to 55.8% of the blastocysts and the “low risk” sera 
from the same group caused only 8.7% undevelopment similar to the controls (Abir et  
al., 1990).  
4.2 The limitations of the pre-implantation rat culture 
The limitations of this method is that it is impossible to evaluate even early post-
implantation periods that equivalents early organogenesis. It cannot be used for the study of 
growth restriction and for the effects of teratogens which affect the embryo in later stage. In 
addition, the small embryonic size limits the possibility to perform various biochemical and 
genetic studies and does not allow the investigation of the effect of the different chemicals 
on isolated organs. 
In conclusion: More pre-implantation mouse blastocytes failed to reach blastocystic 
development when cultured in sera obtained from women with recurrent abortions 
compared to those cultured in control sera.  
5. In vitro studies of the embryotoxicity of sera from patients suffering from 
systemic lupus erythematosus/antiphospholipid syndrome on early somite 
rat embryos in culture 
5.1 The role of IgG antibodies in recurrent abortions 
To test the hypothesis that IgG antibodies from women with recurrent abortions may be 
responsible for the miscarriage, sera from women one day after an abortion were used as 
culture media for 10.5 days old embryos and compared to human control sera obtained from 
women either during a second trimester of a normal pregnancy or a day after normal 
delivery. Anomalies rate increased from 22% among controls to 47% among embryos 
cultured in sera from women who had a history of one abortion and to 54% among embryos 
cultured in sera from women who had a history of two abortions or more. Anomalies 
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included mainly microcephaly, open neural tube, lack of eyes and cardiac anomalies. The 
difference between the sera was more prominent when the sera were classified as low- less 
than 50% anomalies compared to high-more than 50%. The high rate of anomalies was 
particularly characteristic to the highly teratogenic sera while in the other sera anomalies 
rate was similar to controls. This difference may indicate a basic difference between the two 
sera groups: one that has a factor(s) that is teratogenic in this model and the other that 
induces abortions in a different mechanism that is not relevant to this model.  
 
 
Fig. 1. Early somite 10.5 days rat embryo after 28 hours in culture: normal embryo 
To further evaluate whether the embryotoxic factor in this model is IgG, we used high risk 
sera and control sera, separated the IgG fraction and exchanged it between the sera. We 
defined three groups: one in which IgG from controls corrected the anomalies induced by 
the toxic sera, and the IgG from toxic sera induced anomalies in the embryos cultured in 
the control sera, the second in which control sera did not reduce the rate of anomalies but 
the IgG induced anomalies in the controls, and the third in which no effect was 
demonstrated after IgG exchange. We assumed that in these embryos a different factor 
was responsible for the teratogenicity. When the yolk sacs were evaluated by transmission 
electron microscopy we found a morphological damage represented by fewer microvilli 
and more inclusions in the entodermal epithelial cell in the sacs from embryos cultured in 
high risk sera (Abir et al., 1993).  
5.2 The role of IgG antibodies in intra-uterine growth restriction 
Besides recurrent abortions and fetal death, a main morbidity among infants of mothers 
suffering from autoimmune diseases is intra-uterine growth restriction. To investigate the 
role of the IgG antibodies on embryonic and fetal growth we evaluated the effect of high 
levels of antiphospholipid and anti DNA antibodies on 11.5 days rat embryos in culture, a 
stage when most of the organs have already been formed. Reduced fetal growth and yolk  
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Fig. 2. Early somite 10.5 days rat embryo after 28 hours in culture: arrow-open neural tube  
sac diameter were found in embryos cultured in media containing IgG from women 
suffering from SLE / recurrent abortions, compared to IgG from controls or medium 
without IgG. When we evaluated the role of the different IgG fractions (anticardiolipin-β2 
glycoprotein, antiphosphatidylserine, anti-double stranded DNA, anti-laminin, anti-
thyroglobulin and anti-pyruvate dehydrogenase) compared to controls, only embryos that 
were cultured in sera positive for anti-cardiolipin were significantly smaller than the 
embryos cultured in sera containing normal IgG fractions. The embryos cultured in medium 
containing anticardiolipin/ anti DNA/ antiphosphatidylserine had a smaller yolk sac. 
However, embryos cultured in sera from SLE patients with a history of recurrent abortions 
were also smaller even when they were negative for antiphosphatydilserine. In spite of the 
fact that in these experiments the embryos were cultured towards the end of organogenesis 
when many of the organs have already been formed, 15.6% of the embryos exposed to IgG 
purified from women suffering from SLE / recurrent abortions had anomalies, while only 
8.7% of the embryos exposed to IgG purified from sera of healthy women were malformed. 
There was a significant difference in the development of the brain and branchial bars 
between embryos that were exposed to patients’ IgG and those exposed to IgG that was 
purified from healthy women. There was also a significant reduced somite number among 
the experimental group embryos (Matalon et al., 2002). 
5.3 The effect of IgG antibodies on the yolk sac 
The embryos at the early somite stage are surrounded by their yolk sac and by their 
ectoplacental cone which is the trophoblastic part of the cellular complex at the embryonic 
pole of the blastocyst. The ectoplacental cone is responsible for the invasion into the 
decidua. To evaluate the mechanism by which IgG affects the yolk sac, 11.5 days old 
embryos were cultured in two human IgG2 monoclonal antiphosphatidylserine antibodies 
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The embryos at the early somite stage are surrounded by their yolk sac and by their 
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(HL5B, RR7F). The antiphosphatidylserine antibodies were associated with implantation 
failure in previous studies with mainly trophoblastic injury by inhibition of syncytium 
formation, decreased human chorionic gonadatropin (hCG) production, and disturbed 
trophoblast invasion (McIntyre, 2003). The HL5B monoclonal antibody was generated from 
a primary antiphospholipid syndrome patient with multiple central ischemic events and the 
RR7F monoclonal antibody was generated from SLE patient with high titers of circulating 
antiphosphatidylserine and anticardiolipin antibodies, with no history of thrombosis or fetal 
loss. Both antibodies showed reactivity against phosphatidylserine and cross-reactivity with 
cardiolipin but lacked reactivity against β2-glycoprotein and did not have a lupus 
anticoagulant activity. Embryos cultured in both sera had reduced yolk sac diameter 
without significant difference in the rate of anomalies. Apoptotic processes were found in 
some of the giant cells and in most of the cells located in the area between the mature giant 
cells to the small cytotrophoblastic mononuclear cells. More apoptotic cells were counted 
within the ectoplacental giant cells exposed to anti phosphatidylserine in comparison with 
cells that were exposed to the control human IgG. More than 19% of the giant cells that were 
exposed to HL5B (from the patient with multiple ischemic events) underwent apoptosis, 
while only 12.7%of the cells exposed to RR7F (from the patient with high titers of circulating 
antiphosphatidylserine and anticardiolipin, with no thrombosis neither fetal loss) and 7.3 
and 9.6% of the cells exposed to the control IgG or the experimental medium alone 
underwent apoptosis. Both antibodies stained the ectoplacental cone in the rat embryos 
most strongly with the moderately larger cell layer. Cytotrophoblastic mononuclear cells, 
which are located in the center of the ectoplacental cone, were not stained. The control 
antibodies did not stain the ectoplacental cone at all. Immunofluorescence staining proved 
that the anti phosphatidylserine monoclonal antibodies, reacted with 11.5-day ectoplacental 
cone cells (Matalon et al., 2004). 
5.4 The embryotoxicity of oxidative stress 
The role of oxidative damage in disease activity among patients suffering from autoimmune 
diseases has become more evident in the last decade (Wang et al., 2010). Reactive Oxygen 
Species (ROS) have been implicated in causing immunogenic modifications in the DNA and 
causing oxidative damage that may lead to various autoimmune and degenerative diseases. 
Excessive ROS production which disturbs redox status, may damage macromolecules and 
modulate the expression of a variety of immune and inflammatory molecules leading to 
inflammatory processes and affecting tissue damage (Nathan, 2002).  
The role of oxidative stress in SLE was demonstrated in various studies including: an 
association of the oxidative stress parameters with the pro-inflammatory cytokines (Shah et 
al., 2011b); exposure of purified human dsDNA resulting in ROS production that led to 
changes in the primary structure of the dsDNA that rendered it highly immunogenic when 
injected into rabbits (Al Arfaj et al., 2007); a positive correlation between apoptotic cell 
numbers and ROS production and increased numbers of apoptotic cells positively 
correlating with lipid peroxidation in SLE patients (Shah et al., 2011a). The Conflicting 
results on antioxidant enzyme activities may be due to continued oxidative stress and 
measurement of different components of the antioxidant system at different disease stages 
(Ames et al., 1999, Whitaker & Knight, 2008, Zaken et al., 2000). However the role of 
oxidative stress in recurrent fetal death and growth restriction is unclear.  
Despite medical treatment, women with autoimmune diseases suffer from increased rate of 
pregnancy complication. We tried to determine if during remission there is a relation between 
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the clinical history of the SLE patients (i.e. recurrent abortions and/or thromboembolic event) 
and the morphologic and functional damage which their sera induce on the 10.5 days rat 
embryos and yolk sac in culture. We used as culture media sera from SLE /APLs patients 
during remission (The APLs patients were at least one year free of clotting events and the SLE 
patients had SLEDAI (Systemic lupus erythematosus disease activity index-a commulative 
clinical and laboratory index with higher scores representing increased disease activity) 2000 
less than 4 and compared it to control human sera. The survival of the embryos cultured in 
sera of SLE /APLs women decreased significantly from 87.5% to 70.9% in comparison to 
embryos cultured in control sera. There was a positive correlation between survival rate, the 
neurological developmental stage (calculated by summing the score given for the caudal 
neural tube, hind, mid and forebrain) and number of somites. Additionally a significant 
positive correlation between the growth parameters was demonstrated among the embryos 
cultured in sera from patients and controls: the larger embryos had larger yolk sacs; had 
higher general and neurologic developmental score and more somites, implying more mature 
embryos. (Ergaz et al., 2010). A high rate of anomalies in embryos cultured in sera from 
women with recurrent spontaneous abortions (Abir et al., 1994) or following the addition to 
the culture medium of purified IgG from SLE and APLs patients (Abir & Ornoy, 1996), 
differed from the study using sera obtained from non-pregnant patients in remission, where 
there was no increase in the rate of anomalies compared to controls. It can be speculated 
therefore, that the teratogenicity of the sera reflected the patient’s high-activity disease state 
(Clowse et al., 2005). Delayed neurological system development when the brain structures 
development were behind the other embryonic systems was the predominant finding in 
correlation with clinical studies published in the medical literature that reported learning and 
memory impairment among offspring of mothers with SLE (Urowitz et al., 2008, Ross et al., 
2003) and the finding that the main anomalies in our previous studies were neural tube defects 
(Abir et al., 1994). We speculate that the low activity of the disease allowed high survival and 
low anomalies rate in most of the sera but some sera remained teratogenic due to factors that 
were still active despite remission. We defined two sera groups: “toxic” sera with over-all 
survival rate under ⅔ and those cultured in “non-toxic” sera with over-all survival above ⅔. In 
order to define the characteristics of the “toxic” sera we analyzed the correlations between the 
survival rate, the growth parameters, maternal laboratory findings regarding APLs and the 
clinical history of the patients. We did not find a correlation between sera toxicity and: the 
diagnosis of APLs; The levels of the specific antibodies (anti-double stranded DNA, anti-single 
stranded DNA and the antiphospholipid antibodies: anti cardiolipin, anti-β2 glycoprotein, 
antiphosphatidylserine, antiphosphatidylcholine and antiphosphatidylethanolamine) which 
were high compared to human controls. There was no significant correlation between the 
survival rate and any specific antibody measured in those sera, the history of recurrent 
abortions and toxemia and the history of thrombo-embolic attacks. The yolk sac function was 
evaluated by measuring the 14C sucrose endocytic index which did not differ between the 
controls and SLE/APLs non toxic sera, this is explained by the fact that we studied the index 
only in “non toxic” sera.  
To evaluate the antioxidant defense mechanisms which include a variety of intracellular 
enzymes we evaluated superoxide dismutase, catalase like activity, and low molecular 
weight antioxidants. The low molecular weight antioxidants includes lypophilic and 
hydrophilic molecules like glutathione, carnosine, ascorbate (vitamin C), tocopherol 
(vitamin E), carotenoids (vitamin A), bilirubin, uric acid and flavonoids, which act directly 
with various reactive oxygen species, DNA repair enzymes and methionine sulphoxide 
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reductase that repair or remove reactive oxygen species-damaged biomolecules (Ornoy et 
al., 1999). Our previous studies on the reducing power of the low molecular weight 
antioxidants in control rat embryos and yolk sacs revealed only one peak 1 at 560-620 mvolts 
on 9.5-11.5 days of gestation and an additional peak (peak 2) at 950-970 mvolts first 
appearing on day 11.5 of gestation (Zaken et al., 2000), which is the day we ended our 
culture. The major components of peak 1 as measured by HPLC are ascorbic and uric acids, 
Tryptophan, carnosine, melatonine (Beit-Yannai et al., 1997) and thioacetic acid (Chevion et 
al., 2000) were found to be the major components of peak 2 in the rat brain . The low 
molecular weight antioxidants were evaluated by cyclic voltametry (Zaken et al., 2000). 
Most of the embryos cultured in the “toxic” SLE /APLs sera did not have the peak 2 of the 
low molecular weight antioxidants. The lack of the peak 2 in the present study may be the 
reflection of the delayed embryonic maturation as the embryos were smaller and less 
developed. This is similar to our finding of decreased low molecular weight antioxidants 
demonstrated by the absence of peak 2, in 10.5 days embryos cultured for 28 hours under 
diabetic conditions (Zaken et al., 2000). There was also a positive correlation between a 
lower peak 1 of low molecular weight antioxidants and recurrent abortions in the embryos 
cultured in the SLE /APLs sera that was not related to sera toxicity. Catalase and superoxide 
dismutase activity did not vary between the groups. It is unknown whether the oxidative 
insult has a similar effect on the different developing organs. We evaluated the oxidative 
stress in the total embryo, while the different organs and systems in the rat embryo may 
have different expressions under similar circumstances (Dubnov et al., 2000). The normal 
levels of the anti oxidant enzymes evaluated may indicate that sera toxicity is not related to 
oxidative stress.  We did not find any past clinical history or laboratory finding that was in 
correlation with the sera embryotoxicity. The possible causes for the high embryotoxicity of 
about half of the sera in remission are currently unknown. 
5.5 The effect of maternal medical treatment on sera teratogenicity  
The role of some treatment modalities was evaluated by rat embryo cultures in sera from 
women with and without medications. We examined 10.5 days old embryos cultured in sera 
from women suffering from SLE complicated by recurrent abortions, either untreated 
women, or treated with steroids and aspirin and compared the results to embryos cultured 
in sera from control women and to a pool of control rat sera. Untreated sera resulted in 
45.1% death rate compared to 29.8% in treated sera, 3.9% in control human and 5.1% in 
control rat serum. Malformation rate decreased from 73.3% in untreated sera to 37.5% in 
treated sera, 10.2% in human controls and 5.4% in rat controls. Malformations were mostly 
in the heart, brain, limbs and tail (Ornoy et al., 1998). Thus, treatment that improves 
pregnancy outcome also reduces the embryotoxic effects of the sera. 
5.6 The effect of maternal medical treatment on the extent of yolk sac damage 
Transmission electron microscopy of the yolk sacs revealed an increase in intracellular 
inclusions and decrease in microvilli number in both experimental groups, embryos 
cultured in sera from treated or untreated patients compared to controls. Scanning electron 
microscope revealed abnormally large entodermal cells, a decreased number of microvilli 
with sometimes crater formation (Ornoy et al., 1998). The anticoagulant treatment reduced 
fetal anomalies rate but did not improve yolk sac damage implying that yolk sac damage is 
only a component in the different factors leading to fetal damage. 
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5.7 The limitations of the early somite rat embryo culture system 
By using the early somite rat embryo culture system we evaluated the direct effect of sera 
from patients suffering from autoimmune diseases and analyzed the levels of the different 
sera variables during flare and remission. The impact of the different sera was not universal, 
and only some of the sera caused embryonic damage. Since the antiphospholipid antibodies 
were proven as the cause of embryotoxic effect only in some of the sera, we believe that 
other mechanisms are involved in the teratogenic effect and growth restriction as well. A 
disadvantage of this in vitro testing are also the limited culture time and limited period of 
embryogenesis that is undertaken in the commonly used culture system which restricts the 
range of embryotoxicity that can be induced. It may, therefore, render the testing system 
unsuitable for teratogens that are likely to exert their major toxicological effect very early or 
late in gestation (Webster et al., 1997). Additionally we evaluated embryonic growth, 
structural anomalies and yolk sac function. Infants of mothers who suffer from SLE 
experience mainly intra-uterine growth retardation, which may be more prominent at the 
final pregnancy stages not in correlation with the pregnancy stage of early somite rat 
embryos. The lack of change in oxidative stress parameters may reflect the evaluation of the 
embryo as a whole. It is unknown whether the oxidative insult has a similar effect on the 
different developing organs. The different organs and systems in the rat embryo may have 
different expressions under similar circumstances as shown in another murine model 
(Dubnov et al., 2000). 
In conclusion: Early somite rat embryos cultured in sera from women who suffered from 
autoimmune diseases had lower survival rate, increase anomalies rate and delayed 
maturation as reflected by their lower morphological score and less developed anti-oxidant 
system. The damage was related to IgG antibodies only in some of the embryos. 
Morphologic yolk sac damage was constant and did not improve with maternal medical 
treatment. 
6. Placental explants studies 
6.1 The effect of SLE/APLs sera on placental explants  
At the early somite stage the yolk sac is the equivalent of the human chorioallantoic 
placenta.  The inhibition of yolk sac growth even without inhibition of embryonic growth, as 
well as ultrastructural damage to the yolk sac endothelial cells may indicate that the 
primary insult or at least a major insult in SLE /APLs and recurrent abortions may be 
damage to the placenta.  
We therefore examined the effects of sera from the patients on early human placental explants 
obtained from interruptions of normal 5.5 to 7.5 week-old pregnancies (because of 
psychosocial reasons), and compared to the effects of sera from healthy women and of a 
chemically defined medium. Placental explants cultured on sera from untreated non-pregnant 
women with SLE/APLs demonstrated a significant decrease in the trophoblastic cell 
proliferation rate compared with non-pregnant control women (Ornoy et al., 2003). Placental 
extracts cultured in SLE/APLs had a higher rate of apoptosis, and reduced βhCG secretion in 
correlation with antiphospholipid antibodies levels. The sera were analyzed for the presence 
and quantification of anti-double stranded DNA, anti-single stranded DNA and 
antiphospholipid antibodies (anti cardiolipin, anti-β2glycoprotein, antiphosphatidylserine, 
antiphosphatidylcholine and antiphosphatidylethanolamine) and Anti-Ro and anti-La. High 
levels of all the different antiphospholipid atibodies and both anti-dsDNA and anti-ssDNA  
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showed a trend towards reduction in βhCG secretion by the placental extracts in culture. Titers 
of anti-Ro and anti-La did not correlate with a reduction in the βhCG levels, probably because 
anti-Ro and anti-La antibodies exert their effect on pregnancy by a passively transferred 
autoimmune disease in fetuses or newborns, causing neonatal lupus and not through placental 
damage. There was no specific single antibody that could be identified to cause the placental 
damage, but rather a combination of different antibodies was responsible for the cumulative 
damage, in accordance with the inconsistent findings of the effects of the different 
antiphospholipid antibodies (Schwartz et al., 2007). 
6.2 The effect of maternal medical treatment on the degree of damage induced in 
placental explants 
When we evaluated the impact of maternal treatment with steroids and/or aspirin on 
placental explants, treatment significantly increased proliferation rate compared with the 
untreated group but remained significantly lower than that found in the control non-
pregnant women. Additionally, a significant increase in the rate of the trophoblastic cell 
apoptosis was demonstrated compared to explants cultured in sera from treated or control 
women. The apoptotic rate, however, was still significantly higher in the treated group than 
that found in the control human group (Yacobi et al., 2002). 
6.3 The limitations of the placental explants culture system 
The placental explants system allows the investigation of the direct effect of sera on 
trophoblastic proliferation. This system where only young human placental explants are 
cultured does not seem to enable the investigation of late pregnancy damage induced by the 
various mechanisms. Additionally it does not allow the investigation of growth parameters 
which tend to impact the fetus at later pregnancy stages. 
In conclusion: Placental explants culture in SLE/APLs sera had decreased trophoblastic 
cells proliferation, a higher rate of apoptosis, and reduced βhCG secretion in correlation 
with antiphospholipid antibodies levels, and increased yolk sac trophoblastic cell apoptosis.  
7. Conclusions 
The pathophysiology of fetal loss and growth restriction among patients suffering from 
SLE/APLs is still an open question that needs to be studied. The pre-implantation murine 
and early somite rat embryo culture offers a model for evaluation of the direct effect of the 
different antibodies and molecules on survival and growth at different time points during 
pregnancy. The concomitant evaluation of the yolk sac function allows the investigation of 
those molecules on the rodent’s placental equivalent. The addition of the human early 
placental extracts culture improves the understanding of the disturbance to early placental 
differentiation, migration and hormone production induced by similar teratogens. 
8. Future research possibilities  
New molecules associated with fetal death, embryotoxicity and growth failure were 
discovered in the last years. The direct effect of those molecules can be evaluated in vitro on 
placental explants, murine pre-implantation embryos and on early somite rat embryos in 
culture in order to isolate the impact that each molecule has, solely or in combination with 
other molecules on pregnancy outcome. The evaluation of the pathological, immunological 
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and biochemical parameters of the cultured embryos may add more clues to the multi-
factorial mechanism of fetal damage among women suffering from autoimmune diseases. 
The understanding of those mechanisms may help to develop new treatment modalities 
which can also be evaluated in this model. 
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which can also be evaluated in this model. 
9. References 
Abir R, Zusman I, Ben Hur H, Yaffe P, & Ornoy A. The effects of serum from women with 
miscarriages on the in vitro development of mouse preimplantation embryos. Acta 
Obstet Gynecol Scand. 1990;69(1):27-33. 
Abir R, Ornoy A, Ben Hur H, Jaffe P, & Pinus H. IgG exchange as a means of partial 
correction of anomalies in rat embryos in vitro, induced by sera from women with 
recurrent abortion. Toxicol In Vitro. 1993 Nov;7(6):817-26. 
Abir R, Ornoy A, Ben Hur H, Jaffe P, & Pinus H. The effects of sera from women with 
spontaneous abortions on the in vitro development of early somite stage rat 
embryos. Am J Reprod Immunol. 1994 Sep;32(2):73-81. 
Abir R, & Ornoy A. Teratogenic IgG from sera of women with spontaneous abortions seem to 
induce anomalies and yolk sac damage in rat embryos. A possible method to detect 
abortions of immunologic origin. Am J Reprod Immunol. 1996 Feb;35(2):93-101. 
Al Arfaj AS, Chowdhary AR, Khalil N, & Ali R. Immunogenicity of singlet oxygen modified 
human DNA: implications for anti-DNA antibodies in systemic lupus 
erythematosus. Clin Immunol. 2007 Jul;124(1):83-9. 
Alijotas-Reig J, Palacio-Garcia C, & Vilardell-Tarres M. Circulating microparticles, lupus 
anticoagulant and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol. 2009 
Jul;145(1):22-6. 
Ames PR, Alves J, Murat I, Isenberg DA, & Nourooz-Zadeh J. Oxidative stress in systemic 
lupus erythematosus and allied conditions with vascular involvement. 
Rheumatology (Oxford). 1999 Jun;38(6):529-34. 
Beit-Yannai E, Kohen R, Horowitz M, Trembovler V, & Shohami E. Changes of biological 
reducing activity in rat brain following closed head injury: a cyclic voltammetry study 
in normal and heat-acclimated rats. J Cereb Blood Flow Metab. 1997 Mar;17(3):273-9. 
Brown NA, & Fabro S. Quantitation of rat embryonic development in vitro: a morphological 
scoring system. Teratology. 1981 Aug;24(1):65-78. 
Chen LT, & Hsu YC. Development of mouse embryos in vitro: preimplantation to the limb 
bud stage. Science. 1982 Oct 1;218(4567):66-8. 
Chevion S, Roberts MA, & Chevion M. The use of cyclic voltammetry for the evaluation of 
antioxidant capacity. Free Radic Biol Med. 2000 Mar 15;28(6):860-70. 
Clowse ME, Magder LS, Witter F, & Petri M. The impact of increased lupus activity on 
obstetric outcomes. Arthritis Rheum. 2005 Feb;52(2):514-21. 
Cohen D, Buurma A, Goemaere NN, Girardi G, le Cessie S, Scherjon S, et al. Classical 
complement activation as a footprint for murine and human antiphospholipid 
antibody-induced fetal loss. J Pathol. 2011 Mar 10. 
Dubnov G, Kohen R, & Berry EM. Diet restriction in mice causes differential tissue 
responses in total reducing power and antioxidant compounds. Eur J Nutr. 2000 
Feb;39(1):18-30. 
Ergaz Z, Mevorach D, Goldzweig G, Cohen A, Patlas N, Yaffe P, et al. The embryotoxicity of 
sera from patients with autoimmune diseases on post-implantation rat embryos in 
Embryonic and Placental Damage Induced by Maternal  
Autoimmune Diseases - What Can We Learn from Experimental Models 
 
199 
culture persists during remission and is not related to oxidative stress. Lupus. 2010 
Dec;19(14):1623-31. 
Genbacev O, Schubach SA, & Miller RK. Villous culture of first trimester human placenta--
model to study extravillous trophoblast (EVT) differentiation. Placenta. 1992 Sep-
Oct;13(5):439-61. 
Gharavi AE, Vega-Ostertag M, Espinola RG, Liu X, Cole L, Cox NT, et al. Intrauterine fetal 
death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. 
Lupus. 2004;13(1):17-23. 
Halperin R, Elhayany A, Ben-Hur H, Gurevich P, Kaganovsky E, Zusman I, et al. 
Pathomorphologic and immunohistochemical study on the devastation of rat 
embryos by antiphospholipid antibody positive serum. Am J Reprod Immunol. 
2008 Dec;60(6):523-8. 
Kwok LW, Tam LS, Zhu T, Leung YY, & Li E. Predictors of maternal and fetal outcomes in 
pregnancies of patients with systemic lupus erythematosus. Lupus. 2011 May 4. 
Lee JY, Huerta PT, Zhang J, Kowal C, Bertini E, Volpe BT, et al. Neurotoxic autoantibodies 
mediate congenital cortical impairment of offspring in maternal lupus. Nat Med. 
2009 Jan;15(1):91-6. 
Levy RA, Avvad E, Oliveira J, & Porto LC. Placental pathology in antiphospholipid 
syndrome. Lupus. 1998;7 Suppl 2:S81-5. 
Matalon ST, Shoenfeld Y, Blank M, Yacobi S, Blumenfeld Z, & Ornoy A. The effects of IgG 
purified from women with SLE and associated pregnancy loss on rat embryos in 
culture. Am J Reprod Immunol. 2002 Nov;48(5):296-304. 
Matalon ST, Blank M, Matsuura E, Inagaki J, Nomizu M, Levi Y, et al. Immunization of 
naive mice with mouse laminin-1 affected pregnancy outcome in a mouse model. 
Am J Reprod Immunol. 2003 Aug;50(2):159-65. 
Matalon ST, Shoenfeld Y, Blank M, Yacobi S, von Landenberg P, & Ornoy A. 
Antiphosphatidylserine antibodies affect rat yolk sacs in culture: a mechanism for fetal 
loss in antiphospholipid syndrome. Am J Reprod Immunol. 2004 Feb;51(2):144-51. 
McIntyre JA. Antiphospholipid antibodies in implantation failures. Am J Reprod Immunol. 
2003 Apr;49(4):221-9. 
Meroni PL, Gerosa M, Raschi E, Scurati S, Grossi C, & Borghi MO. Updating on the 
pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy 
loss. Clin Rev Allergy Immunol. 2008 Jun;34(3):332-7. 
Nathan C. Points of control in inflammation. Nature. 2002 Dec 19-26;420(6917):846-52. 
New DA, Coppola PT, & Cockroft DL. Comparison of growth in vitro and in vivo of post-
implantation rat embryos. J Embryol Exp Morphol. 1976 Aug;36(1):133-44. 
Ornoy A, Yacobi S, Avraham S, & Blumenfeld Z. The effect of sera from women with 
systemic lupus erythematosus and/or antiphospholipid syndrome on rat embryos 
in culture. Reprod Toxicol. 1998 Mar-Apr;12(2):185-91. 
Ornoy A, Zaken V, & Kohen R. Role of reactive oxygen species (ROS) in the diabetes-
induced anomalies in rat embryos in vitro: reduction in antioxidant enzymes and 
low-molecular-weight antioxidants (LMWA) may be the causative factor for 
increased anomalies. Teratology. 1999 Dec;60(6):376-86. 
Ornoy A, Yacobi S, Matalon ST, Blank M, Blumenfeld Z, Miller RK, et al. The effects of 
antiphospholipid antibodies obtained from women with SLE/APS and associated 
 
Systemic Lupus Erythematosus 
 
200 
pregnancy loss on rat embryos and placental explants in culture. Lupus. 
2003;12(7):573-8. 
Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, et al. Pregnancy loss in the 
antiphospholipid-antibody syndrome--a possible thrombogenic mechanism. N 
Engl J Med. 1997 Jul 17;337(3):154-60. 
Ross G, Sammaritano L, Nass R, & Lockshin M. Effects of mothers' autoimmune disease 
during pregnancy on learning disabilities and hand preference in their children. 
Arch Pediatr Adolesc Med. 2003 Apr;157(4):397-402. 
Schwartz N, Shoenfeld Y, Barzilai O, Cervera R, Font J, Blank M, et al. Reduced placental growth 
and hCG secretion in vitro induced by antiphospholipid antibodies but not by anti-Ro 
or anti-La: studies on sera from women with SLE/PAPS. Lupus. 2007;16(2):110-20. 
Shah D, Aggarwal A, Bhatnagar A, Kiran R, & Wanchu A. Association between T 
lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative 
stress in systemic lupus erythematosus. Free Radic Res. 2011a May;45(5):559-67. 
Shah D, Wanchu A, & Bhatnagar A. Interaction between oxidative stress and chemokines: 
Possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. 
Immunobiology. 2011b Apr 13. 
Suzuki H, Silverman ED, Wu X, Borges C, Zhao S, Isacovics B, et al. Effect of maternal 
autoantibodies on fetal cardiac conduction: an experimental murine model. Pediatr 
Res. 2005 Apr;57(4):557-62. 
Tower C, Crocker I, Chirico D, Baker P, & Bruce I. SLE and pregnancy: the potential role for 
regulatory T cells. Nat Rev Rheumatol. 2011 Feb;7(2):124-8. 
Urowitz MB, Gladman DD, MacKinnon A, Ibanez D, Bruto V, Rovet J, et al. Neurocognitive 
abnormalities in offspring of mothers with systemic lupus erythematosus. Lupus. 
2008;17(6):555-60. 
Wang G, Pierangeli SS, Papalardo E, Ansari GA, & Khan MF. Markers of oxidative and 
nitrosative stress in systemic lupus erythematosus: correlation with disease activity. 
Arthritis Rheum. 2010 Jul;62(7):2064-72. 
Webster WS, Brown-Woodman PD, & Ritchie HE. A review of the contribution of whole 
embryo culture to the determination of hazard and risk in teratogenicity testing. Int 
J Dev Biol. 1997 Apr;41(2):329-35. 
Whitaker BD, & Knight JW. Mechanisms of oxidative stress in porcine oocytes and the role 
of anti-oxidants. Reprod Fertil Dev. 2008;20(6):694-702. 
Yacobi S, Ornoy A, Blumenfeld Z, & Miller RK. Effect of sera from women with systemic 
lupus erythematosus or antiphospholipid syndrome and recurrent abortions on 
human placental explants in culture. Teratology. 2002 Dec;66(6):300-8. 
Zaken V, Kohen R, & Ornoy A. The development of antioxidant defense mechanism in 
young rat embryos in vivo and in vitro. Early Pregnancy. 2000 Apr;4(2):110-23. 
9 
A Rabbit Model of Systemic  
Lupus Erythematosus, Useful  
for Studies of Neuropsychiatric SLE 
Rose G. Mage1 and Geeta Rai2 
1Laboratory of Immunology, NIAID, National Institutes of Health 
 2Department of Molecular and Human Genetics, Faculty of Science  




The aim of this review is to present in one place a summary of the development of a rabbit 
model of SLE conducted using pedigreed rabbits bred and selected at the National Institute of 
Allergy and Infectious Diseases (NIAID), NIH. We provide an overview of the knowledge 
gained by using rabbits (Oryctolagus cuniculus) as models for SLE, and eliciting autoantibodies 
typical of those produced by patients with SLE. We present here summaries of work by 
ourselves and coauthors that can contribute to improved understanding of neuropsychiatric 
SLE (NPSLE) (Sanches-Guerro et al., 2008). Our gene expression studies (Rai, et al., 2010) and 
extensive evaluations of autoantibody responses coupled with observed clinical symptoms of 
animals immunized against peptides from the Smith antigen (Sm) or the NMDA glutamate 
receptor have shown promise to improve understanding NPSLE. 
An overview of immune system development, genetic diversity of immunoglobulin genes 
and somatic diversification during B-cell development in rabbits can be found in a review 
by Mage et al., (2006) and reference therein. Investigations of autoantibodies found in 
patients with NPSLE and the problems of diagnosis and specific treatments are addressed in 
other chapters in this volume.  
2. Our model  
2.1 Earlier studies of SLE models by other laboratories using rabbit 
We set out to develop a model of SLE in pedigreed rabbits because an earlier report showed 
that immunization of non-pedigreed rabbits with peptides such as PPPGMRPP, derived 
from the Sm B/B’ subunit of the spliceosomal Smith autoantigen led to epitope spreading, 
SLE-like autoantibody production and clinically observed seizures. This peptide sequence is 
one of the major regions of reactivity in SLE patients and may mimic the peptide PPPGRRP 
from the EBNA-1 component of Epstein-Barr virus (EBV) (James et al., 1995). Another study 
attempted to reproduce this report but only found some evidence for epitope spreading 
with no suggestion of induced autoimmunity (Mason et al., 1999). We hypothesized that the 
different results may have been obtained because small numbers of rabbits were studied, 
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one of the major regions of reactivity in SLE patients and may mimic the peptide PPPGRRP 
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with no suggestion of induced autoimmunity (Mason et al., 1999). We hypothesized that the 
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and there may have been different genetic susceptibilities among outbred rabbits studied by 
the two groups. Since our work already depended on breeding and maintenance of 
immunoglobulin allotype-defined pedigreed rabbits, we were in a position to pursue this 
idea further.  In addition to using the MAP-8-PPPGMRPP immunogen used in these 
previous studies (termed SM-MAP-8 in the following sections), we chose a new immunogen 
termed GR-MAP-8 based on a report by DeGiorgio et al (2001) that some anti-DNA 
antibodies cross-react with the NMDA glutamate receptor. 
2.2 The model in pedigreed rabbits 
We established a rabbit model of Systemic Lupus Erythematosus (SLE) in which peptide 
immunization led to lupus-like autoantibody production including anti-Sm, -RNP, -SS-A, -
SS-B and -dsDNA. Some neurological symptoms in form of seizures and nystagmus were 
observed (Rai et al., 2006). The animals were selectively bred within the colony of pedigreed, 
immunoglobulin allotype-defined but non-inbred rabbits at the NIAID. We continued 
breeding responders from the first three groups studied (Rai et al., 2006, 2010, Puliyath et al., 
2008, Yang et al., 2009a,b).  Details about genetics, gene expression and cellular studies are 
in the sections below.  The genetic heterogeneity of the pedigreed animals studied may 
correspond to that found among patients of a given ethnicity. 
2.2.1 Methods 
Rabbits: All rabbit experimentation and immunization protocols were reviewed and 
approved by the Animal Care and Use committees of the NIAID, NIH and of Spring Valley 
Laboratories where the animals were bred, housed and monitored. The animals’ 
designations, sexes, and allotypes at the VH a immunoglobulin heavy chain and C b light 
chain loci are summarized in Tables 1A and B. Rabbits of groups 1, 3, 4, 5 and 6 received 
peptides (SM or GR) synthesized on MAP-8 branched lysine backbones and rabbits of group 
2 received the peptides on MAP-4. BB indicates control rabbits that received backbone alone. 
SM animals received MAP-peptide derived from the sequence of the Smith antigen 
spliceosomal B/B' complex. GR animals received MAP-peptide derived from the NMDA 
glutamate receptor sequence. 
Antigens: The peptide immunogens “GR” and “SM” used for the initial rabbit 
immunizations (Rai et al., 2006), were synthesized on branched lysine MAP-8 and MAP-4 
backbones (BB) (AnaSpec) The SM peptide sequence PPPGMRPP corresponds to major 
antigenic regions at 191-198, 216-223 and 231-238 of the nuclear protein Sm B/B’ (James et al, 
1995). The GR peptide sequence DEWDYGLP corresponds to a known rabbit sequence of an 
extracellular epitope of the NR2b subunit of neuronal postsynaptic NMDA receptor.  The 
MAP-BB without peptide was used as a control antigen. For subsequent studies, (Puliyath et 
al., 2008, Yang et al., 2009b, Rai et al. 2010), MAP-8 was the BB of choice because it appeared 
to elicit more diverse autoantibody responses. 
Immunization: Rabbits each received subcutaneous (s.c.) injections of one of the  
MAP-peptides or control BB (0.5 mg/0.5 ml, in borate buffered saline, pH 8.0) emulsified 
with 0.5 ml of complete Freund’s adjuvant (CFA).  Boosts were given s.c. at 3-week 
intervals with the same antigen concentration emulsified with incomplete Freund’s 
adjuvant (IFA). Controls that received only CFA followed by IFA were included in  
one study (Yang et al., 2009b). Sera collected immediately before immunization (pre-
immune) and 1 week after each boost (post-boost) were stored at -20C in multiple 
aliquots for assays. 
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Rabbit ID Rabbit no. Allotype Sex 
Group 1    
SM1 XX129-3 a1/1, b4/5 M 
SM2 2XX127-4 a1/1, b5/5 F 
SM3 2XX288-2 a1/1, b9/9 M 
SM4 1XX288-4 a1/1, b5/9 F 
SM5 2XX127-2 a1/1, b9/9 M 
SM6 2XX92-06 a1/1, b9/9 F 
GR7 XX129-5 a1/1, b4/5 M 
GR8 2XX127-5 a1/1, b9/9 F 
GR9 1XX288-3 a1/1, b5/5 M 
GR10 2XX288-6 a1/1, b5/9 F 
BB11 2XX127-1 a1/1, b5/5 M 
BB12 1XX78-8 a1/1, b9/9 F 
Group 2    
SM13 LL191-1 a1/1, b4/5 M 
SM14 LL191-2 a1/1, b5/5 F 
SM15 2LL179-1 a1/1, b9/9 M 
SM16 1LL163-3 a1/1, b9/9 F 
SM17 LL164-4 a1/1, b9/9 F 
GR18 1LL178-2 a1/1, b9/9 M 
GR19 1LL178-3 a1/1, b4/4 F 
GR20 1LL178-4 a1/1, b9/9 F 
GR21 1LL178-5 a1/1, b4/9 M 
GR22 1LL178-6 a1/1, b4/9 F 
GR23 1LL178-8 a1/1, b4/4 F 
BB24 LL164-1 a1/1, b9/9 M 
BB25 LL164-3 a1/1, b9/9 F 
BB26 2LL179-3 a1/1, b5/9 M 
BB27 1LL163-4 a1/1, b5/9 F 
Group 3    
GR28 LL108-1 a1/1, b5/9 M 
GR29 LL108-3 a1/1, b5/5 F 
GR30 LL108-4 a1/1, b9/9 F 
BB31 2LL179-2 a1/1, b9/9 M 
Group 4    
SM32 1QQ299-2 a1/1, b5/5 M 
SM33 1QQ299-3 a1/1, b4/5 F 
SM34 6QQ299-1 a1/1, b4/9 M 
SM35 6QQ299-2 a1/1, b4/5 F 
GR36 3QQ299-1 a1/1, b4/5 M 
GR37 3QQ299-2 a1/1, b5/9 M 
GR38 3QQ299-4 a1/1, b5/9 M 
GR39 4QQ299-1 a1/1, b5/9 M 
GR40 5QQ299-2 a1/1, b5/9 F 
GR41 5QQ299-3 a1/1, b5/5 F 
BB42 1QQ299-1 a1/1, b5/5 M 
BB43 5QQ299-4 a1/1, b5/5 F 
BB44 6QQ299-3 a1/1, b4/9 F 
PB45 1QQ173-1 a1/1, b5/9 M 
PB46 1QQ173-2 a1/1, b5/5 M 
PB47 1QQ173-3 a1/1, b5/5 M 
Table 1. A. Designations of sexes and allotypes of Groups 1-4. 
PB45, 46, and 47 received injections with phosphate buffered saline only. 
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SM4 1XX288-4 a1/1, b5/9 F 
SM5 2XX127-2 a1/1, b9/9 M 
SM6 2XX92-06 a1/1, b9/9 F 
GR7 XX129-5 a1/1, b4/5 M 
GR8 2XX127-5 a1/1, b9/9 F 
GR9 1XX288-3 a1/1, b5/5 M 
GR10 2XX288-6 a1/1, b5/9 F 
BB11 2XX127-1 a1/1, b5/5 M 
BB12 1XX78-8 a1/1, b9/9 F 
Group 2    
SM13 LL191-1 a1/1, b4/5 M 
SM14 LL191-2 a1/1, b5/5 F 
SM15 2LL179-1 a1/1, b9/9 M 
SM16 1LL163-3 a1/1, b9/9 F 
SM17 LL164-4 a1/1, b9/9 F 
GR18 1LL178-2 a1/1, b9/9 M 
GR19 1LL178-3 a1/1, b4/4 F 
GR20 1LL178-4 a1/1, b9/9 F 
GR21 1LL178-5 a1/1, b4/9 M 
GR22 1LL178-6 a1/1, b4/9 F 
GR23 1LL178-8 a1/1, b4/4 F 
BB24 LL164-1 a1/1, b9/9 M 
BB25 LL164-3 a1/1, b9/9 F 
BB26 2LL179-3 a1/1, b5/9 M 
BB27 1LL163-4 a1/1, b5/9 F 
Group 3    
GR28 LL108-1 a1/1, b5/9 M 
GR29 LL108-3 a1/1, b5/5 F 
GR30 LL108-4 a1/1, b9/9 F 
BB31 2LL179-2 a1/1, b9/9 M 
Group 4    
SM32 1QQ299-2 a1/1, b5/5 M 
SM33 1QQ299-3 a1/1, b4/5 F 
SM34 6QQ299-1 a1/1, b4/9 M 
SM35 6QQ299-2 a1/1, b4/5 F 
GR36 3QQ299-1 a1/1, b4/5 M 
GR37 3QQ299-2 a1/1, b5/9 M 
GR38 3QQ299-4 a1/1, b5/9 M 
GR39 4QQ299-1 a1/1, b5/9 M 
GR40 5QQ299-2 a1/1, b5/9 F 
GR41 5QQ299-3 a1/1, b5/5 F 
BB42 1QQ299-1 a1/1, b5/5 M 
BB43 5QQ299-4 a1/1, b5/5 F 
BB44 6QQ299-3 a1/1, b4/9 F 
PB45 1QQ173-1 a1/1, b5/9 M 
PB46 1QQ173-2 a1/1, b5/5 M 
PB47 1QQ173-3 a1/1, b5/5 M 
Table 1. A. Designations of sexes and allotypes of Groups 1-4. 
PB45, 46, and 47 received injections with phosphate buffered saline only. 
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Group 5    
GR 48 UA345-1 a2/2, b9k/9k M 
GR49 1UA344-1 a1/2, b9k/9k M 
GR50 1UA344-5 a1/2, b9k/9k F 
GR51 1YY119-6 a1/1, b9/9 F 
GR52 1YY119-8 a1/1, b9/9 F 
GR53 2YY119-6 a1/1, b9/9 M 
GR54 2YY299-5 a1/1, b4/9 F 
GR55 2YY299-3 a1/1, b4/9 F 
GR56 UA345-2 a1/2, b4/9k M 
GR57 1UA344-2 a1/2, b5/9k M 
GR58 1UA344-6 a2/2, b5/9k F 
GR59 1YY119-7 a1/1, b9/9 F 
GR60 1YY327-2 a1/1, b5/9 M 
GR61 2YY327-9 a1/1, b4/5 F 
GR62 2YY299-4 a1/1, b4/9 F 
GR63 2YY119-8 a1/1, b9/9 F 
BB64 UA345-4 a2/2, b9k/9k F 
BB65 2UA344-1 a1/2, b9k/9k F 
BB66 1UA344-3 a2/2, b5/9k M 
BB67 2YY327-8 a1/1, b4/5 M 
BB68 UA345-6 a1/2, b4/9k F 
BB69 1YY327-4 a1/1, b5/9 F 
BB70 1YY119-5 a1/1, b9/9 M 
BB71 2YY119-7 a1/1, b9/9 M 
Group 6    
GR72 UA345-5 a2R3/2R3, 4/9k F 
GR73 UA269-3 a1/1, b4/9k F 
BB74 6YY328-4 a1/1, b5/9 M 
BB75 2YY125-6 a1/2, b9k/9k M 
CF1 6YY328-3 a1/1, b5/9 M 
CF2 1UA161-1 a1/1, b9/9 M 
GR76 2YY119-9 a1/1, b9/9 F 
GR77 UA269-1 a1/1, b4/5 M 
BB78 YY118-6 a1/1, b9/9 M 
BB79 1UA161-2 a1/1, b9/9 M 
CF3 1YY125-4 a2/2, b4/9k M 
CF4 2YY125-4 a2/2, b5/9k M 
GR80 XA345-1 a1/2, b9/9k F 
GR81 2UA14-2 a1/1, b5/9 F 
BB82 XA346-2 a1/1, b9/9 M 
BB83 2UA14-3 a1/1, b5/9k F 
CF5 XA345-2 a1/2, b9/9k F 
GR84 XA234-2 a1/2, b5/9 F 
GR85 XA346=1 a1/1, b9/9 M 
BB86 XA234-2 a1/2, b5/9 M 
B87 3XA203-2 a1/ali M 
CF6 2XA344-2 a1/1, b9/9 F 
CF7 1XA344-1 a1/1, b9/9 M 
Table 1. B. Designations of sexes and allotypes of Groups 5 and 6. 
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Clinical Assessments: Rabbits were housed in a separate room equipped with video 
surveillance so that abnormal behavior such as seizure activity and other neurological 
dysfunctions could be detected.  They were observed daily and also received periodic 
complete health evaluations. Hematology using a Bayer Advida, model 120 hematology 
analyzer and blood chemistry assessments of each rabbit were carried out in a Veterinary 
diagnostic laboratory (Antech Diagnostics, Lake Success NY).  
ELISA for anti-peptide antibodies, anti-dsDNA and autoantibodies to nuclear antigens: 
Serum antibody responses to the MAP-peptides and control immunogens were measured 
by solid phase ELISA as previously described (Rai et al 2006). “Polystyrene 96-well plates 
(Corning Inc, Corning, NY, Cat # 3590) were coated with 50 l/well of either SM-, GR- or 
BB- (MAP-8 or MAP–4) at 10 g/ml in bicarbonate buffer, (pH 9.6) and incubated overnight 
at 40C.  Plates were washed three times with PBS (pH 7.2) containing 0.1% Tween 20 and 
blocked with 100 l blocking solution for 1 hr at 370C (Quality Biological Inc, Gaithersburg, 
MD).  Wells were then incubated 1 hr, at 370C with 50 l/well of sera titrated by four-fold 
dilutions in blocking solution, washed 5 times, incubated for 1 hr at 370C with 50 l of a 
1:2000 dilution (0.4 ng/l) of affinity-purified horseradish peroxidase conjugated (HRP) 
goat anti-rabbit IgG (H+L) secondary antibody (Jackson Immunoresearch Laboratories Inc., 
West Grove, PA), developed with 3, 3', 5, 5'- tetramethylbenzidine (TMB) (Inova 
Diagnostics, Inc., San Diego, CA) and the resulting OD read at 450 nm.”  
Commercially available human diagnostic kits (INOVA Diagnostics) were adapted and 
used to assay serum autoantibodies to total extractable nuclear Ags (ENA) and to 
component Ags Sm, Rnp, SS-A, SS-B. Assays for autoantibodies to calf thymus dsDNA were 
adapted similarly using two different commercially available kits (Vidia, Vestec (Kit A); 
Zeus scientific, NJ (Kit B).  Briefly, 100 l rabbit sera diluted 1:100 in the proprietary sample 
diluents were added to antigen-coated wells and incubated for 60 min. at 37C (Kit A) or 30 
min. at RT (Kit B).  Wells were then washed, incubated for 60 min. at 37C (Kit A) or 30 min 
at RT (Kit B) with secondary antibody HRP-goat anti-rabbit IgG Fc (Jackson 
Immunoresearch Laboratories, Inc.) and developed with TMB for reading OD at 450 nm. For 
groups 5 and 6, anti-dsDNA, -ANA, -RNP and -Sm were assayed with the Quantalite kits 
(Inova Diagnostics) substituting affinity purified HRP-goat anti-rabbit IgG Fc for the anti-
human secondary reagent (Puliyath et al., 2008, Yang et al., 2009b). 
Detection of anti-nuclear antibodies (ANA) by indirect immunofluorescence: 
Commercially available slides coated with fixed Hep-2 cells (Antibodies Inc., Davis, CA) 
were incubated with rabbit antisera diluted 1:20 in 5% goat serum (Jackson Immunoresearch 
Laboratories Inc.) for 30 min. at RT.  ANA binding was detected by fluorescence microscopy 
following 30 min incubation at RT with 12.5 ng/l of FITC-goat anti-rabbit IgG Fc (Southern 
Biotech Inc., Birmingham, AL).  Fluorescent binding patterns were compared with reference 
pictures provided by Antibodies, Inc.  
Flow cytometry: Anti-human antibodies that cross reacted with rabbit B-cell activation 
factor (BAFF) (biotin conjugated goat anti-human BAFF polyclonal antibody), 
transmembrane activator and CAML interactor (TACI) (biotin conjugated goat anti-human 
TACI polyclonal antibody)(Antigenix, America, Inc.), BAFF receptor (BR3) (purified goat 
anti-human BR3 antibody) (R&D systems) were used for staining. Briefly, purified PBMCs 
were incubated on ice for 40 min with primary antibody before washing twice with cold PBS 
containing 1% FCS, then subsequent incubation with various secondary reagents or 
secondary antibodies. For BR3 detection, a biotinylated donkey anti-goat IgG was used as 
 
Systemic Lupus Erythematosus 
 
204 
Group 5    
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secondary antibody. Biotinylated antibodies were visualized by PE-conjugated streptavidin 
(Jackson ImmunoResearch laboratories, Inc.). After washing, cells were analyzed using a 
FACS-Calibur flow cytometer  (BD Pharmingen) and FlowJo analytical software (Tree Star). 
Cells were gated on the side scatter x forward scatter (SSCxFSC) profiles to include both 
small and large lymphocytes, as well as monocytes but exclude red blood cells and 
granulocytes; dead cells were excluded by propidium iodide staining. Rabbit IgM+ B cells 
were detected by FITC-conjugated goat anti-rabbit IgM (Southern Biotechnology 
Associates). 
Gene Expression studies: RNA extraction and synthesis of cDNA and cRNA 
Peripheral white blood cells (PWBCs) were lysed with TRIzol (Invitrogen, CA) and total 
RNA was extracted using RNAeasy Mini columns following the manufacturer’s instructions 
(Qiagen, CA). The cRNA probes were prepared from mRNA using the Affymetrix gene chip 
eukaryotic small sample target labeling protocol assay version II (Affymetrix, Santa Clara, 
CA) using 2 cycles of cDNA synthesis and in vitro transcription (IVT) reactions. The cRNA 
thus obtained was used in the final IVT cycle for obtaining biotinylated cRNA using CTP 
and UTP (EnzoBioarray, Enzo Life Sciences, Farmingdale, NY) (Rai et al 2010).   
Microarray analysis Affymetrix U95A human microarray chips were used and hybridization 
of the labeled cRNA was carried out according to the manufacturer's recommended 
protocol.  Non-normalized MAS5 signals were used to compare raw probeset intensity 
values between human and rabbit samples. Final rabbit study analyses were conducted with 
expression values summarized using dChip, log2 transformed and Loess normalized using 
an R package (http://www.elwood9.net/spike). Analyses of the gene sets were done using 
Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov/knowledgebase/) and Ingenuity Pathways Analysis (IPA) 
(Ingenuity Systems, Mountain View, CA; www.ingenuity.com). 
Quantitative real time PCR: Quantitative real time PCR analysis of mRNAs was performed 
on a 7900HT Sequence Detection System (Applied Biosystems). The cDNA synthesized from 
isolated PWBCs was directly used as template for real-time PCR by using TaqMan 2x PCR 
Master Mix Reagents Kit (Applied Biosystems). Each sample from three independent 
experiments was run in duplicate.  The unit number showing relative mRNA levels in each 
sample was determined as a value of mRNA normalized against Peptidylprolyl isomerase A 
(PPIA). RT-PCR data were analyzed by using the 2−CT method. Based on its uniform 
expression among rabbit groups in the microarray analysis, rabbit peptidylprolyl isomerase 
A (PPIA; cyclophilin A) was selected as the housekeeping gene control and used for the 
calculation of CT. Where rabbit sequences were unavailable, primers were designed after 
searching for rabbit sequences with corresponding human gene sequences in the database 
containing the trace archives of the whole genome shotgun sequence of the rabbit 
(Oryctolagus cuniculus) generated by the Broad Institute of MIT and Harvard University 
(NCBI trace archive: cross- species Megablast at http://www.ncbi.nlm.nih.gov/blast/ 
tracemb.shtml) and in assemblies of rabbit scaffolds at Ensembl and UCSC (see NCBI Rabbit 
Genome Resources site) at: http://www.ncbi.nlm.nih.gov/projects/genome/guide/rabbit/ 
2.2.2 Genetics and autoantibody responses 
Figure 1 shows the pedigree and an overview of antibody responses of the rabbits 
immunized and selectively bred during the project to develop a rabbit model of SLE. There 
were 31 1- to 2-year-old rabbits in the initial studies (Rai et al., 2006). Rabbits of groups 2 or 
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3 were descendants of rabbits of groups 1 or 2 and/or their siblings. Rabbits that did not 
respond with autoantibody production after immunization during this initial study by Rai 
et al., (2006) are not shown. The fourth group was described in Rai et al., (2010) and their 
mRNA included along with mRNA from the first three groups for gene expression profiling 
of a total of 46 pedigreed control- or immunized-rabbits as detailed below (section 2.2.3). 
Controls that received only phosphate buffered saline are designated PB. Because the  
GR peptide generally elicited better autoantibody responses than the SM peptide, the  
two subsequent groups [5 (Puliyath et al., 2008) and 6 (Yang et al., 2009b)] were immunized 
with GR-MAP-8 or control BB-MAP-8. The final 6th group also included controls that 
received complete followed by incomplete Freund’s adjuvant but no MAP-BB or  
MAP-peptide, to investigate whether adjuvants alone led to any autoantibody production 
(designated CF).  
An overview of autoantibody responses, and the relationships of males (squares) and 
females (circles) in six immunization groups is shown in Figure 1. The four quadrants 
indicate post-immunization elevations of levels of anti-dsDNA (upper left), anti-Sm and/or 
anti-RNP (lower left), ANA by IFA (upper right) and ANA by ELISA (lower right). For the 
5th (Puliyath et al. 2008) and 6th groups (Yang et al., 2009b), darker shades indicate high 
autoantibody responses. The large circles and squares represent the 6th group developed 
from selective breeding using responders from earlier groups. Figure originally published 
by Yang et al., (2009b) Investigations of a rabbit (Oryctolagus cuniculus) model of systemic 
lupus erythematosus (SLE), BAFF and its receptors. PLoS ONE Vol. 4, 2009. 
The selective breeding led to subsequent progeny (groups 5 and 6) exhibiting more 
consistent autoantibody production. In the pedigree, we can trace the ancestry of some 
responder rabbits back to the first high responders (SM1 and GR9) that also exhibited 
seizures. For example, GR54 and GR55 from litter 2YY299 had high-responder grandsires 
SM1 and SM15 (Puliyath et al. 2008). The model developed using selectively bred pedigreed 
rabbits remains a promising one for further genetic investigations. 
As is found in human sera (Li et al., 2011), some rabbits had detectable pre-immune anti-
nuclear antibodies (ANA) by ELISA. ANA of sixteen of twenty-four rabbits in group 5, 
including four immunized with only MAP-8 backbone had an increased ELISA value (delta 
OD) above pre-immune of 1.0 or more optical density units after the third boost. Anti-
dsDNA increased in 12/24 rabbits after the fifth or seventh boost (Puliyath et al., 2008). 
Figure 2 shows examples of indirect immunofluorescence (ANA-IFA) studies of some sera 
from group 6 (Yang et al. 2009b). As in human SLE sera, the ANA-IFA patterns reflect 
responses to one or more autoantigens in different individuals. Littermates that received GR 
peptide such as UA269-3 and -1 (GR73 and GR77) developed similar patterns after the 3rd 
boost. ANA staining with sera of littermates XA346-1 and -2 (GR85 and BB82) resulted in 
different patterns. GR85 serum exhibited some cytoplasmic and peripheral nuclear staining 
not seen with the serum of BB82.  Puliyath et al., (2008) also noticed that GR-immunized 
littermates had similar ANA-IFA staining patterns but that BB immunized animals’ patterns 
generally differed. 
2.2.3 Gene expression studies 
We extended the information about the rabbit model of SLE by microarray-based  
expression profiling of mRNA from peripheral blood leukocytes following peptide 
immunization (Rai et al., 2010). Data obtained in studies of gene expression in the first four 
groups of immunized rabbits were deposited in the Gene Expression Omnibus and became  
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lupus erythematosus (SLE), BAFF and its receptors. PLoS ONE Vol. 4, 2009. 
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dsDNA increased in 12/24 rabbits after the fifth or seventh boost (Puliyath et al., 2008). 
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public on Jul 23, 2010 at the NCBI website: http://www.ncbi.nlm.nih.gov/geo/query/ 
acc.cgi?acc=GSE23076  
Experiment type: Expression profiling by array. GEO accession: Series GSE23076 Query 
DataSets for GSE23076 
 
 
Fig. 2. Examples of indirect ANA-IFA assays of pre- and post-immune sera. Figure 
originally published by Yang et al., (2009b) Investigations of a rabbit (Oryctolagus cuniculus) 
model of systemic lupus erythematosus (SLE), BAFF and its receptors. PLoS ONE  
Vol.4, 2009. 
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At the time of the gene expression studies, microarrays specific for study of gene expression 
profiles were not available for rabbits. We therefore first conducted comparisons of 
identically prepared rabbit and human cRNA binding to the Affymetrix U95 microarray 
available for human gene expression analyses. We showed that the human microarray could 
be used with rabbit cRNA to yield information on genetic pathways activated and/or 
suppressed in autoantibody-producing immunized rabbits. After demonstrating that human 
expression arrays could be used with rabbit RNA to yield information on molecular 
pathways, we designed a study evaluating gene expression profiles in a total of 46 rabbits 
from 4 groups of the pedigreed control and immunized rabbits. We discovered unique gene 
expression changes associated with lupus-like serological patterns in immunized rabbits. 
Our results also demonstrated that caution must be applied when choosing the structure of 
the carrier Multiple Antigen Peptide (MAP-peptide) for immunization. We discovered that 




Fig. 3. Gene expression patterns differ when the backbone of immunogen is MAP-4 (A) or 
MAP-8 (B). In panel A, Cluster 1 genes were overrepresented in the SM group, Cluster 2 
were common to both, Cluster 3 genes were overexpressed in the GR group and Cluster 4 
genes were decreased in expression in both groups. Count indicates the number of different 
genes associated with each functional term. Figure modified from one originally published 
in The Journal of Immunology. Rai, G., Ray S., Milton, J., Yang, J., Ren, P., Lempicki, R., and 
Mage, R.G. 2010. Gene expression profiles in a rabbit model of systemic lupus 
erythematosus autoantibody production. J. Immunol. 185:4446-4456. Copyright © [2010] The 
American Association of Immunologists, Inc.  
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Figure 3 shows that distinct patterns and clusters of functionally related genes were found 
to be upregulated when peptides SM or GR on MAP-4 backbone (A) were used as 
immunogens compared to when MAP-8 backbone was used (B) (Rai et al., 2010). Validation 
of gene expression data by quantitative real-time PCR was conducted for two genes for 
which primer sequences were available beta2-microglobulin (B2M) and p-21-protein 
(Cdc42/Rac)-activated kinase 1 (PAK1) (Figure 6 in Rai et al., 2010).  These genes appear in 
the interactive pathway shown in Figure 4 below. Among the genes significantly 
upregulated in SLE rabbits were those associated with NK cytotoxicity, antigen 
presentation, leukocyte migration, cytokine activity, protein kinases, RNA spliceosomal 
ribonucleoproteins, intracellular signaling cascades, and glutamate receptor activity (Rai et 
al., 2010). 
 
Functional Annotation p-Value Number of molecules 
Inflammatory Disorder 1.6E-11 25 
Immunological Disorder 3.1E-11 23 
Rheumatic Disease 5.4E-11 19 
Autoimmune Disease 2.7 E-08 18 
Rheumatoid Arthritis 1.7E-06 13 
Glomerulonephritis 2.6E-06 5 
Inflammation 2.5E-05 7 
Lupus Nephritis of Mice 3.2E-04 3 
Table 2. The top functional annotations found using Ingenuity Pathways Analysis (IPA) in 
comparisons of upregulated genes of rabbits making anti-dsDNA to those only making 
other anti-nuclear antibodies. 
Figure 4 and Table 2 summarize the patterns of upregulated gene expression found in the 
rabbits from the three groups immunized with MAP-8-peptides that made anti-dsDNA 
compared to those that only made other anti-nuclear antibodies. Twenty-five genes 
associated with inflammatory disorders were significantly upregulated in expression.  
Subsets of these were associated with various immunological disorders in the IPA databases 
including Autoimmune, Rheumatic, and inflammatory diseases. The results linked 
increased immune activation with up-regulation of components associated with 
neurological and anti-RNP responses, demonstrating the utility of the rabbit SLE model to 
uncover biological pathways related to SLE-induced clinical symptoms, including NPSLE. 
We suggested that our finding of distinct gene expression patterns in rabbits that made anti-
dsDNA should be further investigated in subsets of SLE patients with different 
autoantibody profiles (Rai et al., 2010). In Figure 4, the connecting lines indicate direct 
interactions among the products of these genes. The shapes classify the proteins found as 
transmembrane receptors e.g. CD 40, cytokines/growth factors, e.g. CCL2, kinases, e.g. TYK2, 
peptidases, e.g. MMP9, other enzymes, e.g. ARF1 and transcriptional regulators, e.g. STAT5B. 
Genes shown were common to the pathways listed in Table 2 that were upregulated in the 
anti-dsDNA positive rabbits. Figure 4 was modified from one originally published in the 
Journal of Immunology. Rai, G., Ray S., Milton, J., Yang, J., Ren, P., Lempicki, R., and Mage, 
R.G. 2010. Gene expression profiles in a rabbit model of systemic lupus erythematosus 
autoantibody production. J. Immunol. 185:4446-4456. Copyright © [2010] The American 
Association of Immunologists, Inc.  
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Fig. 4. Interactive pathway network of upregulated genes in anti-dsDNA positive rabbits.  
2.2.4 Rabbit BAFF 
Our laboratory described the expression and localization of rabbit B-cell activating factor 
(BAFF also termed BLys, TNFSF13b TALL1, zTNF4) and its receptor BR3 in cells and tissues of 
the rabbit (Yang et al., 2009a). In addition to its important role in B-cell development and 
survival, disease activity in human lupus patients has been reported to correlate with serum 
BAFF levels (reviewed in Groom et al., 2007) and with elevated expression of mRNA for BAFF 
and two BAFF receptors, BR3 and transmembrane activator and CAML interactor (TACI) in 
PBMC of lupus patients (Petri et al, 2008).  We therefore also investigated BAFF and its 
receptors in our rabbit model of SLE (Yang et al., 2009b). We previously concluded that BAFF 
detected on B cells by flow cytometry represented BAFF bound to its receptors on the cells 
(Yang et al, 2009a). An independent study (Yeramilli, & Knight, 2010) also reported that BAFF-
binding receptors on rabbit B-cells are occupied by endogenous soluble BAFF. These authors’ 
studies also suggested that B cells in rabbit could produce BAFF. With the small number of 
total animals available in group 6 (Table 1B), and no reagents available to detect levels of 
serum BAFF, we could only measure BAFF on cell surfaces by flow cytometry. These studies 
found decreased surface expression of BAFF, BR3 and TACI after immunization and boosting 
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in most animals.  However, two rabbits that produced high anti-dsDNA responses (GR76 and 
GR77) developed higher percentages of BAFF/CD14 and BR3/CD14 positive cells. We did 
observe consistently lower mean fluorescence intensities of staining of TACI on PBMC and 
lower percentages of TACI positive cells. We suggested that since TACI is a negative regulator 
of B cells in mouse and man, perhaps the decrease in TACI in the rabbits producing 
autoantibodies had allowed autoreactive B cells to escape regulation. 
At the time these studies were conducted, clinical trials targeting BAFF/BLys and its 
receptors were in progress. With the FDA approval of Benlysta® (belimumab) in March, 
2011, this monoclonal antibody, that inhibits binding of BLys/BAFF to receptors on B cells, 
became the first United States FDA approved treatment for SLE in over fifty years. 
Unfortunately, the clinical trials did not include SLE patients with severe active central 
nervous system lupus or nephritis. Post-approval trials will be required before this 
treatment can be recommended for these cohorts of patients. 
2.3 Future prospects 
2.3.1 Detection of autoantibodies to other antigens including neuroantigens in the 
rabbit model 
In our rabbits, the development of severe symptoms may not yet have occurred because 
many were euthanized to make room for immunization and testing of their progeny and for 
tissue collection. For example, although nephritis was not observed, our gene expression 
studies identified upregulation of genes associated with Glomerulonephritis and also found 
in mice with Lupus Nephritis (Table 2 and Figure 4). Protein arrays containing microbial 
and autoantigens have been used to extend information on patients’ serum profiles beyond 
the standard tests used in diagnosis (see for example, Robinson et al., 2002; Quintana et al., 
2004; Li et al., 2005; Fattal et al. 2010). Recently, Li et al, (2011) used protein microarrays to 
determine risk factors for ANA positivity in healthy persons and concluded that serum 
profiles of autoantibodies can potentially identify healthy individuals with potential to 
develop lupus and other autoimmune diseases. Their observations extended the widely 
quoted earlier observations by Arbuckle et al, (2003) that autoantibodies develop as much as 
ten years before the clinical onset of SLE. In a NOD mouse model of cyclophosphamide-
accelerated diabetes, Quintana et al (2004) used a protein microarray to predict from 
autoantibody repertoires, resistance or susceptibility to the development of diabetes before 
the induction with cyclophosphamide. Recently Fattal et al, (2010) applied the same 
technology to studies of SLE patients and controls.  They reported highly specific SLE 
profiles that typically show increases in IgG binding to dsDNA, single-stranded DNA, 
Epstein–Barr virus, and hyaluronic acid. Interestingly, a healthy control subject who had the 
SLE antibody profile was later found to develop clinical SLE. Decreases in some specific IgM 
reactivities to autoantigens observed in this and earlier studies (Li et al., 2005) suggest that 
some natural IgM autoantibodies may play a protective role. A project to determine the 
antibody profiles of the rabbits’ serum IgG and IgM, purified anti-dsDNA, and anti-peptide 
on protein microarrays carrying microbial and self antigens including those from the central 
and peripheral nervous system is in progress. 
2.3.2 NPSLE and anti-NMDA glutamate receptors  
The suggestion from extensive studies in the laboratory of Betty Diamond that some anti-
dsDNA antibodies may react with the NMDA receptor and contribute to neurological 
manifestations in some lupus patients (DeGiorgio et al. 2001; Kowal et al, 2004), has led to 
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numerous follow-up studies by the Diamond group, (Diamond & Volpe, 2004) and others. A 
recent editorial (Appenzeller, 2011) provides an updated overview of controversies in the 
field and discusses the accompanying paper by Gono et al., (2011) who report new analyses 
of 107 patients’ sera for cross-reactivities of anti-dsDNA with a peptide derived from the 
sequence of the human NMDA receptor 2A (NR2A) compared with the similar peptide from 
human NR2B. They suggest that the sensitivity for detection of autoantibodies is greater 
with the NR2A peptide although their ELISA results directly comparing serum reactivities 
with each peptide were correlated with high significance (r = 0.94; P<0.0001). They conclude 
that assays of sera for anti-NR2A antibodies may be a better predictor of NPSLE than assays 
for NR2B and suggest that mixed results from other similar studies may be explained by 
small numbers of patients (Husebye et al., 2005) or less sensitive assays. We chose the GR 
peptide used in our immunization protocol based on the human sequence of NR2B because 
the rabbit sequence was not yet known. However, we knew that this sequence was highly 
conserved in several species including mouse, rat, dog, cow and chicken.  
2.3.3 Rabbit genomics 
Future studies of rabbit autoimmune and infectious diseases will benefit from the 
availability of a high quality draft rabbit genome sequence and assembly at ~7 x coverage 
recently completed at the Broad Institute, Boston (OryCun2.0). The donor was from a 
partially inbred strain. NCBI maintains a Rabbit Genome Resources website: 
http://www.ncbi.nlm.nih.gov/projects/genome/guide/rabbit/ 
Rabbit genomic sequences and assemblies from the ENCODE Project, with ~ 1% of rabbit 
genomic sequence from a different, outbred NZW animal are also available in GenBank. The 
selection of peptides for future immunization studies in rabbits can benefit from searching 
these resources. 
3. Conclusion 
The work described in this review documents that rabbits have a strong genetic component 
that leads to predisposition to production of autoantibodies similar to those found in SLE 
patients including those with NPSLE. Breeding and selection for consistent autoantibody 
production in the rabbit model can be accomplished over a few generations.  When one of 
us (RGM) retired to Emeritus status at NIAID, the pedigreed colony was no longer 
maintained.  Some animals related to those studied were distributed to others. In addition, 
although the pedigreed colony was dispersed, there is sperm available from two male 
breeders rabbits LL191-1 (SM13) and 1UA344-1 (GR49). In particular male SM13 and his 
progeny in the breeding scheme shown in Figure 2 generated numerous responders that 
made autoantibodies similar to those found in human Lupus patients. Cryovials of sperm 
from these animals are currently stored at the Twinbrook 3 facility of the Comparative 
Medicine Branch (CMB) of NIAID in liquid nitrogen storage tanks, and monitored weekly 
by their personnel.  Further contact information can be obtained at the website of the CMB, 
of the NIAID, NIH at: http://www.niaid.nih.gov/LabsAndResources/labs/aboutlabs/ 
cmb/Pages/default.aspx.  
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numerous follow-up studies by the Diamond group, (Diamond & Volpe, 2004) and others. A 
recent editorial (Appenzeller, 2011) provides an updated overview of controversies in the 
field and discusses the accompanying paper by Gono et al., (2011) who report new analyses 
of 107 patients’ sera for cross-reactivities of anti-dsDNA with a peptide derived from the 
sequence of the human NMDA receptor 2A (NR2A) compared with the similar peptide from 
human NR2B. They suggest that the sensitivity for detection of autoantibodies is greater 
with the NR2A peptide although their ELISA results directly comparing serum reactivities 
with each peptide were correlated with high significance (r = 0.94; P<0.0001). They conclude 
that assays of sera for anti-NR2A antibodies may be a better predictor of NPSLE than assays 
for NR2B and suggest that mixed results from other similar studies may be explained by 
small numbers of patients (Husebye et al., 2005) or less sensitive assays. We chose the GR 
peptide used in our immunization protocol based on the human sequence of NR2B because 
the rabbit sequence was not yet known. However, we knew that this sequence was highly 
conserved in several species including mouse, rat, dog, cow and chicken.  
2.3.3 Rabbit genomics 
Future studies of rabbit autoimmune and infectious diseases will benefit from the 
availability of a high quality draft rabbit genome sequence and assembly at ~7 x coverage 
recently completed at the Broad Institute, Boston (OryCun2.0). The donor was from a 
partially inbred strain. NCBI maintains a Rabbit Genome Resources website: 
http://www.ncbi.nlm.nih.gov/projects/genome/guide/rabbit/ 
Rabbit genomic sequences and assemblies from the ENCODE Project, with ~ 1% of rabbit 
genomic sequence from a different, outbred NZW animal are also available in GenBank. The 
selection of peptides for future immunization studies in rabbits can benefit from searching 
these resources. 
3. Conclusion 
The work described in this review documents that rabbits have a strong genetic component 
that leads to predisposition to production of autoantibodies similar to those found in SLE 
patients including those with NPSLE. Breeding and selection for consistent autoantibody 
production in the rabbit model can be accomplished over a few generations.  When one of 
us (RGM) retired to Emeritus status at NIAID, the pedigreed colony was no longer 
maintained.  Some animals related to those studied were distributed to others. In addition, 
although the pedigreed colony was dispersed, there is sperm available from two male 
breeders rabbits LL191-1 (SM13) and 1UA344-1 (GR49). In particular male SM13 and his 
progeny in the breeding scheme shown in Figure 2 generated numerous responders that 
made autoantibodies similar to those found in human Lupus patients. Cryovials of sperm 
from these animals are currently stored at the Twinbrook 3 facility of the Comparative 
Medicine Branch (CMB) of NIAID in liquid nitrogen storage tanks, and monitored weekly 
by their personnel.  Further contact information can be obtained at the website of the CMB, 
of the NIAID, NIH at: http://www.niaid.nih.gov/LabsAndResources/labs/aboutlabs/ 
cmb/Pages/default.aspx.  
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1. Introduction   
Systemic lupus erythematosus (SLE) is a wide spectrum disease with many clinical 
manifestations. Lack of awareness of the disease itself, with its common and rare 
presentations results in significant delay in diagnosis and consequently serious compromise 
of patients’ care.  
Physical examination will always retain its importance as the most common diagnostic test 
used by doctors and as an essential tool for modern practice(Joshua, Celermajer et al. 2005). 
Findings from proper musculoskeletal (MSK) examination is extremely useful in diagnosing 
rheumatologic disorders especially where gold standard diagnostic tests are lacking. From 
this perspective there should be much emphasis on basic bedside skills among clinicians 
searching for arthritis. Asking about morning stiffness and joint swelling are simple enough 
to pick up early arthritis (Paget 2007). Performing an active range of motion testing of joints 
as a screening method would pick up limitations in joints mobility from active arthritis. In 
real practice, the picture is not simple as such. Despite the impact of MSK disorders on 
health care, rheumatological diseases are often overlooked or inadequately assessed by 
doctors (Jones, Maddison et al. 1992). This chapter will explore some of the issues around 
this complex clinical and educational problem. 
SLE  (the disease of thousand faces) is not only affecting the joints. Major organ involvement 
can be the first presenting symptom(s) and/or sign(s). Knowledge of some of the common 
presenting features of SLE apart from arthritis would help greatly in early recognition of 
this multisystem disease. Renal, central nervous system (CNS), and cardiovascular system 
(CVS) are commonly affected in SLE patients. Knowing the risk factors, early detection and 
close folllow up will have positive impact on patient’s outcome. This chapter will discuss 
some of the clinical issues arising while managing SLE patients that are commonly 
overlooked by clinicans. Late onset SLE and other rare associations like Kikuchi Fujimoto 
disease  will be disscussed in this chapter as well.  
2. Deficiencies in musculoskeletal examination skills 
MSK symptoms are the most common health complications that require medical attention, 
accounting to 20% of both primary care and emergency-room visits (Rasker 1995).  In a 
health survey, MSK disorders were ranked first in prevalence as the cause of chronic health 
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problems, long term disabilities, and consultations with a health professional (Badley, 
Rasooly et al. 1994). In Saudi Arabia, MSK disorders is the second major cause of outpatients 
visit in primary care centers and private clinics (MOH 2009). A number of different medical 
specialties are involved in treating patients with musculoskeletal complaints, including 
general practitioners, family physicians, internists, orthopedic and surgeons, working in 
teams with other health professionals, but often without a multispecialty focus. In order to 
truly improve the outcome of treatment for musculoskeletal conditions, it is important that 
experts in the various specialties work more closely together and look for commonality of 
approach, as they often treat the same patients but from different angles.  
Despite the high prevalence of musculoskeletal disorders in all fields of clinical practice, 
studies show a lower level of competence and confidence in MSK cognitive and clinical 
skills (including physical examinations) across clinicians (Akesson, Dreinhofer et al. 2003; 
Almoallim, Khojah et al. 2007; Beattie, Bobba et al. 2008).  Also, a continuous neglect of 
musculoskeletal examination skills in clinical practice is observed. We reported a case of SLE 
with active arthritis where the diagnosis was delayed for seven days after hospital 
admission due to the lack of basic skills in MSK examination (Almoallim, Khojah et al. 2007). 
The patient in the report presented to the emergency room with fever and pancytopenia and 
apparently the focus of the treating medical team was mainly on these presenting findings. 
This might had restricted the clerking done on admission to "hematology and infectious 
diseases" while what should had been done was a complete history and thorough physical 
examination regardless of initial impression. Musculoskeletal assessment should be a part of 
routine clerking (Lillicrap, Byrne et al. 2003). Assuring such attitude among clinicians will 
prevent unnecessary delay in diagnosis. If a simple musculoskeletal screening examination 
focused mainly on range of motion testing to assess function was done, this patient's active 
arthritis would have been picked up on admission. This would have initiated early search 
for a rheumatological disease and start treatment without a delay. 
  Despite this impact of MSK disorders on health care, rheumatological diseases are often 
overlooked or inadequately assessed by doctors (Jones, Maddison et al. 1992). Thus, patients 
with complaints about bones and joints are often ignored and their problems 
underestimated by doctors.  In a study among 200 general medical inpatients in a teaching 
hospital, it was found out that the signs and symptoms of MSK disorder which were 
recorded in the hospital notes was only 5.5% and 14% respectively. This compared poorly 
with recorded examinations of other systems and regions for example, cardiovascular 
symptoms were recorded in 100% of the cases; respiratory and abdominal symptoms were 
recorded in 99%,  the nervous system , skin and female breasts symptoms were recorded in 
77% and 13% respectively (Doherty, Abawi et al. 1990). In another report, only 40%of 
patients admitted to general medicine ward  had the history of their MSK symptoms 
recorded and only 14.5% of these patients received comprehensive MSK examination 
(Ahern, Soden et al. 1991).  Furthermore, 80% of symptomatic patients received either no 
treatment for their rheumatic disorders, or treatment that was regarded as suboptimal or 
inappropriate (Ahern, Soden et al. 1991). Another report showed even a higher percentage 
of patients – 63% of all patient admitted to general medicine ward- had MSK symptoms or 
its signs, but relevant MSK history was missed in 49% of the patients records, while signs 
were missed in 78%; 42% of those with MSK conditions would have benefitted from 
additional treatment (Lillicrap, Byrne et al. 2003). A more recent report reviewed 150 patient 
notes in three different hospitals from the acute admission wards for medicine and surgery 
and the medical assessment unit. Factors considered included whether GALS screenings 
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had taken place, documentation of MSK examinations and assessment of confidence of 
junior doctors in assessing MSK conditions. GALS screenings were performed in 4% of 
patients on the medical assessment unit, 7% in acute medical and 0% in acute surgical 
patients on admission. Examination of the MSK system yielded better results with 16%, 22% 
and 10% on each of the respective wards. Interviews with junior doctors found 10% 
routinely screening for MSK conditions, despite 87% feeling confident in taking MSK 
histories (Sirisena, Begum et al.). 
Matzkin et al. (2005) indicated that the majority (79%) of the study respondents including 
medical students, residents, and staff physicians failed the basic MSK cognitive examination. 
This suggests that training in MSK medicine is inadequate in both medical school and in  most 
residency training programs. Worldwide, undergraduate and postgraduate medical 
teaching of MSK disorders is currently brief and not directly relevant to the knowledge and 
skills commonly required for the management of these conditions in an outpatient setting.  
In undergraduate education, inadequate MSK education has been reported. Medical 
students spend very few hours on the MSK system, both in basic science and in clinical 
training. It is quite common for students to leave medical schools without being able to 
make a general assessment of the musculoskeletal system. On the other hand, it would be 
considered a total neglect if a medical graduate is incompetent at adequately assessing the 
heart or lungs. Harvard medical students have reported general dissatisfaction of their 
confidences in examining MSK system as compared to their skills in examining pulmonary 
system (Day, YEh et al. 2007). They suggested more time to be devoted to MSK medicine 
and more integration between pre-medical and clinical courses.  
The American Association of Medical Colleges claims that most medical schools do not 
effectively educate future physicians on MSK medicine in spite of the increasing prevalence 
of MSK conduction across medical practice ((AAMC) 2005). The obvious discrepancy 
between the magnitude of MSK conditions and physicians competences, which mostly 
stemmed from the educational deficiencies at the medical schools, is maintained across 
years ((AAMC) 2005; Day, YEh et al. 2007; Clark, Hutchison et al. 2010). Akesson and 
colleagues (2003) argued that teaching at the undergraduate and graduate programmes is 
not adequate and the resulting competence does not reflect the impact of these conditions on 
individuals and society. A comprehensive study reviewing the curricula of all Canadian 
medical schools indicated that directors of undergraduate MSK programmes felt dissatisfied  
with the curricular time devoted to MSK education (Pinney and Regan 2001). In a 
comprehensive study based on a national survey in Saudi Arabia using the Delphi 
technique, internal medicine knowledge and skills competencies including rheumatology 
were determined and prioritized (Almoallim 2010). Table 1 represents only rheumatological 
skills competencies that were identified. Note that the score of 3: indicates must know the 
topic, 2: should know the topic, 1: interesting to know the topic. It was decided in this 
research that any competency with a score ≥ 2.2 should be considered a core competency. 
Table 2 represents overall disease ratings with the number of competencies identified for 
each disease. Such findings would help greatly in designing educational programmes and 
assessment methods based on priorities and it will help in determining what skills for 
rheumatological diseases should be taught. It is a common recommendation among experts 
to give proper attention to training in MSK conditions for both undergraduate and 
postgraduate training programmes.  
In the postgraduate programme the same limitation was highlighted since the 1980s: 
Goldenberg et al (1985) reported that the majority of directors of residency programs 
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problems, long term disabilities, and consultations with a health professional (Badley, 
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had taken place, documentation of MSK examinations and assessment of confidence of 
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thought that many basic skills and techniques were not taught adequately and that the 
training of their rheumatology residents was not equal to that of residents in cardiology or 
gastroenterology. General dissatisfactions of MSK training was reported among the internal 
medicine residents and family practice. United States residents expressed their 
dissatisfaction of their  competence in performing MSK examinations at various parts of the 
body and revealed that to the inadequate or poor training (Clawson, Jackson et al. 2001).  
2.1 Possible obstacles toward an appropriate MSK medical practice  
Previous studies suggested many reasons related to MSK poor clinical skills and physical 
examinations in particular (Clawson, Jackson et al. 2001; Akesson, Dreinhofer et al. 2003; 
(AAMC) 2005; Matzkin, Smith et al. 2005; Day, YEh et al. 2007; Dequeker, Esselens et al. 
2007; Thompson 2008; MOH 2009; Clark, Hutchison et al. 2010):   
 Vague training of MSK in undergraduate programmes;  
 Underestimate the prevalence of MSK conditions and its impact on individuals and 
society  
 MSK is not considered as main competence among medical graduates because it is not a 
life threatening condition.  
 Number of different specialties  involved in treating patients with MSK conditions  do 
not share common approach regardless of specialties interventions, 
 Lack of a proper teaching in MSK is essential in the low competence in MSK generally 
and physical examinations  
 Lack of summative evaluation of MSK physical examination contributes to medical 
graduate low level of competencies  
 The lack of holistic approach and the focus of specialties  
 The lack of standardize approach to the clinical assessment of MSK problems whether 
presenting to primary care, rheumatology or orthopedics that give a benchmark for this 
competency.  
 The disparity in the approach to examination between rheumatologists and orthopaedic 
surgeons mostly leads to poor performances in MSK physical examinations  
 The lack of appropriate teaching and evaluation of MSK because the physical 
examination teachers are not skilled in MSK examinations and thus bone and joint 
diseases are not screened. 
2.2 Global initiative toward MSK medicine  
The global initiative to disseminate awareness to MSK wellbeing had made the World 
Health Organization (WHO) designate the years 2000 to 2010 as Bone and Joint Decade 
(Lidren 2003). In the light of the worldwide commitment, the focus increases on the 
responsibility of medical education and training programmes in providing adequate 
musculoskeletal education. Therefore, global consensus among international experts from 
different specialties and organizations developed a recommendation for MSK teaching in 
undergraduate medical education (Woolf, WAlsh et al. 2004).  
A standardized approach to the clinical assessment of a musculoskeletal problem is 
suggested by Wolf and Akesson (2008): such a standardized approach will be conducted 
whether the patient is presenting to primary care, rheumatology or orthopedics. It also will 
provide a benchmark for this competency and can also be used as a teaching aid (Woolf and 
Åkesson 2008). The issue is whether this kind of standardization would be widely accepted 
by different displines or not. 
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SN RHEUMATOLOGICAL DISEASES (SKILLS COMPITENCIES)  
EXPERT 
RATING 
1 To demonstrate competency skills in obtaining comprehensive history from patient with rheumatological disorders 2.60 
2 
To demonstrate competency skills in applying general principle of joint 
examination ( screening exam, inspection, palpation, range of motion, 
& special tests) in musculoskeletal examination 
2.50 
3 
To demonstrate competency skills in performing comprehensive 
musculoskeletal examination including (the hands & wrists, elbows, 
shoulders, TMJ, the neck, spine & sacroiliac joints, knees, hips, ankles & 
feet).  
2.20 
4 To interpret the ANAs results 1.80 
5 To interpret synovial fluid analysis results including polarized light microscopy 1.70 
6 To demonstrate competency skills in obtaining comprehensive history from patient with back pain.  2.30 
7 To identify on plain x-ray of joints findings consistent with RA.  1.90 
8 To demonstrate competency skills in examining patient with RA.  2.30 
9 To identify on plain x-ray findings consistent with spondyloarthropathies.  1.70 
10 To identify on plain x-ray findings consistent with crystal related joint disease.  1.70 
11 To identify on plain x-ray findings consistent with JRA.  1.30 
12 To demonstrate competency skills in examining patient with crystal-related joint disease.  1.60 
13 To demonstrate competency skills in examining patient with SLE.  2.30 
14 To demonstrate competency skills in examining patient with scleroderma.  1.80 
15 To demonstrate competency skills in examining patient with rheumatic fever.  2.30 
16 To demonstrate competency skills in examining patient with soft tissue rheumatism.  1.50 
17 To demonstrate competency skills in obtaining comprehensive history from patients suspected to have vasculitis.  2.00 
18 To demonstrate competency skills in examining patient with nerve entrapment syndrome.  1.70 
19 To demonstrate competency skills in eliciting physical signs consistent with spondyloarthropathies.  1.60 
20 To demonstrate competency skills in performing joint aspiration.  1.00 
 
Table 1. Rheumatological diseases (skills compitencies) 
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GALS (Gait, Arms, Legs and Spine) a locomotor screening  was developed and validated  as  
a rapid screening protocol / system for MSK with the aim for a quick identification of 
significant abnormalities (Doherty, Dacer et al. 1992). Various spectrums of health specialties 
could utilize this screening routine before specific examination and teach it to trainees and 
medical students. Tabe 3 represents a quick screening tool for MSK disorders adopted from 










Approach To The Patient With Joint Pain 1.91 13 
Approach To The Patient With Low Back Pain 2.00 6 
Rheumatoid Arthritis 2.12 14 
Spondyloarthropathies(SpA) 1.89 17 
Crystal Related Joint Disease 1.95 16 
Osteoarthritis 2.36 7 
Bacterial Septic Arthritis 2.32 6 
Systemic Lupus Erythematosus 2.13 9 
Scleroderma 1.65 6 
Inflammatory Myopathies(Polymyositis 
&Dermatomyositis) 1.69 7 
Sjogren’s Syndrome 1.65 4 
Vasculitis 1.78 8 
Juvenile Rheumatoid Arthritis (Juvenile Idiopathic 
arthritis) 1.74 5 
Miscellaneous Syndromes 0.90 1 
TOTAL                                                                                                                       119 
Table 2. Disease Specific Ratings For Rheumatological Diseases 
3. Late onset SLE 
It is true that most SLE patients are in the child bearing age but SLE can occur in elderly. 
SLE has always been considered a disease of the young. Little attention has been given to 
late onset disease. In contrast with childhood disease, studies on elderly SLE patients are 
scarce (Boddaert, Huong et al. 2004). Late onset disease is the type of SLE whose 
manifestations begin after the age of 50 in majority of the studies (Boddaert, Huong et al. 
2004; Karoubi Nordon, Hayem et al. 2007; Rovensky and Tuchynova 2008) or after the age of 
65 (Pu, Luo et al. 2000).  SLE should be considered in the differential diagnosis while dealing 
with certain clinical settings in elderly population.  Clincians recognizing this clinical entity 
will help greatly to assure early diagnosis of SLE and avoid unnecessary delay in diagnosis 
and management.  
 




1 "Do you suffer from any pain or stiffness in your arms, legs, neck or back?" 
2 "Do you have any swelling of your joints?" 
3 "Do you have any difficulty with washing and dressing?" 
4 "Do you have any difficulty with going up or down stairs or steps?" 
Screening examination 
Gait 
Observe the patient walking forwards for a few meters, turning 
and walking back again. Recognize abnormalities of the different 
phases—heel strike, stance phase, toe-off and swing phases. 
Look for abnormalities of the movement of arms, pelvis, hips, 
knees, ankles and feet. 
Inspection of 
standing patient 
View the patient from the front, side and back, looking for any 
abnormalities, particularly of posture and symmetry. Apply 
pressure in the midpoint of each supraspinatus and roll an 
overlying skin fold to examine for tenderness. 
Spine 
Ask the patient to flex the neck laterally to each side. Place 
several fingers on the lumbar spinous processes and ask the 
patient to bend forward and attempt to touch their toes whilst 
standing with legs fully extended, observing for normal 
movement and feeling for expansion of space between spinous 
processes. 
Arms 
ask the patient to place both hands behind their head and then 
move elbows right back, then straighten the arms down the side 
of the body and bend elbows to 90° with palms down and 
fingers straight. Turn hands palms up and make a tight fist with 
each hand, then place, in turn, the tip of each finger onto the tip 
of the thumb. Squeeze the metacarpals from second to fifth 
cautiously for tenderness. 
Legs 
get the patient to recline on a couch, then flex, in turn, each hip 
and knee while holding and feeling the knee. Passively rotate the 
hip internally. With the leg extended and resting on the couch, 
press down on the patella while cupping it proximally to 
examine for tenderness or swelling of the knee. Squeeze all 
metatarsals and then inspect the soles of the feet for callosities. 
Table 3. Quick screening tool for msk disorder  
Overall, the incidence of late-onset SLE is low, but there are variable numbers reported in 
the literature, ranging from as low as 3.7% (Costallat and Coimbra 1994) and to as high as 
20.1% (Jacobsen, Petersen et al. 1998). This may be related to the different ethnic 
backgrounds included in the studies and the variable definitions of late-onset SLE. Most of 
the literature indicated that the sex ratio declines with age in SLE. In a pooled analysis of 714 
cases of late-onset SLE reported in the literature and 4700 young SLE patients, the female to 
male ratio observed with age in SLE was 4.4:1 vs. 10.6:1 respectively (Boddaert, Huong et al. 
2004). This probably reflects the relationship between SLE and estrogen status which decline 
in the elderly. 
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Late onset SLE is not a well studied disease and it has distinct clinical features. Although the 
disease activity and major organ involvement is less than in the early onset disease, it can 
cause more morbidity and mortality. In one study, there were significant number of patients 
with late onset SLE who died during the research period which may be related to the 
comorbidities and the use of medication which are age related  rather than the disease itself 
(Bertoli, Alarcon et al. 2006). Skin manifestations, photosensitivity, Raynaud phenomenon, 
arthritis, nephritis and neuropsychiatric manifestations were less frequent in comparison 
with young SLE patients. In late-onset SLE, a higher occurrence of pulmonary involvement, 
serositis, and Sjögren's syndrome were observed (Boddaert, Huong et al. 2004; Rovensky 
and Tuchynova 2008).  
There are variable findings in the literature about the occurrence of anti ds DNA antibodies 
in late-onset SLE (Padovan, Govoni et al. 2007; Rovensky and Tuchynova 2008). These 
antibodies did not correlate with organ complications of late-onset disease in one study 
(Padovan, Govoni et al. 2007). A higher prevalence of rheumatoid factor, anti-Ro and anti-La 
antibodies were observed in late-onset SLE. However, lower prevalence of anti-RNP 
antibodies and hypocomplementemia were observed as well (Maddison 1987; Belostocki 
and Paget 2002; Boddaert, Huong et al. 2004; Padovan, Govoni et al. 2007).  
In general, late onset SLE is characterized by a lower disease activity (Costallat and Coimbra 
1994; Boddaert, Huong et al. 2004). This fact does not exclude significant morbidity 
associated with it. The seriuosness of some clinical presentations may preclude clinicians 
from considering autoimmune diseases as an etiology in their work up. This may result in 
unncessary delay in diagnosing late onset SLE. We reported a case of late onset SLE in a 65 
year old female patient, previously healthy, who presented with progressive paraplegia and 
sensory level at T4 (Almoallim, Bukhari et al. 2009). MRI showed extensive transverse 
myelitis (TM) involving the thoracic spine. Antinuclear antibodies (ANA), anti-double 
stranded DNA antibodies (Anti ds DNA) and lupus anticoagulant were all positive. The 
diagnosis was delayed for a month after hospital admission due to lack of awareness of 
basic work up to diagnose SLE. Obviously, SLE was not considered in the basic differential 
diagnosis of this patient. What had been required was simply considering SLE as a possible 
etiology then ordering ANA as a screening tool for SLE. 
4. Neuropsychiatric manifestations of SLE (NPSLE)  
NPSLE may still present a very difficult diagnostic challenge for clinicians (Joseph, Lammie 
et al. 2007). Neurologic features at the onset of SLE is regarded rare, occurring only in 
approximately 3% in some studies and up to 24% in others (Joseph, Lammie et al. 2007). 
NPSLE affects more than half of SLE patients. It ranges in severity from mild symptoms like 
headache to severe neurological dysfunction. Clinicians particularly general internists and 
neurologists who are dealing primarily with patients presenting with complex neurological 
presentations should consider autoimmune diseases and particularly SLE in their diffrential 
diagnosis. Awarness of the 19 neuropsychiatric syndromes defined by ACR as an associated 
feature with NPSLE is essential. (See corresponding chapters for further details). 
The most prevalent symptoms are headache, seizures, mood disorders and cerebrovascular 
disease. Regarding headaches, data showed that there was no significant difference in the 
prevalence of tension type headache and migraine between the SLE patient and the general 
population (Mitsikostas, Sfikakis & Goadsby, 2004).  
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Simple or complex attention, memory, reasoning, executive skills, language, visual-spatial 
processing and psychomotor speed are normal cognitive functions, and any significant 
deficit in one or all of these functions is defined as cognitive dysfunction by ACR. These 
dysfunctions are usually underestimated and require careful testing to avoid unnecessary 
delay in diagnosis.  
Guillain-Barre syndrome (GBS), myasthenia gravis (MG), plexus injury, TM, aseptic 
meningitis and autonomic dysfunctions are less frequent and rare neurological 
manifestation associated with SLE. GBS is an acute, rapidly progressive, autoimmune 
demylinating polyneuropathy resulting in symmetric, ascending paralysis that can be severe 
involving the respiratory muscles and require mechanical ventilation. This disease is 
relatively rare among SLE patients as it is only associated in 7 out of 1100 GBS cases in an 
early study (Leneman 1966). MG is another autoimmune disorder affecting the proximal, 
bulbar and extraocular muscles due to antibodies directed against the post synaptic 
acetylcholine receptors resulting in weakness of the muscles. Among 78 patients with this 
disease, 6 patients (7.7%) had SLE (Sthoeger, Neiman et al. 2006). It was concluded in this 
study that MG patients should be evaluated for the coexistence of SLE, and assessment for 
MG is suggested in lupus patients with unexplained muscular weakness. Various case 
reports showed the association between them (Vaiopoulos, Sfikakis et al. 1994; Bhinder, 
Majithia et al. 2006). The prevalence of TM in SLE patients is 1-2% (Kovacs, Lafferty et al. 
2000). It can occur as the initial manifestation of SLE in up to 39% or within the first five 
years of a diagnosis of SLE in 42% of the total patient population analyzed in one study 
(Kovacs, Lafferty et al. 2000). The predominant presentation of TM in SLE is a sensory level 
commonly in the thoracic region, spastic paraparesis and sphincter disturbance (Kovacs, 
Lafferty et al. 2000; D'Cruz, Mellor-Pita et al. 2004). TM as a presenting feature of late onset 
SLE is rare. Few cases were reported; one patient out of 15 in a report of TM as a presenting 
feature for SLE (D'Cruz, Mellor-Pita et al. 2004), two patients out of 14 in an older series 
about TM in SLE (Kovacs, Lafferty et al. 2000) and two case reports (Chen, Lai et al. 2004; 
Almoallim, Bukhari et al. 2009). 
5. How to avoid delay in diagnosis and management of renal  
involvment in SLE? 
Lupus nephritis (LN) is one of the most worrisome and potentially serious complication of 
SLE and a delay in rcognition and treatment of LN lead to significant morbidity and 
mortality. LN occurs in 40 to 70% of SLE patients (Cameron,1999a; Seligman et al, 2002) 
especially in the first year after diagnosis during the first three months (Eilertsen et al,2011). 
Early searching for renal involvment in SLE is crucial to prevent it from progression. The 
goal of clinicians taking care of lupus patients is to identify individuals with signs of early 
renal disease who are at risk for renal damage.  Appropriate treatment can be initiated early 
to prevent inflammatory lesions from progression to sclerotic ones (end stage LN).  
There are simple parameters that should be followed in each clinical visit to pick up  
early  disease. Clinicians should monitor blood pressure, urine analysis and possibly  
renal function test and anti ds DNA antibodies in each clinical visit. The following are 
abnormal parameters that suggest renal involvement and mandate biopsy: elevated anti ds 
DNA antibodies and decreased C4 were more commonly seen in proliferative lupus 
nephritis compared with non proliferative lupus nephritis (Wen, 2011), hematuria (>5 red 
blood cells per high power field on urine microscopy), nephrotic (>3.5 g protein/24hrs) or 
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Late onset SLE is not a well studied disease and it has distinct clinical features. Although the 
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in late-onset SLE (Padovan, Govoni et al. 2007; Rovensky and Tuchynova 2008). These 
antibodies did not correlate with organ complications of late-onset disease in one study 
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4. Neuropsychiatric manifestations of SLE (NPSLE)  
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et al. 2007). Neurologic features at the onset of SLE is regarded rare, occurring only in 
approximately 3% in some studies and up to 24% in others (Joseph, Lammie et al. 2007). 
NPSLE affects more than half of SLE patients. It ranges in severity from mild symptoms like 
headache to severe neurological dysfunction. Clinicians particularly general internists and 
neurologists who are dealing primarily with patients presenting with complex neurological 
presentations should consider autoimmune diseases and particularly SLE in their diffrential 
diagnosis. Awarness of the 19 neuropsychiatric syndromes defined by ACR as an associated 
feature with NPSLE is essential. (See corresponding chapters for further details). 
The most prevalent symptoms are headache, seizures, mood disorders and cerebrovascular 
disease. Regarding headaches, data showed that there was no significant difference in the 
prevalence of tension type headache and migraine between the SLE patient and the general 
population (Mitsikostas, Sfikakis & Goadsby, 2004).  
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subnephrotic range proteinuria (>0.5g protein/24hrs),or protein/creatinine ratio (>1.0), 
casts (>5 haemogranular or red blood cast), elevated urea and creatinine and elevated blood 
pressure (BP>140/90 mmHg). 
There is a clear need to consider kidney biopsy early on in the course of the disease to help 
guide therapy and suggest long term prognosis. Kidney biopsy can determine the degree 
and severity of renal involvment through established histopathological guidelines. 
Determining the stage of kidney disease have a signigicant impact on determining response 
to therapy. Most nephrologists agree that kidney biopsy is worthwhile in SLE patients with 
abnormal urine analysis and/or reduced renal function. They suggest that kidney biopsy 
should be performed as soon as clinical signs of renal involvment are evident in order to 
accelerate treatment decisions and minimize risk of inflamation induced irreversible renal 
damage (Contreras et al, 2002). Delaying kidney biopsy is unfortunately a practice that is 
still observed among some rheumatologists and nephrologists. Lack of adequately trained 
nephrologists/radiologists who can perform kidney biopsy safely might be a factor that 
explains this delay. Less frequent follow up visits for lupus patients due to overwhelmed 
rheumatology practices in some parts of the world is another possible factor. Poor 
monitoring,  inadequate control of lupus disease activity, and lack of awareness of the need 
to consider kidney biopsy are all other possible factors.  
It was demonstrated early on in the literature in a cohort of 87 patients with LN that delay 
between the detection of the onset of renal disease and renal biopsy was a significant 
predictor at the time of a first renal biopsy for subsequent renal insufficiency (relative risk 
4.9; 95% confidence interval 1.7 to 14.5; p < 0.001) and death due to lupus renal involvement 
(relative risk 6.7; 95% confidence interval 2.1 to 21.2; p < 0.001) (Esdaile, Joseph et al. 1994). 
Delaying therapy, because of presumably mild disease, is often associated with increased 
glomerular injury and fibrosis and therefore a lesser response to immunosuppressive drugs 
(Esdaile, Joseph et al. 1994). Several other recent studies reported that a delay in renal 
biopsy(and therapy) is a strong independent predictor of poor outcome in LN (Faurscho et 
al,2006; Fiehn et al, 2003). Sometimes significant renal disease (stage 3, 4 and 5) can be found 
in renal biopsy even in the absence of impired renal function or even in the presence of low 
level of protienuria (urine:protien/creatinine ratio < 1.0)(Christopher-Stine et al, 2006). A 
full discussion on issues related to kidney biopsy in SLE is presented in another chapter in 
this book. 
5.1 Control of risk factors in lupus nephritis 
An important goal for proper medical care for lupus patient, particularly from a renal 
perspective is the control of risk factors such as protienuria, hypertension, dyslipidemia and 
diet control. 
5.1.1 Proteinuria and hypertension 
Heavy proteinuria is a common feature of patients with proliferative LN and progressive 
renal impairment (Dubois et al, 1987). Serial studies by the Stanford group demonstrated 
that heavy proteinuria is a predictor of progressive renal impairment (Buckheit et al, 1997). 
Therefore, reduction of proteinuria independent of reduction in blood pressure is associated 
with subsequent beneficial effect on the progression of renal disease (Lewis et al, 1993; 
Maschio et al, 1996; Petersen et al, 1995; The Gisen Group 1997). Early intervention on 
proteinuria has a major impact in preventing the progression of kidney disease in SLE. 
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Aggressive reduction of proteinuria should be a goal for any clinician taking care of LN 
patients.  
A number of reports indicated that aggressive treatment of hypertension inhibits 
progressive renal injury (Petersen et al, 1995; Brazy et al, 1990; Rosansky et al, 1990). Few 
mmHg reduction in blood pressure value does matter on the long term. The hypertension 
detection and follow-up programs showed that patients whose BP was 129/86 mmHg 
versus 130/90 mmHg had greater preservation of renal function (Shulman et al, 1989). It 
should be recognized that hypertension is also a strong risk factor for developing 
atherosclerosis which lead to increased risk of heart attacks and strokes. This is to add to the 
extreme importance of controlling hypertension in lupus patients.  
5.1.2 Dyslipidemia 
Dyslipidemia is a common feature of lupus patients treated with steroids and also with 
progressive renal injury and nephrotic syndrome. There is a strong relation in LN patients 
between cholesterol concentration and proteinuria. There are several reports in non-diabetic 
renal disease with proteinuria that relate increase cholesterol and triglyceride to an increase 
in loss of renal function (Apperloo, de Zeeukw & de Jong,1994; Maschio et al, 1989; 
Samuelsson et al, 1993). Hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors 
(statins) are beneficial in lowering low density lipoprotien (LDL) cholesterol. Fish oils and 
fibric acid analogs are helpful in lowering triglyceride and raising high density lipoprotien 
(HDL) cholesterol and should be considered in patients with dyslipidemia. Again, it is 
hoped that this issue should not be neglected by clinicians taking care of lupus patients. 
5.2 The role of angiotensin converting enzyme inhibitors in patients with  
lupus nephritis 
Angiotensen converting enzyme inhibitors (ACEI) represent a class of drugs used to treat 
many common diseases like hypertension, heart failure, post myocardial infarction, and 
microalbuminuria in diabetic patients and nowadays is also used in SLE for many purposes. 
They work by inhibiting the angiotensin converting enzyme that is responsible for 
converting angiotensin 1 to angiotensin 2. ACEI have an anti-inflamatory property as 
angiotensin 2 has pro-inflamatory effect on the cells of different organ system. ACE  has 
been found to be high in synovial fluid (Veal et al, 1992) and rheumatoid nodule in 
rheumatoid arthritis patients (Goto et al, 1992) which suggest its role in the inflammation. In 
SLE patients, ACEI have an end organ protection effect by its multiple effects on 
hypertension and protienuria. ACEI delay the occurence of renal involvment and are 
associated with decreased risk of disease activity in patients with SLE (Duran-Barragan  et 
al, 2008). This is an impressive and important finding that should alert all clinicans taking 
care of lups patients to be aware of this valuable effect on patients outcome. Every effort 
should be spent to assure that LN patients are maintained on these drugs. Lupus patients 
are chronic steroid users which make them liable for hypertension, diabetes mellitus (DM) 
,and coronary artery disease (CAD). Numerous studies have shown beneficial effects of 
using ACEI in the management and prevention of these conditions. Unfortunately, many 
clinicians including rheumatologists tend not to use ACEI/ARBs (angiotensin receptors 
blockers) commonly in SLE patients or they delay introducing them early in the course of 
the disease. One possible reason for this delay is that physicians tend to focus more on acute 
and dramatic presentations of SLE rather than monitoring risk factors that would show 
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subnephrotic range proteinuria (>0.5g protein/24hrs),or protein/creatinine ratio (>1.0), 
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benefical effects on the long term. Therefore, a comprehensive approach to care for lupus 
patients should be followed. 
6. Cardiovascular involvement in SLE 
SLE is associated with a variety of cardiovascular manifestations; some are life threatening 
(including myocardial infarction)  and others are much less serious. Threre are several risk 
factors for heart related conditions, many of which can be avoided. Cardiovascular disease 
is a major cause of morbidity and mortality in SLE. 
Pericarditis remains the most common cardiovascular disease in SLE and occur in 12- 48% 
(Moder, Miller & Tazelaar, 1999). It should be included in the differential diagnosis of SLE 
patients presenting with shortness of breath, low grade fever,pleuritic chest pain and/or dry 
cough. ANA test should be ordered for any young lady in childbearing age with pleuritic 
chest pain. This is to avoid delaying the diagnosis of SLE as pericarditis can be a presenting 
feature. Other less frequent cardiac manifestations of SLE are myocrditis (which is usually 
silent), endocarditis with one characteristic but rare presentation as Libman-Sack 
endocarditis known as verrucous non bacterial thrombotic endocarditis, valvular disease, 
arrhythmias, pulmonary hypertension, and systemic hypertension. 
6.1 SLE and accelarated atherosclerosis 
Today with SLE patients living longer due to more effective drug therapies, CAD has 
become a leading cause of late mortality in SLE. Women with aged 35-44 were found to 
have 50 times more risk of myocardial infarctions than aged matched  controls (Mazni et al, 
1997). Several case-control studies, both autopsy studies and myocardial perfusion studies 
have consistently shown a 30-40% prevelance of sub-clinical CAD in SLE patient (Korkmaz, 
Cansu & Kasifoqlu, 2007). Despite an increasing appreciation of the importance of 
cardiovascular disease in SLE, recognition of traditional risk factors have been noted to be 
suboptimal. As an example, in one academic rheumatology practice, deficits in knowledge 
and management of cardiac risk factors were observed among both SLE patients and their 
physicians (Costenbader et al, 2004). This is again to emphasize the point of increase 
awareness of this serious issue in lupus patients. Lack of comprehensive approach to care 
for SLE patients may lead to significant delay in diagnosing a reversible cardiac risk factor. 
Obviously, this will result in delay in management and increase in cardiac morbidity and 
mortality. 
Many cases with SLE have evidence of subclinical accelerated atherosclerosis (figure 1). It 
is related to both traditional and non traditional risk factors for CAD. The traditional risk 
factors are demographics, family history, smoking, hypertension, DM, and dyslipidemia, 
while the non traditional risk factors include chronic inflammation, presence of 
autoantibodies, prolonged vascular inflamation, corticosrteroid use (10 mg change in 
prednisolone lead to change in mean arterial pressure of 1.1 mmHg after adjustment for 
age,  weight and antihypertensive drug use, and 10 mg increase in prednisolone was 
associated with a mean weight change of 5.50 ±1.23 (Petri, 2000)), renal disease and 
antiphospholipd antibodies. One factor that has repeatedly been shown to affect the 
prevelance of CAD in SLE is active disease. Appropriate management of active SLE is one 
of the best preventitive measures. Due to the high prevelance of CAD in SLE patient, SLE 
itself should be viewed as a CAD risk factor in the same way as DM is (Bradley, 2009; 
Shah, Shah & Krishnan, 2009). 
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SLE patients should have an annual fasting blood glucose and a urinalysis at every clinic 
visit to assess for protienuria, glucosuria and hematuria. Patients with evidence of impaired 
glucose tolerance should undergo dietary changes to prevent frank diabetes from 
developing. Blood pressure(BP) should be followed at every clinical visit with a goal BP of 
less than 130/80 mmHg. For prehypertensive patients, the physician first should try 
therapeutic lifestyle changes (exercise and diet modification) and assess renal function. If 
blood pressure is consistently above 140/90 mmHg, despite therapeutic lifestyle changes, 
then antihypertensive medications should be started with prefarable drugs such as ACEI. 
The cholesterol recommandation for lupus patients are more stringent than those for the 
average patients. Lupus patients should have an annual fasting lipid profile with a goal  
LDL <100 mg/dl (<2.6 mmol/L) (Wajed et al, 2004).  Statin therapy is indicated for LDL>130 
mg/dl (> 3.4 mmol/L) even in those without traditional CAD risk factors. Statins have been 
shown to directly improve endothelial function even in patient with normal lipid profile 
(Vaughan et al, 2000; Laufs et al, 1998).  Also, these patients should be counseled on 
smoking cessation and weight reduction if their BMI >25. Low dose aspirin should be 
considered for those patients with traditional risk factors and those that are 
antiphospholipid antibody positive (Erkan et al, 2002;  Bertsias et al, 2008; Wahl et al, 2000). 
Screening patients at higher risk by non invasive techniques like carotid Duplex or Single 
Photon Emission Computed Tomography-Dual Isotope Myocardial Perfusion Imaging 
(SPECT-DIMPI) can help in early detection of subclinical atherosclerosis (Sella et al, 2003). 
To prevent long-term cardiovascular consequences, these patients should be treated 
aggressively, both to control their primary lupus disease activity and to minimize 
modifiable CAD risk factors. Life style modification, weight reduction, statins for 
hyperlipidemia, controlling blood pressure, controlling DM and minimizing the 
glucocorticoids use all these can minimize the CAD in SLE patients. 
 
 
Fig. 1. Two-stage model of accelerated atherosclerosis in SLE (Petri, 2000) 
7. The role of antimalarial drugs in SLE  
Currently, there is over-emphasis from many international authorities in SLE on the need to 
maintain all lupus patients on antimalarial drugs (AMD). This is based on the abundance of 
data that confirm their huge beneficial effects in SLE. They are one of the most widely 
tolerated medications used in the treatment of SLE since 1955 (Scherbel, Schuchter & 
Harrison, 1957; Tye et al, 1959). They are safe even during pregnancy. Like any other 
medication, they have their side effects. However, an antimalarial drug like 
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benefical effects on the long term. Therefore, a comprehensive approach to care for lupus 
patients should be followed. 
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SLE is associated with a variety of cardiovascular manifestations; some are life threatening 
(including myocardial infarction)  and others are much less serious. Threre are several risk 
factors for heart related conditions, many of which can be avoided. Cardiovascular disease 
is a major cause of morbidity and mortality in SLE. 
Pericarditis remains the most common cardiovascular disease in SLE and occur in 12- 48% 
(Moder, Miller & Tazelaar, 1999). It should be included in the differential diagnosis of SLE 
patients presenting with shortness of breath, low grade fever,pleuritic chest pain and/or dry 
cough. ANA test should be ordered for any young lady in childbearing age with pleuritic 
chest pain. This is to avoid delaying the diagnosis of SLE as pericarditis can be a presenting 
feature. Other less frequent cardiac manifestations of SLE are myocrditis (which is usually 
silent), endocarditis with one characteristic but rare presentation as Libman-Sack 
endocarditis known as verrucous non bacterial thrombotic endocarditis, valvular disease, 
arrhythmias, pulmonary hypertension, and systemic hypertension. 
6.1 SLE and accelarated atherosclerosis 
Today with SLE patients living longer due to more effective drug therapies, CAD has 
become a leading cause of late mortality in SLE. Women with aged 35-44 were found to 
have 50 times more risk of myocardial infarctions than aged matched  controls (Mazni et al, 
1997). Several case-control studies, both autopsy studies and myocardial perfusion studies 
have consistently shown a 30-40% prevelance of sub-clinical CAD in SLE patient (Korkmaz, 
Cansu & Kasifoqlu, 2007). Despite an increasing appreciation of the importance of 
cardiovascular disease in SLE, recognition of traditional risk factors have been noted to be 
suboptimal. As an example, in one academic rheumatology practice, deficits in knowledge 
and management of cardiac risk factors were observed among both SLE patients and their 
physicians (Costenbader et al, 2004). This is again to emphasize the point of increase 
awareness of this serious issue in lupus patients. Lack of comprehensive approach to care 
for SLE patients may lead to significant delay in diagnosing a reversible cardiac risk factor. 
Obviously, this will result in delay in management and increase in cardiac morbidity and 
mortality. 
Many cases with SLE have evidence of subclinical accelerated atherosclerosis (figure 1). It 
is related to both traditional and non traditional risk factors for CAD. The traditional risk 
factors are demographics, family history, smoking, hypertension, DM, and dyslipidemia, 
while the non traditional risk factors include chronic inflammation, presence of 
autoantibodies, prolonged vascular inflamation, corticosrteroid use (10 mg change in 
prednisolone lead to change in mean arterial pressure of 1.1 mmHg after adjustment for 
age,  weight and antihypertensive drug use, and 10 mg increase in prednisolone was 
associated with a mean weight change of 5.50 ±1.23 (Petri, 2000)), renal disease and 
antiphospholipd antibodies. One factor that has repeatedly been shown to affect the 
prevelance of CAD in SLE is active disease. Appropriate management of active SLE is one 
of the best preventitive measures. Due to the high prevelance of CAD in SLE patient, SLE 
itself should be viewed as a CAD risk factor in the same way as DM is (Bradley, 2009; 
Shah, Shah & Krishnan, 2009). 
 
How to Avoid Delay in SLE Diagnosis and Management 
 
231 
SLE patients should have an annual fasting blood glucose and a urinalysis at every clinic 
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Fig. 1. Two-stage model of accelerated atherosclerosis in SLE (Petri, 2000) 
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hydroxychloroquine (HCQ) on a daily low dose has no or mild side effects and serious 
complications are rare. Ocular toxicity is the most important toxicity of HCQ, so regular 
ophthalmological check up is important. Chloroquine is found to have more side effects 
than hydroxychloroquine. Nowadays, AMD are not only used for patients with organ 
damage or patients with active disease but they are essential and key treatment for all 
patients with SLE. They should be started alone or with other medications once the 
diagnosis is made. A recent data showed the beneficial effects not only on the disease itself 
but on many other factors. For this reason, AMD should never be stopped in patients with 
SLE. Over the last decades many studies were done on AMD (especially HCQ) and it 
showed that HCQ has an effect in lowering fasting glucose and calculated insulin resistance 
(Penn et al, 2010) and reducing insulin degradation (Smith et al, 1987). There is significant 
reduction in total cholesterol, triglyceride (TG), LDL and very low density 
lipoprotein(VLDL) and significant increase in high density lipoprotein (HDL) level among 
patients using AMD and prednisolone than those with prednisolone alone (Borba & Bonfa, 
2001; Rahman, 1999; Tam et al, 2000 ). As the HCQ showed its effect on glycemic control and 
lipid profile, it might decrease the risk for atherosclerosis.  In addition, HCQ inhibits platelet 
aggregation and adhesion (Petri, 1996) so it is a mild anticoagulant and can decrease the risk 
of thrombosis (both arterial and venous) in patients with SLE (Kaiser, Cleveland & Criswell, 
2009; Wallace, 1987) but this effect is still under trials. Data showed protective effect of HCQ 
on the BMD especially on the spine (Mok, Mak & Ma, 2005). Lupus activity was significantly 
reduced among patients who were using HCQ, and can reach up to 50% in some studies 
(Ruiz-Irastorza et al, 2010). It has positive impact on the survival and can protect against 
irreversible organ damage. As SLE and other rheumatological diseases affect female in child 
bearing age and they will have concerns regarding taking medications during pregnancy. 
HCQ does not appear to have effect on the fetus and it is not associated with any congenital 
anomalies. In addition data showed that its use during pregnancy decreases lupus activity. 
Other non-rheumatological specialities like nephrology and obstetrics and gynaecology may 
underestimate the clinical value of continuing AMD in all SLE patients. LN patients who are 
followed exclusively by nephrologists are not maintained on HCQ as observed in some 
centres unfortunately. This is probably because some believe that HCQ is not considered as 
one of the standard therapies for LN. However, AMD are standard therapies for SLE. 
8. Rare manifestations of SLE 
One of the approaches to avoid delay in SLE diagnosis and management is to recognize rare 
presentations of SLE. Fever of unknown origin is an example of this. Fever by itself is very 
common in SLE. It may affect up to 50% of SLE patients as a sign of active disease (Petri, 
2002). Patients with SLE frequently develop abnormalities in one or more of the three blood 
cell lines. Awareness of different hematological abnormalities affecting SLE patients is 
essential. The association between idiopathic thrombocytopenic purpura (ITP), thrombotic 
thrombocytopenic purpura (TTP) and SLE should be noted. Rare entities like Kikuchi-
Fujimoto’s disease (KFD) or histiocytic necrotizing lymphadenitis (a benign, self-limited 
disease of unknown etiology which affects mainly young women, characterized by localized 
lymphadenopathy, predominantly in the cervical region, fever and leukopenia) has been 
reported in association with SLE. It can present before, at the same time, or after the clinical 
appearance of KFD (Boddaert, Huong et al. 2004). 
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8.1 Kikuchi-Fujimoto disease 
Kikuchi-Fujimoto disease (KFD) or Necrotizing Lymphadenitis is a rare, benign, self-limited 
disease that was first reported in Japan in 1972. It affects the female predominantly with 
female to male ratio 4:1 (Al Salloum, 1998; Dorfman, 1987; Lopez et al, 2000). It usually 
resolves spontaneously between one and four months (Santana et al, 2005) and up to six 
months in another study (Kucukardali et al, 2007). Although it is benign, there are reported 
cases of disease progression and mortality rate can reach up to 2.1% (Kucukardali et al, 
2007).  KFD is found to be associated with many comorbid diseases; SLE was the most 
frequently associated with it. Among 224 cases with KFD, 32 of them had SLE. Of these, 
eighteen (56%) had both diseases together, six (19%) developed SLE later, four (12%) already 
had SLE previously and four (12%) had incomplete SLE as they did not  meet the ACR 
criteria for SLE (Kucukardali, Solmazgul et al. 2007).  
8.2 Thrombotic Thrombocytopenia Purpura (TTP) 
TTP is a life threatening condition in which there is platelet aggregation that result in 
microangiopathic haemolytic anaemia (MAHA) and thrombocytopenia. It presents with the 
pentad of MAHA, thrombocytopenia, fever, acute renal failure and neurological 
manifestations. SLE is one of its secondary causes and it correlates with disease activity 
(Cheung, 2006) but rarely occurs as a first manifestation although there was a reported case in 
which a patient was diagnosed to have TTP and SLE simultaneously (Vasoo, Thumboo & 
Fong, 2002). Making the diagnosis of TTP in SLE patient is difficult as classical TTP symptoms 
may be due to SLE disease activity. The diagnosis of TTP can be established by the presence of 
thrombocytopenia, fragmented red blood cells (schistocytes) in blood film, increase billirubin 
and lactate dehydrogenase, high urea and creatinine, normal coagulation profile and negative 
Coomb’s test. It is important to rule out other serious conditions like disseminated 
intravascular coagulation (DIC) and intracranial haemorrhage (thrombocytopenia and 
neurological manifestation) by ordering coagulation profile and CT head respectively. The 
hallmark of TTP is detection fragmented RBC’s in blood film. It is mandatory to have a 
peripheral smear conducted in any SLE patient presenting with new onset of anemia and 
thrombocytopenia. It is obvious that early diagnosis and aggressive treatment can make a 
huge difference in outcome.  
8.3 Immune Thrombocytopenic Purpura (ITP) 
ITP is a disease characterized by the presence of antibodies against platelets. This results in 
early clearance of platelets particularly by the spleen, and decreases their life span from 7-10 
days to few hours. It presents by symptoms related to decrease platelet count as petechial 
haemorrhage, easy bruising, gum bleeding or epistaxis and menorrhagia in women. 
Intracranial bleeding is rare. ITP is a diagnosis of exclusion as more serious conditions like 
haematological malignancies must be ruled out first especially in people more than 60 years 
of age. It is characterized by presence of low platelet and normal haemoglobin and white 
blood cells count (WBC) except if there is concomitant iron deficiency anaemia or anaemia 
of chronic disease, normal PT and PTT, decrease platelet or presence of giant platelet in 
peripheral blood film and increase the number of megakaryocyte in bone marrow. An 
association between ITP and SLE has been recognized for decades and it can be the first 
manifestation in some patients with SLE (Jun, et al, 2008; Mestanza-Peralta et al, 1997). It has 
been estimated that 3-15% of patients with apparently isolated ITP go on to develop SLE 
(Karpatkin, 1980). 
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8.4 Fever of Unknown Origin (FUO) 
FUO is a documented fever of >38C on several occasions, for> 3 weeks without reaching 
the diagnosis after the initial diagnostic workup (Abdelbaky et al., 2011). FUO remains an 
important health problem that requires demanding efforts in order to reach the diagnosis 
despite the presence of advanced technology. Infections, connective tissue diseases, 
neoplasms are major causes that should be first ruled out before thinking about other 
causes. It was shown that among 100 patients with FUO, 50% were found to have infections, 
24% were found to have connective tissue diseases (33.3% of them diagnosed as SLE, 20.8% 
familial Mediterranian fever, 16.6% rheumatoid arthritis, 12.5% Still’s disease & rheumatic 
fever and 4.3% Behcet’s disease/ Chron’s disease), no cause was identified in 11%, while the 
remaining 8% and 7% were found to have miscellaneous causes and neoplasia respectively 
(Abdelbaky et al, 2011).  
 
How to avoid delay in SLE 
diagnosis and management? Action plan 
1. Consider SLE in the differential 
diagnosis of multisystemic 
presentations. 
 Order screening ANA. 
2. Assure screening for MSK 
abnormalities in all acutely ill 
patients. 
 Ask about joint pain, swelling and 
morning stiffness. 
 Perform simple active range of 
motion test as a screening tool for 
MSK abnormalities. 
3. Be aware of neurological 
manifestations of SLE (seizure, 
stroke, TM, MG, GBM, etc). 
 
 Include in your work-up 
screening ANA. 
 Educate clinicians taking care of 
neurological diseases about this. 
 
4. Be aware of CAD risk factors in 
SLE patients 
 
 Life style modifications, weight 
reduction, check BP in every clinic 
visit, annual fasting blood 
glucose, statins for 
LDL>130mg/dl, 
 
5. to decrese disease activity and 
possibly to decrease the risk of 
atherosclerosis. 
 Maintain all patients on HCQ 
6. Fever is common in SLE and it 
might be a presenting feature.  Order screening ANA. 
7. Be aware of different 
hematological abnormalities 
related to SLE (cytopenias, ITP, 
KFD, TTP). 
 Order screening ANA. 
 Order peripheral smear for any 
SLE patient with new onset 
anemia and thrombocytopenia. 
8. SLE can still affect elderly 
population. 
 Order screening ANA as 
appropriate to the clinical 
presentation. 
 Educate clinicians taking care of 
elderly patients about this. 
Table 4. Some recommended steps to avoid delay in SLE diagnosis and management 
 




We discussed in this chapter several issues that can face clinicians in their daily work with 
SLE patients. Our aim was to focus on how to prevent delay in SLE diagnosis and 
management. Table 4 represents some recommended steps that might help in this regard. 
Enhancing MSK examination skills among clinicans in general is an international concern. 
This clearly will result in early detection of patients with clinical evidence of arthritis 
including SLE. There are several clinical settings and presentations where SLE should be 
considered. Late-onset SLE can affect elderly patients with few differences than classical 
SLE patients. NPSLE represents a diagnositic challenge to clinicians. There are 19 
neuropsychiatric syndromes defined by ACR as an associated feature with NPSLE.  Delay 
in considering kidney biopsy in SLE patients once indicated results in poor renal 
outcomes. Adjusting risk factors for renal disease like proteinuria, hypertension and 
dyslipidemia is vaguely considered by some clinicans. The leading cause of mortality in 
SLE is cardiac. Clinicans taking care of SLE patients should put prevention of cardiac 
morbidities and mortalities an important goal in their management agenda. With new 
modalities of treatment and the wide use of AMD since 1955 there is significant 
improvement in survival and quality of life in patients with SLE. Therefore, all lupus 
patients should be maintained on AMD like HCQ. SLE can present initially with a variety 
of hematological maifestations like ITP , TTP and KFD. SLE should be in the differenrtial 
diagnosis of FUO.  
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1. Introduction 
Kidney disease secondary to SLE can affects up to 50% of patients with SLE and largely 
mediated by deposition of immune complex in the kidneys (1) (2). 
The clinical diagnosis of lupus nephritis is usually made following a diagnostic kidney 
biopsy in the presence of proteinuria and/or hematouria,positive serology,and extrarenal 
manifestation of SLE. The presence of kidney disease is the most important predictor of 
morbidity and mortality in the patients with SLE. 
Several demographic,serologic,and genetic risk  factors are associated with an increased risk 
for developing kidney disease. Patient with lupus nephritis are more likely than SLE 
patients without kidney involvement to have a family history of SLE,anemia,high anti-
dsDNA antibody titer,and hypocomplementemia. Children with SLE develop nephritis 
more frequently than adults and so do males.  
2. Pathogenesis 
Autoimmunity plays a major role in the pathogenesis of lupus nephritis. The immunologic 
mechanisms include production of autoantibodies directed against nuclear elements.  
These autoantibodies form pathogenic immune complexes. Deposition of these immune 
deposits in the kidneys initiates an inflammatory response by activating the complement 
cascade and recruiting inflammatory cells that can subsequently be observed on biopsy 
specimens. 
Glomerular thrombosis is another mechanism that may play a role in pathogenesis of lupus 
nephritis, mainly in patients with antiphospholipid antibody syndrome, and is believed to 
be the result of antibodies directed against negatively charged phospholipid-protein 
complexes. 
3. Symptoms and signs of lupus nephritis 
Clinically lupus nephritis varies in its expression mild ,asymptomatic  proteinuria to an 
overt nephrotic syndrome or acute nephritis associated with rapidly progressive azotemia. 
Glomerulonephritis is uncommonly the sentinel manifestation of SLE.  
The key challenge for the clinician  is to detect clinically significant lupus nephritis befor the 
appearance of the overt disease. 
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Patients can present with proteinuria during regular follow up. Hypertention is more 
common in patient with diffuse prolifrative lupus nephritis compared with focal prolifrative 
lupus nephritis or membranous lupus nephritis. Edema is an other presentation of lupus 
nephritis. 
4. Prognostic factors 
Different factors have been identified to predict the prognosis of lupus nephritis (3). 
Histological factors: 
 Histological class IV(diffuse proliferative LN) 
 High activity and chronicity on Biopsy 
 Crescents and interstitial fibrosis 
 Segmental necrotizing lesion 
Clinical Predictors: 
 Hypertension            
 Anemia         
 high baseline creatinine     
 high  base line proteinuria                    
 Delay in therapy 
Epidemiological Predictors  
 Low  socioeconomic  status                        
 African  American Race 
5. Classification of Lupus Nephritis (LN) 
Types of lupus nephritis  
Renal biopsy is essential for the staging the type and the severity of lupus nephritis  and 
planning the treatment. 
Indication of renal biopsy 
Renal  biopsy is indicated  in patients who have one or both of the following clinical 
manifestations: 
 Protein excretion greater than 500 mg/day. 
 An active urinary sediment with hematuria (five or more red blood cells per high 
power field, most of which are dysmorphic) and often pyuria and cellular casts. The 
urine may be contaminated with vaginal blood in menstruating women. Red cells from 
this source are not dysmorphic. 
Lupus patients who have an inactive sediment and less than 500 mg/day of proteinuria are 
unlikely to have focal or diffuse proliferative or membranous lupus nephritis (LN). They 
may have minimal mesangial or mesangial proliferative disease, neither of which requires 
immunosuppressive treatment. 
Such patients should be followed for evidence of progressive disease such as increasing 
proteinuria, emergence of an active sediment, and/or an increase in serum creatinine. These 
manifestations suggest transformation to a more severe lesion and warrant renal biopsy. 
In patients with an inactive sediment and less than 500 mg/day of proteinuria, it is advisable 
to do a urinalysis every three to six months for three years; every three months is preferred in 
patients with anti-double-stranded DNA antibodies and/or hypocomplementemia. 
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The initial classification is WHO that have been modified in 1982 and 1995(4).The most 
recent classification is ISN/RPS 2004(international society of nephrology and renal 
pathology society) (5). 
 
DESIGNATION DESCRIPTION 
Class I: Minimal 
mesangial LGN 
Near-normal glomeruli by LM; mesangial deposits are present by IF 
and/or EM 
Class II: Mesangial 
proliferative LGN 
Mesangial hypercellularity and matrix expansion, with mesangial 
deposits by IF and EM 
Class III: Focal LGN 
<50% of glomeruli display active or inactive segmental (<50% of the 
tuft) or global (>50% of the tuft) endocapillary proliferation or 
sclerosis; predominantly mesangial and subendothelial deposits are 
present on IF and EM 
Class IV: Diffuse 
LGN 
>50% of glomeruli have endocapillary or extracapillary 
glomerulonephritis;predominantly mesangial and  





>50% of affected glomeruli have segmental lesions 
Class IV-G: Global 




Capillary loop thickening in association with predominantly 
subepithelial deposits by IF and EM 
Class VI: Advanced 
sclerosis 
>90% of glomeruli are obsolescent, with substantial activity in 
remaining glomeruli 
Table 1. International Society of Nephrology—Renal Pathology Society, 2004 Classification 
of Lupus Glomerulonephritis  
Characteristic clinical features of patients with the various classes of pathology can be 
summarized as follows:  
 Class I, Minimal mesangial lupus glomerulonephritis (LGN)—normal urine or 
microscopic hematuria 
 Class II, Mesangial proliferative LGN—microscopic hematuria and/or low-grade 
proteinuria 
 Class III, Focal proliferative LGN—nephritic urine sediment and subnephrotic 
proteinuria 
 Class IV, Diffuse proliferative LGN—nephritic and nephrotic syndromes, hypertension, 
azotemia 
 Class V, Membranous LGN—nephrotic syndrome 
 Class VI, Sclerosing disease—hypertension and reduced kidney function 
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summarized as follows:  
 Class I, Minimal mesangial lupus glomerulonephritis (LGN)—normal urine or 
microscopic hematuria 
 Class II, Mesangial proliferative LGN—microscopic hematuria and/or low-grade 
proteinuria 
 Class III, Focal proliferative LGN—nephritic urine sediment and subnephrotic 
proteinuria 
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EM, electron microscopy; IF, immunofluorescence; LGN, lupus glomerulonephritis; LM, light  
microscopy  
Fig. 1. Light microscopic changes in lupus glomerulonephritis (LGN). A,  
Segmental proliferative LGN. The glomerulus shows a discrete segmental lesion  
with karyorrhexis and necrosis (gold arrows); the remaining capillary loops are patent  
with only mild mesangial expansion (hematoxylin and eosin stain). B, Global proliferative 
LGN with an extracapillary cellular crescent (asterisk); the integrity of the glomerular  
tuft is compromised by proliferation and thickening of the capillary loops (hematoxylin  
and eosin stain). C, Pure global proliferative LGN (hematoxylin and eosin stain).  
D, Membranous LGN; capillary loops are uniformly thickened (hematoxylin and  
eosin stain).  
6. Treatment of lupus nephritis 
Treatment depends mainly on the clinical presentation and the pathological classification of 
LN. The treatment usually consists of two phases, the induction phase and the maintenance 
phase. The total duration of treatment around two years but it can varies based on the 
clinical response. But all patients need to be on non-immunosuppressive therapy. 
 




Angiotensin inhibition – Administration of an angiotensin converting enzyme (ACE) 
inhibitor or an angiotensin II receptor blocker (ARB) is recommended in virtually all 
patients with proteinuric chronic kidney disease, since such therapy may significantly 
reduce the rate of disease progression, acting at least in part by lowering the intraglomerular 
pressure. The recommended goal for protein excretion is at least a 60 percent reduction from 
the baseline value and optimally less than 500 to 1000 mg/day. Patients with baseline 




Fig. 2. Ultrastructural changes in lupus glomerulonephritis (LGN). A, Mesangial proliferative 
LGN; electron-dense deposits corresponding to immune complexes are concentrated in 
mesangial region (red arrows). B and C, Continuum of subendothelial and intraluminal 
electron-dense deposits characteristic of proliferative forms of LGN (red arrows). D, 
Subepithelial electron-dense deposits characteristic of membranous LGN (red arrows).  
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Blood pressure control – The goal blood pressure in patients with any form of proteinuric 
chronic kidney disease is less than 130/80 mmHg, if the proteinuria is more than 3.5g/day 
the target is less than 125/70. Reaching  this goal can slow the progression of proteinuric 
chronic kidney disease. It may also provide cardiovascular protection, since chronic kidney 
disease is associated with a marked increase in cardiovascular risk. BP control through 
rennin angiotensin aldosterone(RAAS) blockade is a cornerstone of conservative therapy in 
lupus nephritis. The RAAS, and its pharmacologic blockade, may play a role in the 
pathogenesis and prognosis of SLE independent of its effects on systemic BP and glomerular 
hemodynamics. A number of animal studies have highlighted the inflammatory 
components of the RAAS and the potential  benefits of RAAS blockade in reducing or 
eliminating this inflammation in lupus nephritis (22). 
Lipid lowering – Hyperlipidemia, with often dramatic elevations in the serum cholesterol 
concentration, is commonly present in patients with nephrotic syndrome. Although control 
of serum LDL cholesterol is the main indication for statin therapy, there is some evidence in 
patients with chronic kidney disease that it may also slow the progression of the underlying 
renal disease (22). 
7. Immunosuppressive therapy 
Different immunosuppressive  medication can be used as induction and/or maintenance 










1. Steroids  
During the induction phase Methylprednisolone in doses of 7mg/kg/day as intravenous 
pulse therapy for three days followed by 1 mg/kg/day for 4-6 weeks to be tapered during 
the maintenance phase   slowly according to the clinical response (6).it is usually used in 
combination with other drugs. 
2. Cyclophosphamide  
The most studied in lupus nephritis. The data for using Cyclophosphamide is coming 
mainly from two major randomized control trial. The first one is the National Institutes of 
Health (NIH) study(6), which used cyclophsphamide  as intravenous  monthly  doses for 6 
consecutive months, starting at a dose of 0.5g/m2 body surface not to exceed 1g/m2. After 
the first 6 months .pulse cyclophosphamide is given every 3 months for a total of 24 months. 
The second trial is EURO Lupus trial (7) (8).intravenous cyclophosphamide is given every 2 
weeks in a fixed dose of 500 mg for 6 doses,  followed by Azathioprine  (2mg/kg/day) to 
finish 30 months of treatment. 
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The downside of treatment with cyclophosphamide is the side effect profile associated with 
it including leucopenia, increase  risk of infection, hemorrhagic cystitis ,hair loss and 
increase risk of malignancy. 
Both regimen were equally effective in various renal and extra-renal outcomes. The low 
dose regimen(Euro-lupus) had less toxicity with significantly less sever and total infections 
as  a complication of treatment(8). 
During the treatment with cyclophsphamide  physician need to monitor the patient with 
biweekly WBC count during the first six months them monthly and adjust the dose if the 
WBC count drop below 3000 mm2. 
Mycophenolate mofetil l(MMF) 
The active component of MMF, mycophenolic acid, is an inhibitor of inosine 5'-
monophosphate dehydrogenase, the rate-controlling enzyme in de novo biosynthesis of 
guanosine triphosphate, used by antigen-activated B cells and T cells. Mycophenolic acid 
exhibits a selective antiproliferative effect on lymphocytes with anti-inflammatory effects 
and a profound effect on autoantibody production by B cells. 
Because of its favorable safety profile, there has been great interest in the use of 
Mycophenolate mofet(MMF) as both induction and maintenance therapy(9)(10)(16). Since 
2000 two controlled trials comparing induction therapy with MMF versus 
cyclophosphamide have indicated comparable rates of renal remission and short term renal 
survival but fewer side effects in patients treated with MMF. The best data are from 
international trial (ALMS) that compared MMF in a dose of 3g/day as induction therapy for 
six months  with monthly intravenous Cyclophosphamide(IVC) for six doses (11). Overall 
response rates similar with MMF and IVC in all renal and non-renal parameters. In this trial 
MMF in a dose of 1g twice daily for 36 months was superior to Azathioprine in 
2mg/kg/day as maintenance therapy.  
MMF can be used in a dose of 3g/day in divided dose for 6 months as induction therapy 
followed by 1g twice daily for 36 months as maintenance therapy.  
Cyclosporine (CSA) 
The available data suggest that CSA may be a useful drug in patients with lupus nephritis 
showing persistent sever proteinuria after induction therapy or intolerance to other 
immunosuppressive drugs (12). 
Azathioprine(AZA) 
The role of AZA is much less established as induction therapy. The available data support 
the use of AZA as maintenance therapy for 24-30 months (7) (12). 
preferred in women who are in complete remission and want to become pregnant. 
Cyclosporine is an alternative if azathioprine is not tolerated. MMF has a boxed  
warning because of an increased risk of congenital malformations and spontaneous 
abortion.  
Rituximab  
An anti-CD20 monoclonal antibody that depletes B cells, is useful in inducucing remissions 
in some patients. Currently rituximab is used for refractory or non-responder cases, alone or 
in combination with other immunosuppressive agents (13)(17) 
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Randomized trials showed no add benefit value of plasmapheresis to immunosuppressive 
therapy in patient with lupus nephritis (14) (15). However, plasmapheresis may have a role 
in selected patients, such as those with severe crescentic LN who require dialysis (especially 
those with concomitant ANCA, extrapolating from the MEPEX trial of patients with 
Wegener's granulomatosis) or those with proliferative LN and thrombotic 
thrombocytopenic purpura with antiphospholipid antibodies. 
The above mentioned lines of treatment usually indicated for class three and four. 
Treatment of membranous lupus nephritis still controversial. Most of the clinical trial 
included patients with focal or diffuse proliferative lupus nephritis. 
In general patients with membranous lupus nephritis who have normal renal function and 
subnephrotic proteinuria may not require intensive immunosuppressant while patient with 
high grade nephrotic  syndrome or abnormal renal function or mixed membranous and 
proliferative lesions on biopsy which may be present at diagnosis or develop later need to 
be treated with immunosuppressant. 
The only randomized trial limited to patients with pure lupus MN, the National Institutes  
of Health (NIH) trial, showed equivalent efficacy with cyclophosphamide plus 
glucocorticoids and cyclosporine plus glucocorticoids [18]. There were trends with 
cyclosporine toward higher rates of both remission (83 versus 60 percent at one year) and of 
relapse after the cessation of therapy (60 percent within 36 months versus 20 percent within 
50 months. 
A randomized trial (ALMS) compared MMF with cyclophosphamide in 370 patients  
with LN, including 60 with pure membranous LN [11]. The primary outcome was a 
prespecified reduction in the urine protein-to-creatinine ratio to less than 3 or by at least  
50 percent. Secondary outcomes included stabilization or improvement of the serum 
creatinine, reduction of protein excretion to less than 0.5 g/day, and attainment of inactive 
urinary sediment. At 24 weeks, there was no difference in the two groups in the percentage  
of patients with pure membranous LN who achieved either the primary or secondary 
outcome. 
8. In summary  
1. lupus nephritis stage ІІІ and ІV with active disease( high creatinine and/or proteinuria 
> 500 mg/day and/or active sediment: should be treated with cyclophosphamide 
intravenous as monthly dose for six months as induction therapy followed by 
cyclophosphamide intravenous every 3 months to finish 24 months.  
2. The other approach to treat stage 3 and 4 lupus nephritis is to use cyclophosphamide 
intravenous in a fixed dose 500 mg  every 2 weeks for six doses as induction therapy 
followed by MMF in a dose of 1 mg orally twice daily for 36 months which has been 
superior to Azathioprine as maintenance therapy. This approach is preferable to the 
former approach because the risk of side effect is much less. 
3. If the patient can not take cyclophosphamide  or prefer not to, MMF can be used in a 
dose of 3g/day in divided dose for six months as induction therapy followed by MMF 
in a dose of 1-2 g/day for 36 months as maintenance dose. 
4. For stage 5 lupus nephritis with active disease(nephritic range proteinuria,active 
sediment and/or abnormal renal function, can be treated with oral cyclosporine in a 
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dose of 5mg/kg /day in divided doses but the dose need to be adjusted if the creatinine 
is rising. this treatment need to be continued for one year. 
Intra venous Cyclophosphamide can be used (0.5-1.0g/m2) given every other month for 
one year. 
If patient can not tolerate cyclosporine or cyclophosphamide,MMF can be used as it was 
beneficial in ALMS trial. It can be used in dose of 3g/day for 6 months then to be 
reduced to 1-2g/day.  
9. Criteria for clinical reemission  
Most of the clinical trials defined complete remission can be defined by the following 
criteria, 
1. Inactive urinary sediment   defined as ≤5 red blood cells per high power field, ≤5 white 
blood cells per high power field, a reading of 0 to 1+ on the urine dipstick for heme, and 
no red cell casts. 
2. Normalization of the serum creatinine and protein excretion below 500 mg/day. 
Partial remission can be defined by reduction of proteinuria by 50% or more. 
10. Kidney transplantation in patient with lupus nephritis 
If patient with lupus nephritis progress to ESRD and require dialysis, data suggest that renal 
transplant has better outcome than dialysis in such patients. (19) 
Long-term patient and graft survivals were similar in SLE and non-SLE renal  
transplant recipients. The risk for thrombotic complications was greater among SLE  
patients (19). 
Patients need to be clinically and serologically inactive at the time of transplant.  
The rate of clinically recurrent disease in the renal transplant of 2.0 to 9.0 percent in  
patients with lupus nephritis, which is thought to reflect, diminished immunologic  
activity (20). The incidence of recurrent symptoms of systemic lupus was also low at 5.7 
percent. 
11. Experimental therapy 
Several studies involving novel therapeutic agents for lupus nephritis are underway. The 
agents being evaluated in these studies are summarized in Table 24-3. The Web site 
www.clinicaltrials.gov is a potentially useful resource in searching for studies that may be 
recruiting patients, along with information about eligibility and exclusion criteria. 
12. Prognosis 
The prognosis of class III and IV proliferative lupus nephritis has improved, from a 5-year 
renal survival rate of less than 20% during the period 1960-1980 to a rate of more than 80% 
during 1980-2000. This improvement in prognosis has been ascribed mostly to increasing 
use of cyclophosphamide. Although preliminary data based on achievement of renal 
remission suggest that mycophenolate mofetil may have comparable benefits, it remains to 
be established whether mycophenolate mofetil will achieve comparable long-term renal 
survival. 
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Monoclonal Antibodies (Targets) 
Rituximab (CD20, B cells)[∗ † ‡] 
Epratuzumab (CD22, B cells)[∗] 
MEDI-545 (interferon-α)[‡] 
Belimumab (BLyS cytokine)[‡] 
Tocilizumab (interleukin-6 receptor)[‡] 
Infliximab (tumor necrosis factor)[∗ ‡] 
Costimulation Inhibitors 
CTLA4-Ig, abatacept, belatacept (CD80/86)[‡] 
Tolerogens 
Abetimus, LJP-394 (anti-DNA)[‡] 
Hematopoietic stem cell transplants 
∗  Case reports. 
†  Case series. 
‡  Ongoing clinical trials. 
Table 2. Experimental Therapies for Systemic Lupus Erythematosus and Lupus Nephritis 
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1. Introduction 
Lupus nephritis remains a major cause of morbidity and mortality in systemic lupus 
erythematosus (SLE). Despite overall advances in the clinical management of lupus 
nephritis in recent decades with earlier recognition of disease and optimization of the 
currently available immunosuppressive regimens, an estimated 10-15% of patients progress 
to end-stage renal disease (ESRD) requiring dialysis and/or renal transplantation 
(Mavragani et al, 2003). Proliferative lupus nephritis (International Society of 
Nephrology/Renal Pathology Society classes III & IV) is the most aggressive variant of 
nephritis; figures 1 and 2 illustrate the histology of Class IV nephritis.  
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Fig. 1. Class IV global proliferative lupus nephritis 
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Fig. 2. Class IV segmental proliferative lupus nephritis  
The rate of progression to ESRD is likely to be even higher patients of Afro-Caribbean 
descent (Dooley et al, 1997).  Commonly used therapeutic agents such as corticosteroids, 
cyclophosphamide, mycophenolate mofetil and azathioprine have certainly improved 
clinical outcomes, however a significant proportion of lupus nephritis patients have 
refractory disease and the potential side effects of these therapies are significant.  
A recent retrospective review of lupus nephritis patients over a 30 year period (1975-2005) 
showed that five year mortality decreased by 60% between the first and second decades but 
remained unchanged over the third decade. The rate of progression to ESRD also reached a 
plateau in the third decade. These results suggest that the benefits of conventional 
immunosuppressive therapies have been maximized and if further improvements in lupus 
nephritis outcomes are to be achieved, novel therapeutic targets must be developed (Croca 
et al, 2011).  
2. B-cell depletion therapies 
Lupus nephritis involves a complex interplay of immunologic disturbances with renal 
damage resulting from production of pathogenic autoantibodies and immune complexes, 
which activate complement leading to infiltration of inflammatory cells in the kidney. B 
lymphocytes play an integral role in this process, they are the precursors of plasma cells that  
 




Moab, monoclonal antibody, BLys, B lymphocyte stimulator, TACI-Ig, transmembrane activator and 
calcium modulator and cyclophylin ligand interactor-immunoglobulin, TNF-receptor-IgG, tumour 
necrosis factor-receptor-immunoglobulin 
Table 1. Summary of emerging biologic therapies in systemic lupus erythematosus  
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produce these pathogenic autoantibodies and they also function as antigen presenting cells 
to T lymphocytes. Thus B lymphocytes represent a rational therapeutic target in lupus 
nephritis. By far the most clinical experience in targeting B-lymphocytes to date has been in 
the form of B-cell depletion therapy (BCDT). Rituximab, a monoclonal antibody against the 
cell surface protein, CD20 has been in use clinically for the past decade. Alternative forms of 
BCDT are under development and in ongoing clinical trials.  
2.1 Rituximab (Anti-CD20) 
CD20 is a cell surface protein expressed on B lymphocytes from the early pre-B cell until 
mature B cell stages of development, but is not present on hematopoietic precursor stem 
cells or plasma cells.The CD20 antigen was first targeted in the immunotherapy of B cell 
lymphomas (Grillo-Lopez et al, 1999) (Hainsworth et al, 2000) and, subsequently in 
rheumatoid arthritis (RA) (Edwards et al, 2004). Rituximab is a chimeric mouse/human 
monoclonal antibody against the B cell-specific antigen CD20, a cell surface protein believed 
to function in B cell cycle initiation and differentiation. Rituximab induces cell lysis via 
antibody-dependent cell-mediated cytotoxicity and activation of complement leading to B-
cell depletion in the peripheral blood and bone marrow (Reff et al, 1994). 
Open trials of rituximab over the past decade have shown encouraging results in active and 
refractory SLE including lupus nephritis (Leandro et al, 2002) (Looney et al, 2004) (Leandro et 
al, 2005). However the failure of rituximab to meet its primary and secondary end points in 
randomized controlled trials of non-renal SLE (EXPLORER) and lupus nephritis (LUNAR) has 
been disappointing (Merrill et al, 2010). Issues with study design, concomitant use of high dose 
steroid and other immunosuppressive therapies and the relatively low severity of disease in 
patients enrolled need to be taken into account when interpreting the results of these trials.  
A number of case reports and open-label studies have reported successful treatment of 
lupus nephritis with rituximab. Vigna-Perez et al reported an open study of 22 LN patients 
receiving rituximab (0.5 to 1.0 g at Days 1 and 15). This was added to existing treatment 
consisting of different combinations of azathioprine, mycophenolate, cyclophosphamide 
and corticosteroids. Significant reduction of disease activity and proteinuria was seen 
(P<0.05). One patient died from invasive histoplasmosis at day 70 (Vigna-Perez et al). 
Clinical improvements have also been seen using rituximab in membranous lupus nephritis 
(Jónsdóttir et al, 2010) (Jónsdóttir et al, 2011). 
Pepper et al reported the use of rituximab as induction therapy followed by maintenance 
mycophenolate mofetil in a cohort of eighteen patients with proliferative lupus nephritis. A 
significant decrease in proteinuria from a mean protein: creatinine ratio (PCR) of 325 
mg/mmol at presentation to 132 mg/mmol at 1 year (p = 0.004) was demonstrated and this 
combination of sequential therapy allowed a reduction or total withdrawal of maintenance 
corticosteroids (Pepper et al, 2009).  
The French Autoimmune and Rituximab (AIR) registry reviewed one hundred thirty-six 
patients who received this treatment for SLE. Articular, cutaneous, renal, and haematologic 
improvements were noted in 72%, 70%, 74%, and 88% of patients, respectively. Severe 
infections were noted in 12 patients (9%), with most severe infections occurring within the 
first 3 months after the last rituximab infusion. Five patients died, three due to severe 
infection (n = 3) and two due to refractory autoimmune disease. Overall response was 
observed in 71% of patients and among these, 41% experienced a relapse of disease but 
responded after retreatment with rituximab in 91% of cases (Terrier et al, 2010). 
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Sangle et al noted progression to ESRD in five patients with severe proliferative, crescentic 
lupus nephritis (mean activity score 12/24, mean crescents 38%) with raised serum 
creatinine (mean 278 μmol/l) treated with rituximab, after failure of other 
immunosuppressive drugs (Sangle et al, 2007). This may reflect that the timing of rituximab 
therapy in the course of disease may be important for its efficacy. 
The degree of B-cell depletion achieved  is far more variable in SLE patients treated with 
rituximab as compared to those with RA or lymphoma (Gunnarson et al, 2007) (Sutter et al, 
2008). However the degree and duration of B-cell depletion in SLE patients does correlate to 
some extent with clinical response and those who fail to deplete tend to have a poorer 
clinical response (Albert et al, 2008).  
The most common adverse effects associated with rituximab therapy are mild to moderate 
infusion reactions. Two SLE patients treated with rituximab developed progressive 
multifocal leukoencephalopathy (PML) which should be interpreted in the context of the 
known 20 patients with SLE reported to have developed PML and had not received 
rituximab therapy (Calabrese et al, 2007). 
The rate of development of human anti-chimeric antibodies (HACAs) is significantly higher 
in lupus patients treated with rituximab than RA or lymphoma patients who have received 
this therapy (Smith et al, 2006) (Saito et al, 2005). It is not entirely clear if development of 
HACAs in rituximab treated lupus patients will lead to reduced efficacy of this medication 
with repeated use.  
A cohort of 76 patients with active SLE refractory to standard immunosuppression have 
received repeated cycles of rituximab since 2000 with good clinical response and  favourable 
safety profile (Turner-Stokes et al, 2011). The long-term effects of repeated B-cell depletion 
are unknown, though there is a risk of hypogammglobulinaemia. 
Perhaps further randomized controlled trials in moderate to severe lupus patients and a 
greater understanding from basic science as to why some lupus patients have more 
profound and long-lasting B-cell depletion will clarify the role of rituximab in SLE and in 
particular lupus nephritis. 
2.2 Ocrelizumab (Anti-CD20) 
Ocrelizumab, a fully humanized monoclonal antibody against CD20, is an alternative  
form of BCDT which entered clinical trials for SLE and rheumatoid arthritis (RA).  
The potential benefits of this form of BCDT included avoidance of HACA development 
given its fully humanized structure thus maintaining efficacy and minimizing HACA 
related side effects. Clinical trials in SLE and RA were suspended in 2010 due to excess 
deaths due to opportunistic infections and thus no results are currently available for this 
therapy. 
2.3 Epratuzumab (Anti-CD22) 
CD22 is a B-cell surface restricted marker and member of a class of adhesion molecules that 
regulate B-lymphocyte activation and interaction with T lymphocytes. CD22 is expressed in 
the cytoplasm of pro-B and pre-B cells, and on the surface of maturing B cells (Tedder et al, 
1997). CD22 plays a role in inhibition of BCR signaling by controlling calcium efflux in B 
cells as evidenced by work in CD22-deficient mice (Sato et al, 1998). CD22-deficient mice 
have reduced numbers of mature B cells in the peripheral blood and bone marrow and these 
B cells also have a shorter life span and increased apoptosis indicating that CD22 plays a key 
role in B cell development and survival (Otipoby et al, 1996). 
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role in B cell development and survival (Otipoby et al, 1996). 
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Thus CD22 is an attractive therapeutic target in lupus nephritis. Epratuzumab is a 
recombinant humanized monoclonal IgG antibody to CD22; it mediates antibody-
dependent cellular cytotoxicity and partially depletes B-cells. It is thought that epratuzumab 
modifies B-cell function without killing them but the precise mechanism of action remains 
unclear.  
Safety of epratuzumab was first demonstrated in clinical trials of non-Hodgkins lymphoma 
(Leonard et al, 2004). It has also been successfully used in refractory lymphoma in 
combination with rituximab (Leonard et al, 2005). The main side-effects seen in these studies 
were infusion reactions.  
An open-label non-randomized trial of epratuzumab in mild to moderate SLE showed 
promising results with consistent improvement observed in all patients enrolled for the 12 
week duration of the study, average 35% depletion in B-cell levels, and no evidence of 
HACA development. The duration of response in this study was very heterogeneous for 
different BILAG domains, precluding any firm conclusions from being drawn about the 
specific impact of epratuzumab on lupus nephritis (Dorner et al, 2008). A phase III trial of 
epratuzumab in patients with moderate to severe SLE is underway. 
3. Targeting B-cell survival factors 
3.1 Belimumab 
BLyS (B lymphocyte stimulator) also known as BAFF is a member of the TNF superfamily 
and plays an essential role in B-cell survival and development (Stohl et al, 2003). It binds to 
three different membrane receptors: BCMA (B cell maturation antigen), BAFFR (BR3) and 
TACI (transmembrane activator and calcium modulator and cyclophylin ligand interactor). 
Mice deficient in BLyS have reduced levels of mature B cells and immunoglobulins 
(Schiemann et al, 2001). Overexpansion of BLyS in transgenic mice leads to expansion of B-
cells, hypergammaglobulaemia and autoimmune disease (Mackay et al, 1999). 
Belimumab is a fully humanized monoclonal antibody against BLyS, which can cause 
depletion of circulating B cells however less profoundly than anti-CD20 monoclonal 
antibodies such as rituximab. Belimumab was approved by the FDA for treatment of SLE in 
March 2011, the first lupus drug to be approved since hydroxychloroquine and 
corticosteroids were approved in 1955. The safety and effectiveness of belimumab was 
demonstrated in two clinical trials (BLISS-52, and BLISS-76) that randomized a total of 1684 
patients to receive either belimumab or placebo in combination with standard therapy 
(Wallace et al, 2009) (Jacobi et al, 2010). Treatment with belimumab plus standard therapy 
reduced disease activity and steroid use.  
However, there are reservations regarding the effectiveness of belimumab in the more 
severe organ manifestations of SLE as patients with active lupus nephritis and central 
nervous system (CNS) disease were not studied. Study participants of African American 
descent did not significantly respond well to belimumab, which is also of concern. 
Additional studies need to be conducted to definitively determine the safety and efficacy of 
belimumab in the more severe complications of SLE particularly lupus nephritis.  
3.2 Atacicept 
An alternative therapeutic approach targeting B cell survival is atacicept, a recombinant 
fusion protein containing the ligand-binding domain of the transmembrane activator and 
calcium modulator and cyclophilin-ligand interactor receptor (TACI) and the Fc portion of 
human immunoglobulin (IgG1). Atacicept inhibits B-cell stimulation by binding to both 
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BLys and a profileration-inducing ligand (APRIL). Atacicept is believed to selectively impair 
mature B cells and plasma cells with less impact on progenitor and memory B cells (Nestorov 
et al, 2008). A phase I study has demonstrated the safety and tolerability of atacicept in 
patients with mild to moderate SLE (Pena-Rossi et al, 2009). A phase II/III study of atacicept 
in LN is ongoing and due to be completed in 2012. The study was temporarily discontinued 
due to decreased immunoglobulin levels in study participants and now has been resumed. 
Of note, a phase II trial of atacicept in multiple sclerosis was discontinued due to increased 
disease relapse and new lesions on MRI brain imaging in the study subjects. 
 
 
Fig. 3. Mechanisms of action of novel agents 
4. Blockade of T-cell co-stimulation 
4.1 Abatacept 
Immunological tolerance can be induced by blockade of co-stimulatory interactions between 
T and B lymphocytes. The most well characterized T lymphocyte co-stimulatory ligand is 
CD28, a glycoprotein which interacts with the co-stimulatory receptors B7-1 (CD80) and B7-
2 (CD86). Stimulation of this pathway occurs when naive T cells encounter an antigen 
presenting cell with the appropriate major histocompatibility complex class II bound 
antigen, resulting in T lymphocyte proliferation and differentiation (Ledbetter et al, 1990). 
CTLA4 (cytotoxic T-lymphocyte antigen) is expressed on activated T cells and interacts with 
B7 with higher affinity than CD28 resulting in a negative feedback mechanism that inhibits 
T cell activation (Scheipers et al, 1998) (Reiser et al, 1996) (Brunet et al, 1987).  
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Abatacept is a fusion protein consisting of CTLA-4 combined with the Fc portion of human 
IgG1 (CTLA-4-Ig). Combination therapy of CTLA-4-Ig and cyclophosphamide has been 
demonstrated to significantly reduce proteinuria, autoantibody titres and mortality in 
murine models of lupus nephritis (Daihk et al, 2001), (Finck et al, 1994). 
Abatacept has been used successfully in the clinical management of RA and psoriasis 
(Genovese et al, 2008) (Mease et al, 2011). A randomised double blind placebo controlled 
trial has evaluated the clinical efficacy and safety of abatacept in 175 lupus patients. These 
patients had primarily serositis, musculoskeletal and dermatologic features and the trial was 
not specifically designed to examine the role of CTLA-4-Ig in lupus nephritis. The primary 
end-point of the study was the proportion of patients with a new flare of SLE (defined as 
BILAG score of A or B adjudicated as a flare in any organ system). The primary end point 
was not met. However when reassessed considering only BILAG A flares, 40.7% of patients 
in the abatacept group experienced a  flare after initiation of steroid taper as compared to 
54.5% in the placebo group. (Merrill et al, 2010). A clinical trial of abatacept in combination 
with cyclophosphamide in lupus nephritis is ongoing. 
4.2 Anti-CD40 ligand 
CD40 ligand (CD40L, CD154) is a transmembrane glycoprotein belonging to the TNF 
superfamily and is expressed on CD4 T-cells and activated platelets. It binds with CD40 on 
the surface of B-cells, macrophages and dendritic cells and this interaction between 
CD40/CD40L plays a pivotal role in B-cell class switching (Davidson et al, 2003). CD40L is 
overexpressed in murine lupus and monoclonal antibodies against CD40L have successfully 
treated murine lupus nephritis (Early et al, 1996).  
Two humanised anti-CD40L monoclonal antibodies (IDEC-131 and BG9588) have entered 
clinical trials in SLE patients. Treatment of 85 SLE patients with IDEC-131 failed to 
demonstrate clinical efficacy over placebo at 20 weeks (Kalunian et al, 2002). An open-label 
study of 28 patients with proliferative lupus nephritis treated with BG9588 showed reduced 
anti-dsDNA titres and increased complement levels but was discontinued prematurely due 
to thromboembolic events (Boumpas et al, 2003). Given the unexpected side effects and lack 
of efficacy demonstrated in these studies, it is unlikely that anti-CD40L will progress to 
larger clinical trials in lupus nephritis. 
5. Cytokine therapies 
5.1 Anti-interleukin-6 
Multiple cytokines have been implicated in the pathogenesis of SLE; among these is 
interleukin-6 (Il-6), a pleiotropic cytokine with both proinflammatory and anti-inflammatory 
properties. Evidence from murine models of lupus supports the role of Il-6 in the 
pathogenesis of lupus nephritis. Exogenous IL-6 increases autoantibody production and 
accelerates progression of nephritis in both the NZB/NZW and BXSB lupus mouse models 
(Ryffel et al, 1994) (Yang et al, 1998). On the contrary, injection of lupus prone mice with an 
IL-6 monoclonal antibody decreases anti-dsDNA levels and proteinuria and reduces 
mortality (Liang et al, 2006) (Mihara et al, 1998). In SLE patients, IL-6 levels have been 
shown to correlate with disease activity and anti-dsDNA titres. (Chun et al, 2007) (Linker-
Israeli et al, 1991). Urinary excretion of IL-6 is increased in those with proliferative forms of 
lupus nephritis and this excretion is reduced following cyclophosphamide therapy 
(Peterson et al, 1996) (Tsai et al, 2000). 
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Tocilizumab is a fully humanized monoclonal antibody against the α-chain of the IL-6 
receptor and prevents binding of IL-6 to both membrane bound and soluble IL-6 receptor. A 
phase I trial over a 12 week period has demonstrated the safety and tolerability of 
tocilizumab in lupus patients. Five of the twelve patients recruited to this study had renal 
disease at baseline, all of whom had moderate levels of proteinuria which remained 
unchanged throughout the duration of the study. There was however a reduction in the 
number of patients with active urinary sediment and a decrease in anti-dsDNA antibody 
titres (Illei et al, 2010). The short duration of the study renders it difficult to draw any firm 
conclusions as to the longer term effects of tocilizumab in lupus nephritis. The principal side 
effect noted in the study was neutropenia, which was dose related and white cell counts 
normalized on discontinuation of therapy. Randomized controlled trials of tocilizumab in 
lupus nephritis are awaited. 
5.2 Anti-TNF-α therapies 
Anti-TNF therapies (infliximab, adalimumab, etanercept) have become the mainstay of 
therapy in RA, psoriatic arthritis and ankylosing spondylitis. However the role of anti-TNF 
blocking agents in the treatment of SLE remains controversial. TNF is overexpressed in the 
serum, kidneys and skin of SLE patients and high serum levels of TNF correlate with lupus 
disease activity (Herrera-Esparza et al, 1998 )  (Aringer et al, 2005) (Zampieri et al, 2006) 
(Gabay et al, 1997). Murine models provide further evidence of the role of TNF in lupus 
nephritis. Both MRL/lpr and NZB/NZW lupus mouse models overexpress TNF and this 
correlates with renal inflammation suggesting potential benefit in TNF blockade in SLE 
(Boswell et al, 1988) (Yokoyama et al, 1995) (Brennan et al, 1989).  
However it is well established that patients treated with anti-TNF therapies develop 
autoantibodies similar to those seen in clinical lupus and the concern is that these agents 
when used in SLE patients could induce lupus flares. Anti-nuclear (ANA) antibodies 
develop in up to 50% of patients treated with anti-TNF agents and anti-dsDNA antibodies in 
5-14% (Aringer et al, 2008) (Charles et al, 2000). It should be pointed out that these are 
mainly IgM antibodies. 0.5-1% develop high affinity IgG antibodies to ds DNA (Charles et 
al, 2000). The development of clinical lupus-like syndromes in anti-TNF treated patients is 
rare and in those who do develop this, manifestations are for the main part mild (De Bandt 
et al, 2005). The development of lupus nephritis as a complication of TNF-induced lupus has 
been reported but is extremely rare (Mor et al, 2005) (Stokes et al, 2005) (Neradova et al, 
2009). New onset anti-phospholipid antibodies have also been noted in individuals treated 
with TNF blockers and associated vascular events have been documented (Aringer et al, 
2008).  The development of human anti-chimeric antibodies (HACAs) is also of concern in 
this patient population and these antibodies are more likely to develop in individuals with 
SLE given the autoimmune nature of the disease and potentially lead to an increased rate of 
infusion reactions. 
Small cohorts of SLE patients treated with TNF blockers including those with lupus 
nephritis have been published but as of yet no controlled trials have been conducted 
(Aringer et al, 2004) (Aringer et al, 2009). In four out of six lupus nephritis patients treated 
with anti-TNF therapies in an open-labeled study there was a significant sustained 
reduction in proteinuria following an induction regimen of four infusions of infliximab. 
Repeated infusions did not confer any additional benefit for these patients (Aringer et al, 
2004) (Aringer et al, 2009).  
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Most lupus patients in these reports were treated with the chimeric monoclonal antibody 
infliximab, less is known about the clinical impact of the TNF receptor fusion protein, 
etanercept or the fully humanized TNF monoclonal antibodies adalimumab or golimumab. 
Overall no firm conclusions can be drawn as regards the use of TNF blockade in lupus 
nephritis. There may be potential in using these agents, perhaps the fully humanized forms 
as an induction therapy in lupus nephritis and randomized controlled trials would be 
needed to clarify the role of anti-TNF therapy in the treatment of SLE.  
5.3 Targeting Interferon-α 
The concept of interferon-α playing a role in SLE pathogenesis has been noted in the 
literature since the 1970’s. There is a clear association between IFN activity and elevated 
anti-dsDNA titres and reduction in complement levels, commonly used parameters of 
clinical lupus activity. Further evidence of the relationship between IFN and lupus stems 
from the clinical observation that patients receiving recombinant IFN-α for the treatment of 
hepatitis C or malignancies may develop a lupus-like syndrome and develop 
autoantibodies. Microarray gene expression analysis has shown wide spread activation of 
IFN-inducible genes in lupus patients (Baechler et al, 2003) (Crow et al, 2003). IFN pathway 
activation has been associated with renal disease in lupus (Kirou et al, 2005). IRF5, a lupus 
susceptibility single nucleotide polymorphism with the highest odds ratio after the MHC 
plays a pivotal role in IFN pathways and toll-like receptor signaling (Graham et al, 2006). 
Hence, targeting IFN pathways is a valid therapeutic strategy in lupus patients.  
A number of clinical trials of monoclonal antibodies specific for various IFN-α isoforms are 
ongoing to establish the safety of these agents. An anti-IFN-α monoclonal antibody has been 
shown to inhibit the IFN signature in peripheral blood mononuclear cells and skin in lupus 
patients (Yao et al, 2009). This group has proposed a scoring method based on expression of 
type I IFN-inducible mRNAs, which may divide SLE patients into two distinct subgroups. 
This might enable type I interferon-inducible genes to be used as biomarkers to identify 
patients who might respond better to anti-type I IFN treatment (Yao et al, 2011). 
Blockade of the IFN receptor is another potential therapeutic target. Given the role of IFN-α 
in the host defense against viral infection, close clinical monitoring is mandatory in the 
development of any potential agents targeting this pathway. 
6. Complement therapies 
6.1 Eculizumab 
The importance of the complement system in the pathophysiology of SLE is clear although 
individual complement components play very different roles in the disease process. Early 
complement proteins are critical in the clearance of immune complexes and apoptotic 
material, and their absence predisposes individuals to SLE. Activation of terminal 
complement is associated with exacerbations of disease, particularly in lupus nephritis. 
Monoclonal antibodies that specifically inhibit terminal complement activation while 
preserving early complement function have now been developed. Murine models of lupus 
nephritis treated with anti-C5 have shown delayed onset proteinuria, improved renal 
histological findings and longer survival (Wang et al, 1996).  
Eculizumab, a monoclonal antibody directed against the complement protein C5, inhibits 
the cleavage of C5 to C5a and C5b and thus blocks the formation of the terminal membrane 
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attack complex C5b-9 (Cordeiro et al, 2008). Eculizumab has been approved for use in the 
treatment of paroxysmal nocturnal haemoglobinuria since 2007 (Dmytrijuk et al, 2008). A 
phase I trial has shown that eculizumab is safe and well tolerated in SLE, but no clear 
clinical improvements were evident at day 28 and 56 of the study (Rother et al, 2004). To 
date there have been no further clinical trials to examine the potential efficacy of this 
therapy. 
7. Conclusion 
An increased understanding of the immunopathogenesis of SLE during the past decade has 
lead to the introduction of several new biologic agents into clinical practice.  An array of 
promising new therapies are yet to emerge or are under development. Conventional 
immunosuppressive therapies have transformed survival in lupus nephritis, but their use is 
associated with considerable toxic effects and a substantial subset of patients remain 
refractory to these agents. There is a clear need for new therapeutic agents that overcome 
these issues, and biologic agents offer exciting opportunities.  
An important consideration in the management of lupus nephritis is that patients of 
different ethnicities have varying clinical outcomes and response to therapy. As alluded to 
previously, patients of African American descent are more likely to progress to end-stage 
renal disease (Dooley et al, 1997). Indeed the response to biologic therapy may well vary 
according to ethnicity. This was well demonstrated in the ALMS study where the efficacy 
and safety of mycophenolate mofetil (MMF) and intravenous cyclophosphamide (IVC) as 
induction treatment for lupus nephritis was examined by race, ethnicity and geographical 
region. This study clearly showed that Black and Hispanic patients responded better to 
MMF than IVC (Isenberg et al, 2010). The majority of clinical studies in emerging biologic 
therapies have not addressed the issue of variable clinical response in different ethnic 
groups. Of note, belimumab was found to be less efficacious in African American patients in 
phase III clinical trials (Wallace et al, 2009) (Jacobi et al, 2010). 
Several of the studies of emerging therapeutic strategies described in this chapter, while 
encouraging, have targeted SLE disease manifestations in general rather than focusing on 
outcomes in lupus nephritis. While many of these therapies show promise for their potential 
use in SLE in general, randomised controlled trials specifically examining their clinical 
effects in lupus nephritis are needed. In addition to this, the role of new biologic agents to 
date may have centred on patients who have been refractory to conventional therapies.  
There are few clinical trials examining their role as first line induction or maintenance 
therapy. One exception to this has been the successful use of rituximab as first line induction 
therapy followed by maintenance mycophenolate mofetil in a cohort of eighteen patients 
with proliferative nephritis (Pepper et al, 2009).  
Although so far many biologics e.g. rituximab have been generally well tolerated, (with the 
exception of rare but important cases of PML), we must not be complacent regarding 
toxicity, as we do not yet know the long-term effects of these medications on the immune 
system. Other biologics have had considerable toxicity, such as anti-CD40L (B59588). 
A number of key questions remain. How can these therapies be potentially combined with 
existing proven treatments and indeed with one another to achieve maximum clinical 
benefit with minimal side effects? It is unlikely that any of these emerging therapies is going 
to represent a magic therapeutic bullet for all lupus nephritis patients. As is clear to all 
physicians dealing with the clinical management of SLE this is a heterogeneous disease and 
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Most lupus patients in these reports were treated with the chimeric monoclonal antibody 
infliximab, less is known about the clinical impact of the TNF receptor fusion protein, 
etanercept or the fully humanized TNF monoclonal antibodies adalimumab or golimumab. 
Overall no firm conclusions can be drawn as regards the use of TNF blockade in lupus 
nephritis. There may be potential in using these agents, perhaps the fully humanized forms 
as an induction therapy in lupus nephritis and randomized controlled trials would be 
needed to clarify the role of anti-TNF therapy in the treatment of SLE.  
5.3 Targeting Interferon-α 
The concept of interferon-α playing a role in SLE pathogenesis has been noted in the 
literature since the 1970’s. There is a clear association between IFN activity and elevated 
anti-dsDNA titres and reduction in complement levels, commonly used parameters of 
clinical lupus activity. Further evidence of the relationship between IFN and lupus stems 
from the clinical observation that patients receiving recombinant IFN-α for the treatment of 
hepatitis C or malignancies may develop a lupus-like syndrome and develop 
autoantibodies. Microarray gene expression analysis has shown wide spread activation of 
IFN-inducible genes in lupus patients (Baechler et al, 2003) (Crow et al, 2003). IFN pathway 
activation has been associated with renal disease in lupus (Kirou et al, 2005). IRF5, a lupus 
susceptibility single nucleotide polymorphism with the highest odds ratio after the MHC 
plays a pivotal role in IFN pathways and toll-like receptor signaling (Graham et al, 2006). 
Hence, targeting IFN pathways is a valid therapeutic strategy in lupus patients.  
A number of clinical trials of monoclonal antibodies specific for various IFN-α isoforms are 
ongoing to establish the safety of these agents. An anti-IFN-α monoclonal antibody has been 
shown to inhibit the IFN signature in peripheral blood mononuclear cells and skin in lupus 
patients (Yao et al, 2009). This group has proposed a scoring method based on expression of 
type I IFN-inducible mRNAs, which may divide SLE patients into two distinct subgroups. 
This might enable type I interferon-inducible genes to be used as biomarkers to identify 
patients who might respond better to anti-type I IFN treatment (Yao et al, 2011). 
Blockade of the IFN receptor is another potential therapeutic target. Given the role of IFN-α 
in the host defense against viral infection, close clinical monitoring is mandatory in the 
development of any potential agents targeting this pathway. 
6. Complement therapies 
6.1 Eculizumab 
The importance of the complement system in the pathophysiology of SLE is clear although 
individual complement components play very different roles in the disease process. Early 
complement proteins are critical in the clearance of immune complexes and apoptotic 
material, and their absence predisposes individuals to SLE. Activation of terminal 
complement is associated with exacerbations of disease, particularly in lupus nephritis. 
Monoclonal antibodies that specifically inhibit terminal complement activation while 
preserving early complement function have now been developed. Murine models of lupus 
nephritis treated with anti-C5 have shown delayed onset proteinuria, improved renal 
histological findings and longer survival (Wang et al, 1996).  
Eculizumab, a monoclonal antibody directed against the complement protein C5, inhibits 
the cleavage of C5 to C5a and C5b and thus blocks the formation of the terminal membrane 
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attack complex C5b-9 (Cordeiro et al, 2008). Eculizumab has been approved for use in the 
treatment of paroxysmal nocturnal haemoglobinuria since 2007 (Dmytrijuk et al, 2008). A 
phase I trial has shown that eculizumab is safe and well tolerated in SLE, but no clear 
clinical improvements were evident at day 28 and 56 of the study (Rother et al, 2004). To 
date there have been no further clinical trials to examine the potential efficacy of this 
therapy. 
7. Conclusion 
An increased understanding of the immunopathogenesis of SLE during the past decade has 
lead to the introduction of several new biologic agents into clinical practice.  An array of 
promising new therapies are yet to emerge or are under development. Conventional 
immunosuppressive therapies have transformed survival in lupus nephritis, but their use is 
associated with considerable toxic effects and a substantial subset of patients remain 
refractory to these agents. There is a clear need for new therapeutic agents that overcome 
these issues, and biologic agents offer exciting opportunities.  
An important consideration in the management of lupus nephritis is that patients of 
different ethnicities have varying clinical outcomes and response to therapy. As alluded to 
previously, patients of African American descent are more likely to progress to end-stage 
renal disease (Dooley et al, 1997). Indeed the response to biologic therapy may well vary 
according to ethnicity. This was well demonstrated in the ALMS study where the efficacy 
and safety of mycophenolate mofetil (MMF) and intravenous cyclophosphamide (IVC) as 
induction treatment for lupus nephritis was examined by race, ethnicity and geographical 
region. This study clearly showed that Black and Hispanic patients responded better to 
MMF than IVC (Isenberg et al, 2010). The majority of clinical studies in emerging biologic 
therapies have not addressed the issue of variable clinical response in different ethnic 
groups. Of note, belimumab was found to be less efficacious in African American patients in 
phase III clinical trials (Wallace et al, 2009) (Jacobi et al, 2010). 
Several of the studies of emerging therapeutic strategies described in this chapter, while 
encouraging, have targeted SLE disease manifestations in general rather than focusing on 
outcomes in lupus nephritis. While many of these therapies show promise for their potential 
use in SLE in general, randomised controlled trials specifically examining their clinical 
effects in lupus nephritis are needed. In addition to this, the role of new biologic agents to 
date may have centred on patients who have been refractory to conventional therapies.  
There are few clinical trials examining their role as first line induction or maintenance 
therapy. One exception to this has been the successful use of rituximab as first line induction 
therapy followed by maintenance mycophenolate mofetil in a cohort of eighteen patients 
with proliferative nephritis (Pepper et al, 2009).  
Although so far many biologics e.g. rituximab have been generally well tolerated, (with the 
exception of rare but important cases of PML), we must not be complacent regarding 
toxicity, as we do not yet know the long-term effects of these medications on the immune 
system. Other biologics have had considerable toxicity, such as anti-CD40L (B59588). 
A number of key questions remain. How can these therapies be potentially combined with 
existing proven treatments and indeed with one another to achieve maximum clinical 
benefit with minimal side effects? It is unlikely that any of these emerging therapies is going 
to represent a magic therapeutic bullet for all lupus nephritis patients. As is clear to all 
physicians dealing with the clinical management of SLE this is a heterogeneous disease and 
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there is not one ideal regimen for all. With greater understanding of the pathophysiology of 
lupus particularly from the genetic perspective, the era of personalized therapy may 
represent perhaps the greatest advance that is yet to come in the treatment of lupus 
nephritis.  
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1. Introduction 
Cardiovascular involvement in systemic lupus erythematosus (SLE) was first reported by 
Kaposi in 1872 of cardiac irregularity and dyspnea. In 1924, Libman and Sacks reported 
verrucous endocarditis but ironically did not recognize the association of verrucous 
endocarditis with SLE. (Petri, 2004) In the last decade, newly recognized clinical entities 
have been described with the introduction of very sensitive, non-invasive  and semi-
invasive cardiac imaging techniques.(Turiel, 2005) With the use of very sensitive methods of 
cardiovascular investigations, it has been found the prevalence of cardiac involvement to be 
>50%. (Petri, 2004) 
Several autoantibodies such as antiDNA, anti-phospholipid antibodies (apl), antiSSA (Ro 
antibodies) and antiendothelial cell antibodies present in patients with SLE can mediate 
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trigger mechanisms able to cause heart damage for example, apl can contribute to cardiac 
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Consequences of autoantibody damage has been reported in several heart structures such as 
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course of the disease were due to active SLE and use of high dose steroids  associated with 
complications such as infection and sepsis. Later in the disease course (›5 years after 
diagnosis) deaths were frequently associated with inactive SLE, long duration of 
prednisolone therapy and myocardial infarction (MI) due to atherosclerotic heart disease. 
(Urowitz, 1976) Cardiac disease has recently been acknowledged as a primary cause of 
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atherosclerosis has been characterized. Though cardiac involvement is a uncommon cause 
of flare: it can be forgotten unless a full blown cardiac dysfunction or complication is 
present. In a prospective study of flares, serositis was present in only 7-9% of the flares. 
(Petri, 1991) With prolongation of life by modern immunosuppressive therapies, heart 
lesions develop in all patients at sometime during the course of their disease. 
The present chapter: 
Emphasizes  and describes the cardiac involvement  in SLE which may involve all  three 
layers of the heart (pericardium, myocardium and the endocardium).Appreciate the early 
identification and management of these conditions prevents the late life threatening 
complications and consequences. Recognize the importance of premature atherosclerosis 
and that it is the major cause for mortality and premature death in lupus patients. 
Understand the causation is multifactorial:  traditional risk factors as well as SLE related risk 
factors and inflammatory mediators are involved in the pathogenesis. Early identification 
and treatment of modifiable risk factors in SLE patients are discussed. There have not yet 
been any published randomized, controlled trials in patients with SLE in respect to CVD 
risk factor modifications. Thus treatment and management recommendations are based on 
published guidelines for other populations at high risk for CVD. 
2. Pericarditis 
2.1 Clinical features 
Pericarditis is the most common cardiac manifestation of active lupus, although often it is 
not evident clinically. Pericarditis can occur at any time during the course of SLE, it tends to 
be one of the earlier cardiac manifestations, and can even be the first manifestation of 
lupus.( Brigden, 1960) Pericarditis was the presenting sign of lupus in 4 of  28  patients who 
ultimately developed it in one series.(Godeau et al.1981)  Pericarditis in SLE presents  in the 
typical way, with precordial pain, usually positional (aggravated by lying down), often with 
a pleuritic quality, and sometimes with dyspnea. Coexistent pleurisy and/or effusions are 
common, occurring in 14 of 28 cases in same series. (Godeau et al., 1981) Pericarditis usually 
appears as an isolated attack or as recurrent episodes, with or without symptoms. Patients 
may have fever and tachycardia. Friction rubs are rare, perhaps because they are present 
often for only a few hours and are missed. The “classic” pericardial friction rub has three 
components, occurring with ventricular contraction, atrial contraction, and at the end of 
rapid ventricular filling.( Petri, 2004) In a French series, of 28 cases of pericarditis, 23 had 
pain, 12 had a rub, and 4 required pericardiocentesis because of tamponade.(Godeau et 
al.,1981) Patients with pericardial effusion (as opposed to thickening) are more likely to have 
pericardial pain and active lupus elsewhere.( Leung et al, 1990,Cervera et al, 1992 ) In the 
study by Cervera et al, only the patients with moderate or severe pericardial effusion had 
clinical or electrocardiographic evidence of pericarditis.( Cervera et al, 1992 ) When present, 
pericardial effusions are usually small and do not cause hemodynamic problems. Pericardial 
tamponade is rare and has been reported as an initial presentation (Topaloglu, 2006) and 
even in treated patients. (Shearn, 1959 In a series reported by Rosenbaum, 9 of the 71 
patients with pericardial effusion developed pericardial tamponade( 21%) of which 5 of the 
9 patients required a pericardial  window.(Rosenbaum, 2009) Constrictive pericarditis is 
very rare. Only four cases of constrictive pericarditis have been reported. In two of the four 
cases constrictive pericarditis developed in spite of corticosteroid therapy. All four known 
cases have occurred in males. (Petri, 2004) 
 




Fig. 1. Serositis in a 13-year-old boy with SLE. Contrast-enhanced CT scan shows bilateral 
pleural effusions (*), cardiomegaly, and a pericardial effusion (arrow). Bilateral lower lobe 
atelectasis is also present. (Lalani & Hatieldl, 2004) Copyright permission from RSNA 
2.2 Diagnosis 
If a patient presents for the first time with pericarditis, it is usually impossible to invoke SLE 
as the cause until appropriate laboratory tests are available suggesting the diagnosis. 
However, patients with idiopathic pericarditis more often give a history of recent viral 
infection, and are more often male. In idiopathic pericarditis there is usually a leukocytosis, 
whereas a finding of leucopenia would suggest SLE. Pericardial friction rubs may be heard 
in sicker and untreated patients, but are often absent in milder cases, especially those 
patients already on corticosteroid and/or NSAID treatment. A significant rise in jugular 
venous pressure is unusual. (Petri, 2004) In one series, most patients showed 
electrocardiographic evidence of acute or chronic pericarditis. (Brigden et al, 1960) The 
diagnosis of pericarditis can be confirmed by ECG findings of elevated ST segments and tall 
T waves (although slight T-wave changes or transient elevation of ST segments are most 
characteristic), or by cardiac echocardiogram findings of pericardial effusion or thickened 
pericardium. Serial electrocardiograms may show a progression of changes in pericarditis. 
Initially, a diffuse elevation of ST segments (without reciprocal ST segment depression) is 
found. This is followed by a lowering of ST segments back toward baseline and subsequent 
T-wave inversion. In most cases, T waves then return to normal. (Petri, 2004) Effusions may 
be accompanied by a drop in voltage. After severe attacks, the T waves may not recover to 
their original voltage.(Brigden, 1960) In the series of Godeau et al., of 28  cases, 5 had low 
voltage, 10  had ST changes, and 20 had depolarization changes.(Godeau et al, 1981) Both 
effusion and thickening are frequent in echocardiogram studies. Most effusions are mild. 
Echocardiography (two-dimensional echocardiogram and Doppler echocardiography) is the 
modality of choice in evaluating pericardial disease, because it is both noninvasive and 
sensitive. However, echocardiography may be an insensitive technique in diagnosing 
pericarditis when it is not accompanied by effusion or thickening. (Petri, 2004)  
2.3 Prevalence 
The frequency of pericarditis depends on the modality of diagnosis.Published series  
of patients find pericarditis in 12–47% of living SLE patients.(Petri, 2004) In general, the  
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components, occurring with ventricular contraction, atrial contraction, and at the end of 
rapid ventricular filling.( Petri, 2004) In a French series, of 28 cases of pericarditis, 23 had 
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very rare. Only four cases of constrictive pericarditis have been reported. In two of the four 
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diagnosis of pericarditis can be confirmed by ECG findings of elevated ST segments and tall 
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pericardium. Serial electrocardiograms may show a progression of changes in pericarditis. 
Initially, a diffuse elevation of ST segments (without reciprocal ST segment depression) is 
found. This is followed by a lowering of ST segments back toward baseline and subsequent 
T-wave inversion. In most cases, T waves then return to normal. (Petri, 2004) Effusions may 
be accompanied by a drop in voltage. After severe attacks, the T waves may not recover to 
their original voltage.(Brigden, 1960) In the series of Godeau et al., of 28  cases, 5 had low 
voltage, 10  had ST changes, and 20 had depolarization changes.(Godeau et al, 1981) Both 
effusion and thickening are frequent in echocardiogram studies. Most effusions are mild. 
Echocardiography (two-dimensional echocardiogram and Doppler echocardiography) is the 
modality of choice in evaluating pericardial disease, because it is both noninvasive and 
sensitive. However, echocardiography may be an insensitive technique in diagnosing 
pericarditis when it is not accompanied by effusion or thickening. (Petri, 2004)  
2.3 Prevalence 
The frequency of pericarditis depends on the modality of diagnosis.Published series  
of patients find pericarditis in 12–47% of living SLE patients.(Petri, 2004) In general, the  
 




Fig. 2. Lupus pericarditis in a 42-year-old woman. Contrast-enhanced CT scan demonstrates 
cardiomegaly, a thickened and enhancing pericardium, and a pericardial effusion. . (Lalani 
& Hatieldl, 2004) Copyright permission from RSNA 
echocardiogram is more sensitive than clinical diagnosis, with 19–54% of patients having 
pericardial effusion or thickening. The echocardiogram is an essential tool in the clinical 
management of sick patients with cardiac lupus, because clinical diagnosis alone may be 
faulty. Pericardial abnormalities are the most common echocardiographic finding in SLE 
patients.(Leung, 1990) However, significant pericardial disease is uncommon, even using 
echocardiograms, being found in only 7% in one study by Cervera et al. (Cervera et al , 1992) 
Autopsy studies find a much higher prevalence of pericardial involvement, ranging up to 
61–100%. (Petri, 2004)                        
2.4 Pathology 
Pericardial fluid in SLE is usually exudative, the amount of fluid varying from 100 to more 
than 1000 cc.(Tincani, 2006)White blood counts are in the 30,000 range, primarily 
neutrophils. Although not helpful in patient management, the fluid may contain anti-DNA 
and have low complement levels. Complement-fixing material was found in pericardial 
fluid in patients with SLE, which was felt to be immune complexes. (Petri, 2004)  At autopsy, 
a diffuse or focal fibrinous pericarditis, often with many hematoxylin bodies, with or 
without effusion, was found. In the series of Brigden et al., the layers of the pericardium 
were obliterated with occasional deposits of fresh fibrin or effusion. (Brigden, 1960) In 
another autopsy study, of 11 cases, 6 had acute pericarditis and 5 had chronic obliterative 
pericarditis (2 of these had pericardiomediastinal adhesions). (Bidani, 1980) 
 The histopathology in a case of constrictive pericarditis showed fibrosis and mild chronic 
inflammation, with IgG, IgM, and complement deposition on immunofluorescence. 
Immunopathogenetic analyses of the pericardium in 2 of 9 patients in an autopsy series 
demonstrated the vascular deposition of immunoglobulin and complement. (Bidani, 1980) 
On histopathology, small pericardial blood vessels were surrounded by an infiltrate of 
lymphocytes, plasma cells, macrophages, and rare polymorphonuclear leukocytes. On 
immunofluorescence, IgG was present in a predominantly granular pattern around small 
pericardial vessels.Thus, Bidani and colleagues concluded that immune complex deposition 
was the cause of pericarditis. (Bidani, 1980) 
 




In early studies, pericarditis usually responded quickly to corticosteroids, with serial chest 
x-rays showing rapid and radiologic evidence of resorption of fluid.(Brigden,1960) Shearn 
commented in his review that the “often transient nature of pericarditis makes evaluation of 
therapy for this condition most difficult.(Shearn, 1959) However, many studies have noted 
pericardial effusion developing or persisting even with corticosteroid treatment, such as the 
autopsy study of Kong et al., in which 11 of 12 patients with pericardial effusion had taken 
corticosteroids.(Kong et al,1962) Occasionally patients progressed to the point of 
tamponade.(Rosenbaum, 2009) Nonsteroidal anti-inflammatory drugs are helpful for mild 
cases of pericarditis. Patients presenting with pericardial tamponade may necessitate 
pericardiocentesis. Refractory cases of large pericardial effusions may benefit from a 
pericardial window. (Rosenbaum, 2009) 
3. Myocarditis 
3.1 Clinical features 
Myocarditis, as recognized clinically, is rare in SLE. The clinical detection of myocarditis 
ranges from 3 to 15%, although it appears to be much more common in autopsy studies 
suggesting the largely subclinical nature of the myocardial pathology. Patients may present 
in florid congestive heart failure, or more subacutely with tachycardia and dyspnea. 
Myocardial abnormalities were found in 20% of patients using echocardiograms, but only 
one patient with an echocardiographic pattern of myocarditis developed myocardial 
dysfunction clinically.(Cervera, 1992) 
Even autopsy studies have shown that myocarditis usually does not lead to cardiac 
dilatation.(Griffith & Vural, 1951) Brigden et al. had no patient in whom congestive heart 
failure was attributed solely to myocarditis.(Brigden et al, 1960)  Shearn had only one 
patient with heart failure attributable to myocarditis.(Shearn,1959) 
However, other series have found myocarditis as a cause of congestive heart failure. (Petri, 
2004) Harvey et al found that myocarditis was the cause of heart failure in 8 of their 9 
patients. (Petri, 2004)  Hejtmancik et al. found myocarditis to be the major cause in 6 of their 
10 cases. (Hejtmancik et al, 1964). Kong et al. had 17 patients with cardiomegaly; at autopsy, 
15 had myocarditis but of varying degrees of severity.(Kong et al,1962) 
The differential diagnosis of congestive heart failure in SLE would include lupus 
myocarditis, viral myocarditis, toxic myocarditis due to use of antimalarial drugs, anemia, 
renal failure, pulmonary disease, atherosclerotic heart disease, coronary arteritis, valvular 
disease, and hypertension. 
3.2 Diagnosis 
The clinical recognition of myocarditis can easily be missed. In most cases, the patient who 
had a hematologic and renal flare was not recognized to have myocarditis as well until they 
presented in congestive heart failure. Myocarditis should be considered in patients with 
tachycardia not due to fever, in patients with a third heart sound (S3), in patients with 
abnormal ECGs, in those with new murmurs or conduction disturbances, and in those with 
congestive heart failure. (Shearn, 1959) Brigden et al. suggested that prolongation of the 
conduction time of either P–R, QRS, or Q–T interval would have been evidence of 
myocarditis (in the absence of another cause of ventricular hypertrophy), but that they did 
not encounter these ECG changes in their series.(Brigden, 1960) 
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Hejtmancik et al. made a clinical diagnosis of myocarditis in 21% of their patients (after first 
excluding hypertension and coronary artery disease), based on (1) cardiac enlargement, (2) 
ventricular gallop, and (3) electrocardiographic abnormalities.(Hejtmancik et al, 1964) Kong 
et al. found myocarditis at autopsy in 15 of their 16 patients with gallop rhythm.(Kong et al, 
1962).The diagnosis of myocarditis can be supported by the finding of global hypokinesia on 
cardiac echocardiogram and may be confirmed by right ventricular endomyocardial 
biopsy.(Petri,2004) Although echocardiography cannot diagnose myocarditis with certainty, 
global hypokinesia, in the absence of other known causes, is strongly suggestive.(Busteed et 
al, 2004) Other investigations that may help to diagnose myocarditis include a gallium 
scan18 and magnetic resonance imaging (MRI).(Saremi et al, 2007) Nuclear medicine scans 
rely on labeling of anti myosin antibodies with radiopharmaceuticals, and may not be 
available in all clinical settings. Different MRI techniques may support the diagnosis of 
myocarditis. Contrast enhancement of the myocardium in the setting of acute myocyte 
membrane rupture results in greater passive diffusion of contrast into the affected 
intracellular space. A midwall myocardial hyperenhancement pattern is the most frequent 
finding in both acute and chronic myocarditits, while a subepicardial distribution of lesions 
is reported only in patients with acute myocarditis.(Saremi et al,2007) However, it is 
important to note that MRI alone cannot differentiate viral myocarditis from other causes of 
acute dilated cardiomyopathy. A biopsy is not required in many cases of lupus myocarditis, 
as the sensitivity and specificity are unknown; but can be useful in some patients to confirm 
the clinical diagnosis, determine the severity of myocardial involvement, and distinguish 
this disorder from other causes of myocardial disease  like drug induced etc.(Wijetunga & 
Rockson, 2002) New-onset heart failure of less than 6 days’ duration associated with 
hemodynamic compromise is an American Heart Association/American College of 
Cardiology/European Society of Cardiology class I indication for endomyocardial 
biopsy.(Cooper et al,2007) 
3.3 Prevalence 
In large series of patients, the clinical diagnosis of myocarditis has been made in up to21 %. 
(Petri, 2004) Autopsy studies, mainly done in the 1950s and 1960s, frequently found 
myocarditis. More recent postmortem studies,(Bindani, 1980) reflecting the era of 
corticosteroid treatment, found much lower frequencies, from 0 to 8%. Echocardiographic 
studies cannot definitively diagnose myocarditis, but global hypokinesia, in the absence of 
other known causes, is strongly suggestive. (Appenzeller, 2011) Large echo series have 
found frequencies of global hypokinesis between 5 and 20%. However, segmental areas of 
hyopkinesis on echocardiogram can also be indicative of myocarditis. Newer imaging 
modalities, such as magnetic resonance, are largely unstudied. (Appenzeller, 2011) 
3.4 Pathology 
A common misperception is that myocarditis in SLE is a myositis. CPK levels are usually 
normal.(Petri, 2004) In fact, only one study found any association with myositis 
elsewhere.(Borenstein et al, 1978)  Myocarditis in SLE is a complicated process, with arteritis 
or arteriopathy, not primary disease of the myocardial fibers, playing a major role. Kong et 
al. found pathologic evidence of myocarditis (fibrinoid and collagenous degeneration, 
interstitial edema, necrosis, and/or cellular infiltration) in 15 of 30 autopsies. (Konget al, 
1962) The cellular infiltrates of myocarditis consist of foci of interstitial plasma cells and 
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lymphocytes. Immunofluorescence studies confirm that the etiopathogenesis is vascular. In 
one study, most of the immune deposits were present in the walls of blood vessels of the 
myocardium.(Bidani, 1980) Immunofluorescence studies of endomyocardial biopsies reveal 
perivascular deposits of IgG and vascular deposits of C3.(Appenzeller, 2011)  A rare and 
aggressive form is giant cell myocarditis, which is associated with extensive myocytes 
necrosis, a mixed dense lymphoplasmacytic infiltration, numerous multinucleated giant 
cells and degranulatd esinophils, leads to rapidly developing progressive congestive heart 
failure and arrhythmias.(Chung et al, 2005; Martorell et al, 2008) Antimalarial-related 
myocarditis is often associated with skeletal muscle involvement showing curvilinear and 
myeloid bodies.(Nord et al,2004) 
3.5 Treatment 
Myocarditis that comes to clinical attention is usually an urgent situation. Treatment with 
high-dose intravenous methylprednisolone (such as the “pulse”regimen, 1000 mg daily for 3 
days), followed by high dose IV or oral corticosteroid maintenance therapy, is indicated. 
Intravenous “pulse” cyclophosphamide is added in refractory cases and patients with heart 
failure. Initial six cycle of monthly pulses of cyclophosphamide 750mg/m2, followed by a 
repeated cycle if LVEF has not completely normalized, is relatively well tolerated and 
effective. (Van der Laan Baalbergen et al, 2009) Intravenous immunoglobulin's have been 
used in one or two case reports with some success.(Sherer et al, 1999) 
Supportive therapy for congestive heart failure, including diuresis, digoxin, and afterload 
reduction (such as with angiotensin converting enzyme (ACE) inhibitors) may be necessary. 
Anticoagulation should be considered in those patients who have progressed to the stage of 
cardiomyopathy. Efficacy of therapy can be assessed by serial echocardiographic studies.  
One potential therapeutic option in advanced stages of heart failure regardless of the source 
is cardiac resynchronization therapy (CRT). There have been several reports illustrating the 
successful use of cardiac resynchronization in patients with SLE and resistant 
cardiomyopathy. (Reza et al, 2011) Mortality is higher in giant cell myocarditis than other 
forms of myocarditis. (Cooper et al, 1997)Cardiac transplantation is an option in refractory 
cases. (Reza et al, 2011)    
4. Valvular disease 
4.1 Clinical features 
Verrucous endocarditis can affect valve leaflets, papillary muscles, and the mural 
endocardium, as initially described by Libman and Sacks. However, Libman and Sacks and 
Gross  found the tricuspid valve involved most often, whereas more recent studies have 
found the mitral valve (followed by aortic) to be most affected.(Petri, 2004) In the 
corticosteroid era, valvular vegetations are found less frequently. Shearn found that none of 
11 patients who received corticosteroids had verrucous endocarditis, but 4 patients, who 
died before corticosteroid therapy was available, did. (Shaern, 1959) In their landmark 
autopsy study, Bulkley and Roberts also commented on the rarity of vegetations in 
corticosteroid treated patients. (Bulkley & Roberts, 1975) Occasionally, the presentation may 
be fulminant, with congestive heart failure due to mitral regurgitation, or brain emboli 
secondary to valvular vegetations. Verrucous endocarditis (vegetations, “Libman- Sacks”) 
affects the mitral valve most frequently, followed by the aortic valve. (Petri, 2004) 
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Fig. 3. Libman Sacks Endocarditis.  
The presence of vegetations predisposes patients to bacterial endocarditis.(Brigden et 
al,1960) Although verrucous endocarditis can produce both systolic and diastolic murmurs, 
these are rarely of sufficient hemodynamic importance to cause congestive heart failure. 
There is virtually no correlation between the presence of verrucous endocarditis and cardiac 
murmurs. Shearn found that systolic murmurs occurred in 70% of SLE patients. (Shearn, 
1959) Most murmurs were low intensity, and were heard loudest (47%) at the apex. Because 
murmurs were also associated with fever, infection, tachycardia, and anemia, the 
differential diagnosis of a new murmur was complex.  
Diastolic murmurs occur in only 4% of SLE patients. (Petri, 2004) The differential diagnosis 
of diastolic murmurs in SLE includes rheumatic or congenital heart disease, bacterial 
endocarditis, Libman-Sacks endocarditis, and left ventricular dilatation. In general, even 
when the valvular vegetations of Libman-Sacks endocarditis are large, they do not involve 
the line of closure, and therefore should not deform the valve. Even involvement of the 
chordae tendineae should not be sufficient to distort the valve. There are several 
documented cases, however, in which Libman-Sacks endocarditis appeared to be the only 
explanation for a diastolic murmur. (Petri, 2004) Two of the four patients with Libman-Sacks 
endocarditis in Shear's series had a diastolic murmur suggestive of mitral stenosis. 
However, diastolic murmurs were also heard in two patients without Libman-Sacks 
endocarditis. (Shearn,1959) It is rare for valvular disease in SLE to be clinically significant. In 
a series of 421 patients, only 1 to 2% had significant morbidity or mortality. Of the 14 cases 
with available pathology, only 6 had evidence of SLE valvulopathy, either verrucous 
vegetations or valvulitis with necrosis and vasculitis. (Straaton et al, 1988) 
4.2 Diagnosis 
Transesophageal echocardiogram is the modality of choice in terms of sensitivity in 
detecting valvular disease due to either lupus or anti-phospholipid antibody syndrome. 
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(Petri, 2004) Most previous series used M-mode echocardiography or two-dimensional 
Doppler echocardiography and are not completely comparable. Patients with new murmurs 
or with valvular abnormalities on echocardiogram should have blood cultures to rule out 
bacterial endocarditis. 
4.3 Prevalence 
The prevalence of valvular disease in SLE is very high by echocardiography accounting for 
54% of the patients.(Maksimowicz-McKinnon & Mandell, 2004) Valvular disease, for the 
most part, however, is mild and asymptomatic. 
4.4 Pathology 
Valvular disease occurs predominantly as vegetations (what was termed Libman-Sacks 
endocarditis in the past), or thickening (that can present as either a regurgitant or stenotic 
lesion). The mitral valve is affected most often, followed by the aortic valve. Mitral and 
aortic regurgitation are the most common findings, with stenotic lesions being very rare. 
Aortic cup sclerosis has been identified as common lesion.The typical valvular and mural 
endocarditis lesions, which are verrucous, occur as single vegetation or as mulberry-like 
clusters. When occurring on valves, the vegetations are often on the ventricular surface, 
near, but not distorting, the line of closure. (Shapiro et al, 1977) The original histologic 
description of Libman-Sacks endocarditis emphasized the multiplication of endothelial cells, 
proliferation of Anitschow myocytes, and infiltration of mononuclear cells in the valve ring 
and valve base, especially the valve pocket. Aggregations of hemosiderin were frequent, 
along with some fibrosis. Cells underwent karyolysis to form hematoxylin bodies. The 
mural endothelium was affected, especially near the mitral valve. (Brigden et al, 1960) 
Histologic studies showed three distinct zones, an outer exudative layer of fibrin, nuclear 
debris, and hematoxylin-stained bodies; a middle organizing layer of proliferation of 
capillaries and fibroblasts, and an inner layer of neovascularization. Immunofluorescence 
showed immunoglobulin and complement deposition in the walls of small junctional 
vessels in the inner zone of neovascularization, suggesting that circulating immune 
complexes were critical in the development of the vegetations.(Shapiro et al, 1977) Bidani et 
al. found immunoglobulins and complement deposition in the valve stroma and vegetations 
in one patient with Libman-Sacks endocarditis. (Bidani, 1980) It is not clear whether 
Libman-Sacks endocarditis evolves into the valvular thickening that is the second important 
form of SLE valvulopathy. In modern series, valvular thickening is found more commonly 
than vegetations (Leung, 1990). Galve et al. found that patients with Libman-Sacks 
endocarditis were younger, had shorter disease duration, and had received less 
corticosteroid therapy than those with thickened valves. (Galve et al, 1988)  The patients 
with valvular thickening were more likely to have stenotic or regurgitant lesions and to 
require valve replacement. (Galve et al, 1988)  Some authors have expressed concern that 
corticosteroid treatment might increase the chance that a valve would develop thickening. 
Changes in valve thickening can occur over time, with valve thickening resolving or  
new valve thickening appearing. Studies are conflicting on the role of antiphospholipid 
antibodies playing in the development of the vegetations of Libman-Sacks endocarditis. 
Valvulopathy is common in the primary anti-phospholipid antibody syndrome,  
usually found in about a third of patients in large series. (Khamashta et al, 1990) Thrombus 
formation, usually on the mitral valve, can be massive and require valve replacement.  
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Mitral and/or aortic valve thrombus (or vegetations) can also be a precipitant of embolic 
strokes. In SLE patients, some series have shown significantly more valvulopathy in those 
with anticardiolipin antibody.(Khamashta et al,1990) In patients with the secondary form of 
anti-phospholipid antibody syndrome and valvulopathy, there is deposition of 
immunoglobulin and complement, but in addition there is binding of anticardiolipin 
antibody.(Petri, 2004) 
4.5 Treatment 
Systemic lupus erythematosus patients with large, sterile vegetations should be 
anticoagulated to lessen embolic complications. High-dose corticosteroids for 4 to 6 weeks 
are used to shrunken the vegetations, but this approach is controversial.( Nesher et al, 1997) 
Some studies have suggested that corticosteroid treatment may contribute to ultimate valve 
thickening, but this is unproven. In the presence of significant regurgitation, even in the 
absence of nodules, there is a high risk of bacterial endocarditis particularly in the setting of 
jet lesions and warrant antibiotic prophylaxis. (Roman & Salmon, 2007) 
5. Arrhythmia and conduction defects 
5.1 Clinical features 
Many autoimmune diseases including systemic lupus erythematosus have a high incidence 
of autonomic nervous system dysfunction, especially those of cardiac origin. Conduction 
disturbances and arrhythmias occur in about 10% of patients with SLE. (Mandell, 1987)  
Conduction defects include AV block, BBB and complete heart block, which is rarely seen in 
adults. While the most common arrhythmic manifestation include sinus tachycardia, atrial 
fibrillation, atrial ectopic beat and rarely ventricular arrhythmias. (Eisen et al, 2009) 
Recently, other anti-SSA/Ro-associated cardiac manifestations have been described in 
children born to anti-SSA/Ro positive mothers. These include transient fetal first-degree 
heart block, QTc prolongation, sinus bradycardia, late onset cardiomyopathy, endocardial 
fibroelastosis and cardiac malformations. Anti-SSA/Ro antibodies are usually not 
pathogenic to the adult heart, but recently QTc prolongation has been reported in adult 
lupus patients as well.(Costedoat-Chalumeau et al, 2005) 
Sinus tachycardia is the most common cardiac abnormality seen among SLE patients. It is 
present in about 50% of cases (Hejmancik et al, 1964) and it could be the only manifestation, 
also it can be correlated to the disease activity. (Guzman et al, 1994) Arrhythmia and 
conduction defects in SLE patients may be found incidentally or during disease flare, and 
usually develop with coexisting cardiac manifestation (such as pericarditis, myocarditis and 
coronary heart disease though, arrhythmia may be the first manifestation of SLE . (Cardoso 
et al, 2000)Patients with SLE may have prolonged Q-T interval, and this can be a predictor of 
cardiovascular morbidity and mortality. (Okin et al, 2000) 
5.2 Pathogenesis 
SLE can lead to arrhythmias and conduction disturbances either as a consequence of 
pericarditis and myocarditis through direct injury of the conduction system of the heart by 
inflammatory processes.(Eisen et al, 2009)Supraventricular arrhythmias are usually transient 
and recedes as soon as the disease is controlled and treated.(Mandell, 1987) They can also be 
due to myocardial fibrosis as a consequence of occlusive diseases, ( ischemia ) due to 
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vasculitis and atherosclerosis involvement (Eisen, 2009).These mechanisms will result in 
collage deposits that accumulate within nodes , causing fibrosis and focal degeneration of 
the conduction system.(Barati et al, 1975) Autopsy studies have found arteritis of the sinus 
node, vascular occlusion, vasculopathy, and fibroblastic replacement of the sinuatrial and 
atrioventricular nodes.(Barati et al, 1975) Q-T interval prolongation is hypothesized to be 
due to the subclinical atherosclerosis that is known to be augmented in SLE patients , and 
thus , it can be a marker of silent undetected atherosclerotic vascular disease in SLE 
patients.(Cardoso et al, 2005) In addition to Q-T interval prolongation, refractory ventricular 
arrhythmias could be associated with chronic hydroxychloroquine therapy for SLE. (Chen et 
al, 2006)  
5.3 Management  
Diagnosis of arrhythmia and conduction defects is by electrocardiograms that are performed 
usually in patients with an active disease during hospitalization. Those who have had 
arrhythmias or conduction abnormalities need continuous ECG monitoring. (Petri, 2004) 
The life threatening conduction defects are treated with permanent pacemaker, while the 
supra ventricular arrhythmias (unexplained sinus tachycardia) can be controlled with 
corticosteroids. (Costedoat-Chalumeau, 2005; Guzman et al, 1994)       
6. SLE hypertension 
6.1 Prevalence 
Hypertension has a high prevalence among SLE patients ranging from ( 35 to 74% ) 
according to different studies (Doria et al, 2003; Petri, 2000) and it is considered as a major 
risk factor for the progression of  renal , vascular and cardiovascular diseases.  In addition, 
it’s a major risk factor of severe ischemic stroke, thus reflect the need of regular assessment 
and strict blood pressure control among SLE patients. (Mikdashi, 2007)  
6.2 Pathophysiology    
The pathogenesis of hypertension in SLE is multifactorial where alteration of renal function 
plays a central role; other mechanisms can contribute such as renin angiotensin aldosterone 
system (RAS), endothelin, oxidative stress, sex steroids and metabolic changes. Involvement of 
the kidneys in the course of SLE is common and impaired renal function plays a role in 
development of hypertension by alteration in the renal hemodynamic that leads to reduction 
in glomerular filtration rate (GFR) and increase in BUN and plasma creatinine levels. (Nakaro 
et al, 1998)  Renal tubular lesions are prevalent in SLE patients, (Daniel et al, 2001) as well as 
glomerular injury in the form of glomerulonephritis contributes to SLE hypertension that is 
clinically indicated by the presence of urinary protein in SLE patients. (Ryan, 2009) SLE is 
usually associated with impaired endothelial function as demonstrated by the high risk of 
atherosclerosis, and this may also have a role in development of SLE hypertension. (Ryan, 
2009)The Renin Angiotensin Aldosterone System (RAS) is activated in SLE (Herlitz et al, 1984) 
on basis of effectiveness of BP control with ACE Inhibitors and evidence of increase renin, 
which thus can play a role in developing SLE hypertension. (Ryan, 2009) 
Endothelin 1(ET-1) plays a role in the pathophysiology of hypertension through its potent 
renal vasoconstriction and its ability to cause water and sodium retention.(Miyauchi & 
 
Systemic Lupus Erythematosus 
 
282 
Mitral and/or aortic valve thrombus (or vegetations) can also be a precipitant of embolic 
strokes. In SLE patients, some series have shown significantly more valvulopathy in those 
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anti-phospholipid antibody syndrome and valvulopathy, there is deposition of 
immunoglobulin and complement, but in addition there is binding of anticardiolipin 
antibody.(Petri, 2004) 
4.5 Treatment 
Systemic lupus erythematosus patients with large, sterile vegetations should be 
anticoagulated to lessen embolic complications. High-dose corticosteroids for 4 to 6 weeks 
are used to shrunken the vegetations, but this approach is controversial.( Nesher et al, 1997) 
Some studies have suggested that corticosteroid treatment may contribute to ultimate valve 
thickening, but this is unproven. In the presence of significant regurgitation, even in the 
absence of nodules, there is a high risk of bacterial endocarditis particularly in the setting of 
jet lesions and warrant antibiotic prophylaxis. (Roman & Salmon, 2007) 
5. Arrhythmia and conduction defects 
5.1 Clinical features 
Many autoimmune diseases including systemic lupus erythematosus have a high incidence 
of autonomic nervous system dysfunction, especially those of cardiac origin. Conduction 
disturbances and arrhythmias occur in about 10% of patients with SLE. (Mandell, 1987)  
Conduction defects include AV block, BBB and complete heart block, which is rarely seen in 
adults. While the most common arrhythmic manifestation include sinus tachycardia, atrial 
fibrillation, atrial ectopic beat and rarely ventricular arrhythmias. (Eisen et al, 2009) 
Recently, other anti-SSA/Ro-associated cardiac manifestations have been described in 
children born to anti-SSA/Ro positive mothers. These include transient fetal first-degree 
heart block, QTc prolongation, sinus bradycardia, late onset cardiomyopathy, endocardial 
fibroelastosis and cardiac malformations. Anti-SSA/Ro antibodies are usually not 
pathogenic to the adult heart, but recently QTc prolongation has been reported in adult 
lupus patients as well.(Costedoat-Chalumeau et al, 2005) 
Sinus tachycardia is the most common cardiac abnormality seen among SLE patients. It is 
present in about 50% of cases (Hejmancik et al, 1964) and it could be the only manifestation, 
also it can be correlated to the disease activity. (Guzman et al, 1994) Arrhythmia and 
conduction defects in SLE patients may be found incidentally or during disease flare, and 
usually develop with coexisting cardiac manifestation (such as pericarditis, myocarditis and 
coronary heart disease though, arrhythmia may be the first manifestation of SLE . (Cardoso 
et al, 2000)Patients with SLE may have prolonged Q-T interval, and this can be a predictor of 
cardiovascular morbidity and mortality. (Okin et al, 2000) 
5.2 Pathogenesis 
SLE can lead to arrhythmias and conduction disturbances either as a consequence of 
pericarditis and myocarditis through direct injury of the conduction system of the heart by 
inflammatory processes.(Eisen et al, 2009)Supraventricular arrhythmias are usually transient 
and recedes as soon as the disease is controlled and treated.(Mandell, 1987) They can also be 
due to myocardial fibrosis as a consequence of occlusive diseases, ( ischemia ) due to 
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vasculitis and atherosclerosis involvement (Eisen, 2009).These mechanisms will result in 
collage deposits that accumulate within nodes , causing fibrosis and focal degeneration of 
the conduction system.(Barati et al, 1975) Autopsy studies have found arteritis of the sinus 
node, vascular occlusion, vasculopathy, and fibroblastic replacement of the sinuatrial and 
atrioventricular nodes.(Barati et al, 1975) Q-T interval prolongation is hypothesized to be 
due to the subclinical atherosclerosis that is known to be augmented in SLE patients , and 
thus , it can be a marker of silent undetected atherosclerotic vascular disease in SLE 
patients.(Cardoso et al, 2005) In addition to Q-T interval prolongation, refractory ventricular 
arrhythmias could be associated with chronic hydroxychloroquine therapy for SLE. (Chen et 
al, 2006)  
5.3 Management  
Diagnosis of arrhythmia and conduction defects is by electrocardiograms that are performed 
usually in patients with an active disease during hospitalization. Those who have had 
arrhythmias or conduction abnormalities need continuous ECG monitoring. (Petri, 2004) 
The life threatening conduction defects are treated with permanent pacemaker, while the 
supra ventricular arrhythmias (unexplained sinus tachycardia) can be controlled with 
corticosteroids. (Costedoat-Chalumeau, 2005; Guzman et al, 1994)       
6. SLE hypertension 
6.1 Prevalence 
Hypertension has a high prevalence among SLE patients ranging from ( 35 to 74% ) 
according to different studies (Doria et al, 2003; Petri, 2000) and it is considered as a major 
risk factor for the progression of  renal , vascular and cardiovascular diseases.  In addition, 
it’s a major risk factor of severe ischemic stroke, thus reflect the need of regular assessment 
and strict blood pressure control among SLE patients. (Mikdashi, 2007)  
6.2 Pathophysiology    
The pathogenesis of hypertension in SLE is multifactorial where alteration of renal function 
plays a central role; other mechanisms can contribute such as renin angiotensin aldosterone 
system (RAS), endothelin, oxidative stress, sex steroids and metabolic changes. Involvement of 
the kidneys in the course of SLE is common and impaired renal function plays a role in 
development of hypertension by alteration in the renal hemodynamic that leads to reduction 
in glomerular filtration rate (GFR) and increase in BUN and plasma creatinine levels. (Nakaro 
et al, 1998)  Renal tubular lesions are prevalent in SLE patients, (Daniel et al, 2001) as well as 
glomerular injury in the form of glomerulonephritis contributes to SLE hypertension that is 
clinically indicated by the presence of urinary protein in SLE patients. (Ryan, 2009) SLE is 
usually associated with impaired endothelial function as demonstrated by the high risk of 
atherosclerosis, and this may also have a role in development of SLE hypertension. (Ryan, 
2009)The Renin Angiotensin Aldosterone System (RAS) is activated in SLE (Herlitz et al, 1984) 
on basis of effectiveness of BP control with ACE Inhibitors and evidence of increase renin, 
which thus can play a role in developing SLE hypertension. (Ryan, 2009) 
Endothelin 1(ET-1) plays a role in the pathophysiology of hypertension through its potent 
renal vasoconstriction and its ability to cause water and sodium retention.(Miyauchi & 
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Masaki, 1999) Evidence suggests that ET-1 could have role in the progression of SLE and SLE  
hypertension as the level of ET-1 are found to be increased in SLE.(Julkunen et al, 1991) 
Activated RAS and increased ET 1 levels in SLE could lead to the generation of oxidative stress 
(Ryan, 2007) that is suggested to be important in pathogenesis of SLE( Alves & Grima, 2003)  
and it is recognized as a promoter of hypertension through mechanisms such as vascular 
dysfunction , renal injury and increase sodium reabsorption.(Manning et al, 2003) In addition , 
metabolic factors can contribute in the pathophysiology of hypertension in SLE and these 
include: Leptin, which is found to be increased, insulin resistance, and obesity.(Gehi et al 2003)  
Inflammatory cytokines (IL-6, TNFα, and CRP) correlate in the mechanism of hypertension. 
(Bastista, et al, 2005)As these cytokines are increased in SLE, they are suggested to be 
involved in SLE hypertension through mechanisms such as, promotion of renal vascular 
endothelial dysfunction, generation of oxidative stress and progression of insulin resistance. 
(Garcia-Gonzalez et al, 2002) 
6.3 Management  
(Discussed in the section of management of traditional risk factors 8.6.1.) 
7. Coronary arteritis 
7.1 Clinical features 
Coronary arteritis is extremely rare in SLE. In some cases, it has been found at autopsy, with 
no clinical correlate during life. The most common clinical presentation is angina and/or 
myocardial infarction, in a child or young adult who does not have a long history of 
corticosteroid therapy. (Petri, 2004) There is no clear correlation with extracardiac disease 
activity, although it has been present in some case. (Korkmaz & Cansu, 2007) Three of eight 
SLE patients who had a coronary artery aneurysm had no physical or laboratory evidence of 
active SLE. (Wilson et al, 1992) Aortic aneurysms can also occur in SLE. (Ohara et al, 2000) 
7.2 Diagnosis 
It is often difficult to distinguish coronary arteritis from accelerated atherosclerosis. Serial 
coronary angiography has been proposed as the most useful diagnostic modality. Arteritis is 
suggested when coronary aneurysms are found, if there are smooth focal lesions, or if there 
are rapidly developing stenoses.(Petri, 2004) However, Wilson et al. described a patient with 
rapidly progressive coronary artery occlusions in whom only advanced atherosclerosis was 
found at autopsy. (Wilson et al, 1992) Thrombosis or spasm can further confuse the 
interpretation of coronary angiograms. (Korkmaz & Consu, 2007) 
7.3 Prevalence 
There are few studies that allow any estimate of the prevalence of coronary arteritis. (Petri, 
2004) In one study in the 1960s, 6 of 16 patients were found to have arteritis at autopsy. 
(Hejmancik et al, 1964) 
The cases identified have a predilection for pediatric patients or very young adults, with 
rare exceptions. Unfortunately, where follow is given, the outcome is usually death. 
7.4 Pathology 
Histopathology demonstrates transmural vasculitis with both lymphocytic and neutrophilic 
infiltration of a thrombus. (Korkmaz & Consu, 2007)Immunofluorescence studies 
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demonstrate immunoglobulin and complement deposition in coronary arteritis. (Korbet et 
al, 1984) 
7.5 Treatment 
The differentiation of coronary arteritis from atherosclerosis is essential for appropriate 
management. Coronary artery bypasses surgery, angioplasty, or stent placement would be 
considered in patients with severe atherosclerotic disease, but would be contraindicated in 
patients with coronary arteritis. Case reports suggest that corticosteroid therapy can have 
rapid benefit in patients with coronary arteritis. Corticosteroid therapy resulted in relief of 
angina and angiographic improvement. (Kozkmaz & Cansu, 2007)  Not all patients with 
coronary arteritis do well on corticosteroids, however Heibel et al. describe a patient with 
coronary arteritis who was treated with prednisone and cyclophosphamide, but had new 
myocardial damage after starting therapy. (Heibel et al, 1976) Angina did not resolve for 3 
weeks. (Heibel et al, 1976) 
8. Premature atherosclerosis and systemic lupus erythematosus 
8.1 Background-premature atherosclerosis and systemic lupus erythematosus 
Despite improved life expectancy, patients with systemic lupus erythematosus (SLE) are still 
at considerable risk for premature death.(Galdman & Urowitz, 2002) This has been related 
to the high frequency of vascular events (VE) in young to middle-aged SLE patients, in 
whom atherosclerosis develops at an accelerated pace. (Bruce et al, 2003) Although general, 
modifiable risk factors for atherosclerosis are also relevant in SLE, they cannot fully explain 
the increased rate of atheroma formation. (Esdaile et al, 2001) SLE is the prototype of the 
immune complex mediated systemic inflammatory disorders, and inflammation has a 
central place in the pathogenesis and growth of atherosclerotic plaques. (Thomas et al, 2002; 
Becker & Nossent, 2009) Reducing the level of inflammatory activity in SLE would, thus, be 
a rational way to decrease this VE risk. (Pans-Estel et al, 2009) 
Premature atherosclerosis (ATH) has been recognized as a major comorbid condition in 
systemic lupus erythematosus (SLE). Women with SLE in the 35–44year old age group have 
an estimated 50-fold increased risk of myocardial infarction (MI) compared to age and sex-
matched controls. (Manzi, 1997)  Women with SLE  also have an increased incidence of 
subclinical atherosclerosis; in a study using carotid ultrasounds, a 37.1% prevalence of 
carotid atherosclerosis was found in lupus patients compared to 15.2% of 
controls.(Szeknanecz & Shoenfeld, 2006) Although traditional risk factors as defined by the 
Framingham studies (hypertension, hypercholesterolemia, diabetes mellitus, older age, and 
postmenopausal status) are important in increasing risk for ATH in SLE, they do not 
adequately explain the increase in cardiovascular disease. In a Canadian cohort, after 
controlling traditional risk factors, the relative risk attributed to SLE for myocardial 
infarction (MI) was 10.1 and for stroke 7.9 (Esdaile et al, 2001) It has increasingly become 
evident that inflammation and immune mechanisms play an important role in the 
pathogenesis of atherosclerosis in SLE. For many years, the development of atherosclerosis 
in the general population was regarded as a passive accumulation of lipids in the vessel 
wall. Recently, however, it has been realized that inflammation plays a role not only in the 
development of the atherosclerotic lesion but also in the acute rupture of plaques that occurs 
during acute myocardial ischemic events. (Von Felt, 2008) 
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Masaki, 1999) Evidence suggests that ET-1 could have role in the progression of SLE and SLE  
hypertension as the level of ET-1 are found to be increased in SLE.(Julkunen et al, 1991) 
Activated RAS and increased ET 1 levels in SLE could lead to the generation of oxidative stress 
(Ryan, 2007) that is suggested to be important in pathogenesis of SLE( Alves & Grima, 2003)  
and it is recognized as a promoter of hypertension through mechanisms such as vascular 
dysfunction , renal injury and increase sodium reabsorption.(Manning et al, 2003) In addition , 
metabolic factors can contribute in the pathophysiology of hypertension in SLE and these 
include: Leptin, which is found to be increased, insulin resistance, and obesity.(Gehi et al 2003)  
Inflammatory cytokines (IL-6, TNFα, and CRP) correlate in the mechanism of hypertension. 
(Bastista, et al, 2005)As these cytokines are increased in SLE, they are suggested to be 
involved in SLE hypertension through mechanisms such as, promotion of renal vascular 
endothelial dysfunction, generation of oxidative stress and progression of insulin resistance. 
(Garcia-Gonzalez et al, 2002) 
6.3 Management  
(Discussed in the section of management of traditional risk factors 8.6.1.) 
7. Coronary arteritis 
7.1 Clinical features 
Coronary arteritis is extremely rare in SLE. In some cases, it has been found at autopsy, with 
no clinical correlate during life. The most common clinical presentation is angina and/or 
myocardial infarction, in a child or young adult who does not have a long history of 
corticosteroid therapy. (Petri, 2004) There is no clear correlation with extracardiac disease 
activity, although it has been present in some case. (Korkmaz & Cansu, 2007) Three of eight 
SLE patients who had a coronary artery aneurysm had no physical or laboratory evidence of 
active SLE. (Wilson et al, 1992) Aortic aneurysms can also occur in SLE. (Ohara et al, 2000) 
7.2 Diagnosis 
It is often difficult to distinguish coronary arteritis from accelerated atherosclerosis. Serial 
coronary angiography has been proposed as the most useful diagnostic modality. Arteritis is 
suggested when coronary aneurysms are found, if there are smooth focal lesions, or if there 
are rapidly developing stenoses.(Petri, 2004) However, Wilson et al. described a patient with 
rapidly progressive coronary artery occlusions in whom only advanced atherosclerosis was 
found at autopsy. (Wilson et al, 1992) Thrombosis or spasm can further confuse the 
interpretation of coronary angiograms. (Korkmaz & Consu, 2007) 
7.3 Prevalence 
There are few studies that allow any estimate of the prevalence of coronary arteritis. (Petri, 
2004) In one study in the 1960s, 6 of 16 patients were found to have arteritis at autopsy. 
(Hejmancik et al, 1964) 
The cases identified have a predilection for pediatric patients or very young adults, with 
rare exceptions. Unfortunately, where follow is given, the outcome is usually death. 
7.4 Pathology 
Histopathology demonstrates transmural vasculitis with both lymphocytic and neutrophilic 
infiltration of a thrombus. (Korkmaz & Consu, 2007)Immunofluorescence studies 
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demonstrate immunoglobulin and complement deposition in coronary arteritis. (Korbet et 
al, 1984) 
7.5 Treatment 
The differentiation of coronary arteritis from atherosclerosis is essential for appropriate 
management. Coronary artery bypasses surgery, angioplasty, or stent placement would be 
considered in patients with severe atherosclerotic disease, but would be contraindicated in 
patients with coronary arteritis. Case reports suggest that corticosteroid therapy can have 
rapid benefit in patients with coronary arteritis. Corticosteroid therapy resulted in relief of 
angina and angiographic improvement. (Kozkmaz & Cansu, 2007)  Not all patients with 
coronary arteritis do well on corticosteroids, however Heibel et al. describe a patient with 
coronary arteritis who was treated with prednisone and cyclophosphamide, but had new 
myocardial damage after starting therapy. (Heibel et al, 1976) Angina did not resolve for 3 
weeks. (Heibel et al, 1976) 
8. Premature atherosclerosis and systemic lupus erythematosus 
8.1 Background-premature atherosclerosis and systemic lupus erythematosus 
Despite improved life expectancy, patients with systemic lupus erythematosus (SLE) are still 
at considerable risk for premature death.(Galdman & Urowitz, 2002) This has been related 
to the high frequency of vascular events (VE) in young to middle-aged SLE patients, in 
whom atherosclerosis develops at an accelerated pace. (Bruce et al, 2003) Although general, 
modifiable risk factors for atherosclerosis are also relevant in SLE, they cannot fully explain 
the increased rate of atheroma formation. (Esdaile et al, 2001) SLE is the prototype of the 
immune complex mediated systemic inflammatory disorders, and inflammation has a 
central place in the pathogenesis and growth of atherosclerotic plaques. (Thomas et al, 2002; 
Becker & Nossent, 2009) Reducing the level of inflammatory activity in SLE would, thus, be 
a rational way to decrease this VE risk. (Pans-Estel et al, 2009) 
Premature atherosclerosis (ATH) has been recognized as a major comorbid condition in 
systemic lupus erythematosus (SLE). Women with SLE in the 35–44year old age group have 
an estimated 50-fold increased risk of myocardial infarction (MI) compared to age and sex-
matched controls. (Manzi, 1997)  Women with SLE  also have an increased incidence of 
subclinical atherosclerosis; in a study using carotid ultrasounds, a 37.1% prevalence of 
carotid atherosclerosis was found in lupus patients compared to 15.2% of 
controls.(Szeknanecz & Shoenfeld, 2006) Although traditional risk factors as defined by the 
Framingham studies (hypertension, hypercholesterolemia, diabetes mellitus, older age, and 
postmenopausal status) are important in increasing risk for ATH in SLE, they do not 
adequately explain the increase in cardiovascular disease. In a Canadian cohort, after 
controlling traditional risk factors, the relative risk attributed to SLE for myocardial 
infarction (MI) was 10.1 and for stroke 7.9 (Esdaile et al, 2001) It has increasingly become 
evident that inflammation and immune mechanisms play an important role in the 
pathogenesis of atherosclerosis in SLE. For many years, the development of atherosclerosis 
in the general population was regarded as a passive accumulation of lipids in the vessel 
wall. Recently, however, it has been realized that inflammation plays a role not only in the 
development of the atherosclerotic lesion but also in the acute rupture of plaques that occurs 
during acute myocardial ischemic events. (Von Felt, 2008) 
 





Fig. 4. The bimodal pattern of mortality in SLE patients. (Urowitz et al, 1976; Rubin et al, 
1985) Copyright permission from Elsevier 
8.2 Etiology of premature CVD in SLE 
The pathogenesis of premature atherosclerosis in lupus is multifactorial and includes 
traditional CV risk factors, lupus –related factors and inflammatory risk factors.  Box 1 
8.2.1 The role of inflammation in the pathogenesis of atherosclerosis 
The recruitment of inflammatory cells to the arterial wall Atherosclerotic lesions begin with 
the recruitment of inflammatory cells such as monocytes and T cells to the endothelial wall. 
First, the vascular endothelial cells are stimulated to express leukocyte adhesion molecules, 
including E-selectin, vascular cell adhesion molecule-1(VCAM-1), and intercellular adhesion 
molecule-1 (ICAM-1). (Hansson, 2001)These cell-surface proteins are upregulated during 
periods of inflammation. The expression of adhesion molecules can be induced by 
proinflammatory cytokines such as tumor necrosis factor-a (TNF-a) and interleukin-1 (IL-1), 
which upregulate leukocyte adhesion molecules. (Hansson, 2001) VCAM-1 is also induced 
when endothelial cells are exposed to other inflammatory signals, such as the 
lipopolysaccharides of Gram-negative bacteria, lysophosphatidylcholine (LPC), and 
oxidized phospholipids such as oxidized low density lipoprotein (OxLDL). High-density 
lipoproteins (HDLs) inhibit the expression of adhesion molecules. (Calabresi et al, 1997) 
After leukocytes adhere to the cell surface, they migrate through the endothelium and into 
the intima. (Hansson, 2001) This transmigration is influenced by several factors: first, several 
chemotactic proteins such as monocyte chemotactic protein-1 (MCP-1) are produced by the 
endothelial and smooth cell layers. The expression of MCP-1 in smooth muscle cells and 
endothelial cells can be upregulated by cytokines such as TNF-a, IL-1 and by OxLDL. 
(Hansson, 2001) Conversely, normal HDLs inhibit the expression of MCP-1. The importance 
of MCP-1 in the development of the atherosclerotic plaque is emphasized by the fact that 
elevated circulating levels of MCP-1 are positively related to increased carotid artery IMT in 
humans. (Larson et al, 2005)  
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 Diabetes mellitus 
 Family history 
Novel cardiovascular disease risk factors 
 Cytokines (TNF-α, IFN-α, IL-6 and low IL-10) 
 Endothelial (sVCAM-1, VEGF, Ang-2, apoptosis of circulating angiogenic cells/ 
               endothelial progenitor cells and low annexin V binding) 
 Elevated C-reactive protein 
 Elevated homocysteine 
 Metabolic syndrome/insulin resistance 
Lupus-specific variables 
 Corticosteroids 
 SLE disease activity and SLE disease damage 
 Antiphospholipid antibodies 
 Anti-oxLDL antibodies, reduced antiphosphorylcholine antibodies 
 Proinflammatory HDLs 
 Lupus dyslipoproteinemia (high VLDL, high triglyceride, low HDL, high 
               lipoprotein A); decreased lipoprotein lipase activity 
 Renal disease 
Ang-2: Angiopoietin-2; HDL: High-density lipoprotein; oxLDL: Oxidized low-density 
lipoprotein; SLE: Systemic lupus erythematosus; sVCAM: Soluble vascular cellular 
adhesion molecule; VLDL: Very low-density lipoprotein. 
(Skamra & Ramsey-Goldman, 2010) 
Box 1. Risk factors for cardiovascular disease in systemic lupus erythematosus (Elliot JR, 
Mansi S, 2009. Copyright permission from Elsevier) 
8.2.2 Low-density lipoproteins and the development of foam cells 
Next, low-density lipoproteins (LDLs) are transported into artery walls, where they become 
trapped and bound in the extracellular matrix of the subendothelial space.(McMahon & 
Hahn, 2007) These trapped LDLs are then seeded with reactive oxygen species (ROS) 
produced by nearby artery wall cells, resulting in the formation of proinflammatory-
oxidized LDL . When endothelial cells are exposed to these proinflammatory OxLDL, they 
release cytokines such as MCP-1, M-CSF, and GRO, resulting in monocyte binding, 
chemotaxis, and differentiation into macrophages. (Nawab et al, 2000) 
The OxLDLs are phagocytized by infiltrating monocytes/ macrophages, which then become 
the foam cells around which atherosclerotic lesions are built. Elevated levels of circulating 
OxLDL are strongly associated with documented coronary artery disease in the general 
population.( Tsimikas et al, 2005) Elevated levels of circulating OxLDL have also been 
described in SLE patients, especially in those with a history of cardiovascular 
disease.(Frostegard et al, 2005) 
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Fig. 5. The interplay of LDL, HDL, and OxLDL with endothelial activation, monocyte 
migration, foam cell formation, and reverse cholesterol transport. (Macmohan  M, Hahn 
BV,2007.Copyright permission from Elsevier) 
Next, monocytes and T cells infiltrate the margin of the plaque formed by foam cells, and 
muscle cells from the media of the artery are stimulated to grow. These muscle cells 
encroach on the lumen of the vessel and ultimately lead to fibrosis, which renders the 
plaques brittle. The occlusion that results in MI can occur when one of these plaques 
ruptures, or when platelets aggregate in the narrowed area of the artery. (McMahon & 
Hahn, 2007) 
8.2.3 Normal HDL clears OxLDL from the endothelium: Abnormal proinflammatory 
HDL associate with accelerated atherosclerosis 
There are many mechanisms designed to clear OxLDL from the subendothelial space, 
including macrophage engulfment using scavenger receptors, and enhanced reverse 
cholesterol transport mediated by lipoprotein transporters in HDL. (McMahon & Hahn, 
2007) In addition to reverse cholesterol transport, HDL removes reactive oxygen species 
from LDL (via anti-oxidant enzymes in the HDL, such as paroxonase), thus preventing the 
formation of OxLDL and the subsequent recruitment of inflammatory mediators. (Nawab et 
al, 2000a, Nawab et al, 2004b) 
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Thus, although quantities of HDL partially determine atherosclerotic risk (low levels are 
associated with increased risk), HDL function is equally significant. (Barter et al, 2004) 
During the acute phase response HDL can be converted from their usual anti-inflammatory 
state to proinflammatory, and can actually cause increased oxidation of LDL. This acute 
phase response can also become chronic, and may be a mechanism for HDL dysfunction in 
SLE. It has been found that HDL function is abnormal in many women with SLE, 45% of 
women with SLE, compared to 20% of rheumatoid arthritis patients and 4% of controls, had 
proinflammatory HDL (piHDL) that was not only unable to prevent oxidation of LDL but 
caused increased levels of oxidation.(McMahon et al,2006a)McMahon et al reported  86% of 
patients with SLE who had plaque on carotid ultrasound had piHDL, compared to 39% who 
do not have plaque ( p < 0.0001). (McMahon et al, 2006b) This suggests that detecting piHDL 
may identify SLE patients at high risk for clinical atherosclerosis. The interplay of LDL, 
HDL, and OxLDL with endothelial activation, monocyte migration, foam cell formation, and 
reverse cholesterol transport is illustrated in Figure 9. 
8.3 Traditional risk factors 
Over the past 15 years, traditional CV risk factors have been described in patients with SLE. 
Patients from several large lupus cohorts have been reported to have a greater total number 
of Framingham study and other traditional risk factors, including hypertension, diabetes, 
dyslipidaemia, tobacco use and sedentary lifestyle than matched control subjects. (Asanuma 
et al, 2003) Others have discovered a greater occurrence of both insulin resistance and 
metabolic syndrome. The Toronto Lupus Cohort also reported that SLE patients with CV 
events have a greater total number of traditional CV risk factors than lupus patients without 
events. (Bruce et al, 2003) Premature menopause is commonly seen in lupus patients. 
Compared with age-matched controls, women with lupus are more likely to be post-
menopausal (38% vs. 19%) and reach menopause 4 years earlier. (Urowitz et al, 2007) These 
conventional risk factors of CVD are also associated with sub-clinical measures of 
atherosclerosis in SLE patients. Older age, hypertension, dyslipidaemia and diabetes are 
associated with the presence of carotid plaque. Finally, both hypertension and 
dyslipidaemia are independently predictive of CV events (MI and stroke) in SLE patients. 
(Elliott et al, 2008) 
8.4 Dyslipidaemia in SLE 
An atherogenic lipid profile has been described in SLE patients with elevated total 
cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), very low-density 
lipoprotein (VLDL) and lipoprotein(a) [Lp(a)]  concentrations, as well as decreased high-
density lipoprotein (HDL) cholesterol levels. (Borba et al, 1994) Patients with lupus may also 
have altered HDL function. HDL cholesterol is normally an anti-inflammatory molecule that 
prevents the formation of oxidised LDL (ox-LDL) and foam cells that lead to plaque 
formation in the vasculature. A pro-inflammatory HDL (piHDL) is less able to prevent 
oxidation of LDL. piHDL was found in greater frequency in lupus patients with CVD than 
in those without known coronary disease. (Batuca et al, 2007)Additionally, paraoxonase 1 
(PON1) is an anti-oxidant component of HDL that inhibits oxidation of lipoproteins and 
breaks down ox-LDL. In SLE, PON1 activity is altered, and significant reductions of PON1 
are associated with both CV and cerebrovascular events. (Tripi et al, 2006)   One possible 
mechanism for the reduced PON activity seen in SLE may be due to auto-antibody 
 












Fig. 5. The interplay of LDL, HDL, and OxLDL with endothelial activation, monocyte 
migration, foam cell formation, and reverse cholesterol transport. (Macmohan  M, Hahn 
BV,2007.Copyright permission from Elsevier) 
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production. In a study by Batuca et al., patients with SLE were noted to have higher titres of 
antibodies to HDL and apolipoprotein A-1 (a lipoprotein associated with HDL) than healthy 
controls. (Batuca et al, 2007) PON activity was inversely correlated with the levels of 
antibodies to apolipoprotein A-1. 
8.5 Lupus-related risk factors 
Traditional risk factors alone do not fully explain the increased risk of CVD in lupus 
patients. Esdaile and colleagues reported a 10-fold relative risk of non-fatal MI and 17-fold 
relative risk of death from CHD, even after controlling for Framingham study risk factors. 
(Esdaile et al, 2001)These findings suggest that factors related to lupus itself, as well as its 
therapy, may be independent risk factors for CVD. 
8.5.1 Disease activity 
Ongoing inflammatory SLE disease activity is associated with CV risk. (Manzi et al 1997, 
Roman et al, 2003) A six-point increase in the Systemic Lupus Erythematosus Disease Activity 
Index (SLEDAI) score over 1 year correlated with a 5% increase in a 2-year CV risk. (Karp et al, 
2008) This same increase in SLEDAI score was associated with increases of 3.4 mmHg in 
systolic blood pressure, 1 mg/dl in glucose and 11.6 mg/dl in TG as well as a 2.3- mg/dl 
decrease in HDL cholesterol. In the study performed by Roman and colleagues, the diagnosis 
of SLE itself, a longer duration of disease and greater disease damage (measured by SLICC-
Damage Index [SLICC-DI]) were independent predictors of carotid plaque. (Roman et al, 2003) 
Similarly, Manzi et al. demonstrated that duration of lupus and disease damage (measured by 
SLICC-DI) were significantly associated with a higher carotid plaque index.(Manzi et al, 1999) 
8.5.2 Renal disease 
Renal disease is one of the most common internal organ manifestations of SLE. Both 
hypertension and dyslipidaemia are well described with lupus nephritis and renal disease. 
Lupus renal disease is also associated with increased atherosclerosis. In fact, nearly 50% of 
deaths in lupus patients with renal disease are attributed to CV or cerebrovascular disease. 
(Appel et al, 1994) 
8.5.3 Autoantibody production 
Systemic lupus erythematosus is characterized by autoantibody production. The immune 
reactions involving antibody production modulate atherosclerosis. Antiphospholipid 
antibodies and anti-oxLDL have been associated with CAD mortality in the general 
population. However, the relationship is nonlinear, making antibody status difficult to use 
as a predictor of individual risk. (Erkkila et al, 2005) Patients with SLE and secondary 
antiphospholipid antibody syndrome (APS) had a higher prevalence of carotid plaque than 
patients with primary APS. (Jimenez et al, 2005) In patients with SLE, the prevalence of 
anticardiolipin antibodies is quoted between 24 and 39% and for lupus anticoagulant it is 
quoted as 15–30%. However, only 50% of patients with the antiphospholipid antibodies will 
have a clinical event (defined as arterial or venous thrombosis or pregnancy morbidity), and 
thus have APS. (Giles & Rahman, 2009) A retrospective analysis carried out by Bessant et al. 
demonstrated that patients with SLE just prior to a CVD event (MI, angina, cerebrovascular 
accident [CVA] or peripheral vascular disease) were more likely to have the presence of 
lupus anticoagulant compared with patients with SLE without CVD, after controlling for 
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disease duration.(Bassant et al,2006) Anti-β-2-glycoprotein I antibody has also been 
associated with increased risk of acute coronary syndrome in the general population.( Veres 
et al, 2004). Anti β-2-glycoprotein I antibodies was identified as a significant risk factor for 
arteriosclerosis obliterans in SLE patients, and was associated strongly with ischemic heart 
disease in patients with SLE. (Cederholm et al, 2005) 
Annexin V plays a role in atherosclerotic lesions since it is believed to form a protective 
shield over thrombogenic cell surface proteins.(Fig.10) Decreased annexin V binding to the 
endothelium, caused by anticardiolipin IgG, was found in the sera of patients with SLE and 
CVD. (Cederholm et al, 2005) 
In addition, antibodies against oxLDL have been found in patients with angiographic 
CAD. The oxidation of LDL may lead to the formation of neoepitopes that bind to 
scavenger receptors of macrophages and lead to uptake of oxLDL, accelerating foam cell 
formation in the atherosclerotic plaque. The level of oxLDL was associated with arterial 
disease (defined as clinically evident MI, angina, peripheral claudication or thrombosis). 
(Frostegard et al, 2005) 
In patients with an established history of hypertension, high levels of IgM 
antiphosphorylcholine (anti-PC) antibodies were shown to be atheroprotective; they resulted 
in less progression of IMT on carotid ultrasound (OR: 0.46; 95% CI: 0.25–0.85; p = 0.01) . (Su j et 
al, 2006) Decreased levels of anti-PC antibodies were observed in both SLE cases with CVD 
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Fig. 6. Potential mechanism of atherothrombosis in systemic lupus erythematosus (SLE). 
8.5.4 SLE therapy 
Corticosteroids: 
Corticosteroid therapy in SLE patients is often a double-edged sword. While it is still one of 
the most effective therapies for managing lupus disease activity, it has numerous metabolic 
side effects on blood pressure, blood glucose, lipids andweight. Petri et al. reported that a 
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disease duration.(Bassant et al,2006) Anti-β-2-glycoprotein I antibody has also been 
associated with increased risk of acute coronary syndrome in the general population.( Veres 
et al, 2004). Anti β-2-glycoprotein I antibodies was identified as a significant risk factor for 
arteriosclerosis obliterans in SLE patients, and was associated strongly with ischemic heart 
disease in patients with SLE. (Cederholm et al, 2005) 
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shield over thrombogenic cell surface proteins.(Fig.10) Decreased annexin V binding to the 
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In addition, antibodies against oxLDL have been found in patients with angiographic 
CAD. The oxidation of LDL may lead to the formation of neoepitopes that bind to 
scavenger receptors of macrophages and lead to uptake of oxLDL, accelerating foam cell 
formation in the atherosclerotic plaque. The level of oxLDL was associated with arterial 
disease (defined as clinically evident MI, angina, peripheral claudication or thrombosis). 
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In patients with an established history of hypertension, high levels of IgM 
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8.5.4 SLE therapy 
Corticosteroids: 
Corticosteroid therapy in SLE patients is often a double-edged sword. While it is still one of 
the most effective therapies for managing lupus disease activity, it has numerous metabolic 
side effects on blood pressure, blood glucose, lipids andweight. Petri et al. reported that a 
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change of 10 mg of prednisone leads to an increase of 7.5mg/dl of TC, a 1.1-mmHg increase 
in mean arterial blood pressure and a 2.5-kg weight gain. (Petri et al, 1994) Additionally, 
longer duration of corticosteroid therapy is associated with sub-clinical CVD (Manzi et al, 
1999) and independently predicts CV events in lupus patients. (Elliott et al, 2008) Lupus 
patients on corticosteroids are also likely to have greater inflammatory disease burden, 
placing them at higher CVD risk. MacGregor et al. found a corticosteroid dose-related effect. 
Above a daily dose of 10 mg of prednisolone, the triglyceride (TG) and Apo B levels were 
elevated compared with controls without SLE, but below a daily dose of 10 mg prednisolone 
there was no difference between controls and SLE patients. (Macgregor et al, 1992) Similarly, 
Petri et al. found that prednisone of over 10 mg daily was associated with 
hypercholesterolemia, defined as total cholesterol of more than 200 mg/dl. (Petri, 2000) 
Additionally, Montreal Lupus Clinic researchers reported that SLE patients on 30 mg of 
corticosteroids have a 60% greater 2-year CV risk than do SLE patients with the same 
disease activity and traditional risk factors but not on corticosteroids. This finding 
emphasizes the need for corticosteroid monitoring and the use of steroid-sparing agents in 
the clinical care of SLE patients. (Thompson et al,2008) Patients with SLE and CVD were 
more likely than SLE age-matched controls (without CVD) to have taken a mean dosage of 
prednisone of over 7.5 mg/day (p = 0.04) and more likely to have been treated with pulse 
methylprednisolone (p = 0.03) (Bessant et al, 2006) A longer duration of corticosteroid use 
(11 vs 7 years; p = 0.002) was more common in the patients who had an event than in those 
without an event. (Manzi etal, 1997) Women with SLE who had a longer duration of 
prednisone use and higher cumulative dose of prednisone are more likely to have carotid 
plaque on ultrasound ( Manzi et al,1999) and the IMT progression is associated with years of 
steroid use.(Thompson et al,2008) 
Anti-malarial medication: 
Hydroxychloroquine (HCQ) therapy has been shown to have several beneficial CV effects 
in SLE patients. HCQ use in SLE patients has been shown to reduce TC, LDL and TG 
levels. (Wallace et al, 1990)The lipid lowering effect of HCQ is greatest in younger 
patients (age 16–39 years) and may offset the dyslipidaemia associated with corticosteroid 
therapy. (Rahman et al, 1999) Lupus patients taking HCQ have had significantly lower 
mean glucose levels and markers of insulin resistance. (Petri, 1996) HCQ has been 
postulated to prevent future thrombotic events, (Erkan et al, 2002) and lupus patients on 
HCQ therapy are less likely than those not on it to have carotid plaque. Its protective 
effect on the vasculature may be in part due to inhibition of aPL-mediated platelet 
activation. (Roman et al, 2003) 
Immunosuppressant medications: 
Roman's study demonstrated that patients with carotid plaque by B-mode ultrasound 
were less likely to have been treated with prednisone and cyclophosphamide when 
analyzed by multivariate analysis. (Roman et al, 2003) Mycophenolate mofetil (MMF) has 
been studied in patients with renal and cardiac transplants and found to reduce allograft 
vasculopathy and intimal thickening compared with those treated with azathioprine, as 
reviewed by Gibson and Hayden.(Gibson & Hayden, 2007). While there are no specific 
studies regarding cardiovascular outcomes in patients with SLE who take MMF, 
extrapolating the transplant data suggests this may be a useful choice for treating LN. 
Immunosuppressant medications should be used judiciously and corticosteroid dosage 
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should be minimized, but control of SLE should not be sacrificed to avoid CVD risk. 
(Skamra &Ramsay-Goldman, 2010) 
Estrogens & hormone replacement therapy 
Patients with antiphospholipid antibodies are at increased risk of thrombosis. Thus, general 
recommendations include discontinuing estrogen usage, despite a lack of randomized, 
controlled trials.(Sammaritano, 2007) A prospective study evaluating patients with SLE who 
took hormone replacement therapy (HRT) revealed that HRT was not a risk factor for CAD, 
despite the presence of antiphospholipid antibodies in 74.6% of HRT users.(Hochman et al, 
2009) However, the role of hormones in patients with SLE who lack antiphospholipid 
antibodies has been more clearly defined. Both the Safety of Estrogens in Lupus 
Erythematosus National Assessment (SELENA) study and the LUMINA study found that 
exogenous hormones were safe to use in their patient populations as long as SLE was stable, 
and did not increase the risk of arterial thrombosis in lower risk patients. ( Fernandez et al, 
2007) Based on risk and needs, oral contraceptive and HRT use are recommended in 
properly selected patients who do not have antiphospholipid antibodies.(Skamra &Ramsay-
Goldman, 2010) 
8.5.5 Endothelial dysfunction 
Many soluble markers of endothelial dysfunction have been studied in atherosclerosis, 
including cytokines, chemokines, soluble adhesion molecules and acute phase reactants. 
Their clinical use is limited by their instability, inadequate laboratory performance and lack 
of standardization at this time; however, they may prove to be a valuable tool in the future. 
Biochemical markers of endothelial cell activation, such as soluble thrombomodulin, von 
Willebrand factor and tissue plasminogen activator, are increased in patients with SLE. 
(Constans et al, 2003) While soluble vascular cellular adhesion molecule (sVCAM)-1 was 
elevated only in the patients with SLE and CVD. This is of further interest, since sVCAM-1 is 
associated with systemic TNF-α. There is positive correlation between TNF-α and plasma 
TGs, VLDL TGs and VLDL-C]. SLE patients with a higher IMT value using B-mode 
ultrasound had significantly higher mean plasma VEGF levels compared with controls after 
adjusting for age, smoking and other Framingham risk factors. (Svenungsson et al, 2003) 
Thus, these soluble biomarkers may have a future role in identifying SLE patients at risk for 
CVD.The Tie-2 receptor (a vascular-specific tyrosine kinase receptor), through its interaction 
with angiopoietin (Ang)-1, maintains vessel integrity, inhibits vascular leakage, suppresses 
inflammatory gene expression, and prevents recruitment and transmigration of leukocytes. 
Ang-2 has emerged as a key mediator of endothelial cell activation and facilitates 
endothelial cell inflammation by counterbalancing the effects of Ang-1 and disrupting these 
functions. (Skamra &Ramsay-Goldman, 2010) Ang-2 concentrations were elevated in 
hypertensive patients compared with healthy controls (4.23 ± 3.1 vs 0.88 ± 0.43 ng/ml;  
p < 0.0001); and it was particularly elevated in those patients with atherosclerosis (p = 0.02). 
Furthermore, Ang-2 concentrations correlated with other vascular markers of endothelial 
cell activation, including VCAM-1 and ICAM-1. Mean serum Ang-2 concentrations were 
markedly elevated in patients with active SLE compared with inactive SLE (8.6 vs 1.4 
ng/ml; p = 0.010) and healthy controls (8.6 vs 1.1 ng/ml; p < 0.001), and Ang-2 remained 
significantly elevated in patients with inactive SLE compared with healthy controls. (Skamra 
&Ramsay-Goldman, 2010) Maintaining vascular integrity after damage is a role played by 
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CVD.The Tie-2 receptor (a vascular-specific tyrosine kinase receptor), through its interaction 
with angiopoietin (Ang)-1, maintains vessel integrity, inhibits vascular leakage, suppresses 
inflammatory gene expression, and prevents recruitment and transmigration of leukocytes. 
Ang-2 has emerged as a key mediator of endothelial cell activation and facilitates 
endothelial cell inflammation by counterbalancing the effects of Ang-1 and disrupting these 
functions. (Skamra &Ramsay-Goldman, 2010) Ang-2 concentrations were elevated in 
hypertensive patients compared with healthy controls (4.23 ± 3.1 vs 0.88 ± 0.43 ng/ml;  
p < 0.0001); and it was particularly elevated in those patients with atherosclerosis (p = 0.02). 
Furthermore, Ang-2 concentrations correlated with other vascular markers of endothelial 
cell activation, including VCAM-1 and ICAM-1. Mean serum Ang-2 concentrations were 
markedly elevated in patients with active SLE compared with inactive SLE (8.6 vs 1.4 
ng/ml; p = 0.010) and healthy controls (8.6 vs 1.1 ng/ml; p < 0.001), and Ang-2 remained 
significantly elevated in patients with inactive SLE compared with healthy controls. (Skamra 
&Ramsay-Goldman, 2010) Maintaining vascular integrity after damage is a role played by 
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endothelial progenitor cells (EPCs) and myelomonocytic circulating angiogenic cells. 
Decreased levels or abnormal function of those cells is an established atherosclerotic risk 
factor. (Hill et al, 2003) SLE patients possess significantly fewer numbers of circulating EPCs 
as well as impaired differentiation of EPCs and circulating angiogenic cells into mature 
endothelial cells that are capable of producing VEGF. These abnormalities are triggered by 
IFN-α, which induces EPC and circulating angiogenic cell apoptosis. SLE EPCs/circulating 
angiogenic cells have increased IFN-α expression, which might promote accelerated 
atherosclerosis. (Hill et al, 2003) 
8.5.6 Cytokines 
In addition to the relationship between TNF-α and IFN-α, other cytokines and their 
associated polymorphisms (IL-10 and IL-6) have also been implicated in the relationship 
between CVD and SLE. IL-10 has an atheroprotective role compared with TNF-α, which is 
atherogenic. Both IL-10 and TNF-α are seen increased in SLE patients with CVD compared 
with SLE patients without CVD or controls. IL-6 overproduction has been associated with 
SLE, CVD and C-reactive protein (CRP) elevations. Measurement of individual cytokines is 
laborious and may be difficult to interpret without an overall cytokine profile. The role of 
IL-10 and IL-6 and many other cytokines in SLE and CVD remains to be fully elucidated. 
(Skamra &Ramsay-Goldman, 2010) 
8.5.7 CRP 
In addition to its relationship with arterial stiffness, an elevated level of serum CRP has been 
associated with MI and stroke in the general population. Its role in risk stratification remains 
unclear because it might improve risk prediction beyond the traditional Framingham 
calculation; however, further study will be required before it can be accepted as a standard 
CVD risk factor. (Lloyd-Jones et al, 2006) In patients with SLE, an elevated serum CRP has 
been associated with the presence of carotid plaque. Elevated CRP has also been associated 
with the highest quartile of IMT on carotid ultrasound in SLE patients. (Manzi et al, 1999) 
CRP is also found to have association with cardiovascular events and SLE disease activity as 
measured by the Systemic Lupus Activity Measure, but not with overall damage accrual as 
measured by the SLICC-DI. (Szalai et al, 2005; Bertoli et al, 2008) 
8.5.8 Homocysteine 
Homocysteine is believed to be a toxin that results in endothelial injury and dysfunction in 
patients with CVD, but its exact role remains to be defined. Homocysteine may have a role 
in differentiating between patients with SLE and CVD and those with CVD without SLE. 
Patients with SLE from the Toronto Lupus Cohort had higher mean homocysteine levels 
compared with age-matched controls, despite having higher folate levels. Studies found that 
a homocysteine level above 14.1 mmol/l was an independent risk factor for development of 
CAD in patients with SLE after controlling for established risk factors (Svenungsson et al, 
2001, Petri, 2009) Homocysteine concentration was found to be significantly higher among 
patients with progressive plaque compared with patients without carotid plaque. (Roman et 
al, 2007) In addition to SLE, renal failure is a known cause of hyperhomocysteinemia. While 
the role of homocysteine is not completely defined, Von Feldt suggests that it may be a 
useful initial test in the evaluation of SLE patients in order to determine the presence and 
extent of subclinical atherosclerotic disease. (Von Feldt et al, 2008) 
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8.6 Assessment and management  
8.6.1 Assessment and management of traditional risk factors (table 1.) 
Obesity 
Assessment 
The National Heart, Lung, and Blood Institute (NHLBI), (National Institute of Health,1998) 
American Heart Association (AHA) (Smith et al, 2006)  and the American College of 
Cardiology (ACC) recommends checking weight and height to calculate BMI, as well as 
waist circumference, at each visit. Waist circumference is a marker of visceral or intra-
abdominal fat and should be assessed at the iliac crest. Goal BMI is recommended from 18.5 
to 24.6 kg/m2 and waist circumference should be <40 inches in men and <36 inches in 
women. (Smith et al, 2006)    
Management 
Preventing obesity is the first line of defense. Physicians should educate patients to avoid 
weight gain by promoting healthy eating and physical activity. Specific to lupus itself, 
aggressive control of joint and fatigue symptoms and global lupus disease activity could 
help facilitate physical exercise. As corticosteroid use can lead to weight gain and other 
metabolic risks, minimizing the corticosteroid dose by adding a steroid-sparing agent, such 
as HCQ, or an immunosuppressive agent may be needed. For those patients with a BMI >25 
kg/m2 or whose waist circumference is >40 inches in men or >35 inches in women, a 
combined dietary and physical exercise programs is indicated. These dietary and exercise 
recommendations can also be applied to patients with dyslipidaemia, hypertension and 
diabetes (see below). 
Diet: AHA Diet and Lifestyle recommendations (Lichtenstein et al, 2006) advocate the 
following: a diet rich in fruits, vegetables and whole-grain, high-fiber foods, consuming fish 
(specifically oily fish) twice a week, limiting saturated fat to <7% (trans fat to <1%) and 
cholesterol to <300 mg /day by choosing lean meats and fat-free or low-fat dairy products, 
minimizing beverages and foods with added sugars, low or no salt diet and consuming 
alcohol in moderation. 
Consultation with a nutritionist or dietitian is strongly encouraged. An individualized 
dietary plan, taking into account specific health concerns and medications, will be a 
powerful tool for lupus patients and their CV health. (Elliott &Manzi, 2009) 
Exercise. Physicians should take every office visit as an opportunity to encourage patients to 
exercise. The AHA recommends 30 min of moderate-intensity (brisk walking) aerobic 
activity 5 days per week or 20 min of vigorous-intensity (jogging) 3 days a week for healthy 
adults. Haskell et al, 2007) Resistance training (weight lifting) to improve muscle strength 
and endurance is advocated twice per week and should include all 10 major muscle groups. 
Patients should be encouraged to increase their daily lifestyle activities, such as walking to 
the store and using stairs instead of elevators. For those with cardiac history or recent 
vascular surgery, physicians should provide a medically supervised exercise program. 
(Smith et al, 2006)    
In addition to CV benefits, physical exercise may improve conditions related specifically to 
SLE disease. SLE patients can improve their aerobic capacity and exercise tolerance and 
fatigue after following an exercise program, without aggravating their SLE disease. (Clarke-
Jenssen et al, 2005) Aerobic exercise can also improve quality of life in patients with SLE by 
improving both depression levels and global sense of well-being. (Avan & Martin, 2007)  
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endothelial progenitor cells (EPCs) and myelomonocytic circulating angiogenic cells. 
Decreased levels or abnormal function of those cells is an established atherosclerotic risk 
factor. (Hill et al, 2003) SLE patients possess significantly fewer numbers of circulating EPCs 
as well as impaired differentiation of EPCs and circulating angiogenic cells into mature 
endothelial cells that are capable of producing VEGF. These abnormalities are triggered by 
IFN-α, which induces EPC and circulating angiogenic cell apoptosis. SLE EPCs/circulating 
angiogenic cells have increased IFN-α expression, which might promote accelerated 
atherosclerosis. (Hill et al, 2003) 
8.5.6 Cytokines 
In addition to the relationship between TNF-α and IFN-α, other cytokines and their 
associated polymorphisms (IL-10 and IL-6) have also been implicated in the relationship 
between CVD and SLE. IL-10 has an atheroprotective role compared with TNF-α, which is 
atherogenic. Both IL-10 and TNF-α are seen increased in SLE patients with CVD compared 
with SLE patients without CVD or controls. IL-6 overproduction has been associated with 
SLE, CVD and C-reactive protein (CRP) elevations. Measurement of individual cytokines is 
laborious and may be difficult to interpret without an overall cytokine profile. The role of 
IL-10 and IL-6 and many other cytokines in SLE and CVD remains to be fully elucidated. 
(Skamra &Ramsay-Goldman, 2010) 
8.5.7 CRP 
In addition to its relationship with arterial stiffness, an elevated level of serum CRP has been 
associated with MI and stroke in the general population. Its role in risk stratification remains 
unclear because it might improve risk prediction beyond the traditional Framingham 
calculation; however, further study will be required before it can be accepted as a standard 
CVD risk factor. (Lloyd-Jones et al, 2006) In patients with SLE, an elevated serum CRP has 
been associated with the presence of carotid plaque. Elevated CRP has also been associated 
with the highest quartile of IMT on carotid ultrasound in SLE patients. (Manzi et al, 1999) 
CRP is also found to have association with cardiovascular events and SLE disease activity as 
measured by the Systemic Lupus Activity Measure, but not with overall damage accrual as 
measured by the SLICC-DI. (Szalai et al, 2005; Bertoli et al, 2008) 
8.5.8 Homocysteine 
Homocysteine is believed to be a toxin that results in endothelial injury and dysfunction in 
patients with CVD, but its exact role remains to be defined. Homocysteine may have a role 
in differentiating between patients with SLE and CVD and those with CVD without SLE. 
Patients with SLE from the Toronto Lupus Cohort had higher mean homocysteine levels 
compared with age-matched controls, despite having higher folate levels. Studies found that 
a homocysteine level above 14.1 mmol/l was an independent risk factor for development of 
CAD in patients with SLE after controlling for established risk factors (Svenungsson et al, 
2001, Petri, 2009) Homocysteine concentration was found to be significantly higher among 
patients with progressive plaque compared with patients without carotid plaque. (Roman et 
al, 2007) In addition to SLE, renal failure is a known cause of hyperhomocysteinemia. While 
the role of homocysteine is not completely defined, Von Feldt suggests that it may be a 
useful initial test in the evaluation of SLE patients in order to determine the presence and 
extent of subclinical atherosclerotic disease. (Von Feldt et al, 2008) 
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8.6 Assessment and management  
8.6.1 Assessment and management of traditional risk factors (table 1.) 
Obesity 
Assessment 
The National Heart, Lung, and Blood Institute (NHLBI), (National Institute of Health,1998) 
American Heart Association (AHA) (Smith et al, 2006)  and the American College of 
Cardiology (ACC) recommends checking weight and height to calculate BMI, as well as 
waist circumference, at each visit. Waist circumference is a marker of visceral or intra-
abdominal fat and should be assessed at the iliac crest. Goal BMI is recommended from 18.5 
to 24.6 kg/m2 and waist circumference should be <40 inches in men and <36 inches in 
women. (Smith et al, 2006)    
Management 
Preventing obesity is the first line of defense. Physicians should educate patients to avoid 
weight gain by promoting healthy eating and physical activity. Specific to lupus itself, 
aggressive control of joint and fatigue symptoms and global lupus disease activity could 
help facilitate physical exercise. As corticosteroid use can lead to weight gain and other 
metabolic risks, minimizing the corticosteroid dose by adding a steroid-sparing agent, such 
as HCQ, or an immunosuppressive agent may be needed. For those patients with a BMI >25 
kg/m2 or whose waist circumference is >40 inches in men or >35 inches in women, a 
combined dietary and physical exercise programs is indicated. These dietary and exercise 
recommendations can also be applied to patients with dyslipidaemia, hypertension and 
diabetes (see below). 
Diet: AHA Diet and Lifestyle recommendations (Lichtenstein et al, 2006) advocate the 
following: a diet rich in fruits, vegetables and whole-grain, high-fiber foods, consuming fish 
(specifically oily fish) twice a week, limiting saturated fat to <7% (trans fat to <1%) and 
cholesterol to <300 mg /day by choosing lean meats and fat-free or low-fat dairy products, 
minimizing beverages and foods with added sugars, low or no salt diet and consuming 
alcohol in moderation. 
Consultation with a nutritionist or dietitian is strongly encouraged. An individualized 
dietary plan, taking into account specific health concerns and medications, will be a 
powerful tool for lupus patients and their CV health. (Elliott &Manzi, 2009) 
Exercise. Physicians should take every office visit as an opportunity to encourage patients to 
exercise. The AHA recommends 30 min of moderate-intensity (brisk walking) aerobic 
activity 5 days per week or 20 min of vigorous-intensity (jogging) 3 days a week for healthy 
adults. Haskell et al, 2007) Resistance training (weight lifting) to improve muscle strength 
and endurance is advocated twice per week and should include all 10 major muscle groups. 
Patients should be encouraged to increase their daily lifestyle activities, such as walking to 
the store and using stairs instead of elevators. For those with cardiac history or recent 
vascular surgery, physicians should provide a medically supervised exercise program. 
(Smith et al, 2006)    
In addition to CV benefits, physical exercise may improve conditions related specifically to 
SLE disease. SLE patients can improve their aerobic capacity and exercise tolerance and 
fatigue after following an exercise program, without aggravating their SLE disease. (Clarke-
Jenssen et al, 2005) Aerobic exercise can also improve quality of life in patients with SLE by 
improving both depression levels and global sense of well-being. (Avan & Martin, 2007)  
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Risk factors Monitoring strategies Management strategies 
Obesity Check weight, height, and waist 
circumference at each visit 
Goal BMI <25 kg/m2 
Goal waist circumference <35 inches for 





Referral to nutritionist and exercise 
therapist 
Referral to hospital- or community-
based weight loss programs 
Lowest possible dose of 
corticosteroids 
Dyslipidemia Check fasting lipid panel at initial visit, 
then yearly 
If dyslipidemic, check lipids every 6 
months 
or 6 weeks after medication changes 
Goal LDL <100 mg/dl 
Goal LDL <70 mg/dl for those with 
known CVD or PVD or diabetes 
 
Encourage lifestyle modification 
with diet, exercise, and weight loss 
counseling 




Consider lipid lowering therapy for 
those not at LDL goal 
Consider ASA therapy 
Consider preventive cardiology 
evaluation 
Hypertension Check blood pressure at each visit and 
between visits 
for those on corticosteroids or NSAIDs 
Goal BP <130/80 mmHg 
 
Aggressive blood pressure control 
Encourage lifestyle modification 
with diet, exercise, and weight loss 
counseling 
Addition of ACE inhibitor for those 
with diabetes or renal disease 
Lowest possible dose of 
corticosteroids 






Check fasting glucose yearly 
Consider checking fasting insulin and 
calculate 
insulin resistance 
Oral glucose tolerance test if needed. 
Goal fasting glucose <126 mg/dl 
Goal HbA1c <7% 
 
Endocrinology evaluation 
Early aggressive therapy to maintain 
HbA1c<7% 
Encourage lifestyle modification 




Consider ASA therapy 
Aggressive management of blood 
pressure, lipids, and other CV risk 
factors 
 
Tobacco Use Ask patient about tobacco use at each 
visit 




Discuss importance of tobacco 
cessation 
Assess willingness to quit 
Referral to tobacco cessation 
program 
Suggest pharmacotherapy 
Consider ASA therapy 
BMI: body mass index. LDL: low-density lipoprotein. HDL: high-density lipoprotein. CVD: 
cardiovascular disease. PVD:peripheral vascular disease. BP: blood pressure. NSAIDs: nonsteroidal 
anti-inflammatory drugs. HbA1c: glycosylated hemoglobin.ASA: aspirin. 
Table 1. Assessment and Management strategies of traditional risk factors in patients with 
SLE. (Elliot JR, Mansi S, 2009. Copyright permission from Elsevier) 
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Given these data, physicians should consider referring patients to an exercise physiologist 
or specialists in physical exercise. An individualized exercise plan that takes into account 
patients specific needs and limitations may help to assure their long-term commitment to 
being physically fit. (Elliott &Manzi, 2009) 
Dyslipidaemia: 
Assessment At baseline and yearly, a fasting lipid panel (TC, LDL, HDL and TG levels) 
should be performed on patients with SLE. It is proposed that lupus patients be considered 
CHD risk equivalents, similar to patients with diabetes. Accordingly, based on the National 
Cholesterol Education Program Adult Treatment Panel (ATP III), (National Cholesterol 
Education Program [NCEP], 2001) the goal cholesterol levels in lupus patients should be: TC 
<200 mg/dl, LDL <100 mg/dl, TG <150 mg/dl and HDL >40 mg/dl. 
Management 
Lifestyle modifications should be considered as first-line approach, with an emphasis on 
reducing saturated and transunsaturated fat and cholesterol intake and weight loss. The 
American Diabetes Association (ADA) and the ACC issued a consensus statement 
recommending both lifestyle modifications and lipid pharmacological therapy, regardless of 
LDL level, for all patients with known CVD or for high-risk groups, such as patients with 
diabetes .(Brunzell et al, 2008) They further recommended a tighter LDL goal of <70 mg/dl. 
There is a scarcity of lipid-lowering therapy clinical trials in SLE. Petri et al. reported an 
improvement in carotid IMT in SLE patients treated with atorvastatin.(Petri et al, 2006) Most 
do not advocate the wide-spread use of statins in all SLE patients, (Toloza et al, 2007 but 
reserve its use for those with established vascular disease or diabetes. 
Based on the available literature, Elliott & Manzi propose the following management of 
dyslipidaemia in SLE patients: 
- Regardless of LDL level, corticosteroid therapy should be minimized, HCQ be 
considered and lifestyle modifications be initiated.  
- LDL goal of <100 mg/dl or <70 mg/dl for those with sub-clinical CVD, known CV or 
peripheral vascular disease (PVD), or diabetes 
- Consideration of lipid-lowering therapy for LDL >100 mg/dl or >70 mg/dl for those 
with subclinical CVD, known CVD or PVD, or diabetes 
Hypertension 
Assessment 
The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC 7) continues to define hypertension as exceeding 140/90 mmHg. 
(Chobanian et al, 2003) However, the report recommends for the first time, a more stringent 
goal of <130/80 mmHg for patients with high-risk conditions, such as diabetes or chronic 
kidney disease. Based on this literature, Elliott & Manzi recommended a goal blood pressure 
of <130/80 mmHg for patients with SLE. Additionally, a blood pressure reading should be 
obtained at each physician visit and between visits for lupus patients on corticosteroids and 
non-steroidal anti-inflammatory drugs. 
Management 
Lifestyle modifications regarding diet, specifically salt restriction, exercise, weight control 
and alcohol moderation, is recommended for all patients with a blood pressure >140/90 
mmHg. Except for those with known ischaemic heart disease or diabetes, lowering of blood 
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Risk factors Monitoring strategies Management strategies 
Obesity Check weight, height, and waist 
circumference at each visit 
Goal BMI <25 kg/m2 
Goal waist circumference <35 inches for 





Referral to nutritionist and exercise 
therapist 
Referral to hospital- or community-
based weight loss programs 
Lowest possible dose of 
corticosteroids 
Dyslipidemia Check fasting lipid panel at initial visit, 
then yearly 
If dyslipidemic, check lipids every 6 
months 
or 6 weeks after medication changes 
Goal LDL <100 mg/dl 
Goal LDL <70 mg/dl for those with 
known CVD or PVD or diabetes 
 
Encourage lifestyle modification 
with diet, exercise, and weight loss 
counseling 




Consider lipid lowering therapy for 
those not at LDL goal 
Consider ASA therapy 
Consider preventive cardiology 
evaluation 
Hypertension Check blood pressure at each visit and 
between visits 
for those on corticosteroids or NSAIDs 
Goal BP <130/80 mmHg 
 
Aggressive blood pressure control 
Encourage lifestyle modification 
with diet, exercise, and weight loss 
counseling 
Addition of ACE inhibitor for those 
with diabetes or renal disease 
Lowest possible dose of 
corticosteroids 






Check fasting glucose yearly 
Consider checking fasting insulin and 
calculate 
insulin resistance 
Oral glucose tolerance test if needed. 
Goal fasting glucose <126 mg/dl 
Goal HbA1c <7% 
 
Endocrinology evaluation 
Early aggressive therapy to maintain 
HbA1c<7% 
Encourage lifestyle modification 




Consider ASA therapy 
Aggressive management of blood 
pressure, lipids, and other CV risk 
factors 
 
Tobacco Use Ask patient about tobacco use at each 
visit 




Discuss importance of tobacco 
cessation 
Assess willingness to quit 
Referral to tobacco cessation 
program 
Suggest pharmacotherapy 
Consider ASA therapy 
BMI: body mass index. LDL: low-density lipoprotein. HDL: high-density lipoprotein. CVD: 
cardiovascular disease. PVD:peripheral vascular disease. BP: blood pressure. NSAIDs: nonsteroidal 
anti-inflammatory drugs. HbA1c: glycosylated hemoglobin.ASA: aspirin. 
Table 1. Assessment and Management strategies of traditional risk factors in patients with 
SLE. (Elliot JR, Mansi S, 2009. Copyright permission from Elsevier) 
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Given these data, physicians should consider referring patients to an exercise physiologist 
or specialists in physical exercise. An individualized exercise plan that takes into account 
patients specific needs and limitations may help to assure their long-term commitment to 
being physically fit. (Elliott &Manzi, 2009) 
Dyslipidaemia: 
Assessment At baseline and yearly, a fasting lipid panel (TC, LDL, HDL and TG levels) 
should be performed on patients with SLE. It is proposed that lupus patients be considered 
CHD risk equivalents, similar to patients with diabetes. Accordingly, based on the National 
Cholesterol Education Program Adult Treatment Panel (ATP III), (National Cholesterol 
Education Program [NCEP], 2001) the goal cholesterol levels in lupus patients should be: TC 
<200 mg/dl, LDL <100 mg/dl, TG <150 mg/dl and HDL >40 mg/dl. 
Management 
Lifestyle modifications should be considered as first-line approach, with an emphasis on 
reducing saturated and transunsaturated fat and cholesterol intake and weight loss. The 
American Diabetes Association (ADA) and the ACC issued a consensus statement 
recommending both lifestyle modifications and lipid pharmacological therapy, regardless of 
LDL level, for all patients with known CVD or for high-risk groups, such as patients with 
diabetes .(Brunzell et al, 2008) They further recommended a tighter LDL goal of <70 mg/dl. 
There is a scarcity of lipid-lowering therapy clinical trials in SLE. Petri et al. reported an 
improvement in carotid IMT in SLE patients treated with atorvastatin.(Petri et al, 2006) Most 
do not advocate the wide-spread use of statins in all SLE patients, (Toloza et al, 2007 but 
reserve its use for those with established vascular disease or diabetes. 
Based on the available literature, Elliott & Manzi propose the following management of 
dyslipidaemia in SLE patients: 
- Regardless of LDL level, corticosteroid therapy should be minimized, HCQ be 
considered and lifestyle modifications be initiated.  
- LDL goal of <100 mg/dl or <70 mg/dl for those with sub-clinical CVD, known CV or 
peripheral vascular disease (PVD), or diabetes 
- Consideration of lipid-lowering therapy for LDL >100 mg/dl or >70 mg/dl for those 
with subclinical CVD, known CVD or PVD, or diabetes 
Hypertension 
Assessment 
The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC 7) continues to define hypertension as exceeding 140/90 mmHg. 
(Chobanian et al, 2003) However, the report recommends for the first time, a more stringent 
goal of <130/80 mmHg for patients with high-risk conditions, such as diabetes or chronic 
kidney disease. Based on this literature, Elliott & Manzi recommended a goal blood pressure 
of <130/80 mmHg for patients with SLE. Additionally, a blood pressure reading should be 
obtained at each physician visit and between visits for lupus patients on corticosteroids and 
non-steroidal anti-inflammatory drugs. 
Management 
Lifestyle modifications regarding diet, specifically salt restriction, exercise, weight control 
and alcohol moderation, is recommended for all patients with a blood pressure >140/90 
mmHg. Except for those with known ischaemic heart disease or diabetes, lowering of blood 
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pressure is more important than the choice of anti-hypertensive agent. Anti-hypertensive 
therapy should also be initiated when blood pressure readings are >140/90 mmHg. 
Aggressive combination therapy is often needed to obtain blood pressure goals, and the JNC 
7 recommends starting combination therapy when SBP >150 mmHg or DBP >90 
mmHg.(Chobanian et al, 2003) Angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin receptor blockers (ARBs), calcium channel blockers or thiazide diuretics are 
typically first-line therapy for hypertension. However, a beta-blocker should be used in 
patients with known CAD and an ACE or ARB is recommended in those with diabetes or 
renal disease. Corticosteroid therapy should also continue to be minimized given its 
relationship with blood pressure elevation. (Elliott & Manzi, 2009) 
Diabetes mellitus 
Assessment 
All lupus patients should have a fasting glucose checked yearly. The American Diabetic 
Association (ADA) defines diabetes with either a fasting plasma glucose of >126 mg/dl or a 
glucose tolerance test of >200 mg dl. (Nathan et al, 2006) Goals of therapy should be near-
normal glucose levels and a haemoglobin A1C level of <7%. 
Management 
Lupus patients with diabetes should undergo structured diabetic education programs that 
emphasize aggressive lifestyle changes in diet, exercise and weight management. The ADA 
also recommends metformin therapy in addition to lifestyle changes for all patients newly 
diagnosed with diabetes. (Nathan et al, 2006)  If this regimen is not effective in reaching 
glucose or haemoglobin A1C goals, then another oral diabetic agent or insulin should be 
started. Endocrinology referral should be strongly encouraged for these patients. 
Other risk factors: Other CV risk factors must also be evaluated and aggressively treated. As 
described above, blood pressure therapy is recommended at >140/90 mmHg and statin 
therapy at LDL >100 mg /dl. All patients should be counseled on tobacco cessation and 
considered for aspirin therapy.HCQ should also be considered for all lupus patients with 
impaired glucose function and diabetes. Similarly, corticosteroid therapy should be 
minimized to avoid exacerbations of hyperglycaemia. 
8.6.2 SLE-specific and inflammatory risk factor assessment and management 
A summary of the assessment and management strategies for lupus-specific and 
inflammatory CV risk factors is outlined in Table 2. 
8.7 Conclusion 
Cardiovascular involvement in SLE may easily be overlooked until a full blown cardiac 
dysfunction or complication occurs. 
 Cardiac involvement  in SLE involves all the three layers of the heart (pericardium, 
myocardium, endocardium) 
 Pericarditis is a common cardiac manifestation of SLE and can present rarely with 
cardiac tamponade being the initial presentation. Diagnosis is based on ECG and 
echocardiography findings. Pericarditis responds well to steroid therapy, and rarely 
may progress to cardiac tamponade necessitating pericardiocentesis.Refractory cases 
may require pericardial window. 
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Risk factors Monitoring strategies Management strategies 
SLE Disease activity 
 
 
Assess disease activity 
and medications at each visit 
 
Lowest possible dose of 
corticosteroids 
Add steroid sparing agent if 




Consider ASA therap 
SLE Renal disease Assess renal parameters at each 
visit: BP, serum albumin, 
creatinineو 
and urinalysis 
Goal BP <130/80 mmHg 
Goal to normalize creatinine and 
albumin 
Goal proteinuria <300 mg/dl 
Aggressive blood pressure 
control 
Addition of ACE inhibitor 
Consider ASA therapy 
 
Antiphospholipids 
 or Lupus 
Anticoagulant positivity 
Check antiphospholipids, Lupus 
Anticoagulant, and beta 2 
glycoprotein antibody status 
initially and as needed 
Consider hydroxychloroquine 
therapy 
Consider ASA therapy 
Inflammatory CV risk 









Consider checking as an additive 
predictive factor 





Unclear at this time 
 
Unclear at this time, but consider 
folic acid supplementation for 
hyperhomocysteinemia 
Table 2. Summary of SLE-specific CV risk factors in patients with SLE (Elliot JR, Mansi S, 
2009. Copyright permission from Elsevier) 
 Myocarditis presents in 3-15% of the SLE patients clinically,but a common finding in 
autopsy studies. It may present with florid heart failure or subacutely as tachycardia 
and dyspnea.Myocarditis should be considered in patient with tachycardia and fever, 
with a 3rd heart sound with abnormal ECG in those with a new murmurs or conduction 
disturbances and those with congestive heart failure.Treatment is with high dose 
steroid and with IV cyclophosphamide in refractory cases in addition to antifailure 
therapy.Anticoagugation should be considered in those with cardiomyopathy. 
 Valvular heart disease due to Libman Sacks endocarditis is found less frequently in the 
era of corticosteroids.The mitral valve is the most common valve involved followed by 
the the aortic valve.Echocardiography is the modality of choice for diagnosis.Use of 
steroids to shinken the vegetation is controversial and as may led to fibrosis. Bacterial 
prophylaxis is indicated in patients with significant regurtitation with jet lesions even in 
the absence of nodules. 
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pressure is more important than the choice of anti-hypertensive agent. Anti-hypertensive 
therapy should also be initiated when blood pressure readings are >140/90 mmHg. 
Aggressive combination therapy is often needed to obtain blood pressure goals, and the JNC 
7 recommends starting combination therapy when SBP >150 mmHg or DBP >90 
mmHg.(Chobanian et al, 2003) Angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin receptor blockers (ARBs), calcium channel blockers or thiazide diuretics are 
typically first-line therapy for hypertension. However, a beta-blocker should be used in 
patients with known CAD and an ACE or ARB is recommended in those with diabetes or 
renal disease. Corticosteroid therapy should also continue to be minimized given its 
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dysfunction or complication occurs. 
 Cardiac involvement  in SLE involves all the three layers of the heart (pericardium, 
myocardium, endocardium) 
 Pericarditis is a common cardiac manifestation of SLE and can present rarely with 
cardiac tamponade being the initial presentation. Diagnosis is based on ECG and 
echocardiography findings. Pericarditis responds well to steroid therapy, and rarely 
may progress to cardiac tamponade necessitating pericardiocentesis.Refractory cases 
may require pericardial window. 
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Risk factors Monitoring strategies Management strategies 
SLE Disease activity 
 
 
Assess disease activity 
and medications at each visit 
 
Lowest possible dose of 
corticosteroids 
Add steroid sparing agent if 




Consider ASA therap 
SLE Renal disease Assess renal parameters at each 
visit: BP, serum albumin, 
creatinineو 
and urinalysis 
Goal BP <130/80 mmHg 
Goal to normalize creatinine and 
albumin 
Goal proteinuria <300 mg/dl 
Aggressive blood pressure 
control 
Addition of ACE inhibitor 
Consider ASA therapy 
 
Antiphospholipids 
 or Lupus 
Anticoagulant positivity 
Check antiphospholipids, Lupus 
Anticoagulant, and beta 2 
glycoprotein antibody status 
initially and as needed 
Consider hydroxychloroquine 
therapy 
Consider ASA therapy 
Inflammatory CV risk 









Consider checking as an additive 
predictive factor 





Unclear at this time 
 
Unclear at this time, but consider 
folic acid supplementation for 
hyperhomocysteinemia 
Table 2. Summary of SLE-specific CV risk factors in patients with SLE (Elliot JR, Mansi S, 
2009. Copyright permission from Elsevier) 
 Myocarditis presents in 3-15% of the SLE patients clinically,but a common finding in 
autopsy studies. It may present with florid heart failure or subacutely as tachycardia 
and dyspnea.Myocarditis should be considered in patient with tachycardia and fever, 
with a 3rd heart sound with abnormal ECG in those with a new murmurs or conduction 
disturbances and those with congestive heart failure.Treatment is with high dose 
steroid and with IV cyclophosphamide in refractory cases in addition to antifailure 
therapy.Anticoagugation should be considered in those with cardiomyopathy. 
 Valvular heart disease due to Libman Sacks endocarditis is found less frequently in the 
era of corticosteroids.The mitral valve is the most common valve involved followed by 
the the aortic valve.Echocardiography is the modality of choice for diagnosis.Use of 
steroids to shinken the vegetation is controversial and as may led to fibrosis. Bacterial 
prophylaxis is indicated in patients with significant regurtitation with jet lesions even in 
the absence of nodules. 
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 Arrhythmia and conduction defects occour in 10% of the patients with SLE either as a 
consequence of pericarditis or myocarditis or involment of the conduction system by 
fibrosis or atherosclerosis. AntiSSA/RO associated cardiac manifestations include 
transient fetal heart block, QTc prolongation, sinus bradycardis, late on-set 
cardiomyopathy, endocardial fibroelastosis and cardiac malformations.In the adult 
heart may cause QTc prolongation in lupus patients. 
 Coronary arteritis presents with angina or myocardial infarction in a child or a young 
adult who do not have a long history of corticosteroid therapy.Serial coronary 
angiography is the proposed diagnostic modality.Corticosteroids may have rapid relief 
of the angina and may need cyclophosphamide. 
 Premature atherosclerosis, cardiovascular risk factors and cardiovascular events all 
occur at a younger age in patients with SLE compared with the general population. 
 After controlling for traditional Framingham risk factors, patients with SLE still have a 
7.5-fold (95% CI: 5.1–10.4) excess risk of overall coronary heart disease.This suggests 
that SLE itself carries an independent risk for CVD and exposes the failure of the 
Framingham risk calculator to capture a younger at-risk population. 
 Traditional risk factors, lupus related, and novel inflammatory CV risk factors are 
implicated in the pathogenesis of premature atherosclerosis. 
 Treatment recommendations for patients with SLE are based on other high-risk 
populations since there are no randomized, controlled trials that demonstrate the 
efficacy of interventions on cardiovascular events in SLE. 
 Lifestyle modifications and/or statins should be used to lower LDL-cholesterol below 
100 mg/dl as suggested in the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel III guidelines. 
 Hypertension should be treated to maintain a blood pressure less than 130/80 mmHg. 
First-choice medication for patients with SLE should probably be angiotensin-
converting enzyme inhibitors (or angiotensin receptor blockers), especially in patients 
with concomitant lupus nephritis or diabetes mellitus.  
 Low-dose daily aspirin therapy is recommended in patients with SLE barring an 
absolute contraindication. 
 Use of antimalarial medications in all patients with SLE is recommended. 
 Use of corticosteroids should be minimized and immunosuppressant medications 
should be used judiciously, but control of SLE should not be sacrificed to minimize 
CVD risk. 
 Smoking cessation, regular aerobic exercise and maintaining a normal BMI are 
recommended in all patients with SLE. 
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1. Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women 
of childbearing age with 10:1 female to male ratio.(Siegel & Lee, 1973) Any organ can be 
affected by SLE; pulmonary involvement is usually in the latter course of the disease.(Haupt 
et al., 1981; Orens et al., 1994; Quadrelli et al., 2009) It is important to note that lung 
involvement is proportionately more common in men.(Kamen & Strange, 2010) Any part of 
the pulmonary system can be affected including airways, lung parenchyma, pulmonary 
vasculature, pleura and diaphragm.(Gross et al., 1972; Haupt et al., 1981; Kamen & Strange, 
2010; Orens et al., 1994; Quadrelli et al., 2009; Weinrib et al., 1990) If SLE develops after age 49 
years, it has a higher incidence of serositis, pulmonary involvement and mortality.(Boddaert 
et al., 2004) It is difficult to find out the true prevalence of pulmonary complications of SLE 
since many cases are due to infections.(Kamen & Strange, 2010) A recent autopsy study of 90 
patients diagnosed with SLE, according to the American College of Rheumatology, 
pleuropulmonary involvement occurred in 98% of the autopsies. (Quadrelli et al., 2009) The 
most frequent findings were pleuritis (78%), bacterial infections (58%), alveolar hemorrhage 
(26%), followed by distal airway alterations (21%), opportunistic infections (14%) and 
pulmonary thromboembolism (8%), both acute and chronic.(Quadrelli et al., 2009) In a larger 
series, 25% of patients with SLE had clinical and/or radiographic evidence of pulmonary 
involvement.(Pego-Reigosa et al., 2009) 
2. Clinical features 
SLE can affect the lungs in many ways. In the next section we will review the pulmonary 
diseases associated with SLE according to the anatomic involvement. 
2.1 Pleural diseases 
Pleuritis is the most common pleuropulmonary manifestation of SLE.(Orens et al., 1994) It is 
the initial manifestation in 5% to 10%.(Winslow et al., 1958) Symptoms of pleuritis are 
present in 45% to 60% of patients with SLE and may be associated with pleural 
effusion.(Good et al., 1983; Orens et al., 1994; Pines et al., 1985) Pleural effusion in SLE tends 
to be bilateral, small to moderate in size; however, large effusions may occur.(Bouros et al., 
2008) Typical presentation of pleural involvement is pleuritic chest pain (pain that increases 
with inspiration), dyspnea, and fever. Physical examination may reveal pleural friction rub 
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and signs of pleural effusion. Chest X-ray shows blunting of the costophrenic angle. Some 
patients may have asymptomatic pleural effusion. Other causes of pleural effusion such as 
parapneumonic effusion, pulmonary embolism, and heart failure need to be ruled out. 
Pleural fluid analysis is needed to rule out other etiologies and to confirm the diagnosis of 
lupus pleuritis. Pleural fluid is exudative (elevated pleural fluid protein and lactate 
dehydrogenase levels) when analyzed. Cell counts are elevated with predominance of 
lymphocytes or neutrophils. Pleural fluid glucose level is low, but not as low as in patients 
with rheumatoid arthritis. Special tests reveal low pleural complement level and positive 
anti-nuclear antibody (ANA). These tests are not sensitive enough to rule out lupus pleuritis 
when tests are negative. (Hunder et al., 1972; Small et al., 1982) Pleural fluid ANA titer ≥ 
1:160 and pleural fluid / serum ANA ratio of ≥ 1 strongly support the diagnosis.(Good et 
al., 1983) The finding of lupus erythematosus cells in pleural fluid confirms the diagnosis; 
however this test is rarely performed.(Kamen & Strange, 2010) Pleural biopsy is rarely 
needed, if done it will show a peculiar immunofluorescent pattern characterized by 
staining of nuclei with anti-IgG, anti-IgM and anti-C3.(Pertschuk et al., 1977) Patients with 
pleural disease usually respond to nonsteriodal anti-inflammatory drugs (NSAIDs). Low 
doses of oral glucocorticoids hasten the resolution. Small asymptomatic effusions usually 
resolve without treatment.(Winslow et al., 1958) NSAIDs are sufficient for mild cases; for 
severe cases or for patients on steroids, giving higher doses of steroid is required.( Orens 
et al., 1994; Wiedemann & Matthay, 1989) In refractory pleural effusions tetracycline or 
talc pleurodesis can be an alternative option.( Gilleece et al., 1988; Kaine, 1985; McKnight 
et al., 1991)  
2.2 Parenchymal lung disease 
2.2.1 Acute lupus pneumonitis 
Acute lupus pneumonitis (ALP) is an uncommon but well recognized complication of SLE. 
There is some controversy over the definition ALP.(Swigris et al., 2008) In two recent series, 
the prevalence of ALP in patients with SLE was 2% to 8%.( Kim et al., 2000; Mochizuki et al., 
1999) It is difficult to estimate the exact prevalence given the significant clinical and 
radiological overlap between ALP, bacterial pneumonia and alveolar hemorrhage. ALP 
tends to affect younger patients and those with recent diagnosis of SLE. In 50% of patients 
with SLE who develop ALP, the pulmonary complication is the initial presentation of 
lupus.(Matthay et al., 1975) Clinical presentation includes abrupt onset of fever, cough, 
dyspnea, pleuritic chest pain and occasionally hemoptysis.(Matthay et al., 1975) Physical 
examination usually reveals signs of hypoxia and bibasilar crackles. Radiographic findings 
include bilateral alveolar infiltrates with predominance in lower lung fields (figure 1). 
Pleural effusion occurs in half of the cases.(Matthay et al., 1975) Rarely the initial chest 
radiograph may be normal or may show pulmonary nodules.(Susanto & Peters, 1997) CT 
scan of the chest may show diffuse ground glass opacities and areas of 
consolidation.(Swigris et al., 2008) A fulminant form of ALP may occur during 
pregnancy.(Comer et al., 1996)  The clinical and radiographic features are not specific. Other 
causes of alveolar infiltrates like infectious pneumonia, alveolar hemorrhage, pulmonary 
edema, and organizing pneumonia should be considered. It is important to rule out 
infectious complications. Many of these patients are on systemic steroids and other 
immunosuppressive medications and are at increased risk of opportunistic infections. Early 
bronchoscopy and bronchoalveolar lavage (BAL) with or without transbronchial biopsy is 
mandatory in most cases. BAL should be sent for cell count and differential, bacterial, fungal 
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and viral culture, cytology and for Pneumocystis jiroveci stain. Occasionally a thoracoscopic 
lung biopsy may be needed. The pathological findings are not specific. The most common 
findings include diffuse alveolar damage (DAD) with or without alveolar hemorrhage and 
capillaritis.(Harvey et al., 1954; Keane & Lynch, 2000) Other pathologic features include 
alveolar wall injury, alveolar edema, hyaline membrane formation, immunoglobulin and 
complement deposition. There seems to be some association between ALP and anti-Ro/SSa 
antibodies. One study showed that patients with SLE and pulmonary complications had an 
81% positive result for anti-Ro/SSa antibodies, while patients without pulmonary 
involvement had a 38% positive antibody.(Boulware & Hedgpeth, 1989) A more recent 
review confirmed this association (Mochizuki et al., 1999) The high frequency of anti-Ro/SSa 
antibodies raises the possibility of their role in the pathogenesis of ALP.(Cheema & 
Quismorio, 2000) Prognosis is poor, with mortality reaching up to 50% as reported in an old 
study.(Matthay et al., 1975) The outcome is worse if ALP occurs postpartum.(Matthay et al., 
1975) Eosinophilia or neutrophilia on BAL carries worse prognosis than lymphocytosis.(Witt 
et al., 1996) Because infectious causes can’t be ruled out, empiric broad spectrum antibiotics 
should be started immediately and continued until infection is excluded. There are no 
randomized clinical trials for the treatment of ALP, however it is agreed on that the main 
treatment is systemic corticosteroids (prednisone 1-1.5 mg/kg/day). If no adequate 
response within 72 hours, treatment should be with intravenous pulse steroids (1g 
methylprednisolone daily for three days).(Kamen & Strange, 2010) Additional 
immunosuppresants such as cyclophosphamide should also be considered. In patients 
refractory to corticosteroids, intravenous immunoglobulin, plasma exchange or rituximab 
can be of some help with very little evidence (Eiser & Shanies, 1994; Lim et al., 2006; Pego-
Reigosa et al., 2009; Winder et al., 1993) 
 
 
Fig. 1. Chest X-ray showing diffuse alveolar infiltrates in a patient with acute lupus 
pneumonitis 
2.2.2 Diffuse alveolar hemorrhage 
Diffuse alveolar hemorrhage (DAH) is a rare complication of SLE. ( Badsha et al., 2004; 
Eagen et al., 1978; Zamora et al., 1997) Its prevalence among SLE patients ranges between 
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findings include diffuse alveolar damage (DAD) with or without alveolar hemorrhage and 
capillaritis.(Harvey et al., 1954; Keane & Lynch, 2000) Other pathologic features include 
alveolar wall injury, alveolar edema, hyaline membrane formation, immunoglobulin and 
complement deposition. There seems to be some association between ALP and anti-Ro/SSa 
antibodies. One study showed that patients with SLE and pulmonary complications had an 
81% positive result for anti-Ro/SSa antibodies, while patients without pulmonary 
involvement had a 38% positive antibody.(Boulware & Hedgpeth, 1989) A more recent 
review confirmed this association (Mochizuki et al., 1999) The high frequency of anti-Ro/SSa 
antibodies raises the possibility of their role in the pathogenesis of ALP.(Cheema & 
Quismorio, 2000) Prognosis is poor, with mortality reaching up to 50% as reported in an old 
study.(Matthay et al., 1975) The outcome is worse if ALP occurs postpartum.(Matthay et al., 
1975) Eosinophilia or neutrophilia on BAL carries worse prognosis than lymphocytosis.(Witt 
et al., 1996) Because infectious causes can’t be ruled out, empiric broad spectrum antibiotics 
should be started immediately and continued until infection is excluded. There are no 
randomized clinical trials for the treatment of ALP, however it is agreed on that the main 
treatment is systemic corticosteroids (prednisone 1-1.5 mg/kg/day). If no adequate 
response within 72 hours, treatment should be with intravenous pulse steroids (1g 
methylprednisolone daily for three days).(Kamen & Strange, 2010) Additional 
immunosuppresants such as cyclophosphamide should also be considered. In patients 
refractory to corticosteroids, intravenous immunoglobulin, plasma exchange or rituximab 
can be of some help with very little evidence (Eiser & Shanies, 1994; Lim et al., 2006; Pego-
Reigosa et al., 2009; Winder et al., 1993) 
 
 
Fig. 1. Chest X-ray showing diffuse alveolar infiltrates in a patient with acute lupus 
pneumonitis 
2.2.2 Diffuse alveolar hemorrhage 
Diffuse alveolar hemorrhage (DAH) is a rare complication of SLE. ( Badsha et al., 2004; 
Eagen et al., 1978; Zamora et al., 1997) Its prevalence among SLE patients ranges between 
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<2% and 5.4 % (Santos-Ocampo et al., 2000; Zamora et al., 1997), and the mortality rate 
ranges between 50% to 90%.( Erickson et al., 1994; Schwab et al., 1993) Usually it occurs in 
established disease, especially with lupus nephritis.(Zamora et al., 1997) Other 
extrapulmonary manifestations occur with variable degree.(Abud-Mendoza et al., 1985; 
Barile et al., 1997; Koh et al., 1997; Liu et al., 1998; Myers & Katzenstein, 1986; Schwab et al., 
1993; Zamora et al., 1997) However it can occasionally be the initial presentation of 
SLE.(Zamora et al., 1997) Risk factors thought to be contributing to the development of DAH 
are higher titer of circulating anti-DNA antibody, active extra-pulmonary disease, and 
established SLE diagnosis.(Orens et al., 1994)   
Clinical presentation of patients with DAH is not specific; symptoms include acute 
shortness of breath, cough, hemoptysis and fever. The absence of hemoptysis doesn’t rule 
out DAH. In fact hemoptysis is only present in 54% of patients.(Santos-Ocampo et al., 2000) 
Fever is present in more than 80% of patients.(Santos-Ocampo et al., 2000) Signs of 
respiratory distress and hypoxia are noted upon physical examination. Chest radiograph 
shows bilateral alveolar infiltrates. Unilateral pulmonary infiltrates is noted in up to 
18%.(Santos-Ocampo et al., 2000) CT imaging demonstrates new bilateral ground glass 
opacities and consolidation. Acute drop in hemoglobin is frequently encountered. In most 
series anemia was noted >90 of all episodes of DAH. (Abud-Mendoza et al., 1985; Barile et 
al., 1997; Koh et al., 1997; Liu et al., 1998; Myers & Katzenstein, 1986; Schwab et al., 1993; 
Zamora et al., 1997) If diffusion capacity for carbon monoxide (DLCO) is measured it will be 
elevated due to the excess hemoglobin in the alveolar spaces. An increase of DLCO by 30% 
or a value of >130% predicted suggest DAH in the right clinical setting.(Carette et al., 1984; 
Dweik et al., 1997; Ewan et al., 1976; Harmon & Leatherman, 1988;  Leatherman et al., 1984; 
Young, 1989) Low complement level is found in more than 70% of all episodes of DAH.( 
Koh et al., 1997; Liu et al., 1998; Myers & Katzenstein, 1986; Santos-Ocampo et al., 2000; 
Schwab et al., 1993;) Magnetic resonant imaging (MRI) is another imaging study that can 
suggest the presence of blood in the alveoli given the paramagnetic effect of iron.(Hsu et al., 
1992) BAL is mandatory to rule out infection and help in the diagnosis of DAH.  BAL can 
confirm the diagnosis if bloody return increases with serial aliquots. BAL should be 
evaluated for the presence of hemosiderin-laden macrophages, their presence indicate 
alveolar hemorrhage. Transbronchial biopsy (TBBx) may be attempted in stable patients. 
Unfortunately many of these patients require ventilatory support and may not be able to 
sustain the complication of TBBx. Thoracoscopic lung biopsy is rarely needed. Two 
pathological patterns have been described. Bland hemorrhage is more common and occurs 
in 72% while capillaritis occurs in 14% of the times. Both pathological patterns are associated 
with intra-alveolar hemorrhage and hemosiderin–laden macrophages.(Myers & Katzenstein, 
1986; Schwab et al., 1993b; Zamora et al., 1997) IgG , C3 or immune complexes deposition 
occurs in 50% of the cases.(Myers & Katzenstein, 1986) There are no randomized control 
trials addressing treatment options for DAH.  Supportive care is highly valued since many 
of these patients end up in the intensive care unit requiring mechanical ventilation. The 
most acceptable regimen include pulse intravenous steroids (methylprednisolone 1gm per 
day for three days) followed by 1mg/kg of oral prednisone plus intravenous 
cyclophosphamide every four weeks.(Schwab et al., 1993a; Swigris et al., 2008) DAH is one of 
the few indications where plasmapharesis has been shown to be effective, especially in 
refractory cases. (Erickson et al., 1994; Santos-Ocampo et al., 2000) Plasmapharesis may 
improve survival in patients who failed treatment with high dose steroids and 
cyclophosphamide.(Erickson et al., 1994) More recently rituximab has been used in 
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refractory cases with promising results.(Pottier et al., 2011) The mean duration of alveolar 
hemorrhage from onset to radiographic resolution is 7.8 days.(Santos-Ocampo et al., 2000) 
DAH is known to recur within the same subject. In one study, recurrence occurred in more 
than 40% of patients.(Santos-Ocampo et al., 2000) 
2.2.3 Chronic interstitial lung disease 
Chronic interstitial lung disease (ILD) is a well-recognized pulmonary manifestation of SLE.  
The prevalence of chronic ILD in symptomatic patients with lupus is 3%.(Haupt et al., 1981; 
Weinrib et al., 1990) The prevalence increases with an increase in the duration of 
SLE.(Jacobsen et al., 1998) It may present as a chronic and insidious disease or it may follow 
the development of ALP (Boulware & Hedgpeth, 1989; Weinrib et al., 1990)  Chronic ILD 
occurs more commonly in men and older patients. Pulmonary fibrosis affects 18% of 
patients above 50 years compared to 2% of patients under 18 years.(Cheema & Quismorio, 
2000) Clinically, patients usually present with gradually progressive shortness of breath. 
Chronic dry cough can be the initial presentation in some patients. Physical examination 
may show fine bibasilar inspiratory crackles, however finger clubbing is rare.(Renzoni et al., 
1997) Spirometry shows restrictive pattern with proportionate reduction in forced 
expiratory volume in one second (FEV1) and forced vital capacity (FVC) with normal or 
increased FEV1/FVC ratio. Lung volumes and DLCO are typically reduced. Early on, the 
only abnormality in pulmonary function test is an isolated reduction in DLCO. Chest 
radiographs may be normal at the beginning. As the disease progresses it may show 
irregular linear opacities and marked interstitial markings. Reduced lung volume is a late 
finding. High resolution CT (HRCT) of the chest may show diffuse ground glass opacities. 
Other features include diffuse interstitial infiltrates, sepal thickening, honeycombing and 
traction bronchiectasis (figure2). The pattern of ILD mimics that of idiopathic interstitial 
pneumonia (IIP). The presence of pleural disease is common in patients with SLE while it is 
rare in IIP. One study attempted to correlate HRCT findings with clinical and pulmonary 
function tests (PFTs). There was no correlation between abnormal HRCT, pulmonary 
symptoms, disease activity and drug therapy.(Fenlon et al., 1996) The PFT findings did not 
correlate with the presence or the severity of ILD on HRCT.(Fenlon et al., 1996) This lack of 
correlation was confirmed in another study.(Sant et al., 1997) The rate of abnormal CT 
findings in asymptomatic patients is high, reaching 30%.(Bankier et al., 1995; Fenlon et al., 
1996; Haupt et al., 1981) There is no current recommendation to screen asymptomatic SLE 
patients with HRCT. Bronchoscopy with BAL is done to rule out infections. Thoracoscopic 
lung biopsy is needed to identify the underlying pathology. Several histopathological 
patterns are known to occur. The most common pattern is non-specific interstitial 
pneumonia (NSIP), cellular, fibrotic or mixed.(Tansey et al., 2004) This pattern is 
characterized by homogeneous infiltration of alveolar walls with large number of 
lymphocytes and plasma cells. Organizing pneumonia, which used to be called bronchiolitis 
obliterans organizing pneumonia (BOOP) has also been reported.(Gammon et al., 1992) 
Lymphoid interstitial pneumonia (LIP) and usual interstitial pneumonia (UIP) are found 
more commonly in patients with secondary Sjögren's syndrome or overlap 
syndrome.(Schattner et al., 2003; Tansey et al., 2004)  There are no placebo control trials to 
guide the treatment of ILD in SLE. Systemic corticosteroids (Prednisone 60mg/d for at least 
four weeks) improved respiratory symptoms and DLCO in the majority of patients when 
followed up for a mean of 7.3 years. (Weinrib et al., 1990) In patients who don’t respond to 
corticosteroids, treatment with cyclophosphamide, azathioprine, or mycophenolate should 
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<2% and 5.4 % (Santos-Ocampo et al., 2000; Zamora et al., 1997), and the mortality rate 
ranges between 50% to 90%.( Erickson et al., 1994; Schwab et al., 1993) Usually it occurs in 
established disease, especially with lupus nephritis.(Zamora et al., 1997) Other 
extrapulmonary manifestations occur with variable degree.(Abud-Mendoza et al., 1985; 
Barile et al., 1997; Koh et al., 1997; Liu et al., 1998; Myers & Katzenstein, 1986; Schwab et al., 
1993; Zamora et al., 1997) However it can occasionally be the initial presentation of 
SLE.(Zamora et al., 1997) Risk factors thought to be contributing to the development of DAH 
are higher titer of circulating anti-DNA antibody, active extra-pulmonary disease, and 
established SLE diagnosis.(Orens et al., 1994)   
Clinical presentation of patients with DAH is not specific; symptoms include acute 
shortness of breath, cough, hemoptysis and fever. The absence of hemoptysis doesn’t rule 
out DAH. In fact hemoptysis is only present in 54% of patients.(Santos-Ocampo et al., 2000) 
Fever is present in more than 80% of patients.(Santos-Ocampo et al., 2000) Signs of 
respiratory distress and hypoxia are noted upon physical examination. Chest radiograph 
shows bilateral alveolar infiltrates. Unilateral pulmonary infiltrates is noted in up to 
18%.(Santos-Ocampo et al., 2000) CT imaging demonstrates new bilateral ground glass 
opacities and consolidation. Acute drop in hemoglobin is frequently encountered. In most 
series anemia was noted >90 of all episodes of DAH. (Abud-Mendoza et al., 1985; Barile et 
al., 1997; Koh et al., 1997; Liu et al., 1998; Myers & Katzenstein, 1986; Schwab et al., 1993; 
Zamora et al., 1997) If diffusion capacity for carbon monoxide (DLCO) is measured it will be 
elevated due to the excess hemoglobin in the alveolar spaces. An increase of DLCO by 30% 
or a value of >130% predicted suggest DAH in the right clinical setting.(Carette et al., 1984; 
Dweik et al., 1997; Ewan et al., 1976; Harmon & Leatherman, 1988;  Leatherman et al., 1984; 
Young, 1989) Low complement level is found in more than 70% of all episodes of DAH.( 
Koh et al., 1997; Liu et al., 1998; Myers & Katzenstein, 1986; Santos-Ocampo et al., 2000; 
Schwab et al., 1993;) Magnetic resonant imaging (MRI) is another imaging study that can 
suggest the presence of blood in the alveoli given the paramagnetic effect of iron.(Hsu et al., 
1992) BAL is mandatory to rule out infection and help in the diagnosis of DAH.  BAL can 
confirm the diagnosis if bloody return increases with serial aliquots. BAL should be 
evaluated for the presence of hemosiderin-laden macrophages, their presence indicate 
alveolar hemorrhage. Transbronchial biopsy (TBBx) may be attempted in stable patients. 
Unfortunately many of these patients require ventilatory support and may not be able to 
sustain the complication of TBBx. Thoracoscopic lung biopsy is rarely needed. Two 
pathological patterns have been described. Bland hemorrhage is more common and occurs 
in 72% while capillaritis occurs in 14% of the times. Both pathological patterns are associated 
with intra-alveolar hemorrhage and hemosiderin–laden macrophages.(Myers & Katzenstein, 
1986; Schwab et al., 1993b; Zamora et al., 1997) IgG , C3 or immune complexes deposition 
occurs in 50% of the cases.(Myers & Katzenstein, 1986) There are no randomized control 
trials addressing treatment options for DAH.  Supportive care is highly valued since many 
of these patients end up in the intensive care unit requiring mechanical ventilation. The 
most acceptable regimen include pulse intravenous steroids (methylprednisolone 1gm per 
day for three days) followed by 1mg/kg of oral prednisone plus intravenous 
cyclophosphamide every four weeks.(Schwab et al., 1993a; Swigris et al., 2008) DAH is one of 
the few indications where plasmapharesis has been shown to be effective, especially in 
refractory cases. (Erickson et al., 1994; Santos-Ocampo et al., 2000) Plasmapharesis may 
improve survival in patients who failed treatment with high dose steroids and 
cyclophosphamide.(Erickson et al., 1994) More recently rituximab has been used in 
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refractory cases with promising results.(Pottier et al., 2011) The mean duration of alveolar 
hemorrhage from onset to radiographic resolution is 7.8 days.(Santos-Ocampo et al., 2000) 
DAH is known to recur within the same subject. In one study, recurrence occurred in more 
than 40% of patients.(Santos-Ocampo et al., 2000) 
2.2.3 Chronic interstitial lung disease 
Chronic interstitial lung disease (ILD) is a well-recognized pulmonary manifestation of SLE.  
The prevalence of chronic ILD in symptomatic patients with lupus is 3%.(Haupt et al., 1981; 
Weinrib et al., 1990) The prevalence increases with an increase in the duration of 
SLE.(Jacobsen et al., 1998) It may present as a chronic and insidious disease or it may follow 
the development of ALP (Boulware & Hedgpeth, 1989; Weinrib et al., 1990)  Chronic ILD 
occurs more commonly in men and older patients. Pulmonary fibrosis affects 18% of 
patients above 50 years compared to 2% of patients under 18 years.(Cheema & Quismorio, 
2000) Clinically, patients usually present with gradually progressive shortness of breath. 
Chronic dry cough can be the initial presentation in some patients. Physical examination 
may show fine bibasilar inspiratory crackles, however finger clubbing is rare.(Renzoni et al., 
1997) Spirometry shows restrictive pattern with proportionate reduction in forced 
expiratory volume in one second (FEV1) and forced vital capacity (FVC) with normal or 
increased FEV1/FVC ratio. Lung volumes and DLCO are typically reduced. Early on, the 
only abnormality in pulmonary function test is an isolated reduction in DLCO. Chest 
radiographs may be normal at the beginning. As the disease progresses it may show 
irregular linear opacities and marked interstitial markings. Reduced lung volume is a late 
finding. High resolution CT (HRCT) of the chest may show diffuse ground glass opacities. 
Other features include diffuse interstitial infiltrates, sepal thickening, honeycombing and 
traction bronchiectasis (figure2). The pattern of ILD mimics that of idiopathic interstitial 
pneumonia (IIP). The presence of pleural disease is common in patients with SLE while it is 
rare in IIP. One study attempted to correlate HRCT findings with clinical and pulmonary 
function tests (PFTs). There was no correlation between abnormal HRCT, pulmonary 
symptoms, disease activity and drug therapy.(Fenlon et al., 1996) The PFT findings did not 
correlate with the presence or the severity of ILD on HRCT.(Fenlon et al., 1996) This lack of 
correlation was confirmed in another study.(Sant et al., 1997) The rate of abnormal CT 
findings in asymptomatic patients is high, reaching 30%.(Bankier et al., 1995; Fenlon et al., 
1996; Haupt et al., 1981) There is no current recommendation to screen asymptomatic SLE 
patients with HRCT. Bronchoscopy with BAL is done to rule out infections. Thoracoscopic 
lung biopsy is needed to identify the underlying pathology. Several histopathological 
patterns are known to occur. The most common pattern is non-specific interstitial 
pneumonia (NSIP), cellular, fibrotic or mixed.(Tansey et al., 2004) This pattern is 
characterized by homogeneous infiltration of alveolar walls with large number of 
lymphocytes and plasma cells. Organizing pneumonia, which used to be called bronchiolitis 
obliterans organizing pneumonia (BOOP) has also been reported.(Gammon et al., 1992) 
Lymphoid interstitial pneumonia (LIP) and usual interstitial pneumonia (UIP) are found 
more commonly in patients with secondary Sjögren's syndrome or overlap 
syndrome.(Schattner et al., 2003; Tansey et al., 2004)  There are no placebo control trials to 
guide the treatment of ILD in SLE. Systemic corticosteroids (Prednisone 60mg/d for at least 
four weeks) improved respiratory symptoms and DLCO in the majority of patients when 
followed up for a mean of 7.3 years. (Weinrib et al., 1990) In patients who don’t respond to 
corticosteroids, treatment with cyclophosphamide, azathioprine, or mycophenolate should 
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be considered. Another approach is to start combination therapy; cyclophosphamide and 
oral glucocorticoids for severe cases and oral steroids with azathioprine for less severe 
cases.(Swigris et al., 2008) The prognosis of ILD associated with SLE is better than the 
idiopathic forms.(Renzoni et al., 1997) The course is usually slow and tends to stabilize or 
improve with time.  
2.3 Pulmonary vascular diseases 
2.3.1 Thromboembolic disease 
Patients with SLE are at increased risk of venous thromboembolism (VTE) with a prevalence 
of 9%.(Gladman & Urowitz, 1980) It is usually related to disease activity. Patients with 
antiphospholipid antibodies have an even more increased risk reaching up to 35% to 42%. 
(Love & Santoro, 1990) Antiphospholipid antibodies (aPL) maybe present in up to two 
thirds of patients with lupus.(Ruiz-Irastorza et al., 2004; Somers et al., 2002) The two major 
antibodies that constitute aPL are lupus anticoagulant and anticardiolipin antibodies (IgG or 
IgM). Criteria of diagnosing antiphospholipid syndrome are discussed elsewhere. In 
addition to VTE, patients with antiphospholipid syndrome are at increased risk of recurrent 
abortions, pulmonary hypertension (PH), DAH, acute respiratory distress syndrome 
(ARDS), and cardiac valvular lesions. (Kamen & Strange, 2010; Swigris et al., 2008) If small-
vessel occlusion occurs in three or more organs the condition is known as catastrophic 
antiphospholipid syndrome (CAPS). (Asherson & Cervera, 1995; Asherson et al., 2001; 
Cervera et al., 2007; Cervera & Asherson, 2008) Cardiopulmonary involvement is common 
with this syndrome and it usually results in ARDS ( Asherson et al., 2008; Bucciarelli et al., 
2006) VTE can occur either acutely (deep vein thrombosis or acute pulmonary embolism) or 
chronically resulting in chronic thromboembolic pulmonary hypertension (CTEPH). Clinical 
features and diagnosis of VTE are similar to unprovoked situations. Once VTE develops, 
 
     
Fig. 2. (Left) HRCT chest showing areas of ground glass opacities and traction 
bronchiectasis. Surgical lung biopsy confirmed the diagnosis of non-specific interstitial 
pneumonia (cellular type). (Right) HRCT chest showing interstitial thickening and areas of 
honeycombing.  Fibrotic form of non-specific interstitial pneumonia was evident on lung 
biopsy 
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long term anticoagulation with warfarin and a target INR of 2.0 to 3.0 is highly 
recommended. It used to be recommended to achieve a higher target INR, but in one study, 
high intensity warfarin (target INR 3.0-4.0) was found not superior to moderate intensity 
warfarin (target INR 2.0-3.0). Moderate intensity warfarin had lower rate of major 
bleeding.(Crowther et al., 2003) Recommendation for primary prevention is lacking. Some 
authors use long term low dose aspirin.(Swigris et al., 2008) Patients with CAPS usually 
require systemic glucocorticoids, immunosuppressants, plasmapharesis and intravenous 
immunoglobulin in addition to anticoagulation.(Swigris et al., 2008) Mortality rate can reach 
up to 50%.(Asherson & Cervera, 1995; Asherson et al., 2001, 2008) 
2.3.2 Pulmonary hypertension 
Pulmonary Hypertension (PH) is defined as a mean pulmonary artery pressure (PAP) ≥ 
25mmHg at rest. (McLaughlin et al., 2009)  The prevalence of PH in SLE patients varies 
between 0.5% to 15%. (Asherson & Oakley, 1986; Asherson et al., 1990) In one study, 50 
consecutive patients with SLE were carefully tested by transthoracic echocardiogram to look 
particularly for PH, none was found to have any echocardiographic evidence of PH. In that 
cohort almost one third were found to have an isolated reduction in DLCO, which could be 
a marker of early pulmonary vascular involvement.(Hodson et al., 1983; Gari  et al., 2009) 
The prevalence is definitely lower than those with scleroderma. Raynaud’s phenomenon 
occurs in 75% of SLE associated pulmonary arterial hypertension (PAH) compared to only 
20% of patients with SLE and no PH.(Matthay et al., 1975) The duration of SLE doesn’t 
correlate with the development of PAH.(Asherson & Oakley, 1986; Asherson & Cervera, 
2007) Clinical presentations of SLE associated PAH is similar to idiopathic pulmonary 
arterial pulmonary hypertension (IPAH). Symptoms include dyspnea, fatigue, chest pain 
and lower limb swelling. Physical examination includes jugular venous distension with a 
large v wave, loud pulmonic component  with wide splitting of the second heart sound, 
murmur of tricuspid regurgitation and/or pulmonic insufficiency, and lower limb edema. 
Physical findings may be minimal in mild PH. In patients with suspected PH, transthoracic 
echocardiogram is the best initial diagnostic test. Right ventricular systolic pressure (RVSP) 
which is an approximation of systolic PAP can only be measured if a tricuspid regurgitation 
(TR) signal is detected. TR signal is only available in 30% of population. Although PH is 
more common in SLE patients than general population, other causes of PH need to be ruled 
out. Tests to evaluate for other causes include HIV, hepatitis B and hepatitis C serology, aPL 
antibodies, HRCT chest to evaluate for interstitial lung disease, ventilation perfusion scan 
(V/Q) to look for any evidence of chronic pulmonary emboli leading to CTEPH, and 
polysomnogram if obstructive sleep apnea is suspected. Eventually right heart 
catheterization is required to confirm the diagnosis of PAH and to rule out PH secondary to 
left heart disease. The pathogenesis of SLE associated PAH is not clear; the high prevalence 
of aPL antibodies suggests that thrombosis may play a role. (Prabu et al., 2009) 
Histopathologic changes are identical to IPAH and include plexiform lesions, intimal 
fibrosis, and thickening of the media. In addition, complement and immunoglobulin 
deposits are found in some patients suggesting that immune deposits may be involved in 
the pathogenesis.(Quismorio et al., 1984)  Several aspects need to be considered when it 
comes to treating SLE associated PAH. All patients should receive long term anticoagulation 
especially those with aPL antibodies. Oxygen, diuretics and digoxin should be considered in 
all patients. PH specific therapies used to treat IPAH are also effective in treating SLE 
associated PAH.  Epoprostenol, bosentan, sildenafil, ambrisentan and tadalafil have all been 
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be considered. Another approach is to start combination therapy; cyclophosphamide and 
oral glucocorticoids for severe cases and oral steroids with azathioprine for less severe 
cases.(Swigris et al., 2008) The prognosis of ILD associated with SLE is better than the 
idiopathic forms.(Renzoni et al., 1997) The course is usually slow and tends to stabilize or 
improve with time.  
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of 9%.(Gladman & Urowitz, 1980) It is usually related to disease activity. Patients with 
antiphospholipid antibodies have an even more increased risk reaching up to 35% to 42%. 
(Love & Santoro, 1990) Antiphospholipid antibodies (aPL) maybe present in up to two 
thirds of patients with lupus.(Ruiz-Irastorza et al., 2004; Somers et al., 2002) The two major 
antibodies that constitute aPL are lupus anticoagulant and anticardiolipin antibodies (IgG or 
IgM). Criteria of diagnosing antiphospholipid syndrome are discussed elsewhere. In 
addition to VTE, patients with antiphospholipid syndrome are at increased risk of recurrent 
abortions, pulmonary hypertension (PH), DAH, acute respiratory distress syndrome 
(ARDS), and cardiac valvular lesions. (Kamen & Strange, 2010; Swigris et al., 2008) If small-
vessel occlusion occurs in three or more organs the condition is known as catastrophic 
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long term anticoagulation with warfarin and a target INR of 2.0 to 3.0 is highly 
recommended. It used to be recommended to achieve a higher target INR, but in one study, 
high intensity warfarin (target INR 3.0-4.0) was found not superior to moderate intensity 
warfarin (target INR 2.0-3.0). Moderate intensity warfarin had lower rate of major 
bleeding.(Crowther et al., 2003) Recommendation for primary prevention is lacking. Some 
authors use long term low dose aspirin.(Swigris et al., 2008) Patients with CAPS usually 
require systemic glucocorticoids, immunosuppressants, plasmapharesis and intravenous 
immunoglobulin in addition to anticoagulation.(Swigris et al., 2008) Mortality rate can reach 
up to 50%.(Asherson & Cervera, 1995; Asherson et al., 2001, 2008) 
2.3.2 Pulmonary hypertension 
Pulmonary Hypertension (PH) is defined as a mean pulmonary artery pressure (PAP) ≥ 
25mmHg at rest. (McLaughlin et al., 2009)  The prevalence of PH in SLE patients varies 
between 0.5% to 15%. (Asherson & Oakley, 1986; Asherson et al., 1990) In one study, 50 
consecutive patients with SLE were carefully tested by transthoracic echocardiogram to look 
particularly for PH, none was found to have any echocardiographic evidence of PH. In that 
cohort almost one third were found to have an isolated reduction in DLCO, which could be 
a marker of early pulmonary vascular involvement.(Hodson et al., 1983; Gari  et al., 2009) 
The prevalence is definitely lower than those with scleroderma. Raynaud’s phenomenon 
occurs in 75% of SLE associated pulmonary arterial hypertension (PAH) compared to only 
20% of patients with SLE and no PH.(Matthay et al., 1975) The duration of SLE doesn’t 
correlate with the development of PAH.(Asherson & Oakley, 1986; Asherson & Cervera, 
2007) Clinical presentations of SLE associated PAH is similar to idiopathic pulmonary 
arterial pulmonary hypertension (IPAH). Symptoms include dyspnea, fatigue, chest pain 
and lower limb swelling. Physical examination includes jugular venous distension with a 
large v wave, loud pulmonic component  with wide splitting of the second heart sound, 
murmur of tricuspid regurgitation and/or pulmonic insufficiency, and lower limb edema. 
Physical findings may be minimal in mild PH. In patients with suspected PH, transthoracic 
echocardiogram is the best initial diagnostic test. Right ventricular systolic pressure (RVSP) 
which is an approximation of systolic PAP can only be measured if a tricuspid regurgitation 
(TR) signal is detected. TR signal is only available in 30% of population. Although PH is 
more common in SLE patients than general population, other causes of PH need to be ruled 
out. Tests to evaluate for other causes include HIV, hepatitis B and hepatitis C serology, aPL 
antibodies, HRCT chest to evaluate for interstitial lung disease, ventilation perfusion scan 
(V/Q) to look for any evidence of chronic pulmonary emboli leading to CTEPH, and 
polysomnogram if obstructive sleep apnea is suspected. Eventually right heart 
catheterization is required to confirm the diagnosis of PAH and to rule out PH secondary to 
left heart disease. The pathogenesis of SLE associated PAH is not clear; the high prevalence 
of aPL antibodies suggests that thrombosis may play a role. (Prabu et al., 2009) 
Histopathologic changes are identical to IPAH and include plexiform lesions, intimal 
fibrosis, and thickening of the media. In addition, complement and immunoglobulin 
deposits are found in some patients suggesting that immune deposits may be involved in 
the pathogenesis.(Quismorio et al., 1984)  Several aspects need to be considered when it 
comes to treating SLE associated PAH. All patients should receive long term anticoagulation 
especially those with aPL antibodies. Oxygen, diuretics and digoxin should be considered in 
all patients. PH specific therapies used to treat IPAH are also effective in treating SLE 
associated PAH.  Epoprostenol, bosentan, sildenafil, ambrisentan and tadalafil have all been 
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shown to be effective in treating PAH.( Barst RJ et al.,1996; Galie et al., 2005, 2008, 2009; 
Rubin et al., 2004 )  PAH specific therapies were found to improve 6-minute walk distance 
(6MWD) and functional class. 
Adding immunosuppressants may provide further improvement.  Intravenous 
cyclophosphamide (monthly for six months) was shown to be effective. It reduced the 
systolic PAP when measured by transthoracic echocardiogram, and improved 
6MWD.(Gonzalez-Lopez et al., 2004; Jais et al., 2008) Oral glucocorticoids in conjunction with 
immunosuppressants lowered PAP and improved 6MWD.(Tanaka et al., 2002; Sanchez et al., 
2006) It is not very clear when to use immunosuppressants in SLE associated PAH. Patients 
with mild PH may benefit from immunosuppressive therapy while patients with moderate 
to severe PH need PH specific therapy with or without immunosuppressants.(Swigris et al., 
2008) The prognosis of SLE associated PAH is worse than IPAH, with a 5-year survival of 
only 17% compared to 68% in patients with IPAH.(Chung et al., 2006)  Given the rarity of 
PH in patients with SLE, there is no recommendation to screen asymptomatic patients with 
echocardiogram.  On the other hand, patients with scleroderma should have annual 
transthoracic echocardiogram to evaluate for the presence of PH. 
2.3.3 Acute reversible hypoxia 
This is a rare complication of lupus. In one series 27% of hospitalized patients had this 
condition.(Abramson et al., 1991) It is characterized by an abrupt onset of unexplained 
hypoxia and hypocapnea.  Radiographic chest imaging is normal. Ventilation perfusion 
(V/Q) scan doesn’t show any evidence of thromboembolism. Arterial blood gases 
demonstrates an increase in Alveolar-arterial (A-a) PO2 gradient. The pathogenesis of this 
syndrome is not clear, but it is believed to be due to complement activation leading to 
leukoaggregation within pulmonary capillaries.(Abramson et al., 1991; Belmont et al., 1994) 
Plasma C3a level is markedly elevated if measured during the episode.(Abramson et al., 
1991) Most cases respond quickly to high dose of systemic corticosteroids.(Abramson et al., 
1991; Martinez-Taboada et al., 1995) 
2.4 Airway disease 
2.4.1 Upper airway involvement 
Involvement of the upper airways can occur in up to 30% of patients with SLE. A variety of 
disorders have been described including laryngeal mucosal inflammation or ulceration, 
cricoarytenoiditis, vocal cord paralysis, and necrotizing vasculitis.( Langford & Van Waes, 
1997; Teitel et al., 1992) Patients present with hoarseness and or dyspnea. Severe upper 
airway obstruction due to angioedema requiring mechanical ventilation has also been 
reported.(Thong et al., 2001)  Angioedema usually present with lips and mouth swelling, 
dysphagia, odynophagia and breathing difficulty, it could be due to SLE or medications 
used in SLE like angiotensin-converting enzyme inhibitors.(Agah et al., 1997)   Routine chest 
imaging with Chest x-ray and chest CT is usually normal in patients with upper airway 
obstruction. Spirometry may show flattening of the inspiratory or expiratory loop or both 
depending on the location of the obstruction. Specialized imaging of the upper airways with 
3-D reconstruction is important to demonstrate the site of obstruction. Direct visualization 
with fibro-optic laryngoscopy or bronchoscopy is needed to assess for vocal cord mobility. 
Generally, corticosteroid therapy will be effective in case of laryngeal mucosal inflammation 
or ulceration, and vocal cord paralysis.(Smith et al., 1977; Teitel et al., 1992).  In those who 
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don’t respond to glucocorticoids, infectious causes should be considered. Typical pathogens 
are Haemophilus influenzae and streptococcus, other rare infections include Histoplasma, 
coccidioides, cryptococus, blastomycosis and candida.(Toomey et al., 1974)  
2.4.2 Lower airway involvement 
Diseases involving the lower airways in patient with SLE include bronchial wall thickening, 
bronchiectasias and bronchiolitis obliterans (BO). In a prospective study of 34 subjects with 
SLE, HRCT chest showed bronchial wall thickening and bronchiectasias in 21% of patients. 
These changes were predominantly asymptomatic.(Fenlon et al., 1996) Bronchiolar disorders 
are rare.(Pego-Reigosa et al., 2009) Abnormalities in PFTs have been reported in up to two 
thirds of patient with SLE.(Andonopoulos et al., 1988) In one study of 57 consecutive lupus 
patients, mild to moderate airflow obstruction was noted in 16%.(Groen et al., 1992) BO has 
been rarely reported.( Beylot-Barry et al., 1994; Godeau et al., 1991; Kawahata et al., 2008) The 
disease is characterized by severe airflow obstruction that’s mostly irreversible. Patients 
usually have progressive dyspnea. PFTs show reduction in FEV1/FVC ratio. If obstruction 
is severe, gas trapping (elevated residual volume) and hyperinflation (elevated total lung 
capacity) may be noted. HRCT chest shows mosaic attenuation pattern that gets accentuated 
in the expiratory images (figure 3). Histopathologic confirmation is rarely required. Disease 
is usually progressive. Systemic corticosteroids and immunosuppressive therapies have 
been tried with little success.(Beylot-Barry et al., 1994; Kawahata et al., 2008) More recently 
anticholinergics were reported to have a favorable outcome.(Kawahata et al., 2008) 
 
     
Fig. 3. (Left) Inspiratory HRCT scan of a 35 year old woman with SLE and bronchiolitis 
obliterans showing mosaic attenuation. (Right) Expiratory HRCT scan in the same subject 
showing an increase in mosaic pattern indicating small airways disease. 
2.5 Muscular involvement 
Shrinking lung syndrome (SLS) is a rare manifestation of SLE. 77 patients with SLS have 
been reported in the literature, with a prevalence of 0.6% to 0.9%.(Pego-Reigosa et al., 2009; 
Toya & Tzelepis, 2009)  It was first described in patients with lupus who presented with 
unexplained dyspnea, decreased lung volumes and elevation of the diaphragm on 
radiographic imaging and restriction on pulmonary function tests in the absence of any 
parenchymal disease.(Hoffbrand & Beck, 1965; Karim et al., 2002; Warrington et al., 2000) It 
 
Systemic Lupus Erythematosus 
 
320 
shown to be effective in treating PAH.( Barst RJ et al.,1996; Galie et al., 2005, 2008, 2009; 
Rubin et al., 2004 )  PAH specific therapies were found to improve 6-minute walk distance 
(6MWD) and functional class. 
Adding immunosuppressants may provide further improvement.  Intravenous 
cyclophosphamide (monthly for six months) was shown to be effective. It reduced the 
systolic PAP when measured by transthoracic echocardiogram, and improved 
6MWD.(Gonzalez-Lopez et al., 2004; Jais et al., 2008) Oral glucocorticoids in conjunction with 
immunosuppressants lowered PAP and improved 6MWD.(Tanaka et al., 2002; Sanchez et al., 
2006) It is not very clear when to use immunosuppressants in SLE associated PAH. Patients 
with mild PH may benefit from immunosuppressive therapy while patients with moderate 
to severe PH need PH specific therapy with or without immunosuppressants.(Swigris et al., 
2008) The prognosis of SLE associated PAH is worse than IPAH, with a 5-year survival of 
only 17% compared to 68% in patients with IPAH.(Chung et al., 2006)  Given the rarity of 
PH in patients with SLE, there is no recommendation to screen asymptomatic patients with 
echocardiogram.  On the other hand, patients with scleroderma should have annual 
transthoracic echocardiogram to evaluate for the presence of PH. 
2.3.3 Acute reversible hypoxia 
This is a rare complication of lupus. In one series 27% of hospitalized patients had this 
condition.(Abramson et al., 1991) It is characterized by an abrupt onset of unexplained 
hypoxia and hypocapnea.  Radiographic chest imaging is normal. Ventilation perfusion 
(V/Q) scan doesn’t show any evidence of thromboembolism. Arterial blood gases 
demonstrates an increase in Alveolar-arterial (A-a) PO2 gradient. The pathogenesis of this 
syndrome is not clear, but it is believed to be due to complement activation leading to 
leukoaggregation within pulmonary capillaries.(Abramson et al., 1991; Belmont et al., 1994) 
Plasma C3a level is markedly elevated if measured during the episode.(Abramson et al., 
1991) Most cases respond quickly to high dose of systemic corticosteroids.(Abramson et al., 
1991; Martinez-Taboada et al., 1995) 
2.4 Airway disease 
2.4.1 Upper airway involvement 
Involvement of the upper airways can occur in up to 30% of patients with SLE. A variety of 
disorders have been described including laryngeal mucosal inflammation or ulceration, 
cricoarytenoiditis, vocal cord paralysis, and necrotizing vasculitis.( Langford & Van Waes, 
1997; Teitel et al., 1992) Patients present with hoarseness and or dyspnea. Severe upper 
airway obstruction due to angioedema requiring mechanical ventilation has also been 
reported.(Thong et al., 2001)  Angioedema usually present with lips and mouth swelling, 
dysphagia, odynophagia and breathing difficulty, it could be due to SLE or medications 
used in SLE like angiotensin-converting enzyme inhibitors.(Agah et al., 1997)   Routine chest 
imaging with Chest x-ray and chest CT is usually normal in patients with upper airway 
obstruction. Spirometry may show flattening of the inspiratory or expiratory loop or both 
depending on the location of the obstruction. Specialized imaging of the upper airways with 
3-D reconstruction is important to demonstrate the site of obstruction. Direct visualization 
with fibro-optic laryngoscopy or bronchoscopy is needed to assess for vocal cord mobility. 
Generally, corticosteroid therapy will be effective in case of laryngeal mucosal inflammation 
or ulceration, and vocal cord paralysis.(Smith et al., 1977; Teitel et al., 1992).  In those who 
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don’t respond to glucocorticoids, infectious causes should be considered. Typical pathogens 
are Haemophilus influenzae and streptococcus, other rare infections include Histoplasma, 
coccidioides, cryptococus, blastomycosis and candida.(Toomey et al., 1974)  
2.4.2 Lower airway involvement 
Diseases involving the lower airways in patient with SLE include bronchial wall thickening, 
bronchiectasias and bronchiolitis obliterans (BO). In a prospective study of 34 subjects with 
SLE, HRCT chest showed bronchial wall thickening and bronchiectasias in 21% of patients. 
These changes were predominantly asymptomatic.(Fenlon et al., 1996) Bronchiolar disorders 
are rare.(Pego-Reigosa et al., 2009) Abnormalities in PFTs have been reported in up to two 
thirds of patient with SLE.(Andonopoulos et al., 1988) In one study of 57 consecutive lupus 
patients, mild to moderate airflow obstruction was noted in 16%.(Groen et al., 1992) BO has 
been rarely reported.( Beylot-Barry et al., 1994; Godeau et al., 1991; Kawahata et al., 2008) The 
disease is characterized by severe airflow obstruction that’s mostly irreversible. Patients 
usually have progressive dyspnea. PFTs show reduction in FEV1/FVC ratio. If obstruction 
is severe, gas trapping (elevated residual volume) and hyperinflation (elevated total lung 
capacity) may be noted. HRCT chest shows mosaic attenuation pattern that gets accentuated 
in the expiratory images (figure 3). Histopathologic confirmation is rarely required. Disease 
is usually progressive. Systemic corticosteroids and immunosuppressive therapies have 
been tried with little success.(Beylot-Barry et al., 1994; Kawahata et al., 2008) More recently 
anticholinergics were reported to have a favorable outcome.(Kawahata et al., 2008) 
 
     
Fig. 3. (Left) Inspiratory HRCT scan of a 35 year old woman with SLE and bronchiolitis 
obliterans showing mosaic attenuation. (Right) Expiratory HRCT scan in the same subject 
showing an increase in mosaic pattern indicating small airways disease. 
2.5 Muscular involvement 
Shrinking lung syndrome (SLS) is a rare manifestation of SLE. 77 patients with SLS have 
been reported in the literature, with a prevalence of 0.6% to 0.9%.(Pego-Reigosa et al., 2009; 
Toya & Tzelepis, 2009)  It was first described in patients with lupus who presented with 
unexplained dyspnea, decreased lung volumes and elevation of the diaphragm on 
radiographic imaging and restriction on pulmonary function tests in the absence of any 
parenchymal disease.(Hoffbrand & Beck, 1965; Karim et al., 2002; Warrington et al., 2000) It 
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can rarely be the presenting feature of SLE.(Stevens et al., 1990) The pathogenesis is still 
unclear with conflicting results. One hypothesis is myositis of the diaphragm or phrenic 
neuropathy.( Hardy et al., 2001; Rubin & Urowitz, 1983;) In one study, patients with elevated 
diaphragms had an abnormal transdiaphragmatic pressure, indicating diaphragmatic 
weakness.(Gibson et al., 1977) However normal muscle strength of the diaphragm in 
patients with SLS has been reported.( Hawkins et al., 2001; Laroche et al., 1989) Clinically, 
patients present with dyspnea that is particularly worse when supine. Pleuritic chest pain is 
present in 65% of patients.(Toya & Tzelepis, 2009) Physical examination reveals diminished 
breath sounds at the lung bases with or without basilar crackles. Chest radiographs and CT 
show elevation of both diaphragms with basal linear atelectasis and without any evidence of 
parenchymal lung disease (figure 4). PFT’s show restriction with preserved DLCO corrected 
for alveolar volume (DL/VA). Assessment of respiratory muscles show reduced maximal 
inspiratory pressure (MIP) and stable maximal expiratory pressure (MEP).  Diaphragmatic 
weakness can be established by measuring the transdiaphragmatic pressure or by doing 
electromyography of the diaphragms. Autopsy findings include diffuse fibrosis and atrophy 
of the diaphragms. (Rubin & Urowitz, 1983) There are no randomized clinical trials for the 
treatment of SLS. Several agents have been tried with variable effects. Oral glucocorticoids 
with or without immunosuppressive medications have been shown effective. ( Soubrier et 
al., 1995; Walz-Leblanc et al., 1992) Other treatment options for SLS include theophylline, 
azathioprine, methotrexate, cyclophosphamide and rituximab.( Benham et al., 2010; Karim et 
al., 2002; Soubrier et al., 1995; Toya & Tzelepis, 2009; Van Veen et al., 1993; Walz-Leblanc et 
al., 1992)  Disease usually stabilizes or improves with treatment with good overall 
prognosis.(Martens et al., 1983)  Respiratory failure rarely occurs.(Ernest & Leung, 2010)     
 
 
Fig. 4. Chest X-ray showing gross elevation of both diaphragms in a patient with SLE and 
shrinking lung syndrome 
2.6 Associated lung disorders 
2.6.1 Adult respiratory distress syndrome (ARDS) 
The prevalence of ARDS is 4% to 15% in patients with lupus.(Andonopoulos, 1991; Kim et 
al., 1999) If it develops the mortality rate can reach up to 70%.(Kim et al., 1999)  ARDS 
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related mortality contributes to 30% of all Lupus deaths. The most frequent cause of ARDS 
is sepsis; other causes include ALP, DAH, and CAPS. In lupus patients, ARDS tend to occur 
at a younger age and is more progressive than ARDS in non-SLE patients. (Andonopoulos, 
1991; Kim et al., 1999; Pego-Reigosa et al., 2009) It is important to identify the underlying 
cause. Treatment of ARDS is supportive. 
2.6.2 Infectious complications 
SLE can impair the immune system at multiple levels.(Orens et al., 1994; Rudd et al., 1981 ) 
The clinical significance of this is unknown since the risk of infection in the absence of 
immunosuppression is negligible. Most patients with infectious complications are on 
immunosuppressive drugs. Infections account for 30% to 50% of all deaths of SLE.( 
Bernatsky et al., 2006; Zandman-Goddard & Shoenfeld, 2005;) Bacterial pathogens account 
for 75% of all infections, mycobacteria 12%, fungal infections 7%, and viruses 5%.(Kinder et 
al., 2007) Opportunistic infections such as Pneumocystis jiroveci, Nocardia, Aspergillus and 
Cytomegalovirus have been reported.( Fessler, 2002; Petri, 1998; Zandman-Goddard & 
Shoenfeld, 2005) Clinical picture is indistinguishable from non-infectious complications such 
as ALP and DAH, hence aggressive diagnostic approach is recommended with chest 
imaging, bronchoscopy and BAL. Empiric broad-spectrum antibiotics should be started 
awaiting identification of an organism. Once a pathogen is isolated treatment should be 
tailored accordingly. Risk of infection can be reduced by influenza and pneumococcal 
vaccination.(O'Neill & Isenberg, 2006) Since many patients with SLE require systemic 
glucocorticoids and immunosuppresants at some point, screening for latent Tuberculosis 
(TB) is important, especially in high prevalence areas. This can be done via skin testing or 
interferon gamma release assay (IGRA).  For those taking glucocorticoids, induration of 
5mm or greater is considered a positive tuberculin skin test. If latent TB is identified 
treatment is recommended with a nine month course of Isoniazid. The role of Pneumocystis 
jiroveci pneumonia (PCP) prophylaxis is less clear. It is suggested for those who are on 
heavy immunosuppression.(Li et al., 2006) 
2.6.3 Lung cancer 
Studies have shown an increased risk of lung cancer in patients with SLE.(Bernatsky et al., 
2006; Pego-Reigosa et al., 2009) Histological pattern is similar to that in general population, 
adenocarcinoma being most common. However there is tendency for uncommon thoracic 
malignancies such as carcinoids and bronchoalveolar carcinoma.(Bin et al., 2007; Pego-
Reigosa et al., 2009) 
2.7 Drug reactions 
In this section we will cover two aspects of drugs and SLE. First we will briefly discuss 
drugs that can cause SLE and the associated pulmonary manifestations. After that we  
will elaborate on pulmonary drug toxicity associated with commonly used medications to 
treat SLE.  
Pulmonary manifestations of drug induced lupus are similar to idiopathic SLE.(Cush & 
Goldings, 1985; Yung & Richardson, 1994) Most commonly it presents with pleurisy and 
pleural effusion.(Wiedemann & Matthay, 1989) Common drugs include Procainamide and 
hydralazine. Newer biologic agents such as entanercept have been reported to cause drug 
induced lupus.(Abunasser et al., 2008) 
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can rarely be the presenting feature of SLE.(Stevens et al., 1990) The pathogenesis is still 
unclear with conflicting results. One hypothesis is myositis of the diaphragm or phrenic 
neuropathy.( Hardy et al., 2001; Rubin & Urowitz, 1983;) In one study, patients with elevated 
diaphragms had an abnormal transdiaphragmatic pressure, indicating diaphragmatic 
weakness.(Gibson et al., 1977) However normal muscle strength of the diaphragm in 
patients with SLS has been reported.( Hawkins et al., 2001; Laroche et al., 1989) Clinically, 
patients present with dyspnea that is particularly worse when supine. Pleuritic chest pain is 
present in 65% of patients.(Toya & Tzelepis, 2009) Physical examination reveals diminished 
breath sounds at the lung bases with or without basilar crackles. Chest radiographs and CT 
show elevation of both diaphragms with basal linear atelectasis and without any evidence of 
parenchymal lung disease (figure 4). PFT’s show restriction with preserved DLCO corrected 
for alveolar volume (DL/VA). Assessment of respiratory muscles show reduced maximal 
inspiratory pressure (MIP) and stable maximal expiratory pressure (MEP).  Diaphragmatic 
weakness can be established by measuring the transdiaphragmatic pressure or by doing 
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treatment of SLS. Several agents have been tried with variable effects. Oral glucocorticoids 
with or without immunosuppressive medications have been shown effective. ( Soubrier et 
al., 1995; Walz-Leblanc et al., 1992) Other treatment options for SLS include theophylline, 
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The prevalence of ARDS is 4% to 15% in patients with lupus.(Andonopoulos, 1991; Kim et 
al., 1999) If it develops the mortality rate can reach up to 70%.(Kim et al., 1999)  ARDS 
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related mortality contributes to 30% of all Lupus deaths. The most frequent cause of ARDS 
is sepsis; other causes include ALP, DAH, and CAPS. In lupus patients, ARDS tend to occur 
at a younger age and is more progressive than ARDS in non-SLE patients. (Andonopoulos, 
1991; Kim et al., 1999; Pego-Reigosa et al., 2009) It is important to identify the underlying 
cause. Treatment of ARDS is supportive. 
2.6.2 Infectious complications 
SLE can impair the immune system at multiple levels.(Orens et al., 1994; Rudd et al., 1981 ) 
The clinical significance of this is unknown since the risk of infection in the absence of 
immunosuppression is negligible. Most patients with infectious complications are on 
immunosuppressive drugs. Infections account for 30% to 50% of all deaths of SLE.( 
Bernatsky et al., 2006; Zandman-Goddard & Shoenfeld, 2005;) Bacterial pathogens account 
for 75% of all infections, mycobacteria 12%, fungal infections 7%, and viruses 5%.(Kinder et 
al., 2007) Opportunistic infections such as Pneumocystis jiroveci, Nocardia, Aspergillus and 
Cytomegalovirus have been reported.( Fessler, 2002; Petri, 1998; Zandman-Goddard & 
Shoenfeld, 2005) Clinical picture is indistinguishable from non-infectious complications such 
as ALP and DAH, hence aggressive diagnostic approach is recommended with chest 
imaging, bronchoscopy and BAL. Empiric broad-spectrum antibiotics should be started 
awaiting identification of an organism. Once a pathogen is isolated treatment should be 
tailored accordingly. Risk of infection can be reduced by influenza and pneumococcal 
vaccination.(O'Neill & Isenberg, 2006) Since many patients with SLE require systemic 
glucocorticoids and immunosuppresants at some point, screening for latent Tuberculosis 
(TB) is important, especially in high prevalence areas. This can be done via skin testing or 
interferon gamma release assay (IGRA).  For those taking glucocorticoids, induration of 
5mm or greater is considered a positive tuberculin skin test. If latent TB is identified 
treatment is recommended with a nine month course of Isoniazid. The role of Pneumocystis 
jiroveci pneumonia (PCP) prophylaxis is less clear. It is suggested for those who are on 
heavy immunosuppression.(Li et al., 2006) 
2.6.3 Lung cancer 
Studies have shown an increased risk of lung cancer in patients with SLE.(Bernatsky et al., 
2006; Pego-Reigosa et al., 2009) Histological pattern is similar to that in general population, 
adenocarcinoma being most common. However there is tendency for uncommon thoracic 
malignancies such as carcinoids and bronchoalveolar carcinoma.(Bin et al., 2007; Pego-
Reigosa et al., 2009) 
2.7 Drug reactions 
In this section we will cover two aspects of drugs and SLE. First we will briefly discuss 
drugs that can cause SLE and the associated pulmonary manifestations. After that we  
will elaborate on pulmonary drug toxicity associated with commonly used medications to 
treat SLE.  
Pulmonary manifestations of drug induced lupus are similar to idiopathic SLE.(Cush & 
Goldings, 1985; Yung & Richardson, 1994) Most commonly it presents with pleurisy and 
pleural effusion.(Wiedemann & Matthay, 1989) Common drugs include Procainamide and 
hydralazine. Newer biologic agents such as entanercept have been reported to cause drug 
induced lupus.(Abunasser et al., 2008) 
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Common drugs used to treat lupus and are known to cause pulmonary complications 
include Methotrexate and Cyclophosphamide. 
Pulmonary complications related to methotrexate are rare, estimated less than 1%.(Lateef et 
al., 2005) Methotrexate can cause acute, subacute or chronic lung toxicity. It is usually not 
dose dependent but rather idiosyncratic.(Imokawa et al., 2000; Ohosone et al., 1997)  
Subacute pneumonitis is most common and presents with fever, cough and dyspnea. 
Crackles are usually noted on physical examination. It usually presents within the first year 
of starting the drug. If left unrecognized it can progress into pulmonary fibrosis in up to 
10%.  Radiologic findings are not specific. Ground glass opacities and diffuse interstitial 
infiltrates are frequently noted on HRCT. BAL is needed to rule out infections.  Histologic 
findings include varying degree of inflammation and fibrosis. Ill-defined granulomas, and 
increased tissue eosinophils have been observed. ( Malik et al., 1996; Sostman et al., 1976) 
Once diagnosis is made methotrexate needs to be stooped and systemic steroids should be 
started. Prognosis is usually favorable. 
Cyclophosphamide lung toxicity is also idiosyncratic. It can present as early onset or late 
onset pneumonitis.(Malik et al., 1996) Early onset disease appears within the first six months 
of starting treatment. It presents with non-productive cough, fever and dyspnea. (Pego-
Reigosa et al., 2009) CT chest shows bilateral upper lobe predominant ground glass 
opacities. PFT shows reduction in lung volumes and DLCO. BAL is needed to rule out 
infections. Discontinuing the drug along with systemic glucocorticoids usually improve 
symptoms and lung function.  Late onset pneumonitis usually occurs after several years of 
exposure to cyclophosphamide. It is a slowly progressive disease. It presents with 
progressive dyspnea and dry cough. Chest imaging shows interstitial fibrosis affecting the 
upper lobes. This condition usually does not respond to steroids. Lung transplantation is an 
option in appropriate candidates. 
3. Assessment of patients with dyspnea 
3.1 Assessment of patients with chronic dyspnea 
The work up of patients with SLE and chronic dyspnea can be lengthy (Figure 5). Chronic 
dyspnea can be due to a variety of conditions such as interstitial lung disease related to SLE 
or drugs used to treat lupus, pleural disease, pulmonary hypertension, systolic heart failure, 
upper airway disease, obliterative bronchiolitis, shrinking lung syndrome or chronic 
infections. Certain clues on history can be helpful; for example dyspnea increasing in the 
supine position suggests diaphragmatic involvement due to SLS, dyspnea and hoarseness 
suggest upper airway involvement, Dyspnea with pleuritic chest pain suggests pleuritis 
related to SLE.  All patients require CXR, HRCT chest and full PFT. If chest imaging is 
normal with or without isolated reduction in DLCO, then transthoracic echocardiogram 
should be done to assess for the presence of PH. If PH is detected, patients should not be 
labeled to have SLE associated PAH until other causes have been ruled out. So hepatitis B 
and C serology, HIV testing, and V/Q scan should be done. All patients should have right 
heart catheterization to confirm the presence of PH and to rule out left heart disease. If SLE-
PAH is diagnosed PH specific therapies should be started. If chest imaging shows elevation 
of the diaphragms, especially in the presence of normal DLCO adjusted for alveolar volume, 
shrinking lung syndrome should be suspected. Electromyography or transdiaphragmatic 
pressure measurement should be obtained. Either of these two tests may show evidence of 
diaphragmatic weakness. If confirmed, trial of systemic steroids is advised. The presence of 
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pleural effusion on CXR or CT chest suggests pleural disease associated with SLE. The 
pleural fluid should be analyzed to rule out other causes. In situations where chest imaging 
is normal but there is flattening of the inspiratory loop, expiratory loop or both, upper 
airway obstruction needs to be ruled out. Special imaging of the upper airways is 
recommended. If interstitial changes are the predominant features on chest imaging, 
interstitial lung diseases related to lupus or drugs are the main differential. Bronchoscopy 
with BAL should be done to rule out chronic infections. Thoracoscopic lung biopsy is 
helpful to identify the pathological pattern of involvement. 
3.2 Assessment of patients with acute dyspnea 
Several conditions can predispose patients to episodes of acute dyspnea.  Pulmonary 
infections, ALP, DAH, PE, and acute reversible hypoxia are the major culprits. Assessment 
starts with clinical evaluation. (Figure 6) is a proposed algorithm for work up of patients 
with SLE presenting with acute dyspnea.  Most conditions are indistinguishable on clinical 
bases. The presence of hemoptysis should raise the suspicion of DAH or PE. After clinical 
evaluation and stabilization of the patient it is important to get a CXR. If CXR is normal then 
it is more likely that dyspnea is due to either acute reversible hypoxia or PE. V/Q scan will 
differentiate between the two.  V/Q scan will be normal in the former and it will show 
mismatched perfusion defects in the latter. If CXR shows pleural effusion or wedge shaped  
 
 
Fig. 5. Work-up of patients with SLE presenting with chronic dyspnea. 
bronchoalveolar lavage (BAL); chest x-ray (CXR); diffusion capacity for carbon monoxide 
(DLCO); diffusion capacity for carbon monoxide adjusted for alveolar volume (DL/VA); 
high resolution computed tomography (HRCT); interstitial lung disease (ILD); pulmonary 
arterial hypertension (PAH); pulmonary function test (PFT); pulmonary hypertension (PH); 
right heart catheterization (RHC); shrinking lung syndrome (SLS); systematic lupus 
erythematosus (SLE); video-assisted thorascopic surgery (VATS). 
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Common drugs used to treat lupus and are known to cause pulmonary complications 
include Methotrexate and Cyclophosphamide. 
Pulmonary complications related to methotrexate are rare, estimated less than 1%.(Lateef et 
al., 2005) Methotrexate can cause acute, subacute or chronic lung toxicity. It is usually not 
dose dependent but rather idiosyncratic.(Imokawa et al., 2000; Ohosone et al., 1997)  
Subacute pneumonitis is most common and presents with fever, cough and dyspnea. 
Crackles are usually noted on physical examination. It usually presents within the first year 
of starting the drug. If left unrecognized it can progress into pulmonary fibrosis in up to 
10%.  Radiologic findings are not specific. Ground glass opacities and diffuse interstitial 
infiltrates are frequently noted on HRCT. BAL is needed to rule out infections.  Histologic 
findings include varying degree of inflammation and fibrosis. Ill-defined granulomas, and 
increased tissue eosinophils have been observed. ( Malik et al., 1996; Sostman et al., 1976) 
Once diagnosis is made methotrexate needs to be stooped and systemic steroids should be 
started. Prognosis is usually favorable. 
Cyclophosphamide lung toxicity is also idiosyncratic. It can present as early onset or late 
onset pneumonitis.(Malik et al., 1996) Early onset disease appears within the first six months 
of starting treatment. It presents with non-productive cough, fever and dyspnea. (Pego-
Reigosa et al., 2009) CT chest shows bilateral upper lobe predominant ground glass 
opacities. PFT shows reduction in lung volumes and DLCO. BAL is needed to rule out 
infections. Discontinuing the drug along with systemic glucocorticoids usually improve 
symptoms and lung function.  Late onset pneumonitis usually occurs after several years of 
exposure to cyclophosphamide. It is a slowly progressive disease. It presents with 
progressive dyspnea and dry cough. Chest imaging shows interstitial fibrosis affecting the 
upper lobes. This condition usually does not respond to steroids. Lung transplantation is an 
option in appropriate candidates. 
3. Assessment of patients with dyspnea 
3.1 Assessment of patients with chronic dyspnea 
The work up of patients with SLE and chronic dyspnea can be lengthy (Figure 5). Chronic 
dyspnea can be due to a variety of conditions such as interstitial lung disease related to SLE 
or drugs used to treat lupus, pleural disease, pulmonary hypertension, systolic heart failure, 
upper airway disease, obliterative bronchiolitis, shrinking lung syndrome or chronic 
infections. Certain clues on history can be helpful; for example dyspnea increasing in the 
supine position suggests diaphragmatic involvement due to SLS, dyspnea and hoarseness 
suggest upper airway involvement, Dyspnea with pleuritic chest pain suggests pleuritis 
related to SLE.  All patients require CXR, HRCT chest and full PFT. If chest imaging is 
normal with or without isolated reduction in DLCO, then transthoracic echocardiogram 
should be done to assess for the presence of PH. If PH is detected, patients should not be 
labeled to have SLE associated PAH until other causes have been ruled out. So hepatitis B 
and C serology, HIV testing, and V/Q scan should be done. All patients should have right 
heart catheterization to confirm the presence of PH and to rule out left heart disease. If SLE-
PAH is diagnosed PH specific therapies should be started. If chest imaging shows elevation 
of the diaphragms, especially in the presence of normal DLCO adjusted for alveolar volume, 
shrinking lung syndrome should be suspected. Electromyography or transdiaphragmatic 
pressure measurement should be obtained. Either of these two tests may show evidence of 
diaphragmatic weakness. If confirmed, trial of systemic steroids is advised. The presence of 
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pleural effusion on CXR or CT chest suggests pleural disease associated with SLE. The 
pleural fluid should be analyzed to rule out other causes. In situations where chest imaging 
is normal but there is flattening of the inspiratory loop, expiratory loop or both, upper 
airway obstruction needs to be ruled out. Special imaging of the upper airways is 
recommended. If interstitial changes are the predominant features on chest imaging, 
interstitial lung diseases related to lupus or drugs are the main differential. Bronchoscopy 
with BAL should be done to rule out chronic infections. Thoracoscopic lung biopsy is 
helpful to identify the pathological pattern of involvement. 
3.2 Assessment of patients with acute dyspnea 
Several conditions can predispose patients to episodes of acute dyspnea.  Pulmonary 
infections, ALP, DAH, PE, and acute reversible hypoxia are the major culprits. Assessment 
starts with clinical evaluation. (Figure 6) is a proposed algorithm for work up of patients 
with SLE presenting with acute dyspnea.  Most conditions are indistinguishable on clinical 
bases. The presence of hemoptysis should raise the suspicion of DAH or PE. After clinical 
evaluation and stabilization of the patient it is important to get a CXR. If CXR is normal then 
it is more likely that dyspnea is due to either acute reversible hypoxia or PE. V/Q scan will 
differentiate between the two.  V/Q scan will be normal in the former and it will show 
mismatched perfusion defects in the latter. If CXR shows pleural effusion or wedge shaped  
 
 
Fig. 5. Work-up of patients with SLE presenting with chronic dyspnea. 
bronchoalveolar lavage (BAL); chest x-ray (CXR); diffusion capacity for carbon monoxide 
(DLCO); diffusion capacity for carbon monoxide adjusted for alveolar volume (DL/VA); 
high resolution computed tomography (HRCT); interstitial lung disease (ILD); pulmonary 
arterial hypertension (PAH); pulmonary function test (PFT); pulmonary hypertension (PH); 
right heart catheterization (RHC); shrinking lung syndrome (SLS); systematic lupus 
erythematosus (SLE); video-assisted thorascopic surgery (VATS). 
 




Fig. 6. Work-up of patients with SLE presenting with acute dyspnea. 
acute lupus pneumonitis (ALP); bronchoalveolar lavage (BAL); chest x-ray (CXR); computed 
tomography (CT); computed tomography pulmonary angiogram (CTPA); diffuse alveolar 
hemorrhage (DAH); ground-glass opacities (GGO’s); ventilation/perfusion lung scan (V/Q 
Scan) 
* CTPA is done if pulmonary embolism suspected 
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opacities it is important to get CT pulmonary angiogram to look for evidence of PE. If CXR 
shows mainly alveolar infiltrates, CT chest should be considered. In these situations 
bronchoscopy with BAL, with or without TBBX, is highly recommended. The presence of 
hemosiderin laden macrophages confirms the diagnosis of DAH. If TBBX is performed and 
it showed features of DAD, then the likely diagnosis is ALP. BAL should be routinely sent 
for cultures. Empiric antibiotics should be started immediately until the results of cultures 
are known. It is not unusual to start patients on both broad spectrum antibiotics and 
systemic corticosteroids while the work up is being actively pursued. 
4. Conclusion 
SLE can affect many aspects of the pulmonary system. There is significant overlap in the 
clinical presentation of many SLE associated pulmonary conditions. Aggressive work up is 
needed early on to identify the underlying etiology. 
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Approach to Patients with SLE Presenting  
with Neurological Findings 
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Saudi Arabia 
1. Introduction 
The nervous system is commonly involved by SLE. Its involvement classified as primary 
when it is related to the disease process and secondary when it is related to other factors like 
medication side effect or infection. The nervous system involvement by lupus was described 
by Hebra and Kaposi in 1875 who described a patient with lupus and coma (Appenzeller et 
al.,2006). Shortly after Bowen report case of psychosis and mood disturbance (Appenzeller 
et al., 2006).  
The nervous system involvement rang from overt presentation to more subtle finding. In 
spite the advances in SLE diagnosis and managements, the neuropsychiatric syndromes 
remain one of the major causes of morbidity and mortality in SLE patients. Still they remain 
poorly understood and under recognised. The aim of this chapter is provide an overview of 
neurological presentation in SLE patients. 
2. Definition 
As there is wide Varity of different neurological and psychiatric presentations among SLE 
patient, the American college of Rheumatology (ACR) established in 1999 19 different 
neuropsychiatric SLE (NPSLE) syndromes (table-1). Either central or peripheral nervous 
system can be affected by the disease process. Their involvement can be generalized e.g 
headache, cognitive dysfunction or focal e.g. cerebrovascular disease and demyelinating 
syndromes. 
Before attributing any of the neuropsychiatric (NP) manifestation to SLE secondary causes 
should be ruled out. As most of SLE patient are immunocompromised either by the disease 
process or secondary to immunocompressive therapy infection is a common problem in this 
patients. Other secondary causes can be metabolic impairments or complication from 
hypertension e.g posterior reversible leukoencephalopathy. 
3. Epidemiology 
The reported prevalence of NPSLE is varied from 37- 95 %(Muscal & Brey,2010) depending 
on the case definition used and the inclusion criteria. Most of NPSLE affect central nervous 
system(91.6%) and out of those 79% are diffuse in nature and 21% focal(Hanly et 
al.,2008).The peripheral nervous system involvement is much less than CNS involvement.  
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NPSLE Associated with Central Nervous 
System 
NPSL Associated with Peripheral Nervous 
System  
 
‐ Aseptic Meningitis 
‐ Cerebrovascular disease 
‐ Demyelinating syndromes 
‐ Headaches 
‐ Movement Disorders ( Chorea) 
‐ Myelopathy  
‐ Seizure Disorders 
‐ Acute Confusional State 
‐ Anxiety Disorders 
‐ Cognitive Dysfunction 





‐ Acute Inflammatory 
Demyelinating Syndromes ( 
Gulliain –Barre Syndrome) 
‐ Autonomic Neuropathy 
‐ Mononeuropathy, single or 
multiplex 
‐ Myasthenia Gravis 
‐ Cranial Neuropathy 
‐ Plexopathy 
‐ Polyneuropathy  
 
Table 1. Neuropsychiatric Syndromes Associated with SLE 
The most frequently reported PNS involvement is peripheral neuropathy between 2.4to 7% 
(Hanly et al.,2010)(Ainiala et al.,2001). Recently Hanly and his colleague conducted a large 
cohort of SLE patients. They reported around 40.3% of SLE patient had at least one NP event 
and 17.4% had recurrent events (Hanly et al.,2010). The most frequent NP was headache 
47.1% followed by mood disorders in 16.5%, Seizure in this cohort reported in 7.5% and 
cognitive dysfunction in 5.1%.  
In other studies when a mild cognitive impairment and mild mood disorders were included 
higher prevalence of NPSLE is 80-91% (Ainiala et al.,2001)( Brey et al.,2002). When formal 
neuropsychiatric evaluation is used cognitive dysfunction is reported in 80% of the patient 
(Ainiala et al.,2001)( Brey et al.,2002). In 70% of those are classified as mild cognitive 
impairment with impairment of one or two cognitive domains (Ainiala et al.,2001). 
The reported prevalence of cerebrovascular accident range between 4.7 to 15% (Hanly et al., 
2010) (Ainiala et al.,2001). 
The prevalence of other NPSLE syndromes is much less with reported prevalence of 
demyelinating syndrome and movement disorder of 1%. 
CNS manifestations present as an initial feature of SLE in 24% of cases (Joseph et al.,2007). In 
general around 50-60% of NPSLE occurred at disease onset or within the first year after SLE 
onset. 
3.1 Risk factors 
Risk factors associated with CNS involvements are:- 
1. Generalized disease activity. 
2. Prior history or concurrent NPSLE. 
3. Presence of antiphospholipid  antibodies especially for focal CNS lesions and seizure 
(The European League Aganist Rheumatism EULAR, 2010).It was also noted that 
patients with APS who had a history of two or more abortion are six times more likely 
to have CNS events(Karassa et al.,2000). 
In term of SLE disease activity two studies have shown that skin lesions are the most 
frequent lesions associated with CNS disease (EULAR, 2010)( Karassa et al.,2000). Two 
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studies have shown a protective effect of arthritis to CNS disease ((EULAR, 2010). This was 
not consistent in other study were arthritis was a second common manifestation after skin 
disease (Joseph et al.,2007). 
4. Pathogenesis 
The neuropsychatric lupus has different manifestations. As the manifestations can be 
generalized or focal no single pathophysilogical mechanism has been implicated in its 
pathogenesis.   Different mechanisms are thought to affect the nervous system and caused 
the development of NPSLE.  Those different mechanisms include vasculopathy, 
autoantibodie and cytokines. 
4.1 Vasculopathy 
Vascular occlusion is universally reported in autopsy cases in patient with lupus. Although 
vasculitis is thought to be the cause of small vessels disease in lupus patient, its occurrence 
is rare. The most frequent cause is found to be a non inflammatory vasculopathy.  
On pathology multiple microinfracts, cortical atrophy, gross infracts were seen on the brain. 
Microhemorrhages are common in NPSLE . Larger haemorrhages like intracerebral are rare. 
The most common vascular pathology is noninflammatory lesions characterized by 
endothelial proliferation, intimal fibrosis and lymphocytic infiltration. It may associated by 
thrombosis (Ellison et al.,1993). 
The pathogenesis of the vascular injury initially thought to be secondary to immune 
complex deposition but now it thought to be secondary to complement activation (Muscal & 
Brey, 2010). 
4.2 Autoantibodies 
Autoantibodies play a major role for the development of different manifestations of SLE. 
Different antibodies have been reported in association with NPSLE. Among those the most 
frequent antibodies are antiphospholipid (APl) and antiribosomal abs. 
Antiphospholipid antibodies that includes lupus anticoagulant, anti cardiolipin and anti-
beta2 glycoprotein I antibodies are groups of antibodies which target the phospholipid 
binding plasma proteins such as beta 2 glycoprotein I and prothrombin. As they alter the 
expression and secretion of procoagulant on the cell surface they subsequently prompt 
thrombosis.  
Their presences were associated with recurrent thrombosis and fatal losses. Multiple 
neurological presentations are linked to their presence in patient with and without SLE. It 
associated in particular with focal neurological events like stroke. They also have linked to 
seizure, movement disorders, cognitive impairment and myelitis. 
A subset of anti- DNA antibodies were found to react with NR2 glutamate 
receptors.Glutamate is an exiatatory neurotransmitter in the brain. It react with NMDA( N- 
methyl-D-aspartate) receptors which is present throughout the brain tissue. NMDARS that 
containing NR2A andNR2B are more expressed in CA1 region of the hippocampus and the 
amygdale. Excessive stimulation of NMDARS results into excessive influx of calcium into 
the neuronal tissue causing mitochondrial stress and subsequent neuronal death (Aranow et 
al, 2010). 
In animal models anti NR2 receptors antibodies did not cause brain damage in the 
presence of intact blood brain barrier (BBB). When BBB compromised using bacterial 
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general around 50-60% of NPSLE occurred at disease onset or within the first year after SLE 
onset. 
3.1 Risk factors 
Risk factors associated with CNS involvements are:- 
1. Generalized disease activity. 
2. Prior history or concurrent NPSLE. 
3. Presence of antiphospholipid  antibodies especially for focal CNS lesions and seizure 
(The European League Aganist Rheumatism EULAR, 2010).It was also noted that 
patients with APS who had a history of two or more abortion are six times more likely 
to have CNS events(Karassa et al.,2000). 
In term of SLE disease activity two studies have shown that skin lesions are the most 
frequent lesions associated with CNS disease (EULAR, 2010)( Karassa et al.,2000). Two 
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studies have shown a protective effect of arthritis to CNS disease ((EULAR, 2010). This was 
not consistent in other study were arthritis was a second common manifestation after skin 
disease (Joseph et al.,2007). 
4. Pathogenesis 
The neuropsychatric lupus has different manifestations. As the manifestations can be 
generalized or focal no single pathophysilogical mechanism has been implicated in its 
pathogenesis.   Different mechanisms are thought to affect the nervous system and caused 
the development of NPSLE.  Those different mechanisms include vasculopathy, 
autoantibodie and cytokines. 
4.1 Vasculopathy 
Vascular occlusion is universally reported in autopsy cases in patient with lupus. Although 
vasculitis is thought to be the cause of small vessels disease in lupus patient, its occurrence 
is rare. The most frequent cause is found to be a non inflammatory vasculopathy.  
On pathology multiple microinfracts, cortical atrophy, gross infracts were seen on the brain. 
Microhemorrhages are common in NPSLE . Larger haemorrhages like intracerebral are rare. 
The most common vascular pathology is noninflammatory lesions characterized by 
endothelial proliferation, intimal fibrosis and lymphocytic infiltration. It may associated by 
thrombosis (Ellison et al.,1993). 
The pathogenesis of the vascular injury initially thought to be secondary to immune 
complex deposition but now it thought to be secondary to complement activation (Muscal & 
Brey, 2010). 
4.2 Autoantibodies 
Autoantibodies play a major role for the development of different manifestations of SLE. 
Different antibodies have been reported in association with NPSLE. Among those the most 
frequent antibodies are antiphospholipid (APl) and antiribosomal abs. 
Antiphospholipid antibodies that includes lupus anticoagulant, anti cardiolipin and anti-
beta2 glycoprotein I antibodies are groups of antibodies which target the phospholipid 
binding plasma proteins such as beta 2 glycoprotein I and prothrombin. As they alter the 
expression and secretion of procoagulant on the cell surface they subsequently prompt 
thrombosis.  
Their presences were associated with recurrent thrombosis and fatal losses. Multiple 
neurological presentations are linked to their presence in patient with and without SLE. It 
associated in particular with focal neurological events like stroke. They also have linked to 
seizure, movement disorders, cognitive impairment and myelitis. 
A subset of anti- DNA antibodies were found to react with NR2 glutamate 
receptors.Glutamate is an exiatatory neurotransmitter in the brain. It react with NMDA( N- 
methyl-D-aspartate) receptors which is present throughout the brain tissue. NMDARS that 
containing NR2A andNR2B are more expressed in CA1 region of the hippocampus and the 
amygdale. Excessive stimulation of NMDARS results into excessive influx of calcium into 
the neuronal tissue causing mitochondrial stress and subsequent neuronal death (Aranow et 
al, 2010). 
In animal models anti NR2 receptors antibodies did not cause brain damage in the 
presence of intact blood brain barrier (BBB). When BBB compromised using bacterial 
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lipolysaccharide (LPS) damage to hippocampal neurons took place with no evidence of 
inflammation. Those mice performed badly on memory function (Kowal et al,2004). When 
epinephrine is used to compromise the BBB the hippocampus of those mice was normal 
but the antibodies react with neurons of the amygdale. Those mice had impaired fear 
response (Huerta et al.,2006). 
Studies have shown a correlation between the CSF anti- NR2 level with diffuse NPSLE not 
with focal NPSLE (Arinuma et al, 2008) and no relation to serum anti-NR2 level. This may 
implicate intrathecal production of anti-NR2 antibodies or migration of antibodies through 
compromised BBB. 
Anti- ribosomal P antibodies was reported in association with SLE. Their presence was 
linked to lupus related Psychosis and depression. 
4.3 Cytokine effects 
Elevated level of interleukin (IL-1),IL2,  IL-6, IL-8, and interferon gamma (IFNϒ) were found 
in the  CSF of patient with NPSLE (Rhiannon, 2007)(Chandy et al.,2008).  Also elevated level 
of tumour necrosis factor ( TNF) family ligands BAFF (B- cell activating factor of TNF 
family) and APRIL ( a proliferation- inducing ligand) were seen in CSF of SLE patients. 
However the level of APRIL was higher in NPSLE patients when compared to SLE patient 
without NP (Chandy et al,2008). 
The cytokines are thought to be produced locally by the infiltrating immune cells or by the 
glial cells or the neurons. Different cytokines had different effects. Their role in the 
pathogenesis of NPSLE is related to stimulating antibodies productions, effecting 
neurotransmitter release and the release of corticotrophin releasing hormone (CRH). The 
stimulation of glucocorticoid production results in persistent elevation of glucocorticoid that 
plays a role in hippocampal atrophy. 
5. Approach 
A careful evaluation of SLE patients presenting with new neurological symptoms and signs 
is needed to rule out secondary causes before attributing it to SLE. Different secondary 
causes can be a cause for neurological symptoms in SLE patients. The management will be 
different if the presentation related to lupus or to other causes.  
The evaluation of SLE patients presenting with neurological symptoms and signs will be the 
same as non SLE patients. This includes careful clinical, laboratory and imaging studies. The 
diagnosis of NPSLE is a diagnosis by exclusion. No single laboratory or imaging study will 
confirm that the neurological presentation is caused by SLE itself. The presence of other 
lupus related activity could support the diagnosis of NPSLE. 
5.1 History 
Detailed history is mandatory when evaluating lupus patient presenting with new 
neurological presentation. Detailed description of the neurological symptoms is necessary to 
assist for localization and identifying a potential cause for the problem. The onset of the 
symptoms will help identifying problems with acute versus more chronic disorder. The 
severity of the presentation and associated other neurological symptoms will help in 
determine the nature and will assist further regarding the management plan.  The presence 
of fever may suggest the presence of infection. 
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Detailed SLE history regarding time of diagnosis, disease course, previous neurological 
presentation and complications related to disease are particular important. Most of NPSLE 
present at time of generalized disease activity. Patients with prior neurological involvement 
are also at higher risk to have recurrence or development of other neurological disorders. 
Neurological complications can be also developed secondary to other organ involvement by 
lupus for example acute stroke can be a presentation of libman Sacks endocarditis , or in 
other example patient may develop posterior reversible leukoencephalopathy (PRES) 
secondary to hypertension which can be secondary to renal disease in lupus patient. 
Detailed drug history is important as patient may develop complication related to therapy 
like psychosis from steroid therapy. Patient on immunosuppressive treatment are 
immunocompromised so they are at high risk of development of bacterial, viral and fungal 
infections. Subacute neurological symptom in SLE patient may represent JC virus infection 
that causes progressive multifocal leukoencephalopathy (PML). PML is a demylinating 
disease that mainly reported with HIV patients.  Multiple cases of PML also reported in SLE 
patient either on or not on immunosuppressive therapy (Molloy &Calbrese, 2009).The 
possibility of infection should be ruled out before attributing a neurological presentation to 
SLE and starting aggressive immunosuppressive therapy. 
Other medication history might be the cause for the neurological presentation. In particular 
antipsychotic therapy as they can induce movement disorders. The management in that 
instance will necessitate medication changes rather than immunosuppression. 
Detailed family history of same problem or other neurological disorders may point to 
genetically related neurological diagnosis not necessary attributing it to SLE. 
When patient present acutely with symptoms and signs suggestive of acute stroke a quick 
assessment is necessary not to delay thrombolytic therapy if indicated (further discussion 
regarding cerbrovascular disease is discussed below). 
In patient presenting with seizure careful history to characterize the seizure whether it is 
generalized or focal. The presence of focal seizure could represent structural lesion as a 
cause of the seizure. Careful medication and systemic review is mandatory as the seizure 
can be secondary to metabolic abnormalities e.g. uremia or medication induced seizure. The 
presence of other associated neurological symptoms could point to other possible causes of 
seizure. In particular the presence of headache, disturb conscious level could be related to 
posterior reversible leukoencephalopathy, limbic encephalitis or viral encephalitis. The 
presence of other focal neurological deficit can point to structural lesions such as stroke. One 
should exclude other non lupus related causes of seizure such as head trauma or genetically 
determent epilepsy. 
5.2 Examination 
The aim of the examination is to localize the neurological presentation and reach a possible 
diagnosis which will be supported by the laboratory investigations. 
Careful systemic as well neurological examinations are required when dealing with SLE 
patients with neurological presentation. In particularly patient need to checked for fever, 
and had blood pressure measurements. The presence of other area of vascular occlusion 
could point to vascular cause of the neurological events. 
In patient presenting with cognitive problem full neuropsychological assessment should be 
carried out. That will include assessing simple attention, complex attention, memory, 
visuospatial processing, language, reasoning/problem solving, psychomotor speed and 
executive functions. 
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lipolysaccharide (LPS) damage to hippocampal neurons took place with no evidence of 
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implicate intrathecal production of anti-NR2 antibodies or migration of antibodies through 
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The cytokines are thought to be produced locally by the infiltrating immune cells or by the 
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pathogenesis of NPSLE is related to stimulating antibodies productions, effecting 
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stimulation of glucocorticoid production results in persistent elevation of glucocorticoid that 
plays a role in hippocampal atrophy. 
5. Approach 
A careful evaluation of SLE patients presenting with new neurological symptoms and signs 
is needed to rule out secondary causes before attributing it to SLE. Different secondary 
causes can be a cause for neurological symptoms in SLE patients. The management will be 
different if the presentation related to lupus or to other causes.  
The evaluation of SLE patients presenting with neurological symptoms and signs will be the 
same as non SLE patients. This includes careful clinical, laboratory and imaging studies. The 
diagnosis of NPSLE is a diagnosis by exclusion. No single laboratory or imaging study will 
confirm that the neurological presentation is caused by SLE itself. The presence of other 
lupus related activity could support the diagnosis of NPSLE. 
5.1 History 
Detailed history is mandatory when evaluating lupus patient presenting with new 
neurological presentation. Detailed description of the neurological symptoms is necessary to 
assist for localization and identifying a potential cause for the problem. The onset of the 
symptoms will help identifying problems with acute versus more chronic disorder. The 
severity of the presentation and associated other neurological symptoms will help in 
determine the nature and will assist further regarding the management plan.  The presence 
of fever may suggest the presence of infection. 
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Detailed SLE history regarding time of diagnosis, disease course, previous neurological 
presentation and complications related to disease are particular important. Most of NPSLE 
present at time of generalized disease activity. Patients with prior neurological involvement 
are also at higher risk to have recurrence or development of other neurological disorders. 
Neurological complications can be also developed secondary to other organ involvement by 
lupus for example acute stroke can be a presentation of libman Sacks endocarditis , or in 
other example patient may develop posterior reversible leukoencephalopathy (PRES) 
secondary to hypertension which can be secondary to renal disease in lupus patient. 
Detailed drug history is important as patient may develop complication related to therapy 
like psychosis from steroid therapy. Patient on immunosuppressive treatment are 
immunocompromised so they are at high risk of development of bacterial, viral and fungal 
infections. Subacute neurological symptom in SLE patient may represent JC virus infection 
that causes progressive multifocal leukoencephalopathy (PML). PML is a demylinating 
disease that mainly reported with HIV patients.  Multiple cases of PML also reported in SLE 
patient either on or not on immunosuppressive therapy (Molloy &Calbrese, 2009).The 
possibility of infection should be ruled out before attributing a neurological presentation to 
SLE and starting aggressive immunosuppressive therapy. 
Other medication history might be the cause for the neurological presentation. In particular 
antipsychotic therapy as they can induce movement disorders. The management in that 
instance will necessitate medication changes rather than immunosuppression. 
Detailed family history of same problem or other neurological disorders may point to 
genetically related neurological diagnosis not necessary attributing it to SLE. 
When patient present acutely with symptoms and signs suggestive of acute stroke a quick 
assessment is necessary not to delay thrombolytic therapy if indicated (further discussion 
regarding cerbrovascular disease is discussed below). 
In patient presenting with seizure careful history to characterize the seizure whether it is 
generalized or focal. The presence of focal seizure could represent structural lesion as a 
cause of the seizure. Careful medication and systemic review is mandatory as the seizure 
can be secondary to metabolic abnormalities e.g. uremia or medication induced seizure. The 
presence of other associated neurological symptoms could point to other possible causes of 
seizure. In particular the presence of headache, disturb conscious level could be related to 
posterior reversible leukoencephalopathy, limbic encephalitis or viral encephalitis. The 
presence of other focal neurological deficit can point to structural lesions such as stroke. One 
should exclude other non lupus related causes of seizure such as head trauma or genetically 
determent epilepsy. 
5.2 Examination 
The aim of the examination is to localize the neurological presentation and reach a possible 
diagnosis which will be supported by the laboratory investigations. 
Careful systemic as well neurological examinations are required when dealing with SLE 
patients with neurological presentation. In particularly patient need to checked for fever, 
and had blood pressure measurements. The presence of other area of vascular occlusion 
could point to vascular cause of the neurological events. 
In patient presenting with cognitive problem full neuropsychological assessment should be 
carried out. That will include assessing simple attention, complex attention, memory, 
visuospatial processing, language, reasoning/problem solving, psychomotor speed and 
executive functions. 
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5.3 Laboratory examination 
Full laboratory assessment to rule out infection and metabolic abnormality that could be the 
cause for the neurological events. That will include complete blood count, electrolytes, 
kidney and liver function test.   
Cerebrospinal fluid assessment is necessary in certain cases to rule out infection or other 
unrelated condition. In patient with subacute presentation and demylination on imaging the 
CSF should be sent for JC virus PCR. The CSF level of autoantibodies and inflammatory 
mediators are not recommended now as it still a research interest. 
5.4 Supplementary tests 
EEG is indicated in patient presenting with seizure or in patient with acute confusional 
state. For patient with seizure the EEG will help in determine the subset of patients who are 
at high risk of seizure recurrence. The most frequent EEG abnormalities reported in SLE 
patient is bitemporal slowing in 65% of patients ( Lampropoulos et al., 2005). 
Nerve conduction study and electromyography is indicated in patient presenting with 
peripheral nervous system related complaints.  
5.5 Imaging 
In acute setting in patient presenting with acute onset neurological events computerized 
tomography  (CT) brain is the imaging modality of choice to rule out haemorrhage. It is also 
an easily accessible and widely available. The use of CT brain initially will be important to 
identify a subset of patients who may need thrombolytic therapy.  
MRI (magnetic resonance imaging)is a preferred imaging modality to evaluate lupus 
patients with neurological symptoms. It is more sensitive than CT in detecting anatomical 
abnormalities and determines the extent of disease process. The most frequent abnormalities 
in MRI is hyperintense white matter lesions which is seen in 70% of patients (Appenzeller et 
al.,2007).Their presence have been linked to the presence of Apl . Cerebral atrophy is seen in 
6-12% in SLE patients (Huizinga et al.,2001)(Appenzeller et al.,2005-2007). 
Other advanced imaging technique may be of value in assessing patients with NPSLE 
although there clinical uses are not widely available. Those includes MTR ( magnetization 
transfer ratio), diffusion weighted images, MRS (magnetic resonance spectroscopy), 
functional MRI and single photon emission computed tomography.  
 
Investigation  
Laboratory                                   CBC, Electrolytes, Kidney and liver function 
CSF                                                WBC, Glucose, protein,  
                                                       Gram stain and culture 
                                                       Viral PCR 
Imaging                                        CT brain 
                                                       MRI brain and spinal cord 
Electrophysiology                       EEG 
                                                       EMG 
CBC, complete blood count; WBC, white blood cell; CT computerized tomography; MRI , magnetic 
resonance imaging; EEG, electroencephalogram 
Table 2. Recommended investigation in SLE patient with neurological presentation 
 




Once the diagnosis of NPSLE is confirmed the treatment will include treatment of potential 
aggravating factors, symptomatic treatment for the events and more specific treatment 
related to SLE itself. 
In some condition symptomatic treatment will be required first before specific therapy is 
indicated. For example in patient presenting with seizure after excluding secondary causes 
starting antiepileptic is required before the decision on specific treatment is made(Hanly & 
Harrison, 2005). 
The severity and the nature of neurological events will also play a role in the decision on 
treatment. For example patient with non serious headache will require only symptomatic 
treatment. 
In the presence of severe neurological disease the Europan League Aganist Rheumatism ( 
EULAR, 2010) recommends the use corticosteroid alone or with cyclophosphamide.  A 
Cochrane review of cyclophosphamid versus methylprednisolone in treatment of NPSLE 
did not find a randomised clinical trial comparing the two.  
When patient failed to respond to conventional treatment or in the presence of severe 
disease multiple reports suggested the addition of other treatment modalities can be 
effective. Those include plasma exchange, rituximab or intravenous immunoglobulin. 
The combination of the treatment modalities ( cyclophosmaide/corticosteroid/ plasma 
exchange(Bartolucci et al.,2007) or plasmapheresis alone or with cyclophosphamide 
(Neuwelt,2003)) was evaluated in small series of refractory disease. Results from those 
showed favourable outcome with combination modalities. 
Rituximab is an anti-CD20 antibody that directly target B cells. Rituximab was studied in 
refractory cases of NPSLE and showed a rapid improvement of clinical as well radiological 
finding in those patients (Takunaga et al.,2006). 
In the presence of thrombotic disease the management will depend whether patient had 
arterial versus venous thrombosis and the presence of antiphospholipid.  Anticoagulation is 
recommended for venous thrombosis as well in the presence of arterial thrombosis with 
antiphospholipid antibodies.  In absence of antiphospholipid antibodies and the presence of 
arterial thrombosis careful evaluation and management for secondary risk factors with the 
use of antiplatelets are indicated. 
7. Common neurological disorders associated with SLE 
7.1 Headache 
Headache is one of the most commonly reported neurological symptoms associated with 
SLE. There is no specific type of headache found to have increase prevalence in patient with 
SLE (Mitsikostas,2004). 
When patient with SLE patient present with acute headache, special attention is 
warranted to rule out infection, aseptic meningitis and venous sinus thrombosis. On 
examination special attention is required looking for fever, meningeal signs and 
examination for the fundi to rule papilledema. In the presence for focal finding, 
papilldema or altered mental status brain imaging is required. Brain MRI with venogram 
is preferred to rule out venous sinus thrombosis. In presence of fever or signs of infection 
CSF examination is mandatory. 
No specific treatment is required for nonspecific headache. 
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5.3 Laboratory examination 
Full laboratory assessment to rule out infection and metabolic abnormality that could be the 
cause for the neurological events. That will include complete blood count, electrolytes, 
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Once the diagnosis of NPSLE is confirmed the treatment will include treatment of potential 
aggravating factors, symptomatic treatment for the events and more specific treatment 
related to SLE itself. 
In some condition symptomatic treatment will be required first before specific therapy is 
indicated. For example in patient presenting with seizure after excluding secondary causes 
starting antiepileptic is required before the decision on specific treatment is made(Hanly & 
Harrison, 2005). 
The severity and the nature of neurological events will also play a role in the decision on 
treatment. For example patient with non serious headache will require only symptomatic 
treatment. 
In the presence of severe neurological disease the Europan League Aganist Rheumatism ( 
EULAR, 2010) recommends the use corticosteroid alone or with cyclophosphamide.  A 
Cochrane review of cyclophosphamid versus methylprednisolone in treatment of NPSLE 
did not find a randomised clinical trial comparing the two.  
When patient failed to respond to conventional treatment or in the presence of severe 
disease multiple reports suggested the addition of other treatment modalities can be 
effective. Those include plasma exchange, rituximab or intravenous immunoglobulin. 
The combination of the treatment modalities ( cyclophosmaide/corticosteroid/ plasma 
exchange(Bartolucci et al.,2007) or plasmapheresis alone or with cyclophosphamide 
(Neuwelt,2003)) was evaluated in small series of refractory disease. Results from those 
showed favourable outcome with combination modalities. 
Rituximab is an anti-CD20 antibody that directly target B cells. Rituximab was studied in 
refractory cases of NPSLE and showed a rapid improvement of clinical as well radiological 
finding in those patients (Takunaga et al.,2006). 
In the presence of thrombotic disease the management will depend whether patient had 
arterial versus venous thrombosis and the presence of antiphospholipid.  Anticoagulation is 
recommended for venous thrombosis as well in the presence of arterial thrombosis with 
antiphospholipid antibodies.  In absence of antiphospholipid antibodies and the presence of 
arterial thrombosis careful evaluation and management for secondary risk factors with the 
use of antiplatelets are indicated. 
7. Common neurological disorders associated with SLE 
7.1 Headache 
Headache is one of the most commonly reported neurological symptoms associated with 
SLE. There is no specific type of headache found to have increase prevalence in patient with 
SLE (Mitsikostas,2004). 
When patient with SLE patient present with acute headache, special attention is 
warranted to rule out infection, aseptic meningitis and venous sinus thrombosis. On 
examination special attention is required looking for fever, meningeal signs and 
examination for the fundi to rule papilledema. In the presence for focal finding, 
papilldema or altered mental status brain imaging is required. Brain MRI with venogram 
is preferred to rule out venous sinus thrombosis. In presence of fever or signs of infection 
CSF examination is mandatory. 
No specific treatment is required for nonspecific headache. 
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7.2 Cognitive dysfunction 
It is one of the most commonly reported NPSLE syndromes. Most of the patient had mild to 
moderate impairment, only around 3-5% had severe impairment ( EULAR, 2010).  The most 
commonly reported abnormality is overall slowing, decrease memory, impaired working 
memory and executive dysfunction (Hanly,2005). 
Different report linked cognitive impairment to the presence of Apl (McLurin et al.,2005)( 
Denburg et al, 1997).  It is also reported in patient who suffered from stroke and with Apl 
microinfracts although the pattern is different between the two. Cognitive dysfunction 
from stroke develops acutely and remains the same in contrast to those with microinfract 
as it shows stepwise deterioration. Different studies have showed a contradicting results 
regarding the association between global disease activity and the presence of cognitive 
impairment (Kozora et al.,1996)(Hay et al.,1992)(Carbotte etal.,1995). Some of the studies 
found an association and other did not found any association.  The use of glucocorticoid 
associated with cognitive impairment in middle age patients irrespective of disease 
activity (McLurin et al.,2005). The effect of prednisone use was not significant for young 
and old patients. 
Other causes can alter the cognitive function. Of those the development of mood disorders 
are particularly important. It is very well known that depression worsen cognitive function 
and even cause a pseudodementia. Patients with SLE also under psychological stress from 
the disease itself or from medications and that also can alter cognitive function even in 
absence of psychiatric disease (Hanly,2005). 
Formal neuropsychological testing is required to diagnose cognitive dysfunction. The main 
limitation of formal neuropsychological testing is time consuming and it need to be 
administered by an expert.  The minimental test is not a good tool for screening for cognitive 
impairment. 
MRI is indicated if the patient is less than 60 years, rapid and unexplained moderate to 
severe impairment, recent and significant head trauma, presence of other neurological 
symptoms or signs and the development of it in the setting of immunosuppressive therapy 
or antiplatelets (EULAR, 2010). 
Patient should be screened and treated for potential precipitating factors such as metabolic 
and endocrine abnormalities. Associated psychiatric disorders should be treated. Control of 
cardiovascular risk factors also is recommended. Mclaurine in 2005 reported a beneficial 
effect of regular aspirin use on cognitive function in elderly patient with other vascular risk 
factors particularly in diabetics (McLurin et al.,2005). 
The use of glucocorticoid with or without immunosuppressive will be considered in the 
presence of SLE disease activity or other NPSLE events. 
Memantine is a drug used to treat dementia.  One randomized clinical trial looked at the use 
of memantine to treat patient with SLE and cognitive impairment. No significant 
improvement in cognitive function in the treated group. At current the use of memantine for 
SLE patient with cognitive impairment is not recommended. Further clinical trial is needed 
(Petri et al.,2011). 
7.3 Cerbrovascular disease 
SLE patients are at high risk of developing vascular complications. Among those are stroke 
and transit ischemic attacks.  Multiple causes can lead to strokes in SLE patients.  The most 
frequent cause is atherosclerotic diseases. Other rare causes include embolic strokes from 
libman Sacks endocarditis and cerebral vasculitis. 
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In study of carotid ultrasound in asymptomatic SLE patients carotid plaques were seen in 
25-40% of patients. Different risk factors were associated with the development of strokes in 
SLE patients. Those includes high disease activity, moderate to high titres of 
antiphospholipid antibodies, heart valve disease, hypertension, age and smoking (EULAR, 
2010) (Toloza et al,2004)(Bessantbet al.,2004)(Futrell & Millikan,1988). 
Evaluation of stroke/TIA patient will be the same as non SLE patient. Thrombolytic therapy 
can be given unless there are contraindications. Patient should be screened for 
cardiovascular risk factors and have aggressive measures to control them.  Further 
managements will include the use of antiplatelet and carotid endartectomy if indicated. 
Patients who fill full the criteria of antiphospholipid syndromes chronic anticoagulant 
therapy is indicated with a target INR of 2-3 (EULAR,2010)(Crowther et al,2003)(Finazzi et 
al.,2005). 
7.4 Seizure 
Seizure in SLE patient can be attributed to the disease activity or it could be related to 
secondary causes. The secondary causes of seizure in SLE patients are:- infection, 
electrolytes abnormalities, uremia, hypertension, medication side effect or hypoxia. It also 
can be a presentation of unrelated condition such as brain tumours. 
The reported prevalence of seizure is between 7.5% to 14% ( Hanly et al.,2010)(Mikdashi et 
al.,2005)(Appenzeller et al.,2004). Seizure present at disease onset in 31.7% of patients 
(Mucal & Brey,2010), and most frequently occurred within 5 years from diagnosis. Most of 
the patient 88.3% had single events and around 11.7% had epilepsy.  The most frequently 
reported seizure type is generalized tonic clonic seizure followed by complex partial seizure. 
Seizure can present as the only NP syndrome or accompany other neurological events 
mainly ischemic or hemorrhagic strokes and psychosis. 
Multiple studies confirmed the relation between seizure and the presence of Apl(Mikdashi 
et al.,2005)( Appenzeller et al.,2004 )(Gibbs & Husain,2002)(Herranza et al.,1994)(Liou et 
al.,1996). Also the presence of Apl were associated with shorter time to seizure occurrence 
(Andrade et al.,2008). Seizure occurrence is related to high diasese activity, severe organ 
damage in particular nephritis and the presence of Apl. Factors associated with epilepsy are 
the same as those associated with seizure. Patients who had epilepsy are more likely to be 
men (Mikdashi et al.,2005) and more likely to have abnormal MRI and EEG. 
The most frequent abnormality reported in brain MRI in patient with seizure is global 
atrophy and the presence of multiple subcortical hyperintense lesions.  The most frequent 
EEG finding is diffuse slowing. The presence of interictal epileptic activity is associated with 
high recurrence rate of epileptic seizure. 
As most of the patients will have only one seizure, treatment with antiepileptic is not 
recommended. The patient should be investigated with EEG, brain MRI and have Apl 
antibody screening. Patient who had positive test for Apl should be monitored carefully as 
they have high recurrence rate. In the presence of other SLE activity or flare treatment with 
glucocorticoid with or without immunosuppressive is recommended (EULAR, 2010). 
7.5 Acute confusional state 
It is a condition characterized by acute onset of altered mental state with decrease attention. 
A carful exclusion of secondary causes such as metabolic, infection and side effect of 
medications is mandatory. CSF examination is required to exclude infection. Brain imaging 
is indicated to rule out structural lesions. EEG is also indicated to rule out seizure disorders. 
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7.2 Cognitive dysfunction 
It is one of the most commonly reported NPSLE syndromes. Most of the patient had mild to 
moderate impairment, only around 3-5% had severe impairment ( EULAR, 2010).  The most 
commonly reported abnormality is overall slowing, decrease memory, impaired working 
memory and executive dysfunction (Hanly,2005). 
Different report linked cognitive impairment to the presence of Apl (McLurin et al.,2005)( 
Denburg et al, 1997).  It is also reported in patient who suffered from stroke and with Apl 
microinfracts although the pattern is different between the two. Cognitive dysfunction 
from stroke develops acutely and remains the same in contrast to those with microinfract 
as it shows stepwise deterioration. Different studies have showed a contradicting results 
regarding the association between global disease activity and the presence of cognitive 
impairment (Kozora et al.,1996)(Hay et al.,1992)(Carbotte etal.,1995). Some of the studies 
found an association and other did not found any association.  The use of glucocorticoid 
associated with cognitive impairment in middle age patients irrespective of disease 
activity (McLurin et al.,2005). The effect of prednisone use was not significant for young 
and old patients. 
Other causes can alter the cognitive function. Of those the development of mood disorders 
are particularly important. It is very well known that depression worsen cognitive function 
and even cause a pseudodementia. Patients with SLE also under psychological stress from 
the disease itself or from medications and that also can alter cognitive function even in 
absence of psychiatric disease (Hanly,2005). 
Formal neuropsychological testing is required to diagnose cognitive dysfunction. The main 
limitation of formal neuropsychological testing is time consuming and it need to be 
administered by an expert.  The minimental test is not a good tool for screening for cognitive 
impairment. 
MRI is indicated if the patient is less than 60 years, rapid and unexplained moderate to 
severe impairment, recent and significant head trauma, presence of other neurological 
symptoms or signs and the development of it in the setting of immunosuppressive therapy 
or antiplatelets (EULAR, 2010). 
Patient should be screened and treated for potential precipitating factors such as metabolic 
and endocrine abnormalities. Associated psychiatric disorders should be treated. Control of 
cardiovascular risk factors also is recommended. Mclaurine in 2005 reported a beneficial 
effect of regular aspirin use on cognitive function in elderly patient with other vascular risk 
factors particularly in diabetics (McLurin et al.,2005). 
The use of glucocorticoid with or without immunosuppressive will be considered in the 
presence of SLE disease activity or other NPSLE events. 
Memantine is a drug used to treat dementia.  One randomized clinical trial looked at the use 
of memantine to treat patient with SLE and cognitive impairment. No significant 
improvement in cognitive function in the treated group. At current the use of memantine for 
SLE patient with cognitive impairment is not recommended. Further clinical trial is needed 
(Petri et al.,2011). 
7.3 Cerbrovascular disease 
SLE patients are at high risk of developing vascular complications. Among those are stroke 
and transit ischemic attacks.  Multiple causes can lead to strokes in SLE patients.  The most 
frequent cause is atherosclerotic diseases. Other rare causes include embolic strokes from 
libman Sacks endocarditis and cerebral vasculitis. 
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In study of carotid ultrasound in asymptomatic SLE patients carotid plaques were seen in 
25-40% of patients. Different risk factors were associated with the development of strokes in 
SLE patients. Those includes high disease activity, moderate to high titres of 
antiphospholipid antibodies, heart valve disease, hypertension, age and smoking (EULAR, 
2010) (Toloza et al,2004)(Bessantbet al.,2004)(Futrell & Millikan,1988). 
Evaluation of stroke/TIA patient will be the same as non SLE patient. Thrombolytic therapy 
can be given unless there are contraindications. Patient should be screened for 
cardiovascular risk factors and have aggressive measures to control them.  Further 
managements will include the use of antiplatelet and carotid endartectomy if indicated. 
Patients who fill full the criteria of antiphospholipid syndromes chronic anticoagulant 
therapy is indicated with a target INR of 2-3 (EULAR,2010)(Crowther et al,2003)(Finazzi et 
al.,2005). 
7.4 Seizure 
Seizure in SLE patient can be attributed to the disease activity or it could be related to 
secondary causes. The secondary causes of seizure in SLE patients are:- infection, 
electrolytes abnormalities, uremia, hypertension, medication side effect or hypoxia. It also 
can be a presentation of unrelated condition such as brain tumours. 
The reported prevalence of seizure is between 7.5% to 14% ( Hanly et al.,2010)(Mikdashi et 
al.,2005)(Appenzeller et al.,2004). Seizure present at disease onset in 31.7% of patients 
(Mucal & Brey,2010), and most frequently occurred within 5 years from diagnosis. Most of 
the patient 88.3% had single events and around 11.7% had epilepsy.  The most frequently 
reported seizure type is generalized tonic clonic seizure followed by complex partial seizure. 
Seizure can present as the only NP syndrome or accompany other neurological events 
mainly ischemic or hemorrhagic strokes and psychosis. 
Multiple studies confirmed the relation between seizure and the presence of Apl(Mikdashi 
et al.,2005)( Appenzeller et al.,2004 )(Gibbs & Husain,2002)(Herranza et al.,1994)(Liou et 
al.,1996). Also the presence of Apl were associated with shorter time to seizure occurrence 
(Andrade et al.,2008). Seizure occurrence is related to high diasese activity, severe organ 
damage in particular nephritis and the presence of Apl. Factors associated with epilepsy are 
the same as those associated with seizure. Patients who had epilepsy are more likely to be 
men (Mikdashi et al.,2005) and more likely to have abnormal MRI and EEG. 
The most frequent abnormality reported in brain MRI in patient with seizure is global 
atrophy and the presence of multiple subcortical hyperintense lesions.  The most frequent 
EEG finding is diffuse slowing. The presence of interictal epileptic activity is associated with 
high recurrence rate of epileptic seizure. 
As most of the patients will have only one seizure, treatment with antiepileptic is not 
recommended. The patient should be investigated with EEG, brain MRI and have Apl 
antibody screening. Patient who had positive test for Apl should be monitored carefully as 
they have high recurrence rate. In the presence of other SLE activity or flare treatment with 
glucocorticoid with or without immunosuppressive is recommended (EULAR, 2010). 
7.5 Acute confusional state 
It is a condition characterized by acute onset of altered mental state with decrease attention. 
A carful exclusion of secondary causes such as metabolic, infection and side effect of 
medications is mandatory. CSF examination is required to exclude infection. Brain imaging 
is indicated to rule out structural lesions. EEG is also indicated to rule out seizure disorders. 
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Treatment includes symptomatic treatment with antipsychotics to control agitation, 
glucocorticoid and immunosuppressive agents. 
7.6 Myelopathy 
Patient with SLE may present with symptoms and signs of spinal cord dysfunction which 
may indicate the presence of myelitis.  Myelitis is less commonly reported than other 
NPSLE syndromes ( 1-3% of patient) (Lukjanowicz & Brzosko,2009). Most commonly 
patient will present with acute transverse myelitis and less commonly will have 
longitudinal myelitis. 
Acute transverse myelitis involves less than 4 segments of the spinal cord in contrast to 
longitudinal myelitis which involve more than 4 segments of the cord. The thoracic cord is 
the most commonly affected followed by the cervical cord (D’Cruz et al.,2004). 
Around 73% of SLE patient presenting with myelitis were positive for apl (D’Cruz et 
al.,2004). 
Patient with myeliitis present acutely with motor weakness and sensory symptoms. The 
extent of the symptoms depends on the level of the lesion and the extent of the 
inflammatory changes. Bladder and bowel dysfunction is seen in all patients with myelitis.  
Lupus myelitis is usually developed in the first 5 years after disease onset (Kovacs et 
al.,2000)(Chan & Boey, 1996). One third of the cases have another major NPSLE 
(EULAR,2010). In 21-48% of patients will have associated optic neuritis (Kovacs et al.,2000) 
(Chan & Boey, 1996) . The recurrence rate for myelitis is seen in 21-55% of patients (Kovacs 
et al.,2000)( Chan & Boey, 1996)(Lehnhardt et al.,2006). 
When patient with SLE present with feature of myleopathy a careful exclusion of other 
causes of myeolpathy is necessary before attributing the presentation to SLE. A contrast 
enhanced MRI of spinal cord is mandatory to rule out mass lesions as a cause for 
myelopathy. The most frequently reported abnoramlites is T2 hyperintensities which 
become more pronounced after contrast (Lukjanowicz &Brzosko,2009)(Provenzale et 
al.,1994)(Boumpas et al.,1990)(Salmaggi et al,1994). In a group of patients the intial MRI can 
be normal especially if it was done early. If the initial MRI is normal repeat study in 2-7 days 
after onset is recommended (Lukjanowicz &Brzosko,2009).  Brain MRI is indicated when 
there is associated neurological symptoms and to help differentiating it from multiple 
sclerosis. 
Cerbrospinal fluid examination is recommended to rule out infectious aetiology 
(EULAR,2010). In 50-70% of cases mild CSF abnormalities are seen including mild 
lymphocytosis and elevated protein with normal glucose. 
An inflammatory CSF with granulocytes pleocytosis, elevated protein and low glucose is 
reported with lupus myelitis especially with longitudinal myelitis. In the presence of this 
finding a carful exclusion of infectious cause is mandatory. 
In the presence of longitudinal myelitis and associated optic neuritis serum should be send 
for anti neuromyelitis antibodies( anti- NMO IgG) to rule out the presence of neuromyelitis 
optica. Anti NMO IgG is a highly sensitive and specific antibody that target aquaporin 4 the 
main water channel in the CNS. 
An aggressive treatment with immunosuppressive is recommended in a setting of ATM.  
The presence of inflammatory CSF should not delay the start of immunosuppressive. In 
that case a combined treatment of antimicrobial with immunosuppressive is 
recommended waiting for the culture results. Antimicrobial should be discontinued once 
infection is ruled out.  
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Treatment with intravenous steroid should be initiated followed by cyclophosphamide with 
oral steroid. 
The treatment should be initiated early in the disease course.  
Plasmapheresis has been used with immunosuppressive medication in severe cases in 
particular in patient with of longitudinal myelitis ((D’Cruz et al.,2004). Although an earlier 
reports by Kovacs showed patients who had combined treatment of steroid, 
immunosuppressive and plasmapheresis did worse than patient who had only steroid with 
or without imunnosupressive ( Kovacs et al.,2000). This is may be because patients who had 
aggressive treatments with three modalities had higher disease activity at the onset of 
myelitis. 
In the presence of Apl anticoagulant therapy is recommended with the immunosuppressive 
therapy. Patients with apl and Transverse myelitis who had combination therapy of 
immunosuppressive and anticoagulant have good functional outcome (D’Cruz et al.,2004 ). 
The functional outcome is good for patient who had early treatment. The presence of 
longitudinal transverse myelitis is associated with poor functional prognosis 
(Gertner,2007)(Kimura et al.,2002). 
7.7 Movement’s disorders 
The most frequently reported movement disorder with SLE patient is chorea. It has been 
linked to antiphospholipid antibodies. Other causes of chorea such as hereditary, metabolic, 
endocrine causes should be excluded. Brain imaging is indicated to rule out structural 
causes in the presence of focal neurological signs.  
Patient need to be treated symptomatically with dopamine antagonist and in severe cases 
the use of glucocoticoid and immunosuppressive therapy is recommended. In the presence 
of antiphospholipid antibodies patient need to be on antiplatelets or anticoagulants 
depending on the presence of other APS related symptoms. 
Parkinsonism is also reported in association with SLE in multiple cases. Usually it is 
associated with severe multisystem CNS involvements. The good response of the reported 
cases to immunosuppressive therapy suggests that it is a manifestation of the disease not a 
coincidence of Parkinson disease and SLE. 
7.8 Peripheral nervous system Involvements 
Peripheral neuropathy is the most frequent reported peripheral nervous system ( PNS ) 
involvement with SLE. The most frequent type is sensory neuropathy followed by 
sensorimotor neuropathy then pure motor neuropathy (Goransson et al.,2006).A subset of 
SLE patients may present with sensory symptoms and still have normal NCS. This is 
because the NCS evaluate the large myelinated fibers and the presence of normal study does 
not rule out small fiber neuropathy. In studies when symptomatic patients with negative 
NCS had skin biopsy an evidence of small fiber nruropathy was found ( Goransson et 
al.,2006)(Omdal et al.,2002). This indicates that small fiber neuropathy is the cause of the 
symptomatic patients with normal NCS. Managements of peripheral neuropathy include 
symptomatic treatments for neuropathic pain as well glucocorticoid with or without 
immunosuppressive therapy depending on the severity of the disease.  In the presence of 
severe cases, or failure of conventional treatments other modalities such as plasmaphersis, 
intravenous immunoglobulin and rituximab can be used. 
Other PNS involvements by SLE are much less. Patient may present with mononeuritis 
multiplex, acute demylenating polyradiculopathy, chronic demylinating polyradiculopathy 
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Treatment includes symptomatic treatment with antipsychotics to control agitation, 
glucocorticoid and immunosuppressive agents. 
7.6 Myelopathy 
Patient with SLE may present with symptoms and signs of spinal cord dysfunction which 
may indicate the presence of myelitis.  Myelitis is less commonly reported than other 
NPSLE syndromes ( 1-3% of patient) (Lukjanowicz & Brzosko,2009). Most commonly 
patient will present with acute transverse myelitis and less commonly will have 
longitudinal myelitis. 
Acute transverse myelitis involves less than 4 segments of the spinal cord in contrast to 
longitudinal myelitis which involve more than 4 segments of the cord. The thoracic cord is 
the most commonly affected followed by the cervical cord (D’Cruz et al.,2004). 
Around 73% of SLE patient presenting with myelitis were positive for apl (D’Cruz et 
al.,2004). 
Patient with myeliitis present acutely with motor weakness and sensory symptoms. The 
extent of the symptoms depends on the level of the lesion and the extent of the 
inflammatory changes. Bladder and bowel dysfunction is seen in all patients with myelitis.  
Lupus myelitis is usually developed in the first 5 years after disease onset (Kovacs et 
al.,2000)(Chan & Boey, 1996). One third of the cases have another major NPSLE 
(EULAR,2010). In 21-48% of patients will have associated optic neuritis (Kovacs et al.,2000) 
(Chan & Boey, 1996) . The recurrence rate for myelitis is seen in 21-55% of patients (Kovacs 
et al.,2000)( Chan & Boey, 1996)(Lehnhardt et al.,2006). 
When patient with SLE present with feature of myleopathy a careful exclusion of other 
causes of myeolpathy is necessary before attributing the presentation to SLE. A contrast 
enhanced MRI of spinal cord is mandatory to rule out mass lesions as a cause for 
myelopathy. The most frequently reported abnoramlites is T2 hyperintensities which 
become more pronounced after contrast (Lukjanowicz &Brzosko,2009)(Provenzale et 
al.,1994)(Boumpas et al.,1990)(Salmaggi et al,1994). In a group of patients the intial MRI can 
be normal especially if it was done early. If the initial MRI is normal repeat study in 2-7 days 
after onset is recommended (Lukjanowicz &Brzosko,2009).  Brain MRI is indicated when 
there is associated neurological symptoms and to help differentiating it from multiple 
sclerosis. 
Cerbrospinal fluid examination is recommended to rule out infectious aetiology 
(EULAR,2010). In 50-70% of cases mild CSF abnormalities are seen including mild 
lymphocytosis and elevated protein with normal glucose. 
An inflammatory CSF with granulocytes pleocytosis, elevated protein and low glucose is 
reported with lupus myelitis especially with longitudinal myelitis. In the presence of this 
finding a carful exclusion of infectious cause is mandatory. 
In the presence of longitudinal myelitis and associated optic neuritis serum should be send 
for anti neuromyelitis antibodies( anti- NMO IgG) to rule out the presence of neuromyelitis 
optica. Anti NMO IgG is a highly sensitive and specific antibody that target aquaporin 4 the 
main water channel in the CNS. 
An aggressive treatment with immunosuppressive is recommended in a setting of ATM.  
The presence of inflammatory CSF should not delay the start of immunosuppressive. In 
that case a combined treatment of antimicrobial with immunosuppressive is 
recommended waiting for the culture results. Antimicrobial should be discontinued once 
infection is ruled out.  
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Treatment with intravenous steroid should be initiated followed by cyclophosphamide with 
oral steroid. 
The treatment should be initiated early in the disease course.  
Plasmapheresis has been used with immunosuppressive medication in severe cases in 
particular in patient with of longitudinal myelitis ((D’Cruz et al.,2004). Although an earlier 
reports by Kovacs showed patients who had combined treatment of steroid, 
immunosuppressive and plasmapheresis did worse than patient who had only steroid with 
or without imunnosupressive ( Kovacs et al.,2000). This is may be because patients who had 
aggressive treatments with three modalities had higher disease activity at the onset of 
myelitis. 
In the presence of Apl anticoagulant therapy is recommended with the immunosuppressive 
therapy. Patients with apl and Transverse myelitis who had combination therapy of 
immunosuppressive and anticoagulant have good functional outcome (D’Cruz et al.,2004 ). 
The functional outcome is good for patient who had early treatment. The presence of 
longitudinal transverse myelitis is associated with poor functional prognosis 
(Gertner,2007)(Kimura et al.,2002). 
7.7 Movement’s disorders 
The most frequently reported movement disorder with SLE patient is chorea. It has been 
linked to antiphospholipid antibodies. Other causes of chorea such as hereditary, metabolic, 
endocrine causes should be excluded. Brain imaging is indicated to rule out structural 
causes in the presence of focal neurological signs.  
Patient need to be treated symptomatically with dopamine antagonist and in severe cases 
the use of glucocoticoid and immunosuppressive therapy is recommended. In the presence 
of antiphospholipid antibodies patient need to be on antiplatelets or anticoagulants 
depending on the presence of other APS related symptoms. 
Parkinsonism is also reported in association with SLE in multiple cases. Usually it is 
associated with severe multisystem CNS involvements. The good response of the reported 
cases to immunosuppressive therapy suggests that it is a manifestation of the disease not a 
coincidence of Parkinson disease and SLE. 
7.8 Peripheral nervous system Involvements 
Peripheral neuropathy is the most frequent reported peripheral nervous system ( PNS ) 
involvement with SLE. The most frequent type is sensory neuropathy followed by 
sensorimotor neuropathy then pure motor neuropathy (Goransson et al.,2006).A subset of 
SLE patients may present with sensory symptoms and still have normal NCS. This is 
because the NCS evaluate the large myelinated fibers and the presence of normal study does 
not rule out small fiber neuropathy. In studies when symptomatic patients with negative 
NCS had skin biopsy an evidence of small fiber nruropathy was found ( Goransson et 
al.,2006)(Omdal et al.,2002). This indicates that small fiber neuropathy is the cause of the 
symptomatic patients with normal NCS. Managements of peripheral neuropathy include 
symptomatic treatments for neuropathic pain as well glucocorticoid with or without 
immunosuppressive therapy depending on the severity of the disease.  In the presence of 
severe cases, or failure of conventional treatments other modalities such as plasmaphersis, 
intravenous immunoglobulin and rituximab can be used. 
Other PNS involvements by SLE are much less. Patient may present with mononeuritis 
multiplex, acute demylenating polyradiculopathy, chronic demylinating polyradiculopathy 
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and myasthenia gravis also reported. The managements of those patients will be the same as 
non SLE patients. 
8. Prognosis 
In spite of recent advances in diagnosis and management, NPSLE remain one of the major 
causes of disease related morbidity.  Swedish study of SLE patients did not find difference 
in mortality in SLE patients with or without NP. However patients with NPSLE have more 
functional impairments when compared to non NPSLE patients (Jonsen, 2002). Prompt 
diagnosis and management may played a role in reducing mortality but significant 
morbidity and functional incapacity still a major problem in SLE patients with 
neuropsychiatric symptoms. 
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1. Introduction 
The pathophysiology of Neuropsychiatric SLE (NPSLE) will be described in this chapter. 
Systemic Lupus Erythematosis (SLE) is a multiorgan and multisystem autoimmune 
disorder and its pathophysiology may have protean effects on all components of the 
nervous system. The central (CNS) and peripheral nervous systems (PNS) may be 
involved in SLE. About 25 % of SLE may begin in childhood and SLE may present both 
steadily chronic and more episodic neurologic symptoms as well throughout the life span. 
The presentation of symptoms and clinical signs is a reflection of the location and type of 
pathophysiology of the disease in which there is chronic inflammation of varied degrees 
that may wax and wane. The chronic disease process is responsible for making the CNS 
for example more vulnerable to lowered seizure threshold and episodic seizures despite 
the ongoing more chronic pathophysiology involving the inflammation of the blood 
vessels. The disease may exert effects on peripheral nerves and over time accumulated 
lesions or immune mediated damage may make tissues more susceptible to damage. 
Chronic inflammation or immune mediated damage or vasculitis of blood vessels or the 
vascular supply of the nerves may predispose to neuropathy and lead to progressive 
deterioration in function over time as lesion burden accumulates in the PNS. Similarly, 
SLE may also damage various end organs that may impact the nervous system once 
affected. For example, SLE may impact the heart and cardiovascular system or be 
associated with antiphospholipid antibodies that may contribute to embolic strokes. Other 
end organs may be affected for example kidney dysfunction or renal failure that may lead to 
uremic encephalopathy. Having a rash present or palpable purpura and multiorgan 
involvement may present clinical clues that SLE is the diagnosis along with clinical 
evidence of multisystem involvement. Other pathophysiology exists as noted below. In 
these regards, this chapter seeks to characterize the pathophysiology of the major 
categories of disease and syndromes on the  nervous system in SLE. The categorization of 
the signs and symptoms and overall disease state and pathophysiology and structures 
involved will relate to how these conditions are ultimately diagnosed and treated. 
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Neurologists need to be aware of the varied presentations of SLE as neurologic symptoms 
may be the first signs or symptoms that come to medical attention for evaluation. 
Unfortunately since SLE results from chronic and indolently progressive 
pathophysiology, often only subtle neurologic signs develop insidiously over years and 
therefore often the diagnosis of SLE may be only possible retrospectively in these regards 
in some cases. 
2. The proposed autoimmune mechanism of SLE on the nervous system and 
resultant effects 
While the definitive mechanisms are unknown, the general principle is that antibodies or 
immune complexes may attack the blood supply to the neural structures. HLA type may 
regulate the susceptibility to SLE. Studies of twins seem to indicate that many other factors 
may work in conjunction with HLA typing to produce clinical disease. Although 
antineuronal antibodies exist, it is unclear how they exert their effects. Over time, it is 
thought that progressive inflammation may lead to progressive decline and dysfunction. 
Recent articles or case reports that delineate that antithyroglobulin antibodies, 
antimicrosomal antibodies, anti cardiolipin antibodies, B2Glycoprotein I antibodies, 
antinuclear antibodies, the presence of lupus anticoagulant, and other antibodies may be 
some of the proposed mediators of immune damage of the CNS. Arguably, much research is 
needed in this area and complete mechanisms are not understood. SLE mediated attack on 
tissues is a diverse one including varied mechanisms of deposition of immune complexes, 
cytokines, and numerous modulators of these activities are postulated to be involved. 
Studies indicate that there may be attack of neural elements or tissues through the 
autoantibodies and activated leukocytes. 
Medications (such as phenytoin) may produce drug induced lupus, which often spares  
the kidneys and CNS. The antibody profile of this entity and general immunology however 
may also differ from non-medication induced SLE. Over time, SLE in the CNS may  
cause demyelination and various demyelinating syndromes or multiple sclerosis like  
illness that may seemingly relapse and remit. Similarly a vasculitis may progress either 
fulminantly or indolently. Multiple yet to be described pathophysiologies may account for 
the varied syndromes noted below. Varied preponderances or ratios of antibody types in 
local tissues may also explain somehow whether or nor there is more central or more 
peripherally mediated neural damage. While the above observations are noted, the 
mechanism of CNS involvement remains unknown since neither the presence of 
antineuronal and antiastrocyte antibodies correlate with any CNS pathology or level of 
involvement. The literature and clinical experience notes that neurological complications 
may be fulminant or fatal. In general, diagnosis is made on a clinical basis although 
laboratory confirmation of positive antinuclear antibodies, anti-DNA, anti-RNA, and low 
complements are supportive in many cases along with identifying other systemic or 
multiorgan involvement. 
3. The importance of the physical and neurological examination: A clinical 
key to pathophysiology 
If SLE or NPSLE is suspected, a careful and detailed meticulous history and physical is 
mandatory. Specific attention to nearly every organ system in the general medical 
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examination may yield clues about the presence of an underlying autoimmune or infiltrative 
or inflammatory disorder. From the moment the patient enters the office, one may notice the 
malar rash or the anterior tibial vasculitic infiltrative leucocytoclastic mediated rash. 
Specifically with regards to the neurologic system, a systematic approach should be used in 
gathering history and examination of mental status, cranial nerves, motor function, reflexes, 
coordination/cerebellar function, as well as sensory function and gait.  Auscultation of the 
carotid and vertebral arteries, the heart, and looking for Lhermitte’s sign and stigmata of 
emboli are mandatory. Because of the infiltrative nature of SLE, CNS manifestations of the 
disease include cognitive dysfunction, headaches, confusion, fatigue, depression, mood 
disorders, demyelinating syndromes, seizures, movement disorders, and strokes. 
Headaches, depression, fatigue, mood disorders, and cognitive disorders are associated with 
SLE but the mechanisms of the pathophysiology producing these exact symptoms or 
syndromes is poorly understood. It is postulated that various degrees of lesion burden in 
various locations on the CNS may be associated with these symptoms. 
In the peripheral nervous system, peripheral nerve damage causing peripheral neuropathy, 
facial pain, tingling, burning, or numbness may occur. Chronic inflammatory diseases may 
cause dysfunction of individual named nerves, usually by interfering with their blood supply, 
thereby causing a mononeuritis or if multiple nerves are involved, a more confluent and 
diffuse or regionalized mononeuritis multiplex may result over time. Of note, SLE itself or 
associated treatments such as with corticosteroids that can cause papilledema or pseudotumor.  
4. Diagnosing CNS lupus and ancillary testing- a window into the 
pathophysiology of neuropsychiatric SLE 
Laboratory testing may give clues about the pathophysiology of NPSLE. Abnormal CSF is 
identified in about 50 % of cases with increased mononuclear cells along with oligoclonal 
bands, and antineuronal antibodies. CT scans and angiograms and MRI scans collectively 
may be unhelpful when there are no focal findings or if there is mild and diffuse disease, 
although MRI is the most sensitive radiologic tool to detect virtually any inflammatory, 
demyelinating, or infiltrative pathology relating to NPSLE. Laboratory markers often do not 
correlate with neurologic disability although high IgG titers of antineuronal antibodies in 
CSF may correlate with diffuse disease or high lesion burden on the nervous system. 
Although 70% of patients may have abnormal electroencephalograms, the findings on the 
EEG are not necessarily diagnostic of NPSLE by these EEG abnormalities themselves. 
NPSLE may mimic demyelinating disease and most often the patient may need evidence of 
multisystem or multiorgan involvement to make the diagnosis. The multiorgan or 
multisystem manifestations according to previously published guidelines include the 
presence of malar rash, a discoid rash, the presence of photosensitivity, oral ulcers, arthritis, 
serositis, renal disease or neurologic or hematologic disorders, or immunologic disorders or 
the presence of antinuclear antibodies. According to these guidelines if four such clinical 
criteria are present at any time during the course of the disease, a diagnosis of SLE may be 
made with 98 % specificity and 97 % sensitivity.  
5. CNS disease: General principles 
NPSLE may involve as many as 75% of SLE cases according to Johnson and Richardson. 
Impaired mentation, consciousness, seizures, cranial neuropathies and derangements of  
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Neurologists need to be aware of the varied presentations of SLE as neurologic symptoms 
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examination may yield clues about the presence of an underlying autoimmune or infiltrative 
or inflammatory disorder. From the moment the patient enters the office, one may notice the 
malar rash or the anterior tibial vasculitic infiltrative leucocytoclastic mediated rash. 
Specifically with regards to the neurologic system, a systematic approach should be used in 
gathering history and examination of mental status, cranial nerves, motor function, reflexes, 
coordination/cerebellar function, as well as sensory function and gait.  Auscultation of the 
carotid and vertebral arteries, the heart, and looking for Lhermitte’s sign and stigmata of 
emboli are mandatory. Because of the infiltrative nature of SLE, CNS manifestations of the 
disease include cognitive dysfunction, headaches, confusion, fatigue, depression, mood 
disorders, demyelinating syndromes, seizures, movement disorders, and strokes. 
Headaches, depression, fatigue, mood disorders, and cognitive disorders are associated with 
SLE but the mechanisms of the pathophysiology producing these exact symptoms or 
syndromes is poorly understood. It is postulated that various degrees of lesion burden in 
various locations on the CNS may be associated with these symptoms. 
In the peripheral nervous system, peripheral nerve damage causing peripheral neuropathy, 
facial pain, tingling, burning, or numbness may occur. Chronic inflammatory diseases may 
cause dysfunction of individual named nerves, usually by interfering with their blood supply, 
thereby causing a mononeuritis or if multiple nerves are involved, a more confluent and 
diffuse or regionalized mononeuritis multiplex may result over time. Of note, SLE itself or 
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4. Diagnosing CNS lupus and ancillary testing- a window into the 
pathophysiology of neuropsychiatric SLE 
Laboratory testing may give clues about the pathophysiology of NPSLE. Abnormal CSF is 
identified in about 50 % of cases with increased mononuclear cells along with oligoclonal 
bands, and antineuronal antibodies. CT scans and angiograms and MRI scans collectively 
may be unhelpful when there are no focal findings or if there is mild and diffuse disease, 
although MRI is the most sensitive radiologic tool to detect virtually any inflammatory, 
demyelinating, or infiltrative pathology relating to NPSLE. Laboratory markers often do not 
correlate with neurologic disability although high IgG titers of antineuronal antibodies in 
CSF may correlate with diffuse disease or high lesion burden on the nervous system. 
Although 70% of patients may have abnormal electroencephalograms, the findings on the 
EEG are not necessarily diagnostic of NPSLE by these EEG abnormalities themselves. 
NPSLE may mimic demyelinating disease and most often the patient may need evidence of 
multisystem or multiorgan involvement to make the diagnosis. The multiorgan or 
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CNS functions may either occur transiently, mildly, or late in the disease as lesion burden 
accumulates. CSF analysis may be basically normal or show only a mild lymphocytic 
pleocytosis with an increased protein. According to some sources, most of the central 
nervous system manifestations can be accounted for the pathophysiology of numerous 
micro infarcts due to the accumulation of lesions in arterioles and capillaries.  
The literature postulates that deposition of immune complexes in the vascular 
endothelium mediates vascular injury and since many patients also have concomitant 
hypertension, this also affects cerebral blood vessels predisposing them to hemorrhage. 
As mentioned above, cardiac injury can predispose to embolic complications of 
endocarditis. Visual complaints are common, especially in children and may include 
retinal artery occlusion, retinal hemorrhage, cotton wool exudates, papilledema and optic 
neuritis. Complications of SLE may lead to hypertensive encephalopathy, cerebral vein 
thrombosis, cranial neuropathies, brainstem dysfunction, and rarely myelopathy. SLE 
may predispose to bacterial or fungal meningitis or opportunistic infection or cause an 
aseptic meningitis. 
6. Pathophysiology of encephalopathy 
Encephalopathy is a general term indicating impaired brain function and this may occur 
with any amount of brain or CNS involvement in NPSLE. Clinically encephalopathies may 
present with confusion, lethargy or coma. Encephalopathies may also present more 
chronically as “brain failure” in which a patient may exhibit dementia or cognitive 
dysfunction. There are both acute and chronic presentations involving psychiatric 
symptoms. The literature notes that in general, patients with neuropsychiatric 
manifestations of SLE in the CNS may have abnormalities on functional neuroimaging and 
MRI suggesting either a disruption of normal blood flow or a dysregulation of normal 
metabolic function.  Encephalopathies may be due to cerebritis. NSAIDS or nonsteroidal 
anti-inflammatory drugs may also contribute to encephalopathy by producing aseptic 
meningitis.  
Since many patients with SLE are on chronic immunosupression, the CNS may be  
infected with opportunistic organisms and result in meningitis, encephalitis, or abscess. 
Medications used for treatment of these entities may also contribute or cause 
encephalopathy.  
Posterior Reversible Encephalopathy Syndrome (PRES) generally occurs in patients with 
uncontrolled hypertension who are on immunosupression therapy. Renal involvement of 
SLE is common with PRES. This syndrome may present as a fulminant encephalopathy 
involving bi-occipital patchy swelling on MRI neuroimaging which has been described in 
the literature. Fortunately with control of the hypertension, clinical and radiologic 
reversibility may occur. The pathophysiology of this condition in NPSLE is unknown but is 
thought to be due to abnormal permeability of blood vessles. 
Brain biopsy may be needed to clarify the pathophysiology when MRI findings cannot 
distinguish cerebritis from another process such as neoplasm like changes or those of 
opportunistic infection. Meningeal biopsy may be needed to diagnose chronic meningitis 
when other methods fail in cases of idiopathic chronic encephalopathies. 
Focal neurological deficits may result from strokes due to either cardioembolic valvular 
disease or fulminant vasculitic changes of the cerebrovasculature, or thrombosis associated 
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with the antiphospholipid antibodies. Dyskinesias may occur and the pathophysiology is 
thought to be due to the effects of the antiphospholipid antibodies.  
7. Pathophysiology of demyelinating disease 
SLE may cause changes in both CNS and PNS myelin. The changes may relapse and 
remit, thereby mimicking attacks of Multiple Sclerosis(MS) like illnesses radiologically 
and clinically. It should be noted that the neuroimmunology of these conditions may 
differ substantially, and that the pathophysiology of both entities and the differences are 
not fully understood. The spectrum of radiological involvement can identify minor and 
non specific white matter changes to more confluent appearing lesions throughout the 
neuraxis. NPSLE pathophysiology may therefore mimic what are termed the clinically 
isolated syndromes of MS such as optic neuritis, transverse myelitis, and more wide 
spread pathology. A Devic-like syndrome in which there is optic neuritis and changes in 
the spinal cord is possible, and Devic’s disease or Neuromyelitis Optica may be 
differentiated by the occurrence of NMO antibodies or the presence of antibodies to 
aquaporin 4 which are noted in Devic’s disease. 
8. The pathophysiology of seizures in NPSLE 
Seizures occur in up to about 25% of patients with NPSLE compared with about 1% in  
the general population. Seizures may present early in the course of NPSLE. While  
focal seizures are postulated to be caused from microinfarcts that damage the cortex, 
systemic derangements and metabolic disturbances and certain medications may cause 
generalized seizures. Seizures are thought to result from cortical injury from cerebral 
vascultis, cardioembolism, or any lesion that may develop within the brain. The presence 
of cortical location and the presence of cortical hemorrhage or blood products generally 
increase the likelihood of seizures. The literature indicates that high dose steroid therapy 
given in pulses is associated with the development of status epilepticus by an unknown 
mechanism. Focal seizures may also become generalized seizures, and virtually  
any seizure type may be seen in SLE. Generalized or multifocal onset seizures are 
common in children with SLE and occur about 10 % of cases. While antiepileptic therapy 
is often prescribed, these medications do not generally treat what is thought to represent 
the underlying pathophysiology as the seizures may relate to ongoing inflammation  
that is somehow contributing to cortical irritability. Nonetheless, many patients are  
often managed in the short term with anti-seizure medications. Some authors suggest  
that anti-epileptic medication should be continued until a normal or benign EEG pattern 
is observed. No study on this however has been performed, and guidelines on how  
long anti-epileptic medication should continue are lacking. It should be noted that a 
benign or normal EEG may be seen in patients who have seizure disorders. EEG or  
EEG monitoring may be useful in patients who may be at risk or have ongoing subclinical 
status epilepticus during a fulminant NPSLE related encephalopathy but it is unknown  
if persistence of status epilepticus correlates with a certain type or subset of ongoing 
pathophsyiology of NPSLE in that circumstance. Treatment using antiseizure medications 
may be useful in an acute setting but these medications do not alter the direct 
pathophysiology of NPSLE. Since multiorgan failure may contribute to encephalopathy, 
electrolyte disturbances, or hypertension, treatment of these entities are necessary to  
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distinguish cerebritis from another process such as neoplasm like changes or those of 
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with the antiphospholipid antibodies. Dyskinesias may occur and the pathophysiology is 
thought to be due to the effects of the antiphospholipid antibodies.  
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SLE may cause changes in both CNS and PNS myelin. The changes may relapse and 
remit, thereby mimicking attacks of Multiple Sclerosis(MS) like illnesses radiologically 
and clinically. It should be noted that the neuroimmunology of these conditions may 
differ substantially, and that the pathophysiology of both entities and the differences are 
not fully understood. The spectrum of radiological involvement can identify minor and 
non specific white matter changes to more confluent appearing lesions throughout the 
neuraxis. NPSLE pathophysiology may therefore mimic what are termed the clinically 
isolated syndromes of MS such as optic neuritis, transverse myelitis, and more wide 
spread pathology. A Devic-like syndrome in which there is optic neuritis and changes in 
the spinal cord is possible, and Devic’s disease or Neuromyelitis Optica may be 
differentiated by the occurrence of NMO antibodies or the presence of antibodies to 
aquaporin 4 which are noted in Devic’s disease. 
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Seizures occur in up to about 25% of patients with NPSLE compared with about 1% in  
the general population. Seizures may present early in the course of NPSLE. While  
focal seizures are postulated to be caused from microinfarcts that damage the cortex, 
systemic derangements and metabolic disturbances and certain medications may cause 
generalized seizures. Seizures are thought to result from cortical injury from cerebral 
vascultis, cardioembolism, or any lesion that may develop within the brain. The presence 
of cortical location and the presence of cortical hemorrhage or blood products generally 
increase the likelihood of seizures. The literature indicates that high dose steroid therapy 
given in pulses is associated with the development of status epilepticus by an unknown 
mechanism. Focal seizures may also become generalized seizures, and virtually  
any seizure type may be seen in SLE. Generalized or multifocal onset seizures are 
common in children with SLE and occur about 10 % of cases. While antiepileptic therapy 
is often prescribed, these medications do not generally treat what is thought to represent 
the underlying pathophysiology as the seizures may relate to ongoing inflammation  
that is somehow contributing to cortical irritability. Nonetheless, many patients are  
often managed in the short term with anti-seizure medications. Some authors suggest  
that anti-epileptic medication should be continued until a normal or benign EEG pattern 
is observed. No study on this however has been performed, and guidelines on how  
long anti-epileptic medication should continue are lacking. It should be noted that a 
benign or normal EEG may be seen in patients who have seizure disorders. EEG or  
EEG monitoring may be useful in patients who may be at risk or have ongoing subclinical 
status epilepticus during a fulminant NPSLE related encephalopathy but it is unknown  
if persistence of status epilepticus correlates with a certain type or subset of ongoing 
pathophsyiology of NPSLE in that circumstance. Treatment using antiseizure medications 
may be useful in an acute setting but these medications do not alter the direct 
pathophysiology of NPSLE. Since multiorgan failure may contribute to encephalopathy, 
electrolyte disturbances, or hypertension, treatment of these entities are necessary to  
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gain control of the seizures that are provoked through those pathophysiologies in  
NPSLE. The author advises caution in diagnosing patients with first time seizures as 
idiopathic and in general such patients ought to be seen in follow up to ensure no other 
systemic or multiorgan involvement may be developing. It may be only in retrospective 
analysis that these patients might be diagnosed with NPSLE. The epidemiology and 
pathophysiology of these cases is unknown although the author has noted the subsequent 
onset of SLE or at least the fulfillment of SLE by clinical criteria over time in several such 
patients. Since NPSLE is a chronic disease, there may also be a need for lifetime 
prophylaxis with anti-seizure medications but trials and definitive guidelines on this are 
lacking, and anecdotally patients with epilepsy and NPSLE may be noted to be best 
controlled in general when the systemic SLE is controlled. 
9. Psychiatric symptoms 
Psychosis is common with NPSLE and steroids may accentuate clinical psychiatric features, 
although an although an associated cognitive disorder may be temporary or progressive. It 
may be difficult to distinguish corticosteroid induced encephalopathies with psychiatric 
symptoms from those of SLE. Since psychiatric symptoms may occur with numerous 
disease states, these symptoms combined with multisystem involvement of SLE are 
especially characteristic and may lead to diagnosis. The pathophysiology is unknown 
although depression and anxiety and psychiatric symptoms may be the initial symptoms of 
NPSLE. Combinations of depression, anxiety, progressive cognitive dysfunction, and 
encephalopathy are thought to be mediated by the previously noted mechanisms of chronic 
inflammation. 
10. Vasculitis 
Vasculitis in NPSLE often becomes a consideration in patient with autoimmune disease and 
in young patients with ischemic or hemorrhagic strokes. Patients often have an 
accompanying encephalopathy, fever, headaches, seizures, and cognitive changes. If there 
are multifocal levels of neurologic dysfunction, malar rash or palpable purpura present, or 
an abnormal urine sediment, then SLE as a clinical diagnosis may be likely.  
Since angiography typically shows irregular beading and caliber changes of large and 
medium branches of the anterior, middle, and posterior cerebral arteries, it is believed that 
the major pathophysiolgy of vasculitis in NPSLE is due to this finding. While angiography 
may be positive, histology often shows degeneration within the walls of the smallest blood 
vessels, while more inflammatory mediators and infiltrates of such are noted in the medium 
and large vessels. Complete understanding of these mechanisms are being studied. There 
may ultimately be both inflammatory and non inflammatory processes involved. Aggressive 
treatment with intravenous steroids and immune modulators are required to treat this often 
fulminantly presenting, fatal or devastating process.  
11. Pathophysiology of ischemic stroke in NPSLE 
Ischemic stroke may result from cardiogenic embolism that is due to nonbacterial or from 
Libman-Sachs endocarditis which occurs on the ventricular or atrial surface of the mitral 
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valve. The presence of antiphospholipid antibodies may also predispose to strokes and 
venous thrombosis as previously noted. Ischemic stroke in NPSLE occurs in children and 
is usually caused by small vessel vascultits. The literature indicates that stroke may occur 
in up to 10 % of pediatric series of NPSLE and occur by mechanisms noted above. 
Thrombotic strokes may present in a more evolving or subacute pattern often with 
premonitory symptoms, and ischemic ones generally present abruptly with deficits 
maximally present at onset.  
Stroke should be clinically distinguished from hemorrhage and other CNS pathologies and 
hemorrhage may be likely in association with cardiac emboli or with cerebral venous 
thrombosis which can also present with seizures. 
12. Pathophysiology of chorea in NPSLE 
Chorea in NPSLE may precede systemic symptoms of SLE by about 1 year as some 
articles indicate and can resolve prior to the evolution of other symptoms or signs. The 
mechanism is unknown. In children, distinguishing this from Sydenham’s chorea may be 
quite difficult since NPSLE may also falsely elevate serum antistreptococcal antibody 
titres which are characteristically seen in Sydenham’s disease. Dopamine blockers such as 
haloperidol or chlorpromazine may be useful as well as aspirin or corticosteroids. The 
diagnosis may be made by finding the presence of lupus anticoagulant or with recurrent 
vascular thrombosis or spontaneous abortions in patients not meeting full criteria for 
diagnosis of SLE. Chorea in pregnancy (Chorea gravidarum) may also be a manifestation 
of NPSLE. A pattern of relapsing and remitting chorea of different intensities may suggest 
NPSLE. 
13. Pathophysiology of fatigue in NPSLE 
This has been described in the literature and it is suggested that many of such patients do 
not have evidence of muscle disease or myopathy. Therefore the mechanism is postulated to 
be due to brain or CNS dysfunction however further details about the pathophysiology is 
unknown. Depression, myopathy, sleep disorder, and systemic disease may need to be 
excluded. The literature indicates that chronic orthostatic hypotension should be excluded 
since this condition also may present with fatigue, although it is not known if infiltration of 
autonomic nerves in NPSLE is the causative pathophysiology which may actually 
predispose to orthostatic hypotension. 
14. Cranial nerve involvement 
Cranial nerve involvement is thought to be rare and transient, generally affecting cranial 
nerve III. Other cranial nerve involvement has been reported and although the mechanism 
of cranial neuropathy in NPSLE in general is not fully understood, the pathophysiology is 
thought to be due to vasculitic changes in the blood supply of the cranial nerves similar to 
that of a mononeuritis multiplex. While involvement of the nuclei or fasicles of the various 
cranial nerves is possible within the brain or brainstem, case series and pathologic correlates 
on this are lacking.  
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valve. The presence of antiphospholipid antibodies may also predispose to strokes and 
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15. Pathophysiology of vision and migraine in NPSLE 
The literature indicates that visual and migrainous disturbances occur bilaterally and  
late in the course of SLE. NPSLE is associated with retinal disease, optic neuritis, and 
migraine headaches. While the presence of an acute headache in NPSLE could ultimately 
simply be migraine, it is recommended that one should only make this diagnosis as a 
diagnosis of exclusion since other encephalopathies, opportunistic infections, meningitis  
or cerebritis, or venous thromboses or stroke may also present with headache and may 
occur in SLE.  
16. Spinal cord involvement/myelopathy 
While this is noted to occur, it is thought to occur rarely. Little literature is available. The 
author notes experience with patients who have had a fulminant course of CNS disease 
either from vasculitis or encephalopathy who may also have evidence of myelopathy 
develop. The mechanism on this and its relative rarity is not well understood. The literature 
indicates that spinal involvement and pathophysiology in NPSLE is often functionally 
devastating and may occur acutely, subacutely, or chronically. Syndromes involving a 
transverse myelitis type presentation, infarction, or the identification of a rapidly expanding 
type lesion have been described.  
17. Peripheral nervous system involvement and  
neuromuscular disease 
Peripheral manifestations of NPSLE involve progressive neropathy, myopathy, and diseases 
of the neuromuscular junction(NMJ). NPSLE affecting the NMJ may appear clinically 
similar to myasthenia gravis. Peripheral neuropathy is postulated to be caused by vasculitic 
injury to the blood supply of the nerves- the vasa nervorum – which as noted previously 
produces either a mononeuritis multiplex or a regionalized or more confluent, generalized 
apparent polyneuropathy. SLE may produc peripheral demyelination. Chronic 
demyelination can result in a chronic sensory or sensorimotor polyneuropathy.  SLE acutely 
may exhibit pathophysiology present resembling acute inflammatory demyelinating 
polyradiculoneuropathy or (AIDP) and may mimic Guillian-Barre syndrome. Patients may 
present with burning or numbness sensations, usually starting distally and as disease 
progresses and as lesion burden accumulates on the peripheral nerves, more proximal 
involvement may become evident over time.  
Myopathy may result from the inflammatory cascade and may mimic dermatomyositis or 
polymyositis. One also has to keep in mind that patients diagnosed with SLE may be on 
chronic steroid regimens. The pathophysiology of steroid regimens may contribute to 
muscle fiber atrophy without inflammatory infiltrates. Various medications may also 
contribute to pathophysiology of myopathy in NPSLE.  
Distinguishing between neuromuscular disease and polyradiculopathy may be difficult, and 
EMG, CPK and aldolase testing, and muscle biopsies may be required. CPK/Creatine kinase 
and aldolase may be mildly elevated in SLE myopathy and may not be able to exclude other 
causes of myopathy for example from medications. 
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EMG and Nerve conduction studies(NCS) may provide useful clinical data. In  
an inflammatory myopathy which would be expected in cases of NPSLE, the EMG may  
be very active with fibrillations and positive sharp waves and simply may be a marker  
of muscle irritability. There may be increased insertional activity and myopathic motor 
units and recruitment abnormalities noted along with complex repetitive discharges. 
Caution is advised in evaluating patients on treatment for SLE with chronic 
immunosupression or steroids since a normal needle examination on EMG may be 
obtained despite the presence of disease and it is not known how much disease burden is 
required for this testing to be positive. Repetitive stimulation may be useful in evaluating 
neuromuscular junction failure or pathology which is rare but described in NPSLE. NCS 
may identify multiple nerves involved from mononeuritis multiplex, sensory or 
sensorimotor symmetric distal polyneuropathy, or AIDP (Acute Immune-mediated 
Demyelinating Polyradiculopathy). Abnormal F waves and H response abnormalities may 
indicate more proximal root dysfunction.  
Nerve biopsy may be useful in identifying active vasculitis as pathology early in the clinical 
course this may be positive. In more indolent confluent polyneuropathies, there may simply 
be noted nonspecific demyelination. Muscle biopsy may be used to differentiate 
inflammatory from other causes of myopathy.  
Nerve biopsies may identify inflammatory infiltrates, necrotizing vasculitis in epineurial 
arterioles or perivascular infiltrates. Immunoflorescence may be useful in identifying 
immune complexes or complement deposition onto vessel walls. Demyelination or nerve 
fiber count reduction may be noted.  
In Summary, the pathophysiology of NPSLE is complex and mechanisms are at best  
only partly understood. Hopefully in the future, new developments along multiple lines 
will lead to a better understanding of the disease state which could lead to additional 
treatments. 
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Systemic lupus erythematosus (SLE) is the most common multisystem connective tissue 
disease. It is characterised by a wide variety of clinical features and presence of numerous 
auto-antibodies, circulating immune complexes and widespread immunologically 
determined tissue damage [1]. Hematological abnormalities are common in SLE. All the 
cellular elements of the blood & coagulation pathway can be affected in SLE patients.  
The major hematological manifestations of SLE are anemia, leucopenia, thrombocytopenia, 
and antiphospholipid syndrome (APS). Hematological abnormalities in patients with this 
disease require careful long-term monitoring and prompt therapeutic intervention. 
Throughout the chapter we will analyze each abnormality, enumerate and explain the 
causes of each one and discuss an approach to the management. 
2. Anemia in systemic lupus erythematosus 
Anemia is found in about 50% of SLE patients, many mechanisms contribute to the 
development of anemia, including inflammation,  renal insufficiency,  blood loss,  dietary 
insufficiency, medications, haemolysis, infection, hypersplenism, myelofibrosis, 
myelodysplasia, and aplastic anemia that is suspected to have an autoimmune pathogenesis 
[2-9] table 1. 
2.1 Anemia of chronic disease 
A frequent cause of anemia in SLE is suppressed erythropoiesis from chronic 
inflammation (anemia of chronic disease or anemia of chronic inflammation), being the 
most common form (60 to 80 %) [5]. this type of anemia is normocytic and normochromic 
with a relatively low reticulocyte count. Although serum iron levels may be reduced, bone 
marrow iron stores are adequate and the serum ferritin concentration is elevated. In the 
absence of either symptoms attributable to anemia (eg: dyspnea on exertion, easy 
fatigability) or renal insufficiency, anemia of chronic inflammation does not require 
specific treatment. 
Patients with symptoms due to anemia of chronic inflammation, who have no other definite 
indication for glucocorticoid or other immunosuppressive therapy, may be given a trial of 
an agent that promotes erythropoiesis. The following two agents are an example: 
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Table 1. Causes of anemia in patients with SLE 
 Epoetin alfa (recombinant human erythropoietin) 
 Darbepoetin alfa, a unique molecule that stimulates erythropoiesis with a longer half-
life than recombinant human erythropoietin.  
In one study that assessed the response to erythropoietin in patients with SLE and anemia of 
chronic inflammation, 58 percent had an adequate response to erythropoietin 
supplementation [7]. 
Patients who are symptomatically anemic, having signs of active inflammations, and do not 
respond to an agent that promotes erythropoiesis, often improve when glucocorticoids are 
used in high doses(1 mg/kg per day of prednisone or its equivalent in divided doses). If, after 
approximately one month of treatment, the response is unsatisfactory (eg, hemoglobin still <11 
g/dL) the dose of glucocorticoids should be rapidly reduced, and discontinued if there is no 
other indication for their use. If there is a response, the dose should be tapered as rapidly as to 
possible to the lowest dose that maintains the improvement.  Immunosuppressive agents also 
may help, but carry a risk of further bone marrow suppression. 
2.2 Renal insufficiency 
An inappropriately low level of erythropoietin is a hallmark of anemia due to renal 
insufficiency. The primary cause of anemia in this setting is typically deficient production of 
erythropoietin by the diseased kidneys. In the patient with SLE, anemia, and renal 
insufficiency who does not have other evidence of active inflammation, administration of 
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erythropoiesis-stimulating agents may be indicated when the anemia is causing symptoms 
or the hemoglobin concentration is <11 gm/dL. 
2.3 Iron deficiency anemia 
Anemia may reflect acute or chronic blood loss from the gastrointestinal tract, usually 
secondary to medications (nonsteroidal antiinflammatory drugs or steroids), or may be due 
to excessive menstrual bleeding. Iron deficiency anemia is not uncommon, especially among 
teenagers or young women. Long-term anemia of chronic inflammation can also lead to iron 
deficiency, since, hepcidin, the key inducer of the anemia of chronic inflammation, inhibits 
iron absorption from the gastrointestinal tract. 
Pulmonary hemorrhage is a rare cause of anemia in SLE. Not all patients have hemoptysis. 
Other symptoms of alveolar hemorrhage are dyspnea and cough. The presence of alveolar 
infiltrates on a chest radiograph or ground-glass opacities on chest CT are suggestive of 
alveolar hemorrhage.  
2.4 Red cell aplasia 
Red cell aplasia, probably due to antibodies directed against either erythropoietin or bone 
marrow erythroblasts, has been observed, although it is rare [5,6,10]. This form of anemia 
usually responds to steroids, although cyclophosphamide and cyclosporine have been 
successfully employed.  
Even rarer are isolated case reports of aplastic anemia, presumably mediated by auto 
antibodies against bone marrow precursors; immunosuppressive therapy also may be 
effective in this setting [11-13]. 
In addition, bone marrow suppression can also be induced by medications, including 
antimalarials and immunosuppressive drugs. 
2.5 Autoimmune hemolytic anemia 
Overt autoimmune hemolytic anemia (AIHA), characterized by an elevated reticulocyte 
count, low haptoglobin levels, increased indirect bilirubin concentration, and a positive 
direct Coombs' test, has been noted in up to 10 percent of patients with SLE [2-4,8,14]. The 
presence of hemolytic anemia may be associated with other manifestations of severe disease 
such as renal disease, seizures, and serositis [14]. 
Other patients have a positive Coombs' test without evidence of overt hemolysis. The 
presence of both immunoglobulin and complement on the red cell is usually associated with 
some degree of hemolysis, while the presence of complement alone (eg, C3 and/or C4) is 
often not associated with hemolysis [1-4].  
AIHA responds to steroids (1 mg/kg per day of prednisone or its equivalent in divided 
doses) in 75 to 96 percent of patients [15, 16]. Once the hematocrit begins to rise and the 
reticulocyte count falls, steroids can be rapidly tapered. If there is no response, we can 
consider pulse steroids (eg,1000 mg methylprednisolone intravenously daily for three days) 
[15], azathioprine (up to 2 mg/kg per day) [17], cyclophosphamide (up to 2 mg/kg) [18], or 
splenectomy. Success rates for splenectomy as high as 60 percent have been reported [19], 
although others have found no benefit [20]. 
Other described approaches to patients with refractory AIHA include intravenous immune 
globulin [18], danazol [21-23], mycophenolate mofetil [24], and rituximab [25]. 
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2.6 Microangiopathic hemolytic anemia 
Lupus has also been associated with a thrombotic microangiopathic hemolytic anemia 
[26] as manifested by a peripheral blood smear showing schistocytes and elevated serum 
levels of lactate dehydrogenase (LDH) and bilirubin. Many affected patients also have 
thrombocytopenia, kidney involvement, fever, and neurologic symptoms. This pentad of 
features is compatible with a diagnosis of thrombotic thrombocytopenic purpura (TTP). 
However, the pathogenesis of TTP in these patients is likely heterogeneous, as it may reflect 
vasculitis or antiphospholipid syndrome as well [27, 28]. 
Whether the occurrence of both SLE and TTP in an individual patient is a coincidence or 
represents a true association is an unsettled question. 
Other patients with microangiopathic red cell destruction do not have fever or neurologic 
disease, producing a pattern of hemolytic-uremic syndrome. The pathogenesis of this 
syndrome is not completely understood. In one report of 4 patients plus 24 others identified 
from a literature review, antiphospholipid antibodies (aPL) were searched for in eight and 
found in five [26]. 
The presence of aPL in SLE patients with severe hemolytic anemia, renal dysfunction, and 
central nervous system involvement has also been reported [31].  
In a review of 28 reported patients, those treated with plasma infusions or plasmapheresis, 
glucocorticoids alone, or no therapy had mortality rates of 25, 50, and 100 percent, 
respectively [26]. However, in another series of 15 patients with SLE and microangiopathic 
hemolytic anemia, all responded to treatment with high-dose glucocorticoids and none were 
treated with plasmapheresis [32]. In a retrospective study [27] in which 70 percent of 
patients with SLE and TTP underwent plasma exchange, the response rate of 74 percent was 
comparable to that observed in patients with idiopathic TTP. 
Patients with SLE, severe microangiopathic hemolytic anemia, and other major organ 
dysfunction should be treated with plasmapheresis and plasma infusion as in other cases of 
thrombotic thrombocytopenic purpura or the hemolytic-uremic syndrome. Those with less 
severe disease may be treated with high-dose glucocorticoids and observed carefully with 
the addition of plasmapheresis should they deteriorate or fail to improve with steroid 
treatment alone. 
3. An approach to lupus patient with anaemia 
After the detailed analysis and discussion of each type of anemia associated with SLE, here 
is a simple approach to anemic SLE patient with an easy mechanism to the diagnosis. 
Anaemia can be divided into those conditions with impaired red cell production (marrow 
suppression, nutrient deficiency) and those with increased red cell destruction (haemolysis, 
hypersplenism) or blood loss. Measurement of reticulocyte production (reticulocyte index) 
usually used to make this distinction and it is the major step for determination of causes of 
anaemia. IDA is defined by serum ferritin level below: 20 μg/dl. Pernicious anemia (PA) is 
defined by serum vitamin B12 of less than: 180 pmol/l together with one or more of the 
following: an abnormal Schilling test result or the presence of anti-intrinsic factor antibody 
in the blood.  
It is also important to mention that the examination of the peripheral blood smear is a 
mandatory step in the initial evaluation of all SLE patients with hematologic disorders. The 
examination of blood films stained with Wright's stain frequently provides important clues 
in the diagnosis of anemias and various disorders of leukocytes and platelets and we can 
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discover a life threatening conditions like TTP early on. For example, some of the 
abnormalities suspicious for the presence of hemolysis in blood smear include the following: 
 Spherocytes (microspherocytes and elliptocytes) indicate autoimmune hemolytic anemia 
 Fragmented RBC (schistocytes, helmet cells) indicating the presence of 
microangiopathic hemolytic anemia ( thrombotic thrombocytopenic purpura-hemolytic 
uremic syndrome )  
 Acanthocytes (spur cells) in patients with liver disease. 
 Blister or "bite" cells due to the presence of oxidant-induced damage to the red cell and 
its membrane (G-6-PD).  
 RBCs with inclusions, as in malaria, babesiosis, and Bartonella infections (" non-
immune hemolytic anemia due to systemic disease", ''). 
 Teardrop RBCs with circulating nucleated RBC and early white blood cell forms, 
indicating the presence of marrow involvement, as in primary myelofibrosis or tumor 
infiltration. 
So at a practical level, when you are faced with SLE anaemia, it will be easy to differentiate 
among the possible mechanisms with only a few tests. If the reticulocytes are increased, a 
haemolytic process or acute bleeding should be the probable cause. If the reticulocytes are 
inadequate, you should rule out a nutritional deficiency of iron, vitamin B12, or folate. 
Ferritin determination suffices for diagnosing IDA. If the ferritin concentration is greater 
than 20 μg/dl, IDA is virtually never present and a bone marrow examination may be 
considered, but we have to mention that ferritin is an acute phase reactant and it can be 
elevated in any patients with inflammatory process due to any cause, although the 
diagnostic yield may be very low and anaemia of chronic disease is the most common 
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discover a life threatening conditions like TTP early on. For example, some of the 
abnormalities suspicious for the presence of hemolysis in blood smear include the following: 
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 Fragmented RBC (schistocytes, helmet cells) indicating the presence of 
microangiopathic hemolytic anemia ( thrombotic thrombocytopenic purpura-hemolytic 
uremic syndrome )  
 Acanthocytes (spur cells) in patients with liver disease. 
 Blister or "bite" cells due to the presence of oxidant-induced damage to the red cell and 
its membrane (G-6-PD).  
 RBCs with inclusions, as in malaria, babesiosis, and Bartonella infections (" non-
immune hemolytic anemia due to systemic disease", ''). 
 Teardrop RBCs with circulating nucleated RBC and early white blood cell forms, 
indicating the presence of marrow involvement, as in primary myelofibrosis or tumor 
infiltration. 
So at a practical level, when you are faced with SLE anaemia, it will be easy to differentiate 
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inadequate, you should rule out a nutritional deficiency of iron, vitamin B12, or folate. 
Ferritin determination suffices for diagnosing IDA. If the ferritin concentration is greater 
than 20 μg/dl, IDA is virtually never present and a bone marrow examination may be 
considered, but we have to mention that ferritin is an acute phase reactant and it can be 
elevated in any patients with inflammatory process due to any cause, although the 
diagnostic yield may be very low and anaemia of chronic disease is the most common 







SLE + ANEMIA 
(Hb of 12 g/dl or 
less for women & 




















Systemic Lupus Erythematosus 368 
4. Leukopenia in systemic lupus erythematosus 
Leukopenia is common in SLE and usually reflects disease activity. A white blood cell count 
of less than 4500/microL has been noted in approximately 50 percent of patients, especially 
those with active disease [3, 4], while lymphocytopenia occurs in approximately 20 percent 
[3]. In comparison, a white blood cell count below 4000/microL (an American College of 
Rheumatology criterion for SLE) occurs in only 15 to 20 percent of patients [3, 33]. 
Neutropenia, lymphocytopenia, and decreased circulating eosinophils and basophils may 
all contribute to leukopenia. 
4.1 Neutropenia 
Neutropenia in patients with SLE can result from: immune mechanisms, medications (eg, 
cyclophosphamide or azathioprine), bone marrow dysfunction, or hypersplenism [3,4,33,34]. 
Other clinical features that may be associated with moderate to severe neutropenia (absolute 
neutrophils <1000/microL) include infection, anemia, thrombocytopenia, and a history of 
neuropsychiatric involvement [34]. 
4.2 Lymphocytopenia 
Lymphocytopenia (lymphocytes less than 1500/microL), especially involving suppressor  
T cells, has been observed in 20 to 75 percent of patients, particularly during active disease  
[1-3, 37, 38]. This finding is strongly associated with IgM, cold reactive, complement fixing, 
and presumably cytotoxic antilymphocyte antibodies; such antibodies were noted in 26 of  
29 patients with SLE and the antibody titer correlated directly with the degree of lymphopenia 
[39]. 
4.3 Decreased eosinophils and basophils 
Steroid therapy may result in low absolute eosinophil and monocyte counts [41]. The 
number of basophils may also be decreased in SLE, particularly during active disease  
[42].  
4.4 Leukopenia  
In SLE rarely needs treatment. An exception is the patient with neutropenia and recurrent 
pyogenic infections. One problem is the toxicity of the usual therapies. Prednisone (10 to 60 
mg/day) can raise the white blood cell count but can also result in an increased risk  
of infections; immunosuppressive agents such as azathioprine or cyclophosphamide have 
the potential to cause worsening of the leukopenia via bone marrow suppression, 
respectively [43]. 
Cautious use of azathioprine, with careful monitoring of the white blood cell count, may be 
considered in this setting. 
5. Leukocytosis in systemic lupus erythematosus 
Leukocytosis (mostly granulocytes) can occur in SLE. When present, it is usually due to 
infection or the use of high doses of glucocorticoids [43], but may occur during acute 
exacerbations of SLE. A shift of granulocytes to more immature forms (a "left" shift) suggests 
infection. 
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6. Thrombocytopenia in systemic lupus erythematosus  
Mild thrombocytopenia (platelet counts between 100,000 and 150,000/microL) has been 
noted in 25 to 50 percent of patients; while counts of less than 50,000/microL occur in only 
10 percent [1, 3,4,33]. There are several potential causes of thrombocytopenia in patients 
with SLE. Immune mediated platelet destruction is most often the cause, but platelet 
consumption may also occur in association with microangiopathic hemolytic anemia (see 
'Microangiopathic hemolytic anemia' above) or could be due to impaired platelet production 
as a result of the use of cytotoxic, immunosuppressive, or other drugs. 
The major mechanism is immunoglobulin binding to platelets followed by phagocytosis in 
the spleen, as in idiopathic thrombocytopenic purpura (ITP) [47]. Membrane glycoproteins 
(GP) are most often the target of such antibodies (eg, GP IIb/IIIa) but anti-HLA specificity 
also occurs [48]. 
Antigen-dependent B cell development in lymphoid tissues is influenced by binding of 
CD40 on B cells to CD40-ligand on activated T cells. The finding of autoantibodies to CD40-
ligand in patients with SLE, APS, and ITP, but not in the serum of healthy blood donors 
suggests that interference with T cell and B cell interaction may play a role in the 
development of thrombocytopenia [49]. 
Other important mechanisms in selected patients include bone marrow suppression by 
immunosuppressive drugs (other than corticosteroids), increased consumption due to a 
thrombotic thrombocytopenic purpura [TTP] [26], the antiphospholipid syndrome, or 
antibodies that block the thrombopoietin receptor on megakaryocytes or their precursors.  
ITP may be the first sign of SLE, followed by other symptoms as long as many years later. It 
has been estimated that 3 to 15 percent of patients with apparently isolated ITP go on to 
develop SLE [50].  
Evans syndrome (ie, both autoimmune thrombocytopenia and autoimmune hemolytic 
anemia) also may precede the onset of SLE. Severe bleeding from thrombocytopenia is only 
experienced by a minority of patients; however, SLE patients with thrombocytopenia are 
more likely to have associated significant organ damage, such as heart and kidneys and the 
CNS [51]. 
6.1 Medical therapy 
Platelet counts between 50,000/microL and 20,000/microL rarely cause more than a 
prolonged bleeding time, while counts of less than 20,000/microL may be associated with 
petechiae, purpura, ecchymoses, epistaxis, gingival, and other clinical bleeding.  
Treatment of thrombocytopenia is usually recommended for symptomatic patients with 
counts of less than 50,000/microL and for all patients with counts of less than 
20,000/microL. 
The treatment of ITP in SLE is the same as that in patients without lupus. 
Briefly, the mainstay of treatment is glucocorticoid therapy. Older studies used prednisone 
(1 mg/kg per day in divided doses) [54, 55]. However, treatment with four to eight cycles of 
oral high dose dexamethasone (40 mg per day for four days) at intervals of two weeks to 
four weeks may result in similar remission rates and better long-term responses than those 
observed in historical controls treated with daily prednisone [56]. 
Most patients respond to glucocorticoid therapy within one to eight weeks [57]. If there is no 
significant increase in the platelet count within one to three weeks or side effects are 
intolerable, the following options may be considered and used depends upon the severity of 
the thrombocytopenia and the presence or absence of other manifestations of SLE: 
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 Azathioprine  
 Cyclophosphamide [58].  
 Intravenous immune globulin is very effective and may be preferred to azathioprine or 
cyclophosphamide when a rapid rise in platelet count is necessary (as in the patient 
who is actively bleeding or requires emergent surgery) [59]. 
 Mycophenolate mofetil may be useful in the patient refractory to other medical therapy 
[60]. 
 Rituximab has been used to treat ITP in patients without SLE who were refractory to 
other treatments and this B lymphocyte depleting approach may be beneficial for other 
manifestations of lupus [25].  
6.2 Splenectomy 
Splenectomy can raise the platelet count but it does not reliably produce a durable remission 
of thrombocytopenia. Relapse following splenectomy may occur and has been noted at 
varying times from 1 to 54 months after surgery [62]. 
6.3 Thrombocytopenia following splenectomy 
Patients with persistent thrombocytopenia after splenectomy may subsequently respond to 
azathioprine, cyclophosphamide, rituximab, intravenous immunoglobulin, or danazol 
[23,63,64]. If possible, splenectomy should be preceded by immunization with 
pneumococcal vaccine to reduce the risk of pneumococcal sepsis. 
7. Thrombocytosis in systemic lupus erythematosus 
Thrombocytosis is a less frequent finding in patients with SLE and it might be occurring as 
an acute phase reactant and a sign of active disease.  
8. Pancytopenia in systemic lupus erythematosus 
Although peripheral destruction of red cells, leukocytes, and platelets may occur together 
and lead to clinically significant pancytopenia, depression of all three cell lines also suggests 
bone marrow failure, as in the case in aplastic anemia. Thus, bone marrow examination is 
the most important diagnostic test to perform.  
Causes of marrow failure include drugs and coincidental diseases including: the acute 
leukemias, large granular lymphocyte leukemia, the myelodysplastic syndromes, marrow 
replacement by fibrosis or tumor, severe megaloblastic anemia, paroxysmal nocturnal 
hemoglobinuria (PNH), and overwhelming infection. In addition, unexplained cytopenia 
can be associated with bone marrow necrosis, dysplasia, and distortion of the bone marrow 
architecture [70]. 
Among patients with SLE an unusual cause of pancytopenia is the macrophage activation 
syndrome. The clinical characteristics of 12 patients with SLE-associated macrophage 
activation syndrome included [71]: 
Fever (100%), weight loss (80%), arthritis (50%), pericarditis (42%), rash (66%) myocarditis 
(33%), nephritis (33%), splenomegaly (27%), hepatomegaly (13%), lymphadenopathy(73%), 
anemia (100%), leukopenia (87%), hyperferritinemia (100%), anti-DNA antibodies (80%),low 
CRP (<30 mg/L) (90%), hypocomplementemia (60%). 
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The demonstration of hemophagocytosis in the bone marrow or in material obtained from 
peripheral lymph nodes is a characteristic finding. 
The few reported cases of macrophage activation syndrome in patients with SLE have 
usually responded to treatment with glucocorticoids and immunosuppressive agents. 
Optimal treatment is uncertain.  
9. Lymphadenopathy and splenomegaly in systemic lupus erythematosus 
Enlargement of lymph nodes occurs in approximately 50 percent of patients with SLE. The 
nodes are typically soft, nontender, discrete, varying in size from 0.5 to several centimeters, 
and usually detected in the cervical, axillary, and inguinal areas. Lymphadenopathy is more 
frequently noted at the onset of disease or in association with an exacerbation. Biopsies 
reveal areas of follicular hyperplasia and necrosis, the appearance of hematoxylin bodies is 
highly suggestive of SLE, although unusual [1]. 
Lymph node enlargement can also be due to infection or a lymphoproliferative disease in 
SLE. When infections are present, the enlarged nodes are more likely to be tender. 
Prominent lymphadenopathy may also be a manifestation of angioimmunoblastic T cell 
lymphoma. This disorder has other clinical features (arthritis, Coombs-positive hemolytic 
anemia, skin rash, fever, and weight loss) that are suggestive of systemic lupus 
erythematosus or systemic onset juvenile rheumatoid arthritis (Still's disease). Enlargement 
of the spleen occurs in 10 to 46 percent of patients, particularly during active disease. 
Splenomegaly is not necessarily associated with a cytopenia. Pathologic examination of 
spleen reveals an onion skin appearance of the splenic arteries, a lesion that is thought to 
represent healed vasculitis. 
In view of the frequent presence of lymphadenopathy and splenomegaly in SLE, the 
possibility of a lymphoproliferative malignancy may be considered. The risk of non-
Hodgkin lymphoma appears to be increased four- to five fold in patients with lupus. 
A lymph node biopsy may be warranted when the degree of lymphadenopathy is out of 
proportion to the activity of the lupus. 
One of the rare diseases that reported to be associated with SLE is: 
9.1 Kikuchi-Fujimoto’s disease (KFD) 
Also called histiocytic necrotizing lymphadenitis which is a rare benign and self limited 
disease, of unknown etiology, affects mainly young women [77]. It presents with localized 
lymphadenopathy, predominantly in the cervical region, less commonly include axillary 
and mesenteric lymphadenopathy accompanied by fever and leucopenia in up to 50% of the 
cases [78, 79]. KFD has been reported in association with systemic lupus erythematosus 
(SLE), the relation between Kikuchi’s disease and SLE is not yet completely understood and 
remains complex. The reports imply that SLE may be present before, at the same time, or 
after the clinical appearance of KFD [77-79]. 
KFD can be a complication of prolonged and multiple immunosuppressant use in SLE 
patients, There is a published case report in 2011 of KFD that diagnosed based on a lymph 
node biopsy in a 31 year old Saudi female patient with an established diagnosis of stage IV 
lupus nephritis. She presented with fever, axillary lymphadenopathy and neutropenia. The 
patient is known to have SLE for 16 years prior to the presentation with history of 
prolonged use of many immunosuppressive medications. The patient treated with 
intravenous antibiotic as a case of febrile neutropenia and recovered spontaneously. They 
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concluded that in most of the cases the diagnosis of KFD was made before or at the same 
time of the diagnosis of SLE. In this case report the diagnosis of KFD was made years after 
the diagnosis of SLE. They also noted that the patient received prolonged courses of 
immunosuppressant medications including mycophenolate mofetil, and then 6 cycles of 
cyclophosphamide, she was placed then on azothioprine and hydroxychloroquine. So they 
consider the prolonged use of immunosuppressant medications a risk factor for KFD in a 
well established SLE with lupus nephritis.  
10. Antibodies to clotting factors and anti-phospholipids syndrome in 
systemic lupus erythematosus 
Antibodies to a number of clotting factors, including VIII, IX, XI, XII, and XIII have been 
noted in patients with SLE [1,2,33]. These antibodies may not only cause abnormalities of in 
vitro coagulation tests but may also cause bleeding.  
Much more common are aPL (antiphospholipid antibodies), the presence of which has been 
associated with a prolongation of the partial thromboplastin time (PTT) (lupus 
anticoagulant activity) and an increased risk of arterial and venous thrombosis, 
thrombocytopenia, and fetal loss [72, 73]. Antibodies to other phospholipids and to 
phospholipid binding proteins (eg, anticardiolipin antibodies) in moderate or high levels 
may also be associated with these clinical phenomena. When aPL occurs in association with 
one or more of these clinical features in a patient with SLE it suggests the presence of  
the APS.  
10.1 Antiphospholipid syndrome 
The antiphospholipid syndrome (APS) is defined by two major components:  
1. The occurrence of at least one clinical feature: vascular event or pregnancy morbidity 
AND  
2. The presence of at least one type of autoantibody known as an antiphospholipid 
antibody (aPL). 
In addition, there are aPL-related clinical manifestations that are not part of the APS 
Classification Criteria, such as livedo reticularis, thrombocytopenia, cardiac valve disease, or 
aPL-nephropathy. 
APL is directed against serum proteins bound to anionic phospholipids and may be 
detected by a: Lupus anticoagulant tests, Anticardiolipin antibody ELISA and Anti-ß2 
glycoprotein-I ELISA. 
The full clinical significance of other autoantibodies, including those directed against 
prothrombin, annexin V, phosphatidylserine, and phosphatidylinositol, remain unclear. 
APS occurs as a primary condition or in the setting of an underlying systemic autoimmune 
disease, particularly SLE [72]. 
 Classification criteria have been developed for research purposes. They may be helpful 
to clinicians, but not all the classification criteria need to be met to make a clinical 
diagnosis of APS.  
Definite APS is considered present if at least one of the following clinical criteria and at least 
one of the following laboratory criteria are satisfied: 
 Clinical: one or more episodes of venous, arterial, or small vessel thrombosis and/or 
morbidity with pregnancy. 
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 Thrombosis: unequivocal imaging or histological evidence of thrombosis in any tissue 
or organ, OR  
 Pregnancy morbidity : otherwise unexplained death at ≥10 weeks gestation of a 
morphologically normal fetus, OR  
 One or more premature births before 34 weeks of gestation because of eclampsia, 
preeclampsia, or placental insufficiency, OR  
 Three or more embryonic (<10 week gestation) pregnancy losses unexplained by 
maternal or paternal chromosomal abnormalities or maternal anatomic or hormonal 
causes. 
 Laboratory : the presence of aPL, on two or more occasions at least 12 weeks apart and 
no more than five years prior to clinical manifestations, as demonstrated by one or more 
of the following: IgG and/or IgM aCL in moderate or high titer), antibodies to ß2-GP-I 
of IgG or IgM isotype at a high titer. LA activity detected according to published 
guidelines [72, 75]. 
10.1.1 Pathology 
The characteristic pathologic finding in the APS is a bland thrombosis with minimal 
vascular or perivascular inflammation. This change is not specific for the APS, as it also 
occurs in the kidney in a variety of other disorders including the hemolytic-uremic 
syndrome/thrombotic thrombocytopenic purpura, systemic sclerosis (scleroderma), and 
malignant hypertension. Larger vessels, both arteries and veins, may develop in situ 
thrombosis or be sites from or into which emboli originate or lodge. 
10.1.2 Clinically 
 The APS is characterized by venous or arterial thromboses, morbidity occurring in the 
setting of pregnancy, and/or aPL-related clinical manifestations that are not part of the 
APS Classification Criteria, such as livedo reticularis, thrombocytopenia, cardiac valve 
disease, or aPL-nephropathy [73, 74]. 
In a series of 1000 patients with either primary or secondary APS, the various disease 
features were [74]: 
Deep vein thrombosis (32%), Thrombocytopenia (22%), Livedo reticularis (20%), Stroke 
(13%), Superficial thrombophlebitis (9%), Pulmonary embolism (9%), Fetal loss (8 %), TIA 
(7%), Hemolytic anemia (7%). 
In rare patients, APS results in multi-organ failure because of multiple blood vessel 
occlusions, a condition referred to as "catastrophic antiphospholipid syndrome".  
In addition to those already mentioned above, other possible aPL-related clinical 
manifestations include migraine headache, Reynaud phenomenon, pulmonary 
hypertension, avascular necrosis, cutaneous ulcers that resemble pyoderma gangrenosum, 
adrenal insufficiency due to hemorrhagic infarction, and cognitive deficits [72-75].  
 Thrombosis: the risk of both venous and arterial thrombosis and/or thromboembolism 
is increased in individuals with positive tests for LA activity or medium or high levels 
of aCL. The risk of recurrent thrombosis or thromboembolism may be further enhanced 
in those with positivity to three aPL activities (LA, aCL, and ß2-glycoprotein-I) upon 
repeated testing [74]. 
Initial site: venous thromboses are more common than arterial thromboses in the APS [73, 
74]. The most common site of DVT is the calf, but the renal veins, the hepatic, axillary, 
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concluded that in most of the cases the diagnosis of KFD was made before or at the same 
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In a series of 1000 patients with either primary or secondary APS, the various disease 
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Deep vein thrombosis (32%), Thrombocytopenia (22%), Livedo reticularis (20%), Stroke 
(13%), Superficial thrombophlebitis (9%), Pulmonary embolism (9%), Fetal loss (8 %), TIA 
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In rare patients, APS results in multi-organ failure because of multiple blood vessel 
occlusions, a condition referred to as "catastrophic antiphospholipid syndrome".  
In addition to those already mentioned above, other possible aPL-related clinical 
manifestations include migraine headache, Reynaud phenomenon, pulmonary 
hypertension, avascular necrosis, cutaneous ulcers that resemble pyoderma gangrenosum, 
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of aCL. The risk of recurrent thrombosis or thromboembolism may be further enhanced 
in those with positivity to three aPL activities (LA, aCL, and ß2-glycoprotein-I) upon 
repeated testing [74]. 
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subclavian, and retinal veins, the cerebral sinuses, and the vena cava may also be involved. 
The most common site of arterial thrombosis is the cerebral vessels, but coronary, renal, and 
mesenteric arteries and arterial bypass graft occlusions have also been noted. 
To some degree, the site of thrombosis may be related to the type of aPL present. This was 
illustrated in a retrospective study of 637 patients with APS in which DVT and PE were 
more frequent among patients with LA, while coronary, cerebrovascular, and peripheral 
arterial events were more likely in those with elevated levels of IgG or IgM aCL. 
 Deep venous thrombosis: APL can be detected in approximately 5 to 21 percent of all 
patients with DVT [72]. The incidence of DVT may correlate with the level of aCL. As 
an example, one study found that DVT occurred in 44% of patients with high titers of 
aCL, in 29% with low titers, and in only 10% of those without these antibodies [73]. 
Stroke: the APS is strongly linked to ischemic stroke [74, 80]. The occurrence of livedo 
reticularis in association with a stroke is known as Sneddon's syndrome [73]. In the great 
majority of cases, Sneddon's syndrome is associated with detectable aPL. 
A thrombotic stroke occurring in a young patient with no overt risk factors for cerebrovascular 
disease is the classic setting to suspect the APS. In one study, aPL was found in 25% of patients 
younger than 45 years of age who presented with a stroke of unclear etiology [81]. In another 
report, 20 percent of stroke victims under the age of 50 had aPL [74]. Ischemic stroke may be a 
manifestation in situ thrombosis or due to embolism arising from a valvular heart disease. If 
routine transthoracic echocardiography is normal, transesophageal echo may be indicated to 
assess for vegetations due to nonbacterial endocarditis. 
Several studies have evaluated the risk of stroke associated with the presence of aPL: 
In a review of 2000 healthy male subjects, the relative risk of stroke at 15 years of follow-up 
was 2.2 in subjects with aPL []. Events were observed primarily in subjects who had both ß2-
GP-I and IgG aCL (ie, ß2-GP-I dependent aCL).  
In the Stroke Prevention in Young Women study, the presence of LAs and aCL was 
evaluated in 160 cases and 340 controls [74]. After adjustment for potential confounders, the 
relative odds of stroke for women with an aCL of any isotype or an LA was 1.87 (95% CI 1.2 
to 2.8). Similar findings of an increased risk of ischemic stroke associated with aCL limited 
to women were noted in a report from the Framingham Cohort and Offspring Study 
(hazard ratio for women 2.6; 95% CI 1.3 to 5.4) [73]. 
Neurologic syndromes besides stroke: strong associations are now recognized between the 
presence of aPL and the occurrence of cognitive deficits and/or white matter lesions. 
However, the link with the APS is less strong for other neurological associations. 
White matter lesions: see chapter of neurology in SLE. 
Other neurological associations: epilepsy, depression, psychosis, chorea and hemiballismus, 
transverse myelopathy, sensorineural hearing loss, orthostatic hypotension, migraine. 
Recurrent thrombotic events: are common in APS. Most but not all observers have noted 
that an initial arterial thrombosis tends to be followed by an arterial event, and that an initial 
venous thrombosis is usually followed by a venous event [72]. 
Pregnancy loss and preeclampsia: the presence of APS may be related to several types of 
morbidity during pregnancy. These include fetal death after 10 weeks gestation, premature 
birth due to severe preeclampsia or placental insufficiency, or multiple embryonic losses 
(<10 weeks gestation).  
In patients with preeclampsia or HELLP syndrome, the possibility of the catastrophic APS 
must be considered, particularly in patients with histories of thrombosis or spontaneous 
abortions [73]. 
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Hematologic manifestations: prominent hematologic manifestations of APS include 
thrombocytopenia, microangiopathic hemolytic anemia and, in rare cases, bleeding: 
Thrombocytopenia: a review of 13 studies of 869 patients with SLE, found that 
thrombocytopenia was more common in those with LA (55 percent) and aCL (29 PERCENT) 
than in those without these antibodies [50]. Conversely, patients with thrombocytopenia 
associated with autoimmune disorders frequently have aPL (eg, 70 to 82 percent of patients 
with SLE and thrombocytopenia, and 30 to 40 percent of those with ITP [26, 49, 50]. 
Thrombotic microangiopathy: APL has been implicated in some cases of TTP/HUS that 
occur in SLE. See hematological manifestations in SLE. 
Bleeding episodes: the presence of antibodies to prothrombin should be suspected when a 
patient with a known LA also has a low prothrombin level and develops bleeding 
complications rather than thrombosis. 
Pulmonary disease: pulmonary embolism occurs in approximately one-third of patients 
with the APS who develop DVT. Other recognized pulmonary complications of the APS 
include [26, 48-50]: Pulmonary arterial thrombosis with or without thromboembolic 
pulmonary hypertension and alveolar hemorrhage.  
In addition, fibrosing alveolitis, adult respiratory distress syndrome, and 
nonthromboembolic pulmonary hypertension have been reported in association with aPL 
[50, 72]. However, the relationship to these disorders to aPL is unclear 
Cardiovascular disease: patients with aPL commonly have cardiac disease, including 
valvular thickening, mitral valve nodules, and nonbacterial vegetations. Involvement of the 
mitral and aortic valves can lead to valvular regurgitation and rarely to stenosis. 
APL have also been incriminated in intracardiac thrombi, pericardial effusion, 
cardiomyopathy, emboli in those with or without infective endocarditis, premature 
restenosis of vein grafts for coronary bypass, and peripheral vascular disease [50].  
Cutaneous: APL has been associated with many cutaneous abnormalities including splinter 
hemorrhages, livedo reticularis, cutaneous necrosis and infarction, [49, 50]. 
Gastrointestinal disease: patients with aPL may have ischemia involving the esophagus, 
stomach, duodenum, jejunum, ileum, or colon resulting in gastrointestinal bleeding, 
abdominal pain, an acute abdomen, esophageal necrosis with perforation, or giant gastric or 
atypical duodenal ulceration [73]. Splenic or pancreatic infarction may also occur. In 
addition, the liver may involved; hepatic or portal venous thrombosis may result in the 
Budd-Chiari syndrome, hepatic-veno-occlusive disease, hepatic infarction, portal 
hypertension, and cirrhosis. [72]. 
Ocular manifestations: amaurosis fugax, retinal venous and arterial occlusion, and anterior 
ischemic optic neuropathy have occurred in patients with aPL [72].  
Catastrophic APS: a small subset of patients with APS has widespread thrombotic disease 
with multiorgan failure, which is called "catastrophic APS." Preliminary criteria proposed 
for classification .purposes have been published and validated (Among 1000 patients with 
the APS followed for a mean of seven years, only 8 (0.8 percent) developed catastrophic APS 
[73, 74]. In the majority of these patients, multiorgan involvement was present at the time of 
diagnosis of APS. 
Patients with catastrophic APS may have laboratory features such as elevated fibrin 
degradation products, depressed fibrinogen levels, or elevated D-dimer concentrations that 
are more typically found with disseminated intravascular coagulation (DIC). 
Catastrophic APS is frequently fatal, with a reported mortality rate approaching 50 percent 
despite anticoagulant and immunosuppressive treatment [74]. 
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10.1.3 Primary APS versus SLE 
The antiphospholipid syndrome was first described as a complication of the disease ‘SLE’. 
However, in many cases – indeed probably the vast majority did NOT have any evidence of 
lupus. This gave rise to the term ‘Primary Antiphospholipid Syndrome’ (PAPS).  
For those patients where the clotting tendency is secondary to another disease such as 
lupus, the condition is often called ‘Secondary Anitphospholipid Syndrome'.  
It should be stressed that the majority of patients with ‘Primary’ APS (Hughes Syndrome) 
do NOT go on to develop lupus in later life. The inter-relationship between lupus and APS 




some data suggest that the clinical manifestations of primary APS and APS associated with 
SLE are similar [73]. In contrast, a subsequent study of 122 patients noted that the frequency 
of arterial thromboses, venous thromboses, and fetal loss was greater in patients with APS 
and SLE than in those with primary APS [72]. 
A separate issue is the frequency of evolution of APS into SLE or lupus-like disease. Three 
studies involving 70 to 128 patients with APS found a variable rate of development of SLE 
over time: 
Zero percent at five years, 4 percent at 6.5 years, 13 percent at nine years. 
10.1.4 Mortality 
The presence of aPL in the serum of patients with SLE has been identified as an independent 
risk factor for premature death. There was an increased risk of premature death in patients 
with aPL, thrombocytopenia, and arterial occlusion. Other factors associated with 
premature death were the intensity of anticoagulation treatment, renal involvement, 
pleuritis, and disease activity. 
10.1.5 Management and recommendation  
Current therapies for the APS include the following medications: low molecular weight 
heparin , unfractionated heparin, warfarin, antiplatelet agents, aspirin , clopidogrel, 
hydroxychloroquine (see below). 
Initial approach to thrombosis: 
treatment for venous thromboembolic disease is part of the American Colleuge of Chest 
Physicians (ACCP) Evidence-Based Clinical Practice Guidelines (8th Edition), as the following:  
for patients with objectively confirmed deep vein thrombosis (DVT) or pulmonary 
embolism (PE), we recommend anticoagulant therapy with subcutaneous (SC) low-
molecular-weight heparin (LMWH), monitored IV, or SC unfractionated heparin (UFH), 
unmonitored weight-based SC UFH, or SC fondaparinux (all Grade 1A). For patients with a 
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high clinical suspicion of DVT or PE, we recommend treatment with anticoagulants while 
awaiting the outcome of diagnostic tests (Grade 1C).  
For patients with confirmed PE, we recommend early evaluation of the risks to benefits of 
thrombolytic therapy (Grade 1C); for those with hemodynamic compromise, we recommend 
short-course thrombolytic therapy (Grade 1B); and for those with nonmassive PE, we 
recommend against the use of thrombolytic therapy (Grade 1B). 
In acute DVT or PE, we recommend initial treatment with LMWH, UFH or fondaparinux for 
at least 5 days rather than a shorter period (Grade 1C); and initiation of vitamin K 
antagonists (VKAs) together with LMWH, UFH, or fondaparinux on the first treatment day, 
and discontinuation of these heparin preparations when the international normalized ratio 
(INR) is > or = 2.0 for at least 24 h (Grade 1A).  
For patients with DVT or PE secondary to a transient (reversible) risk factor, we recommend 
treatment with a VKA for 3 months over treatment for shorter periods (Grade 1A). For 
patients with unprovoked DVT or PE, we recommend treatment with a VKA for at least 3 
months (Grade 1A), and that all patients are then evaluated for the risks to benefits of 
indefinite therapy (Grade 1C).  
We recommend indefinite anticoagulant therapy for patients with a first unprovoked 
proximal DVT or PE and a low risk of bleeding when this is consistent with the patient's 
preference (Grade 1A), and for most patients with a second unprovoked DVT (Grade 1A). 
We recommend that the dose of VKA be adjusted to maintain a target INR of 2.5 (INR range, 
2.0 to 3.0) for all treatment durations (Grade 1A).  
For prevention of post-thrombotic syndrome (PTS) after proximal DVT, we recommend use 
of an elastic compression stocking (Grade 1A). For DVT of the upper extremity, we 
recommend similar treatment as for DVT of the leg (Grade 1C). Selected patients with 
lower-extremity (Grade 2B) and upper-extremity (Grade 2C). DVT may be considered for 
thrombus removal, generally using catheter-based thrombolytic techniques. For extensive 
superficial vein thrombosis, we recommend treatment with prophylactic or intermediate 
doses of LMWH or intermediate doses of UFH for 4 weeks (Grade 1B). 
The optimal duration of anticoagulation for venous thromboembolic disease following a 
first event is uncertain. However, given the high likelihood of recurrence in the untreated 
patient and the potentially devastating nature of recurrent thromboembolic events, we 
recommend lifelong anticoagulation for patients with the APS (Grade 1B) [86-89].  
Prophylaxis of the asymptomatic patient 
In the absence of symptoms or a history of symptoms attributable to the APS, we do not 
recommend the use of aspirin as prophylaxis (Grade 2B). For patients with SLE and aPL but 
no APS manifestations, the combination of low-dose aspirin and hydroxychloroquine may 
be considered (Grade 2C)[80-89].  
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heparin , unfractionated heparin, warfarin, antiplatelet agents, aspirin , clopidogrel, 
hydroxychloroquine (see below). 
Initial approach to thrombosis: 
treatment for venous thromboembolic disease is part of the American Colleuge of Chest 
Physicians (ACCP) Evidence-Based Clinical Practice Guidelines (8th Edition), as the following:  
for patients with objectively confirmed deep vein thrombosis (DVT) or pulmonary 
embolism (PE), we recommend anticoagulant therapy with subcutaneous (SC) low-
molecular-weight heparin (LMWH), monitored IV, or SC unfractionated heparin (UFH), 
unmonitored weight-based SC UFH, or SC fondaparinux (all Grade 1A). For patients with a 
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high clinical suspicion of DVT or PE, we recommend treatment with anticoagulants while 
awaiting the outcome of diagnostic tests (Grade 1C).  
For patients with confirmed PE, we recommend early evaluation of the risks to benefits of 
thrombolytic therapy (Grade 1C); for those with hemodynamic compromise, we recommend 
short-course thrombolytic therapy (Grade 1B); and for those with nonmassive PE, we 
recommend against the use of thrombolytic therapy (Grade 1B). 
In acute DVT or PE, we recommend initial treatment with LMWH, UFH or fondaparinux for 
at least 5 days rather than a shorter period (Grade 1C); and initiation of vitamin K 
antagonists (VKAs) together with LMWH, UFH, or fondaparinux on the first treatment day, 
and discontinuation of these heparin preparations when the international normalized ratio 
(INR) is > or = 2.0 for at least 24 h (Grade 1A).  
For patients with DVT or PE secondary to a transient (reversible) risk factor, we recommend 
treatment with a VKA for 3 months over treatment for shorter periods (Grade 1A). For 
patients with unprovoked DVT or PE, we recommend treatment with a VKA for at least 3 
months (Grade 1A), and that all patients are then evaluated for the risks to benefits of 
indefinite therapy (Grade 1C).  
We recommend indefinite anticoagulant therapy for patients with a first unprovoked 
proximal DVT or PE and a low risk of bleeding when this is consistent with the patient's 
preference (Grade 1A), and for most patients with a second unprovoked DVT (Grade 1A). 
We recommend that the dose of VKA be adjusted to maintain a target INR of 2.5 (INR range, 
2.0 to 3.0) for all treatment durations (Grade 1A).  
For prevention of post-thrombotic syndrome (PTS) after proximal DVT, we recommend use 
of an elastic compression stocking (Grade 1A). For DVT of the upper extremity, we 
recommend similar treatment as for DVT of the leg (Grade 1C). Selected patients with 
lower-extremity (Grade 2B) and upper-extremity (Grade 2C). DVT may be considered for 
thrombus removal, generally using catheter-based thrombolytic techniques. For extensive 
superficial vein thrombosis, we recommend treatment with prophylactic or intermediate 
doses of LMWH or intermediate doses of UFH for 4 weeks (Grade 1B). 
The optimal duration of anticoagulation for venous thromboembolic disease following a 
first event is uncertain. However, given the high likelihood of recurrence in the untreated 
patient and the potentially devastating nature of recurrent thromboembolic events, we 
recommend lifelong anticoagulation for patients with the APS (Grade 1B) [86-89].  
Prophylaxis of the asymptomatic patient 
In the absence of symptoms or a history of symptoms attributable to the APS, we do not 
recommend the use of aspirin as prophylaxis (Grade 2B). For patients with SLE and aPL but 
no APS manifestations, the combination of low-dose aspirin and hydroxychloroquine may 
be considered (Grade 2C)[80-89].  
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1. Introduction  
Lymphoproliferative disorders can develop in the setting of many immunosupressive 
conditions, and they have been well established following solid organ transplantation or 
allogeneic bone marrow transplantation (Blaes & Morrison, 2010). The incidence varies, 
depending on the type of organ transplanted, the degree of immunosuppression, the 
number of episodes of acute rejection and the patient's immune status to Epstein-Barr virus. 
The 2008 World Health Organization Classification of Tumours of Haematopoietic and 
Lymphoid Tissues defines monomorphic posttransplant lymphoproliferative disorders 
(PTLD) as lymphoid or plasmacytic proliferations that fulfill the criteria for one of the B-cell 
or T/NK-cell neoplasms recognized in immunocompetent patients. However, indolent B-
cell lymphomas, such as extranodal marginal zone lymphoma of mucosa-associated 
lymphoid tissue (MALT lymphoma), are specifically excluded from this category. 
Autoimmune and chronic inflammatory disorders are also associated with increased risks of 
non-Hodgkin lymphoma (NHL). Concretely in rheumatoid arthritis and systemic lupus 
erythematosus (SLE), an increased risk of malignant lymphomas has been described 
repeatedly, whereas the evidence is less consistent for other inflammatory disorders that 
display autoimmune phenomena, such as psoriasis, inflammatory bowel disorders and 
sarcoidosis. The risk of NHL in SLE patients is estimated to be 3- to 4-fold higher (Smedby et 
al., 2008a). Although the incidence of PTLD is thought to be bimodal and typically related to 
Epstein-Barr virus in the first year after solid-organ transplantation, the relationship 
between Epstein-Barr virus and NHL in SLE and other autoimmune diseases is not yet well 
established. 
Because different NHL subtypes develop at different stages of lymphocyte differentiation, 
the incidence of specific NHL subtypes varies based on the type of autoimmune and 
inflammatory disorder as well as on the type and amount of autoimmune therapy. Data 
regarding the histology of the NHL that develops in patients with SLE suggest that these 
lesions derive from lymphocytes that have been exposed to antigen (Bernatsky et al., 2005a). 
Lymphoma development after the antigen-exposure stages of differentiation might suggest 
that chronic antigenic stimulation has a role in auto immunity-related lymphomas. From the 
lymphoma perspective, diffuse large B-cell lymphomas seem to display the most 
pronounced and general association with autoimmunity and inflammation, although certain 
specific T-cell lymphomas have been linked to distinct autoimmune conditions (e.g. 
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specific T-cell lymphomas have been linked to distinct autoimmune conditions (e.g. 
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enteropathy-type T-cell lymphoma to coeliac disease) (Smedby et al., 2008b). Studies of 
lymphoproliferative disorders occurring in patients with SLE have shown an increased risk 
of marginal zone lymphoma, predominantly of the MALT type, and of diffuse large B-cell 
lymphoma (DLBCL) (Bernatsky et al., 2005b). 
The mechanisms responsible for the association between lymphoma and SLE remain 
unknown. Exposure to immunosuppressive agents has been blamed for the elevated risk of 
lymphoma, but cases of lymphoma in patients with no history of having received 
immunosuppressive drugs have also been reported. The study of Bernatsky et al looking for 
the incidence of cancer in patients with SLE, reports that the highest relative risk of 
hematological malignancy occurred in the first year after diagnosis of SLE which indicates 
that cancer risk is not completely explained by cumulative doses of immunosuppressive 
drugs (Bernatsky et al., 2005b). 
2. Objective 
SLE is an autoimmune disease characterized by immune mediated attacks against  
the body’s own tissues. The aetiology of the illness is unknown. In essence the 
fundamental rules of tolerance are violated and autorreactive B and T cell clones 
cooperate, proliferate and lead the production of pathogenic auto-antibodies. The 
development of lymphomas and autoimmunity involves an intrincate interplay among 
various pathogenic factors. Besides genetic abnormalities, a variety of environmental and 
microbial factors, as well as abnormal immune-regulatory processes and tolerance 
mechanisms can lead to autoimmunity and the generation of different lymphoma 
subtypes. Within germinal centers, naïve B cells undergo activation, proliferation, somatic 
hypermutation of rearranged V regions genes, isotype switching, and subsequent positive 
and/or negative selection by antigen.  However, the germinal center exclusion of 
autorreaction is defective in SLE and the existence of a defective check point in the 
maintenance of peripheral B cell tolerance appears to be specific to patients with SLE. This 
is important because, some autorreactive B cells may initiate germinal center reactions 
and autorreactivity arises de novo in the germinal center through somatic mutations. 
Moreover, in patients with active SLE a marked B cell lymphopenia that affects naïve  
B cells leads to a relative predominance of memory B cells with multiple somatic 
mutations. Somatic mutations are introduced at a high rate in the germinal center and are 
implicated usually in single nucleotide exchanges. However, deletions and insertions may 
also occur. The involvement of the hypermutation machinery in deletions and insertions 
seem to be the main cause of generation of several lymphoproliferative disorders in  
these patients. 
The aim of the present review is to summarize potential harmful steps in the development 
of lymphocytes, tolerance checkpoints  (anergy, deletion, germinal centre exclusion, receptor 
editing and revision, memory check points, somatic hypermutation) and immune responses 
that induce the acquisition and proliferation of neoplastic lymphocytes in the contex of SLE. 
We also review the different subtypes of lymphoproliferative disorders associated with SLE 
and its management. 
3. Development of B cell repertoire 
B cells are derived from CD34+CD19-CD10+cells. The earliest lineage-committed B cell is 
the pro-B cell, which is characterized by a CD19+ phenotype (Wang et al., 1998). The pro-B 
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cell stage is defined by immunoglobulin (Ig) heavy chain rearrangement initiated via the 
recombinase activating genes RAG1 and RAG2 (Blom & Spits, 2006; LeBien & Tedder, 2008). 
In these cells, DH to JH gene rearrangements occur, often, but not always in both IgH 
alleles, which are located on chromosome 14 in humans (Cobett, et al., 1997; Ravetch, et al., 
1981). In the next, step VH gene segment is rearranged to a DHJH (Cook  & Tomlinson, 
1995). If the first VH/DH/JH rearrangement is nonproductive, the B cell precursor has a 
second chance to generate a productive IgH gene rearrangement by using the second IgH 
allele. When heavy chain gene rearrangement is successful, then Ig class is 
expressed on the cell surface in association with  heavy chain and the signal 
transducing molecules CD79a/b to form the pre-B cell receptor. This is accompanied 
by loss of CD34 and TdT expression and marks the transition to the pre-B-cell stage of 
development. Pre-B cells discontinue further IgH gene rearrangements, divide several times, 
and then initiate light chain gene rearrangements (Rajewsky, 1996). Internalization of the pre-B 
cell receptor and rearrangement of the light chains occur next, defaulting to the kappa gene. 
Lambda gene rearrangement and expression generally occur only if kappa gene 
rearrangement is unsuccessful. Successful light chain rearrangement induces the expression of 
sIgM composed by IgH and either  or  light chains. Failure to rearrange either the heavy or 
light chains induces apoptosis. If immature B cells react with self antigens, mechanisms of 
negative selection can induce apoptosis, receptor edition or anergy (LeBien, 2000).  
Secondary B cell development is characterized by the migration of immature B cells to the 
spleen, where they differentiate into mature naïve B cells, now characterized by surface IgD 
in addition to IgM, CD21 and CD22, as well as a loss of CD10. Positive selection 
subsequently commences, with cells failing to react succumbing to cell death. Following this 
process, mature cells migrate to secondary lymphoid tissue whereupon they can further 
differentiate to plasma cells or establish a germinal center when they recognize an antigen 
(DiLillo, et al., 2008).  
4. Germinal centre reaction 
Within germinal centers, activated B cells undergo the process of somatic hypermutation. 
Centrally proliferating B cells are referred to as centroblasts, which divide to form smaller 
centrocytes that migrate to periphery of the germinal center.  Centroblasts first remove the 
surface immunoglobulin, then undergo several rounds of division and then re-express 
mutated immunoglobulin receptors as centrocytes. Centrocytes expressing BCR with 
increased affinity will be able to appropriately interact with germinal centre T cells and 
follicular dendritic cells and be positively selected. Surviving centrocytes subsequently 
depend on CD40-based interactions with T cells to facilitate differentiation into long lived 
plasma cells and memory B cells (MacLennan, 1994).  
5. Tolerance B cell check points  
B cell precursors undergo immunoglobulin gene rearrangements to generate a population of 
mature B cells bearing surface immunoglobulin (sIg) with a range of specificities. Random 
V/D/J gene assembly generates many self-reactive B-cell receptors (BCR). To avoid 
autoimmunity, B cells displaying self-reactive immunoglobulin are deleted centrally in the 
bone marrow and at subsequent check points in the periphery (Yurasov et al., 2005a) (Fig. 
1). Self reactivity arising during V/D/J recombination could be corrected by receptor 
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editing, clonal deletion and anergy. In normal subjects the number of self reactive B cells 
decreases significantly as B cells progress though normal development. Nevertheless, 
central tolerance appears not enough to control self-reactive B cells in SLE patients. 
Significantly, the frequency of autoreactive antibodies declines from 75% in the bone 
marrow to 20% in the circulating naïve compartment (Yurasov et al., 2005b). However, 
several of these check points appear deficient in SLE patients (Yurasov S, et al., 2005b). In 
patients with SLE, mature naïve B cell compartment comprises 40% to 50% of autoreactive 
clones.  This fact indicates that SLE patients have defects in censoring self reactive B cells 
early in development even in SLE patients in remission (Yurasov et al., 2006). Because 
signaling through the BCR is a primary mechanism for triggering deletion, anergy, or 
receptor edition abnormal BCR signaling is likely to play a role in breakdown tolerance 
(Kamradt & Mitchinson, 2001). Interestingly, circulating mature B cells from SLE patients 
demonstrate a heightened response to BCR crosslinking. Even more SLE patients have low 
levels of intracellular tyrosine kinase Lyn that can diminish BCR signaling through 
phosphorylation of inhibitory receptor such CD22 and FCRIIb (Flores-Borja, et al., 2005). 
 
 
Fig. 1. Defective central tolerance in development of B cell repertoire in SLE. 
Patients with SLE have increased numbers of self-reactive B cells. We speculate that  
defects in complement could contribute to this phenomena. We propose that although 
receptor edition works well in SLE patients if immature B cells cannot test their BCR with 
self-antigens it is possible that they mature to naive self-reactive B cells and leave bone 
marrow and migrate to secondary lymphoid organs.  
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During central tolerance in bone marrow, receptor editing appears to be the preferred 
mechanism to establish early B cell self-tolerance (Tiegs et al., 1993; Gay et al., 1993; Halverson 
et al., 2004). Self reactive BCR can apparently be purged by receptor editing, a mechanism 
through which antigen binding in bone marrow induces continued rearrangement of 
immunoglobulin gene segments; this process results in a change in the specificity of a 
previously autorreactive BCR (Melamed, et al., 1997). Interestingly, although receptor editing 
works well in patients with SLE, it is possible that it could be insufficient to avoid the 
development of self-reactive B cells (Dörner, et al., 1999) and subsequent emigration to lymph 
nodes or spleen. However, the basic question as to whether receptor editing is increased or 
decreased during lupus requires further study (Luning-Prak et al., 2011). Interestingly, 
receptor edition can contribute to generating lymphoproliferative disorders (Chiorazzi, et al., 
2005; Wang, et al., 2008; García-Muñoz et al., 2009; Hatzidimitriou, et al., 2009). 
There are also data showing that regulatory checkpoints exist for B cells in the periphery in 
germinal center and in the late stages of B cell differentiation to memory or long-lived 
plasma cells (Cappione A 3rd et al., 2005; William et al., 2006)  
Germinal center exclusion of self reactive B cells (9G4 B cells) that express self-reactive 
antibodies encoded by the IGVH 4-34 gene is an important peripheral checkpoint to avoid 
interaction of autoreactive B cells with T cells and subsequent generation of 
autoantibodies. For this reason, 9G4 B cells are present only in 5-10% of the naïve B cell in 
healthy donors as well as in the IgM memory compartment and these cells participate in 
less than 1 % of germinal centers of tonsil biopsies.  However, germinal center exclusion is 
defective in SLE patients and evaluation of lymphoid tissue from tonsillar biopsies and 
spleens reveals that the frequency of germinal center 9G4 B cells  in this population is 15% 
to 20% (Cappione A 3rd et al., 2005). The expression of IGHV4-34 heavy chains in 
antibodies is synonymous of autoreactivity against N-acatyllactosamine (NAL) 
determinants expressed by the iI blood group antigen and other self glycoproteins 
including CD45 (Silberstein et al., 1991; Pugh-Bernard et al., 2001. Cappione  AJ, et al., 
2004). Importantly, antibodies against anti-B cell CD45 and a significant fraction of anti-
native double stranded DNA (anti-DNA) use VH4-34 heavy chain and are detected in 
patients with SLE (Pugh-Bernard et al., 2001) and represent about 10-45% of total serum 
IgG in this patients.  However, IGHV4-34 antibodies are virtually undetectable in healthy 
sera because IGHV4-34 cells are censored at multiple check points during B cell 
development to avoid autoimmunity (Pugh-Bernard et al., 2001).  
Preventing the generation of self-reactive memory B cells or long lived plasma cells is 
another important peripheral checkpoint to stay away from autoimmunity. B cells 
expressing self reactive antibodies and broadly bacterially reactive antibodies are 
continuously removed from the repertoire in the transition from naïve to IgM memory B 
cells and selection against self reactive antibodies is implemented before the onset of 
somatic hypermutation (Tsuiji et al., 2006). This checkpoint is supported by data showing a 
decrease in frequency of autoreactive IgM+ memory B cells to 2% from 20% in the mature 
naive B cell population in healthy individuals (Tsuiji et al., 2006). Even when dysfunction of 
this checkpoint in SLE is not yet determined, the fact that memory B cells with IGHV4-34 
have been detected in patients with SLE (Odendhal et al., 2000) provides indirect support 
for some deficiency in this checkpoint.  
The presence of extensive somatic mutations seen in autoantibodies derived from SLE 
patients strongly supports the notion of germinal center maturation of pathogenic, self 
reactive B cells and support defects at several check points. 
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Fig. 1. Defective central tolerance in development of B cell repertoire in SLE. 
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6. Lymphomagenesis in SLE 
Chronic immune stimulation by self antigens and infectious agents together with genetic 
variations of TNF- and IL-10 expression have been suggested to explain 
lymphomagenesis in SLE (Dias et al., 2011; Bertansky et al., 2009). However, the 
mechanism underlying the association between SLE and lymphoma remains unexplained. 
Lymphoproliferative neoplasm could arise from precursor B cells development and in 
pre-germinal center, germinal center or post germinal center differentiation. During 
development and maturation of B cells, they can acquire mutations, deletions or 
translocations that direct the generation of lymphomas. Rearrangements of V/D/J genes, 
receptor editing, somatic hypermutation, and class switching are responsible for DNA 
strand breaks that lead chromosomal aberrations that are in part responsible for 
lymphomagenesis (Küppers et al.,1999). A reasonable hypothesis is that the accumulation 
of clonally expanded self-reactive B cells that recognize self-antigens in the lymph nodes 
may predispose these B cells to DNA breaks, facilitating tumorigenesis (Xu et al., 2001). In 
support of this viewpoint, lymph nodes of patients with SLE have extensive necrosis with 
apoptotic debris (self antigens), with numerous plasma cells within germinal centers. On 
the one hand, these histopathologic features suggest that in lymph nodes it is possible that 
self reactive B cells can suffer somatic hypermutation, class switching and receptor 
edition/revision induced by apoptotic bodies increasing the risk of suffering DNA breaks 
and translocations. On the other hand, B cells with self-reactive specificity are likely to 
present self peptides to autoreactive T cells (Chan et al., 1999). In this context, T cells 
contribute to rescuing and supporting the maturation of self-reactive B cells to plasmatic B 
cells or memory B cells. Significantly, during this process it is possible that some cells 
acquire translocations and DNA alterations that contribute to development of lymphoma. 
In addition, in combination with recognition of self antigens in lymph nodes, self reactive 
B cells also recognize self antigens in bone marrow and acquire translocations or genetic 
alterations during B cell development. Autoreactive B cells may suffer receptor editing 
and V/D/J gene recombination in bone marrow. Recent evidence shows that L chain 
receptor editing occurs not only in bone marrow with a pre-B/immature B cell phenotype 
but also in immature/transitional splenic B cells. Nevertheless, editing at the H chain 
locus appears to occur exclusively in bone marrow cells with pro-B phenotype (Nakajima 
et al., 2009). Receptor editing appears to work well in patients with SLE. However, a 
feature of SLE is an increased production of self-reactive B cells that migrate from bone 
marrow to secondary lymphoid organs. This implies that other mechanisms or defects are 
necessary to maintain central tolerance in bone marrow. Significantly, defects in 
elimination of apoptotic cells and defects in complement components have been proposed 
to explain impaired central tolerance in bone marrow (Carrol, 2004). Interestingly, this 
model suggest that autoantigens from apoptotic cells are presented to immature B cells by 
immune complexes containing C1q, C4b and IgM in bone marrow. In support of this 
model Tripodo, et al., discovered C1q production by bone marrow stromal cells, an 
important part of complement that is involved in clearance of apoptotic cells (Tripodo et 
al., 2007).  
We speculate that the impaired elimination of apoptotic cells in bone marrow and  
lymph nodes could contribute to persistent autoantigenic overstimulation leading to 
refractoriness of autoimmunity and increased risk of chromosomal alterations and 
lymphomas (Fig. 2).  
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7. Hypothetical immunologic mechanisms implicated in generation of 
lymphomas in patients with SLE (Fig 2)  
Deficiency in self-antigen retention induced by defects in complement components or 
impaired clearance of apoptotic B cells will possibly lead to an increased release of self-
reactive B cells from bone marrow to periphery. On the one hand, defects in the complement 
system might produce deficient presentation of antigens in bone marrow and diminish the  
 
 
Fig. 2. Lymphoma development in patients with SLE. 
Impaired clearance of apoptotic cells in concert with insufficiency in germinal centre 
exclusion of self-reactive B cells might induce constant stimulus of these B cells. Naive self-
reactive B cells recognize auto-antigens and become memory B cells and plasma cells that 
produce auto antibodies. Continuous activation of memory B cells raises the risk of 
transformation into DLBC (activated subtype) and marginal zone B cell lymphomas. SLE 
activity and decrease in complement components could contribute to a defect in both  
central tolerance and clearance of apoptotic cells.   
protection of receptor edition mechanism. On the other hand, impaired clearance of 
apoptotic cells in bone marrow induces increased stimulation of immature self-reactive B 
cells that could suffer increased receptor edition in bone marrow or avoid tolerance. 
Importantly, receptor edition also can produce polyreactive B cells or a simple change in 
recognition from an auto-antigen for others that recognize the new edited BCR in an 
immature B cell. These two mechanisms could be implicated in generation of mantle cell 
lymphoma (García-Muñoz et al.,2009) or chronic lymphocytic leukemia with unmutated 
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IGHV genes (Hadzidimitriou et al. 2009). Increased variable region gene recombination and 
heavy or light chain receptor edition in self-reactive B cells of patients with SLE in bone 
marrow could in theory contribute to lymphomagenesis. Self reactive B cells that leave bone 
marrow, enter germinal centres because germinal center exclusion is defective in patients 
with SLE. Within germinal centers, self-reactive B cells recognize self-antigens from 
apoptotic cells and suffer somatic hypermutation, receptor revision, and class switch-
recombination. Some of this self-reactive B cells can be converted into memory B cells or 
plasmatic B cells that produce autoantibodies and return to the sites of antigen stimulation. 
During this process self-reactive B cells can acquire translocations, deletions or mutations 
that make a subtype of lymphoma. Germinal center derived lymphomas are derived by 
transformation from either variable region gene recombination (BCL-2-IgH) in follicular 
lymphoma, somatic hypermutation (BCL-6) in diffuse large B cell lymphoma, or class 
switching in c-myc sporadic Burkitt´s lymphoma (Küppers et al.,1999). (Fig. 3) Post-
germinal center B cell lymphomas are marginal zone lymphoma, small lymphocytic 
lymphoma/chronic lymphocytic leukemia and plasmacytoma and are derived from 
memory B cells and plasma cells (Jaffe ES et al., 2008) (Fig. 3). Interestingly, post-germinal 
center derived lymphomas are commonly associated with antigen stimulation by self-
antigens or infectious agents (Suarez et al., 2006). In a study of 24 patients with malignant 
lymphoma and rheumatic diseases including SLE the majority of diffuse large B cell 
lymphomas exhibited activated phenotype and EBV associated lymphoma comprised only a 
small fraction (Kojima et al., 2006). 
8. Lymphoma and SLE; Therapy 
8.1 Lymphoma subtypes in SLE patients 
Patients with SLE have an increased risk to develop lymphomas specially diffuse large B cell 
lymphoma (Löfstrom et al., 2007; Bernatsky et al., 2005; Bernatsky  et al., 2006: King & 
Costenbader, 2007; Lin et al., 2003; Rossi et al., 2011; Biasiotta et al., 2010; Simon et al., 2007)  
and marginal zone lymphomas (Maeda et al., 2008; Gonzalez et al., 2009; Tektonidou, 2010) 
however, several subtypes have been reported.  
8.2 Highly aggressive B cell lymphomas 
Burkitt lymphoma is a highly aggressive B cell malignancy typically characterized by a 
rapid proliferation rate and the translocation of c-myc [t(8;14), t(8;22) or t(2;8)]. The typical 
immunophenotype of Burkitt lymphoma is sIg+, CD10+,CD19+, CD20+, TdT -, Ki-67+ (90-
100% of cells), bcl-2 -, bcl-6 + (Ferry, 2006) Patients with Burkitt lymphoma often present 
with symptoms of a rapidly enlarging abdominal mass and B symptoms. Bone marrow 
involvement is found in up to 70% of patients, and leptomaningeal spread is common 
(Perkins et al., 2008). Data from patients with SLE and Burkitt lymphoma are scarce, 
however: some case reports or case series include patients with SLE that develop this rare 
malignancy (Posner et al., 1990; Bernatsky et al., 2005). The treatment of Burkitt lymphoma 
is based on intensive chemotherapy. Some highly effective regimens include CODOX-M 
(cyclophosmphamide, vincristine, doxorubicin, high dose methotrexate) alternating with 
IVAC (ifosfamide, etoposide and high-dose cytarabine)(Magrath et al., 1996.) or Hyper-
CVAD (hyper fractioned cyclophosphamie, vincristine, doxorubicin, dexametasona) 
(Thomas et al., 2006) both plus Rituximab. 
 




Fig. 3. Origin of Non Hodgkin B cell lymphomas and mechanisms related to their 
development  
During development B cells can acquire translocations, deletions or mutations that make a 
subtype of lymphoma. Pre-germinal center derived lymphomas are CLL unmutated and 
mantle cell lymphoma and some follicular lymphomas. Germinal center derived 
lymphomas are derived by transformation from either variable region gene recombination 
(BCL-2-IgH) in follicular lymphoma, somatic hypermutation (BCL-6)  in diffuse large B cell 
lymphoma, or class switching in c-myc sporadic Burkitt´s lymphoma. Post-germinal center 
B cell lymphomas are marginal zone lymphoma, small lymphocytic lymphoma/chronic 
lymphocytic leukemia and plasmacytoma and are derived from memory B cells and plasma 
cells. 
8.3 CD5+ B cell lymphomas 
CD5+ B cell lymphomas comprises Mantle Cell lymphoma (MCL) and Chronic lymphocytic 
leukemia/Small lymphocytic lymphoma (CLL/SLL). Sometimes patients with SLE develop 
this subtypes of lymphomas (Munzert  et al., 1997; Lugassy et al., 1992). 
8.3.1 Mantle cell lymphoma 
MCL can have a varied initial presentation and clinical course. Most patients are diagnosed 
when they already present an advanced stage disease. Common sites of involvement  
include lymph nodes, spleen, bone marrow gastrointestinal tract and the lymphoid tissue of 
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Waldeyer´s ring. MCL is characterized by the translocation t(11;14)(q13;q32) which leads to 
the overexpression of cyclin D1. Mutation analysis of the rearranged immunoglobulin´s 
heavy chain variable region (IGHV) genes shows a major subset with unmutated IGHV and 
a smaller  subset displaying mutated IGHV genes (Swerdlow et al., 2008). The treatment of 
MCL is by intensive chemotherapy with R-HyperCVAD (rituximab, cyclophosphamide, 
vincristine, doxorubicin and Dexametasone) alternating with R-MA (Rituximab plus high-
dose methotrexate and cytarabine) (Romaguera et al., 2005) followed by consolidation with 
myeloablative chemotherapy with autologous stem cell transplant in selected patients in 
first complete remission (Dreyling et al., 2005). However, other less intensive treatment 
options include R-CHOP (Howard OM, et al., 2002), Bendamustine (Rummel et al., 2005) 
and Bortezomib (Fisher et al., 2006).  
8.3.2 Chronic lymphocytic leukemia/small lymphocytic lymphoma 
CLL/SLL is an indolent B cell malignancy, which is believed to originate in memory 
antigen-experienced B-cells. Tumors usually involve not only the peripheral blood and 
bone marrow but also lymph nodes, spleen and liver.  The diagnosis of SLL is typically 
applied if the presentations predominantly nodal and the diagnosis of CLL is made when 
the principal involvement is bone marrow and blood. CLL remains an incurable tumor 
and clinical features have very variable presentation, course, and outcome. Risk markers 
and stratification in CLL can be divided in two different entities.  High risk phenotype 
usually expresses unmutated immunoglobulin heavy variable genes (Hamblin et al.,1999) 
CD38 surface marker (Damle et al.,1999), zeta-associated protein 70 (ZAP-70)(Crespo et 
al., 2003) and chromosomal aberrations as 17p (the site of the tumor protein p53) or 11q23 
deletions (the site of the ataxia telangiectasia mutated ATM)(Dörner et al., 2000). Low risk 
phenotype habitually expresses mutated IGVH, lack CD38 and ZAP-70 and has a normal 
karyotype or 13q14 deletion. Additional adverse predictive factors include advanced Rai 
(Rai et al., 1975) and Binet clinical staging (Binet et al., 1981), usage of VH3-21 
independent of VH mutation status (Throsélius et al., 2006) and short lymphocyte 
doubling time (Montserrat et al., 1986). There is no evidence that early treatment of 
asymptomatic patients benefits them. The current advice is that patients who are 
asymptomatic should be managed by watchful waiting until they present symptoms or  
International Workshop on Chronic Lymphocytic Leukemia indications for treatment are 
met (Hallek et al., 1996). First line treatment includes chlorambucil, fludarabine, 
Bendamustine or fludarabine plus cyclophosphamide, either alone or in combination with 
Rituximab (Hallek, 2010) . The choice of therapy is influenced by co-morbidities and 
status performance of patients.   
8.4 Follicular lymphoma 
Coexistence of follicular lymphoma (FL) and SLE has previously been reported (Löftröm et 
al., 2007; Suvajdzic et al., 2011). FL is a neoplasm composed of follicle center (germinal 
center) B cells (typically both centrocytes and centroblast) which usually has at least a partial 
follicular pattern. FL is genetically characterized by the translocation t(14;18)(q32;q21) and 
BCL-2 rearrangements.  
FL involves lymph nodes, spleen, peripheral blood and Waldeyer ring. FL may occasionally 
be primary in extranodal sites. Most patients have widespread disease at diagnosis, 
including peripheral and central (abdominal and thoracic) lymphadenopathy and 
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splenomegaly. Despite widespread disease, patients are usually otherwise asymptomatic 
(Harris et al., 2008). Multiple treatment options exist for patients with newly diagnosed FL, 
ranging from observation only to a variety of combined chemoimmunterapy regimens 
(Bendandi, 2008; Cheson et al., 2011). 
8.5 Diffuse large B-cell lymphomas 
Studies specifically investigating lymphoma and SLE have noted that DLBCL are the most 
common histology when lymphoma occurs in these patients (Gayed et al., 2009). This 
aggressive subtype makes up 30% of lymphomas in the general population, but in SLE 
groups, it accounts for between 38% and 53% of lymphomas (Smedby et al., 2006; Bernatsky 
et al., 2005a). Although DLBCL can occur at any age, it is, in general, a disease of middle-
aged and older adults. Unlike indolent Iymphomas that are almost always widely 
disseminated at diagnosis, DLBCL present as early-stage disease in approximately 30% of 
cases. Clinically, presentation with a rapidly enlarging symptomatic mass is very common, 
with B symptoms (fever, unexplained weight loss > 10% over 6 month interval, or night 
sweats) in one-third of the cases. Extranodal disease in DLBCL can be present in up to 40% 
of cases; common sites include the gastrointestinal tract, bone, and CNS. 
With the application of microarray techniques, three subgroups of DLBCL with distinctive 
gene-expression profiles have been identified on the basis of hierarchical clustering: 
germinal-center B-cell-like, activated B-cell-like, and type 3 DLBCL (Rosenwald et al., 2002). 
A number of recent studies have attempted to define germinal-center and non-germinal 
center phenotypes in DLBCL, using immunohistochemistry markers such as bcl-6, CD10 for 
germinal center and MUM1, IRF4 and CD38 for post-germinal center. In general, a germinal 
center immunophenotype, particularly including Bcl-6 expression, has been associated with 
a better prognosis (Lossos et al., 2004). 
8.5.1 Therapy 
For nearly 20 years anthracycline-based chemotherapy has been the mainstay of treatment, 
because of its proven efficacy, the CHOP (cyclophosphamide/doxorubicin/vincristine/ 
prednisone) regimen being the gold standard of therapy for aggressive NHL. Application of 
this treatment resulted in curing 30% of patients with DLBCL. The standard chemotherapy 
regimen has changed little in the past three decades, but a variety of strategies have been 
tested to identify regimens that might increase the disease-free survival rate for aggressive 
lymphomas. Monoclonal-antibody therapy has been added to the armamentarium and 
represents an advance in therapeutic options. The anti-CD20 monoclonal antibody 
rituximab has been combined with the chemotherapy regimen of CHOP in an attempt to 
improve outcomes; increased remission and survival have been reported with no additional 
toxicity (Friedberg JW & Fisher RI., 2006).  
8.5.2 Limited stages 
Classically, external beam radiation therapy was employed as a single modality in the 
therapy for localized DLBCL, with prolonged disease-free survival of approximately 35%. 
However with the success of anthracycline based chemotherapy in treating advanced 
stage DLBCL, the combination of CHOP with radiotherapy emerged as the strategy of 
choice for treating localized DLBCL (Miller et al., 1998). Several cooperative groups have 
developed clinical assays in order to elucidate which is the best chemotherapy regimen to 
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combine with radiotherapy in these patients. The SWOG group showed advantage for 
progression-free survival (PFS) and overall survival (OS) in patients receiving 3 cycles of 
CHOP followed by involved field radiation (40-50 Gy) versus those who received 8 cycles 
of CHOP alone (Miller et al., 2001). Results worsened with the acquisition risk factors.  
Similar results in advantage for disease-free survival but not for OS were published for 
the ECOG group of patients receiving 8 cycles of CHOP followed by radiotherapy 
consolidation (Horning et al., 2004). The GELA group has also addressed this issue in 
several clinical trials suggesting no advantage for patients receiving radiotherapy and a 
short course of chemotherapy compared to those receiving standard chemotherapy (Reyes 
et al., 2005). Recent reports about the addition of rituximab showed advantages in PFS 
and OS to the historical experience without rituximab therapy (Persky, 2008). Nowadays, 
R-CHOP rather than CHOP would be recommended for these patients. However, no data 
exist to support the use of three courses of R-CHOP chemotherapy with radiation 
consolidation for limited stage disease. In view of the activity of R-CHOP in more 
advanced disease and in spite of the lack of a randomized trial to demonstrate its 
superiority in the setting of three rather than six courses, most clinicians prefer to use R-
CHOP rather than CHOP. 
8.5.3 Advanced stages 
After rituximab was found to have activity in B cell NHL, the GELA group conducted a 
randomized trial to compare CHOP alone vs. R-CHOP in elderly patients (60 to 80 years 
old) with DLBCL. Chemotherapy courses were given every 3 weeks. Patients were 
randomly assigned to receive either eight cycles of CHOP every 21 days or eight cycles of R-
CHOP. They concluded that the addition of rituximab to the CHOP regimen increases the 
complete remission rate and prolongs event-free and OS in this group of patients, without a 
clinically significant increase in toxicity (Coiffier et al., 2002). Once the GELA group proved 
the superiority of R-CHOP-21, Pfreundschuh et al. decided to conduct the trial known as 
MabThera International Trial (MInT) to evaluate CHOP-21, R-CHOP-21, CHOEP-21 and R-
CHOEP-21 in patients aged 18–60 years with favorable prognosis (0-1 adverse risk factors 
according to age-adjusted International Prognostic Index). They concluded that rituximab 
added to six cycles of CHOP is an effective treatment for young patients with good-
prognosis DLBCL (Pfreundschuh et al., 2006). The addition of rituximab to CHOP seems to 
eliminate the advantage of CHOEP over CHOP. This study also proved for the first time 
that rituximab when added to CHOP or CHOEP is effective in patients younger than 60 
with favorable IPI. Following these results, the RICOVER-60 trial was developed to asses 
whether six courses were as effective as eight cycles and whether the addition of rituximab 
to CHOP-14 could improve outcome of patients treated with the CHOP-14 regimen. 
Conclusions of this study were that six cycles of R-CHOP-14 significantly improved event-
free, PFS and OS over six cycles of CHOP-14 treatment. The other major conclusion of this 
study was that six cycles of chemotherapy with or without rituximab was as effective as 
eight cycles (Pfreundschuh et al., 2008). The RICOVER trial has been criticized for not 
including an arm with R-CHOP-21. As CHOP-14 is superior to CHOP-21, and R-CHOP-14 is 
superior to CHOP-14, it is logical to think that R-CHOP-14 should also be superior to R-
CHOP-21. However, many investigators refuse to accept that R-CHOP-14 is the gold 
standard for treatment of DLCL until a randomized study with a control arm of R-CHOP-21 
is carried out (Cabanillas, 2010). 
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8.5.4 Special considerations in DBCL and SLE therapy 
When treatment options for DLBCL in the context of SLE are considered, special caution 
should be taken in order to manage the prognostic factors related to the tumor (e.g. 
histology, genetics and stage) as well as patient-specific factors (e.g. age, comorbidity, and 
general health status), because many lymphoma treatments are gruelling, particularly for 
old or frail individuals (Sehn et al., 2007). Patients with SLE often have both the 
hematopoietic reserve reduced and the immune function altered due to immunossupressive 
drugs thus being therapy-related infections a major problem in these patients. In this 
particular subset of patients with SLE and DLBCL, aggressive surveillance, prophylaxis, and 
treatment of infections are essential to prevent morbidity and mortality. Granulocyte colony 
stimulating factors (G-CSF) are largely used in the treatment of hematologic disorders to 
improve the myelosuppression indirectly induced by the chemotherapy regimen. G-CSF 
reduces the depth and duration of neutropenia in lymphoma patients and thus allows the 
design of more dose intense chemotherapy regimens which were shown to improve 
outcome particularly in patients with DLBCL (Lionne-Huyghe et al., 2006). 
Besides, many SLE patients have deteriorated the glomerular filtration rate and a delay in 
drug excretion, needing the adjust of cytotoxic drugs to creatinine clearance. For this reason, 
management of tumor lysis syndrome in these patients can also be problematic. In order to 
avoid these problems, patients with SLE and renal impairment should be handled following 
chemotherapy schedules with a prephase treatment, in the same way on which are treated 
very aggressive lymphomas and elderly patients (Pfreundschuh, 2004, 2010). Sufficient fluid 
intake must be ensured, and appropriate supportive measures must be provided, including 
frequent electrolyte controls and allopurinol or even rasburicase administration to prevent 
hyperuricemia and tumor lysis syndrome. 
SLE is associated with high cardiovascular morbidity and mortality. Clinically silent 
pulmonary hypertension, right ventricular dysfunction and myocardial perfusion defects 
usually asymptomatic are common in SLE patients (Plazak et al., 2011). A careful evaluation 
by means of echocardiography preferably with tissue doppler study and lung function test 
should be part of the pre-treatment studies to prevent anthracycline toxicity (Buss et al., 
2010). Recommendations for therapy should be similar to elderly DLBCL patients. R-CHOP 
should be administered with close functional monitoring or even excluded if they present 
with cardiac-failure New York Heart Association > 2 and/or an ejection fraction < 50% or 
have a forced expiratory volume in 1 second (FeV1) level < 50% or a diffusion capacity < 
50%. If cardiomyopathy is the only limiting condition, doxorubicin should be replaced by 
liposomal doxorubicin under close monitoring of the cardiac function. (Pfreundschuh, 2010; 
Zaja et al., 2006) 
8.6 Marginal zone lymphoma 
The marginal zone of lymphoid tissues is a unique B-cell compartment that contains B cells 
with a high surface density of IgM and complement receptor 2, and which exhibits a rapid 
activation and immunoglobulin secretion in response to blood-borne T-independent (Weill 
et al., 2009). This micro-anatomic compartment is well developed in lymphoid organs such 
as spleen, mesenteric lymph nodes and mucosa-associated lymphoid tissue or MALT where 
circulation of antigens occurs. Marginal B-cell lymphomas (MZL) are a well categorized 
group of indolent B-cell NHL that arise from the marginal zone of lymphoid tissues. The 
WHO-classification of tumors of hematopoietic and lymphoid tissues distinguish three 
different MZL types: extranodal, splenic and nodal (Isaacson et al., 2008).  
 
Systemic Lupus Erythematosus 
 
394 
combine with radiotherapy in these patients. The SWOG group showed advantage for 
progression-free survival (PFS) and overall survival (OS) in patients receiving 3 cycles of 
CHOP followed by involved field radiation (40-50 Gy) versus those who received 8 cycles 
of CHOP alone (Miller et al., 2001). Results worsened with the acquisition risk factors.  
Similar results in advantage for disease-free survival but not for OS were published for 
the ECOG group of patients receiving 8 cycles of CHOP followed by radiotherapy 
consolidation (Horning et al., 2004). The GELA group has also addressed this issue in 
several clinical trials suggesting no advantage for patients receiving radiotherapy and a 
short course of chemotherapy compared to those receiving standard chemotherapy (Reyes 
et al., 2005). Recent reports about the addition of rituximab showed advantages in PFS 
and OS to the historical experience without rituximab therapy (Persky, 2008). Nowadays, 
R-CHOP rather than CHOP would be recommended for these patients. However, no data 
exist to support the use of three courses of R-CHOP chemotherapy with radiation 
consolidation for limited stage disease. In view of the activity of R-CHOP in more 
advanced disease and in spite of the lack of a randomized trial to demonstrate its 
superiority in the setting of three rather than six courses, most clinicians prefer to use R-
CHOP rather than CHOP. 
8.5.3 Advanced stages 
After rituximab was found to have activity in B cell NHL, the GELA group conducted a 
randomized trial to compare CHOP alone vs. R-CHOP in elderly patients (60 to 80 years 
old) with DLBCL. Chemotherapy courses were given every 3 weeks. Patients were 
randomly assigned to receive either eight cycles of CHOP every 21 days or eight cycles of R-
CHOP. They concluded that the addition of rituximab to the CHOP regimen increases the 
complete remission rate and prolongs event-free and OS in this group of patients, without a 
clinically significant increase in toxicity (Coiffier et al., 2002). Once the GELA group proved 
the superiority of R-CHOP-21, Pfreundschuh et al. decided to conduct the trial known as 
MabThera International Trial (MInT) to evaluate CHOP-21, R-CHOP-21, CHOEP-21 and R-
CHOEP-21 in patients aged 18–60 years with favorable prognosis (0-1 adverse risk factors 
according to age-adjusted International Prognostic Index). They concluded that rituximab 
added to six cycles of CHOP is an effective treatment for young patients with good-
prognosis DLBCL (Pfreundschuh et al., 2006). The addition of rituximab to CHOP seems to 
eliminate the advantage of CHOEP over CHOP. This study also proved for the first time 
that rituximab when added to CHOP or CHOEP is effective in patients younger than 60 
with favorable IPI. Following these results, the RICOVER-60 trial was developed to asses 
whether six courses were as effective as eight cycles and whether the addition of rituximab 
to CHOP-14 could improve outcome of patients treated with the CHOP-14 regimen. 
Conclusions of this study were that six cycles of R-CHOP-14 significantly improved event-
free, PFS and OS over six cycles of CHOP-14 treatment. The other major conclusion of this 
study was that six cycles of chemotherapy with or without rituximab was as effective as 
eight cycles (Pfreundschuh et al., 2008). The RICOVER trial has been criticized for not 
including an arm with R-CHOP-21. As CHOP-14 is superior to CHOP-21, and R-CHOP-14 is 
superior to CHOP-14, it is logical to think that R-CHOP-14 should also be superior to R-
CHOP-21. However, many investigators refuse to accept that R-CHOP-14 is the gold 
standard for treatment of DLCL until a randomized study with a control arm of R-CHOP-21 
is carried out (Cabanillas, 2010). 
 
Lymphoproliferative Disorders in Patients with Systemic Lupus Erythematosus 
 
395 
8.5.4 Special considerations in DBCL and SLE therapy 
When treatment options for DLBCL in the context of SLE are considered, special caution 
should be taken in order to manage the prognostic factors related to the tumor (e.g. 
histology, genetics and stage) as well as patient-specific factors (e.g. age, comorbidity, and 
general health status), because many lymphoma treatments are gruelling, particularly for 
old or frail individuals (Sehn et al., 2007). Patients with SLE often have both the 
hematopoietic reserve reduced and the immune function altered due to immunossupressive 
drugs thus being therapy-related infections a major problem in these patients. In this 
particular subset of patients with SLE and DLBCL, aggressive surveillance, prophylaxis, and 
treatment of infections are essential to prevent morbidity and mortality. Granulocyte colony 
stimulating factors (G-CSF) are largely used in the treatment of hematologic disorders to 
improve the myelosuppression indirectly induced by the chemotherapy regimen. G-CSF 
reduces the depth and duration of neutropenia in lymphoma patients and thus allows the 
design of more dose intense chemotherapy regimens which were shown to improve 
outcome particularly in patients with DLBCL (Lionne-Huyghe et al., 2006). 
Besides, many SLE patients have deteriorated the glomerular filtration rate and a delay in 
drug excretion, needing the adjust of cytotoxic drugs to creatinine clearance. For this reason, 
management of tumor lysis syndrome in these patients can also be problematic. In order to 
avoid these problems, patients with SLE and renal impairment should be handled following 
chemotherapy schedules with a prephase treatment, in the same way on which are treated 
very aggressive lymphomas and elderly patients (Pfreundschuh, 2004, 2010). Sufficient fluid 
intake must be ensured, and appropriate supportive measures must be provided, including 
frequent electrolyte controls and allopurinol or even rasburicase administration to prevent 
hyperuricemia and tumor lysis syndrome. 
SLE is associated with high cardiovascular morbidity and mortality. Clinically silent 
pulmonary hypertension, right ventricular dysfunction and myocardial perfusion defects 
usually asymptomatic are common in SLE patients (Plazak et al., 2011). A careful evaluation 
by means of echocardiography preferably with tissue doppler study and lung function test 
should be part of the pre-treatment studies to prevent anthracycline toxicity (Buss et al., 
2010). Recommendations for therapy should be similar to elderly DLBCL patients. R-CHOP 
should be administered with close functional monitoring or even excluded if they present 
with cardiac-failure New York Heart Association > 2 and/or an ejection fraction < 50% or 
have a forced expiratory volume in 1 second (FeV1) level < 50% or a diffusion capacity < 
50%. If cardiomyopathy is the only limiting condition, doxorubicin should be replaced by 
liposomal doxorubicin under close monitoring of the cardiac function. (Pfreundschuh, 2010; 
Zaja et al., 2006) 
8.6 Marginal zone lymphoma 
The marginal zone of lymphoid tissues is a unique B-cell compartment that contains B cells 
with a high surface density of IgM and complement receptor 2, and which exhibits a rapid 
activation and immunoglobulin secretion in response to blood-borne T-independent (Weill 
et al., 2009). This micro-anatomic compartment is well developed in lymphoid organs such 
as spleen, mesenteric lymph nodes and mucosa-associated lymphoid tissue or MALT where 
circulation of antigens occurs. Marginal B-cell lymphomas (MZL) are a well categorized 
group of indolent B-cell NHL that arise from the marginal zone of lymphoid tissues. The 
WHO-classification of tumors of hematopoietic and lymphoid tissues distinguish three 
different MZL types: extranodal, splenic and nodal (Isaacson et al., 2008).  
 
Systemic Lupus Erythematosus 
 
396 
Despite its common cell origin these three subtypes display differences in their frequency 
and clinical presentation and features according to the organ where the lymphoma arises. 
Extranodal MZL, also known as low-grade B-cell lymphoma of mucosa-associated 
lymphoid tissue (or MALT lymphoma) is the most common MZL subtype accounting for 
approximately 70% of all MZLs (Isaacson et al., 2004, 2008). These subtypes can arise at 
virtually any extranodal site and are commonly associated with chronic antigenic 
stimulation, either as a result of infection (eg, Helicobacter pylori in the stomach) or 
autoimmune disease. Splenic MZL accounts for approximately 20% of all MZLs. (Matutes et 
al., 2008). Patients typically present with an enlarged spleen, involvement of abdominal 
lymph nodes, and bone marrow disease. Liver and leukemic involvement are not 
infrequent.  Nodal MZL is the least common, representing approximately 10% of all MZLs. 
(Arcaini et al., 2009). Patients with nodal MZL, by definition, have lymph node-based 
disease without involvement of the spleen or extranodal sites. 
8.6.1 Therapy 
Therapy of patients with MZL and SLE should not differ from that administered to patients 
without the latter condition. While some patients obtain cure of MALT lymphoma with an 
antibiotic treatment of the infectious causing agent, as occurs in the case of the infections for 
H. pylori, other patients require treatment with radio chemotherapy and immunotherapy 
(Martinelli et al., 2005; Zucca E & Dreyling M., 2008). Approximately 75 % of patients with 
gastric MALT lymphoma achieve a remission following the elimination of H. pylori  
with antibiotics (Du & Isaccson, 2002; Wundisch et al., 2005). The interval of histological 
regression following this treatment is variable, ranging from 1 to 25 months. In the  
cases both of persistent infection or resistant lymphoma, a second attempt with  
the antibiotic therapy is usually recommended (Psyrri et al., 2008). Although antibiotics 
have demonstrated efficacy in early stages of disease, its use is also recommended in 
patients with advanced stages, in those without apparent infection for H. pylori, as in those 
with primary non-gastric disease. However, a therapeutic consensual guide for these 
patients has not yet established, much less for patients with the rare condition of MALT 
lymphoma and SLE. 
In addition, the therapeutic role of treatments against infectious pathogens in non-gastric 
MALT lymphoma is less defined. The therapeutic application of antibiotics against B. 
Bugdorferi in cutaneous MALT lymphoma has been described, as well as the treatment 
against C. psittaci in MALT lymphoma of ocular adnexa  (Bertoni & Zucca, 2005; Ferreri et 
al., 2005). However the association of these pathogens with MALT lymphoma seems to 
show a marked geographical variation and the antibiotic effectiveness of the treatments has 
not been confirmed yet (Husain et al., 2007 ). 
Treatment with the anti-CD20 monoclonal antibody rituximab, chemotherapy and radiation 
therapy as single agents or in combination are alternative therapies for patients failing to 
treatment with antibiotics. Rituximab has demonstrated efficacy in gastric MALT lymphoma 
without H. pylori evidence, in cases of refractory disease, in relapses and in advanced 
disease as well as in localized disease in non-gastric MALT lymphoma (Martinelli et al., 
2005; Thieblemont & Coiffier, 2006). The combined administration of rituximab with 
chemotherapy increases the efficacy of the monoclonal antibody. 
The regimens of chemotherapy include alkylating agents, commonly used in low-grade 
lymphomas, analogues of purines, like the fludarabine, whose use combined with rituximab 
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has proven to be efficacious in patients with gastric and non-gastric MALT lymphoma (Levy et 
al., 2002). Recently, the combination of bendamustine (a new agent combining the alkylating 
and the purine analogue properties) with rituximab has demonstrated a great efficacy in 
achieving remission in MALT lymphoma of any origin with a very successful toxicity profile 
(Kahl et al., 2010). Anthracycline based regimes are occasionally used for young patients with 
aggressive gastric disease and for refractory patients to conventional treatments. 
Splenic MZL is a disease with a relatively indolent course, but the optimal treatment 
strategy and outcome of splenic MZL remains undefined. Patients without a marked 
lymphocytosis, anemia or thrombocytopenia may not require treatment. However there is a 
significant group of patients who die from the lymphoma in a short interval of time (Chacón 
et al., 2002). Before rituximab, the recommended treatment for splenic MZL with 
symptomatic splenomegaly or threatening cytopenia was splenectomy, since chemotherapy 
had limited efficacy. Responses to splenectomy occurred in approximately 90% of patients 
(Sagaert X & Tousseyn T, 2010). Chemotherapy with CHOP and purine analogues such as 
fludarabine or pentostatine demonstrated objective responses (Franco et al., 2003). Presently, 
treatment of such patients with rituximab administered as a single agent or in combination 
has shown remarkable responses with an overall survival comparable to that reported 
following splenectomy (Bennett M & Schechter GP., 2010). Rituximab in combination with 
purine nucleosides may provide further improvement in PFS; however, confirmatory 
prospective trials are necessary. 
As shown, in MZL chronic infections and autoimmune diseases such as SLE induce a 
chronic antigenic stimulation in B lymphocytes, through BCR. This constant stimulation 
induces the molecular NF-κB way, which probably plays a role in the initiation of the 
development of subsequent lymphoma (Thome, 2004; Ngo et al., 2011) Regarding therapy 
we can speculate with the future utility of drugs interacting the NF-κB way such as 
proteosome inhibitors (O'Connor, 2005). 
8.7 Other lymphomas 
Interestingly, a wide variety of lymphomas types with low prevalence has been reported in 
SLE patients. These subtypes include lymphoplasmacytic lymphoma (Papadaki et al., 2003), 
intravascular lymphoma (Sanchez-Cano et al., 2007), Franklin´s disease (García-Muñoz et 
al., 2008.), subcutaneous panniculitis-like T cell lymphoma (Pincus et al., 2009.), ALK-
negative T cell anaplastic large cell lymphoma (Suvajdizc et al.,2003), peripheral T cell 
lymphoma (Löfström et al., 2007) and T cell leukemia/lymphoma (Frisch Stork et al.,2009). 
9. Conclusions 
SLE has an excess of lymphoma unrelated to immunosuppressive therapy. The 
mechanisms underlying the association between SLE and lymphoma remain unknown, 
but it is possible that impaired clearance of apoptotic cells in bone marrow and lymph 
nodes induces amplified stimulation of self-reactive B cells, increasing the risk to DNA 
damage and lymphomagenesis. Patients with SLE have shown an increased risk of 
marginal zone lymphoma, predominantly of the MALT type, and of DLBCL. Treatment of 
lymphoproliferative disorders in SLE does not differ from that administered to patients 
without SLE. Because the outcome is dependent on treatment, patients with SLE and 
suspected lymphoma should be evaluated jointly by both a rheumatologist and a 
hematologist with experience in lymphoproliferative disorders.  
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disease without involvement of the spleen or extranodal sites. 
8.6.1 Therapy 
Therapy of patients with MZL and SLE should not differ from that administered to patients 
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induces the molecular NF-κB way, which probably plays a role in the initiation of the 
development of subsequent lymphoma (Thome, 2004; Ngo et al., 2011) Regarding therapy 
we can speculate with the future utility of drugs interacting the NF-κB way such as 
proteosome inhibitors (O'Connor, 2005). 
8.7 Other lymphomas 
Interestingly, a wide variety of lymphomas types with low prevalence has been reported in 
SLE patients. These subtypes include lymphoplasmacytic lymphoma (Papadaki et al., 2003), 
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negative T cell anaplastic large cell lymphoma (Suvajdizc et al.,2003), peripheral T cell 
lymphoma (Löfström et al., 2007) and T cell leukemia/lymphoma (Frisch Stork et al.,2009). 
9. Conclusions 
SLE has an excess of lymphoma unrelated to immunosuppressive therapy. The 
mechanisms underlying the association between SLE and lymphoma remain unknown, 
but it is possible that impaired clearance of apoptotic cells in bone marrow and lymph 
nodes induces amplified stimulation of self-reactive B cells, increasing the risk to DNA 
damage and lymphomagenesis. Patients with SLE have shown an increased risk of 
marginal zone lymphoma, predominantly of the MALT type, and of DLBCL. Treatment of 
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without SLE. Because the outcome is dependent on treatment, patients with SLE and 
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1. Introduction 
Notwithstanding that life expectancy in patients with systemic lupus erythematosus (SLE) has 
improved progressively in the last few decades, the mortality rates remain three times higher 
as compared with the general population (Uramoto et al, 1998). Reported causes of death vary 
according to the region of the world, yet there is agreement on the bimodal curve of mortality 
rate in these patients, with an initial peak occurring early after diagnosis, strongly related with 
disease activity and infections, and a later escalade associated with cardiovascular disease, 
accrued damage, and infections too (Rubin et al, 1985). It may be due to its complexity that 
infectious disease is often considered a grim topic in SLE, but it is undeniable that infections 
are important contributors of mortality in every stage of the disease. 
The range of infections in lupus patients varies widely, from opportunistic infections -
attributable in some level to immunological dysfunction- to common bacterial and viral 
infections with typical or atypical presentations. Moreover, patients with lupus exhibit 
increased proclivity to hospital acquired infections than hospitalized patients with other 
diagnosis. Some authors have stressed out the association that certain conditions have with 
the risk of infections in patients with lupus.  Some of these include: high disease activity, 
specific immune dysregulation; drug-induced immune deficiency; and organ failure due to 
irreversible damage.  
On the other hand, several clinical manifestations like fever, lymphadenopathy, unexplained 
confusion, pulmonary infiltrates, skin and mucosal injuries, coagulation disorders, and others, 
represent true diagnostic challenges for the clinician who may take them as clues of a lupus 
flare, or may be compelled to commence a trial of antimicrobial treatment because these may 
also be the clinical expression of a life-threatening infection, or perhaps, as it often occurs in the 
field treat both conditions simultaneously. Some evidence suggests that certain infections, 
particularly of viral nature, might participate in disease initiation, disease flare or worsening of 
an active lupus condition. 
In this chapter we will review the current information regarding infections in patients with 
SLE, and recommendations to prevent and treat them. 
2. Immune dysfunction and infection in SLE 
Patients with SLE are known to have defects both in the humoral and the cellular branches 
of the immune system. Some of these defects participate in the inadequacy of immune 
 
Systemic Lupus Erythematosus 
 
406 
Thomas DA, Farderl S, O´Brien S, Bueso-Ramos C, et al. (2006) Chemoimmunotherapy with 
hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt-type 
lymphoma or acute lymphoblastic leukemia. Cancer 2006;106(7):1569-1569-1580. 
Thome M. (2004). CARMA1, BCL-10 and MALT1 in lymphocyte development and 
activation. Nat Rev Immunol. 2004 May;4(5):348-59 
Throsélius M, Krober A, Murray F, et al.(2006) Striklingly homologous immunoglobulin 
gene rearrangements and poor outcome in VH3-21 using CLL patients independent 
of geographic origin and mutational status. Blood 2006;107:2889-94. 
Tiegs SL, Russell DM, Nemazee D. (1993) Receptor editing in self-reactive bone marrow B 
cells. J. Exp. Med. 1993;177:1009-1020. 
Tripodo C, Porcasi R, Guarnotta C, Ingrao S, Campisi V, Florena AM, et al. (2007) C1q 
production by bone marrow stromal cells. Scand J Immunol 2007;65:308-309. 
Tsuiji M, Yurasov S, Velinzon K, Thomas S, Nussenzweig MC, Wardemann H. (2006) A 
check point for autorreactivity in human IgM memory B cell development. J Exp 
Med 2006;203(2):393-400 
Wang YH, Nomura J, Faye-Petersen OM, Cooper MD. (1998) Surrogate light chain 
production during B cell differentiation: differential intracellular vs cell surface 
expression. J Immunol 1998; 161:1132-9 
Wang JH, Alt FW, Gostissa M, et al. (2008) Oncogenic transformation in the absence of Xrcc4 
targets peripheral B cells that have undergone editing and switching. J Exp Med. 
2008 Dec 22;205(13):3079-90 
Weill JC, Weller S, Reynaud CA.(2009). Human marginal zone B cells. Annu Rev Immunol. 
2009;27:267-85. 
William J, Euler C, Primarolo N et al. (2006) B cell tolerance checkpoints that restrict 
pathways of antigen-driven differentiation. J Immunol. 2006;176(4):2142-2151. 
Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, Ye H, Du MQ, Kim TD, 
Bayerdörffer E, Stolte M, Neubauer A. (2005). Long-term follow-up of gastric 
MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005 Nov 
1;23(31):8018-24. 
Xu Y, Wiernik P. Systemic lupus erythematosus and B cell hematologic neoplasm. Lupus 
2001;10(12):841-50. 
Yurasov S, Wardemann H, Hammersen J, et al. (2005a) Defective B cell tolerance checkpoints 
in systemic lupus erythematosus. J Exp Med 2005. Feb 28;201(5):703-711 
Yurasov S, Hammersen J, Tiller T et al. (2005b) B cell tolerance checkpoints in healthy 
humans and patients systemic lupus erythematosus. Ann N Y Acad Sci. 2005. 
Dec;1062:165-174 
Yurasov S, Tiller T, Tsuiji M, Velinzon K, Pascual V, Wardemann H, Nussenzweig MC. 
(2005c) Persistent expression of autoantibodies in SLE patients in remission. J Exp 
Med 2006;203:2255–2261. 
Zaja F, Tomadini V, Zaccaria A, Lenoci M, Battista M, Molinari AL, Fabbri A, Battista R, 
Cabras MG, Gallamini A, Fanin R. (2006). CHOP-rituximab with pegylated 
liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell 
lymphoma. Leuk Lymph 2006;47(10):2174-2180. 
Zucca E & Dreyling M; ESMO Guidelines Working Group. (2008). Gastric marginal zone 
lymphoma of MALT type: ESMO clinical recommendations for diagnosis, 
treatment and follow-up. Ann Oncol. 2008 May;19 Suppl 2:ii70-1 
19 
Infections and Systemic Lupus Erythematosus 
C. Alejandro Arce-Salinas and Pablo Villaseñor-Ovies 
Hospital Central Sur de Alta Especialidad, PEMEX 
Instituto Nacional de Rehabilitación, SSA 
México City  
México 
1. Introduction 
Notwithstanding that life expectancy in patients with systemic lupus erythematosus (SLE) has 
improved progressively in the last few decades, the mortality rates remain three times higher 
as compared with the general population (Uramoto et al, 1998). Reported causes of death vary 
according to the region of the world, yet there is agreement on the bimodal curve of mortality 
rate in these patients, with an initial peak occurring early after diagnosis, strongly related with 
disease activity and infections, and a later escalade associated with cardiovascular disease, 
accrued damage, and infections too (Rubin et al, 1985). It may be due to its complexity that 
infectious disease is often considered a grim topic in SLE, but it is undeniable that infections 
are important contributors of mortality in every stage of the disease. 
The range of infections in lupus patients varies widely, from opportunistic infections -
attributable in some level to immunological dysfunction- to common bacterial and viral 
infections with typical or atypical presentations. Moreover, patients with lupus exhibit 
increased proclivity to hospital acquired infections than hospitalized patients with other 
diagnosis. Some authors have stressed out the association that certain conditions have with 
the risk of infections in patients with lupus.  Some of these include: high disease activity, 
specific immune dysregulation; drug-induced immune deficiency; and organ failure due to 
irreversible damage.  
On the other hand, several clinical manifestations like fever, lymphadenopathy, unexplained 
confusion, pulmonary infiltrates, skin and mucosal injuries, coagulation disorders, and others, 
represent true diagnostic challenges for the clinician who may take them as clues of a lupus 
flare, or may be compelled to commence a trial of antimicrobial treatment because these may 
also be the clinical expression of a life-threatening infection, or perhaps, as it often occurs in the 
field treat both conditions simultaneously. Some evidence suggests that certain infections, 
particularly of viral nature, might participate in disease initiation, disease flare or worsening of 
an active lupus condition. 
In this chapter we will review the current information regarding infections in patients with 
SLE, and recommendations to prevent and treat them. 
2. Immune dysfunction and infection in SLE 
Patients with SLE are known to have defects both in the humoral and the cellular branches 
of the immune system. Some of these defects participate in the inadequacy of immune 
 
Systemic Lupus Erythematosus 
 
408 
defense against pathogens. The relationship between altered immune function and 
infections in SLE is exceedingly complex, as infectious agents can interact with the immune 
system in several ways, and the immune system itself works as an intricate, overlapping and 
sometimes redundant network of signals and checkpoints under different levels of control. 
Of course, the defective immune function is not universal and as in other aspects of the 
disease, its expression is not homogenous among lupus patients and hence susceptibility to 
different pathogens is reasonably variable. The potential role of macrophage and 
polymorphonuclear defects, reduced numbers and dysfunction of T-cells and B-cells, defects 
in the production of immunoglobulin and altered function of the reticuloendothelial system 
are all considered to take part in the altered immune response against pathogens that is 
present in a proportion of patients with SLE (Sebastiani  & Galeazzi, 2009; Iliopoulos & 
Tsokos, 1996). 
All this is further complicated by the almost obligated use of immunosuppressant drugs to 
control disease activity. Nevertheless, the young readers will be surprised to know that 60 
years ago, lupus was not treated with steroids or immunossuppresants and despite that, 
infection was still one of the major causes of death in lupus patients. (Klemperer, et al 1941) 
2.1 Defects in the complement system 
The complement system plays a crucial role in host defense against pathogens and the 
increased infection rates observed in SLE patients have been attributed in part to defects of 
the complement system that are in turn, frequent in SLE. Genetic deficiencies of early 
components of the classical pathway are major risk factors for the development of lupus, 
particularly C1q deficiency. Since C1q plays an important role in complement activation 
through the recognition and clearance of apoptotic material, antibodies and structural 
proteins on bacteria and viruses, it is not surprising that a deficient state would increase 
susceptibility to infection. Also the consumption of complement components by immune 
complexes is also considered to limit the amount of complement available to be used against 
invading pathogens. Reduction of other components of the complement system comes with 
various risk degrees of specific infections, i.e. C3: encapsulated bacteria, C5-C9: Neisserial 
infections. (Pickering et al, 2000; Figueroa & Densen, 1991) 
2.2 Mannose-Binding Lectin (MBL) and Infections in SLE 
The lectin pathway of complement activation is also implicated in the pathogenesis of lupus 
and most likely in the increased propensity to infections in this disease, as well. MBL is a 
serum protein that serves as a recognition particle in the lectin pathway of complement 
activation. Additionally, MLB may directly opsonise pathogenic microorganisms and 
activate phagocytes. Several studies have demonstrated that variant alleles of MBL are 
associated with an increased risk for the development of SLE. Furthermore, among patients 
with SLE, those homozygous for MBL allelic variants had an increased risk of serious 
infections in comparison with patients heterozygous of homozygous for the normal allele 
(M.Y. Mok et al, 2007a). Other studies have failed to demonstrate a connection between 
functional MBL activity and the occurrence of infections (Bultink et al, 2006). This 
discrepancy between the genotypic and phenotypic data could be explained by the fact that 
functional activity of MBL is not only determined by mutations on its encoding gene. Also, 
the immune system has redundancies and in most cases, increased susceptibility to infection 
with MBL deficiency arises when other factors are inducing immune dysfunction (i.e. 
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immunosuppressive drugs). In fact, low levels of MBL are associated with poorer outcomes 
in severe infections, even in otherwise immunocompetent individuals. In synthesis, a 
proportion of patients with lupus appear to have increased frequency of infections related to 
allele variants of MBL; such infections are for the most part from encapsulated bacteria, and 
most likely owing to defective opsonization (Monticielo et al, 2008; Super et al. 1989). 
2.3 Cellular immune defects 
The diminished phagocytic activity observed in monocytes from patients with lupus, may 
be due to a decrease in the production of TNF-α, deficit in the generation of superoxide, or 
by the presence of specific autoantibodies against receptor Fcγ. These autoantibodies may 
have a wider effect over the immune system because these receptors also exist on the surface 
of B-cells, natural killer cells, and some T-cells (Boros et al, 1993; Yu et al, 1989). Defective 
phagocytosis has also long been noticed in polymorphonuclear leukocytes in patients with 
lupus. Although the presence of antibodies against neutrophil cytoplasmic components, 
some of which are directly involved in pathogen fighting (i.e. lactoferrin, elastase and 
lysozyme), has been reported in SLE, its clinical significance is still obscure. Their presence 
has no influence over total number of neutrophils and their precise contribution to the 
increased susceptibility to infections in SLE, remains to be determined (Lee et al, 1992; 
Schnabel et al, 1995).  
T-cell lymphopenia is the most common quantitative disorder observed in the blood of 
patients with lupus. Lymphopenia correlates with disease flares and responds to 
immunosuppressive treatment. It is generally considered to be a major contributor in the 
increased propensity to infections. T-cells also exhibit important functional deficits. 
Impaired T-cell cytolytic activity is largely attributable to a decreased production of 
interleukin-2 and γ-interferon and is more prominent within the CD8+ T-cell population. On 
top of the reduced delayed hypersensitivity skin response that happens in patients with 
SLE. A group of studies pointed out that an important proportion of patients with SLE have 
altered in vitro immune responses to alloantigens and recall antigens, and that such 
dysfunction correlates with higher disease activity. (Yu et al, 1989; Gumma et al, 1994). 
In general, B-cell functions seem unaltered in SLE. Antibody production and immunization 
are preserved in the majority of cases, but some B-cell and immunoglobulin alterations have 
been described. Scattered reports of transient or permanent hypogammaglobulinemia with 
an increased risk of infections were informed prior to the use of anti-CD20 therapies. 
Alternatively, many patients with SLE display a prominent polyclonal B-cell activation and 
hypergammaglobulinemia (Yong et al, 2008, Karim 2006; Battafarano et al 1998). 
Transient or permanent spleen dysfunction is associated with diverse autoimmune diseases 
including SLE. In SLE, functional asplenia, defined as failure of splenic uptake of a 
radiolabeled colloid is present in approximately 5% and seems to correlate with disease 
activity. Asplenia increases vulnerability to pneumoccocal and Salmonella infections (Fishman 
& Isenbert, 1997). Table 1 summarizes factors predisposing SLE patients to infections. 
3. Epidemiology of infections in systemic lupus erythematosus 
Although infections in SLE remain as an important clinical concern that should have a 
prominent place in the research agenda in lupus, there is a notorious absence of high-quality 
studies addressing this phenomenon. The majority of studies involve hospitalized patients, 
a population that certainly has a selection bias and limits their external validity; also, we  
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top of the reduced delayed hypersensitivity skin response that happens in patients with 
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altered in vitro immune responses to alloantigens and recall antigens, and that such 
dysfunction correlates with higher disease activity. (Yu et al, 1989; Gumma et al, 1994). 
In general, B-cell functions seem unaltered in SLE. Antibody production and immunization 
are preserved in the majority of cases, but some B-cell and immunoglobulin alterations have 
been described. Scattered reports of transient or permanent hypogammaglobulinemia with 
an increased risk of infections were informed prior to the use of anti-CD20 therapies. 
Alternatively, many patients with SLE display a prominent polyclonal B-cell activation and 
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  T-cell lymphopenia 
  Impaired T-cell cytotoxic activity 
  Altered recall of antigens 
  Diminution of NK-cell function and number 
 
Humoral immunity 
  Antibodies against Fcγ	receptor	
  Antibodies against neutrophil cytoplasmic components 
  Hypogammaglobulinemia 
 
Phagocytic deficiency 
  Mononuclear cell defective phagocytosis 
  Deficit in superoxide generation 
 
Cytokine defects and other immune anomalies 
  Mannose-binding lectin allelic variants 
  Hypocomplementemia 
  Decrease in the production of TNF-α 
  Decrease of IL-2 production 
  Other cytokine imbalance (IL-10, γ‐interferon,	IL‐1) 
 
Disease related 
  Disease activity and/or glucocorticoid use 
  Transient or permanent spleen dysfunction 
  Accrued damage (irreversible damage, i.e. ESRD, lung fibrosis, etc.) 
 
Treatment related 
  Immunosuppressive drugs 
  Glucocorticoids 
  Immune targeted biologic agents 
 
Table 1. Summary of factors related to infection propensity in SLE 
found a great number of patient series and case reports of outstanding features but only a 
few prospective cohorts in most of which the outpatient setting had been neglected. 
Morbidity of lupus patients varies with the chronological stage of the disease. In subjects with 
short disease duration, the most important causes of hospitalization and medical attention are 
related to disease activity and common bacterial or viral infections and few opportunistic 
infections. With the improved survival rates and longer disease duration, other morbid 
conditions are commonly identified in longstanding disease; the most regularly described are 
accelerated atherosclerosis and cardiovascular disease, osteoporosis, osteonecrosis, cognitive 
dysfunction, chronic fatigue, fibromyalgia, malignancies and the coexistence with other 
chronic illnesses such as diabetes mellitus and systemic hypertension. However, infectious 
disease is still one of the most important causes of hospitalizations and death in this group.  
In a large cohort of patients with SLE followed in several European countries, the annual 
incidence of infection was 27% during the first 5 years. A follow-up report indicates that 
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infections continued to be the cause of one fifth of all hospitalizations in the second half of 
the 10 year follow-up, with a notorious reduction in the diagnosis of sepsis in this later 
period (Cervera et al, 2003). Other authors have reported on the burden of infectious disease 
in SLE: close to 15% of patients with lupus are hospitalized for major infections every year; 
the risk of major infection is 60% higher in SLE as compared with other chronic diseases, 
and many of them are treated in the ICU. A bacterial etiology is detected in the majority of 
cases and lower respiratory tract is the most important site of infection. Mexican researchers 
performed a study to determine the incidence of infections in their group; among the 
ambulatory patients, 57% of hospitalizations were due to infection of any kind, and 
although diagnostic confirmation was achieved only in one third of their cohort, all patients 
with suspicion of infection, received complete antibiotic courses. They found 12.5% of 
nosocomial infections in non-infected subjects admitted for other reasons (Navarro-Zarza et 
al, 2010). Furthermore, Al-Arfaj in Arabia found, in patients followed by almost 30 years 
with a remarkable long-term survival, that 50% of deceases were related to severe bacterial 
sepsis, mainly in subjects with renal failure (Al-Arfaj & Khalil, 2009). Other groups in 
different regions of the world report similar rates of infections in SLE, emphasizing that 
these complications remain as a significant problem both in the outpatient care and in the 
hospital setting.  
Infections are also a prominent cause of death among lupus patients. On the early 1980’s, a 
multicenter evaluation in more than 1,000 lupus patients was reported, revealing that one 
third of registered deaths were caused by infections and another third because of disease 
activity. Other authors, in different regions of the world, have assessed the issue of mortality 
due to infections, and with different methodological approaches, mortality rate associated to 
this cause is reported from 14 to 50% of all deaths (Cervera et al, 2003; Zandman-Goddard & 
Shoenfeld, 2003; Gladman et al, 2002).Table 2 depicts impact of infections in general 
mortality of SLE patients. 
The nature of most infections in lupus patients either in the ambulatory or nosocomial 
settings is mainly of bacterial origin, being lower respiratory and urinary tract infections the 
most frequently registered, with less cases of sepsis of unknown cause, soft tissue & skin 
and other common bacterial infections (Gladman et al, 2002; Iliopoulos & Tsokos, 1996). 
Nevertheless, it should be underlined that non-complicated infections occurring on 
ambulatory settings are not usually recorded, and it is possible these may be 
underestimations of the true burden they give. In a prospective study of an outpatient clinic, 
an incidence of 32% of infections along 2 years of follow-up was observed. Urinary tract 
infections (UTI) due to Escherichia coli, skin infections produced by Staphylococcus aureus, and 
simultaneous infections of different sites were the most frequently registered; the majority 
were treated on ambulatory basis with good results (Zonana-Nacach et al, 2001).  
Nosocomial infections are a noteworthy issue to address in this scenery. Some investigators 
reported that more than a half of infections diagnosed in SLE patients are of a nosocomial 
source, mostly upper and lower respiratory and bloodstream infections; patients with organ 
dysfunctions and with high-steroid dose are more susceptible to acquire nosocomial 
infections. The most important information in this regard comes from Navarro-Zarza’s 
cohort, indicating an incidence rate of 12.5% among patients who had neither symptoms nor 
clinical suspicion of infection at admission, and afterward develop nosocomial infections; 
higher disease activity score measured by the Mex-SLEDAI (Guzmán et al, 1992), high 
damage scores (SLICC/ACR), immunosuppressive treatment and length of hospital stay 
were all risk factors for the development of nosocomial infection (Navarro-Zarza et al, 2010). 
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Consequently, lupus patients admitted for hospital care are at higher risk of infection and 
any action to lower their incidence, by every member of the healthcare team should be 
implemented with emphasis. 
 
Author, year/Site # of patients followed by time 
# of 
deaths Survival 
% of deceases 
due to 
infections 
C.C.Mok, 2000/China 186 by 7 y 9 93% - 5 y 75% 
Kasitanon, 2002 
/Thailand 349 by 14 y 52 84% - 5 y; 75% - 10 y 35% 
Cervera, 2003/Europe 1,000 by 10 y 68 97% - 5 y; 92% - 10 y 25% 
Pons-Estel 2004/Latin 
America 1,214 by 3 y 34 ND 58% 
Bernatsky, 2006/North-
America§ 9,547 by 30 y 1,255 ND 5% 
Wadee, 2007/South 
Africa 226 by 15 y 55 72% - 5 y; 58% - 10 y 44% 
Nossent, 2007/Europe 2,500 by 5 y 91 ND 57% 
Al-Arfaj, 2009/ Saudi 
Arabia 624 by 30 y 25 98% - 5 y; 97% - 10 y 48% 
Goldblatt, 2009/UK 104 (of 407) by 29 y¶ 67 ND 25% 
¶ Only reports results of 104 patients hospitalized form a cohort of 470 
§ Study in 23 Centers of US, Canada and UK, only 1 in Sweden and 1 in Iceland 
Table 2. Percentage of deaths due to infections in some studies around the world. 
Infectious diseases in SLE patients admitted to the ICU require an additional comment. 
Most admissions to the ICU in lupus patients are related to infection, and a considerable 
mortality is usually observed (45-86%); the most often reported predictive markers are: 
higher APACHE-II scores, length of stay in the ICU, and inadequate initial selection of 
antibiotics. It has been shown that not infected patients with SLE admitted to the ICU with 
lupus flares, exhibit high mortality rates (75-95%), and nosocomial acquired infections are a 
relevant complication in most cases. These reports, as well as others (Alzeer et al, 2004), 
highlight the importance of pneumonia and bacterial sepsis of unknown origin as the most 
frequent reason for admission to ICU, and their relationship with poor outcomes. 
3.1 Usual bacterial infections 
Common microorganisms underlie the majority of infections among lupus patients. 
Pneumonia and respiratory tract infections are the most recognized (Petri, 2008). Some 
immune defects increase susceptibility to certain bacteria, but no comparative studies have 
made clear the possible connection that such defects may have with specific infections. 
Continuing on the subject of common infections, S. aureus and Streptococcus pyogenes persist 
as the most frequent etiology of respiratory infections. However, as mentioned, information 
related to respiratory infection in the outpatient setting is scarce, and not surprisingly 
pathogens differ in the hospitalized subject; gram-negative bacteria appear as key pathogens 
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in respiratory infections in these circumstances, being Klebsiella sp, Pseudomonas aeruginosa, 
and E. coli mainly involved. Streptococcus pneumoniae has been reported as a cause of 
septicemia; interestingly, lower rates of pneumococcal septicemia have been seen after the 
implementation of routine vaccination. 
Bladder dysfunction seems to be more prevalent among women with SLE; in an outpatient 
cohort, near to 10% suffered of recurrent infection and depict abnormal voiding function 
tests, with small bladder capacity, reduced bladder sensation, residual urine and abnormal 
urinary flows. These data were alike to those reported by others, and also shows a possible 
association of these abnormalities and disease activity. Urinary tract infections are very 
common among women with SLE, and the functional derangements previously mentioned 
are found often, particularly in cases of recurrent infections. E coli and Streptococcus agalactiae 
were the most prevalent recovered microorganisms (Durán-Barragán et al, 2008). 
Infections due to Salmonella species are important cause of bacteremia after ingestion of 
contaminated food; inasmuch as underdeveloped countries have more risk conditions to 
this infection, it has been reported more frequently in these regions of the world. Lupus 
patients’ conditions are prone to develop primary bacteremia, extra-intestinal collections, 
osteomyelitis, septic arthritis, infective endocarditis, bloodstream and endovascular 
infections, even in absence of gastrointestinal symptoms. Infections of different Salmonella 
serogroups are also related to high mortality, as it has been shown after bacteremia 
episodes. Risk factors for mortality due to Salmonella infection are re-infection, older age and 
concomitant infection with other microorganisms; a high index of suspicion is vital, insofar 
as salmonellosis and SLE have similarities in clinical manifestations like fever, rash, 
pleurisy, abdominal complaints and synovitis. Table 3 describes the main pathogens 
observed in prospective or relevant studies in different regions of the world. 
3.2 Infections due to Mycobacteria 
Infections as a consequence of Mycobacterium species are of two groups: infections due to M 
tuberculosis, that trend to occur early in the course of lupus, related to disease activity and 
treatment, and usually resulting mainly from reactivation of latent infection or to 
reinfection; and infections to non-tuberculous Mycobacterium (NTM), presenting later in the 
course of disease and predominantly as a new infection, including M. avium complex, M. 
chelonae, M. haemophilum or M. fortitum (Cuchacovich & Gedalia, 2009). Mok et al (M.Y. Mok 
et al, 2007b) describes 11 cases of NTM infections localized in skin and soft tissues, in 
patients with long disease duration and long cumulative prednisone dose. In transplant 
patients, SLE remains as a risk factor for tuberculosis with a substantial increase of mortality 
among patients with this infection. 
Mycobacterium tuberculosis infections represent a great problem to many countries around 
the world. The HIV pandemic and use of biologic immune-regulator agents for other 
rheumatic conditions are related to rise of tuberculosis (TB) in regions where TB was 
believed near to ending (Mathers & Loncar, 2006). In point of fact, since the first use of high-
steroid doses in rheumatic diseases, an increase of TB infections was noticed, as well as 
reactivation of previously treated TB once steroids were newly administered (Yun et al, 
2002); besides, occurrence of TB is closely and directly interrelated to the mean daily doses 
or cumulative steroid-dose. In lupus patients, TB is a major contributor of morbidity and 
mortality. There seems to be a higher risk for this infection and clinical illness in these 
patients is often extra-pulmonary (miliary) where hematogenous dissemination is usually  
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Consequently, lupus patients admitted for hospital care are at higher risk of infection and 
any action to lower their incidence, by every member of the healthcare team should be 
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in respiratory infections in these circumstances, being Klebsiella sp, Pseudomonas aeruginosa, 
and E. coli mainly involved. Streptococcus pneumoniae has been reported as a cause of 
septicemia; interestingly, lower rates of pneumococcal septicemia have been seen after the 
implementation of routine vaccination. 
Bladder dysfunction seems to be more prevalent among women with SLE; in an outpatient 
cohort, near to 10% suffered of recurrent infection and depict abnormal voiding function 
tests, with small bladder capacity, reduced bladder sensation, residual urine and abnormal 
urinary flows. These data were alike to those reported by others, and also shows a possible 
association of these abnormalities and disease activity. Urinary tract infections are very 
common among women with SLE, and the functional derangements previously mentioned 
are found often, particularly in cases of recurrent infections. E coli and Streptococcus agalactiae 
were the most prevalent recovered microorganisms (Durán-Barragán et al, 2008). 
Infections due to Salmonella species are important cause of bacteremia after ingestion of 
contaminated food; inasmuch as underdeveloped countries have more risk conditions to 
this infection, it has been reported more frequently in these regions of the world. Lupus 
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osteomyelitis, septic arthritis, infective endocarditis, bloodstream and endovascular 
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observed in prospective or relevant studies in different regions of the world. 
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among patients with this infection. 
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the world. The HIV pandemic and use of biologic immune-regulator agents for other 
rheumatic conditions are related to rise of tuberculosis (TB) in regions where TB was 
believed near to ending (Mathers & Loncar, 2006). In point of fact, since the first use of high-
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reactivation of previously treated TB once steroids were newly administered (Yun et al, 
2002); besides, occurrence of TB is closely and directly interrelated to the mean daily doses 
or cumulative steroid-dose. In lupus patients, TB is a major contributor of morbidity and 
mortality. There seems to be a higher risk for this infection and clinical illness in these 
patients is often extra-pulmonary (miliary) where hematogenous dissemination is usually  
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(Percentage of total) Characteristics 
Oh, 
1993/Singapore 28 38 
S. aureus (21%) 
P. aeruginosa (11%) 
Klebsiella sp. (11%) 
E. coli (7%) 
M. tuberculosis (7%) 
 
Hospitalized patients 
followed by 8 months 
Zonana-Nacach, 
2001/Mexico 200 65 
E. coli (25%) 
S. aureus (8%) 
Candida sp. (6%) 
M. tuberculosis (2%) 
Salmonella sp. (2%) 
 
Outpatient only. Two 
years of observation 
Leone, 2007/Brazil 71 48 
S aureus (50%) 
P. aeruginosa (17%) 
Candida sp. (17%) 
Aspergillus sp. (17%) 
 
Juvenile SLE, 18 
deaths.  
Ramírez-Gómez, 
2007/Colombia ND 123 
E. coli (22%) 
Staphylococcus sp. (15%) 
Klebsiella sp. (9%) 
Candida sp. (9%) 





(SLEDAI > 11). Three 
years of observations 
Ruiz-Irastorza, 
2009/Spain 249 88 
E. coli 16% 
S. aureus 14% 
M. tuberculosis 12% 
S. pneumoniae 9% 









E. coli (48%) 
Candida sp. (21%) 
Staphylococcus sp. (15%) 
Streptococcus sp. (12%) 
M. tuberculosis 4.5% 
 
Community acquired 
infections seen along 
5 years 
Table 3. Pathogens frequency in some prospective studies around the world 
the mechanism involved (Hou et al, 2008). Extra-pulmonary tuberculosis presents a wide 
range of symptoms, which may confound with other diseases, or with disease activity; 
symptoms like arthritis, lymphadenopathy, lung nodules, pulmonary infiltrates, pleural 
effusion, weight loss and renal abnormalities offer this challenge, so, workup to identify 
mycobacteria is imperative. Moreover, in a review of patients with central nervous system 
involvement, M. tuberculosis represents a frequent cause of meningitis that requires prompt 
recognition and treatment, since it is linked to high mortality and severe functional sequels 
(Yang et al, 2007). Burden of TB in SLE is higher in countries were TB is endemic; for 
instance, incidence may vary from less than 1% in industrialized countries to 11.6% in India 
(Falagas et al, 2007) with a 6-fold risk of TB among SLE patients in Spain to 15-fold in Hong 
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Kong and 60-fold in India. In a study of overall infections among lupus patients, TB was the 
most frequently diagnosed and extra-pulmonary localization was present in one quarter of 
patients. In addition, TB was found during the first year of lupus diagnosis in 60% and 80% 
in the first 24 months, mainly linked to a major organ dysfunction or aggressive treatment 
(Shyam & Malaviya, 1996). 
Diagnosis of TB and NTM infections in lupus patient represents a challenge for clinicians 
due to the overlap of symptoms and laboratorial abnormalities produced by both 
conditions; however, search for mycobacteria in tissues and corporal fluids, cultures and 
serological test, even with genetic material amplification, as well as ADA assay, tuberculin 
test, and γ-interferon assays seem to be equally accurate than in non-SLE patients. It’s fair to 
mention that some variations have been reported in the diagnostic yield of some of these 
tests that require further assessment. (Prabu et al, 2010). Treatment of TB and NTM 
infections should be provided accordingly to WHO guidelines taking into account the local 
antimicrobial resistance rates. The question of isoniazid prophylaxis in these patients will be 
discussed later. 
3.3 Opportunistic infections 
Immunological abnormalities in lupus patients related to dysregulation of both, humoral 
and cellular responses have been extensively documented. Besides, drugs used to treat SLE 
exert diverse degrees of immune system turndown that deepen the problem of immune 
fighting against pathogens (I. Kang et al, 2003). Opportunistic infections, considered as those 
caused by non-pathogenic microorganisms not often seen in individuals with normal 
immune conditions, which lead to clinically significant consequences in 
immunocompromised subjects, are frequently reported in SLE patients. Furthermore, its 
difficult to know the real load that this type of infections represent in SLE since frequency 
rates  are yet to be determined for most of them. On the other hand, case-reports and small 
case series are abundant on this topic. Nonetheless, in all cohorts describing lupus patients 
with infectious diseases there are cases with opportunistic infections either of bacterial, 
fungal, protozoan or viral origin; lot of cases had overlapping manifestations between 
disease activity and infection leading to treatment delay and poor outcomes. 
3.3.1 Opportunistic infections of viral origin 
Viral infections in SLE have been suspected to play a pathogenic role on development, 
trigger and flare of disease. Some authors have demonstrated activation of immune system 
and antibodies production during acute viral infections, as we mentioned before. On the 
other hand, besides its suggested pathogenic role in autoimmune diseases, acute viral 
infections are frequently reported as partners of disease flares or at disease presentation, 
confusing and favoring misinterpretation of clinical signs and deferral of adequate 
treatment (Ramos-Casals et al, 2008). 
Herpes zoster (HZ) is the symptomatic reactivation of the varicella-zoster virus (VZV), an 
infection frequently acquired at childhood; virus prevails in a latent stage in the dorsal root 
ganglia for long periods of time; more than 90% of adults have serologic evidence of a 
previous VZV infection. Control of latent virus at ganglia is exerted by humoral and cellular 
mechanisms; its reactivation requires a change of immune system balance. The incidence 
rate of HZ is 32.5/1,000 patients-year, from a group of prospectively followed lupus 
patients, which is at least 2-3 fold greater than the general population (T.Y. Kang et al, 2005). 
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involvement, M. tuberculosis represents a frequent cause of meningitis that requires prompt 
recognition and treatment, since it is linked to high mortality and severe functional sequels 
(Yang et al, 2007). Burden of TB in SLE is higher in countries were TB is endemic; for 
instance, incidence may vary from less than 1% in industrialized countries to 11.6% in India 
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Kong and 60-fold in India. In a study of overall infections among lupus patients, TB was the 
most frequently diagnosed and extra-pulmonary localization was present in one quarter of 
patients. In addition, TB was found during the first year of lupus diagnosis in 60% and 80% 
in the first 24 months, mainly linked to a major organ dysfunction or aggressive treatment 
(Shyam & Malaviya, 1996). 
Diagnosis of TB and NTM infections in lupus patient represents a challenge for clinicians 
due to the overlap of symptoms and laboratorial abnormalities produced by both 
conditions; however, search for mycobacteria in tissues and corporal fluids, cultures and 
serological test, even with genetic material amplification, as well as ADA assay, tuberculin 
test, and γ-interferon assays seem to be equally accurate than in non-SLE patients. It’s fair to 
mention that some variations have been reported in the diagnostic yield of some of these 
tests that require further assessment. (Prabu et al, 2010). Treatment of TB and NTM 
infections should be provided accordingly to WHO guidelines taking into account the local 
antimicrobial resistance rates. The question of isoniazid prophylaxis in these patients will be 
discussed later. 
3.3 Opportunistic infections 
Immunological abnormalities in lupus patients related to dysregulation of both, humoral 
and cellular responses have been extensively documented. Besides, drugs used to treat SLE 
exert diverse degrees of immune system turndown that deepen the problem of immune 
fighting against pathogens (I. Kang et al, 2003). Opportunistic infections, considered as those 
caused by non-pathogenic microorganisms not often seen in individuals with normal 
immune conditions, which lead to clinically significant consequences in 
immunocompromised subjects, are frequently reported in SLE patients. Furthermore, its 
difficult to know the real load that this type of infections represent in SLE since frequency 
rates  are yet to be determined for most of them. On the other hand, case-reports and small 
case series are abundant on this topic. Nonetheless, in all cohorts describing lupus patients 
with infectious diseases there are cases with opportunistic infections either of bacterial, 
fungal, protozoan or viral origin; lot of cases had overlapping manifestations between 
disease activity and infection leading to treatment delay and poor outcomes. 
3.3.1 Opportunistic infections of viral origin 
Viral infections in SLE have been suspected to play a pathogenic role on development, 
trigger and flare of disease. Some authors have demonstrated activation of immune system 
and antibodies production during acute viral infections, as we mentioned before. On the 
other hand, besides its suggested pathogenic role in autoimmune diseases, acute viral 
infections are frequently reported as partners of disease flares or at disease presentation, 
confusing and favoring misinterpretation of clinical signs and deferral of adequate 
treatment (Ramos-Casals et al, 2008). 
Herpes zoster (HZ) is the symptomatic reactivation of the varicella-zoster virus (VZV), an 
infection frequently acquired at childhood; virus prevails in a latent stage in the dorsal root 
ganglia for long periods of time; more than 90% of adults have serologic evidence of a 
previous VZV infection. Control of latent virus at ganglia is exerted by humoral and cellular 
mechanisms; its reactivation requires a change of immune system balance. The incidence 
rate of HZ is 32.5/1,000 patients-year, from a group of prospectively followed lupus 
patients, which is at least 2-3 fold greater than the general population (T.Y. Kang et al, 2005). 
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In a national survey in an Asian country, SLE was the most important risk factor to develop 
HZ at population level. Major complications of HZ are visceral dissemination with CNS, 
lung and liver involvement. Use of immunosuppressant drugs is the most relevant risk 
factor for complicated HZ; presence of lupus nephritis and disease activity has been also 
mentioned. Particular genetic abnormalities have not been found in association with HZ 
infection. Lupus patients have more severe forms of infection, with disseminated disease in 
11-20% of cases, higher number of cases with ocular involvement, and post-herpetic 
neuralgia (Borba et al, 2010). Treatment of this condition should be carried out accordingly 
to current guidelines. A live attenuated varicella virus vaccine has not been tested in SLE 
patients and is not recommended in patients using any type of immunosuppressant. 
Cytomegalovirus (CMV) infection is a life-threatening that endangers organ function in 
immunocompromised host, either as primary infection or as a reactivation of latent CMV. 
Although in other conditions associated with immune dysfunction reports of visceral, eye, 
CNS involvement and graft rejection due to this viral disease are ubiquitous. CMV infection 
is also relevant in pregnant women since it is a frequent cause of newborn morbidity and 
mortality. Seroprevalence of CMV antibodies in healthy population have been found to 
range from 50 to 80% in US. In lupus patients, clinical infections often come from 
reactivation of latent virus when aggressive immunosuppressive therapy is installed. 
Clinical pictures are wide: pneumonia and alveolar hemorrhage, skin ulcers, proteinuria 
and renal failure, thrombocytopenia, pancytopenia, hepatitis, vasculitis, retinitis and 
encephalitis. It may be underseeked and hence underdiagnosed but only few cases with any 
of these complications are reported in SLE (Ramos-Casals et al, 2008). Diagnosis of CMV is 
made with serology, although a note of caution should be taken: false positive reactions are 
not infrequent, presumably because of secondary production by auto-reactive B-cells. Other 
tools for diagnosis are DNA amplification of viral material as well as the characteristic 
cellular changes seen in biopsies. Antiviral agents to treat this disease should be initiated 
once a reasonable suspicion is present because it is linked to a considerable mortality and 
irreversible organ dysfunction, and in the clinical arena it is often difficult to wait for an 
unquestionable diagnosis; ganciclovir and its pro-drug valganciclovir, foscarnet and 
cidofovir are currently used in this setting, with the necessity of a tight monitoring due to its 
potential serious adverse effects. Up till now, attempts to develop an effective vaccine to 
prevent CMV infection by several researches around the world, either in the general 
population or in some special groups, have not been successfully (Gandhi & Khanna, 2004). 
Epstein-Barr virus (EBV) infection importance resides in its temporal relationship with lupus 
initiation; moreover, EBV infection is relevant because of the immunological abnormalities 
found during and after exposure to this virus (Barzilai et al, 2007), the defective control of 
latent infection seen in lupus patients (I. Kang, 2004) and the higher prevalence of serum 
antibodies against EBV observed in subjects with SLE as compared with other patient groups. 
In Ramos-Casals’ review, only a few cases with EBV infection were obtained, and no patient 
had organ-specific involvement; such cases had lymphadenopathy, fever and rash often 
considered manifestation of disease activity may well represent mild infections with EBV. We 
found very interesting a report of lymphoma with EBV infection in a patient receiving 
azathioprine that regressed after withdrawal of immunosuppressive therapy (Evans et al, 
2008). No specific treatment for this condition has been described. 
Human papillomavirus infection has demonstrated to be cause of genital, rectal and 
laryngeal cancer. Uterine cancer is the most important malignancy of those linked to HPV 
infection, due to its high incidence in third world countries. In 2010 it remains a public 
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health problem in poor countries, in spite of the many healthcare programs of prevention, 
early detection and treatment of pre-malignant lesions (Clifford et al, 2005). Lupus women 
have higher prevalence of HPV infection compared with a control group, as well as high-
risk variants of the virus (Klumb et al, 2010). Furthermore, there might be more risk  
of squamous intraepithelial lesion because of a higher prevalence of identified factors of 
disease progression, such as persistence of high-risk HPV variants and the use of 
cyclophosphamide.  Progression to neoplasia is probably more frequent among SLE patients 
also. Therefore, SLE women require close follow-ups, particularly in women with sexual 
activity and/or presence of the virus in the cervix. Treatment of those with high-risk 
variants and adherence to management guidelines of squamous epithelial lesions  
and cervical intraepithelial neoplasia should be warranted. No evidence of impact of 
recently applied programs of vaccination in these patients can be made due to current short 
length of follow-up. 
Parvovirus infection has also been associated with pure red-cell aplasia, hydrops fetalis and 
acute and chronic arthropathy; other clinical manifestations such as rash, fever, 
lymphadenopathy, and blood cell abnormalities may also puzzle the clinician into a 
misdiagnosis of SLE. Careful assessment and follow-up will differentiate between both 
conditions (Severin et al, 2003). Diagnosis of infection is made by serology or viral DNA 
amplification, no treatment for this condition has been described as a great majority of cases 
have self-limited disease. No methods of prevention are available. 
Hepatitis C-virus (HCV) infection has a worldwide distribution and is endemic in some 
regions. It is the most common cause of chronic liver disease and the global prevalence has 
been estimated in 2%, more than 120 million people around the world might be currently 
infected (Shepard et al, 2005). Coexistence of SLE and HCV infection is therefore not an 
unusual treat. HCV infection is the viral illness with the most described muscle skeletal and 
autoimmune manifestations resembling rheumatic conditions, mostly acute and chronic 
polyarthritis, vasculitis, glomerulonephritis, neuropathy, thrombocytopenia, cryoglobulinemia 
and other laboratory anomalies, including positive antinuclear antibodies, low complement 
levels and anti-DNA antibodies, which are indistinguishable of the idiopathic diseases. In a 
comparison of lupus patients with and without HCV infection, some authors found a large 
prevalence of infection among SLE patients belonging from the same population, with lower 
frequency of cutaneous features and anti-dsDNA antibodies, as well as a higher prevalence of 
cryoglobulinemia, hypocomplementemia and liver test abnormalities (Ramos-Casals et al, 
2000). HCV infection may mimic not only SLE, but Sjögren syndrome, polyarteritis nodosa 
and rheumatoid arthritis also (Sharlala & Adebajo, 2008; Becker & Winthrop, 2010) and may 
play a pathogenic role in autoimmune thyroiditis and Behçet´s disease. On the other hand, α2-
interferon therapy used for the treatment of chronic HCV may induce SLE which may or may 
not regress after withdrawal. Also, clinicians should bear in mind that SLE has been described 
as a remarkable cause of false positive serology for HCV. 
Other viral infections in lupus patients such as mumps, measles, herpesvirus-6, or herpes 
simplex virus are seldom reported and seem not to have relevance interactions of these viral 
agents and SLE (Ramos-Casals et al, 2008).  
3.4 Rare bacterial infections 
Listeria monocytogenes is a ubiquitous pathogen that causes disease in animals and humans. 
Outbreaks of listeriosis in relation to contaminated food have been reported in 
immunocompetent hosts. In immune deficient patients it is frequently a fatal infection with 
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simplex virus are seldom reported and seem not to have relevance interactions of these viral 
agents and SLE (Ramos-Casals et al, 2008).  
3.4 Rare bacterial infections 
Listeria monocytogenes is a ubiquitous pathogen that causes disease in animals and humans. 
Outbreaks of listeriosis in relation to contaminated food have been reported in 
immunocompetent hosts. In immune deficient patients it is frequently a fatal infection with 
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sepsis and CNS involvement. In an analysis of 38 lupus patients with CNS infections, Yang 
et al (Yang et al, 2007) found tuberculosis in a half, L. monocytogenes in 3, other gram-positive 
and gram-negative bacteria in 3 cases, Cryptococcus neoformans in 12 and Aspergillus 
fumigatus in 1; high steroid dose and low albumin were related to unfavorable outcome.  In 
other series, listeriosis mainly manifested as meningitis in SLE patients with remarkable 
high mortality (Kraus et al, 1994). Antibiotic regimen in acute bacterial meningitis in lupus 
patients should include an agent with anti-listerial activity.  
The Nocardia genus includes a group of soil gram-positive saprophyte aerobic actinobacteria. 
Nocardia causes human infections that are difficult to diagnose because of unspecific clinical 
or histological manifestations. There are reports of several lupus cases complicated with 
Nocardia infections; lungs were the most common site of involvement (81%), followed by the 
central nervous system (C.C. Mok et al, 1997). A high degree of suspicion to identify this 
infection is required.  
3.5 Opportunistic Infections of fungal origin 
Fungal infectious disease is more often recognized in hospitalized patients owing to the 
more extensive use of broad-spectrum antibiotics. In lupus patients, the most common 
fungal infections are, as in other chronic immune deficient states, those produced by Candida 
species, which may affect pharynx, esophagus, and the urinary tract or may present 
themselves as a primary bloodstream infection. A relationship with high steroid doses and 
intense immunosuppression is suggested by many. Pneumocystis jiroveci (formerly carinii) 
has been acknowledged as a cause of severe pulmonary involvement in chronic disease with 
deficient immune function. There are several reports of P. jiroveci pneumonia in patients 
with rheumatic disorders after intense immunosuppression. It has been suggested that SLE 
patients have more dramatic disease behavior and higher mortality rates, but this remains 
speculative. Patients receiving high dose steroids (>40 mg of prednisone or equivalent, for 
more than three months) or a combination of immunosuppressants, and with lung 
involvement of SLE (i.e. autoimmune alveolitis) may be considered for a prophylactic trial 
of antimicrobials. (Vernovsky & Dellaripa, 2000). 
C. neoformans is ubiquitous encapsulated yeast that causes severe neurological infections and 
other disseminated diseases in immunocompromised hosts. In several fatal cases of lupus 
patients with meningeal infection, C. neoformans has been seen as a causative agent. 
Moreover, in a group of lupus patients with invasive fungal infections, C. neoformans 
represented almost 70% of cases, with both meningeal and disseminated disease. Prompt 
initiation of active antifungal treatment is mandatory in accordance to the elevated mortality 
registered in these cases. Other fungal agents such as Aspergillus fumigatus and mucor 
species have been reported and recently reviewed (Arce-Salinas et al, 2010). 
3.6 Parasitic infections in SLE 
Parasitic diseases remain as a major cause of morbidity and mortality in the tropical areas 
and in the underdeveloped world. Malaria persists in at least 109 countries and affects 300 
million people around the world. No relevant association with clinical manifestations of 
lupus or with its treatment has been reported. Also, no particular clinical picture of 
malaria in this population has been mentioned. Nevertheless, relationship of the parasite 
and lupus resides in the production of antibodies cross-reacting against Plasmodium 
parasites found in some patients (Zanini et al, 2009); and the fact that anti-ribosomal P 
protein antibodies produced by lupus patients cross-react with the ribosomal 
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phosphoprotein P0 of Plasmodium falciparum and exert a potent inhibition of the parasite 
growth in vitro (Singh et al, 2001), the clinical significance of this interesting observation 
remains elusive. On the other hand, IgM anti-phospholipid antibodies have been 
recognized in patients with active malaria infection (Jakobsen et al, 1993), mainly against 
phosphatidylinositol, phsophatidylcholine and cardiolipin; high titers correlated with 
infection severity and poor outcome.  
Exposure to Toxoplasma gondii accordingly to seroprevalence studies is widely distributed; 
its importance increases in pregnant women (increased risk of fetal neurological damage), 
and in immune deficient hosts, in whom encephalitis, retinal damage, pneumonitis and 
other severe manifestations may occur. In lupus patients there are a few case-reports of 
patient with neurological or ocular involvement, as well lymphadenopathy and fever, again 
mimicking disease activity (Seta et al, 2002).  
Strongyloides stercoralis, a soil worm that infects humans in tropical areas should be in mind 
of every clinician caring for SLE patients. S. stercolaris clinical infection has a prevalence that 
ranges from 0.1 to 11% depending the way in which it is sought (serum antibodies, stool ova 
or other methods). Generally its infection produces a few intestinal symptoms and its 
relevance, besides its infectivity, is a consequence of the autoinfection cycle that permits 
blood larvae migration. Without effective cellular immune control disseminated disease 
develops. Some lupus cases complicated with overwhelming strongyloidosis have been 
described; some authors suggest that stool examination looking for parasite’s ova and 
preventive treatment could be recommended for patients at risk who will receive intense 
treatment for SLE. Albendazol or ivermectin have been used in chronic and disseminated 
infection, and the few reports describing this condition are related with poor outcome 
(Caramaschi et al, 2010).  
4. Approach to fever in SLE 
Fever in lupus patients represents a challenge for the clinician, who must face up with 
finding ways to determine the most likely origin between a lupus flare and active infection, 
bearing in mind that often both require prompt treatment. In an old report Harvey, said 
fever was a manifestation of disease activity in at least 86% of their patients, later Daniel 
Wallace draw attention to the decline of fever as a symptom of disease activity in reports of 
the 1980’s and early 1990’s; he thought that such decrease was related with frequent and 
earlier use of NSAIDs and glucocorticoids. Moreover, febrile lupus patients are habitually 
seen in both the outpatient clinic and the hospital wards. The workup requires an intelligent 
and sequential approach to recognize the true nature of fever. Lupus patients with fever 
may show certain patterns of clinical behavior that correspond, more or less, to clinical 
scenarios that entail different actions. Firstly, a patient recently diagnosed, without 
treatment and with active lupus disease including fever among other manifestations; in 
these cases, treatment beginning, particularly with steroids, produces a rapid disappearance 
of fever; when fever persists, the search of an infectious source is mandatory with 
appropriate cultures. Secondly, patients with fever who have inactive disease or mild 
disease activity in their last follow-up visits, often in the outpatient situation, and may or 
may not be receiving low steroid dose, antimalarials or a mild immunosuppressive regimen; 
in this cases, a thorough clinical assessment and studies in hunt of common bacterial 
infections followed by currently recommended empirical antibiotic treatment is warranted 
and associated with resolution of fever. 
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remains elusive. On the other hand, IgM anti-phospholipid antibodies have been 
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phosphatidylinositol, phsophatidylcholine and cardiolipin; high titers correlated with 
infection severity and poor outcome.  
Exposure to Toxoplasma gondii accordingly to seroprevalence studies is widely distributed; 
its importance increases in pregnant women (increased risk of fetal neurological damage), 
and in immune deficient hosts, in whom encephalitis, retinal damage, pneumonitis and 
other severe manifestations may occur. In lupus patients there are a few case-reports of 
patient with neurological or ocular involvement, as well lymphadenopathy and fever, again 
mimicking disease activity (Seta et al, 2002).  
Strongyloides stercoralis, a soil worm that infects humans in tropical areas should be in mind 
of every clinician caring for SLE patients. S. stercolaris clinical infection has a prevalence that 
ranges from 0.1 to 11% depending the way in which it is sought (serum antibodies, stool ova 
or other methods). Generally its infection produces a few intestinal symptoms and its 
relevance, besides its infectivity, is a consequence of the autoinfection cycle that permits 
blood larvae migration. Without effective cellular immune control disseminated disease 
develops. Some lupus cases complicated with overwhelming strongyloidosis have been 
described; some authors suggest that stool examination looking for parasite’s ova and 
preventive treatment could be recommended for patients at risk who will receive intense 
treatment for SLE. Albendazol or ivermectin have been used in chronic and disseminated 
infection, and the few reports describing this condition are related with poor outcome 
(Caramaschi et al, 2010).  
4. Approach to fever in SLE 
Fever in lupus patients represents a challenge for the clinician, who must face up with 
finding ways to determine the most likely origin between a lupus flare and active infection, 
bearing in mind that often both require prompt treatment. In an old report Harvey, said 
fever was a manifestation of disease activity in at least 86% of their patients, later Daniel 
Wallace draw attention to the decline of fever as a symptom of disease activity in reports of 
the 1980’s and early 1990’s; he thought that such decrease was related with frequent and 
earlier use of NSAIDs and glucocorticoids. Moreover, febrile lupus patients are habitually 
seen in both the outpatient clinic and the hospital wards. The workup requires an intelligent 
and sequential approach to recognize the true nature of fever. Lupus patients with fever 
may show certain patterns of clinical behavior that correspond, more or less, to clinical 
scenarios that entail different actions. Firstly, a patient recently diagnosed, without 
treatment and with active lupus disease including fever among other manifestations; in 
these cases, treatment beginning, particularly with steroids, produces a rapid disappearance 
of fever; when fever persists, the search of an infectious source is mandatory with 
appropriate cultures. Secondly, patients with fever who have inactive disease or mild 
disease activity in their last follow-up visits, often in the outpatient situation, and may or 
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infections followed by currently recommended empirical antibiotic treatment is warranted 
and associated with resolution of fever. 
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In a lupus patient hospitalized because of persistent fever, a meticulous clinical evaluation is 
critical, followed by the workup study based on its findings and suspected diagnosis; an 
assessment of disease activity with a validated index is also suggested, activity biomarkers 
are not perfect discriminative elements and are not always available. Adjustment of lupus 
treatment or initiation of a trial of empiric antibiotics should be determined based on the 
initial findings and patient status. Often both are required initially and tailored when a 
clearer scenario is at hand. An extensive assessment of a lupus cohort tested two 
hypotheses, demonstrating that fever is rarely associated with lupus flares in patients taking 
low dose of prednisone (median 10 mg per day), with only one case presenting with fever 
among 73 flare episodes (Rovin et al, 2005). And also, in SLE patients with recent onset 
fever, moderate doses of prednisone (20 to 40 mg/day) were related with a rapid resolution 
of the symptom, except in cases when infection was the cause. 
Differentiation between infection and disease activity is highly important but difficult. 
Acute infections, systemic response to infection and disease activity share many clinical and 
laboratorial abnormalities. Certain biomarkers have been proposed as discriminative 
elements in such scenarios. C-reactive protein could be a useful tool to differentiate both 
conditions (Roy & Tan, 2001), although others reports do not support this, it is our believe 
that the issue remains inconclusive. Procalcitonin, a precursor of calcitonin hormone is a 
novel marker of bacterial infection; nowadays, determination of serum level is routinely 
performed in hospitals as a bedside rapid measurement to provide evidence of bacterial 
infection, in circumstances when clinical or bacteriological diagnosis is not clear. It was 
suggested, that procalcitonin might be useful for distinction of infection or disease activity; 
however, a recent careful evaluation rejected this hypothesis; procalcitonin exerted a poor 
diagnostic accuracy for differentiation of both conditions, and is no longer being used with 
this purpose (Lanoix et al, 2011).  
Systemic lupus is also reported as a cause of fever of unknown origin (FUO) in different 
settings, corresponding to a relevant proportion of cases with this entity being in some 
reports a repeated diagnosis among the inflammatory non-infectious conditions, which 
represent at least one third of all causes of FUO (Arce-Salinas et al, 2005). 
5. Prevention strategies 
Preventive strategies should begin with the identification and amendment of factors that 
predispose SLE patients to infections. This is, however easier said than done. Even though 
infection rates were as high as 40% prior to the widespread use of corticosteroids for the 
treatment of SLE, several studies have demonstrated that high dose steroids, the current 
angular stone of SLE treatment, increase the risk of infection. Weaker associations have been 
reported with the use of cyclophosphamide. Other commonly reported risk factors for 
infection in SLE are: high disease activity, damage accrual, nephritis and neurologic disease 
activity (Gladman et al, 2002; Fessler 2002). No published evidence has shown that the 
steroids effect over the risk of infection is independent of disease activity, and this will 
probably remain as it is, in view of the difficulty to dissect these two conditions. 
Considering this information it seems fair to admit that measures aimed at lowering disease 
activity should be considered the backbone of the preventive strategy against infection in 
SLE, even given their immunosuppressive nature. 
Although inconclusive evidence suggests that certain measures of prophylaxis against 
infective pathogens may be in order for specific subgroups of patients based on their 
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particular risks (Table 4), there are no guidelines as to which subgroups of patients may 




 Influenza vaccination safe and effective (antibody response) in 
SLE. (Abu-Shakra et al, 2007) 
 Pneumococcal vaccine safe. Significant minority left unprotected 
(risk factors: high disease activity and immunosuppressive use). 
(Battafarano et al, 1998) 
Tuberculosis 
 Screening for latent TB is critical prior to high dose PDN and other 
lupus drugs (anergy is frequent). (ATS, 2005) 
 In endemic areas prophylaxis with isoniazid may reduce the risk 
of developing TB in patients taking > 15 mg/day of PDN 
(Hernández-Cruz B et al, 1999). 
Herpes Zoster 
 Frequency of herpes zoster is higher in patiens taking CFM than 
other lupus drugs. Lower doses of CFM reduce risk (Houssiau F 
et al, 2002). 
 No data on (live attenuated) vaccine use in patients with SLE. 
B & C Hepatitis 
 Minimal data on the course of HBV and HCV infections, antiviral 
treatment in SLE, and effect of lupus drugs in viral replication and 
hepatic necrosis. 
 Increase risk of autoimmune symptoms after HBV vaccine (Geier 
D.A. & Geier M.R., 2005). 
 Effect of SLE on response to HBV vaccination not clear. 
Fungal 
infections 
 No primary prevention is suggested for Candida, Cryptotoccus or 
Aspergillus. 
 Prophylaxis for pneumocystis in severe lupus mostly with lung 
involvement is suggested (Vernovsky & Dellaripa, 2000). No real 
data.  
Other 
 Meningococcal vaccination recommended in asplenia but not 
formally examined in SLE 
 Haemophilus influenzae type B recommended in asplenia. Safe and 
effective in SLE (antibody response). (Battafarano et al, 1998) 
Table 4. Preventive Management of Selected Infection in SLE. 
A common problem that physicians often face is whether immunization is a safe and 
effective strategy to prevent infections in patients with SLE or not. Concern has been raised 
from a group of reports that link vaccination to autoimmune manifestations. However, data 
from observational cohorts denotes that vaccinations are safe for the majority of SLE 
patients, when inactivated and component vaccines are used. For instance, a group of 70 
patients with SLE received pneumococcal, tetanus and H. influezae type B vaccines, and none 
had a disease flare or any significant change in the activity status. (Battarfarano et al, 1998). 
The efficacy of vaccination in SLE remains elusive for the majority of vaccines. While most 
patients with SLE show an antibody response to vaccination, this does not imply that the 
patients actually gain an advantage against the pathogen. No study so far, has looked into 
the true protective effect (i.e.: rates of pneumonia infection) that vaccines are supposed to 
offer, in patients with SLE. 
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particular risks (Table 4), there are no guidelines as to which subgroups of patients may 
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The reader is encouraged to read the guidelines proposed by the British Society for 
Rheumatology (www.rheumatology.org.uk). Here it is recommended that live vaccines 
should not be used in patients taking immunosuppressive drugs or a few months after 
cessation of them. They also recommend that when non-live vaccines are given, an 
assessment of response should be sought, and to consider a booster when antibody titers are 
low. Finally, Barber et al proposed a set of strategies for prevention of opportunistic 
infections in SLE, briefly: yearly influenza vaccination, quinquenal pneumococcal 
vaccination, regular pap smears, TB skin test prior to starting immunosuppressive treatment 
and treatment with isoniazid for patients with latent TB infection. Hepatitis B, hepatitis C 
and HIV serology should be screened at baseline, as well as S. stercoralis in endemic areas 
(Barber et al, 2011). 
6. Final remarks 
It has been said that infections loom, like the Sword of Democles, over patients with SLE, 
and this is certainly not an understatement. About half of the patients with SLE will suffer a 
major infection in their lives and a great proportion of them will have an infection 
attributable death. In spite of this, only a few studies have addressed the issues that would 
provide clinicians with better management alternatives for infectious disease in SLE and its 
prevention. It is believed that SLE patients are at high risk for infections owing to intrinsic 
underlying immunological derangements and to the use of therapeutic regimens with 
immunosuppressive agents. 
The use of high dose glucocorticoids, high disease activity, organ dysfunction and use other 
immunosuppressants, are the strongest risk factors for the development of an infection in SLE.  
Fever, among other findings challenges the clinician into a discriminative endeavor to 
establish its relation with disease activity and/or infection. Workup in such scenarios 
depends on a thorough physical exam. Some biomarkers have been proposed to be 
discriminative in this situation. 
Specific measures of prophylaxis may offer benefit in patients with lupus against infection, 
but for the most, no controlled studies support their use. Reports of autoimmune induction 
with vaccination are scarce and for the majority of patients, vaccination is a safe procedure. 
Pneumococcal and influenza vaccinations are recommended, but no probe of true efficacy 
exist for these or other vaccines in patients SLE.   
Many questions remain unanswered in the field of infections and SLE, among others: 1) 
Determining true predictors of infection in SLE such as specific immune defects, genetic 
markers or other biomarkers that indicates proclivity to infection. 2) Studying which specific 
immune derangements underlie the increase susceptibility to specific infections. 3) 
Evaluating which measures is likely to prevent infectious disease in SLE patients, who 
should receive them and what is the best timing to do so; these include studies of long-term 
efficacy vaccines and cost-effectiveness of their routine application in SLE. 4) Testing of 
proposed biomarkers that may help clinician solve a frequent diagnostic dilemma between 
disease activity and active infections. 
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The reader is encouraged to read the guidelines proposed by the British Society for 
Rheumatology (www.rheumatology.org.uk). Here it is recommended that live vaccines 
should not be used in patients taking immunosuppressive drugs or a few months after 
cessation of them. They also recommend that when non-live vaccines are given, an 
assessment of response should be sought, and to consider a booster when antibody titers are 
low. Finally, Barber et al proposed a set of strategies for prevention of opportunistic 
infections in SLE, briefly: yearly influenza vaccination, quinquenal pneumococcal 
vaccination, regular pap smears, TB skin test prior to starting immunosuppressive treatment 
and treatment with isoniazid for patients with latent TB infection. Hepatitis B, hepatitis C 
and HIV serology should be screened at baseline, as well as S. stercoralis in endemic areas 
(Barber et al, 2011). 
6. Final remarks 
It has been said that infections loom, like the Sword of Democles, over patients with SLE, 
and this is certainly not an understatement. About half of the patients with SLE will suffer a 
major infection in their lives and a great proportion of them will have an infection 
attributable death. In spite of this, only a few studies have addressed the issues that would 
provide clinicians with better management alternatives for infectious disease in SLE and its 
prevention. It is believed that SLE patients are at high risk for infections owing to intrinsic 
underlying immunological derangements and to the use of therapeutic regimens with 
immunosuppressive agents. 
The use of high dose glucocorticoids, high disease activity, organ dysfunction and use other 
immunosuppressants, are the strongest risk factors for the development of an infection in SLE.  
Fever, among other findings challenges the clinician into a discriminative endeavor to 
establish its relation with disease activity and/or infection. Workup in such scenarios 
depends on a thorough physical exam. Some biomarkers have been proposed to be 
discriminative in this situation. 
Specific measures of prophylaxis may offer benefit in patients with lupus against infection, 
but for the most, no controlled studies support their use. Reports of autoimmune induction 
with vaccination are scarce and for the majority of patients, vaccination is a safe procedure. 
Pneumococcal and influenza vaccinations are recommended, but no probe of true efficacy 
exist for these or other vaccines in patients SLE.   
Many questions remain unanswered in the field of infections and SLE, among others: 1) 
Determining true predictors of infection in SLE such as specific immune defects, genetic 
markers or other biomarkers that indicates proclivity to infection. 2) Studying which specific 
immune derangements underlie the increase susceptibility to specific infections. 3) 
Evaluating which measures is likely to prevent infectious disease in SLE patients, who 
should receive them and what is the best timing to do so; these include studies of long-term 
efficacy vaccines and cost-effectiveness of their routine application in SLE. 4) Testing of 
proposed biomarkers that may help clinician solve a frequent diagnostic dilemma between 
disease activity and active infections. 
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1. Introduction  
There are new drugs in medicine represent a revolution in therapeutics in the current era. 
These drugs are produced by different molecular biological techniques. Anti-tumor 
necrosis factor- α (anti-TNF-α) agents are important new class of the biological therapy of 
disease modifying antirheumatic drugs (DMARD). They target specific proteins of tumor 
necrosis factor- α (TNF-α) in the immune systems known to increase the inflammatory 
processes. Anti-TNF–α agents are increasingly used for a rapidly expanding number of 
rheumatic autoimmune diseases including rheumatoid arthritis (RA), ankylosing 
spondylitis (AS), crohn’s disease (CD), ulcerative colitis (UC), psoriasis, and psoriatic 
arthritis (PsA). They can increase odds of remission in both randomized controlled trials 
and clinical practice in early and established rheumatoid arthritis. They can withhold the 
radiological progression of certain diseases like RA. They can produce a dramatic 
normalization of acute phase reactants. Due to prolonged follow up periods, side effects 
profile for these agents is growing. This is in addition to their ability to neutralize specific 
immune pathways resulting in many adverse events.  Autoimmune syndromes with 
cutaneous and systemic manifestations including systemic lupus erythematosus may 
occur in patients receiving anti-TNF-α therapies (Ramos-Casals, Brito-Zeron et al. 2007). 
These agents represent a challenge for the practicing clinician with a range of judgments 
for optimal use and management of adverse events. In this chapter an overview of TNF-α 
will be demonstrated including its wide use in clinical practice. A more focus on anti-
TNF-α agents side effects profile will be presented particularly anti-TNF-α induced lupus 
erythematosus (ATIL). The chapter will address the various aspects related to ATIL 
including clinical manifestations, autoantibodies profile, management, prognosis and 
preventive strategies. 
2. Tumor necrosis factor-α (TNF-α)  
TNF and TNF receptors are members of a family of molecules (including Fas-ligand/fas, 
CD40 ligand/CD40) possessing crucial regulatory functions that include activation and 
apoptosis. TNF-α is an attractive therapeutic target owing to its abundant expression in 
the rheumatoid joint and plethora of proinflammatory effects that include regulation of 
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other proinflammatory mediators. TNF-α is a cytokine produced primarily by monocytes 
and macrophages but may also be produced by other cell types (e.g., B cells, T cells, mast 
cells, fibroblasts). TNF-α may further contribute to the pathogenesis of RA by induction of 
proinflammatory cytokines such as interleukin (IL)-1 and IL-6, enhancement of leukocyte 
migration by increasing endothelial layer permeability and expression of adhesion 
molecules by endothelial cells and leukocytes, activation of neutrophils and eosinophils, 
induction of the synthesis of acute-phase reactants, and the induction of tissue-degrading 
enzymes (matrix metalloproteinase enzymes) produced by synoviocytes and/or 
chondrocytes (Cush, Kavanaugh et al. 2011). It is expected then to have numerous 
biological effects in vivo with agents that inhibit the production or function of this 
cytokine.   
3. Anti-tumor necrosis factor-α (TNF-α) agents 
There are two strategies for inhibition of  TNF-α which can be achieved either with 
monoclonal antibody such as infliximab (Remicade), adalimumab (Humira), certolizumab 
pegol (Cimzia), and golimumab (Simponi), or with a circulating receptor fusion protein such 
as etanercept (Enbrel) (Fig 1).  
 
 
Fig. 1. Structure of anti- TNF-α agents.  
3.1 Infliximab (Remicade)   
Infliximab (Remicade) is a human/mouse chimeric monoclonal antibody against TNF-α and 
it was the first anti-TNF-α agent used to treat inflammatory disease. It was initially 
approved by the U.S. Food and Drug Administration (FDA) for the treatment of Crohn's 
disease in August 1998. Later on, it was approved by the FDA for the treatment of ulcerative 
colitis.  Infliximab works by blocking the action of TNF-α by preventing it from binding to 
its receptor in the cell and neutralizing its action. However, the powerful action of 
infliximab that it causes programmed cell death of TNF-α expressing activated T 
lymphocytes, a cell type mediating inflammation, which explains its efficacy in Crohn's 
disease.(Van den Brande, Braat et al. 2003). This is in contrast to another TNF-α neutralizing 
medication, etanercept, which is worse than a placebo in Crohn's disease.(Van Den Brande, 
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Peppelenbosch et al. 2002) Infliximab is administered as an intravenous infusion, on a 2-4 
weekly initially and then on a 6-8 weekly basis. 
3.2 Etanercept (Enbrel) 
Etanercept (Enbrel) is a p75 TNF--α receptor fusion protein produced through expression of 
recombinant DNA and conjugated to the Fc region of human immunoglobulin G (IgG1) 
which inhibits the binding of TNF to its cell surface receptor. Etanercept was developed by 
researchers at Immunex, and was released for commercial use in late 1998, soon after the 
release of infliximab.  There are two types of TNF receptors: those found embedded in white 
blood cells that respond to TNF by releasing other cytokines, and soluble TNF receptors 
which are used to deactivate TNF and blunt the immune response. Etanercept mimics the 
inhibitory effects of naturally occurring soluble TNF receptors, the difference being that 
etanercept, because it is a fusion protein rather than a simple TNF receptor, has a greatly 
extended half-life in the bloodstream, and therefore a more profound and long-lasting 
biologic effect than a naturally occurring soluble TNF receptor. (Madhusudan, 
Muthuramalingam et al. 2005) The FDA has licensed etanercept for moderate to severe 
rheumatoid arthritis, moderate to severe polyarticular juvenile idiopathic arthritis, psoriatic 
arthritis, ankylosing spondylitis, and moderate to severe plaque psoriasis. Etanercept is 
administered as a subcutaneous injection with a dose of 25 mg twice weekly or 50 mg once 
weekly. 
3.3 Adalimumab (Humira) 
Adalimumab (Humira), the third approved TNF-α inhibitor after infliximab and etanercept, 
is a human anti-TNF-α monoclonal antibody. It binds to TNF-α preventing the activation of  
TNF receptors; adalimumab was constructed from a fully human monoclonal antibody, 
while infliximab is a mouse/human chimeric antibody. In 2008, adalimumab has been 
approved by the FDA for the treatment of rheumatoid arthritis, ankylosing spondylitis, 
psoriatic arthritis, and crohn's disease. It is administered subcutaneously bi-weekly as 
preloaded 0.8 mL syringes or preloaded pen devices.  
3.4 Other anti- TNF-α agents 
Other two monoclonal antibodies targeting TNF-α are golimumab (Simponi), and 
certolizumab pegol (Cimzia); which is a Fab fragment of human anti-TNF-α antibody 
attached to a polyethylene glycol (PEG) moiety. In 2008, the FDA approved Cimzia for use 
in the treatment of crohn's disease in people who did not respond sufficiently or adequately 
to standard therapy. Large, randomized, double-blind trials in patients with rheumatoid 
arthritis have shown that golimumab in combination with methotrexate was more effective 
than methotrexate alone.(Oldfield and Plosker 2009). 
4. Indications 
The introduction of the TNF- α blocking therapies (anti-TNF) in 1998 marked the beginning 
of a new era in the treatment of chronic inflammatory human diseases, including RA, AS, 
psoriasis and PsA, and inflammatory bowel diseases. Infliximab, Etanercept, and 
adalimumab are the most common anti- TNF-α agents to be used with great response and 
disease control in the treated patients. The U.S FDA has approved the indications of anti 
TNF-α therapy (table 1). 
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Indication Etanercept Infliximab Adalimumab 
Rheumatoid 
arthritis (RA) 
Yes 1 Yes 1R Yes 1 
Early RA Yes Yes Yes 
Polyarticular 
juvenile arthritis 
Yes 2 -- -- 
Psoriatic arthritis Yes 3E Yes 3 Yes 3 
Ankylosing 
spondylitis 
Yes 4 Yes 4 Yes 4 
Psoriasis Yes 5 Yes -- 
Crohn disease -- Yes 6 Yes 6 
Ulcerative colitis -- Yes 7 -- 
1- Indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and 
improving physical function for patients with moderately to severely active rheumatoid arthritis. It can 
be initiated alone or in combination with methotrexate. 
       1R- Infliximab is approved for use in combination with methotrexate only. 
2- Indicated for reducing signs and symptoms of moderately to severely active polyarticular course 
juvenile rheumatoid arthritis patients who have had an inadequate response to one or more DMARDs. 
3- Indicated for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis. 
       3E- Only etanercept is indicated to inhibit the progression of structural damage and improve 
physical function for patients with moderately to severely active psoriatic arthritis. It can be used in 
combination with methotrexate in patients who do not respond adequately to methotrexate alone. 
4- Indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. 
5-  Indicated for the treatment of adult patients (>18 years) with chronic moderate to severe plaque 
psoriasis who are candidates for systemic therapy or phototherapy. 
6- Indicated for reducing signs and symptoms and inducing or maintaining clinical remission in 
patients with moderately to severely active Crohn’s disease who have had an inadequate response to 
conventional therapy. Infliximab is also indicated for reducing the number of enterocutaneous and 
rectovaginal fistulas and maintaining fistula closure in fistulizing Crohn disease. 
7- Only infliximab is indicated for reducing signs and symptoms, achieving clinical remission and 
mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active 
ulcerative colitis who have had an inadequate response to conventional therapy. 
Table 1. U.S. Food and Drug administration-approved indications for anti-TNF-α therapy 
(Cush, Kavanaugh et al. 2011). 
4.1 Rheumatoid Arthritis (RA)  
RA is a chronic inflammatory autoimmune disease associated with debilitating and 
destructive polyarthritis and other systemic manifestations. DMARDs are used for 
treatment of patient with well-established RA and ongoing inflammation like methotrexate, 
sulfasalazine or hydroxychloroquine. If a patient had an inadequate response or intolerance 
to the usual treatment, biological therapy of anti-TNF-α can be used as monotherapy or in 
combination with other DMARDs. These recommendations have recently been modified 
because large controlled trials in early RA patients now allow their use as the initial 
DMARDs in RA. 
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4.2 Ankylosing Spondylitis (AS) 
AS is a chronic inflammatory disease, that affect young males. It is characterized by its 
association with HLA B27 antigen and spinal inflammation mainly in form of sacroilitis. 
Patients with active AS who did not respond to conventional therapies can be managed with 
anti -TNF-α therapy. 
4.3 Psoriasis and psoriatic arthritis 
Psoriatic arthritis is a potentially debilitating disease that may affect small and large 
peripheral joints, and the axial skeleton, seen in more than 10% of patients with plaque 
psoriasis. Arthritis may precede onset of skin disease. The conventional therapy of psoriatic 
arthritis includes non-steroidal anti-inflammatory drugs (NSAID), systemic and intra-
articular corticosteroids, and disease-modifying anti rheumatic drugs (DMARD) such as 
sulfasalazine or methotrexate. Recent trials in Psoriatic arthritis have shown excellent results 
with anti TNF-α therapy which have positive effects not only on joints, but also on the skin 
lesions.  
4.4 Inflammatory Bowel Diseases (IBD) 
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders of the 
gastrointestinal tract. Although the primary etiological defect still remains unknown, 
genetic, environmental and microbial factors have been reported in activation of  
the mucosal immune response. TNF-α is one of the central cytokines in the underlying 
pathogenesis of mucosal inflammation which is responsible for the effectiveness of anti -
TNF-α therapy. Infliximab, adalimumab and certolizumab all seems to be effective in  
CD. Infliximab is the only anti-TNF agent currently approved for UC. Although 
etanercept is a TNF-α blocker, it is not approved and marketed for IBD. A randomized, 
controlled trial showed that etanercept was no better than placebo in IBD (Sandborn, 
Hanauer et al. 2001). Both etanercept and infliximab neutralized TNF-α, but only 
infliximab bounds to T lymphocytes and induces apoptosis of these cells (Van den 
Brande, Braat et al. 2003). 
4.5 Relative contraindications 
Due to the accumulative experience developing from the worldwide use of these drugs, 
certain conditions considered relative contraindications for the use of anti-TNF-α agents. 
Most of these conditions were obtained mainly from observations in randomized controlled 
trials and post-marketing phase IV trials. These conditions include systemic lupus 
erythematosus, lupus overlap syndrome, a history of demyelinating disorder (multiple 
sclerosis, optic neuritis), untreated active or latent tuberculosis, congestive heart failure, and 
pregnancy. The use of a TNF-α inhibitor in these conditions is currently experimental in 
terms of risks and benefits.   
5. Side effects  
Short- and long-term therapy with anti-TNF-α agents is well tolerated; however, the 
increased risk of infrequent but serious complications warrant sustained vigilance on the 
part of physicians and patients alike. 
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psoriasis. Arthritis may precede onset of skin disease. The conventional therapy of psoriatic 
arthritis includes non-steroidal anti-inflammatory drugs (NSAID), systemic and intra-
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with anti TNF-α therapy which have positive effects not only on joints, but also on the skin 
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4.4 Inflammatory Bowel Diseases (IBD) 
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders of the 
gastrointestinal tract. Although the primary etiological defect still remains unknown, 
genetic, environmental and microbial factors have been reported in activation of  
the mucosal immune response. TNF-α is one of the central cytokines in the underlying 
pathogenesis of mucosal inflammation which is responsible for the effectiveness of anti -
TNF-α therapy. Infliximab, adalimumab and certolizumab all seems to be effective in  
CD. Infliximab is the only anti-TNF agent currently approved for UC. Although 
etanercept is a TNF-α blocker, it is not approved and marketed for IBD. A randomized, 
controlled trial showed that etanercept was no better than placebo in IBD (Sandborn, 
Hanauer et al. 2001). Both etanercept and infliximab neutralized TNF-α, but only 
infliximab bounds to T lymphocytes and induces apoptosis of these cells (Van den 
Brande, Braat et al. 2003). 
4.5 Relative contraindications 
Due to the accumulative experience developing from the worldwide use of these drugs, 
certain conditions considered relative contraindications for the use of anti-TNF-α agents. 
Most of these conditions were obtained mainly from observations in randomized controlled 
trials and post-marketing phase IV trials. These conditions include systemic lupus 
erythematosus, lupus overlap syndrome, a history of demyelinating disorder (multiple 
sclerosis, optic neuritis), untreated active or latent tuberculosis, congestive heart failure, and 
pregnancy. The use of a TNF-α inhibitor in these conditions is currently experimental in 
terms of risks and benefits.   
5. Side effects  
Short- and long-term therapy with anti-TNF-α agents is well tolerated; however, the 
increased risk of infrequent but serious complications warrant sustained vigilance on the 
part of physicians and patients alike. 
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5.1 Injection site reaction 
Administration of anti -TNF-α either by intravenous infusion or subcutaneous injection may 
result in site reactions including development of redness, swelling, itching or even skin rash. 
Some patients report an allergic response to infliximab, possible reason may be due to its 
chimeric monoclonal antibody that has human part and mouse part.  
5.2 Infections 
TNF-α is a cytokine that plays a crucial role in the body's immune defense against bacterial 
infections. Infections are mainly consisting of upper respiratory tract infections, bronchitis 
and urinary tract infections. A systematic review of adverse effects of anti- TNF-α therapies 
as they were used in rheumatoid arthritis concluded that patients taking these agents are at 
2.0 time higher risk for serious infections. Serious infections that were observed, included 
pneumonia, sepsis and pyelonephritis (Leombruno, Einarson et al. 2009).                              
It has been documented well in the literature that treatment with anti-TNF-α agents is 
associated with increased rate of tuberculosis, in form of miliary, lymphatic, peritoneal, as 
well as pulmonary tuberculosis. Most of the cases of tuberculosis occurred within the first 
eight months after initiation of anti -TNF-α therapy.(Gomez-Reino, Carmona et al. 2003) As 
a result, it is recommended that patients should be screened with a TB skin test prior to 
starting these medications. If there is evidence of prior exposure with positive skin test, 
treatment for TB can be given in combination with the anti-TNF-α agents.                          
Other reported infections in patients on TNF-α inhibitors are fungal infections, such as 
pulmonary and disseminated histoplasmosis, coccidioidomycosis, and blastomycosis.  It is 
recommended that patients with active infections should not be started on anti -TNF-α 
agents until their infection resolve. Furthermore, these agents should be temporarily 
discontinued in those patients who develop an infection while on therapy.  
5.3 Malignancy 
The use of anti-TNF-α agents is accompanied by some worries about their long-term safety. 
Thus, it seems important to investigate whether blocking the action of this TNF-α cytokine 
might lead to an increased risk of malignancy. The particular worry concerns of 
lymphoproliferative malignancies, because these malignancies occur at an increased rate in 
immunosuppressed patients.  There are concomitant risk factors that may predispose to 
lymphoma in patients with RA who are using anti-TNF-α therapy. Patients with RA per se 
have an increased risk for developing lymphoma(Van den Brande, Braat et al. 2003). 
Patients specifically treated with anti -TNF-α agents are likely to have more severe disease 
regarding both disease duration and disease severity, which may increase the risk of 
malignant transformation. The accompanying use of medication, especially 
cyclophosphamide and azathioprine may increase the risk of developing malignancy (Van 
den Brande, Braat et al. 2003). In one study, it has been observed that there is an increased 
risk of lymphoproliferative malignancies in patients with RA who were treated with high-
dose azathioprine compared with non– azathioprine-treated RA controls (Silman, Petrie et 
al. 1988). In another study, an increased risk of bladder and skin cancer was observed in 
patients with RA who were treated with cyclophosphamide (Radis, Kahl et al. 1995). Most of 
the reported cases of lymphoma in patients with RA who were treated with methotrexate 
are related to Epstein-Barr virus (EBV) (Georgescu and Paget 1999). Methotrexate exposure 
is almost a universal practice in anti -TNF-α treated patients and could be an important 
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confounder of the subsequent risk for lymphoproliferative malignancies. In response to this 
risk of lymphoma, the US Food and Drug Administration (FDA) convened a meeting in 
March 2003 to review the safety data on TNF-α antagonists, focusing on the risk of 
malignancy in general and lymphoproliferative malignancies in particular(Kovacs, 
Vassilopoulos et al. 1996; Cush JJ 2003). Six lymphomas were found among 6303 RA patients 
treated with TNF-α inhibitors in controlled clinical trials, but none were observed in 
placebo-treated patients. A total of 23 lymphomas were observed (9 etanercept, 4 infliximab, 
10 adalimumab) during drug treatment, with an increased standardized incidence ratio 
(SIR, relative risk) of 3.47, 6.35, and 5.42, respectively (Cush JJ 2003). However, the 95% 
confidence intervals for these SIRs were particularly wide and overlapping, thus not 
permitting any separation of lymphoma risk due to drug or active RA alone. Rates of solid 
tumors were not increased when anti-TNF-α agents associated malignancies were compared 
with population expectations at an FDA meeting in 2003. Similarly, in registry studies, no 
overall increase in risk has been reported in RA patients whether or not exposed to TNF 
inhibitors (Cush JJ 2003). For all this evidence, there is no clear answer regarding the risk of 
developing lymphoma in patients with RA and on anti -TNF-α therapy, either if it is related 
to anti-TNF-α therapy or to RA itself and other confounding factors. 
5.4 Autoimmune diseases 
Anti-TNF-α agents are widely being used for a large number of patients with different 
rheumatic and systemic autoimmune diseases. As a result of this use, these agents have 
been associated with an increasing incidence of autoimmune diseases as adverse effects, 
principally vasculitis, lupus like syndrome, antiphospholipid-like features, and interstitial 
lung disease. Other autoimmune diseases have been described, such as sarcoidosis, 
autoimmune hepatitis, uveitis, and thyroiditis (Ramos-Casals, Brito-Zeron et al. 2008). The 
clinical characteristics, outcome and pattern of autoimmune diseases following TNF-α 
targeted therapies have been analyzed through a baseline Medline search of articles 
published between January 1990 and May 2008. A total of 379 cases have been reported with 
drug induced autoimmune diseases (table 2) (Ramos-Casals, Brito-Zeron et al. 2008). 
The reported cases of vasculitis have been classified into cutaneous vasculitis and visceral 
vasculitis (table 3) (Ramos-Casals, Brito-Zeron et al. 2008). Most of these cases of vasculitis 
overwhelmingly presented as cutaneous lesions, in form of purpura, ulcerative lesions, 
nodules or digital vasculitis. Regarding the biopsy, 75% of specimens were leukocytoclastic 
vasculitis, 15% necrotizing vasculitis, 5% lymphocytic vasculitis, and 2% urticarial 
vasculitis(Ramos-Casals, Brito-Zeron et al. 2008). Other patients may develop visceral 
vasculitis including peripheral nerve, renal, lung, and CNS involvements. Peripheral 
neuropathy may present in a form of axonal peripheral neuropathy, mononeuropathy 
multiplex, multifocal motor neuropathy with conduction block, or chronic inflammatory 
demyelinating polyradiculoneuropathy (Ramos-Casals, Brito-Zeron et al. 2008). Patients on 
anti -TNF-α   agents may develop glomerulonephritis (GN) with a biopsy of pauci-immune 
GN, crescenting necrotizing GN or IgA GN (Ramos-Casals, Brito-Zeron et al. 2008). 
Pulmonary involvement has been described in association with patients who are having 
perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) focal segmental necrotizing GN 
and crescentic GN. Rare cases have been reported with CNS involvement presented as 
central retinal artery occlusion, confusion of unclear origin and seizure(Ramos-Casals, Brito-
Zeron et al. 2008). Systemic vaculitis has been reported in a form of temporal arteritis, 
Henoch-Schonlein purpura, and polyarteritis nodosa (Ramos-Casals, Brito-Zeron et al. 2008).  
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Interstitial lung disease (ILD) has been developed after starting anti -TNF-α therapy in a form 
of interstitial pneumonitis, pulmonary hemorrhage and bronchiolitis obliterans organizing 
pneumonia. The specific feature of the ILD associated with anti-TNF-α therapy is the poor 
prognosis in spite of cessation of these agents. Therefore initiation of corticosteroids and 






















a) Systemic autoimmune diseases      
 • DIL 140 49.51 ± 1.68 77 72, 7, 11 37, 33, 25, 6 
 • Vasculitis 139 51.55 ± 2.68 79 92, 7, 8 43, 42, 7, 7 
 • APS/APS-like disease 42 50.00 ± 3.79 70 26, 11, 26 45, 41, 5, 9 
 • Sarcoidosis 38 49.41 ± 2.05 65 60, 37, 0 26, 61, 10, 3 
b) Organ-specific autoimmune diseases      
 • Optical neuritisa 123 43.47 ± 3.29 63 37, 17, 25 43, 49, 7, 1 
 • Interstitial lung disease 118 62.79 ± 1.98 77 77, 6, 4 43, 47, 3, 7 
 • Inflammatory ocular disease 87 45.96 ± 2.16 81 41, 48, 0 18, 79, 2, 0 
 • MS/MS-likea 55 42.83 ± 1.99 70 59, 17, 12 20, 51, 27, 2 
 • Peripheral neuropathiesb 44 52.47 ± 2.16 66 61, 16, 16 74, 12, 14, 0 
 • Autoimmune hepatitis 19 45.24 ± 2.83 76 32, 47, 21 79, 10, 10, 0 
DIL: drug-induced lupus; APS: antiphospholipid syndrome; MS: multiple sclerosis; RA: rheumatoid 
arthritis; Sp: spondyloarthropathies; IBD: inflammatory bowel disease; INF: infliximab; ETA: 
etanercept; ADA: adalimumab; SEM: standard error of the mean. 
a Eight patients had the two processes. 
b Excluding those appearing in patients with vasculitis. 
Table 2. Characteristic of main autoimmune diseases associated with biological agents 
(BIOGEAS Registry, last update July 15, 2009)(Ramos-Casals, Roberto Perez et al.).  
 
Clinical characteristics of Vasculitis Number of cases 





Not biopsied 37 
Peripheral neuropathy 18 
Glomerulonephritis 17 
Central nervous system 6 
Pulmonary involvement 3 
Systemic vasculitis 5 
Table 3. Clinical characteristics of 145 patients with vasculitis related to TNF-α targeted 
therapy.  
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6. Anti-TNF-α Induced Lupus Erythematosus (ATIL) 
Drug induced lupus is a syndrome with symptoms, signs, and laboratory findings similar to 
idiopathic SLE. The diagnosis requires a temporal relationship between symptoms and 
therapy for at least four American Congress of Rheumatology criteria for SLE (Ramos-
Casals, Brito-Zeron et al. 2007). More than 80 drugs have been implicated in drug-induced 
lupus, with sulfadiazine being the first reported in 1945 (Vasoo 2006). The relationship 
between drugs and induced lupus was confirmed by the disappearance of symptoms with 
drugs withdrawal.  
Treatment with anti-TNF-α agents have been reported to be associated with drug-induced 
lupus erythematosus, most commonly with infliximab and etanercept, and rarely related to 
adalimumab (Haraoui and Keystone 2006; van Rijthoven, Bijlsma et al. 2006), as infliximab 
and etanercept have been used wider and for longer period than adalimumab. Lupus-like 
syndrome and ATIL were the most common in a registry of autoimmune diseases associated 
with anti-TNF-α agents (Ramos-Casals, Brito-Zeron et al. 2007). In this study, analysis of 92 
cases with ATIL revealed that all had clinical and immunological features suggestive of SLE, 
94% had positive autoantibodies, 89% had cutaneous features, 39% had musculoskeletal 
manifestations and general symptoms were presented in 29% (Ramos-Casals, Brito-Zeron et 
al. 2007).  
Majority of patients with ATIL were diagnosed with RA as it will be shown below. It can be 
argued that the development of ATIL was actually due to a change induced by anti-TNF-α 
agents from RA to SLE?  It is well recognized clinically that patients may evolve from one 
disease to another. It can be argued as well that those RA patients who developed ATIL 
were actually carrying the diagnosis of SLE but with a predominant presentation of 
polyarthritis and the use of anti-TNF-α agents had just triggered other lupus manifestations? 
This notion is supported, as it will be shown below by the fact that some patients with ATIL 
had positive ANA prior to initiation of Anti-TNF-α agents. All these arguments remain 
areas for ongoing research to help clinicians learn more about Anti-TNF-α agents and the 
actual pathogenesis of ATIL. It has to be noted that ATIL developed not only in RA patients 
but in patients with PsA, CD, and AS as well.  The abundance of case reports and case series 
support the notion that anti-TNF-α therapy can induce a lupus-like syndrome as a separate 
and well recognized clinical entity. Rigorous exclusion of SLE prior to initiation of Anti-
TNF-α agents is extremely important as a preventive action (see below).  
6.1 Role of TNF-α in the pathogenesis of SLE  
TNF-α is pleiotropism cytokine that has both immunoregulatory and proinflammatory 
effects, and its blockage has been proposed to be beneficial for the majority of patients with 
rheumatoid arthritis or inflammatory bowel disease. However, anti-TNF-α therapy has led 
in some cases to a significant incidence of drug-induced autoantibodies production and 
ATIL. TNF-α blocking could relieve the inflammation induced by TNF-α, at the same time 
the immunoregulatory and antiapoptotic effects of TNF-α could also be blocked which may 
lead to autoimmunity (Ramos-Casals, Brito-Zeron et al. 2007).  
6.1.1 Immunoregulatory effects and apoptosis of TNF-α in SLE 
In an experimental study, a heterozygous mice was generated which has reduced TNF-α 
production, by crossing NZB mice with TNF-α deficient mice. These mice developed 
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Interstitial lung disease (ILD) has been developed after starting anti -TNF-α therapy in a form 
of interstitial pneumonitis, pulmonary hemorrhage and bronchiolitis obliterans organizing 
pneumonia. The specific feature of the ILD associated with anti-TNF-α therapy is the poor 
prognosis in spite of cessation of these agents. Therefore initiation of corticosteroids and 






















a) Systemic autoimmune diseases      
 • DIL 140 49.51 ± 1.68 77 72, 7, 11 37, 33, 25, 6 
 • Vasculitis 139 51.55 ± 2.68 79 92, 7, 8 43, 42, 7, 7 
 • APS/APS-like disease 42 50.00 ± 3.79 70 26, 11, 26 45, 41, 5, 9 
 • Sarcoidosis 38 49.41 ± 2.05 65 60, 37, 0 26, 61, 10, 3 
b) Organ-specific autoimmune diseases      
 • Optical neuritisa 123 43.47 ± 3.29 63 37, 17, 25 43, 49, 7, 1 
 • Interstitial lung disease 118 62.79 ± 1.98 77 77, 6, 4 43, 47, 3, 7 
 • Inflammatory ocular disease 87 45.96 ± 2.16 81 41, 48, 0 18, 79, 2, 0 
 • MS/MS-likea 55 42.83 ± 1.99 70 59, 17, 12 20, 51, 27, 2 
 • Peripheral neuropathiesb 44 52.47 ± 2.16 66 61, 16, 16 74, 12, 14, 0 
 • Autoimmune hepatitis 19 45.24 ± 2.83 76 32, 47, 21 79, 10, 10, 0 
DIL: drug-induced lupus; APS: antiphospholipid syndrome; MS: multiple sclerosis; RA: rheumatoid 
arthritis; Sp: spondyloarthropathies; IBD: inflammatory bowel disease; INF: infliximab; ETA: 
etanercept; ADA: adalimumab; SEM: standard error of the mean. 
a Eight patients had the two processes. 
b Excluding those appearing in patients with vasculitis. 
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(BIOGEAS Registry, last update July 15, 2009)(Ramos-Casals, Roberto Perez et al.).  
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in some cases to a significant incidence of drug-induced autoantibodies production and 
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the immunoregulatory and antiapoptotic effects of TNF-α could also be blocked which may 
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6.1.1 Immunoregulatory effects and apoptosis of TNF-α in SLE 
In an experimental study, a heterozygous mice was generated which has reduced TNF-α 
production, by crossing NZB mice with TNF-α deficient mice. These mice developed 
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enhanced autoimmunity and severe renal disease similar to the classic mice model of SLE. 
Autoimmune responses were associated with an early spontaneous increase in serum levels 
of antinuclear antibodies (ANA) and hyperproliferating B cells which readily express anti-
double stranded DNA antibodies  (anti-ds DNA) antibodies specificities in response to 
polyclonal and T helper stimuli. These findings demonstrate a physiological role for TNF-α 
in suppressing the emergence of autoreactive lymphocytes in the NZB model and indicate 
that defective TNF-α function may be causative of the autoimmune and pathological 
phenomena in lupus. Loss of physiological TNF-α production in an autoimmunity prone 
background suffices to exacerbate antinuclear autoimmunity and the development of 
disease (Kontoyiannis and Kollias 2000).   
Apoptosis (programmed cell death (PCD)) plays an important role in the homeostasis of the 
immune response. Peripheral blood lymphocytes (PBLs) from SLE patients exhibit increased 
spontaneous and diminished activation induced apoptosis. Increased spontaneous 
apoptosis of PBLs has been linked to chronic lymphopenia and release of nuclear 
autoantigens in patients with SLE (Gergely, Grossman et al. 2002). The appearance of high 
numbers of autoreactive lymphocytes in the peripheral blood of patients with SLE might be 
a consequence of defective activation-induced cell death (Emlen, Niebur et al. 1994). It has 
been showed that permeabilitized lupus T cells displayed significantly lower amounts of 
TNF-α, a functional Fas/Fas-ligand path and adequate amounts of intracellular TNF-α were 
needed for the CD3-mediated T cell death. Prolonged survival of autoreactive T cells can 
lead to increased autoantibody production. Defective activation-induced apoptosis in lupus 
would worsen under TNF blockage (Kovacs, Vassilopoulos et al. 1996). 
The clinical reports about the levels of TNF-α in SLE patients’ were controversial. In most 
studies, TNF-α is found to be increased and appeared to be bioactive in the sera of patients 
with active SLE, and levels of TNF-α have been shown to correlate with SLE disease activity 
(Aringer, Feierl et al. 2002; Aringer and Smolen 2003). In another study, it has been found 
that SLE patients had elevated plasma levels of TNF-α with no correlation of disease activity 
(Zhu, Landolt-Marticorena et al. 2010).  Furthermore, in a third study, it has been 
demonstrated that TNF-α levels were higher in patients with inactive disease compared with 
patients with very active disease, suggesting that TNF-α could be a protective factor in SLE 
patients (Gomez, Correa et al. 2004).  
HLA-DR2 and DQwl positive subjects frequently exhibit low production of TNF-α whereas 
DR3 and DR4 positive subjects show high levels of TNF-α production. DR2 and DQwl 
positive SLE patients show low levels of TNF-α inducibility; this genotype is also associated 
with an increased incidence of lupus nephritis (LN). DR3 positive SLE patients, on the other 
hand, are not predisposed to nephritis, and these patients have high TNF-α production. DR4 
haplotype is associated with high TNF-α inducibility and is negatively correlated with LN. 
These data suggested that low TNF-α production may be involved in the genetic 
predisposition to LN, and may help explain the association between HLADR2/DQwl and 
susceptibility to LN (Jacob, Fronek et al. 1990).  
As TNF receptor1 (TNFR1)—TNFR associated death domain (TRADD)--Fas-associated 
death domain (FADD) system leading to apoptotic signaling, the down regulation of 
TRADD, FADD in patients with SLE may promote an anti-apoptotic effect. Defects in 
expression of these genes may increase the likelihood that lymphocytes avoid the normal 
processes used by the immune system to eliminate unwanted lymphocytes or to down-
regulate an immune response. If patients carry this autoimmune gene expression signature, 
signaling pathways essential for the maintenance of tolerance may not function properly. 
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This may permit lymphocytes to escape tolerance and adopt a pro survival agenda that 
increases the likelihood of autoimmune diseases (Rosen and Casciola-Rosen 2001), 
(Balomenos and Martinez 2000). 
The dysregulation of programmed cell death is suggested to be involved in the generation of 
autoantibodies. The low expression of TRADD, receptor-interacting protein 1 (RIP-1), and 
TNF receptor associated factor 2 (TRAF-2) might be one of the etiopathogeneses leading to 
redundant apoptotic death in SLE patients. It has been indicated that decreased expression 
of TRADD, RIP-1, and TRAF-2 and restrained pathogenesis for the loss of immune tolerance 
and redundant apoptotic cell death, leading to massive production of autoantibodies in SLE 
patients (Zhu, Yang et al. 2007).  
6.1.2 Inflammatory effects of TNF-α in the pathogenesis of SLE 
TNF-α is the most important proinflammatory cytokine and a harbinger of tissue 
destruction, and it is at the top of a pro-inflammatory “cascade” leading to tissue damage. In 
contrast to the complex role of TNF-α in apoptosis and in immune regulation, its powerful 
proinflammatory effects are unequivocal. It has been found that TNF-α is clearly expressed 
in glomeruli of LN patients, mainly by infiltrating macrophages but also by endothelial 
cells, glomerular visceral epithelium, and mesangial cells, with WHO class III and IV LN, 
while no TNF-α is detected in healthy kidney tissues. Most of the conducted studies have 
demonstrated that TNF-α is expressed in LN of all WHO classes and high TNF-α expression 
is associated with high histological disease activity. Also, it has been found that 
upregulation of renal expression of TNF-α in class III and class IV LN by 
immunohistochemical studies, and the upregulation of TNF-α was correlated with increased 
number of proliferating cell nuclear antigen (PCNA-)positive cells, CD68-positive cells and 
the activity index of renal pathologic changes (Aringer and Smolen 2004). 
6.2 Clinical trials of anti- TNF-α therapy in SLE 
SLE is a multifactorial autoimmune disease characterized by breakdown of self-tolerance, B 
cell hyperactivity, autoantibody production, aberrant formation of immune complexes, and 
inflammation of multiple organs. As TNF-α is a proinflammatory cytokine, participate in 
inflammatory tissue damage and in SLE pathogenesis, few clinical trials have been 
conducted regarding the use of anti TNF-α agents in patients with active SLE. 
In 2008, an open-label study was reported about the safety and efficacy of TNF-blockade in 
SLE. Seven patients with SLE were treated with infliximab at weeks 0, 2, 6, and 10 in 
combination with azathioprine or methotrexate. Autoantibodies to ds-DNA increased in 5 of 
7 patients. Histone levels were increased in 4 of 7 patients, and IgM anti-cardiolipin 
antibodies were also increased in 4 of 7 patients, peaking 4–10 weeks after the last infliximab 
infusion. This trial suggested that while anti-TNF-α agent was clinically effective, the 
majority of SLE patients treated with infliximab showed an increase in autoantibodies to 
nuclear antigens and phospholipids. These increases were transient and were not associated 
with disease flares (Aringer and Smolen 2008). A long-term follow up study was conducted 
of 13 patients about the adverse events and efficacy of TNF-α blockade with infliximab in 
SLE patients. It indicated that short-term therapy with four infusions of infliximab in 
combination with azathioprine was relatively safe and had remarkable long-term efficacy 
for LN and, potentially, also interstitial lung disease. Long-term therapy with infliximab, 
however, was associated with severe adverse events in two out of three SLE patients, which 
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may have been provoked by infliximab and/or by their long-standing refractory SLE and 
previous therapies(Aringer, Houssiau et al. 2009). 
6.3 Development of autoantibodies 
The induction of autoantibodies and anti-TNF-α therapy has been widely documented (De 
Bandt, Sibilia et al. 2005). Most of patients who were treated with anti-TNF-α agents 
developed antibodies that normally found almost exclusively in patients with SLE, however, 
these patients do not have any clinical features suggestive of SLE (Charles, Smeenk et al. 
2000). Therefore, discontinuation of these agents is not indicated but this evident do not 
exclude potential induction of clinical lupus signs or symptoms and patients need further 
close follow up and observation (Charles, Smeenk et al. 2000). TNF-α antagonists lead into 
an elevated titers of ANA with a homogeneous pattern in patients who already started 
treatment with positive serology of ANA. In addition, new onset of positive ANA may 
develop in previously negative ANA patients treated with TNF-α inhibitors (FDA 2008; Lin, 
Ziring et al. 2008). Development of new onset of anti-ds DNA antibodies, more specific 
antibodies of SLE, was reported during anti- TNF-α therapy which represents a strong 
evidence for diagnosis of induction of lupus-like syndrome following treatment with these 
agents. However, anti-ds DNA antibodies are found in 50-70% of patients with idiopathic 
SLE while their prevalence is from 9% to 33% in patients treated with anti- TNF-α (FDA 
2008; Lin, Ziring et al. 2008). It has been reported that patients on anti-TNF-α agents had 
serum antibodies to ds DNA of IgG, IgM, and IgA subtypes. In all reported patients, most 
common induced antibodies were solely of the IgM subtype. This finding is in marked 
contrast to the patients with idiopathic SLE, in whom although IgM antibodies to ds DNA 
are fairly common, it is extremely rare to find this response without accompanying IgG anti-
ds DNA antibodies (Charles, Smeenk et al. 2000). Anti-histone antibodies are detected in 
57% among patients with ATIL in one study (Costa, Said et al. 2008) and only in 17% in 
another study (De Bandt, Sibilia et al. 2005). It should be noted that anti-histone antibodies 
are not pathognomonic for drug-induced SLE and occur in more than 95% of cases, they are 
also found in 75% of cases with idiopathic SLE (Katz and Zandman-Goddard 2010). 
Hypocomplementemia is found in up to 59% of patients with ATIL while this finding is 
extremely rare in other drug-induced lupus (Costa, Said et al. 2008). The occurrence of 
anticardiolipin (ACL) antibodies were detected in anti-TNF-α treated patient. Up to 25% of 
patients on anti- TNF-α agents for RA developed IgG or IgM ACL, but thrombosis is 
observed in much fewer patients (about 4%) (Cambien, Bergmeier et al. 2003). It is also 
known that TNF-α has potent antithrombotic properties. It is therefore conceivable that the 
association of ACL antibodies and inhibition of TNF-α could lead to an increase risk of 
thrombosis. The presence of anti-Smith antibodies is almost exclusive of idiopathic SLE and 
rarely found in drug-induced SLE. Anti-nucleosome antibodies of the IgG subtype are 
considered to be a more sensitive marker for SLE than anti-dsDNA and anti-histone 
antibodies (Amoura, Koutouzov et al. 2000). Although there are number of patients who 
develop anti-nucleosome antibodies during treatment with anti- TNF-α agents, this number 
is not statistically significant. Positive ENAs also may develop in patients on these agents 
(Costa, Said et al. 2008). A comparison of different autoantibodies produced in ATIL 
reported in three different studies is presented in (table 4) (Williams, Gadola et al. 2009).  
It has been confirmed that the induction of ANA and anti-dsDNA antibodies occur in 
patients who started treatment with anti-TNF-α agents, and the presence of this serological 
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finding is unrelated to the genetic background or the underlying disease process. The 
development of only anti-dsDNA antibodies with absence of other lupus specific antibodies 
in the consequence of anti- TNF-α therapy is reassuring in terms of the safety of this 
treatment; however, long term observation is mandatory. 
Among laboratory findings, the hematological results that have been reported secondary to 
anti-TNF-α agents that are typical of idiopathic SLE which include leukopenia, 
thrombocytopenia, and lymphopenia (Costa, Said et al. 2008). 
 
Autoantibody Costa et al., 2008, 
(Britain), (n=33) 
Ramos et al., 2007, 
(Spain), (n=72) 
De Bandt et al., 
2005, (French), 
(n=12) 
ANA, n (%) 32/32 (100) 57 (79) 12 (100) 
dsDNA, n (%) 29/32 52 (72) 11 (92) 
Histone, n (%) 16/28 (57) Not reported 2 (17) 
aPL, n (%) Not reported 8 (11) 6 (50) 
ENAs, n (%) 10/19 (53) Anti-Sm 7 (10) 
Anti-Ro/La 9 (12) 
Anti-RNP 5 (7) 
5 (42) 
Table 4. Comparison of the developed antibodies in ATIL reported in three different studies 
(Williams, Gadola et al. 2009). ANA: antinuclear antibodies, dsDNA: double stranded DNA, 
aPL: antiphospholipid antibodies, ENAs: extractable nuclear antigens. 
6.4 Clinical manifestations of anti-TNF-induced SLE (ATIL) 
The true incidence of ATIL is difficult to establish due to the paucity of data and lack of 
double blind placebo-controlled prospective studies, difficulty to establish causality and 
lack of universal recognition of this relatively new entity (Katz and Zandman-Goddard). 
Post marketing studies on the three licensed anti-TNF-α agents have suggested an estimated 
incidence of ATIL of 0.19%–0.22% for infliximab, 0.18% for etanercept and 0.10% for 
adalimumab (De Bandt, Sibilia et al. 2005; Schiff, Burmester et al. 2006). However, the 
prevalence of ATIL in the main randomized controlled trials (RCTs) using anti-TNF agents 
is higher, with 14 (0.76%) cases in the 1842 patients included in 17 studies (Ramos-Casals, 
Roberto Perez et al.).  It has to be realized that this is an accumulative figure and it does not 
represent the exact prevalence. The mean duration of disease before initiation of anti-TNF-α 
therapy was 13.5 years in one cohort (range, 1-35 years)(Wetter and Davis 2009). Onset of 
symptoms ranges from less than one month to more than 4 years (Williams and Cohen). In 
another larger report, the mean latency time until the manifestations of ATIL was 41 weeks 
(Ramos-Casals, Brito-Zeron et al. 2007). There was, in this series, a 5:1 female : male ratio.  
The most common disease for which anti-TNF-α was used for was RA (Ramos-Casals, Brito-
Zeron et al. 2007; Costa, Said et al. 2008). Other diseases include but not limited to juvenile 
idiopathic arthritis, PsA, AS, CD. In one cohort, most patients who developed ATIL were 
having CD (Wetter and Davis 2009). The most common anti-TNF-α agent in use currently is 
infliximab as it is the first to be approved and introduced to clinical practice. Obviously, 
most of the cases of ATIL were due to infliximab use followed by etanercept and 
adalimumab respectively (Ramos-Casals, Brito-Zeron et al. 2007; Costa, Said et al. 2008). 
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may have been provoked by infliximab and/or by their long-standing refractory SLE and 
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finding is unrelated to the genetic background or the underlying disease process. The 
development of only anti-dsDNA antibodies with absence of other lupus specific antibodies 
in the consequence of anti- TNF-α therapy is reassuring in terms of the safety of this 
treatment; however, long term observation is mandatory. 
Among laboratory findings, the hematological results that have been reported secondary to 
anti-TNF-α agents that are typical of idiopathic SLE which include leukopenia, 
thrombocytopenia, and lymphopenia (Costa, Said et al. 2008). 
 
Autoantibody Costa et al., 2008, 
(Britain), (n=33) 
Ramos et al., 2007, 
(Spain), (n=72) 
De Bandt et al., 
2005, (French), 
(n=12) 
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ENAs, n (%) 10/19 (53) Anti-Sm 7 (10) 
Anti-Ro/La 9 (12) 
Anti-RNP 5 (7) 
5 (42) 
Table 4. Comparison of the developed antibodies in ATIL reported in three different studies 
(Williams, Gadola et al. 2009). ANA: antinuclear antibodies, dsDNA: double stranded DNA, 
aPL: antiphospholipid antibodies, ENAs: extractable nuclear antigens. 
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literature up to December 2006 (Ramos-Casals, Brito-Zeron et al. 2007). (Table 6) 
demonstrates comparison of different features of ATIL reported in some studies (Williams, 
Gadola et al. 2009). 
 
Main Characteristic  No. (%) 
Underlying rheumatic disease (n=92)   
     Rheumatoid arthritis 
     Crohn disease 
     Ankylosing spondylitis  
     Psoriatic arthritis  






Anti-TNF agent (n=62)  
     Infliximab 
     Etanercept 




Demographic characteristics (n=62)  
     Female/male 
     Mean age at diagnosis of vasculitis 
(yr±SEM) 
     Length of anti-TNF treatment ± SEM 
(wk) 
52/10 
50.9 ± 2.3 
41.2 ± 5.7 
SLE criteria (n=72)  
     ANA  
     Anti-dsDNA 
     Cutaneous features  
     Arthritis 
     Cytopenia  
     Serositis  
     aPL 
     Anti-Sm antibodies  
     Nephropathy  
     Oral ulcers  












Number of SLE criteria fulfilled (n=72)  
≥ 4 (defined SLE) 
3 (lupus-like syndrome) 




Outcome (n=72)  
     Improvement  
     Time of improvement (mo ± SEM) 
      Rechallenge phenomenon 
71 
9.9 ± 1.4 
2/8 (33%) 
Table 5. Clinical characteristics of 92 patients with lupus related to TNF-targeted therapy 
(Ramos-Casals, Brito-Zeron et al. 2007). 
 




criteria for lupus  
BSRBR data, 
(Britain), (n=41) 
Coasta et al., 
2008, (USA), 
(n=33) 
Ramos-Casal et al., 
(Spain), (n=72) 
De Bandt et al., 
2005, (France), 
(n=12) 
Malar rash. N (%) Not reported Not reported Not reported 5 (42) 
Discoid rash, n (%) 25 (61) 24 (73) 48 (67) 0 
Photosensitivity, n 
(%) 
4 (10) Not reported Not reported 5 (42) 
Oral ulcer, n (%) 5 (12) 1 (3) 3 (4) 0 
Arthritis, n (%) 3 (7) 17 (52) 22 (31) 6 (50) 
Serositis, n (%) 0 3 (18) 9 (12) 3 (25) 
Renal Disorder,  
n (%) 
0 3 (9) 5 (7) 0 
Neurological 
disorder, n (%) 
0 0 2 (3) 0 
Hematological 
disorder, n (%) 
1(2) 20 (61) Cytopenia-16 (22) 6 (50) 
Immunological 
disorder, n (%) 




antibodies, n (%) 
13 (32) 32 (97) 57 (79) 12 (100) 
Table 6. Features of patients with ATIL based on case reports and case series in some studies 
(Williams, Gadola et al. 2009).  
6.4.1 Development of cutaneous manifestations  
ATIL may present in variable forms of clinical features, either in form of isolated cutaneous 
manifestations or systemic manifestations. Most of the reported clinical features of anti-
TNF-α-induced SLE are in form of cutaneous lesions (tables 5 and 6). Most of these 
symptoms are similar to that symptoms present with idiopathic SLE. The cutaneous features 
of ATIL are most commonly malar rash, pruritic rash, photosensitive rash or purpura 
(Ramos-Casals, Brito-Zeron et al. 2008). Other cutaneous features are discoid rash, mucosal 
ulcers, and alopecia (Ramos-Casals, Brito-Zeron et al. 2008). The diagnosis of these 
cutaneous symptoms is based upon the clinical features in combination with concurrent use 
of an implicated drug. Therefore, many of the reported cases did not have skin lesions 
biopsied for diagnosis (Wetter and Davis 2009). When described, the pathological changes of 
this adverse effect are similar to those observed in patients with non-drug-associated 
idiopathic SLE (De Bandt, Sibilia et al. 2005; Costa, Said et al. 2008).  
6.4.2 Development of systemic manifestations 
Patients on anti- TNF-α therapy may develop systemic features of SLE that usually resolve 
after discontinuation of the offending drug. The associated general features include 
constitutional symptoms of fever, malaise, and weight loss which are considered as common 
symptoms of SLE after anti- TNF-α therapy and they often present in association with 
positive serology of autoantibodies. Other systemic symptom that reported is induction of 
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of an implicated drug. Therefore, many of the reported cases did not have skin lesions 
biopsied for diagnosis (Wetter and Davis 2009). When described, the pathological changes of 
this adverse effect are similar to those observed in patients with non-drug-associated 
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new onset of polyarthritis or progression to worsening symptoms of presented arthritis in 
form of joint tenderness, swelling, and effusion, some other patients develop arthralgia 
without evidence of arthritis (De Bandt, Sibilia et al. 2005). Arthritis was the first sign to 
develop in 71% in a cohort of patients in one center (Wetter and Davis 2009). It was also the 
most debilitating sign. Other rare and serious clinical characteristics may develop as side 
effects in patients on anti-TNF-α agents include serositis with pleurisy or pericarditis, 
pleural or pericardial effusions, deep venous thrombosis, life-threating pneumonitis, and 
neuritis (Costa, Said et al. 2008) (Table 7). Two cases of biopsy-confirmed proliferative lupus 
nephritis were described in patients treated with etanercept for juvenile RA (Mor, Bingham 
et al. 2005; Stokes, Foster et al. 2005). Renal biopsies revealed severe hypercellularity, 
endocapillary proliferation, wire loops and intraluminal deposits. Immunofluoresence 
shared positive staining for all immunoglobulin isotypes as well as C3 and Clq. Extensive 
electron-dense deposits were visualized by electron microscopy. Of note, focal proliferative 
lupus nephritis (Class III) was described with adalimumab (Stokes, Foster et al. 2005).  
 
Clinical manifestation Number of reported cases % of reported cases 
Rash 24/33 73 %  
Polysynovitis 17/33 52 % 
Fever 17/33 52 % 
Myalgias 8/33 24 % 
Pericardial/pleural effusion 3/33 9 % 
Nephritis 3/33 9 % 
Valvulitis 1/33 3 % 
Pneumonitis 1/33 3 % 
Deep venous thrombosis 1/33 3 % 
Oral ulcer 1/33 3 % 
Table 7. Clinical features of 33 reported cases with ATIL (Costa, Said et al. 2008). 
ATIL may present with unusual manifestation that is even uncommon feature of idiopathic 
SLE. This requires clinical suspension for ATIL in any patient presenting with unusual 
clinical findings. Invasive methods may be required to confirm the diagnosis. In a case that 
we reported (Almoallim 2011), adalimumab was initiated in a patient to control her 
symptoms of RA. She presented with prolonged morning stiffness and severe polyarthritis 
evident by swelling and tenderness in her metacarpophalangeal joints (MCPs), elbows, 
shoulders, knees and ankles. Serology for RF, anti-citrullinated protein antibodies (ACPA), 
and ANA (1:160) were all positive. While the patient was on adalimumab therapy, she 
showed significant improvement with complete remission of her disease. Within one year of 
this treatment, she developed diffuse muscle weakness mainly proximal rather than distal 
which made her unable to get up from the bed, climb stairs or even stand from sitting 
position. She had signs of active arthritis in two MCP joints in the right and bilateral wrist 
joints. She had mild hyperpigmented area around the mouth with no skin rashes elsewhere. 
She had a very high titer of ANA (1:1280) with emerging of a new onset of strongly positive 
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anti-ds DNA antibodies, her creatinine kinase was entirely normal. Electromyograghy 
(EMG) was suggestive of inflammatory myopathy. MRI deltoid and thigh showed mild 
edema involving the right triceps muscle with minimal enhancement in the post contrast 
sequence (Figure.2). Deltoid biopsy showed focal mild perivascular and endomysial 
lymphohistiocytic which revealed inflammatory myositis (Figure.3). Based on the clinical 
findings, the positive serology of ANA and anti-ds DNA, and the biopsy findings, the 
diagnosis of adalimumab induced lupus myositis was made. Given the profound muscle 
weakness that she had, she received 1 gm of pulse methylprednisolone intravenously daily 
for three days then she was maintained on 60 mg/day, in addition she received rituximab 
1000 mg intravenously, two doses in two weeks. This regimen was well tolerated and she 
recovered fully. Ten months later, she was asymptomatic with normal power, negative 
serology for anti-dsDNA antibodies and off treatment. In another case report, the patient 
developed severe myositis as a part of complex overlap syndrome following treatment with 
adalimumab, with positive serology for ANA and anti-dsDNA antibodies (Liozon, Ouattara 









Fig. 2. MRI right arm showed mild edema involving the right triceps muscle with minimal 
enhancement in the post contrast sequence in comparison to other muscles which appeared 
mildly atrophied. 
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anti-ds DNA antibodies, her creatinine kinase was entirely normal. Electromyograghy 
(EMG) was suggestive of inflammatory myopathy. MRI deltoid and thigh showed mild 
edema involving the right triceps muscle with minimal enhancement in the post contrast 
sequence (Figure.2). Deltoid biopsy showed focal mild perivascular and endomysial 
lymphohistiocytic which revealed inflammatory myositis (Figure.3). Based on the clinical 
findings, the positive serology of ANA and anti-ds DNA, and the biopsy findings, the 
diagnosis of adalimumab induced lupus myositis was made. Given the profound muscle 
weakness that she had, she received 1 gm of pulse methylprednisolone intravenously daily 
for three days then she was maintained on 60 mg/day, in addition she received rituximab 
1000 mg intravenously, two doses in two weeks. This regimen was well tolerated and she 
recovered fully. Ten months later, she was asymptomatic with normal power, negative 
serology for anti-dsDNA antibodies and off treatment. In another case report, the patient 
developed severe myositis as a part of complex overlap syndrome following treatment with 
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Fig. 2. MRI right arm showed mild edema involving the right triceps muscle with minimal 
enhancement in the post contrast sequence in comparison to other muscles which appeared 
mildly atrophied. 
 




Fig. 3. Biopsy from right arm (triceps muscle) using Hematoxylin and Eosin stain, original 
magnification 400, which revealed inflammatory myositis (focal mild perivascular and 
endomysial lymphohistiocytic inflammation). 
6.5 Differences between ATIL and classic Drug Induced Lupus Erythematosus (DILE) 
These comparisons are observations based on the abundance of case reports in the literature. 
Skin rashes for example are thought to be more common in ATIL in comparison to DILE 
(Costa, Said et al. 2008). It is noticed that the classical cutaneous features of SLE is rare in 
DILE (Katz and Zandman-Goddard).  While myalgias is more common in DILE (Yung and 
Richardson 1994) in comparison to ATIL. The incidence of fever is similar in both diseases in 
one series (Costa, Said et al. 2008). (Table 8) represents the prevalence of clinical 
manifestations and laboratory features in ATIL, DILE and SLE as reported in three different 
studies (Ramos-Casals, Brito-Zeron et al. 2007).  
 
Feature Anti-TNF-related lupus (%) 
Procainamide-
realted lupus (%) Idiopathic SLE (%) 
ANA 79 >95 99 
Anti-dsDNA 72 <5 90 
Rash/cutaneous 
involvement 
67 <5 54-70 
Arthritis 31 20 83 
Fever/general symptoms 23 45 42 
Hypocomplementemia 17 <5 48 
Leukopenia 14 15 66 
Serositis 12 50 28 
Anticardiolipin antibodies 11 5-20 15 
Glomerulonephritis 7 <5 34 
Thrombocytopenia 6 <5 31 
Neuropsychiatric  3 <5 12 
Anti-histone antibodies Not reported >95 50-60 
Table 8. Prevalence of clinical manifestations and laboratory features in lupus related to 
anti-TNF agents compared with idiopathic SLE (Ramos-Casals, Brito-Zeron et al. 2007). 
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6.5 Diagnosis of Anti-TNF-α-induced lupus erythematosus 
Development of SLE in patients who is being treated with anti-TNF-α agents is well 
documented throughout the literature and the diagnosis of this side effect is crucial. The 
clinical presentation of ATIL can vary, and specific diagnostic criteria have not been 
established. However, in the most reported cases, the diagnosis was made on the basis of the 
development of one or more symptoms compatible with SLE, ongoing exposure to an anti--
TNF-α agent, no prior history of SLE, and resolution of symptoms when the offending drug 
is discontinued. The strict application of the American College of Rheumatology criteria for 
idiopathic SLE (ACR criteria) would probably exclude the diagnosis of ATIL in many 
patients receiving anti-TNF-α therapy. Therefore, for the purpose of early diagnosis; the 
following criteria can be considered (De Bandt, Sibilia et al. 2005): (1) a temporal relationship 
between symptoms and anti-TNF-α-therapy; (2) at least 1 serologic finding that compatible 
with ACR criteria eg, ANA, anti-dsDNA antibodies, and (3) at least 1 non serologic finding 
that compatible with ACR criteria eg, arthritis, serositis, hematologic disorder, malar rash. 
The musculoskeletal symptoms were taken into account only if they reappeared with other 
lupus symptoms in a patient in whom they had previously disappeared while receiving 
anti- TNF-α therapy as in the case reported above in section 6.4.2. Isolated positive results 
for ANAs or anti-dsDNA antibodies were not considered for diagnosis, given their high 
frequency in patients receiving this therapy (De Bandt, Sibilia et al. 2005). 
6.6 Treatment of Anti-TNF-α-induced Lupus Erythematosus (ATIL) 
The main approach regarding the treatment of ATIL is the withdrawal of offending drug. 
The time until symptoms resolution ranges from three weeks to six months (De Bandt, 
Sibilia et al. 2005; Wetter and Davis 2009). The level of autoantibodies have been either 
normalized or decreased in response to drug withdrawal (De Bandt, Sibilia et al. 2005; 
Wetter and Davis 2009). However, some investigators have suggested that TNF-α 
antagonists do not need to be discontinued if the patient has isolated induction of 
autoantibodies without any clinical manifestations of lupus (Ramos-Casals, Brito-Zeron et 
al. 2007; Kerbleski and Gottlieb 2009). It has to be realized that autoimmune diseases may 
coexist and there is always the possibility of latent idiopathic SLE triggered by anti-TNF-α 
agents. Strongly positive autoantibodies should raise the suspicion for ATIL. In addition to 
discontinuing of anti- TNF-α therapy, many patients required to be treated by the 
traditional therapy for idiopathic SLE to achieve full resolution of their lupus symptoms. 
The Spanish Study Group of Biological Agents in Autoimmune Diseases (BIOGEAS) 
classified all patients with autoimmune diseases secondary to the use of biologic agents into 
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Brito-Zeron et al. 2007). In a reported case of a patient who developed ATIL in a form of a 
pruritic photo-distributed skin rash after initiation of etanercept therapy, patient has been 
treated with hydroxychloroquine beside drug discontinuation and systemic 
corticosteroids(Williams and Cohen 2011). We reported case of a patient who developed 
lupus myositis after treatment with adalimumab for rheumatoid arthritis. She received 
pulse steroid therapy and two doses of rituximab. The treatment was well tolerated with 
complete recovery. The patient was then maintained on hydroxychloroquine and 
azothioprine. She remained asymptomatic for 10 months of follow up (Almoallim 2011).  An 
important question is whether patients with ATIL can safely receive an alternative anti–
TNF-α agent? There are limited evidences that support the safety of re-challenging with 
alternative anti-TNF-α agents.  Reports regarding this issue are scarce, but one author 
described 4 patients who were re-challenged with the same or different agents and had no 
recurrence of lupus symptoms (3 received etanercept and 1 received adalimumab)(Cush 
2004).   In another study, 4 of 5 patients tolerated an alternative TNF inhibitor (adalimumab 
for 3 patients, etanercept for 1) without recurrence of ATIL after discontinuation of 
infliximab (Wetter and Davis 2009). Nevertheless, these findings should be interpreted 
cautiously, given the small number of patients who were re-challenged.  In addition, some 
of these reports were conducted on patients with ATIL with mild disease and few clinical 
findings. The successful continued therapy with an alternative anti-TNF-α agent reported 
for one patient (Williams and Cohen), was actually manifested with only cutaneous 
findings. The clinical decision to continue an alternative anti-TNF-α agent in ATIL patients 
with severe and systemic involvement is really hard to make. Exposing patients to the risk 
of developing another serious complication from an offending drug, even if it were another 
drug in the same class is against the basic principles of safe practice.    
6.7 Prognosis of Anti-TNF-α -induced Lupus Erythematosus (ATIL) 
Most patients who developed ATIL had a good prognosis upon discontinuation of these 
agents. Normalization of the emerged autoantibodies and resolution of lupus symptoms 
occur when the offending drugs is stopped without recurrence. Some patients might need to 
be started on corticosteroids and immunosuppressive agents for full recovery as described 
above. However, patients who developed serious side effects in form of renal or 
neurological involvements may have residual effects (Ramos-Casals, Brito-Zeron et al. 2007).   
6.8 Prevention of Anti-TNF-α-induced Lupus Erythematosus (ATIL) 
ATIL is a well documented entity. Physicians need to use these biological agents in caution 
with close follow up. It is not known whether ATIL and other autoimmune phenomena are 
a contributing factor for the high rate of long-term drug failure/discontinuation of anti-
TNF-α therapy(Papagoras, Voulgari et al.) Rigorous follow up and early recognition of any 
complication developing while patients receiving anti-TNF-α agents, are essential to assure 
patients safety on the long term. This should help clinicians to learn more about these agents 
and identify appropriate approaches in different clinical settings encountered. As the use of 
anti-TNF-α agents has become more widely spread, the incidence of ATIL will likely also 
increase. There are currently no recommendations for prevention of ATIL. It has been 
suggested that concurrent use of immunosuppressive agents may reduce the incidence of 
autoantibody formation and thereby reduce the incidence of ATIL (Eriksson, Engstrand et 
al. 2005). Indeed, methotrexate can exert a suppressive effect on the production of 
autoantibodies in patients with isolated cutaneous lupus (Boehm, Boehm et al. 1998). 
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Although direct comparison between studies is difficult, as the majority of patients on anti-
TNF will also be taking MTX, data from clinical trials of infliximab in patients with RA 
suggest that concurrent therapy with DMARDs is not protective (Charles, Smeenk et al. 
2000; Eriksson, Engstrand et al. 2005). It has to be noted also that some RA patients had 
lupus features before the initiation of anti-TNF-α agents (Ramos-Casals, Brito-Zeron et al. 
2007). Use of anti-TNF-α agents may have triggered or unmasked the symptoms of SLE in 
some patients. For this reason, assuring the diagnosis of RA prior to initiation of anti-TNF-α 
therapy is an extremely important aspect in the prevention process. Presence of SLE is 
considered a contraindication to the use of anti-TNF-α therapy. Therefore, it is 
recommended to perform a thorough baseline immunological screening for any patient with 
definite polyarthritis to assure accurate diagnosis. It is recommended to perform a detailed 
immunological screening for any patient whom you are considering anti-TNF-α therapy for. 
Some recommendations have been suggested for each patient upon starting anti-TNF-α 
therapy which will help in the therapeutic approach for autoimmune diseases induced by 
these biological agents (Ramos-Casals, Brito-Zeron et al. 2007). First, perform baseline 
immunological analysis and chest X-ray before treatment. Second, maintain specific follow 
up centered on the possible development of cutaneous, articular, or pulmonary 
manifestations. Third, evaluate adverse effects related to anti-TNF-α accurately, discarding 
the existence of undiagnosed autoimmune diseases (mainly systemic vasculitis). Fourth, 
preexisting SLE, especially in the presence of sever organ involvement (renal, pulmonary, or 
neurogical), should be considered as a precautionary scenario for the use of anti-TNF-α 
therapy. Finally, anti-TNF-α agents should not be used in patients with preexisting 
interstitial lung disease (table 9). 
 
1. Perform baseline immunological analysis and chest X-ray before treatment. 
2. Maintain specific follow up centered on the possible development of cutaneous, 
articular, or pulmonary manifestations. 
3. Evaluate adverse effects related to anti-TNF-α accurately, discarding the existence of 
undiagnosed autoimmune diseases (mainly systemic vasculitis). 
4. Preexisting SLE, especially in the presence of sever organ involvement (renal, 
pulmonary, or neurogical), should be considered as a precautionary scenario for the 
use of anti-TNF-α therapy. 
5. Anti-TNF-α agents should not be used in patients with preexisting interstitial lung 
disease.   
Table 9. Some recommendations for each patient upon starting anti-TNF-α therapy. 
Adopted with modifications from (Ramos-Casals, Brito-Zeron et al. 2007).   
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1. Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs. 
Disease flares can occur at any time during pregnancy and postpartum without any clear 
pattern. 
The hormonal and physiological changes that occur in pregnancy can induce lupus activity. 
Likewise the increased inflammatory response during a lupus flare can cause significant 
complications in pregnancy. Distinguishing between signs of lupus activity and pregnancy 
either physiological or pathological can be difficult [Clowse, 2007]. 
Pregnancy is a crucial issue that needs to be clearly discussed in details in all female patients 
with SLE who are in the reproductive age group. There are two essential concerns. The first 
one is the Lupus activity on pregnancy and the second one is the influence of pregnancy on 
Lupus. That is the reason why pregnancy should be planned at least six months of remission 
with close follow-up for SLE flares. 
Women with SLE usually have complicated pregnancies out of which one third will result in 
cesarean section, one third will have preterm delivery and more than 20% will be 
complicated by preeclampsia [Clowse, 2006; Clark, 2003]. Rarely an SLE patient with a 
controlled disease activity may deteriorate as pregnancy advances, but still the pregnancy 
outcome can be better if pregnancy is well timed and managed. 
2. Physiology of pregnancy 
There are increased demands by the mother, fetus and the placenta during pregnancy which 
is to be met by the mother’s organ systems. Therefore there are some cardiovascular, 
hematological, immunological, endocrinal and metabolic changes in the mother in normal 
pregnancy. 
2.1 Cardiovascular system 
The most important physiological changes that occur in pregnancy are the increase in 
cardiac output, retention of sodium and water leading to increase in the blood volume, 
reduction in systemic vascular resistance and blood pressure. These changes begin as early 
as fourth week of pregnancy [Chapman, 1998], reaching their peak during the second 
trimester, and then remain relatively constant until delivery. As the increase in the red cell 
volume is proportionately less than the increase in plasma volume there is hemodilution 
(physiological anemia) by the end of second trimester [Table 1]. The plasma volume gain is 
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between 1000ml to 1500ml while the blood volume at term is about 100ml/kg which could 
commonly present as mild pedal edema [Jansen, 2005] 
The increased levels of plasma erythropoietin is responsible for steady increase in the red 
cell mass by 20-30% who take iron supplements and by 15-20% in those who do not take 
iron supplements. The physiological anemia that occurs in pregnancy reduces the cardiac 
work load and helps for better placental perfusion by decreasing the blood viscosity.  
It also decreases the risk of thrombosis in utero-placental circulation. The increased blood 
volume also protects against the usual blood loss in the peripartum period [Stephansson, 
2000]. The hemoglobin begins to increase from the third postpartum day and the blood 
volume returns to non-pregnant level by two months postpartum.  
Cardiac output- It increases by 30-50% during normal pregnancy [Robson, 1989]. This is as a 
result of increase in the preload due to rise in blood volume, decrease in afterload due to 
decrease in systemic vascular resistance and increase in the maternal heart rate by 15-20 
beats/min without any change in the ejection fraction. Twin pregnancy increase the cardiac 
output by another 20%. However, maternal heart rate, stroke volume, and cardiac output 
during pregnancy may vary when mother changes from lateral to supine position 
[Lang,1991, Kametas,2003].  
Hemodynamic changes related to labor and delivery — Normal labor and delivery is 
associated with significant hemodynamic changes due to anxiety, exertion, labor pains, 
uterine contractions, uterine involution, and bleeding. Cardiovascular effects also occur in 
some women due to infection, hemorrhage, or the administration of anesthesia or analgesia. 
The cardiac output and systemic vascular resistance gradually return to non-pregnant levels 
over a period of three months [Capeless, 1991]. 
2.2 Hematological changes 
The total white cell count is increased up to 40% due to the increase in neutrophils as a 
result of demargination seen in pregnancy. Therefore the WBC count increases gradually in 
pregnancy as follows: 
1st trimester- 3000-15,000 (Mean increase 9500/mm3)    
2nd and 3rd trimesters- 6000-16,000 (mean 10,500)  
During labor-may increase up to 30,000/ mm3 
The platelet count gradually decreases till the term although they do not fall below 
100,000/cu mm, most of the time they are in the lower range of normal values. This is as a 
result of dilutional effect, increased destruction and turn over. 
The RBC increased by 20% due to increased production of erythropoietin but as the plasma 
volume is increased more than the red cell volume there is a drop in the hemoglobin causing 
physiological anemia [McColl, 1997]. 
2.3 Changes in systemic coagulation 
Pregnancy is associated with changes in several coagulation factors that result in a 20 
percent reduction of prothrombin and the partial thromboplastin times. The main changes 
are:  
 Increased Resistance to activated protein C in the second and third trimesters  
 Decreased levels of Protein S  
 Increased levels of Factors I, VII, VIII, IX, and X    
 Increased Activity of the fibrinolytic inhibitors PAI-1 and PAI-2, although total 
fibrinolytic activity may not be impaired       
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       PARAMETER  IN PREGNANCY 
                         
CHANGE (+/-) 
 
Stroke volume                   
Heart rate                         
Cardiac output                   
Oxygen consumption        
SVR (systemic vascular resistance)  
Systolic BP                        
Diastolic BP                      











Blood volume                 
Plasma volume               
Red blood cell volume  
Renal plasma flow 
Glomerular filtration rate (GFR) 
Polymorphonuclear leukocytes      
Hemoglobin  (11 g%) 
Leucocytosis  (15,000/cmm) 
Platelet  (may drop upto 100,000) 

















PT & APTT 
Bleeding time & clotting time 
Fibrinolytic activity        










Table 1. Changes in maternal physiology in pregnancy 
(Christopher Ficiliberto & Gertic F.Marx.(1998). Physiological changes 
associated with pregnancy. Physiology, 9(2):1-3)  
The net effect of these pregnancy-induced changes is to produce a hypercoagulable state, 
which is a double-edged sword, both for protection (e.g., hemostasis contributing to 
reduced blood loss at delivery) and increased risk (e.g., thromboembolic phenomenon). 
Venous thrombosis in pregnancy occurs in approximately 0.7 per 1000 women, and is three 
to four folds higher in the puerpurium than during pregnancy. The risk is increased in 
women with underlying inherited thrombophilia (e.g. factor V Leiden or the prothrombin 
gene mutation) [Talbert, 1964; Hellgren, 1981]. 
2.4 Changes in the maternal immune system 
The local adaptation of the maternal immune system is responsible for the successful 
coexistence between the mother and the fetus/placenta expressing both maternal (self) and 
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during pregnancy may vary when mother changes from lateral to supine position 
[Lang,1991, Kametas,2003].  
Hemodynamic changes related to labor and delivery — Normal labor and delivery is 
associated with significant hemodynamic changes due to anxiety, exertion, labor pains, 
uterine contractions, uterine involution, and bleeding. Cardiovascular effects also occur in 
some women due to infection, hemorrhage, or the administration of anesthesia or analgesia. 
The cardiac output and systemic vascular resistance gradually return to non-pregnant levels 
over a period of three months [Capeless, 1991]. 
2.2 Hematological changes 
The total white cell count is increased up to 40% due to the increase in neutrophils as a 
result of demargination seen in pregnancy. Therefore the WBC count increases gradually in 
pregnancy as follows: 
1st trimester- 3000-15,000 (Mean increase 9500/mm3)    
2nd and 3rd trimesters- 6000-16,000 (mean 10,500)  
During labor-may increase up to 30,000/ mm3 
The platelet count gradually decreases till the term although they do not fall below 
100,000/cu mm, most of the time they are in the lower range of normal values. This is as a 
result of dilutional effect, increased destruction and turn over. 
The RBC increased by 20% due to increased production of erythropoietin but as the plasma 
volume is increased more than the red cell volume there is a drop in the hemoglobin causing 
physiological anemia [McColl, 1997]. 
2.3 Changes in systemic coagulation 
Pregnancy is associated with changes in several coagulation factors that result in a 20 
percent reduction of prothrombin and the partial thromboplastin times. The main changes 
are:  
 Increased Resistance to activated protein C in the second and third trimesters  
 Decreased levels of Protein S  
 Increased levels of Factors I, VII, VIII, IX, and X    
 Increased Activity of the fibrinolytic inhibitors PAI-1 and PAI-2, although total 
fibrinolytic activity may not be impaired       
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       PARAMETER  IN PREGNANCY 
                         
CHANGE (+/-) 
 
Stroke volume                   
Heart rate                         
Cardiac output                   
Oxygen consumption        
SVR (systemic vascular resistance)  
Systolic BP                        
Diastolic BP                      











Blood volume                 
Plasma volume               
Red blood cell volume  
Renal plasma flow 
Glomerular filtration rate (GFR) 
Polymorphonuclear leukocytes      
Hemoglobin  (11 g%) 
Leucocytosis  (15,000/cmm) 
Platelet  (may drop upto 100,000) 

















PT & APTT 
Bleeding time & clotting time 
Fibrinolytic activity        










Table 1. Changes in maternal physiology in pregnancy 
(Christopher Ficiliberto & Gertic F.Marx.(1998). Physiological changes 
associated with pregnancy. Physiology, 9(2):1-3)  
The net effect of these pregnancy-induced changes is to produce a hypercoagulable state, 
which is a double-edged sword, both for protection (e.g., hemostasis contributing to 
reduced blood loss at delivery) and increased risk (e.g., thromboembolic phenomenon). 
Venous thrombosis in pregnancy occurs in approximately 0.7 per 1000 women, and is three 
to four folds higher in the puerpurium than during pregnancy. The risk is increased in 
women with underlying inherited thrombophilia (e.g. factor V Leiden or the prothrombin 
gene mutation) [Talbert, 1964; Hellgren, 1981]. 
2.4 Changes in the maternal immune system 
The local adaptation of the maternal immune system is responsible for the successful 
coexistence between the mother and the fetus/placenta expressing both maternal (self) and 
 
Systemic Lupus Erythematosus 460 
paternal (non-self) genes [Mor, 2009; Robertson, 2010]. The cell- mediated adaptive immune 
responses are diminished, bypassed or even eliminated but the anti-body mediated 
immunity is altered while the natural immunity (innate immunity) remains intact which 
continues to provide the host defense against infection [Nagamatsu, 2010]. 
During insemination, transforming growth factor β1 (TGF- β1), found in the seminal fluid 
stimulates the production of granulocyte-macrophage colony- stimulation factor (GM-CSF) 
and recruitment of inflammatory cell infiltrates in the uterus. During implantation of the 
fertilized ovum, the majority of the lymphocytes infiltrating the decidua are distinctive uterine 
natural killer (NK) cells which are CD56++, CD16- & CD3- and express various receptors. 
Uterine decidua and the feto-placental unit produces large number of cytokines which 
contribute to shift of the immune response from T helper -1 (Th1) to T helper-2 (Th2) response 
where cytokines IL-10, IL-4, IL-5,IL-6 and IL-13 predominate while pregnancy rejection is 
mediated by Th1 response where IFN-α, TNF-β, IL-2, and IL-12  predominate [Lim,2000]. 
There are many specific mechanisms for immunological protection against the fetus. The 
most important one is altered HLA expression. 
2.4.1 HLA class I 
Very specific expression of the HLA class I molecules in trophoblasts is the main factor for 
protection against paternal HLA class I antigen. The extra-villous trophoblasts (EVT) will not 
express the HLA class Ia antigens-A, B, C or HLA II antigens but instead they express weak 
antigens of HLA class Ib – G, E & F which dampen the immune response by interacting with 
leukocyte inhibitory receptor (LIRs) on uterine natural killer (NK) cells and macrophages and 
with the T-cell receptors on CD8+ cells [Tilburgs, 2010; Le, 1997; Hunt, 2006). 
2.4.2 Natural killer cells 
There is a change in the relative population of lymphocytes in the uterus. The T & B cells 
become scarce and the uterine natural killer (NK) cell population shifts from endometrial 
NK cells to decidual NK cells. 
2.4.3 Progesterone 
The role of progesterone, the hormone of pregnancy, seems to be crucial in the maintenance 
of pregnancy.  Progesterone leads to release of progesterone-induced blocking factor (PIBF), 
which controls cytokine production (IL-10 & others) and NK cell behavior. Increased 
embryo loss is associated with decreased levels of PIBF & IL-10 and increased levels of IL-12 
and IFN-α [Ito, 1995; Nilsson, 1994]. 
2.5 Hormonal changes in pregnancy  
Maternal changes in pregnancy involve hypothalamus, pituitary, parathyroid, adrenal 
glands, and ovaries to accommodate the needs of the fetal-placental-maternal unit. The 
hypothalamus still regulates much of the endocrine system through hypothalamic-pituitary 
axis, directly affecting the function of the above mentioned endocrine organs. Hence an 
intact hypothalamus is very much essential for normal pregnancy [Chrousos, 1995]. 
2.5.1 Hypothalamus 
Secretes stimulatory hormones like gonadotropin-releasing hormone (GnRH), 
corticotrophin-releasing hormone (CRH), growth hormone-releasing hormone (GHRH), 
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thyrotropin-releasing hormone (TRH) and inhibitory hormones like somatostatin and 
prolactin-inhibiting factors. These hormones are present in high concentrations in portal 
circulation where they are biologically active and the circulating concentrations of many of 
these hormones are also elevated in pregnancy due to placental production of identical or 
variant hormones. The most important changes are seen in the following hormones 
[Stojilkovic, 1994]. 
GnRH levels increases during pregnancy whose main source is placenta and plays a main 
role in placental growth and function. It also produces kisspeptin (KISS-1) which controls 
the gonadotropic axis and placental kisspeptin gradually increases with pregnancy which 
has a role in placentation [Bilban, 2004]. 
CRH from hypothalamus is involved in stress response in pregnancy and delivery. It is also 
secreted by placenta, chorionic trophoblasts, amnion and decidual cells. The placental CRH 
do not stimulate ACTH secretion but helps in initiation of labor. Besides CRH the 
gestational tissues also secretes urocortin which shares the same function of placental CRH, 
and urocortin-2 (stresscopin- related peptide) and urocortin-3 (stresscopin) which controls 
the tone of vascular endothelium also play a major role in parturition [Imperatore,2006; 
Florio, 2007]. 
2.5.2 Pituitary gland 
Changes occur both in the anterior as well as the posterior lobe of pituitary gland. 
Anterior lobe of pituitary gland enlarges to 3-fold during gestation due to hypertrophy and 
hyperplasia of lactotrophs and it takes at least six months after delivery to return to normal 
volume. FSH, LH & TSH levels are decreased while GH, ACTH & PRL levels are increased 
(mainly due to placental synthesis) [Lonberg, 2003]. 
The serum prolactin concentration (PRL) increases throughout pregnancy, reaching a peak 
at delivery to prepare the breast for lactation (figure 1) [Tyson, 1972], though the magnitude 
of the increase is quite variable. 
 
 
Fig. 1. Serum prolactin concentrations, as a function of time of gestation, showing the 
increase in prolactin as pregnancy progresses. The zone lines represent the range of values 
that can be seen. (Tyson, 1972) 
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paternal (non-self) genes [Mor, 2009; Robertson, 2010]. The cell- mediated adaptive immune 
responses are diminished, bypassed or even eliminated but the anti-body mediated 
immunity is altered while the natural immunity (innate immunity) remains intact which 
continues to provide the host defense against infection [Nagamatsu, 2010]. 
During insemination, transforming growth factor β1 (TGF- β1), found in the seminal fluid 
stimulates the production of granulocyte-macrophage colony- stimulation factor (GM-CSF) 
and recruitment of inflammatory cell infiltrates in the uterus. During implantation of the 
fertilized ovum, the majority of the lymphocytes infiltrating the decidua are distinctive uterine 
natural killer (NK) cells which are CD56++, CD16- & CD3- and express various receptors. 
Uterine decidua and the feto-placental unit produces large number of cytokines which 
contribute to shift of the immune response from T helper -1 (Th1) to T helper-2 (Th2) response 
where cytokines IL-10, IL-4, IL-5,IL-6 and IL-13 predominate while pregnancy rejection is 
mediated by Th1 response where IFN-α, TNF-β, IL-2, and IL-12  predominate [Lim,2000]. 
There are many specific mechanisms for immunological protection against the fetus. The 
most important one is altered HLA expression. 
2.4.1 HLA class I 
Very specific expression of the HLA class I molecules in trophoblasts is the main factor for 
protection against paternal HLA class I antigen. The extra-villous trophoblasts (EVT) will not 
express the HLA class Ia antigens-A, B, C or HLA II antigens but instead they express weak 
antigens of HLA class Ib – G, E & F which dampen the immune response by interacting with 
leukocyte inhibitory receptor (LIRs) on uterine natural killer (NK) cells and macrophages and 
with the T-cell receptors on CD8+ cells [Tilburgs, 2010; Le, 1997; Hunt, 2006). 
2.4.2 Natural killer cells 
There is a change in the relative population of lymphocytes in the uterus. The T & B cells 
become scarce and the uterine natural killer (NK) cell population shifts from endometrial 
NK cells to decidual NK cells. 
2.4.3 Progesterone 
The role of progesterone, the hormone of pregnancy, seems to be crucial in the maintenance 
of pregnancy.  Progesterone leads to release of progesterone-induced blocking factor (PIBF), 
which controls cytokine production (IL-10 & others) and NK cell behavior. Increased 
embryo loss is associated with decreased levels of PIBF & IL-10 and increased levels of IL-12 
and IFN-α [Ito, 1995; Nilsson, 1994]. 
2.5 Hormonal changes in pregnancy  
Maternal changes in pregnancy involve hypothalamus, pituitary, parathyroid, adrenal 
glands, and ovaries to accommodate the needs of the fetal-placental-maternal unit. The 
hypothalamus still regulates much of the endocrine system through hypothalamic-pituitary 
axis, directly affecting the function of the above mentioned endocrine organs. Hence an 
intact hypothalamus is very much essential for normal pregnancy [Chrousos, 1995]. 
2.5.1 Hypothalamus 
Secretes stimulatory hormones like gonadotropin-releasing hormone (GnRH), 
corticotrophin-releasing hormone (CRH), growth hormone-releasing hormone (GHRH), 
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thyrotropin-releasing hormone (TRH) and inhibitory hormones like somatostatin and 
prolactin-inhibiting factors. These hormones are present in high concentrations in portal 
circulation where they are biologically active and the circulating concentrations of many of 
these hormones are also elevated in pregnancy due to placental production of identical or 
variant hormones. The most important changes are seen in the following hormones 
[Stojilkovic, 1994]. 
GnRH levels increases during pregnancy whose main source is placenta and plays a main 
role in placental growth and function. It also produces kisspeptin (KISS-1) which controls 
the gonadotropic axis and placental kisspeptin gradually increases with pregnancy which 
has a role in placentation [Bilban, 2004]. 
CRH from hypothalamus is involved in stress response in pregnancy and delivery. It is also 
secreted by placenta, chorionic trophoblasts, amnion and decidual cells. The placental CRH 
do not stimulate ACTH secretion but helps in initiation of labor. Besides CRH the 
gestational tissues also secretes urocortin which shares the same function of placental CRH, 
and urocortin-2 (stresscopin- related peptide) and urocortin-3 (stresscopin) which controls 
the tone of vascular endothelium also play a major role in parturition [Imperatore,2006; 
Florio, 2007]. 
2.5.2 Pituitary gland 
Changes occur both in the anterior as well as the posterior lobe of pituitary gland. 
Anterior lobe of pituitary gland enlarges to 3-fold during gestation due to hypertrophy and 
hyperplasia of lactotrophs and it takes at least six months after delivery to return to normal 
volume. FSH, LH & TSH levels are decreased while GH, ACTH & PRL levels are increased 
(mainly due to placental synthesis) [Lonberg, 2003]. 
The serum prolactin concentration (PRL) increases throughout pregnancy, reaching a peak 
at delivery to prepare the breast for lactation (figure 1) [Tyson, 1972], though the magnitude 
of the increase is quite variable. 
 
 
Fig. 1. Serum prolactin concentrations, as a function of time of gestation, showing the 
increase in prolactin as pregnancy progresses. The zone lines represent the range of values 
that can be seen. (Tyson, 1972) 
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The probable cause of hyperprolactinemia is the increasing serum estradiol concentration 
during pregnancy. By six weeks after delivery, estradiol secretion decreases and the basal 
serum prolactin concentration returns to normal range as in non-breast feeding mother. In 
women who are nursing, the decline in serum prolactin level is slower and marked by 
intermittent hyperprolactinemia related to suckling. Pregnancy appears to permanently 
reduce pituitary prolactin secretion. The serum prolactin concentration was lower in parous 
women at up to 12 years postpartum [Musey, 1987]. 
Posterior lobe of pituitary gland is a storage terminal for antidiuretic hormone (ADH) and 
oxytocin produced by supraoptic and paraventricular hypothalamic nuclei. 
ADH- Its concentration remains in the non-pregnant range throughout pregnancy. Its 
metabolic clearance is increased due to vasopressinase released by placenta. The plasma 
sodium concentration falls by 5 meq/ L due to resetting of osmoreceptors as a result of 
increased levels of HCG. 
Oxytocin- Its levels increases gradually throughout gestation and is involved in parturition 
and lactation [Lindheimer, 1991]. 
2.5.3 Thyroid gland 
The size of the thyroid gland remains the same throughout the pregnancy but there is 
increase in the thyroxin-binding globulin (TBG). This leads to increased levels of both serum 
total thyroxin (T4) and triiodothyroxin (T3) but not the physiologically important serum free 
T4 & free T3 levels [Glinoer, 1990]. 
2.5.4 Adrenal gland 
This gland does not undergo morphological changes during pregnancy. The renin-
angiotensin-aldesterone system is stimulated during pregnancy due to decrease in 
peripheral vascular resistance and blood pressure and progressive decline in vascular 
responsiveness to angiotensin II. The aldesterone levels increased by 4-6 folds and the blood 
pressure usually reduced by 10mmHg. Relaxin, which is produced by the placenta, is  
a vasodilator factor, and aldesterone are critical in maintaining sodium balance in the setting 
of peripheral vasodilatation. During pregnancy there is increase in the levels of maternal  
& placental ACTH, cortisol-binding protein, atrial natriuretic peptide (ANP), plasma  
rennin activity (PRA), sex hormone-binding protein and testosterone levels [Homsen, 1993; 
Clerico, 1980]. 
2.6 Changes in the renal system in pregnancy  
Both kidneys increase in size by 1 to 1.5 cm during pregnancy. Kidney volume increases 
by 30 percent, primarily due to an increase in renal vascular and interstitial volume. The 
renal pelvises and caliceal systems may be dilated as a result of progesterone effects and 
mechanical compression of the ureters at the pelvic brim. Dilatation of the ureters and 
renal pelvis (hydroureter and hydronephrosis) is more prominent on the right than the 
left and is seen in up to 80 percent of pregnant women [Beydoun, 1985]. All the above 
changes may not resolve until 6 to 12 weeks postpartum. Urinary frequency, nocturia, 
dysuria, urgency, and stress incontinence are the common symptoms during pregnancy 
[Nel, 2001]. 
Renal hemodynamics — Normal pregnancy is characterized by widespread vasodilatation 
with increased arterial compliance and decreased systemic vascular resistance. These global 
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hemodynamic changes are accompanied by increases in renal perfusion and glomerular 
filtration rate. In late gestation, assumption of the left lateral position is associated with 
increases in glomerular filtration rate and sodium excretion [Almeida, 2009]. The increase in 
GFR which is approximately 40-50% is mainly due to increased glomerular plasma flow 
than increased intraglomerular capillary pressure. The renal blood flow increases by 80% 
above non-pregnant levels. As a result, the serum creatinine and BUN falls below the non-
pregnant levels. 
The mechanisms for decreased vascular resistance and increased renal plasma flow during 
pregnancy are not fully understood. Reduced vascular responsiveness to vasopressors such 
as angiotensin II, norepinephrine, and vasopressin is well-documented. Nitric oxide 
synthesis increases during normal pregnancy and may contribute to the systemic and renal 
vasodilatation and the fall in blood pressure [Danielson’, 1995]. 
The ovarian vasodilator hormone, relaxin,  appears to be a key upstream mediator of 
enhanced nitric oxide signaling in pregnancy. Relaxin increases endothelin and nitric oxide 
production in the renal circulation, leading to generalized renal vasodilatation, decreased 
renal afferent and efferent arteriolar resistance, and a subsequent increase in renal blood 
flow and GFR.  There is increased urinary protein excretion up to 200 mg/day in the third 
trimester [Novak, 2001]. 
3. Distinguishing lupus activity from signs and symptoms of pregnancy 
Systemic lupus erythematosus (SLE) primarily affects women in their reproductive years of 
life, making the issue of pregnancy important to many of these patients. Pregnancy changes 
affecting disease severity can be attributed to placental or maternal hormones, increased 
circulation, increased fluid volume, increased metabolic rate, hemodilution, circulating fetal 
cells, or other factors. Lupus flares are common in pregnancy at rate of 0.06-0.136 per 
patient-month [Table 2]. 
Likewise, the increased inflammatory response during a lupus flare can cause significant 
pregnancy complications. Distinguishing lupus activity from signs of both healthy and 
pathologic pregnancy is not straight forward and can be very difficult at times [Table 4]. 
Therefore, activity scales specific for pregnancy which takes into account these issues, have 
been established. One of them, the Lupus Activity Index in Pregnancy is actually validated, 
showing high sensitivity, specificity and predictive values for detecting flares during 
pregnancy [Clowse, 2006]. 
There is an increase in disease activity during pregnancy, according to many studies.  
In some patients, this will mean a dramatic worsening of symptoms that can be  
life threatening. Most patients, however, will have a modest increase in symptoms 
making pregnancy uncomfortable but not affecting their long-term survival. The 
increasing levels of estrogens that are seen in normal pregnancy to promote physiologic 
and immunologic changes required may also increase the lupus activity [Cohen-Solal, 
2006; Grimaldi, 2006]. Even though it is highly debated, at least some studies have found a 
two- to threefold increase in SLE activity during pregnancy [Petri, 1997; Lim, 1995; II 
Dong, 2011].  
40-50% of the patients will have increased SLE activity, majority of which are mild but in 
1/3 of cases it may be moderate to severe [Cortes-Hernandez., 2002]. Fortunately, the 
majority of SLE activity in pregnancy is not severe and in most studies, it is the skin, joint, 
and constitutional symptoms that are commonly seen. The physiological changes that occur 
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The probable cause of hyperprolactinemia is the increasing serum estradiol concentration 
during pregnancy. By six weeks after delivery, estradiol secretion decreases and the basal 
serum prolactin concentration returns to normal range as in non-breast feeding mother. In 
women who are nursing, the decline in serum prolactin level is slower and marked by 
intermittent hyperprolactinemia related to suckling. Pregnancy appears to permanently 
reduce pituitary prolactin secretion. The serum prolactin concentration was lower in parous 
women at up to 12 years postpartum [Musey, 1987]. 
Posterior lobe of pituitary gland is a storage terminal for antidiuretic hormone (ADH) and 
oxytocin produced by supraoptic and paraventricular hypothalamic nuclei. 
ADH- Its concentration remains in the non-pregnant range throughout pregnancy. Its 
metabolic clearance is increased due to vasopressinase released by placenta. The plasma 
sodium concentration falls by 5 meq/ L due to resetting of osmoreceptors as a result of 
increased levels of HCG. 
Oxytocin- Its levels increases gradually throughout gestation and is involved in parturition 
and lactation [Lindheimer, 1991]. 
2.5.3 Thyroid gland 
The size of the thyroid gland remains the same throughout the pregnancy but there is 
increase in the thyroxin-binding globulin (TBG). This leads to increased levels of both serum 
total thyroxin (T4) and triiodothyroxin (T3) but not the physiologically important serum free 
T4 & free T3 levels [Glinoer, 1990]. 
2.5.4 Adrenal gland 
This gland does not undergo morphological changes during pregnancy. The renin-
angiotensin-aldesterone system is stimulated during pregnancy due to decrease in 
peripheral vascular resistance and blood pressure and progressive decline in vascular 
responsiveness to angiotensin II. The aldesterone levels increased by 4-6 folds and the blood 
pressure usually reduced by 10mmHg. Relaxin, which is produced by the placenta, is  
a vasodilator factor, and aldesterone are critical in maintaining sodium balance in the setting 
of peripheral vasodilatation. During pregnancy there is increase in the levels of maternal  
& placental ACTH, cortisol-binding protein, atrial natriuretic peptide (ANP), plasma  
rennin activity (PRA), sex hormone-binding protein and testosterone levels [Homsen, 1993; 
Clerico, 1980]. 
2.6 Changes in the renal system in pregnancy  
Both kidneys increase in size by 1 to 1.5 cm during pregnancy. Kidney volume increases 
by 30 percent, primarily due to an increase in renal vascular and interstitial volume. The 
renal pelvises and caliceal systems may be dilated as a result of progesterone effects and 
mechanical compression of the ureters at the pelvic brim. Dilatation of the ureters and 
renal pelvis (hydroureter and hydronephrosis) is more prominent on the right than the 
left and is seen in up to 80 percent of pregnant women [Beydoun, 1985]. All the above 
changes may not resolve until 6 to 12 weeks postpartum. Urinary frequency, nocturia, 
dysuria, urgency, and stress incontinence are the common symptoms during pregnancy 
[Nel, 2001]. 
Renal hemodynamics — Normal pregnancy is characterized by widespread vasodilatation 
with increased arterial compliance and decreased systemic vascular resistance. These global 
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hemodynamic changes are accompanied by increases in renal perfusion and glomerular 
filtration rate. In late gestation, assumption of the left lateral position is associated with 
increases in glomerular filtration rate and sodium excretion [Almeida, 2009]. The increase in 
GFR which is approximately 40-50% is mainly due to increased glomerular plasma flow 
than increased intraglomerular capillary pressure. The renal blood flow increases by 80% 
above non-pregnant levels. As a result, the serum creatinine and BUN falls below the non-
pregnant levels. 
The mechanisms for decreased vascular resistance and increased renal plasma flow during 
pregnancy are not fully understood. Reduced vascular responsiveness to vasopressors such 
as angiotensin II, norepinephrine, and vasopressin is well-documented. Nitric oxide 
synthesis increases during normal pregnancy and may contribute to the systemic and renal 
vasodilatation and the fall in blood pressure [Danielson’, 1995]. 
The ovarian vasodilator hormone, relaxin,  appears to be a key upstream mediator of 
enhanced nitric oxide signaling in pregnancy. Relaxin increases endothelin and nitric oxide 
production in the renal circulation, leading to generalized renal vasodilatation, decreased 
renal afferent and efferent arteriolar resistance, and a subsequent increase in renal blood 
flow and GFR.  There is increased urinary protein excretion up to 200 mg/day in the third 
trimester [Novak, 2001]. 
3. Distinguishing lupus activity from signs and symptoms of pregnancy 
Systemic lupus erythematosus (SLE) primarily affects women in their reproductive years of 
life, making the issue of pregnancy important to many of these patients. Pregnancy changes 
affecting disease severity can be attributed to placental or maternal hormones, increased 
circulation, increased fluid volume, increased metabolic rate, hemodilution, circulating fetal 
cells, or other factors. Lupus flares are common in pregnancy at rate of 0.06-0.136 per 
patient-month [Table 2]. 
Likewise, the increased inflammatory response during a lupus flare can cause significant 
pregnancy complications. Distinguishing lupus activity from signs of both healthy and 
pathologic pregnancy is not straight forward and can be very difficult at times [Table 4]. 
Therefore, activity scales specific for pregnancy which takes into account these issues, have 
been established. One of them, the Lupus Activity Index in Pregnancy is actually validated, 
showing high sensitivity, specificity and predictive values for detecting flares during 
pregnancy [Clowse, 2006]. 
There is an increase in disease activity during pregnancy, according to many studies.  
In some patients, this will mean a dramatic worsening of symptoms that can be  
life threatening. Most patients, however, will have a modest increase in symptoms 
making pregnancy uncomfortable but not affecting their long-term survival. The 
increasing levels of estrogens that are seen in normal pregnancy to promote physiologic 
and immunologic changes required may also increase the lupus activity [Cohen-Solal, 
2006; Grimaldi, 2006]. Even though it is highly debated, at least some studies have found a 
two- to threefold increase in SLE activity during pregnancy [Petri, 1997; Lim, 1995; II 
Dong, 2011].  
40-50% of the patients will have increased SLE activity, majority of which are mild but in 
1/3 of cases it may be moderate to severe [Cortes-Hernandez., 2002]. Fortunately, the 
majority of SLE activity in pregnancy is not severe and in most studies, it is the skin, joint, 
and constitutional symptoms that are commonly seen. The physiological changes that occur 
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in pregnancy interfere with assessment of disease activity in SLE. So the signs and 
symptoms of pregnancy can easily be mistaken for increased lupus activity. 
Fatigue can be a distressing complaint throughout normal pregnancy. The fatigue of 
fibromyalgias increases during pregnancy. As there is no inflammation in this condition the 
excess sex hormones as well as steroids do not relieve pain. 




















Table 2. Impact of pregnancy on lupus activity (adopted from Megan, 2007) 
Arthralgias, joint effusions, headaches and low back pain are also common in pregnancy 
due to the effects of relaxin, increased levels of estrogens and fluid retention. The increased 
shortness of breath is due to elevation of diaphragm as a result of upward growth of gravid 
uterus. The hair loss particularly during puerpurium and post-partum is a common finding 
in normal pregnancy.  
The HAQ (Health assessment questionnaire) score increases for normal pregnant women 
from 0.02 in the first trimester to 0.16 in the second and 0.48 in the third trimester.  
As the blood volume increases in pregnancy by 50% there is an effect of hemodilution in the 
body which decreases hemoglobin and platelets, however the hemolytic anemia and 
platelets less than 100,000/c mm do not occur in normal pregnancy, if present suspect either 
lupus activity, severe preeclampsia or HELLP (Hemolysis, Elevated Liver enzymes, Low 
Platelets) [Buyon, 1999].  
The risk for skin disease during pregnancy is higher (25-90%) than arthritis (20%), 
thrombocytopenia (10-40%) or nephritis (4-30%). Women with previous history of lupus 
nephritis have a higher chance for relapse of nephritits (20-30%). 
Due to increased blood volume and glomerular filtration rate the serum creatinine falls 
gradually and proteinuria increases during normal pregnancy. Therefore a stable serum 
creatinine that is maintained during pregnancy without a fall suggests renal insufficiency. 
Only proteinuria which is more than double the baseline is to be taken as abnormal, as 
proteinuria up to 300mg/24 hours can occur in normal pregnancy. A serum creatinine level 
                          Impact of pregnancy on SLE activity 
	
 Pregnancy probably increases lupus activity: 
 About 50% of women will have measurable SLE activity during pregnancy 
 Most of the disease activity will be mild to moderate 
 15% to 30% of women will have highly active SLE in pregnancy 
 Most common types of SLE activity in pregnancy: 
1. Cutaneous disease (25-90%) 
2. Arthritis (20%) 
3. Hematologic disease (10-40%) 
 
 Risk factors for increased lupus activity: 
1. Active lupus within the 6 months before conception 
2. Multiple flares in the years before conception 
3. Discontinuation of hydroxychloroquin	
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>140 µmol/L is associated with a 50% pregnancy loss and this increases to 80% if the level is 
>400 µ mol/L [Megan, 2007]. 
 
Symptoms of pregnancy that can mimic lupus activity 
Constitutional Fatigue that can be debilitating in entire pregnancy. 
Skin Palmar erythema and a facial blush due to increased estrogen. 
Face 
 
Melasma: ‘‘mask of pregnancy.’’ A macular, photosensitive 
Hyperpigmented area over cheeks and forehead. 
Hair 
 
Increased hair growth and thickness during pregnancy. 
Hair loss in the weeks to months postpartum. 
Pulmonary     Increased respiratory rate from progesterone. 





Back pain in second and third trimesters. 
  -Relaxin loosens sacroiliac joint and symphysis pubis 
  -Gravid uterus increases lumbar lordosis. 






Headache can be part of normal pregnancy 
or associated with hypertension. 
Seizures occur in eclampsia. 
Cerebral vascular accidents can be caused by preeclampsia or 
antiphospholipid syndrome. 
Table 3. Symptoms in pregnancy that mimics lupus activity 
(Adopted from Tsokos GC et al. Systemic lupus erythematosus, A companion to 
rheumatology. St. Louis: Mosby; 2007)  
Complement C3, C4, anti-dsDNA titer, autoimmune target testing (AITT) and  
lupus activity  
The activity of the lupus cannot accurately be assessed by the C3/C4 level and anti-dsDNA 
titers as in non-pregnant lupus patients. C3 and C4 may be decreased with increased lupus 
activity because these proteins are consumed in the inflammatory process [Ho A, 2001]. In 
pregnancy, however, the complement levels may increase 10-50% in response to increased 
hepatic protein synthesis [Buyon, 1992].  
During pregnancy, C3 and C4 may rise to supranormal levels, and thus a flare with 
complement activation may occur despite apparently normal levels of C3 and C4. 
Conversely C3and C4 may be low in the absence of a flare, probably due to synthetic 
defects. However, if C3 or C4 levels drop by >25%, this may be reasonably ascribed to 
disease activity [Buyon, 1999]. Therefore, the utility of complement measurement in 
pregnancy is unclear. However, the combination of low complement levels and high-activity 
lupus leads to a 3-5-fold increase in pregnancy loss and preterm birth [Clowse, 2004].  
AITT uses the macrophage cell line (IT-1) as a substrate that is wider than the ANA test 
in clinical applications   
The anti- dsDNA titer is very sensitive for the diagnosis of lupus and can be indicative of 
increased lupus activity, especially if the kidney is involved [Ho A, 2001]. Increased dsDNA 
which is considered for diagnosis and increased activity of the disease can be seen in 43% of 
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in pregnancy interfere with assessment of disease activity in SLE. So the signs and 
symptoms of pregnancy can easily be mistaken for increased lupus activity. 
Fatigue can be a distressing complaint throughout normal pregnancy. The fatigue of 
fibromyalgias increases during pregnancy. As there is no inflammation in this condition the 
excess sex hormones as well as steroids do not relieve pain. 




















Table 2. Impact of pregnancy on lupus activity (adopted from Megan, 2007) 
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thrombocytopenia (10-40%) or nephritis (4-30%). Women with previous history of lupus 
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                          Impact of pregnancy on SLE activity 
	
 Pregnancy probably increases lupus activity: 
 About 50% of women will have measurable SLE activity during pregnancy 
 Most of the disease activity will be mild to moderate 
 15% to 30% of women will have highly active SLE in pregnancy 
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 Risk factors for increased lupus activity: 
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2. Multiple flares in the years before conception 
3. Discontinuation of hydroxychloroquin	
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>140 µmol/L is associated with a 50% pregnancy loss and this increases to 80% if the level is 
>400 µ mol/L [Megan, 2007]. 
 
Symptoms of pregnancy that can mimic lupus activity 
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Face 
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Hair 
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Hair loss in the weeks to months postpartum. 
Pulmonary     Increased respiratory rate from progesterone. 





Back pain in second and third trimesters. 
  -Relaxin loosens sacroiliac joint and symphysis pubis 
  -Gravid uterus increases lumbar lordosis. 






Headache can be part of normal pregnancy 
or associated with hypertension. 
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Cerebral vascular accidents can be caused by preeclampsia or 
antiphospholipid syndrome. 
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activity because these proteins are consumed in the inflammatory process [Ho A, 2001]. In 
pregnancy, however, the complement levels may increase 10-50% in response to increased 
hepatic protein synthesis [Buyon, 1992].  
During pregnancy, C3 and C4 may rise to supranormal levels, and thus a flare with 
complement activation may occur despite apparently normal levels of C3 and C4. 
Conversely C3and C4 may be low in the absence of a flare, probably due to synthetic 
defects. However, if C3 or C4 levels drop by >25%, this may be reasonably ascribed to 
disease activity [Buyon, 1999]. Therefore, the utility of complement measurement in 
pregnancy is unclear. However, the combination of low complement levels and high-activity 
lupus leads to a 3-5-fold increase in pregnancy loss and preterm birth [Clowse, 2004].  
AITT uses the macrophage cell line (IT-1) as a substrate that is wider than the ANA test 
in clinical applications   
The anti- dsDNA titer is very sensitive for the diagnosis of lupus and can be indicative of 
increased lupus activity, especially if the kidney is involved [Ho A, 2001]. Increased dsDNA 
which is considered for diagnosis and increased activity of the disease can be seen in 43% of 
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pregnant lupus women without disease activity, but rising titers of dsDNA is suggestive of 
increased lupus activity [Table 4]. However, this antibody does not predict pregnancy 
outcomes. Instead, the combination of a positive anti-dsDNA titer and highly active SLE 
contribute toward a 4-6-fold increase in perinatal mortality and a 2-3-folds decrease in full-
term birth [Clowse, 2004].  
 




Cutaneous Inflammatory rash Cloasma or  
Palmar erythema , 
Post partum alopecia 
Musculoskeletal Inflammatory arthritis Arthralgias 
Bland effusion 
Hematological  New leucopenia 
New Thrombocytopenia  
(PLT <80,000) 
Mild anemia 
ESR up to 40 mm 
Serological  Rising titer  
anti-dsDNA 
 
   
Constitutional  Fever not due to infection Fatigue 
   
Pulmonary Pain on inspiration Mild SOB, 
Hyperventilation 2° to 
Progesterone 
Source: JP Buyon MD  Rheumatologia  2(4) 199  (2004) 
Table 4. Criteria for lupus flare 
LE cell phenomenon is seen in lupus patient's blood. LE cell test was the first autoimmune 
disease test of using this phenomenon that showed lower sensitivity and specificity. So 
HEp-2 cell using the conventional antinuclear antibody (ANA) test is currently being used 
as a standard test. However AITT uses the macrophage cell line (IT-1) as a substrate that is 
wider than the ANA test in clinical applications. 
The ESR is unreliable in pregnancy because it increases significantly in normal pregnancy 
but if it is very high (>40mm/hr) it can be taken for increased lupus activity. In non-
pregnant SLE patients, CRP may increase with a lupus flare. The use of CRP has not been 
systematically tested in SLE pregnancies [Ho A, 2001]. As CRP is not elevated in pregnancy, 
it is to be considered for increased activity of the disease. Therefore elevated CRP is a better 
indicator for increased lupus activity than elevated ESR [Ruiz, 2004; Megan, 2007]. 
In a study (Table 5), complement C3 levels were statistically significant in hematuria, 
leucopenia, hypertension, high serum CRP levels, and preterm premature rupture of 
membranes. Complement C4 levels were statistically significant in kidney disease status, 
hematologic diseases and admissions to NICU. Anti-dsDNA was statistically significant in 
oligohydramnios, elevated CRP and neonatal anti-SSB (La) antibody detection. It is helpful 
to predict neonatal diseases.  AITT is statistically significant in high ESR values and Apgar 
score. This helps to predict state of the newborn immediately after birth [II Dong Kim, 2011]. 
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Complement C3 Complement C4 Anti-dsDNA AITT 




Elevated CRP  Elevated CRP Elevated ESR 
Hypertension Proteinuria   
Hematuria Hematuria   
Premature rupture 
of Membranes  (PRM) 
Admission to NICU Oligohydramnios 1 & 5 minute 
Apgar score 
AITT=  Auto-immune Target Testing   
Table 5. Correlation of pregnancy complications with C3, C4, Anti-dsDNA and AITT  
Source: II Dong Kim et al. Korean J Obstet Gynecol 2011; 54:17-25 
In conclusion, although it is difficult to differentiate lupus activity from changes that occur 
in pregnancy, one needs to consider carefully all the above factors in a lupus pregnancy 
with high clinical suspicion of active disease for the diagnosis of increased lupus activity. 
4. Influence of pregnancy on SLE 
SLE patients suffer from different kinds of pregnancy related complications more than non-
SLE women. The following are the common pregnancy related complications. 
4.1 Hypertension 
Blood pressure levels tend to drop during pregnancy starting from the first trimester and 
increases at term.  Hypertension complicates 5% to 7% of all pregnancies. About 25% of 
lupus patients will develop hypertension and proteinuria in the second-half of pregnancy.  
In case of prior nephropathy of any type, hypertension develops in 41% of patients during 
pregnancy [How, 1985]. Pre-existing hypertension is the most common predisposing factor 
for preeclampsia. 
The risk of preterm birth, IUGR, and fetal loss, all increase in hypertensive pregnant lupus 
patients. Yasmeen, et al identified 555 deliveries in women with SLE and compared those 
pregnancy outcomes with outcomes in control group of 600,000 deliveries in women 
without SLE. The results showed that women with SLE had higher rates of adverse 
outcomes of pregnancy, including hypertensive complications, preterm delivery, cesarean 
delivery, IUGR, and fetal deaths, than did women without SLE.  The rate of hypertensive 
disorders of pregnancy were found to be 2.9% as compared to the controlled population 
which is only 0.4% [Yasmeen, 2001]. Hypertension can present in pregnancy as 
 Pregnancy-induced hypertension or gestational hypertension (blood pressure > 
140/90mmHg seen first time during pregnancy, returns to normal levels 12 weeks post 
partum)  
 Chronic hypertension (blood pressure > 140/90mmHg before pregnancy or diagnosed 
before 20 weeks of gestation or hypertension first diagnosed after 20 weeks of gestation 
and persistent after 12 weeks post partum) 
 Preeclampsia (blood pressure > 140/90mmHg after 20 weeks of gestation with  
proteinuria of  > 300mg/24hrs) 
 Eclampsia (preeclampsia with seizures) 
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pregnant lupus women without disease activity, but rising titers of dsDNA is suggestive of 
increased lupus activity [Table 4]. However, this antibody does not predict pregnancy 
outcomes. Instead, the combination of a positive anti-dsDNA titer and highly active SLE 
contribute toward a 4-6-fold increase in perinatal mortality and a 2-3-folds decrease in full-
term birth [Clowse, 2004].  
 




Cutaneous Inflammatory rash Cloasma or  
Palmar erythema , 
Post partum alopecia 
Musculoskeletal Inflammatory arthritis Arthralgias 
Bland effusion 
Hematological  New leucopenia 
New Thrombocytopenia  
(PLT <80,000) 
Mild anemia 
ESR up to 40 mm 
Serological  Rising titer  
anti-dsDNA 
 
   
Constitutional  Fever not due to infection Fatigue 
   
Pulmonary Pain on inspiration Mild SOB, 
Hyperventilation 2° to 
Progesterone 
Source: JP Buyon MD  Rheumatologia  2(4) 199  (2004) 
Table 4. Criteria for lupus flare 
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disease test of using this phenomenon that showed lower sensitivity and specificity. So 
HEp-2 cell using the conventional antinuclear antibody (ANA) test is currently being used 
as a standard test. However AITT uses the macrophage cell line (IT-1) as a substrate that is 
wider than the ANA test in clinical applications. 
The ESR is unreliable in pregnancy because it increases significantly in normal pregnancy 
but if it is very high (>40mm/hr) it can be taken for increased lupus activity. In non-
pregnant SLE patients, CRP may increase with a lupus flare. The use of CRP has not been 
systematically tested in SLE pregnancies [Ho A, 2001]. As CRP is not elevated in pregnancy, 
it is to be considered for increased activity of the disease. Therefore elevated CRP is a better 
indicator for increased lupus activity than elevated ESR [Ruiz, 2004; Megan, 2007]. 
In a study (Table 5), complement C3 levels were statistically significant in hematuria, 
leucopenia, hypertension, high serum CRP levels, and preterm premature rupture of 
membranes. Complement C4 levels were statistically significant in kidney disease status, 
hematologic diseases and admissions to NICU. Anti-dsDNA was statistically significant in 
oligohydramnios, elevated CRP and neonatal anti-SSB (La) antibody detection. It is helpful 
to predict neonatal diseases.  AITT is statistically significant in high ESR values and Apgar 
score. This helps to predict state of the newborn immediately after birth [II Dong Kim, 2011]. 
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In conclusion, although it is difficult to differentiate lupus activity from changes that occur 
in pregnancy, one needs to consider carefully all the above factors in a lupus pregnancy 
with high clinical suspicion of active disease for the diagnosis of increased lupus activity. 
4. Influence of pregnancy on SLE 
SLE patients suffer from different kinds of pregnancy related complications more than non-
SLE women. The following are the common pregnancy related complications. 
4.1 Hypertension 
Blood pressure levels tend to drop during pregnancy starting from the first trimester and 
increases at term.  Hypertension complicates 5% to 7% of all pregnancies. About 25% of 
lupus patients will develop hypertension and proteinuria in the second-half of pregnancy.  
In case of prior nephropathy of any type, hypertension develops in 41% of patients during 
pregnancy [How, 1985]. Pre-existing hypertension is the most common predisposing factor 
for preeclampsia. 
The risk of preterm birth, IUGR, and fetal loss, all increase in hypertensive pregnant lupus 
patients. Yasmeen, et al identified 555 deliveries in women with SLE and compared those 
pregnancy outcomes with outcomes in control group of 600,000 deliveries in women 
without SLE. The results showed that women with SLE had higher rates of adverse 
outcomes of pregnancy, including hypertensive complications, preterm delivery, cesarean 
delivery, IUGR, and fetal deaths, than did women without SLE.  The rate of hypertensive 
disorders of pregnancy were found to be 2.9% as compared to the controlled population 
which is only 0.4% [Yasmeen, 2001]. Hypertension can present in pregnancy as 
 Pregnancy-induced hypertension or gestational hypertension (blood pressure > 
140/90mmHg seen first time during pregnancy, returns to normal levels 12 weeks post 
partum)  
 Chronic hypertension (blood pressure > 140/90mmHg before pregnancy or diagnosed 
before 20 weeks of gestation or hypertension first diagnosed after 20 weeks of gestation 
and persistent after 12 weeks post partum) 
 Preeclampsia (blood pressure > 140/90mmHg after 20 weeks of gestation with  
proteinuria of  > 300mg/24hrs) 
 Eclampsia (preeclampsia with seizures) 
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4.2 Lupus flares 
There is conflicting data on whether SLE activity increases during pregnancy.  The risk of 
lupus flare is increased if the woman has had active lupus in the last 6 months of pregnancy. 
Therefore, inactive disease at the onset of pregnancy provides optimum protection against 
the occurrence of flare during pregnancy [Urowitz, 1993]. 
Lupus may flare during any trimester of pregnancy or post partum period.  The flares are 
usually mild mainly involving the joints, skin and blood. Some of the physiological changes 
of pregnancy can mimic the symptoms of the active disease such as palmar erythema, 
arthralgia, myalgia and lower limb edema [Table 4]. 
High prolactin levels, presence of lupus anticoagulant and increased SLE activity, have poor 
outcome in pregnancy [Jara, 2007a]. Oral Bromocriptine may play a role in the prevention of 
maternal-fetal complication such as premature rupture of membrane, preterm birth and 
active disease as reported in one of the clinical trials but this needs to be confirmed by 
further trials [Jara, 2007b]. 
The most important laboratory data to differentiate lupus flare in pregnancy from 
pregnancy changes include rising titer of anti-double strand DNA antibodies, presence of 
red blood cell casts in the urine, positive direct Coomb’s test and presence of antiplatelet 
antibody with thrombocytopenia. Complement levels can be in normal range as 
complement levels increases during pregnancy due to estrogen-induced hepatic synthesis of 
complements. 
In normal pregnancy the increased glomular filtration rate observed in the second 
trimester leads to increase in proteinuria.  Thrombocytopenia is seen in pregnancy, 
although it is generally mild and occurs only in 8% of women [Burrow, 1988].  The lupus 
activity index in pregnancy (LAI-P) scale which is a modified activity scale specific for 
pregnancy, studied by Ruiz-Irastorza G, et al showed ( LAI-P) high sensitivity to changes 
in lupus activity, and has a significant correlation with modified physician global 
assessment (M-PGA). This index has high sensitivity, specificity, predictive values, and 
likelihood ratios for diagnosing SLE flares during pregnancy and puerpurium [Riuz, 
2004].  
4.3 Preeclampsia 
SLE in general and hypertension and/or renal disease in particular were agreed upon by 
most studies to increase the risk for preeclampsia [Clowse, 2007].  Patients with class III and 
IV SLE nephritis have a significantly higher prevalence of preeclampsia (28% to 38%) as 
compared to class II or I (11.1%) or to lupus controls without nephritis (4.6%). 
It is important to differentiate isolated preeclampsia from lupus nephritis during pregnancy, 
as the corner stone in preeclampsia management is delivery of the fetus.  Preeclampsia as 
we mentioned previously is blood pressure levels of over 140/90 along with proteinuria of > 
300mg per 24 hour after 20 weeks gestation [Table 6].  Sometimes it can be associated with 
features of HELLP syndrome. If preeclampsia presents very early (< 20 weeks) one should 
look for the presence of APS (Antiphospholipid antibody syndrome).  Very severe cases of 
PET may evolve into eclampsia. 
In patients with no previous history of renal involvement and with normal baseline urinary 
parameters, preeclampsia is strongly supported by the onset of proteinuria in the third 
trimester, new onset hypertension, inactive urinary sediment, absence of anti-DNA 
antibodies and normal complements levels. 
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Anti-ds DNA Abs 
Present or Absent 
 >500 mg/24 hr if normal at 
baseline 
 Doubling if >500 mg/24 hr at 
baseline 
 Occur before 3rd trimester 
Present / Absent 
Present / Absent 
Normal or Elevated 
Low 
Rising 
Diastolic BP > 90 mm Hg 
 >300 mg/24 hr if 
normal at baseline 
 
 Occur during  
3rd trimester 





Table 6. Broad Guidelines to differentiate Lupus Nephrites from Preeclampsia (Buyon, 2004) 
Antiplatelet agents during pregnancy, particularly the use of low dose Aspirin as primary 
prevention in PET are associated with moderate but consistent reduction in the relative risk 
of premature birth before 34 weeks gestation, and of having a pregnancy without serious 
adverse outcome [Askie, 2007].  A systemic review showed that Aspirin reduces the risk of 
perinatal death and preeclampsia in women with a history of risk factors such as 
preeclampsia, chronic hypertension, diabetes, and renal disease.  Given the importance of 
these outcomes and the safety along with low cost of aspirin, low dose aspirin should be 
considered in all women with the above risk factors [Coomarasamy, 2003].  Previous studies 
have suggested that several factors, including pre-existing hypertension, renal insufficiency, 
presence of APS, and active SLE, may increase the risk of preeclampsia in pregnancies 
complicated by SLE [Mascola, 1997]. The features which differentiate preeclampsia from 
lupus nephritis are given in Table 6. 
4.4 Lupus Nephritis (LN) 
Pregnant women with long-standing LN are at risk of spontaneous abortions and increased 
perinatal mortality.  However, the outlook of pregnancy in patients with stable LN at 
conception is relatively favourable. Remission in lupus nephritis has been defined as stable 
renal function, a serum creatinine within the normal range, urinary red cells below 5/high 
power field, proteinuria below 0.5g/day and normal serum C3 levels for the last 12-18 
months (Table 6) [Gayed, 2007].   
The incidence of obstetric complications and maternal mortality is high in patients with 
active lupus nephropathy associated with pre-existing hypertension.  Pregnant women with 
LN require intense fetal and maternal surveillance for a better outcome of pregnancy 
[Rahman, 2005]. The increase in proteinuria can be secondary to the usual increase in 
glomerular filtration rate observed in the second trimester of pregnancy. Moderate renal 
impairment at the onset of pregnancy, as reflected by serum creatinine level of 120µmoles/L 
or greater, has a greater decline in renal function than would be expected in a non-pregnant 
patient for a similar time period [Hou, 1985]. 
The fetal loss in patients with active LN in pregnancy occurs in 36% to 52% of the 
pregnancies, as compared to fetal loss in pregnant patients with history of LN but with 
stable creatinine and minimal proteinuria during pregnancy, which is only 11% to 13% 
[Huong, 2001; Moroni, 2002].  A study of 24 pregnancies in 22 women with LN noticed 
 
Systemic Lupus Erythematosus 468 
4.2 Lupus flares 
There is conflicting data on whether SLE activity increases during pregnancy.  The risk of 
lupus flare is increased if the woman has had active lupus in the last 6 months of pregnancy. 
Therefore, inactive disease at the onset of pregnancy provides optimum protection against 
the occurrence of flare during pregnancy [Urowitz, 1993]. 
Lupus may flare during any trimester of pregnancy or post partum period.  The flares are 
usually mild mainly involving the joints, skin and blood. Some of the physiological changes 
of pregnancy can mimic the symptoms of the active disease such as palmar erythema, 
arthralgia, myalgia and lower limb edema [Table 4]. 
High prolactin levels, presence of lupus anticoagulant and increased SLE activity, have poor 
outcome in pregnancy [Jara, 2007a]. Oral Bromocriptine may play a role in the prevention of 
maternal-fetal complication such as premature rupture of membrane, preterm birth and 
active disease as reported in one of the clinical trials but this needs to be confirmed by 
further trials [Jara, 2007b]. 
The most important laboratory data to differentiate lupus flare in pregnancy from 
pregnancy changes include rising titer of anti-double strand DNA antibodies, presence of 
red blood cell casts in the urine, positive direct Coomb’s test and presence of antiplatelet 
antibody with thrombocytopenia. Complement levels can be in normal range as 
complement levels increases during pregnancy due to estrogen-induced hepatic synthesis of 
complements. 
In normal pregnancy the increased glomular filtration rate observed in the second 
trimester leads to increase in proteinuria.  Thrombocytopenia is seen in pregnancy, 
although it is generally mild and occurs only in 8% of women [Burrow, 1988].  The lupus 
activity index in pregnancy (LAI-P) scale which is a modified activity scale specific for 
pregnancy, studied by Ruiz-Irastorza G, et al showed ( LAI-P) high sensitivity to changes 
in lupus activity, and has a significant correlation with modified physician global 
assessment (M-PGA). This index has high sensitivity, specificity, predictive values, and 
likelihood ratios for diagnosing SLE flares during pregnancy and puerpurium [Riuz, 
2004].  
4.3 Preeclampsia 
SLE in general and hypertension and/or renal disease in particular were agreed upon by 
most studies to increase the risk for preeclampsia [Clowse, 2007].  Patients with class III and 
IV SLE nephritis have a significantly higher prevalence of preeclampsia (28% to 38%) as 
compared to class II or I (11.1%) or to lupus controls without nephritis (4.6%). 
It is important to differentiate isolated preeclampsia from lupus nephritis during pregnancy, 
as the corner stone in preeclampsia management is delivery of the fetus.  Preeclampsia as 
we mentioned previously is blood pressure levels of over 140/90 along with proteinuria of > 
300mg per 24 hour after 20 weeks gestation [Table 6].  Sometimes it can be associated with 
features of HELLP syndrome. If preeclampsia presents very early (< 20 weeks) one should 
look for the presence of APS (Antiphospholipid antibody syndrome).  Very severe cases of 
PET may evolve into eclampsia. 
In patients with no previous history of renal involvement and with normal baseline urinary 
parameters, preeclampsia is strongly supported by the onset of proteinuria in the third 
trimester, new onset hypertension, inactive urinary sediment, absence of anti-DNA 
antibodies and normal complements levels. 
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Antiplatelet agents during pregnancy, particularly the use of low dose Aspirin as primary 
prevention in PET are associated with moderate but consistent reduction in the relative risk 
of premature birth before 34 weeks gestation, and of having a pregnancy without serious 
adverse outcome [Askie, 2007].  A systemic review showed that Aspirin reduces the risk of 
perinatal death and preeclampsia in women with a history of risk factors such as 
preeclampsia, chronic hypertension, diabetes, and renal disease.  Given the importance of 
these outcomes and the safety along with low cost of aspirin, low dose aspirin should be 
considered in all women with the above risk factors [Coomarasamy, 2003].  Previous studies 
have suggested that several factors, including pre-existing hypertension, renal insufficiency, 
presence of APS, and active SLE, may increase the risk of preeclampsia in pregnancies 
complicated by SLE [Mascola, 1997]. The features which differentiate preeclampsia from 
lupus nephritis are given in Table 6. 
4.4 Lupus Nephritis (LN) 
Pregnant women with long-standing LN are at risk of spontaneous abortions and increased 
perinatal mortality.  However, the outlook of pregnancy in patients with stable LN at 
conception is relatively favourable. Remission in lupus nephritis has been defined as stable 
renal function, a serum creatinine within the normal range, urinary red cells below 5/high 
power field, proteinuria below 0.5g/day and normal serum C3 levels for the last 12-18 
months (Table 6) [Gayed, 2007].   
The incidence of obstetric complications and maternal mortality is high in patients with 
active lupus nephropathy associated with pre-existing hypertension.  Pregnant women with 
LN require intense fetal and maternal surveillance for a better outcome of pregnancy 
[Rahman, 2005]. The increase in proteinuria can be secondary to the usual increase in 
glomerular filtration rate observed in the second trimester of pregnancy. Moderate renal 
impairment at the onset of pregnancy, as reflected by serum creatinine level of 120µmoles/L 
or greater, has a greater decline in renal function than would be expected in a non-pregnant 
patient for a similar time period [Hou, 1985]. 
The fetal loss in patients with active LN in pregnancy occurs in 36% to 52% of the 
pregnancies, as compared to fetal loss in pregnant patients with history of LN but with 
stable creatinine and minimal proteinuria during pregnancy, which is only 11% to 13% 
[Huong, 2001; Moroni, 2002].  A study of 24 pregnancies in 22 women with LN noticed 
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flares in 50% with proteinuria, 42% with hypertension, and 25% with preeclampsia 
[Soubassi, 2004].  Lupus nephritis flare can be associated with other evidence of active lupus 
such as serositis, arthritis, and high titers of anti-DNA antibodies. The proteinuria of 
preeclampsia decreases after delivery but not that of active lupus patient. 
4.5 Thrombocytopenia  
It is not unusual to see this in pregnancy. It is encountered in at least 8% of all pregnancies.  
In gestational thrombocytopenia, the degree of thrombocytopenia is usually mild, with no 
history of bleeding or preconception history of thrombocytopenia. The platelet count 
usually returns to normal within 2-12 weeks post partum [Jeffrey, 2002].  Also, 
thrombocytopenia may occur for a variety of reasons in pregnancy such as SLE, APS, 
HELLP or medication particularly Heparin or expanding of circulatory volume.  
4.6 Other complications   
Pregnant lupus patients can face other problems like HELLP syndrome (Hemolysis Elevated 
Liver enzymes and Low Platelets) and Gestational diabetes [Joya, 2010, Josephine, 2006]. 
5. Influence of SLE on pregnancy  
5.1 Effect on fertility 
Systemic lupus erythematosus (SLE) is not known to affect the fertility directly and 
therefore SLE patients are as fertile as any other female in general population [Kamashta, 
1996]. Lowered fertility rate is seen in patients with active disease on high dose steroids, 
patients with established renal disease and moderate to severe renal failure [Hou, 1975].  
End-stage renal disease secondary to lupus nephritis can result in amenorrhea, although 
amenorrhea in renal patients may also be due to ovarian failure secondary to 
cyclophosphamide or of auto-immune origin [Kong, 2006]. 
5.2 Effect of flare on conception 
SLE patients can experience disease flare at anytime during pregnancy with potential 
negative effects on the conception.  Lupus flares occur more during pregnancy and post 
partum period in SLE patients than non-SLE pregnant patients [Petri, 1991].  Increased 
lupus activity is seen after pregnancy in 1/3 of cases [Seng, 2008]. Therefore, for better 
outcome of lupus pregnancy it is essential to control disease activity and achieve clinical 
remission at least 6 months before pregnancy [Georgion, 2000]. 
Exacerbations or relapses occur during the course of pregnancy and immediate post partum 
period in 25% to 60% of cases.  However, the likelihood of increased clinical activity of SLE 
during pregnancy is influenced by signs of activity present at onset of pregnancy.  In the 
absence of signs of clinical activity for at least 6 months before conception, relapses occur 
only in one-third of cases, whereas in patients with clinical activity at onset of pregnancy, 
persistent activity or exacerbations occur in approximately two-thirds. 
Fetal survival in these patients parallels with the incidence of SLE activity: Hence fetal 
survival is seen in 85% to 95% in the group with inactive disease at conception and 50% to 
80% in subjects with active disease at the onset of pregnancy [Weyslett, 1991]. More recent 
studies have shown a 2-3 fold increase in SLE activity during pregnancy [Rehman, 2005]. 
Adverse live-birth outcome was significantly associated with low pre-gestational serum 
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albumin level, elevated gestational anti-ds DNA antibody, and diabetes mellitus.  
Spontaneous abortion was directly associated with low levels of pre-gestational serum 
albumin, positive anticardiolipin IgA, anti-B2-glycoprotein IgM, and anti-La antibodies. 
 
Complication Moderate to severely active SLE (n=57) 
Inactive or mildly 
active SLE (n=210) 
P-
value 
Miscarriage 7% 7% 0.9 
Stillbirth: 16% 5% <0.01 
Extreme Preterm (<28 weeks 
gestation) 17% 6% 0.09 
Late Preterm (28 to 37 weeks 
gestation) 49% 26% <0.001 
Small for gestational age baby (<10th 
percentile weight for gestational age) 30% 21% 0.23 
Table 7. Increased Lupus Activity in Pregnancy Increases Pregnancy Complications 
(Data from Clowse MEB et al. The impact of increased lupus activity on obstetric outcomes. 
Arthritis Rheum, 2005. 52(2): p. 514–21) 
5.3 Effect of lupus nephritis  
The obstetric complications and maternal mortality is high in patients with active lupus 
nephropathy associated with pre-existing hypertension [Rahman, 2005]. Pregnant women 
with long-standing lupus nephritis are at high risk of spontaneous abortions and increased 
perinatal mortality. However, the outlook of pregnancy in patients with stable lupus 
nephritis at conception is relatively favorable [Table 7]. Patients with the combination of 
either high clinical activity of SLE and low complement or positive anti-ds DNA had the 
highest rate of pregnancy loss and preterm birth [Clowse, 2011]. 
Female recipients transplanted for renal failure secondary to lupus nephritis can maintain 
pregnancy successfully. Outcomes are comparable to renal recipients with other diagnoses.  
Newborns in both groups were often premature and had low birth weight [McGrory, 2003].  
The second trimester Doppler ultrasound examination is the best predictor of late 
pregnancy outcome in systemic lupus erythematosus and/or the anti-phospholipids 
syndrome [Lethi, 2006]. 
Management of pregnant women with renal disease involves awareness of physiological 
changes such as decreased serum creatinine and increased proteinuria. Worsening 
proteinuria may be due to lupus flare but differential diagnosis also includes preeclampsia.  
In fact, women with severe renal impairment (serum creatinine over 300µmols/L) have a 
chance lower than 30% of having successful pregnancy [Germin, 2006]. 
5.4 Effect of Antiphospholipid Syndrome (APS) 
Anti-phospholipids antibodies (APL), which include lupus anti-coagulant (LAC),  
anti-cardiolipin antibodies (ACL), and B2glycoprotein are frequently found in patients with 
SLE, and their presence has been associated with increased fetal loss. If APL are present,  
the fetuses are susceptible to placental insufficiency. APL but not anti-Ro and anti-La  
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End-stage renal disease secondary to lupus nephritis can result in amenorrhea, although 
amenorrhea in renal patients may also be due to ovarian failure secondary to 
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5.2 Effect of flare on conception 
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partum period in SLE patients than non-SLE pregnant patients [Petri, 1991].  Increased 
lupus activity is seen after pregnancy in 1/3 of cases [Seng, 2008]. Therefore, for better 
outcome of lupus pregnancy it is essential to control disease activity and achieve clinical 
remission at least 6 months before pregnancy [Georgion, 2000]. 
Exacerbations or relapses occur during the course of pregnancy and immediate post partum 
period in 25% to 60% of cases.  However, the likelihood of increased clinical activity of SLE 
during pregnancy is influenced by signs of activity present at onset of pregnancy.  In the 
absence of signs of clinical activity for at least 6 months before conception, relapses occur 
only in one-third of cases, whereas in patients with clinical activity at onset of pregnancy, 
persistent activity or exacerbations occur in approximately two-thirds. 
Fetal survival in these patients parallels with the incidence of SLE activity: Hence fetal 
survival is seen in 85% to 95% in the group with inactive disease at conception and 50% to 
80% in subjects with active disease at the onset of pregnancy [Weyslett, 1991]. More recent 
studies have shown a 2-3 fold increase in SLE activity during pregnancy [Rehman, 2005]. 
Adverse live-birth outcome was significantly associated with low pre-gestational serum 
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albumin, positive anticardiolipin IgA, anti-B2-glycoprotein IgM, and anti-La antibodies. 
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The obstetric complications and maternal mortality is high in patients with active lupus 
nephropathy associated with pre-existing hypertension [Rahman, 2005]. Pregnant women 
with long-standing lupus nephritis are at high risk of spontaneous abortions and increased 
perinatal mortality. However, the outlook of pregnancy in patients with stable lupus 
nephritis at conception is relatively favorable [Table 7]. Patients with the combination of 
either high clinical activity of SLE and low complement or positive anti-ds DNA had the 
highest rate of pregnancy loss and preterm birth [Clowse, 2011]. 
Female recipients transplanted for renal failure secondary to lupus nephritis can maintain 
pregnancy successfully. Outcomes are comparable to renal recipients with other diagnoses.  
Newborns in both groups were often premature and had low birth weight [McGrory, 2003].  
The second trimester Doppler ultrasound examination is the best predictor of late 
pregnancy outcome in systemic lupus erythematosus and/or the anti-phospholipids 
syndrome [Lethi, 2006]. 
Management of pregnant women with renal disease involves awareness of physiological 
changes such as decreased serum creatinine and increased proteinuria. Worsening 
proteinuria may be due to lupus flare but differential diagnosis also includes preeclampsia.  
In fact, women with severe renal impairment (serum creatinine over 300µmols/L) have a 
chance lower than 30% of having successful pregnancy [Germin, 2006]. 
5.4 Effect of Antiphospholipid Syndrome (APS) 
Anti-phospholipids antibodies (APL), which include lupus anti-coagulant (LAC),  
anti-cardiolipin antibodies (ACL), and B2glycoprotein are frequently found in patients with 
SLE, and their presence has been associated with increased fetal loss. If APL are present,  
the fetuses are susceptible to placental insufficiency. APL but not anti-Ro and anti-La  
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Term Definition 
Spontaneous abortions or miscarriages Pregnancy loss <20 weeks of gestation 
Recurrent abortion  or recurrent 
miscarriages 
≥3 spontaneous abortions 
Fetal loss Pregnancy loss from 10 weeks of gestation and 
onwards 
Intrauterine fetal demise (IUFD) or 
stillbirth 
Fetal death occurring at ≥20 weeks of gestation 
Fetal wastage Sum of spontaneous abortions and stillbirths 
Neonatal death Infant born live but died up to 28 days after birth 
Small for gestational age Birth weight <10th percentile 
Low birth weight Birth weight <2500 g 
Very low birth weight Birth weight <1500 g 
Preterm birth or prematurity Gestational age <37 weeks 
Table 8. Adverse pregnancy outcomes  
(Data from Josephine P et al-Lupus and pregnancy: complex yet manageable  
Clin Med Res 2006 Dec; 4(4):310-321) 
antibodies might have a role in direct placental damage. The levels of β-hCG are reduced in 
women with history of recurrent pregnancy loss or thromboembolic  events. High titers of 
APL were found to cause the largest reduction in β-hCG. Anti-Ro and anti-La did not 
induce placental damage [Schwartz, 2007]. APL also have direct effect on trophoblast 
possibly through exposed anionic phospholipids and/ or adherent B2glycoprotein “B2GP1”, 
resulting in altered trophoblast intercellular fusion, gonadotropin secretion and trophoblast 
invasiveness [Di Simone, 2005]. 
Typical fetal loss secondary to APS is characterized by progressive intrauterine growth 
restriction (IUGR) ultimately leading to fetal death [Birdsall, 1996].  Both early and late fetal 
deaths are associated with APS [Rai, 1995].  The live birth of an APS pregnancy rate 
increased from 19% in untreated patients to 70% in treated patients [Lima, 1996].  The risk of 
pregnancy loss in women with anti-phospholipids antibodies (APL) and with a previous 
pregnancy loss has been estimated at over 60%. APS pregnancy is not without complications 
in the mother [Table 9]. 
Beside those already mentioned, pregnancy confers a higher risk of thrombosis in women 
who are already at increased risk or with a past history of thrombotic events [Branch, 1992]. 
The incidence of extensive infarction, decidual vasculopathy, decidual thrombosis and 
perivillous fibrinoid change, which have been thought to be characteristic lesions of APS 
placenta, was significantly higher in LAC, or ACL or both LAC & ACL positive patients 
than in the patients without APL.  LAC and ACL double-positivity is an important risk 
factor for fetal death in the SLE patient [Petri, 2004; Ogishima, 2000]. 
As the placenta positive for IgG-APL showed pathogenic findings such as infarction, 
degeneration, thrombus formation and fibrinoid deposits, it is suggested that IgG-APL 
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bound to the placental tissue might cause direct pathologic damage to the placenta which 
results in IUFD, or IUGR by uteroplacental insufficiency [Katoro, 1995]. 
 
Fetal Risks Maternal Risks 
 Recurrent miscarriage (first and 
second trimester)  Thrombosis 
 Intrauterine growth restriction  Severe early onset preeclampsia 
 Fetal death   Preterm labour, rupture of membranes 
 Premature delivery  Worsening of pre-existing thrombocytopenia 
 Congenital malformations/ 
intracerebral haemorrhage  
(If Warfarin is administered) 
 Placental abruption 
 Other bleeding complications 
Table 9. Obstetric risks associated with anti-phospholipid syndrome 
(Adapted from S Stone, MA Khamashta, and L Poston [Stone, 2001]) 
Fetal risk had been reduced progressively in the past 40 years.  Although it still continues to 
be higher than that occurring in pregnancies of healthy women. The presence of APL 
considerably worsens the fetal outcome [Moroni, 2005]. It is suggested that patients with 
early-onset severe preeclampsia be screened for APL, if antibodies are detected, then these 
women should be considered for prophylactic anticoagulation therapy [Branch, 1989]. 
A retrospective case-control study of 242 pregnancies in 112 patients concluded that the risk 
of fetal loss in SLE is 2.5 times higher than that in the normal population.  The presence of 
LAC indicated a high risk of fetal loss, while the absence of APL is an indication of a 
favorable pregnancy outcome.  No individual APL test seems to be clearly superior to the 
others to detect patients at high risk for fetal loss.  However, by combining ACL with LAC, a 
reasonably good sensitivity and specificity can be achieved.  Regardless of APL, infants of 
women with SLE are born more prematurely and are more retarded in growth than the 
infants in the normal population.  Thus, factors other than APL also contribute to the 
adverse fetal outcome in lupus pregnancy [Heikki, 1993]. 
5.5 Effect of anti-ro/and or anti-la antibodies 
SLE is the most recognized Rheumatic disease in which auto antibodies, anti-Ro and/or 
anti-La can pass from the mother to the fetus across the placenta during pregnancy. Anti-
Ro/SSA antibodies are associated with neonatal lupus but do not negatively affect other 
gestational outcomes, and the general outcome of these pregnancies is now good.  A large 
multi-centers cohort prospective controlled study of 100 anti-Ro/SSA positive women 
concluded that anti-Ro/SSA antibodies are responsible for congenital heart block but do not  
affect other outcomes of pregnancy, both in SLE and non-SLE women.   
The general outcome for these pregnancies is now very good, if prospectively followed by 
multidisciplinary teams [Antonio, 2011; Brucato, 2002], although various studies considered 
the anti-Ro/SSA antibody as a possible causative factor for unexplained pregnancy loss.  A 
significant greater fetal wastage is seen in black anti-Ro (SSA) positive women as compared 
to black anti-RNP positive women.  No significant difference in fetal wastage was noted 
between the white SLE and the non-SLE women in either antibody group. These data 
suggest that black SLE patients with anti-Ro (SSA) antibody may be at increased risk of fetal 
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antibodies might have a role in direct placental damage. The levels of β-hCG are reduced in 
women with history of recurrent pregnancy loss or thromboembolic  events. High titers of 
APL were found to cause the largest reduction in β-hCG. Anti-Ro and anti-La did not 
induce placental damage [Schwartz, 2007]. APL also have direct effect on trophoblast 
possibly through exposed anionic phospholipids and/ or adherent B2glycoprotein “B2GP1”, 
resulting in altered trophoblast intercellular fusion, gonadotropin secretion and trophoblast 
invasiveness [Di Simone, 2005]. 
Typical fetal loss secondary to APS is characterized by progressive intrauterine growth 
restriction (IUGR) ultimately leading to fetal death [Birdsall, 1996].  Both early and late fetal 
deaths are associated with APS [Rai, 1995].  The live birth of an APS pregnancy rate 
increased from 19% in untreated patients to 70% in treated patients [Lima, 1996].  The risk of 
pregnancy loss in women with anti-phospholipids antibodies (APL) and with a previous 
pregnancy loss has been estimated at over 60%. APS pregnancy is not without complications 
in the mother [Table 9]. 
Beside those already mentioned, pregnancy confers a higher risk of thrombosis in women 
who are already at increased risk or with a past history of thrombotic events [Branch, 1992]. 
The incidence of extensive infarction, decidual vasculopathy, decidual thrombosis and 
perivillous fibrinoid change, which have been thought to be characteristic lesions of APS 
placenta, was significantly higher in LAC, or ACL or both LAC & ACL positive patients 
than in the patients without APL.  LAC and ACL double-positivity is an important risk 
factor for fetal death in the SLE patient [Petri, 2004; Ogishima, 2000]. 
As the placenta positive for IgG-APL showed pathogenic findings such as infarction, 
degeneration, thrombus formation and fibrinoid deposits, it is suggested that IgG-APL 
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bound to the placental tissue might cause direct pathologic damage to the placenta which 
results in IUFD, or IUGR by uteroplacental insufficiency [Katoro, 1995]. 
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(Adapted from S Stone, MA Khamashta, and L Poston [Stone, 2001]) 
Fetal risk had been reduced progressively in the past 40 years.  Although it still continues to 
be higher than that occurring in pregnancies of healthy women. The presence of APL 
considerably worsens the fetal outcome [Moroni, 2005]. It is suggested that patients with 
early-onset severe preeclampsia be screened for APL, if antibodies are detected, then these 
women should be considered for prophylactic anticoagulation therapy [Branch, 1989]. 
A retrospective case-control study of 242 pregnancies in 112 patients concluded that the risk 
of fetal loss in SLE is 2.5 times higher than that in the normal population.  The presence of 
LAC indicated a high risk of fetal loss, while the absence of APL is an indication of a 
favorable pregnancy outcome.  No individual APL test seems to be clearly superior to the 
others to detect patients at high risk for fetal loss.  However, by combining ACL with LAC, a 
reasonably good sensitivity and specificity can be achieved.  Regardless of APL, infants of 
women with SLE are born more prematurely and are more retarded in growth than the 
infants in the normal population.  Thus, factors other than APL also contribute to the 
adverse fetal outcome in lupus pregnancy [Heikki, 1993]. 
5.5 Effect of anti-ro/and or anti-la antibodies 
SLE is the most recognized Rheumatic disease in which auto antibodies, anti-Ro and/or 
anti-La can pass from the mother to the fetus across the placenta during pregnancy. Anti-
Ro/SSA antibodies are associated with neonatal lupus but do not negatively affect other 
gestational outcomes, and the general outcome of these pregnancies is now good.  A large 
multi-centers cohort prospective controlled study of 100 anti-Ro/SSA positive women 
concluded that anti-Ro/SSA antibodies are responsible for congenital heart block but do not  
affect other outcomes of pregnancy, both in SLE and non-SLE women.   
The general outcome for these pregnancies is now very good, if prospectively followed by 
multidisciplinary teams [Antonio, 2011; Brucato, 2002], although various studies considered 
the anti-Ro/SSA antibody as a possible causative factor for unexplained pregnancy loss.  A 
significant greater fetal wastage is seen in black anti-Ro (SSA) positive women as compared 
to black anti-RNP positive women.  No significant difference in fetal wastage was noted 
between the white SLE and the non-SLE women in either antibody group. These data 
suggest that black SLE patients with anti-Ro (SSA) antibody may be at increased risk of fetal 
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wastage [Watson, 1986].  Hull et al reported three SLE patients with anti-Ro/SSA and a 
history of spontaneous abortions [Hull, 1983]. 
Ro52, Ro60 and La IgG antibodies all are transferred from the mothers to their fetus in utero 
and were present in the infant at birth as detected by enzyme-linked immunosorbent assay 
using recombinant antigens and a synthetic peptide.  A significant decrease in Ro52, Ro60 
and LA IgG auto antibody levels the infants was observed from birth to 4-5 weeks of the 
age. Ro- and La-specific IgA and IgM antibodies were detected in the serum from a subset of 
mothers.  However, Ro- and La-specific IgA and IgM antibody levels were low or non-
detectable in children raised both with and without breastfeeding.  These findings support a 
role for placental materno-fetal transfer of the IgG auto antibodies in the pathogenesis of 
neonatal lupus erythematosus (NLE) and indicate that refraining from breast-feeding does 
not protect from NLE skin involvement [Klauinger, 2009]. 
Studies focusing on the neuropsychological development of SLE offspring show an 
increased number of learning disabilities in children with normal intelligence levels.  The 
presence of anti-Ro/La antibodies and disease activity (flare) in mothers during pregnancy 
were significantly related to higher prevalence of learning disabilities in offspring.  Mainly 
sons of women with SLE were significantly more likely to have learning disabilities than 
daughters of women with SLE or children of either sex in the control group as these 
maternal antibodies likely affect the fetal brain of male offspring and result in later learning 
problems.  These findings should promote greater awareness and early educational 
intervention in those children [Ross, 2003].  
5.6 Other risks  
Prospective studies indicate that the majority of lupus mothers can sustain pregnancy 
without detrimental effects, provided that the pregnancy is planned during the inactive 
phase of the disease.  Nevertheless the fetal risk, although progressively reduced during the 
last 40 years, continues to be higher, particularly in patients with anti-phospholipids 
antibodies (APL), than in pregnancies in healthy women [Moroni, 2003]. 
Premature rupture of membranes (PROM) is more common in pregnancies occurring in 
women with SLE which is the major etiology for preterm births [Johnson, 1995]. SLE is 
associated with increased risk of spontaneous abortion (pregnancy loss prior to 20 weeks 
gestation), preeclampsia, stillbirth (pregnancy loss after 20 weeks gestation), premature 
rupture of membrane (PROM), intrauterine growth restriction and fetal death. 
The risk of thrombosis, infection, thrombocytopenia and requirement for transfusions is 
higher in women with SLE.  Lupus patients also have a higher risk for cesarean sections, 
preeclampsia, and are also more likely to have other medical conditions like diabetes, 
hypertension, and thrombophilia which are also associated with adverse pregnancy 
[Clowse, 2008]. 
SLE women belong to category of high-risk pregnancy.  Highly active lupus during 
pregnancy leads to increased premature birth and a decrease in live births, with almost one-
quarter of these pregnancies resulting in fetal loss.  The Hopkins Lupus Center Database has 
identified a combination of two factors: high clinical activity and serologic activity. These 
two are very important factors which predict preterm birth.  Pregnancies in lupus patients 
must be closely watched and treated during all the three trimesters to improve pregnancy 
outcomes [Urowitz,1993; Chandran, 2005]. 
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6. Conclusion  
SLE is a chronic multisystem disease occurring in young women in their childbearing  
age. And therefore, the collaboration of rheumatologist and obstetrician who are 
experienced in high risk pregnancies management, are essential for managing these 
women with lupus who becomes pregnant to have a successful outcome as these women 
already have high risk in terms of fetal loss and spontaneous abortions [Georgion, 2000]. 
The manifestations of normal pregnancy can be mistaken as signs of lupus activity 
making the diagnosis and treatment challenging. Therefore, understanding of pregnancy 
and lupus interaction has resulted in better methods of monitoring and treating this 
particular clinical situation. 
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wastage [Watson, 1986].  Hull et al reported three SLE patients with anti-Ro/SSA and a 
history of spontaneous abortions [Hull, 1983]. 
Ro52, Ro60 and La IgG antibodies all are transferred from the mothers to their fetus in utero 
and were present in the infant at birth as detected by enzyme-linked immunosorbent assay 
using recombinant antigens and a synthetic peptide.  A significant decrease in Ro52, Ro60 
and LA IgG auto antibody levels the infants was observed from birth to 4-5 weeks of the 
age. Ro- and La-specific IgA and IgM antibodies were detected in the serum from a subset of 
mothers.  However, Ro- and La-specific IgA and IgM antibody levels were low or non-
detectable in children raised both with and without breastfeeding.  These findings support a 
role for placental materno-fetal transfer of the IgG auto antibodies in the pathogenesis of 
neonatal lupus erythematosus (NLE) and indicate that refraining from breast-feeding does 
not protect from NLE skin involvement [Klauinger, 2009]. 
Studies focusing on the neuropsychological development of SLE offspring show an 
increased number of learning disabilities in children with normal intelligence levels.  The 
presence of anti-Ro/La antibodies and disease activity (flare) in mothers during pregnancy 
were significantly related to higher prevalence of learning disabilities in offspring.  Mainly 
sons of women with SLE were significantly more likely to have learning disabilities than 
daughters of women with SLE or children of either sex in the control group as these 
maternal antibodies likely affect the fetal brain of male offspring and result in later learning 
problems.  These findings should promote greater awareness and early educational 
intervention in those children [Ross, 2003].  
5.6 Other risks  
Prospective studies indicate that the majority of lupus mothers can sustain pregnancy 
without detrimental effects, provided that the pregnancy is planned during the inactive 
phase of the disease.  Nevertheless the fetal risk, although progressively reduced during the 
last 40 years, continues to be higher, particularly in patients with anti-phospholipids 
antibodies (APL), than in pregnancies in healthy women [Moroni, 2003]. 
Premature rupture of membranes (PROM) is more common in pregnancies occurring in 
women with SLE which is the major etiology for preterm births [Johnson, 1995]. SLE is 
associated with increased risk of spontaneous abortion (pregnancy loss prior to 20 weeks 
gestation), preeclampsia, stillbirth (pregnancy loss after 20 weeks gestation), premature 
rupture of membrane (PROM), intrauterine growth restriction and fetal death. 
The risk of thrombosis, infection, thrombocytopenia and requirement for transfusions is 
higher in women with SLE.  Lupus patients also have a higher risk for cesarean sections, 
preeclampsia, and are also more likely to have other medical conditions like diabetes, 
hypertension, and thrombophilia which are also associated with adverse pregnancy 
[Clowse, 2008]. 
SLE women belong to category of high-risk pregnancy.  Highly active lupus during 
pregnancy leads to increased premature birth and a decrease in live births, with almost one-
quarter of these pregnancies resulting in fetal loss.  The Hopkins Lupus Center Database has 
identified a combination of two factors: high clinical activity and serologic activity. These 
two are very important factors which predict preterm birth.  Pregnancies in lupus patients 
must be closely watched and treated during all the three trimesters to improve pregnancy 
outcomes [Urowitz,1993; Chandran, 2005]. 
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6. Conclusion  
SLE is a chronic multisystem disease occurring in young women in their childbearing  
age. And therefore, the collaboration of rheumatologist and obstetrician who are 
experienced in high risk pregnancies management, are essential for managing these 
women with lupus who becomes pregnant to have a successful outcome as these women 
already have high risk in terms of fetal loss and spontaneous abortions [Georgion, 2000]. 
The manifestations of normal pregnancy can be mistaken as signs of lupus activity 
making the diagnosis and treatment challenging. Therefore, understanding of pregnancy 
and lupus interaction has resulted in better methods of monitoring and treating this 
particular clinical situation. 
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1. Introduction 
The initiating point to manage pregnancy in lupus patient is ideally before the onset of 
pregnancy. Therefore, at preconception counseling, the physician not only estimates the risk 
profile of the patients but also reviews their drugs. This is to avoid known teratogenic 
drugs, to discontinue certain medications and to initiate other drugs as a golden goal to 
protect the mother and fetus from adverse effects of these medications. Hence, it is essential 
to observe the mother at least six months before attempting conception for a better outcome 
in lupus pregnancy. 
The management of SLE pregnancy should be a multidisciplinary approach and needs 
good coordination and follow-ups with experts in the field like rheumatologist, 
obstetrician who is experienced in dealing with high risk pregnancies and nephrologist if 
the renal impairment is also present. Therefore, all lupus pregnancies should be closely 
monitored. 
This chapter covers general guidelines for the management of SLE during Pregnancy and 
post partum period in addition to safety of contraceptive methods in lupus women. 
2. Management issues  
Once the pregnancy test results are positive we should have a baseline evaluation of the 
disease activity, its severity and major organ involvement [Table1]. 
 Prenatal care visits: Every 4 weeks up to 20 weeks, then every 2 weeks until 28 weeks, 
then weekly until delivery. 
SLE presents several challenges in managing a pregnant woman and her fetus, as SLE 
affects almost every organ system in the body and shows a broad spectrum of disease 
manifestations ranging from mild to life-threatening conditions [Boumpas, 1995]. 
Due to the improvement of treatment modalities more and more women with this disease 
are able to become pregnant.  Pregnancy outcomes have improved dramatically over the last 
40 years, with a decrease in pregnancy loss rate from a mean of 43%   in 1960-1965 to 17%  
in 2000 - 2003 [Clark, 2005]. 
Pregnant patients with SLE on immunosuppressive therapy need prophylaxis for infection, 
(including antibiotics for invasive procedures), and immunization with influenza & 
pneumococcal vaccine.  
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  Baseline CBC, electrolytes, serum creatinine, liver enzymes, uric acid. 
 Fasting blood glucose, fasting lipid profile if at high risk, for example if 
patient is nephritic or on steroids 
 Normal antenatal check up 
 ANA, Anti-DsDNA, anti-Ro and anti-La, antibody titers 
 Complements levels (C3,C4,CH50) 
 Anticardiolipin antibodies, lupus anticoagulant and β2 glycoprotein 














  Baseline laboratory studies 
 Anti-DsDNA 
 Complements levels (C3,C4,CH50) , urinalysis 
 Obstetric ultrasound: Every 4 weeks from 20 weeks of gestation until 
delivery “to monitor fetal growth” 
 Mother with positive Anti-Ro and/or Anti-La antibodies, serial fetal 












  Repeat laboratory studies  
 Urinalysis, 24-hour urine protein collection if proteinuria is present 
 Weekly fetal non-stress test (NST) and/or biophysical profile (BPP) scoring 
from 28 weeks gestation 




 Careful blood pressure measurement 
 Urine dipstick for proteinuria 
Table 1. Guidelines for assessment of pregnant patients with lupus 
2.1 Safety of medications 
SLE is common in women of childbearing age. Physicians should be aware of which 
medications to be used safely at preconception & conception, and effects on infants exposed 
to certain drugs. 
The Food and Drug Administration (FDA) has a classification system for pregnancy risk 
(Table 2). The pharmacological management of SLE is challenging as it has an unpredictable 
clinical course, with the variable organ system involvement and the lack of clear 
understanding of disease pathogenesis [Francis L, 2009].  
2.1.1 Antihypertensive drugs 
Hypertensive disorders of pregnancy are the leading cause of maternal mortality and 
morbidity.  Blood pressure tends to decrease in the first and second trimesters of pregnancy.  
The most appropriate blood pressure threshold and goal of antihypertensive treatment are 
controversial.  For women with severe hypertension (defined as a sustained systolic BP of 
>160mmHg and/or a diastolic BP of > 110mmHg), there is consensus that antihypertensive 
therapy should be given to lower the maternal risk of central nervous system complications.  
The target BP of safety in Pregnancy is less than 140/90 mm of Hg. 
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                           United States FDA Pharmaceutical Pregnancy Categories 
Pregnancy 
Category A 
Adequate and well-controlled human studies have failed to demonstrate a 
risk to the fetus in the first trimester of pregnancy (and there is no evidence 
of risk in later trimesters). 
Pregnancy 
Category B 
Animal reproduction studies have failed to demonstrate a risk to the fetus 
and there are no adequate and well-controlled studies in pregnant women 
OR Animal studies have shown an adverse effect, but adequate and well-
controlled studies in pregnant women have failed to demonstrate a risk to 
the fetus in any trimester. 
Pregnancy 
Category C 
Animal reproduction studies have shown an adverse effect on the fetus and 
there are no adequate and well-controlled studies in humans, but potential 




There is positive evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience or studies in humans, but 




Studies in animals or humans have demonstrated fetal abnormalities and/or 
there is positive evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience, and the risks involved in use 
of the drug in pregnant women clearly outweigh potential benefits. 
Table 2. United States FDA pharmaceutical pregnancy categories 
The bulk of evidence relates to use of parenteral hydralazine or labetalol, and oral 
nifedipine, labetalol or methyldopa [Magee, 2011].  It is essential to keep the blood pressure 
in the normal range.  Patients with new onset hypertension in pregnancy should be 
evaluated for PET. The medications that are best studied are methyldopa and labetalol.  
Methyldopa is the only antihypertensive agent for which there has been long-term follow-
up of children exposed in utero [Antonio, 2011]. 
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers should be 
avoided prior to conception as they are contraindicated and cannot be considered safe. And 
these drugs are also associated with higher incidence of fetopathy [Cooper, 2006]. 
2.1.2 Aspirin  
Treatment with low doses of Aspirin during pregnancy would be indicated in women  
with SLE, APS, hypertension, history of preeclampsia, and renal disease. Aspirin can cross 
the placenta and can cause congenital anomalies in animals but these are rare in human 
beings. Several large prospective studies failed to confirm a significant increase in  
cleft palate or congenital anomalies [Jick, 1981].  Low dose of Aspirin is safe throughout 
pregnancy. Women who took Aspirin had a significantly lower risk of preterm delivery than 
those treated with placebo but there is no significant difference in perinatal mortality 
[Kozer, 2003]. 
A meta-analysis showed reduction in the risk of preeclampsia, preterm delivery before 34 
weeks of gestation and serious adverse outcomes among women taking low-dose Aspirin or 
dipyridamole [Aski, 2007]. 
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risk to the fetus in the first trimester of pregnancy (and there is no evidence 
of risk in later trimesters). 
Pregnancy 
Category B 
Animal reproduction studies have failed to demonstrate a risk to the fetus 
and there are no adequate and well-controlled studies in pregnant women 
OR Animal studies have shown an adverse effect, but adequate and well-
controlled studies in pregnant women have failed to demonstrate a risk to 
the fetus in any trimester. 
Pregnancy 
Category C 
Animal reproduction studies have shown an adverse effect on the fetus and 
there are no adequate and well-controlled studies in humans, but potential 




There is positive evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience or studies in humans, but 




Studies in animals or humans have demonstrated fetal abnormalities and/or 
there is positive evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience, and the risks involved in use 
of the drug in pregnant women clearly outweigh potential benefits. 
Table 2. United States FDA pharmaceutical pregnancy categories 
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these drugs are also associated with higher incidence of fetopathy [Cooper, 2006]. 
2.1.2 Aspirin  
Treatment with low doses of Aspirin during pregnancy would be indicated in women  
with SLE, APS, hypertension, history of preeclampsia, and renal disease. Aspirin can cross 
the placenta and can cause congenital anomalies in animals but these are rare in human 
beings. Several large prospective studies failed to confirm a significant increase in  
cleft palate or congenital anomalies [Jick, 1981].  Low dose of Aspirin is safe throughout 
pregnancy. Women who took Aspirin had a significantly lower risk of preterm delivery than 
those treated with placebo but there is no significant difference in perinatal mortality 
[Kozer, 2003]. 
A meta-analysis showed reduction in the risk of preeclampsia, preterm delivery before 34 
weeks of gestation and serious adverse outcomes among women taking low-dose Aspirin or 
dipyridamole [Aski, 2007]. 
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Aspirin has anti-prostaglandin effects and therefore it is better discontinued 8 weeks prior 
the expected delivery to avoid prolonged gestation and labour. This also reduces bleeding 
during delivery and bleeding complications in the fetus. 
2.1.3 Non-steroidal anti-inflammatory drugs (NSAIDs)  
The effect of NSAIDs use on the fetus depends upon the term of pregnancy.  A number of 
cohort studies looking at the teratogenic risk of NSAIDs use during the first trimester have 
not found an increased risk of congenital malformation [Janssen, 2000].  However, due to 
the shared property of inhibition of prostaglandin synthesis, adverse effects such as 
constriction of the ductus arteriosus in utero, persistent pulmonary hypertension, renal 
dysfunction in the neonate, increased maternal blood loss, and prolongation of pregnancy & 
labour are possible when administered to pregnant patients. NSAID should be given in the 
lowest effective dose, and should be withdrawn before 8 weeks of expected date of delivery 
[Ostensen, 1994]. 
Prostaglandins (PGs) increase uterine contractions, enhance platelet aggregation and 
increase the fetal renal blood flow. Therefore, NSAIDs by inhibiting the PG synthesis, may 
decrease the fetal urinary output. NSAIDs, by inhibiting cyclooxygenase, decrease the PG 
synthesis.  
If NSAID is clinically indicated in the first or second trimester, Ibuprofen would be the 
preferred one. 
NSAIDs can potentially inhibit contractions and thereby prolong gestation. Because of the later 
effect, indomethacin, a potent NSAID, has been used in the treatment of premature labour. 
NSAID inhibition of fetal urinary output may cause oligohydramnios and this is reversible 
once the NSAID is stopped. Inhibition of prostaglandin synthesis by NSAID may also result in 
constriction of the ductus arteriosus which can cause fetal pulmonary hypertension. In the 
studies with indomethacin, these effects were first noticed in the 27th week of gestation but 
most marked in the 32nd week of gestation [Janssen, 2000; En Hams, 2002]. 
2.1.4 Anti-malarial drugs  
Hydroxychloroquine: “HCQ” is the commonest anti-malarial drug used in SLE.  It has been 
used in pregnancy for malarial prophylaxis with no teratogenic effects [Lewis, 1973].  
HCQ main mechanism of action is through inhibition of antigen processing and 
inflammatory cytokine release [Fox, 1996].  These drugs are highly effective for discoid 
lupus erythematosus (DLE) cutaneous lesions.  HCQ improves photosensitive skin lesions 
and prevents lupus flares [Gladman, 1998].  Studies have shown that HCQ can prevent renal 
and central nervous system lupus.  It also exhibits the role of a prophylactic agent against 
some of the major morbidities of SLE and its treatment, namely hyperlipidemia, diabetes 
mellitus and thrombosis [Mpetvi, 1996]. 
As it has a long half life of eight weeks and accumulates in the body, discontinuation of 
drug immediately after conception does not prevent the exposure of fetus to the drug. A 
systemic review of hydroxychloroquin use in pregnant patients with auto-immune diseases 
from 1980 to 2007 showed that HCQ is not associated with any increased risk of congenital 
defects, spontaneous abortions, fetal death, prematurity or decreased number of live births 
in patients with auto-immune disease [Sperber, 2009]. 
RA Levy et al observation in prospective randomized placebo controlled study revealed  
that HCQ can be used safely in pregnancy with additional benefits on the disease activity. 
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The neonatal results (Apgar score, weight and gestation age) were significantly better in  
the HCQ group with absence of teratogenic effects after 3 years of follow-up in children 
[Levy, 2001]. 
HCQ is often needed to manage hyperactivity of the disease, as it appears to be safe and 
decreases lupus activity during pregnancy. 
2.1.5 Corticosteroids  
It is relatively safe to use during pregnancy but we should pay attention to maternal 
hypertension, gestational diabetes, infection, weight gain, acne and proximal muscle 
weakness. Therefore close monitoring with the use of the lowest possible dose of 
corticosteroid needed to control disease flare along with vitamin D and calcium 
supplements. Although animal studies have suggested an increased risk of oral clefts 
associated with glucocorticoid, several human studies have failed to demonstrate either 
teratogenic or toxic effects [Raybum, 1992]. 
Corticosteroids (Prednisalone, Prednisone, and Methylprednisolone) are metabolized by 
placenta II-beta-hydroxy steroid dehydrogenase (II-beta-HSD) which converts active 
cortisone to inactive cortisone.  Therefore, fetal blood levels are approximately 10% of the 
mother’s level [69], while fluorinated corticosteroids (dexamethasone and betamethasone) 
do cross the placenta in an un-metabolized form. Therefore, neonates should be monitored 
for evidence of adrenal insufficiency. 
If our concern is to treat the mother, the most suitable corticosteroid is prednisalone, 
prednisone or methylprednisolone. But if our concern is to treat the fetus, then it is either 
dexamethasone or betamethasone, which is not inactivated by placental 11-beta 
hydroxysteroid dehydrogenase and are best suited for fetal treatment as they clearly reduce 
the risk of death and respiratory distress syndrome in the preterm infants [NICHHD, 1994]. 
It is currently recommended that obstetricians give only a single course of antenatal 
corticosteroids to pregnant women to enhance lung maturity instead of giving repeated 
doses as weekly courses of antenatal corticosteroid which did not reduce composite 
neonatal morbidity compared with a single course of treatment.  Weekly courses of 
antenatal corticosteroids should not be routinely prescribed for women at risk of preterm 
delivery [Guinn, 2001]. 
Separate meta-analysis of the data in the Cochrane review showed that betamethasone and 
not dexamethasone reduces neonatal morbidity [Crowley, 2000] as betamethasone may offer 
better long-term neuro developmental outcome for the fetus [Lee BH, 2008]. 
In patients with chronic corticosteroid treatment during pregnancy, “stress doses” of 
hydrocortisone are recommended for prolonged labor, delivery, caesarian section, or any 
emergency surgery. 
2.1.6 Immunosuppressive agents  
Cyclophosphamide 
Fetal survival is strongly in doubt when cyclophosphamide is required to treat lupus 
during pregnancy.  The high risk for loss of the fetus should be discussed with the patient 
prior to administration of cyclophosphamide [Clowse MEB, 2005]. Patients undergoing 
therapy with cyclophosphamide must avoid pregnancy during therapy, especially in the 
first trimester. Attempts of conception should be delayed until three months after 
cessation of therapy. 
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Aspirin has anti-prostaglandin effects and therefore it is better discontinued 8 weeks prior 
the expected delivery to avoid prolonged gestation and labour. This also reduces bleeding 
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and prevents lupus flares [Gladman, 1998].  Studies have shown that HCQ can prevent renal 
and central nervous system lupus.  It also exhibits the role of a prophylactic agent against 
some of the major morbidities of SLE and its treatment, namely hyperlipidemia, diabetes 
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As it has a long half life of eight weeks and accumulates in the body, discontinuation of 
drug immediately after conception does not prevent the exposure of fetus to the drug. A 
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from 1980 to 2007 showed that HCQ is not associated with any increased risk of congenital 
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The neonatal results (Apgar score, weight and gestation age) were significantly better in  
the HCQ group with absence of teratogenic effects after 3 years of follow-up in children 
[Levy, 2001]. 
HCQ is often needed to manage hyperactivity of the disease, as it appears to be safe and 
decreases lupus activity during pregnancy. 
2.1.5 Corticosteroids  
It is relatively safe to use during pregnancy but we should pay attention to maternal 
hypertension, gestational diabetes, infection, weight gain, acne and proximal muscle 
weakness. Therefore close monitoring with the use of the lowest possible dose of 
corticosteroid needed to control disease flare along with vitamin D and calcium 
supplements. Although animal studies have suggested an increased risk of oral clefts 
associated with glucocorticoid, several human studies have failed to demonstrate either 
teratogenic or toxic effects [Raybum, 1992]. 
Corticosteroids (Prednisalone, Prednisone, and Methylprednisolone) are metabolized by 
placenta II-beta-hydroxy steroid dehydrogenase (II-beta-HSD) which converts active 
cortisone to inactive cortisone.  Therefore, fetal blood levels are approximately 10% of the 
mother’s level [69], while fluorinated corticosteroids (dexamethasone and betamethasone) 
do cross the placenta in an un-metabolized form. Therefore, neonates should be monitored 
for evidence of adrenal insufficiency. 
If our concern is to treat the mother, the most suitable corticosteroid is prednisalone, 
prednisone or methylprednisolone. But if our concern is to treat the fetus, then it is either 
dexamethasone or betamethasone, which is not inactivated by placental 11-beta 
hydroxysteroid dehydrogenase and are best suited for fetal treatment as they clearly reduce 
the risk of death and respiratory distress syndrome in the preterm infants [NICHHD, 1994]. 
It is currently recommended that obstetricians give only a single course of antenatal 
corticosteroids to pregnant women to enhance lung maturity instead of giving repeated 
doses as weekly courses of antenatal corticosteroid which did not reduce composite 
neonatal morbidity compared with a single course of treatment.  Weekly courses of 
antenatal corticosteroids should not be routinely prescribed for women at risk of preterm 
delivery [Guinn, 2001]. 
Separate meta-analysis of the data in the Cochrane review showed that betamethasone and 
not dexamethasone reduces neonatal morbidity [Crowley, 2000] as betamethasone may offer 
better long-term neuro developmental outcome for the fetus [Lee BH, 2008]. 
In patients with chronic corticosteroid treatment during pregnancy, “stress doses” of 
hydrocortisone are recommended for prolonged labor, delivery, caesarian section, or any 
emergency surgery. 
2.1.6 Immunosuppressive agents  
Cyclophosphamide 
Fetal survival is strongly in doubt when cyclophosphamide is required to treat lupus 
during pregnancy.  The high risk for loss of the fetus should be discussed with the patient 
prior to administration of cyclophosphamide [Clowse MEB, 2005]. Patients undergoing 
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first trimester. Attempts of conception should be delayed until three months after 
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It is a teratogenic drug and should only be used after the first trimester unless the mother’s 
life is threatened [Briggs, 2005].  To avoid fetal loss and malformations from inadvertent first 
trimester exposure during cyclophosphamide therapy, strict adherence to birth control 
measures, as well as a pregnancy test prior to pulse therapy should be the routine practice 
[Clowse MEB, 2005]. 
In patients with life-threatening disease, the use of cyclophosphamide may be considered 
after the first trimester. 
Azathioprine (AZA) 
It is a purine analogue which interferes with the synthesis of nucleic acid. Although 
azathioprine crosses the placenta, only minimal amount reaches the fetal blood.  
Azathioprine metabolites 6-thioguanine nucleotide (6-TGN) was slightly lower in the RBC 
of the infant than the mother, while other azathioprine metabolite 6-methylmercaptopurine 
(6-MMP) could not be detected in the infant which means the placenta forms a (relative) 
barrier to AZA and its metabolites [Da Boer, 2006]. 
Methotrexate (MTX) 
It is contraindicated in pregnancy (FDA risk category x) because of severe adverse effects on 
both the fetus and the course of the pregnancy [Janssen, 2000].  Plan for conception should 
be taken after three months of methotrexate withdrawal as the active metabolites remain in 
the body for approximately two months after its discontinuation. MXT acts as a folate 
antagonist and therefore leads to folate depletion during MTX treatment. Hence folate 
supplementation should be continued throughout pregnancy. 
Mycophenolate mofetil (MMF)  
It is mainly used in renal lupus, and there are very few data concerning its use.  It is 
advisable to switch to azathioprine before conception.MMF currently used as a maintenance 
therapy for lupus nephritis, and also used for resistant skin lupus, lupus disease activity and 
hematological manifestations [Karim, 2002]. 
Based on toxicity shown in animal studies, patients should not become pregnant while 
taking MMF.  Women taking MMF who wish to become pregnant should discontinue the 
drug at least 6 weeks prior to conception. 
Cyclosporine (CSA)  
Cyclosporine is an immunosuppressant that was first used for pregnant transplant rejection.  
CSA does not appear to be a major human teratogen.  It may be associated with increased 
rate of prematurity [Bar, 2001]. 
2.1.7 Biologic agents  
Anti-tumor necrosis factor alpha (Anti-TNFα)  
Maternal immunoglobulin (IgG) concentrations in fetal blood increase from early second 
trimester through term as maternal antibodies transported across the placenta to protect the 
new born.  Most antibodies are acquired during the third trimester.  The three commercially 
available TNF-α inhibitors (infliximab, etanercept, adalimumab) constructed based on IgG, 
so that these can cross the placenta to the fetus in the first trimester and more efficiently 
during the second and third trimesters.  
Anti-TNFα medications have led to improvements in the treatment of inflammatory 
conditions.  The safety of these drugs during pregnancy is an important issue.  Prospectively 
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collected data appear to be reassuring. However, an analysis of the FDA-reported anomalies 
has raised some questions.  It appears that significant levels of these drugs cross the placenta 
as the pregnancy nears term, but very little passes into the breast milk.  Prior to usage of 
these medications during pregnancy, their risks and benefits, other treatment options, and 
the ongoing inflammatory conditions, all must be carefully weighed by both doctor and 
patient [Clowse, 2010]. 
The FDA classified these biological agents as pregnancy risk category B, which means that 
no adverse pregnancy effect have been observed in animals studies but there have been 
insufficient controlled human studies.  The published experience with anti-TNF during 
pregnancy consists of a limited number of case reports, series, and ongoing registry data. 
Many patients have experienced successful pregnancies following TNF exposure.  Patients 
with unplanned pregnancies exposed to TNF inhibitors either before or after conception 
does not require termination of pregnancy unless additional maternal-fetal assessments 
suggest untoward or dangerous effects. While most of the existing data on TNF inhibitors 
use in pregnancy have been generated during conception and the first trimester of 
pregnancy, there is limited and inadequate information regarding their use throughout 
pregnancy or during breast feeding [Ali, 2010]. At present the use of biological agents 
cannot be recommended throughout pregnancy [Sorensen, 2011]. Therefore, it is better to 
stop anti-TNF once the pregnancy test is positive.  
Rituximab   
It is a chimeric anti-CD20 monoclonal β-cell depleting antibody. One should continue to 
counsel the women to avoid pregnancy for up to 12 months after rituximab exposure 
[Chakra Varty, 2011]. Therefore, it must be withdrawn before a planned pregnancy.  
Experience with rituximab during pregnancy is too limited to allow any statement on safety 
in pregnancy.  When administered in the second and third trimester, β-cell depletion occurs 
in the fetus.  Long-term studies on β-cell and immune function of children exposed in utero 
are lacking [Ostensen, 2008].  Rituximab is potentially unsafe because of reversible fetal 
cytopenias including β-cell depletion have occurred in infants of mothers who are given this 
drug during pregnancy [Doria, 2008]. 
2.1.8 Other therapeutic measures  
Intravenous Immunoglobulin (IVIG)  
During pregnancy, intravenous Immunoglobulin (IVIG) may be used if needed to control 
severe maternal lupus activity.  It does not appear to cause any fetal abnormalities.  This 
drug has been used for many years without any adverse effects [Bonnie, 1995].  In a study 
comparing twelve SLE-suffered pregnant patients from recurrent spontaneous abortion 
(RSA) treated with a high dose of IVIG as against twelve SLE-RSA pregnant patients treated 
with prednisalone and NSAIDs showed a beneficial clinical response following IVIG 
treatment in all patients, and the antibodies and complement levels also tended to normalize 
in most of the patients. So IVIG is considered safe and effective [Perricone, 2008].  
Plasmapheresis (PP)  
It is safe, expensive, labor-intensive procedure. Its absolute indications include hyper 
viscosity, cryoglobulinemia, pulmonary hemorrhage and TTP. PP may be useful in 
cyclophosphamide resistant and serious organ–threatening disease [Erickson, 1994; 
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Wallance, 2001]. It is safe in children and pregnant females [Wallance, 2001]. Removal of 
anticardiolipin antibodies or Lupus anticoagulant by plasmapheresis during pregnancy or 
its use in those with recurrent thromboembolic episodes has been the subject of numerous 
case reports but no prospective studies have been done. However, it is believed that 
plasmapheresis during pregnancy definitely removes anticardiolipin antibodies. 
[Koblayash, 1992].  
Aphaeresis is well tolerated among pregnant patients, and has been used to remove 
antiphspholipid antibodies and Anti-Ro (SSA). It has been suggested that weekly 
Plasmapheresis can decrease anti-52 kD reactivity and might prevent heart block if it is 
initiated in the first trimester [Vonderleij, 1994]. 
2.2 Delivery 
Systemic lupus erythematosus is not an indication for delivery by cesarean section; although 
high rates of preeclampsia and cesarean section in connective tissue disease pregnancies 
were documented in a population based study they mainly emphasized on the importance 
of monitoring and obstetrical interventions [John Fredrick, 2000]. 
A team approach guarantees to the pregnant women with SLE, a safe vaginal delivery and 
allows performing a cesarean section for obstetric indications only.   
In a study of 555 lupus pregnancies, cesarean sections were needed in 38.2% of these 
patients versus 19.7% of controls [Yasmeen, 2001] .The major indications for cesarean section 
are fetal distress and maternal preeclampsia. One should remember that, general 
anaesthesia in a pregnant women has a mortality rates of 16.7% which is much greater than 
that of epidural or subarachnoid anesthesia [Hawkins, 1997]. It is ideal that the obstetrician, 
the anesthesiologist and the rheumatologist should evaluate the condition of the mother and 
the fetus and plan the type of delivery accordingly. 
Generally , in the case of vaginal delivery the anesthesiologist can guarantee an epidural 
analgesia with no greater risks than those of  a healthy parturient. In the event of cesarean 
section we can usually administer a neuro-axial anesthesia as the preferred type of 
anesthesia reserving the general anesthesia only to obstetrical emergencies [Rawetz, 2004]. 
The indications for cesarean section include maternal causes such as avascular necrosis of 
the hips with inadequate hip abduction, placental abruption or fetal causes such as fetal 
distress, prolapsed umbilical cord, abnormal non- stress test,  cephalo-pelvic disproportion 
and transverse presentation. Delivery should be in a hospital which has neonatal intensive 
care unit. Pregnant women with lupus treated with systemic steroid within two years of the 
anticipated delivery should receive steroid stress coverage during delivery.  
2.3 Puerpurium  
The optimum management is not over with the birth of a healthy baby. In fact, postpartum 
period should be considered as a high risk for pregnant lupus patients with several possible 
complications ahead. First, the mother can suffer a lupus flare, since several studies have 
confirmed the postpartum period is particularly high risk for increased lupus activity. A 
close surveillance in the first four weeks after delivery is thus warranted, especially in 
women with recent activity or with a previous history of severe disease. However no 
specific prophylactic therapy, such as increasing the dose of steroid, is recommended. 
The puerpurium has also high risk for thromboembolic complications. This is especially true 
in women with APS, in whom adequate thrombo-prophylaxis with low molecular weight 
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heparin (LMWH) should be extended 4-6 weeks after delivery. Those with previous history 
of thrombosis can be back on their usual full anticoagulant therapy within first 2-3 days 
postpartum. It should be remembered that both warfarin and heparin are safe during 
lactation [Guillermo Ruiz-Irastorza et al, 2009].   
2.4 Lactation  
The increasing prevalence of breast feeding along with the increased frequency of 
pregnancies in females with chronic medical conditions have increased the number of 
patients who face possible harmful effects on the newborn of medication excreted in breast 
milk.  Generally, drugs known to be extensively protein bound are excreted in breast milk to 
a lesser extent than drugs that are poorly bound to plasma proteins. 
 
             
         Factors related to breast milk 
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Table 3. Factors that determine the safety of the drugs used during breastfeeding.  (Adapted 
from Howard & Lawrence, 1999.) 
There are multiple factors that determine the concentration of the drug in breast milk  
which include maternal, infant, and drug-related factors [Bowes, 1980] as shown in the table 
(Table 3). It is recommended to take the medication immediately after breastfeeding the 
baby, to ensure least possible concentration of the drug in breast milk.  Safety of medication 
is very important during lactation.  
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Nursing mothers should avoid large doses of Aspirin.  The American Academy of Pediatrics 
recommends that Aspirin be used cautiously by the mother of the nursing infant and large 
doses of it should be avoided [Pediatrics, 1994]. 
2.4.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
The American Academy of Pediatrics considers Ibuprofen, Indomethacin, and Naproxen to 
be compatible with breastfeeding [Pediatrics, 1994], although most NSAIDs do not achieve 
high concentrations in breast milk [Ostensen, 1996].  Ibuprofen presents extremely low level 
in breast milk and has very short half-life; therefore it is considered to be a reasonable choice 
as an analgesic in the lactating women. 
2.4.3 Hydroxychloroquin (HCQ) 
The amount of HCQ received by children through lactation seems to be very low.  HCQ 
should probably be maintained throughout pregnancy in patients with SLE as it is also safe 
in breastfeeding [Cosedoat, 2005]. The American Academy of Pediatrics classifies the drug 
as compatible with breastfeeding.  Excretion into breast milk was very low (0.2mg/kg/day) 
and this level is not thought to be toxic [Costedoat, 2002].  Drug levels in milk reached a 
peak 2 hours after ingestion of hydroxychloroquine and declined after 9 hours.  It was 
estimated that a nursing child would ingest between 0.06-0.2mg/kg/day or approximately 
2% of the mother’s weight-adjusted dose [Notionn, 1984; Ostensen, 1985].  Routine eye 
exams of breastfed children are not indicated as the follow-up studies of exposed children 
are re-assuring [Costedoat, 2002].  
2.4.4 Corticosteroids 
Corticosteroids do not enter breast milk in large quantities.  The American Academy of 
Pediatrics has declared prednisone and prednisalone as safe and compatible with 
breastfeeding.  Infant exposure to prednisalone through breast milk can be minimized by 
dosing prednisalone at infrequent intervals and avoiding nursing for at least 4 hours 
following a dose [Alan Kamada, 1994] as peak milk steroid levels occurred approximately 2 
hours after a dose of prednisalone.  No data are available on the use of dexamethasone or 
betamethasone in lactating women. 
2.4.5 Cyclophosphamide 
Lactation is contraindicated during cyclophosphamide use as it is found in substantial 
concentrations in human breast milk [Wiernik, 1971].  Patient with life-threatening 
condition, who received cyclophosphamide during second or third trimester, their offspring 
should be monitored for immunosuppression and the development of secondary 
malignancies.  
2.4.6 Azathioprine (AZA) 
Nursing is not recommended in patients on AZA, because of the long-term potential of 
immunosuppression and carcinogenesis [Pediatrics, 1994], although, there were no reports 
to confirm this.  A report on a series of 4 patients treated with azathioprine while lactating, 
the breast milk samples were analyzed for 6-mercaptopurine (6-MP) in 2 of the mothers.  
Levels of 6-MP were undetectable.  Therefore, relative infant dose would have been less 
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than 0.09% of the maternal weight-adjusted dose.  No adverse effects were encountered in 
any of the 4 infants.  So, maternal azathioprine use during lactation does not appear to pose 
a significant immediate clinical risk to the suckling infant.  Continued monitoring and long-
term assessment of these infants are warranted [Moretti, 2006].  
2.4.7 Methotrexate 
The American Academy of Pediatrics considers methotrexate to be contraindicated during 
breastfeeding because of several patient problems, which include immunosuppression, 
neutropenia, adverse effects on growth, and carcinogenesis [Pediatrics, 1994].  So, 
breastfeeding during methotrexate treatment is not recommended. 
2.4.8 Cyclosporine 
The American Academy of Pediatrics considers cyclosporine to be contraindicated during 
lactation because of the potential long-term effects of immune-suppression, neutropenia, 
and a potential association with carcinogenesis [Pediatrics, 1994].  Breastfeeding should be 
discouraged in women using cyclosporine [Flecher, 1995]. 
2.4.9 Mycophenolate Mofetil (MMF) 
There is no enough data regarding the excretion of MMF into breast milk.  Lactation is not 
recommended while using MMF [EGRT, 2002]. 
2.4.10 Sulfasalazine 
This is compatible with nursing.  In eight mothers who were breastfeeding and taking 
sulfasalazine, analyses were done from mothers’ serum, breast milk and serum from their 
children. The results showed that the amount of sulfasalazine and sulfa pyridine 
transferred to the child in the breast milk is negligible with regards to the risk of 
kernicterus [Eshjorner, 1987].  
2.4.11 Tumor necrosis Factor α inhibitors (Anti-TNFα) 
At present it is not known whether TNFα inhibitors are secreted into breast milk and can be 
ingested by mothers with breastfed child.  Mothers who wish to breastfeed their children 
should be informed that there is insufficient knowledge to provide them with adequate 
information [Ostensen, 2008].  
2.4.12 Rituximab 
There is insufficient data to support breastfeeding in patients who are on Rituximab.  So it is 
better to avoid Rituximab during lactation.  
2.4.13 Intravenous Immunoglobulin (IVIG) 
No data regarding IVIG excretion in breast milk.  Therefore, we suggest avoiding 
breastfeeding while the patient is on IVIG. 
2.5 Safety of contraception in SLE women 
Premenopausal women with SLE should have access to safe and effective birth control 
measures.  Women who have diminished fertility may seek hormonal manipulation to 
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2.4.13 Intravenous Immunoglobulin (IVIG) 
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2.5 Safety of contraception in SLE women 
Premenopausal women with SLE should have access to safe and effective birth control 
measures.  Women who have diminished fertility may seek hormonal manipulation to 
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stimulate ovulation, and women receiving cyclophosphamide may need methods for 
preserving fertility.  Furthermore, exogenous estrogen may be used not only to prevent 
glucocorticoid-induced osteoporosis but also to treat ovarian cysts, endometriosis, irregular 
menses, and menorrhagia.  
The high rate of elective abortion among women with SLE may reflect the failure of the 
birth-control method used or the absence of an adequate birth-control program [Petri, 
2005; Leona, 1981]. As the disease activity during pregnancy is generally high in women 
who conceive, pregnancy can be particularly risky in women with active disease or on 
teratogenic medications. So, pregnancy should be planned to begin during period of 
disease quiescence making contraception an important issue for these women.  All 
women with rheumatologic disease have contraceptive options, including barrier 
methods, the intrauterine device (IUDs) and oral contraceptive pills (OCPs) [Wayslett, 
1991; Clowse, 2010]. 
Progestin-only contraceptives are not widely used because of their effects on the 
endometrial bleeding pattern [Mintz, 1984].  Oral contraceptives (OCPs) remain one of the 
most effective forms of birth control [Lauterbach, 2000]. The Safety of Estrogens in Lupus 
Erythematosus National Assessment (SELENA) trial of oral contraceptives versus placebo 
was a prospective, randomized, double blind trial that examined the effects of oral 
contraceptives (containing 35mg ethinyl estradiol) i.e. low estrogen dose on disease activity 
in 183 premenopausal women with SLE. This concluded with only 7 severe flares occurring 
in 91 patients receiving oral contraceptives, the same number which was recorded for the 92 
women receiving placebo.  To the surprise of most physicians, OCP was equivalent to 
placebo in terms of severe flares.  So, the available data support the use of OCPs containing 
estrogen as birth control choice for patients with inactive or stable SLE who are at low risk 
of thrombosis [Petri, 2005]. 
The SELENA trial does not pertain to women with very active SLE, such as active lupus 
nephritis, or those with the lupus anticoagulant or with high titer anticardiolipin, which 
were excluded. OCPs cannot be prescribed to all SLE women, but when appropriate, may 
demonstrably improve the quality of life [Petri, 2008].  Given the high prevalence of 
antiphospholipid antibodies in SLE, it seems prudent not to prescribe OCPs to women with 
lupus anticoagulant or medium-to-high titer anticardiolipin or anti-β2 glycoprotein [Petri, 
2001].  Despite a lack of randomized studies, evidence strongly suggests that the elevated 
risk of thrombosis makes estrogen-containing contraceptives unsuitable for patients with 
APS, prior thromboembolic episodes, and severe migraine.  Decisions should be 
individualized according to the patients’ medical status, personal preference and stage of 
reproductive life [Sammaritano, 2007; Ashorson, 1986]. 
Another study evaluating the safety of OCP was conducted as a randomized, single-blinded 
12-month clinical trial in women with SLE to evaluate the effects on disease activity of 
combined oral contraceptives, as compared to progestin-only pill and IUD.  Disease activity 
remained mild and stable in all groups throughout the study.  There were no significant 
differences among the groups during the trial in disease activity, incidence or probability of 
flares on medication use.  Thromboses occurred in four patients (two in each of the two 
groups receiving hormones) [Sanchez, 2005]. 
The risk of infection associated with IUD insertion is too small to warrant routine use of 
prophylactic antibiotics. Recently, FDA removed immunosuppression from list of 
contraindications to IUD use. The use of combined oral contraceptives is possible in stable 
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premenopausal SLE, and who do not have any evidence of APS.  Lupus patients who are 
APL positive or have APS should be treated with progestogens only pills (oral or 
Parenteral) or IUD. 
2.6 Assisted reproductive therapy (ART) 
Young lupus patient exposed to I.V. cyclophosphamide face the risk of premature ovarian 
failure.  In vitro fertilization (IVF) and its associated technologies are used for infertility in 
patients with a wide range of etiologies, including those with SLE, and/or APS. 
The first phase of ART is ovulation induction followed by in vitro fertilization (IVF) and 
embryo transfer (ET) in the uterus.  The most threatening conditions in affected women 
undergoing ovarian stimulation are lupus flares and thrombosis, with the latter being 
especially associated with the occurrence of an overt ovarian hyper-stimulation syndrome 
(OHSS). 
SLE manifestations in acute flares, badly controlled arterial hypertension, pulmonary 
hypertension, advanced renal disease, severe valvulopathy or heart disease, and major 
previous thrombotic events are situations in which to ARTs are to be discouraged. It  
is especially due to the high risk of complications in both mother and fetus during 
pregnancy and puerpurium.  Therefore, ovarian stimulation for ovulation induction  
and IVF seems to be safe and successful in well-selected women with SLE and APS 
[Beliver, 2009]. 
The ovulation induction therapy (OIT) may precipitate SLE activity or APS.  A careful 
review of the patient’s history and appropriate laboratory tests should be undertaken before 
OIT.  Clomiphene adverse effects are rare.  When gonadotropins are prescribed, preventive 
anti-inflammatory therapy should be considered in women with SLE, in addition to heparin 
and/ or anti-aggregate therapy in patients with asymptomatic antiphospholipid antibodies 
or prior thrombotic events [Huong, 2002]. 
3. Pre-pregnancy counseling 
Couples with SLE with or without recurrent pregnancy loss require empathy and 
understanding as early pregnancy loss is an emotionally traumatic experience, similar to 
that associated with still birth. As many patients with SLE are young women in 
reproductive age and some being young men, wanted to have healthy children they need to 
be reassured that if they follow the expert doctor’s advice with careful follow-up during 
pregnancy, they could still have normal children. Therefore, one needs to stress the 
importance of preconception counseling (Table 4). 
3.1 Fertility  
The vast majority of patients have no problems with fertility. However occasionally  
some female patients may develop antibodies to ovarian tissue that interfere with 
development of ovum, others may have disrupted ovarian cycles which need further 
investigations. Infertility could be a problem in patients on long-term cyclophosphamide 
(more than 6 months) and its use can also cause congenital abnormalities. Therefore  
while the patients are on cyclophosphamide they need to be told to use reliable methods 
of contraception for the total duration on this drug and three months thereafter  
[Handa, 2006]. 
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Assess for risk factors 
Stratify high/low risk 
Give realistic, evidence-based estimates for  likely  
          success and chance of problems 
Discuss prematurity and handicap 
Advise against pregnancy if appropriate 
Make and agree prospective plan of care 
Table 4. Preconception Counseling (Ruiz, 2008) 
For pregnancies with lupus, the risk of abortion, hypertension, and embryo deformity by a 
therapeutic agent is higher compared to healthy pregnancies. Lupus flares can occur at any 
time during pregnancy, as well as several months after delivery [Clowse, 2007]. Fortunately, 
the majority of gravidae do not have severe SLE activity but only mild flares mainly 
involving skin, joints, or constitutional symptoms [Izmirly, 2010]. 
Not all women with SLE have the same risk of complications during pregnancy. Thus, pre-
pregnancy counseling is essential to estimate the chance of both fetal and maternal mortality 
and morbidity (Table 4).  
To reduce the risk of pregnancy it is better to have a planned pregnancy. Therefore 
Pregnancy is usually undertaken when 
 The disease has been in remission for at least 6 months  
 Who require less than equivalent of 7.5  mg of prednisone per day 
 No previous renal disease, hypertension, thrombocytopenia or anti-phospholipid 
antibodies 
High-risk patients are shown in Table 5. 
An obstetrician experienced in management of high risk pregnancies is particularly desirable 
for women with one of these features for a better outcome of pregnancy. A previous 
complicated pregnancy is, by itself, an important adverse prognostic variable. Likewise, the 
presence of APS is closely associated with maternal thrombosis and embryo-fetal demise. 
Maternal anti-Ro and anti-La antibodies may cause congenital heart block in 2% of babies.  
This is fortunately a rare, but very serious condition, with a high mortality rate with or 
without cardiomyopathy and a high chance of permanent pacemaker for majority of 
children with CHB [Clowse, 2007). Defining a high risk pregnancy is not absolute as it 
differs from patient to patient due to the presence of other confounding factors. 
The testing for Anti-SSA/SSB/ U1RNP antibodies are done only in high risk population like 
Women with SLE, Sjogren’s syndrome, Undifferentiated connective tissue disease or other 
connective tissue diseases, since they comprise 50-60% of NLE mothers. It is also done in 
mothers with previous child having neonatal lupus as the risk of neonatal lupus in next 
pregnancy reaches up to 25%. 
Management of a case of APS is shown in the flow chart (figure 1). 
Chronic renal failure is also associated with other obstetric complications, such as 
hypertensive disorders and miscarriage, which are more likely to occur if renal impairment 
is more severe. Restrictive pulmonary disease may also worsen during pregnancy due to the 
thoracic compression by the growing uterus. Secondary APS is the main predictor of 
pregnancy complication in the form of miscarriage, fetal death, prematurity and 
preeclampsia. The disease activity has shown a clear association with fetal loss and 
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prematurity and the lupus anticoagulant confers the highest risk of miscarriages among the 
antibodies of APS [Handa, 2006]. 
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Contraindications to Pregnancy  in SLE 
(high maternal & fetal risk) 
Severe pulmonary hypertension  
       ( PAP >50 mm Hg or symptomatic) 
Restrictive lung disease (FVC <1 L) 
Heart failure 
Chronic renal impairment with Cr >250 µmols/L 
H/O  severe PET or HELLP  
       (despite ASA/LMWH) 
Stroke in <6 months 
Severe lupus flare in<6 months 
H/O arterial thrombosis or PE 
Table 6. Contraindications to pregnancy in SLE (Ruiz, 2008) 
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In some extreme situations, the physicians should advise against pregnancy (Table 6).  
Women with current or recent lupus activity, particularly if affecting internal organs, should 
avoid pregnancy. The same recommendation applies to women with APS and recent 
thrombosis, particularly in the arterial bed. Women with severe kidney, lung or heart 
disease should also be discouraged from getting pregnant due to the high risk of maternal 
complications. Likewise, pregnancy should be considered an absolute contraindication in 
women with symptomatic severe pulmonary hypertension, which carries a higher than 30% 
maternal mortality during late pregnancy and the puerpurium.  
In patients having a serum creatinine over 250 µmols/L the chance of having a successful 
pregnancy is <30%. Despite aggressive treatment of secondary anti-phospholipid antibody 
syndrome the risk of thrombo-embolism and fetal death is still high. 
A major reason for discrepant results is in the definition of a lupus flare during pregnancy.  
In applying the Systemic Lupus Activity Measure (SLAM) to the pregnant lupus patient, 
fatigue, alopecia, decreased hematocrit, and increase ESR may not represent lupus activity. 
Suggestions for “valid” criteria attributable to a flare are characteristic dermatologic 
involvement, arthritis, hematuria, fever not secondary to infection, lymphadenopathy, 
leukopenia, alternative-pathway hypocomplementemia, and rising titers of antibodies to 
DNA. The patients with least risk in pregnancy are the patients who are in remission on < 
7.5 mg of prednesalone per day, normal renal functions, no proteinuria, normal blood 
counts, normal BP, normal levels of complement levels and no detectable dsDNA. 
The patients with moderate risk but still can be allowed to continue pregnancy with  
caution are- 
 Patients with mild flare with arthritis, mild pleuro-pericarditis, recalcitrant skin lesions, 
requiring 10-15 mg of prednisalone daily for continued symptoms. 
 Asymptomatic patients who have persistently elevated dsDNA and low levels of 
complement. 
Because SLE is a progressive disease and is not curable we should not stop the couples from 
going for children as delaying may cause them not to have children at all. Hence, to have 
children earlier is better than later. Therefore one should weigh the risks and benefits and 
involve the patients fully in decision making. 
Even platelets of 30,000-60,000, mild renal insufficiency (Cr=<200 µmols/L), proteinuria 1-
2gm/day may have greater risk of flare and fetal demise but still may have successful 
pregnancy. Therefore such woman needs to be counseled about high likelihood of 
premature delivery, preeclampsia and potential need for early hospitalization for delivery 
[Buyon, 2004]. 
The minimum diagnostic work up of the couples with SLE before preconception counseling 
includes, detail history taking including medical, surgical, genetic, obstetrical and family 
history as well as thorough physical examination. Complete antibody profile needs to be 
done [Anti-SSA/Ro, anti-SSB/La, anti-U1 RNP antibodies, ANA, dsDNA, etc]. Anti-
cardiolipin (ACL, both IgG & IgM), lupus anticoagulant (LA) are to be checked twice 6-8 
weeks apart to exclude false positive results. Anti-dsDNA and complement levels to be 
checked every trimester, to assess the activity of the disease, along with it test for 24 hr 
urinary protein and serum albumin [Clowse, 2007]. 
Patients who are positive to anti-SSA/SSB/U1RNP needs to follow the flow chart [figure 3] 
for diagnosis and management of CHB which is the common presentation and has the 
highest mortality and morbidity in neonatal lupus [Buyon, 2004]. 
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Screen for hypothyroidism as there is increased risk of miscarriage in subclinical 
hypothyroidism and incidence of hypothyroidism is found to be higher in SLE from recent 
studies. Test for diabetes mellitus and hyperprolactinemia and treat if present. If disease 
activity is present before pregnancy, the treatment needs to be started and patient should be 
free from disease activity at least for 6 months prior to pregnancy. 
 
 
Fig. 3. Decision tree for diagnosis & management of CHB  
High risk pregnancy needs a multi-disciplinary approach involving expert rheumatologist, 
experienced obstetrician skilled in managing high risk pregnancies, nephrologist, and 
neonatologist. Treatment of APS with aspirin or heparin as indicated before, during and 
after pregnancy.  
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The independent Risk Factors for pregnancy loss are Lupus activity in any trimester (but 
more in the first trimester), proteinuria, thrombocytopenia, hypertension in first trimester, 
APS and renal impairment, while the independent risk factors for pre-term delivery are 
increased lupus activity (before & during delivery), dose of prednisalone >7.5mg/day and 
hypertension [Ruiz, 2008). 
Finally patients with severe active disease, high degree of end organ damage such as severe 
PAH, CHF, severe restrictive pulmonary disease, severe chronic renal failure are advised 
against becoming pregnant as they are absolute contraindications. 
A significant rise in proteinuria and active sediment with or without falling complement 
values and rising DNA antibodies is justified to initiation the equivalent of 1 mg/kg per day 
of prednisalone. Moreover, the presence of proteinuria itself, even in the absence of active 
sediment, may warrant a trial of steroids. Persistent proteinuria > 3 grams/24 hr does not 
generally predict a good outcome for the mother or fetus. 
In the absence of any response within two weeks, a reassessment of the situation is 
warranted with consideration given to the addition of cytotoxic agents and early 
termination, especially in the setting of deteriorating renal function and an active urinary 
sediment. 
All patients have to practice hygienic way of living: No smoking, no alcohol, no recreational 
drugs, less caffeine consumption (<250mg/day) and to take folic acid supplements (at least 
400 mcg/ day). All the medications prescribed needs to be checked by her attending 
physician and approved [Ruiz, 2011; Izmirly, 2010)]. 
4. Conclusion 
Better outcome occurs by careful planning, patient education, close monitoring and 
aggressive management. All the above is important for a successful pregnancy outcome. 
Appropriate preconception counseling on management plans and shared care with special 
obstetrical & peri-natal attention will reduce the maternal and fetal morbidity and 
mortality. 
In pregnant lupus patients the medication has to be adjusted to the patient needs depending 
on the disease activity, prior obstetric history, presence or absence of APS, presence of anti-
SSA/Ro, SSB/La antibodies and the course of present pregnancy. So the disease 
manifestations, the course of pregnancy and the medications together will decide the 
morbidity of the mother and the child [Isenberg, 2004]. 
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1. Introduction  
Neonatal lupus erythematosus (NLE) or neonatal lupus syndrome (NLS) is a rare syndrome 
seen in 1-2% of neonates with auto-antibodies to SSA/Ro, SSB/La and or U1 RNP, passively 
transferred transplacentally from the mother who is either asymptomatic or having 
manifestations of Sjogren’s syndrome, SLE or other systemic rheumatic disease, 
characterized by cutaneous, cardiac or rarely both clinical manifestations. 
The skin manifestations are seen at least in 30% of these patients, in the form of periorbital 
annular erythematous plaques later spreading to other areas of face, scalp, trunk  
and extremities which is non-scarring and non-atrophic. This is usually transient lasting 
for days to months. But, the cardiac manifestations are seen in up to 60% of the patients  
is mainly in the form of complete congenital heart block (CHB) which is irreversible and  
is associate with cardiomyopathy in at least 10% of the cases. Cardiomyopathy is 
associated with increased morbidity and mortality. Almost all the patients having cardiac 
lupus require permanent pacemaker. The recurrence rate of neonatal lupus is as much as 
25% in the subsequent pregnancies. There has been better understanding of 
aetiopathogenesis of the disease which is due to the rapid advances in field of medicine 
[Buyon, 2001, 2007].  
2. Historical aspects  
The first case reported by Aylward in 1928, who described two siblings with CHB born to a 
mother who had Sjogren’s syndrome. Plant & Stevens described CHB as a manifestation of 
NLE in 1945 [Plant, 1945). But the first report linking autoimmune disease in mother with 
cutaneous lupus was McCuistion and Schoch in 1954. In 1957 Hogg noted the possible 
relation between autoimmune disease of the mother and congenital heart block in her child. 
Finally in 1980 Weston reported the association of neonatal lupus (NLE) with maternal anti-
Ro auto- antibodies [Lee LA, 1997]. 
The term, neonatal lupus erythematosus (NLE) has been challenged, because although 
cutaneous lupus resembles subacute cutaneous adult lupus, the cardiac manifestation of 
CHB is not seen in the adult lupus. So a better term could have been “Neonatal anti-Ro 
antibody associated disease”, but the disease has become so popular with the name of 
neonatal lupus erythematosus (NLE). It is also called as Neonatal lupus syndrome (NLS) 
due to protean clinical manifestations of the disease.  
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3. Epidemiology  
The prevalence of Anti-SSA antibodies in women is 1:200 while the incidence of neonatal 
lupus is only 1 in 20,000 live births [Neiman, 2000]. And less than 1:50 of women with anti-
SSA antibodies will have child with CHB. Only 1-2% of the infants of mothers with anti-
SSA/Ro with or without anti-SSB/La antibodies develop neonatal lupus, although it ranges 
from 0.6% to 25% with an average of 7.2% by various studies. The incidence increases to 3% 
if the mother has anti- La antibodies in addition to anti- Ra antibodies. 
If the mother has also SLE along with anti-SSA antibodies the incidence of NLE may be up 
to 6-13%. This is much higher and reaches up to 25% if the mother already had a child with 
NLE. 15-20% present as CHB and 6% present as cutaneous lupus. A recent study reported 
that the overall recurrence rate for any manifestation of NLE was 49% out of which 18.2% 
were complicated by cardiac NLE, 29.9% by cutaneous NLE, and 1.3% by 
hematologic/hepatic NLE. On follow up studies it was found that there were no significant 
differences in the maternal risk factors for having a subsequent child with either cardiac or 
cutaneous NLE [Izmirly, 2010]. 
The incidence of CHB is seen in 50-60% while the cutaneous lupus is seen in 25-30% and the 
combination of cutaneous and cardiac manifestations seen only in 4-10% of the patients with 
NLE [Eronen, 2000]. The incidence of cutaneous lupus may be higher but under reported as 
the rash is transient and may not be noticed at times and these neonates are usually 
asymptomatic. The antibody titers are three fold higher for cardiac lupus as compared to 
cutaneous lupus. 
Race: No racial predilection has been observed. However, NLE appears to be more common 
in African Americans, Latin Americans, and Asian children. So it is more common in non-
white than white population (3:1).  
Sex: Girls are affected more often than boys (2:1) and the cutaneous lupus is much more 
common in girls (3:1), whereas cardiac lupus is seen in equal ratio in males and females 
while anti-RNP neonatal cutaneous lupus is seen mainly in males [Jaeggie, 2010]. 
During a 20 year follow-up study of asymptomatic mothers with NLE, 50-60% of them have 
developed rheumatologic disease in the form of SLE, Sjogren’s or undifferentiated 
connective tissue disease approximately in the ratio of 1:2:2. The incidence of rheumatologic 
disease is more in cutaneous lupus (up to 70%) and the incidence of Sjogren’s disease is 
more common in mothers having infants with CHB than cutaneous lupus [Waltuck, 1994]. 
The overall risk of a woman with SLE having a child with CHB is 1:60 and it increases to 
1:20 in presence of anti-SSA/Ra antibodies [Watson, 1986]. 
The prevalence of anti-SSA/Ro antibodies in general population (pregnant & non-pregnant) 
ranges from 1-10% and its average prevalence in SLE patients is up to 50%. The prevalence of 
anti-SSB/La antibodies in SLE is less than anti-SSA/Ro (15-20%) and usually associated with 
anti-SSA/Ro in 90% of cases. Rarely anti-SSB/La or anti-U1 RNP can be present without anti-
SSA/Ro which may rarely cause cutaneous lupus [Singsen, 1986; Goldsmith, 1989].  
4. Pathophysiology  
NLE is presumed to result from trans-placental passage of maternal anti-SSA/Ro and/or 
anti-SSB/La auto-antibodies. The precise mechanism of injury to specific tissues, such as the 
skin and heart, is not known. The pathogenesis of disease probably involves more than 
simple trans-placental passage of antibodies because:  
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 The disease itself is very rare. 
 The mothers who have these auto antibodies, half of them are asymptomatic. 
 There is discordance of disease even in monozygotic twins. 
 And finally the anti-Ro/SSA and anti-La/SSB are associated with a variety of clinical 
syndromes in adults. 
4.1 Pathogenesis of CHB in NLE  
The trans-placental passive transfer of IgG auto antibodies is the initiating factor. The auto 
antibodies are usually anti-SSA/Ro against usually 52kD or 60kD protein or anti-SSB/La 
against 48kD protein or rarely anti-U1RNP antibodies and the incidence for these antibodies 
in the mother for CHB and CNL (cutaneous neonatal lupus) is 100 and 91% for anti-SSA and 
91 and 73% for anti-SSB and the incidence in the mother without NLE is only 47 and 15% 
respectively, strengthening the role of these antibodies in the pathogenesis. Anti-52 kD 
component of anti-SSA/Ro for a particular peptide fragment p200-239 has greatest risk for 
CHB than to p177-196, the later seen in unaffected children [Clansy, 2005]. 
Other autoantibody specificities reported to be associated with neonatal lupus include 
antibodies to   calreticulin, a 57 kD protein, a 75-kD phosphoprotein, a-fodrin, the neonatal 
heart M1 muscarinic acetylcholine receptor, and the serotoninergic 5-HT4 receptor 
[Sontheimer,1996; Maddison 1995; Wang,1999; Miyagawa,1998; Borda, 2001; Eftekhari,2001].  
Ro- and La-specific IgA and IgM antibodies were detected in the serum from a subset of 
mothers.  However, Ro- and La-specific IgA and IgM antibody levels were low or non-
detectable in children raised with or without breastfeeding [Klauinger, 2009]. This supports 
the role of transplacental passively transferred maternal antibodies than fetal antibodies in 
pathogenesis. 
These auto antibodies later enter the myocardial cell causing exaggerated apoptosis which 
leads to expression of the antibodies on the surface of the cardiocyte. These results suggest 
that resident cardiocyte participate in physiologic clearance of apoptotic cardiocyte, but that 
clearance is inhibited by opsonization via maternal auto- antibodies, resulting in 
accumulation of apoptotic cells promoting inflammation , stimulating macrophages which 
secretes cytokines mainly, transforming growth factor-beta (TGF- β), that stimulates 
fibroblast proliferation later on leading to fibrosis of the conduction system (causing CHB) 
or myocardium (leading to cardiomyopathy or Endocardial fibroelastosis) or both as shown 
in Fig.1. 
Histopathology of the affected heart shows fibrosis and calcification of the atrioventricular 
nodal region and replacement of that region with fibrous tissue explaining the irreversibility 
of the heart block in most patients [Lee LA, 1997). Infants exposed to low titers of anti-
SSB/La or anti-U1 RNP were more likely to have non-cardiac manifestations of neonatal 
lupus or only cutaneous lupus while the antibody titers are at least three-fold higher  in 
cardiac than cutaneous lupus [Jaeggie, 2010].  
In addition to inducing tissue damage, anti-SSA/Ro and/or anti-SSB/La antibodies inhibit 
calcium channel activation or the cardiac L- and T-type calcium channels themselves. L-type 
channels are crucial to action potential propagation and conduction in the AV node [Xiao 
GQ, 2001; Silverman, 1995].  
Very few neonates who have maternal antibodies develop neonatal lupus. Therefore factors 
other than attachment of the antibodies to the target antigens to be considered like fetal, 
uterine, viral and genetic factors. 
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3. Epidemiology  
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 The disease itself is very rare. 
 The mothers who have these auto antibodies, half of them are asymptomatic. 
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Fig. 1. Proposed pathologic cascade (Buyon, 2004) 
(This leads from inflammation to fibrosis whereby maternal antibodies initiate events  
that lead to a persistent myofibroblasts, a phenotype associated with scarring.  Apoptosis  
of cardiocyte results in the surface expression of SSA/Ro and SSB/La components, 
subsequent opsonization by cognate antibodies, and the secretion by macrophages  
of cytokines (e.g., TGF-β) which modulate fibroblasts into scar promoting  
myofibroblasts) 
Genetic factors in particular the HLA alleles DR3, B8, DQw2 and DRw52 and a 
polymorphism in the promoter region of the gene for tumor necrosis factor alpha (-308A, 
associated with higher TNF-α production) may play a role at least in cutaneous lupus. 
There are many questions that still remain. Why only few develop the disease while many 
do not develop? Why do some babies develop skin disease, others develop heart disease, 
and very few develop both? Studies from the laboratory failed to show differences between 
auto-antibodies from mothers who had babies with skin disease and auto-antibodies from 
mothers who had babies with cardiac disease. The sera were not different with regard to 
IgG antibody subclass, immunoblotting patterns against skin and heart extracts, and 
immuno-precipitation of Ro-associated hY RNAs. The only significant difference noted was, 
the lower titers of maternal anti-Ro60 in the skin disease subset, but the reason for that 
difference is also not clear [Lee LA, 1994, 1996; Bennion, 1990]. 
Again the discordance in the homozygotic twins goes against the genetic factors playing a 
major role in NLE. Post mortem studies in the neonates revealed deposition of IgG1 & IgG3 
along with complement (including C1q, C4, C3d, C6, and C9), and fibrin [6. Silverman, 1995; 
Salomonsson 2002] leading initially to pancarditis and later on to fibroelastosis of the heart. 
Thus it can involve almost all the structures of the heart. So fibrosis starts near the AV nodal 
region and extends to the other regions of the heart. As the process of inflammation starts 
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mainly in the second trimester, when the organogenesis is complete, structural defects in the 
heart are rare. 
It was also noticed that there is reduction of the protective molecules like the complement 
regulatory proteins (decay accelerating factor (DAF, CD55), protectin (CD59), and 
membrane cofactor protein (MCP, CD46) which predispose complement -mediated damage 
to the heart [Clancy, 2006; Miranda, 2000]. 
Some observational studies in monozygotic twins and triplets need clarification. Some 
neonates are affected while others are not affected. Even in the affected neonates each one 
will have different type of manifestations, regardless of them sharing a common placenta or 
not [Botard, 2000; Shimosegawa, 1997; Yazici, 2000]. Many studies revealed that type 1 
interferon pathway is not involved in NLE pathogenesis [Niewold, 2002, 2008]. 
All the above indicate that the maternal antibodies to SSA/Ro and SSB/La recognize their 
respective antigens in the immature cardiac conduction system and the fetal myocardium, 
gain access perhaps through apoptosis, causing in utero an inflammatory reaction of the 
conduction system and endo-myo-pericardium, resulting in fibrosis of the conduction 
system with heart block and myocarditis.  
4.2 Pathogenesis of cutaneous lupus  
The same maternal antibodies recognize the antigens present in the neonatal skin exposed to 
UV light and high estradiol concentrations and cause the cutaneous manifestations of NLE. 
And the cutaneous lupus is due to deposition of anti-Ro IgG auto- antibodies throughout 
the epidermis and not the epidermo-dermal junction or dermis, which is seen even in the 
unaffected areas of skin. Probably deposition of antibodies in the affected organ is not 
leaving enough antibodies to be deposited in other organs to cause disease manifestations. 
And it is not known whether this could be the reason why usually only one organ is 
involved in one patient and other in another patient in neonatal lupus. 
At this time, although there is compelling evidence that maternal auto- antibodies are a 
major factor in the genesis of disease, the factors that determine which child will be affected 
and which organs will be affected are largely unknown. These factors should be predictable 
so that one day it may be possible to identify the fetus at high risk, particularly for heart 
blocks, and target that particular fetus for prevention or effective treatment [Izmirly, 2007].  
5. Patient history  
The mother usually discovers her affected child either has skin rash shortly after birth or 
that her infant is highly sensitive to sunlight (intense photosensitivity). Mothers may be 
asymptomatic or have symptoms of lupus erythematosus, Sjogren’s syndrome or 
undifferentiated CTD. When carefully questioned, they may report dry eyes, arthralgias, 
myalgias, or arthritis. A recent report linked the presence of hypothyroidism in mothers 
with anti-SSA/Ro with an increased risk of CHB. Cardiac involvement can be revealed in 
ultrasound exam of fetus from routine antenatal check-up from 20-24 weeks gestation in the 
form of bradycardia which may suggest cardiac lupus (CHB) or by physical exam at birth.  
6. Clinical manifestations  
A fetus/newborn can have either cutaneous or cardiac or both as the major manifestations 
of NLE. Cardiac manifestations usually occur at 18 to 24 weeks gestation. The rash is often 
present at birth, but can appear up to four months of age. 
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The commonest manifestation, CHB, is seen in 61%, cutaneous manifestations in 26.9% both 
cardiac & cutaneous manifestations in 8.7% and hepatic or hematological involvement in 
3.2% but the recent literature shows that cutaneous, cardiac, hepatobiliary, and 
hematological involvement was found in 70.6%, 64.7%, 52.9%, and 35.3% of infants 
respectively with a mortality of 11.8% in 64.7% of asymptomatic mothers in recent literature 
[Wisuthsarewong, 2011]. NLE can also involve liver (6.2%), blood (5.2%), CNS (0.8%), lung 
(0.8%) and kidney (0.4%). It is usually common to see NLE with affection of one organ, 
although involvement of multiple organs can occur [Buyon, 2001]. 
6.1 Neonatal cutaneous lupus  
This is seen in 15-30% of neonatal lupus and the incidence may be higher than this as it may 
be under reported because the skin rash is transient and majority of their mothers are 
usually asymptomatic. It is more common in female (3:1) than male neonates. 
Cutaneous findings in neonatal lupus erythematosus [Wisuthsarewong, 2011] 
 Annular erythematous plaques with a small scales characterize neonatal lupus 
erythematosus. Atrophic lesions may develop; however, over time, even these lesions 
leave little residual change. These lesions are usually not present at birth but may 
become evident shortly afterward, particularly in infants exposed to light therapy 
[Figure 2].  
 
 
Fig. 2. Neonatal cutaneous lupus erythematosus 
 These skin lesions are usually non-scarring and non-atrophic.  
 The lesions are mainly seen on the face, scalp, trunk and extremities. The lesions are 
very dense in the periorbital area which gives an “eye-mask” or “owl-eye appearance 
(with ice-pick lesions located to the superior aspect of face, lateral edges of eyes, 
spreading into the temple regions bilaterally). Mild erythema on the face was observed 
at birth.  
 An erythematosus raccoon-like patch began to develop on the face following sun 
exposure. 
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 It becomes plaque like and develop scaling and desquamation  
 Intense photosensitivity is another striking feature in neonatal cutaneous lupus. 
 Telangiectasia is often prominent and is the sole cutaneous manifestation reported in 
some patients, sometimes to the extent of forming muco-cutaneous and visceral 
hemangiomas [Spalding, 2007]. 
 Dyspigmentation is frequent, but, with time, this change spontaneously resolves. It may 
last as long as one year. 
 Although histology is typical but it is not needed in most cases due to characteristic 
appearance of rash in the presence of auto-antibodies [Lee LA, 1993]. 
The lesional histology supports the clinical descriptions of sub acute cutaneous lupus with 
basal cell damage in the epidermis and a superficial mononuclear cell infiltrate in the upper 
dermis. As observed in sub acute cutaneous lupus, immunofluorescence is positive with the 
finding of a particulate pattern of IgG in the epidermis. The histopathology of the 
erythematous-desquamative lesions more closely resembles that of sub acute cutaneous 
lupus erythematosus (SCLE) than discoid lupus. Typical findings are vacuolar alterations at 
the dermo-epidermal interface and adnexal structures. 
Some patients present with urticaria-like lesions that have superficial and deep perivascular 
and periadnexal lymphocytic infiltrates [Silverman, 2010, Penate, 2009]. The identification of 
cutaneous NL in an anti-SSA/Ro antibody-exposed infant is particularly important, since it 
predicts a 6-10-fold risk of a subsequent child developing cardiac NL [Izmirly, 2010].  
6.2 Neonatal cardiac lupus 
The commonest cardiac manifestation of neonatal lupus is congenital complete heart block 
and the next one is cardiomyopathy with or without heart failure. There are other rare 
cardiac manifestations that may be seen [Table 1).  
6.2.1 Congenital complete heart block (CHB) 
The most dangerous and life threatening cardiac manifestation of NLE is complete heart 
block (CHB) which is more common in female neonates (3:1) and usually appear in fetus 
from 20-24 weeks of gestation by fetal ultrasound exam and in 90% of cases it is seen by 
birth. It is mainly due to the anti-SSA/Ro with or without anti-SSB/La antibodies. Anti-
SSB/La and anti-U1 RNP alone are not associated with cardiac lupus. It is seen in 62% cases 
of NLE as against 31% of cases with cutaneous lupus and together with cutaneous lupus it is 
seen only in 4% of cases. CHB is usually detected by fetal US exam as fetal bradycardia  
(40-80 beats/min) [Brucato, 1995, 2007; Agarwala, 1996]. NLE is responsible for 90-95% of 
CHB presenting in utero and only 5% of cases of CHB after birth.  The incidence of CHB in 
the general population varies between 1 in 15,000 to 1 in 22,000 live-born infants 
[Michaëlsson, 1972]. 
Presentation in the neonate: 
 Bradycardia 
 Intermittent cannon waves in the neck, 
 First heart sound that varies in intensity, 
 Intermittent gallops and murmurs.  
 The newborn at greatest risk has a rapid atrial rate, often 150 beats/min or faster, and a 
ventricular rate less than 50 beats/min.  With junctional or atrioventricular (AV) nodal 
escape or ectopic rhythm 
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  First or second degree heart block found in infants at birth can progress to complete 
heart block [Jaggie, 2002]. 
It may take just one week for a neonate to develop CHB from a normal PR interval, so 
weekly fetal echo is very important between 16-24wks. 
Presentation in the childhood: 
Only 60% present before six years as the ventricular rate is adequate from the junctional 
release rhythm so they become symptomatic later in their life and the CHB is  
usually intermittent initially before becoming persistent. They are usually picked up for 
slow pulse which is not symptomatic. Some patients present with bradycardia-related 
symptoms like 
 Reduced exercise tolerance and  
 Pre-syncope or syncope (Stokes-Adams attacks) -26% 
 Sudden death has also been described -6% 
The sinoatrial (SA) node also may be involved and sinus bradycardia has been described in 
3.8 percent of fetuses but is usually not permanent. 
Other types of electrical disturbances can be there as reported in the table 1. There are host 
of other cardiac manifestations which are not that common.  
    
Electrical Mechanical Structural 
CHB 
II° Heart block 




Prolonged QT interval 
(sudden death) 
Cardiomyopathy  
CHF Hydrops fetalis 







Valvular lesions  (rare) 
Intramyocardial 




Patent foramen ovale 
Pulmonary  stenosis 
Pulmonary regurgitation 
Coarctation of Aorta 
Tetrology of Fallot 
Hypoplastic  RV 
Anomalous Pulmonary Venous 
Drainage 
PV dysplasia, 
Fusion of chordae tendineae of 
the  valves,  causing MR & TR 
Table 1. Cardiac disorders reported in neonatal cardiac lupus  
(Data adopted from Buyon et al, 1998, 2007, Hornberger, 2010]. 
6.2.2 Cardiomyopathy/ CHF/ hydrops fetalis  
This is the second most common cardiac abnormality commonly in the presence of CHB 
but can occur rarely in the absence of CHB. It may be due to various reasons. It may be 
due to the extension of fibrotic process into the myocardium causing myocardial fibrosis 
and CHF or it may be due to compensatory ventricular dilatation to increase the stroke 
volume due to bradyarrhythmia or it can also be due to the ventricular asynchrony due to 
right ventricular pacing alone. It is seen in 10% of cases and the mortality is higher in the 
neonates presented early with CHB than presenting after birth. CHF is rarely seen in CHB 
presenting after birth. 
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Structural heart disease has been reported occasionally in association with NLE. However, 
caution is needed in interpreting such reports because the inflammatory fibrosis of 
conduction system occurs usually after the organogenesis is complete (after first trimester) 
and some structural abnormalities may cause heart block per se (e.g., L-transposition of the 
great vessels with a single ventricle, ostium primum type atrial septal defect, and rarely 
ventricular septal defects ). Out of all these anomalies, only VSD has been reported in 
association with NLE. The commonest among these are ASD, PDA and VSD [Buyon, 1998; 
Falcini, 1998; Houssiau, 1986]. 
Other congenital structural cardiac anomalies have also been observed in association with 
NLE (persistent patent ductus arteriosus, patent foramen ovale, pulmonary  stenosis, 
pulmonary regurgitation, coarctation of aorta, tetrology of Fallot, hypoplastic right ventricle, 
anomalous pulmonary venous drainage, pulmonary valvular dysplasia, fusion of chordae 
tendinae of the tricuspid valve, TR, MR, and ostium secundum type atrial septal defects 
[Table 1].  
NLE with CHB has been associated with endocardial fibroelastosis (EFE). In a report of 13 
affected children, seven had EFE at presentation (four fetal and three postnatal), and six 
developed EFE weeks to as long as five years after the diagnosis of complete heart block. 
Eleven either died or underwent cardiac transplantation because of the EFE. EFE has also 
been reported in the absence of a conduction defect in infants with maternal anti-Ro and 
anti-La antibodies [Nield, 2002]. 
6.3 Hematological manifestations  
They are commonly asymptomatic in the form of thrombocytopenia (frequently associated 
with splenomegaly), anemia (Coombs-positive hemolytic anemia or microangiopathic 
hemolytic anemia), leucopenia, neutropenia (in up to 25% of NLE) and rarely aplastic 
anemia. The thrombocytopenia and anemia very rarely can be so severe requiring blood 
transfusions and sterioid therapy. Lymphopenia, which is commonly seen in adult lupus, is 
not usually seen in neonatal lupus [Wolach, 1993].  
6.4 Hepatic and gastrointestinal manifestations  
They are seen in 10-25%. Three types of liver manifestations were observed. Liver failure, 
with histological features of neonatal iron storage disease, occurring in utero or shortly 
after birth and resulting in fatality; cholestasis with conjugated hyperbilirubinemia and 
minimal transaminase elevations occurring a few weeks after birth and eventually 
resolving; and mild or moderate transaminase elevations occurring a few weeks or 
months after birth and resolving. Rarely patients can have cirrhosis and gastrointestinal 
hemorrhage. The pathology resembles idiopathic neonatal giant cell hepatitis [Silverman, 
2010; Izmirly, 2010].  
6.5 Neurological manifestations  
They are seen in less than 1% of patients in the form of myelopathy, aseptic meningitis, 
seizures with or without hypocalcaemia, myasthenia gravis (transient) [Kaye, 1987], 
hydrocephalus, microcephaly, macrocephaly, non- specific white matter changes, 
calcification of basal ganglia, vasculopathy and neuropsychiatric dysfunction/attention 
deficient disorders [Boros, 2007].  
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  First or second degree heart block found in infants at birth can progress to complete 
heart block [Jaggie, 2002]. 
It may take just one week for a neonate to develop CHB from a normal PR interval, so 
weekly fetal echo is very important between 16-24wks. 
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volume due to bradyarrhythmia or it can also be due to the ventricular asynchrony due to 
right ventricular pacing alone. It is seen in 10% of cases and the mortality is higher in the 
neonates presented early with CHB than presenting after birth. CHF is rarely seen in CHB 
presenting after birth. 
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6.6 Other rare manifestations  
They can be in the form of pulmonary (Pneumonia), renal (nephritis or nephritic syndrome), 
bony (chondrodysplasia punctata) [Silverman, 2010] or multiple thrombosis due to maternal  
cardiolipin antibodies [Tabbut, 1994]. 
The NLE occurring in the subsequent pregnancies after a lupus child is up to 36%, out of 
which 12.8% were complicated by cardiac NL and 23.1% by cutaneous NLE. There were no 
significant differences in the following maternal risk factors for having a subsequent child 
with cardiac or cutaneous NLE: age, race, ethnicity, anti-SSB/La status, diagnosis, use of 
non-fluorinated steroids, or breastfeeding. The sex of the subsequent fetus did not influence 
the development of cardiac or cutaneous NL [Izmirly, 2010]. 
The manifestation of anti-RNP positive is a rare occurrence. It was noted that infants 
affected with NLE from anti-RNP antibodies developed only cutaneous lesions and were all 
male [Boh, 2004]. 
The transient hematologic abnormalities and skin disease of the neonate reflect the effect of 
passively acquired auto- antibodies on those organ systems that have the capacity of 
continual regeneration, in contrast to the heart, which apparently lacks this capability, 
because, to date, third-degree heart block is irreversible [Buyon, 2007].  
7. Diagnosis  
The diagnosis of NLE is made when a fetus or newborn of a mother with anti-SSA/Ro 
and/or anti-SSB/La, or anti-RNP, antibodies develops heart block and/or the typical rash, 
hepatic or hematologic manifestations,  in the absence of other causes. The following 
recommendations for prenatal screening and postnatal diagnosis are based upon the 
potential cardiac manifestations of neonatal lupus (NLE) and their associated morbidity and 
mortality.  
7.1 Prenatal screening (antibodies)  
Prenatal screening for anti-SSA/Ro and anti-SSB/La antibodies is warranted for women 
who are known to be at risk of having a pregnancy complicated by NLE. Women who are 
more likely to have anti-SSA/Ro and anti-SSB/La antibodies include those with lupus, 
Sjogren’s syndrome, an undifferentiated autoimmune disease, or NLE in a previous 
pregnancy. Women with these identifiable risk factors should be tested before conception or 
early pregnancy as soon as possible.  
7.2 Intra-natal diagnosis  
CHB in an offspring can be the first sign in the mother that has anti-SSA/Ro and anti-
SSB/La antibodies. These antibodies are not part of routine prenatal testing in 
asymptomatic women. 
7.2.1 Fetal echocardiography  
Women who test positive for SSA/Ro and SSB/La auto antibodies may benefit from more 
intense assessment for fetal heart block with frequent fetal echocardiographic testing during 
pregnancy. There are no formal guidelines for the type or the frequency of testing to detect 
fetal heart block, but performing weekly pulsed Doppler fetal echocardiography from the 
16th through the 26th week of pregnancy and then every other week until 32 weeks should 
 
Neonatal Lupus Erythematosus (NLE) 
 
517 
be strongly considered. The most vulnerable period for the fetus is during the period from 
18 to 24 weeks gestation. Normal sinus rhythm can progress to complete block in seven days 
during this high-risk period. New onset of heart block is less likely from 26 to 30 weeks, and 
it rarely develops after 30 weeks of pregnancy.  
7.2.2 Pulsed Doppler echocardiography  
Less-advanced degrees of heart block can be detected in utero by this technique [Glickstein, 
2000]. And it depends upon measurement of the mechanical PR interval as determined from 
the onset of atrial contraction (initiation of mitral valve movement) to ventricular 
contraction (aortic pulsation). It is generally accepted that women with low titer antibodies 
are less likely to have offspring with cardiac NLE than women with high titers. The problem 
is that laboratories have different cutoff values and most women with these antibodies have 
high titers.  
7.2.3 Fetal auscultation (fetoscope) / fetal ultrasound  
Complete heart block (and usually second-degree block) results in fetal bradycardia that can 
be detected by even routine fetal auscultation or ultrasonography (sonogram). The use of 
echocardiographic monitoring may present a way to more selective use interventions to 
prevent or reverse the development of more advanced heart block. Fetal monitoring may 
include a biophysical profile and non-stress test [Vesel, 2004; Sonesson, 2004].  
7.2.4 Biophysical profile  
A biophysical profile (BPP) score is calculated to assess the fetus' health. It consists of five 
components which include non-stress testing and ultrasound measurement of four fetal 
parameters: fetal body movements, breathing movements, fetal tone (flexion and extension 
of an arm, leg, or the spine) and measurement of the amniotic fluid levels. Each component 
is scored individually, with two points given for a normal result and zero points given for 
an abnormal result. The maximum possible score is 10. The amniotic fluid level is an 
important variable in the BPP because a low volume (called oligohydramnios) may increase 
the risk of umbilical cord compression and may be a sign of changes in the blood flow 
between the baby and mother. Amniotic fluid levels can become reduced within a short time 
period, even a few days.  
7.2.5 Non-stress testing  
Non-stress testing is done by monitoring the baby's heart rate with a small device that is 
placed on the mother's abdomen. The device uses sound waves (ultrasound) to measure the 
baby's heart rate over time, usually for 20 to 30 minutes. Normally, the baby's baseline heart 
rate should be between 110 and 160 beats per minute and should increase above its baseline 
by at least 15 beats per minute for 15 seconds when the baby moves. The test is considered 
reassuring (called "reactive") if two or more fetal heart rate increases are seen within a 20 
minute period. Further testing may be needed if these increases are not observed after 
monitoring for 40 minutes.  
7.3 Postnatal diagnosis  
Testing for maternal anti-SSA/Ro antibodies should be performed in any neonate with heart 
block, because these antibodies account for 80 to 95 percent of reported cases of CHB in the 
 
Systemic Lupus Erythematosus 
 
516 
6.6 Other rare manifestations  
They can be in the form of pulmonary (Pneumonia), renal (nephritis or nephritic syndrome), 
bony (chondrodysplasia punctata) [Silverman, 2010] or multiple thrombosis due to maternal  
cardiolipin antibodies [Tabbut, 1994]. 
The NLE occurring in the subsequent pregnancies after a lupus child is up to 36%, out of 
which 12.8% were complicated by cardiac NL and 23.1% by cutaneous NLE. There were no 
significant differences in the following maternal risk factors for having a subsequent child 
with cardiac or cutaneous NLE: age, race, ethnicity, anti-SSB/La status, diagnosis, use of 
non-fluorinated steroids, or breastfeeding. The sex of the subsequent fetus did not influence 
the development of cardiac or cutaneous NL [Izmirly, 2010]. 
The manifestation of anti-RNP positive is a rare occurrence. It was noted that infants 
affected with NLE from anti-RNP antibodies developed only cutaneous lesions and were all 
male [Boh, 2004]. 
The transient hematologic abnormalities and skin disease of the neonate reflect the effect of 
passively acquired auto- antibodies on those organ systems that have the capacity of 
continual regeneration, in contrast to the heart, which apparently lacks this capability, 
because, to date, third-degree heart block is irreversible [Buyon, 2007].  
7. Diagnosis  
The diagnosis of NLE is made when a fetus or newborn of a mother with anti-SSA/Ro 
and/or anti-SSB/La, or anti-RNP, antibodies develops heart block and/or the typical rash, 
hepatic or hematologic manifestations,  in the absence of other causes. The following 
recommendations for prenatal screening and postnatal diagnosis are based upon the 
potential cardiac manifestations of neonatal lupus (NLE) and their associated morbidity and 
mortality.  
7.1 Prenatal screening (antibodies)  
Prenatal screening for anti-SSA/Ro and anti-SSB/La antibodies is warranted for women 
who are known to be at risk of having a pregnancy complicated by NLE. Women who are 
more likely to have anti-SSA/Ro and anti-SSB/La antibodies include those with lupus, 
Sjogren’s syndrome, an undifferentiated autoimmune disease, or NLE in a previous 
pregnancy. Women with these identifiable risk factors should be tested before conception or 
early pregnancy as soon as possible.  
7.2 Intra-natal diagnosis  
CHB in an offspring can be the first sign in the mother that has anti-SSA/Ro and anti-
SSB/La antibodies. These antibodies are not part of routine prenatal testing in 
asymptomatic women. 
7.2.1 Fetal echocardiography  
Women who test positive for SSA/Ro and SSB/La auto antibodies may benefit from more 
intense assessment for fetal heart block with frequent fetal echocardiographic testing during 
pregnancy. There are no formal guidelines for the type or the frequency of testing to detect 
fetal heart block, but performing weekly pulsed Doppler fetal echocardiography from the 
16th through the 26th week of pregnancy and then every other week until 32 weeks should 
 
Neonatal Lupus Erythematosus (NLE) 
 
517 
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fetus and neonate. Infants up to eight months of age with an annular or polycyclic rash 
and/or any degree of heart block should be tested for anti-SSA/Ro and anti-SSB/La 
antibodies. A positive test in the child or mother fulfills the diagnostic criteria for NLE 
[Buyon, 2001, Jaeggi, 2002, Johansen, 1998]. 
An infant diagnosed with NLE who has compatible clinical manifestations and detectable 
auto antibodies (i.e., anti-SSA/Ro and/or anti-SSB/La in the mother or infant), but no 
electrocardiographic evidence of heart block of any degree at birth, is at very low risk of 
subsequently developing conducting system disease. However, there have been rare cases of 
isolated cardiomyopathy reported. 
8. Differential diagnosis  
8.1 Differential diagnosis of cutaneous neonatal lupus  
 
Polycyclic Skin Lesions Isolated Annular Erythematosus 
Urticaria  
Erythema marginatum  
Tinea Seborrheic dermatitis  
Ichthyosiform genodermatosis  
Erythema annulare centrifugum  
Familial annular erythema  
Erythema multiforme  
Infantile epidermodysplastic erythema  
Pityrosporum (Malassezia species) dermal 
infection  
Annular erythema of infancy  
Erythema gyratum atrophicans 
Table 2. Differential diagnosis of cutaneous  neonatal  lupus 
(Data adopted from Lee LA, 1997)  
The differential diagnosis includes various rashes seen in the newborn period. These other 
rashes are not associated with maternal anti-SSA/Ro, anti-SSB/La, or anti-RNP antibodies 
or with congenital heart block [Table 2]. 
8.2 Differential diagnosis of cardiac neonatal lupus  
Differential diagnosis of congenital CHB [Jaeggi et al, 2002] 
Although neonatal lupus is responsible for 95% of congenital CHB in neonate but it is a 
cause for CHB after birth in only 5% of the children. The other causes of CHB are: 
 Myocarditis  
 Various structural cardiac defects 
 Congenitally corrected transposition of the great arteries,  
 Atrioventricular discordance, 
 Polysplenia with atrioventricular canal defect.  
 Several hereditary disorders 
In complicated congenital lesions such as transposition of great vessels it is difficult to say 
whether it is due to NLE or due to the cardiac defect itself. 
The patients who present with congenital CHB can be differentiated from other causes of 
CHB by early presentation (20-24wks of gestation) as fetal bradycardia and/or fetal PR 
interval and may have additional structural cardiac abnormalities commonest being VSD & 
endocardial fibroelastosis along with presence of antibodies to SSA/SSB. They may also 
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have complications due to CHB like hydrops fetalis, endocardial fibroelastosis, pericardial 
effusion, and spontaneous intrauterine fetal death. 
9. Treatment  
9.1 Treatment of congenital heart block  
Prenatal testing for anti-SSA/Ro and anti-SSB/La antibodies is being done only in high risk 
women, like women with SLE, Sjogren’s syndrome, or other systemic rheumatic diseases 
(UCTD or UAS) and previous child with NLE where the risk is up to 25%. Careful 
monitoring during gestation with fetal ultrasound and echocardiography from 16th week of 
pregnancy is to be done. The best treatment for CHB is prevention as once CHB is 
diagnosed medical treatment seems to be unsuccessful. Testing for candidate antibodies is 
important prior to initiating therapy for a presumed case of neonatal cardiac lupus, because 
there are cases of heart block not associated with anti-SSA/Ro and SSB/La antibodies. 
9.1.1 Preventive therapy 
As the incidence of congenital heart block is only 2% in the offspring of unselected anti-Ro 
antibody positive mothers the preventative therapy cannot be advocated for this group.  
However, in women with a previous child with congenital heart block the risk is greater, in 
the region of 17–19%. Graham Hughes has proposed that in this group of patients, maternal 
administration of intravenous immunoglobulins (IVIG) may reduce the risk of recurrences.  
A multinational open label study is currently underway based at The Lupus Unit, St. 
Thomas’ Hospital, London, UK [Gordon, 2007] to confirm or refute the efficacy of IVIG in 
preventing congenital heart block. 
Another potential strategy to prevent recurrence in subsequent pregnancies was immune-
suppression with fluorinated steroids, which cross the placenta. However, the toxicity of 
these agents precludes their use as a preventative therapy. Serious effects on the fetus such 
as spontaneous abortions, stillbirth, IUGR, low birth weight, mild adrenal insufficiency, left 
ventricular myocardial hypertrophy and delayed psychomotor development were noticed 
with these drugs apart from the adverse effects on the mother [Gordon, 2007]. A case control 
study suggests that hydroxychloroquine, a Toll-like receptor (TLR) inhibitor the usage of 
which carries minimal risk to the mother and fetus, may decrease the risk of neonatal 
cardiac lupus related to anti-SSA/SSB antibodies. But prospective studies are needed for its 
confirmation [Izmirly, 2010].  
9.1.2 Care of neonates at risk for complete heart block 
Careful observation of infants whose second-degree atrioventricular block has been 
reversed in utero is necessary in the postnatal period, as there is still a risk of progression to 
a higher degree heart block, even with clearance of maternal auto antibodies. If prenatal 
screening or fetal monitoring has detected any degree of heart block in utero, consultation 
with a pediatric cardiologist should be obtained. Some infants with complete heart block 
will require insertion of a cardiac pacemaker, especially if the heart rate at delivery is less 
than 55 beats per minute [Izmirly, 2010].  
An electrocardiogram (ECG) should be performed in all neonates born to mothers with anti-
SSA/Ro and/or anti-SSB/La antibodies to detect first-degree heart block; infants with first-
degree heart block are at risk of postnatal progression to higher degree block [Lawrence, 
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have complications due to CHB like hydrops fetalis, endocardial fibroelastosis, pericardial 
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study suggests that hydroxychloroquine, a Toll-like receptor (TLR) inhibitor the usage of 
which carries minimal risk to the mother and fetus, may decrease the risk of neonatal 
cardiac lupus related to anti-SSA/SSB antibodies. But prospective studies are needed for its 
confirmation [Izmirly, 2010].  
9.1.2 Care of neonates at risk for complete heart block 
Careful observation of infants whose second-degree atrioventricular block has been 
reversed in utero is necessary in the postnatal period, as there is still a risk of progression to 
a higher degree heart block, even with clearance of maternal auto antibodies. If prenatal 
screening or fetal monitoring has detected any degree of heart block in utero, consultation 
with a pediatric cardiologist should be obtained. Some infants with complete heart block 
will require insertion of a cardiac pacemaker, especially if the heart rate at delivery is less 
than 55 beats per minute [Izmirly, 2010].  
An electrocardiogram (ECG) should be performed in all neonates born to mothers with anti-
SSA/Ro and/or anti-SSB/La antibodies to detect first-degree heart block; infants with first-
degree heart block are at risk of postnatal progression to higher degree block [Lawrence, 
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2000]. A normal ECG is reassuring. However, even a normal EKG at birth cannot exclude 
the subsequent development of second degree heart block. There are reports of anti-Ro 
antibody associated cardiomyopathy also, in the absence of heart block [Gordon, 2007].  
9.1.3 Treating of fetal heart block  
Complete heart block is irreversible even with glucocorticoid therapy [Saleeb, 1999]. Second-
degree heart block may be reversible, but it also may progress to complete heart block 
despite therapy [Yamada, 1999]. The clinical relevance of first-degree heart block is unclear, 
since progression from first-degree block to more advanced heart block in untreated fetuses 
has not been reported. 
Fluorinated glucocorticoids such as dexamethasone and betamethasone, which are 
not inactivated by placental 11-beta hydroxysteroid dehydrogenase, may suppress the 
associated pleuro-pericardial effusion or hydrops and may improve outcomes. Fluorinated 
glucocorticoids are also considered for signs of a more global cardiomyopathy. However, 
the effectiveness of these agents in the treatment of endocardial fibroelastosis is unknown. 
Maternal dexamethasone in conjunction with transplacental β-adrenergic stimulation for 
bradycardia in fetus with HR of <55 beats/mt was reported to be effective in CHB [Jaeggi et 
al, 2010).  
Many children with congenital heart block (33–53%) require pacing as newborns. Due to 
the long-term risk of sudden death the vast majority of patients are paced by the time they 
reach adult life. Data from several studies suggest that right ventricular apex pacing may 
cause left ventricular dysfunction secondary to asynchronous right and left ventricular 
contraction and relaxation. Thus, late onset cardiomyopathy, in at least some congenital 
heart block patients, may be due to right ventricular apex pacing rather than the 
underlying disease process. Pacing at earlier age and higher rate of pacing may accentuate 
this problem [Lawrence, 2000]. 
A prolonged QTc is a recognized feature of congenital heart block and occurs in 15–22% of 
patients. Due to the risk of torsades de pointes these patients should be paced and treated 
with a beta-blocker. A prolonged QTc has been reported to occur in isolation in children 
born to anti-Ro positive mothers, although prospective studies do not suggest this as a 
common occurrence [Gordon, 2007]. 
Prolonged in-utero exposure to fluorinated glucocorticoids (e.g., betamethasone or 
dexamethasone) can lead to adrenal hypoplasia and result in neonatal adrenal insufficiency 
[Costedoat-Chalumeau, 2003]. This is a rare complication that can be anticipated and tested 
for. Neonatal hypotension that potentially results from adrenal insufficiency should be 
treated empirically with hydrocortisone in addition to standard supportive care.  
9.1.4 Laboratory evaluation and management (Buyon, 2001) 
1. ELISA- If this initial screening test is negative for anti-SSA/Ro and anti-SSB/La 
antibodies the pregnancy has no known risk for CHB. If positive, 
2. Immunoblot testing to be done to stratify the risk into low, moderate and high. 
a. Negative immunoblot defines low risk pregnancy (<2% probability of CHB) 
b. Positive 52kD and 60kD Ro and La antibodies  is moderate risk (2-5% probability of 
CHB) 
c. Positive 52kD and 60kD Ro and La antibodies with previous NLE child is high risk 
pregnancy (15-20% probability of CHB) 
 




Low risk- Fetal echo alternate weeks from 16-36wks & continuous auscultation 
Moderate risk- Fetal echo every week from 16-26 wks and then alternate weeks from 26-36  
  Wks & Continued auscultation 
High risk- Fetal echo weekly from 16-36 wks & continued auscultation 
If echo shows prolonged mechanical PR interval or advanced degree block then follow the 
therapeutic approach which depends on degree of block and fetal morbidity at presentation 
[Jaeggi et al, 2004]. 
1a. III° AVB >2wks from detection=serial echo, fetal US, no therapy initiated 
1b. III° AVB <2wks from detection=start oral dexamethasone-4mg/day for 6wks 
                                               If no change taper the dose  
                                               If reversed to II° AVB or less continue till delivery, and then  
   taper 
1c. Alternating III° AVB with II° AVB = start oral dexamethasone-4mg/day for 6wks 
                                                 If it progress to III° AVB taper the dose  
                                                   If reversed to II° AVB or less continue till delivery, and then 
    taper 
1d. II° or I° AVB =start oral dexamethasone-4mg/day till delivery, and then taper 
                                                 If it progress to III° AVB give for 6 wks, and then taper 
2. Heart block with signs of myocarditis, CHF, and/of hydropic changes 
                                                 Start oral Dexamethasone until improvement, and then taper 
3. Severe hydrops fetalis= start oral dexamethasone-4mg/day +  
                                                +Plasmapheresis (to remove the antibodies rapidly) 
                                                +Deliver if the lungs are mature  
Fluorinated steroids cross the placental barrier, therefore dexamethasone or betamethasone 
is chosen for treatment. However, data during the same period at Guy’s Hospital, London, 
has not supported the hypothesis that the improved survival can be attributed to 
dexamethasone therapy. As such a prospective study is needed to establish the role of 
routine dexamethasone therapy in congenital heart block. 
At present, given the potential toxicity of dexamethasone to the fetus it is perhaps advisable 
to take a conservative approach and reserve the use of fluorinated steroids for cases where 
there is evidence of hydrops, poor ventricular function, or both. In compromised fetuses 
with a heart rate below 55 bpm maternal administration of β-sympathomimetic agents may 
be considered.   New ultrasound methods allow measurement of the fetal atrioventricular 
time interval which provides a ‘mechanical’ PR interval and therefore it is now possible to 
detect first-degree heart block in utero.  
If the natural history of congenital heart block involves the development of lesser degrees of 
heart block progressing to complete congenital heart block, detection of first-degree 
congenital heart block could theoretically provide a window of opportunity where 
therapeutic intervention is beneficial, either reversing the heart block or preventing 
progression to complete congenital heart block. The PRIDE (PR interval and dexamethasone 
evaluation) study is assessing this possibility by frequent measurement of the mechanical 
PR interval, weekly from 16 to 26 weeks gestation and then biweekly until 34 weeks, in 
pregnancies where the mother is anti-Ro antibody positive [Gordon,2007]. 
Thus even with intense monitoring lesser degrees of heart block are frequently not detected 
prior to the development of complete congenital heart block, providing little opportunity for  
 
Systemic Lupus Erythematosus 
 
520 
2000]. A normal ECG is reassuring. However, even a normal EKG at birth cannot exclude 
the subsequent development of second degree heart block. There are reports of anti-Ro 
antibody associated cardiomyopathy also, in the absence of heart block [Gordon, 2007].  
9.1.3 Treating of fetal heart block  
Complete heart block is irreversible even with glucocorticoid therapy [Saleeb, 1999]. Second-
degree heart block may be reversible, but it also may progress to complete heart block 
despite therapy [Yamada, 1999]. The clinical relevance of first-degree heart block is unclear, 
since progression from first-degree block to more advanced heart block in untreated fetuses 
has not been reported. 
Fluorinated glucocorticoids such as dexamethasone and betamethasone, which are 
not inactivated by placental 11-beta hydroxysteroid dehydrogenase, may suppress the 
associated pleuro-pericardial effusion or hydrops and may improve outcomes. Fluorinated 
glucocorticoids are also considered for signs of a more global cardiomyopathy. However, 
the effectiveness of these agents in the treatment of endocardial fibroelastosis is unknown. 
Maternal dexamethasone in conjunction with transplacental β-adrenergic stimulation for 
bradycardia in fetus with HR of <55 beats/mt was reported to be effective in CHB [Jaeggi et 
al, 2010).  
Many children with congenital heart block (33–53%) require pacing as newborns. Due to 
the long-term risk of sudden death the vast majority of patients are paced by the time they 
reach adult life. Data from several studies suggest that right ventricular apex pacing may 
cause left ventricular dysfunction secondary to asynchronous right and left ventricular 
contraction and relaxation. Thus, late onset cardiomyopathy, in at least some congenital 
heart block patients, may be due to right ventricular apex pacing rather than the 
underlying disease process. Pacing at earlier age and higher rate of pacing may accentuate 
this problem [Lawrence, 2000]. 
A prolonged QTc is a recognized feature of congenital heart block and occurs in 15–22% of 
patients. Due to the risk of torsades de pointes these patients should be paced and treated 
with a beta-blocker. A prolonged QTc has been reported to occur in isolation in children 
born to anti-Ro positive mothers, although prospective studies do not suggest this as a 
common occurrence [Gordon, 2007]. 
Prolonged in-utero exposure to fluorinated glucocorticoids (e.g., betamethasone or 
dexamethasone) can lead to adrenal hypoplasia and result in neonatal adrenal insufficiency 
[Costedoat-Chalumeau, 2003]. This is a rare complication that can be anticipated and tested 
for. Neonatal hypotension that potentially results from adrenal insufficiency should be 
treated empirically with hydrocortisone in addition to standard supportive care.  
9.1.4 Laboratory evaluation and management (Buyon, 2001) 
1. ELISA- If this initial screening test is negative for anti-SSA/Ro and anti-SSB/La 
antibodies the pregnancy has no known risk for CHB. If positive, 
2. Immunoblot testing to be done to stratify the risk into low, moderate and high. 
a. Negative immunoblot defines low risk pregnancy (<2% probability of CHB) 
b. Positive 52kD and 60kD Ro and La antibodies  is moderate risk (2-5% probability of 
CHB) 
c. Positive 52kD and 60kD Ro and La antibodies with previous NLE child is high risk 
pregnancy (15-20% probability of CHB) 
 




Low risk- Fetal echo alternate weeks from 16-36wks & continuous auscultation 
Moderate risk- Fetal echo every week from 16-26 wks and then alternate weeks from 26-36  
  Wks & Continued auscultation 
High risk- Fetal echo weekly from 16-36 wks & continued auscultation 
If echo shows prolonged mechanical PR interval or advanced degree block then follow the 
therapeutic approach which depends on degree of block and fetal morbidity at presentation 
[Jaeggi et al, 2004]. 
1a. III° AVB >2wks from detection=serial echo, fetal US, no therapy initiated 
1b. III° AVB <2wks from detection=start oral dexamethasone-4mg/day for 6wks 
                                               If no change taper the dose  
                                               If reversed to II° AVB or less continue till delivery, and then  
   taper 
1c. Alternating III° AVB with II° AVB = start oral dexamethasone-4mg/day for 6wks 
                                                 If it progress to III° AVB taper the dose  
                                                   If reversed to II° AVB or less continue till delivery, and then 
    taper 
1d. II° or I° AVB =start oral dexamethasone-4mg/day till delivery, and then taper 
                                                 If it progress to III° AVB give for 6 wks, and then taper 
2. Heart block with signs of myocarditis, CHF, and/of hydropic changes 
                                                 Start oral Dexamethasone until improvement, and then taper 
3. Severe hydrops fetalis= start oral dexamethasone-4mg/day +  
                                                +Plasmapheresis (to remove the antibodies rapidly) 
                                                +Deliver if the lungs are mature  
Fluorinated steroids cross the placental barrier, therefore dexamethasone or betamethasone 
is chosen for treatment. However, data during the same period at Guy’s Hospital, London, 
has not supported the hypothesis that the improved survival can be attributed to 
dexamethasone therapy. As such a prospective study is needed to establish the role of 
routine dexamethasone therapy in congenital heart block. 
At present, given the potential toxicity of dexamethasone to the fetus it is perhaps advisable 
to take a conservative approach and reserve the use of fluorinated steroids for cases where 
there is evidence of hydrops, poor ventricular function, or both. In compromised fetuses 
with a heart rate below 55 bpm maternal administration of β-sympathomimetic agents may 
be considered.   New ultrasound methods allow measurement of the fetal atrioventricular 
time interval which provides a ‘mechanical’ PR interval and therefore it is now possible to 
detect first-degree heart block in utero.  
If the natural history of congenital heart block involves the development of lesser degrees of 
heart block progressing to complete congenital heart block, detection of first-degree 
congenital heart block could theoretically provide a window of opportunity where 
therapeutic intervention is beneficial, either reversing the heart block or preventing 
progression to complete congenital heart block. The PRIDE (PR interval and dexamethasone 
evaluation) study is assessing this possibility by frequent measurement of the mechanical 
PR interval, weekly from 16 to 26 weeks gestation and then biweekly until 34 weeks, in 
pregnancies where the mother is anti-Ro antibody positive [Gordon,2007]. 
Thus even with intense monitoring lesser degrees of heart block are frequently not detected 
prior to the development of complete congenital heart block, providing little opportunity for  
 




Fig. 3. Decision tree for diagnosis & management of CHB [Buyon, 2000] 
intervention. Second-degree heart block detected in utero responds to treatment with 
fluorinated steroids. Whilst first-degree heart block detected in utero resolves following 
fluorinated steroid therapy, however its natural history is unclear with many cases resolving 
spontaneously. 
Management of congenital heart block in utero and in the perinatal period can include  
 steroid therapy if associated with anti-Ro/SSA and anti-La/SSB antibodies, and 
  isoproterenol (β- sympathomimetic stimulation) 
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 And/or pacemaker insertion immediately postpartum.  
The principal therapeutic decision after the immediate perinatal period involves the need 
for pacemaker placement. Most patients ultimately have a pacemaker inserted, regardless of 
the time of onset of the syndrome. Even patients who are free of symptoms at age 15 remain 
at risk for syncope or sudden cardiac death. And pacemaker is usually inserted in at least 90 
percent by age 60 [Michaëlsson M, 1995]. 
Pacemaker: The type of pacemaker implanted is often based upon physician preference; 
either a ventricular (with rate responsiveness) or dual chamber pacemaker can be used. 
However, most physicians prefer physiologic dual chamber pacing in young patients as 
right ventricular pacing alone can cause ventricular asynchrony, which over long period of 
time can itself lead to cardiomyopathy. In addition if patient is not paced the 
bradyarrhytmia itself try to compensate with ventricular dilatation to increase the stroke 
volume which also can lead to heart failure. 
In general implantation of permanent pacemaker in advanced second or third degree heart 
block which is either intermittent or permanent is in one of any of the following: 
 Symptomatic bradycardia (syncope or presyncope) 
 Ventricular dysfunction or low cardiac output 
 A wide QRS escape rhythm 
 Complex ventricular ectopy 
 In an infant, ventricular rates <55 beats per minute or <70 beats per minute when 
associated with congenital heart disease 
However any patient with CHB is at the risk of syncope or presyncope with stokes- Adam 
attacks and sudden death, therefore they need a pacemaker.  
9.2 Treatment of neonatal cutaneous lupus  
It does not require much therapy beyond avoidance of sun exposure and use of sun block 
and hydrocortisone cream. Systemic steroids are usually not required and systemic 
antimalarials are not advised due to slow onset of action in a transient illness and because of 
its potential toxicity in infants [Lee La, 1997].  
10. Course  
10.1 Early outcome  
The rash of neonatal lupus (NLE) generally does not cause scarring or atrophy and 
disappears within six to eight months. Appearance of NLE skin lesions postnatally is 
independent of breastfeeding [Klauninger, 2009]. Thus, breastfeeding is not contraindicated 
in mothers with anti-SSA/Ro and/or anti-SSB/La antibodies. 
There is little risk of later cardiac involvement in patients who had no evidence of heart 
block of any degree at birth or who had non-cardiac manifestations of NLE (rash or 
hematologic/liver abnormalities) at the time of diagnosis. However, infants with non-
cardiac manifestations of NLE should at least have an ECG, and possibly an 
echocardiogram, since first-degree block is clinically silent and can progress postnatally. 
There have been no reported cases, nor has the Research Registry for Neonatal Lupus 
recorded the occurrence, of subsequent development of heart block following a normal 
electrocardiogram. As noted previously, second-degree block detected in utero and first 
or second degree heart block found at birth, can progress to complete heart block 
[Askanase, 2010].  
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10.2 Childhood mortality 
The early outcome in infants with congenital complete heart block had a mortality of 43% 
if diagnosed in utero but only 6% for cases diagnosed at birth and among survivors 89% 
were paced [Jaeggi, 2010]. Therefore the mortality is higher for CHB diagnosed in utero 
than at birth. Late mortality may occur from arrhythmias, pacemaker failure or CHF. 
Mortality due to refractory heart failure is about 10% while the average mortality due to 
CHB is up to 20%. 
The majority of the deaths occur in utero and first three months of life. And one year 
mortality is up to 41% (12%-41%) out of which 27% die within the first week of birth and 9% 
in the first three month but the mortality is only 3% for cases diagnosed after birth.  
Predictors of early mortality include a fetal heart rate<55 beats/min, delivery prior to 34 
weeks and hydrops. The mortality is 3% in the 2nd year and another 3% in the 3rd year and 
no deaths related to cardiac lupus after three years in a study by Buyon and his colleagues. 
The main cause of early death is cardiac failure secondary to cardiomyopathy particularly in 
children between 2 and 4 years. 
These children developed late onset cardiomyopathy despite early pacing. Survival also 
depends on the gestational age of birth. The earlier they are born the more the mortality is. 
The children born before 34 weeks the mortality is 52% than children born later in whom the 
mortality is only 9% [ Buyon, 1998].  
10.3 Long-term prognosis of the child  
Infants and young children with complete heart block who are asymptomatic usually 
remain well until later childhood, adolescence, or adulthood. However, exercise limitation 
and even death are possible in the absence of pacing. The prognosis following pacemaker 
implantation is excellent for most children, although development of heart failure may 
occur.  
Children who have had NLE may be at increased risk of developing an autoimmune and/or 
rheumatic disease, although it is rare. They are usually SLE, Juvenile RA, Sjogren’s 
syndrome, undifferentiated connective tissue disease (UCTD), Hashimoto thyroiditis, 
Psoriasis, Iritis, type 1 DM, Raynaud's phenomenon or nephritic syndrome. Probably the 
longer the follow up period the higher the incidence of autoimmune disease in the child 
with NLE but, it is usually around 10% [Martin, 2007]. 
10.4 Maternal health & long-term outcome of mothers  
At least 50% of the mothers with NLE had rheumatologic disease at presentation. Out of 
which 10% have SLE, 20% Sjogren’s syndrome and 20% undifferentiated (UCTD). And 50% 
of the remaining asymptomatic patients developed disease in 20 year follow-up period 
mainly Sjogren’s syndrome, SLE, UCTD, and others. Greater proportion of mothers has 
rheumatologic disease whose children have cutaneous NLE than CHB. 
The development of lupus nephritis in mothers of children with NLE is relatively 
uncommon. In a review of the database of the Research Registry for Neonatal Lupus, 50 
percent of mothers had some progression of their health status toward development of 
autoimmune (rheumatologic) symptoms. These asymptomatic mothers had a 19 percent risk 
of developing SLE and a 28 percent chance of developing probable or definite Sjogren’s 
syndrome within 10 years. The NLE manifestations were not predictive of maternal disease 
progression. 
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The incidence of hypothyroidism is increased in women with anti-SSA/Ro antibodies, 
which is about 10% and the incidence of CHB in these mothers with hypothyroidism is 
higher than those without (56% Vs 13%). Therefore evaluation of thyroid disorders is 
warranted in any mother of an infant with neonatal lupus who complains of hair loss or 
fatigue [Askanase et al, 2006).  
11. Conclusion  
Neonatal lupus is due to passive transplacental transfer of maternal IgG auto-antibodies 
to SSA/Ro, SSB/La or U1RNP. It is seen in 1-2% of these neonates. The incidence is  
higher if the mother also has autoimmune disease. The incidence increases 5-10 folds in 
mothers who already have a child with neonatal lupus. The pathogenesis is mainly due to 
fibrosis of the atrioventricular node with or without cardiomyopathy caused by auto 
antibodies.  
It can cause cutaneous lupus which is transient and self-limiting which usually do not 
require treatment. It can also present with complete heart block which is usually permanent 
requiring permanent pacemaker in most of the patients. They are prone for cardiomyopathy 
either as a result of the disease or due to right ventricular pacing which also contributes to 
mortality at least by 10%. The diagnosis is made by detecting auto-antibodies to SSA or SSB 
or U1 RNP and the CHB is made mainly in utero by periodic fetal echocardiography from 16 
weeks onwards. 
Fluorinated glucocorticoids (oral dexamethasone 4 mg per day or betamethasone 3 mg per 
day) are given for mothers of fetuses with second-degree heart block, cardiomyopathy or 
hydrops. It is not effective in CHB and not recommended in first degree heart block as they 
do not progress to advanced heart block and the adverse side effects of the drugs also limit 
its use. 
The mortality is high in children who were detected of having CHB in utero than that 
detected after birth and it is mainly high in the first year and more so in the first three 
months of life. Many aspects of its pathogenic mechanisms are revealed but still research is 
needed as many questions are unanswered which could help in the preventive and 
therapeutic aspects of these patients.  
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requiring permanent pacemaker in most of the patients. They are prone for cardiomyopathy 
either as a result of the disease or due to right ventricular pacing which also contributes to 
mortality at least by 10%. The diagnosis is made by detecting auto-antibodies to SSA or SSB 
or U1 RNP and the CHB is made mainly in utero by periodic fetal echocardiography from 16 
weeks onwards. 
Fluorinated glucocorticoids (oral dexamethasone 4 mg per day or betamethasone 3 mg per 
day) are given for mothers of fetuses with second-degree heart block, cardiomyopathy or 
hydrops. It is not effective in CHB and not recommended in first degree heart block as they 
do not progress to advanced heart block and the adverse side effects of the drugs also limit 
its use. 
The mortality is high in children who were detected of having CHB in utero than that 
detected after birth and it is mainly high in the first year and more so in the first three 
months of life. Many aspects of its pathogenic mechanisms are revealed but still research is 
needed as many questions are unanswered which could help in the preventive and 
therapeutic aspects of these patients.  
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1. Introduction 
Pregnancy markedly alters the normal physiology of the women and immune response 
mechanisms. During normal pregnancy the immune system is reinforced to maintain the 
well-being of the mother and fetus by modifying the manner that a mother responds to the 
environment, in such a way that recognition, communication, trafficking and repair 
mechanisms are all uniformly regulated. In spite of the fact that the fetus could be 
considered a stranger to the mother´s immune system, maternal tolerance develops; the 
latter could be the result of the integration of numerous mechanisms promoted by different 
cells present in the decidua. 
Autoimmunity even in the absence of clinically manifest autoimmune disease can affect 
each event of pregnancy and can induce fetal and maternal complications as well as adverse 
outcomes. The effect pregnancy has on the course of systemic lupus erythematosus (SLE) 
remains speculative. Elevated levels of auto-antibodies are frequently are associated with 
lost pregnancy, as they can cross placental barrier and make contact with blood vessels. 
Fetal endothelial cells make the first encounter with maternal cells or molecules that cross 
the placental barrier and this initial contact induces some primary regulation on endothelial 
cell activity thereby modifying inflammatory response or vascular tone, amongst others. If 
maternal antibodies cross the placental barrier, this could induce the expression of 
proinflammatory molecules, such as TNF-alpha, IL-6 or IL-8 (Yazici et al., 2001), by 
endothelial cells or could induce the formation of immune complexes that can cause fetal 
damage. Pregnant lupus patients are susceptible to preeclampsia, especially if they suffer 
lupus nephritis, and also to steroid-induced hypertension and hyperglycemia. At the same 
time fetuses are susceptible to placental insufficiency if antiphospholipid antibodies or other 
procoagulant states are present, and to neonatal lupus in the presence of anti-Ro/La 
antibodies (Lockshin & Sammaritano, 2003). The study of the physiology and immunology 
of pregnancy in SLE mothers may enhance our understanding of SLE and the possible 
consequences on the child development and quality of life. 
2. Objective  
To describe the effects of maternal SLE on the development of the immune and endocrine 
systems of the fetus during pregnancy and their postnatal consequences.  
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3. Immune system deregulation in SLE pregnant women 
Systemic lupus erythematosus may remain silent, even undiagnosed, during many years in 
some women, but in others it may become more aggressive during pregnancy, placing both 
the mother and the fetus at risk. In general, active inflammation from rheumatic or 
autoimmune diseases poses a stronger threat to the well-being of both the mother and fetus 
than many immunosuppressant medications. Therefore, continued immune-suppression 
could be useful to allow for the most optimal pregnancy outcomes. Autoantibodies are a 
hallmark in autoimmune diseases but the real problem is the diminishing of their clearance 
and the subsequent immune complex formation that alters immune responses. Furthermore, 
the altered production of sexual hormones has an influence on immunity, since sexual 
dimorphism related to SLE development exists. 
3.1 Pro-inflammatory molecules 
The placenta serves as an immunologic barrier between the maternal and fetal circulations 
in normal situations. This barrier prevents the potential damage of maternal immune 
responses, since the fetus is considered a semiallogeneic graft. The trophoblast is the fetal 
tissue in most intimate contact with the maternal deciduas and it is crucial to the 
development of the normal placenta; it participates in the regulation of maternal immune 
responses but the mechanisms involved are still not clear. The placental barrier is 
continuously changing during pregnancy but the first hurdle between the invasive 
trophoblast and the circulating cells of the maternal immune system is the maternal 
endothelium of local vessels. Therefore, specialized mechanisms may exist regulating 
leukocyte extravasation into the deciduas, implicating an interaction between trophoblast 
antigens and maternal leukocytes.  
Leukocyte recruitment is mediated by specialized cell adhesion molecules on the surface of 
circulating cells and their counterreceptors or ligands on the endothelium, especially 
integrins. The a4b7 integrin, for example, is a lymphocyte homing receptor for the mucosal 
vascular addressin MAdCAM-1 (mucosal addressin cell adhesion molecule 1), which is 
expressed by high endothelial venules (HEV) in mucosal lymphoid tissues. Another 
integrin, a4b1, binds to the vascular cell adhesion molecule 1 (VCAM-1), which can be 
induced in diverse sites of inflammation (Butcher et al., 1999). The major change in the end-
term pregnant uterus is that the decidua basalis contains remarkably few maternal 
leukocytes in the lumina of the maternal vessels and in the tissue, suggesting decreased 
recruitment at this stage and it is associated with a loss of selectivity from trophoblast and 
maternal endothelial cells (Kruse et al., 2002). 
Inflammatory cytokines and cell adhesion molecules (CAM) appear to be centrally involved 
in the pathogenesis of autoimmune diseases. During pregnancy it is possible that placental 
dysfunction may account for some complications. Hopefully in SLE pregnancy an 
inflammatory state where TNF-alpha, IL-1 or IL-6 could be elevated, is present. These 
cytokines can stimulate endothelial cells to express cell adhesion molecules like E-Selectin or 
P-Selectin, VCAM-1 and/or ICAM-1 to promote leukocyte migration. It has been observed 
that TNF-alpha may increase the level of IL-6 in human vein endothelial cells (HUVEC) both 
in SLE and normal mothers, without difference, but E-Selectin, VCAM-1 and ICAM-1 are 
reduced (Rodriguez et al., 2008). Therefore it is possible that the immune response in the 
offspring of SLE mothers could be diminished because endothelial cells of corial villi might 
not be activated or be noncompliant to stimulus, or in the SLE mother it could be 
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diminished because there are increased levels of VCAM-1 and ICAM-1 in maternal serum 
related with a endothelial cells activation and those may contribute to an increased 
migration of leukocytes into placenta. Although circulating maternal concentration of 
soluble cell adhesion molecules showed differences between SLE patients and controls, no 
differences were observed when placental tissues were immunostained with the same cell 
adhesion molecule antibodies (Lakasing et al., 2000).  
Antiphospholipid antibodies have been associated with thrombosis and endothelial cell 
activation, so they can enable the increased expression of CAMs and other cytokines by the 
endothelium, thus enhancing a proinflammatory state. TNF-alpha levels are increased in some 
diseases related to miscarriage. It is known that TNF-alpha modulates endothelial cells 
through the activation of NF-kappaB, a transcription factor which activates genes of 
proinflammatory molecules such as CAMs, but also prothrombotic factors such as tissue factor 
(TF), thrombomodulin and plasminogen activator inhibitor (PAI-1) (Scarpati & Sadler, 1989). 
This proinflammatory state would contribute to the malformation of the placenta, miscarriage 
and fetal circulating system alterations. TF expression on endothelial cells, monocytes and 
neutrophils is a hallmark of inflammatory conditions, such as sepsis, atherosclerosis, 
inflammatory bowel disease and systemic lupus erythematosus (Girardi et al., 2008). 
3.2 The complement system 
This system has a crucial role as an effector mechanism in placental and fetal damage that 
conduce to ill-fated pregnancy outcomes. In normal pregnancies there are many potential 
sites where the complement system could be activated as the intervillous space or deciduas, 
by interaction with the trophoblast. It has been suggested that complement activation 
during placentation should be highly regulated by locally expressed membrane-bound 
complement regulators, such as DAF, MCP and CD59, providing protection to the fetus 
(Girardi et al., 2011).  
The complement is part of the innate immune system and can be activated through one of 
three pathways: the classical, the alternative, or the mannose-binding lectin. Central to each 
of these pathways is the cleavage of C3, resulting in the production of C3a and C3b. Upon 
its generation, C3b attaches covalently to cells and has binding affinity for a variety of 
circulating and cell-bound proteins, meanwhile C3a contributes to inflammatory responses 
such as leukocyte accumulation and enhancement of vascular permeability occurring in 
various infectious and noninfectious states. The final stage of complement activation by any 
pathway, is the formation of C5b by C5-convertase, where C3b is an important component. 
C5b, together with other complement molecules, form an attack complex bound to the 
membrane that destroys cells.  
Girardi, et al. (2011) have proposed that the activation of complement system during 
placental and fetal injury is produced by antiphospholipid-autoantibodies, lack of 
regulatory proteins or activated T-cells. In patients with SLE, recurrent miscarriage, fetal 
growth restriction and intrauterine fetal death are frequently occurring complications of 
pregnancy, and it is highly possible that the auto-antibodies produced in SLE form an 
immune complex recognized by C1, which is the triggering of the complement system 
classical pathway. C1q, a component of C1, deserves special consideration for its role 
promoting trophoblast invasion of deciduas, a crucial step in normal placental development 
(Bulla, 2008). But, in human placenta of women with SLE, immunohistochemically stained 
for C4d and C1q, the presence of both molecules was observed and the presence of C4d was 
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strongly related to adverse fetal outcome in the setting of SLE. The excessive deposition of 
C4d supports the concept of severe autoantibody-mediated injury at the fetal-maternal 
interface (Cohen et al., 2011).  
The role of C3a in the pathogenesis of SLE has not been defined, but it has been found that 
the inhibition of complement activation at the level of C3-convertases significantly reduced 
renal disease in MRL/lpr mice (Bao et al., 2003). Given that inhibition of C3-convertases 
prevents generation of C3a (as well as C3b, C5a, and C5b-9), it is conceivable that the use of 
C3-convertase inhibitors, which limit C3a generation, might be of invaluable therapeutic 
benefit (Bao et al., 2005). One of the possible mechanisms that damage the developing 
placenta is through the action of anaphylotoxin C5a, which promotes neutrophil infiltration 
into the deciduas, leading to fetal death (Girardi et al., 2003). In some, but not in all, mice 
models of antiphospholipid syndrome (APS), complement activation plays a major role in 
pregnancy loss, with a massive accumulation of C3 in the placenta. Interestingly, C3 
deficient mice do not show fetal reabsorption. Based upon these findings, anti-phospholipid 
antibodies and complement activation (via C3a, C5a, and MAC) may cooperate in the 
triggering a local inflammatory process, eventually leading to placental thrombosis, 
hypoxia, and neutrophil infiltration (Tincani et al., 2010).  
3.3 Th1 and Th2 responses 
Cytokines secreted by the embryos and cells within the uterus are important for the 
implantation process, but they can also be responsible for causing miscarriages. The activity 
of cytokines has been characterized as proinflammatory and anti-inflammatory depending 
on whether they are secreted by Th1 or Th2 T cells. Prolonged exposure to Th1 cytokines is 
detrimental to pregnancy, while Th2 cytokines are necessary to stimulate the invasion of the 
blastocyst and the formation of blood vessels during the implantation period. Trophoblastic 
cells, as well as uterine epithelium and maternal immune cells, secrete cytokines, which 
promote immunotolerance. Some of these cytokines are transforming growth factor beta, 
progesterone-induced blocking factor, and regeneration and tolerance factor. The sources of 
proinflamatory cytokines, such as interleukins, chemokines and TNF-alpha, are 
macrophages and NK cells, which infiltrate the implantation sites thus favoring pregnancy 
loss (Cerkiene et al., 2010).  
The immune response is regulated by components of the innate immunity, including 
antigen-presenting cells (APCs) such as monocyte/macrophage and other phagocytic cells, 
as well as by components of the acquired immunity such as T helper (Th) cells, subdivided 
into subclasses Th1 and Th2. Th1 cells produce the cytokines interleukin IL-2, IL-12, 
interferon (IFN)- and tumor necrosis factor-alpha (TNF-alpha) and TNF-beta, whereas Th2 
cells produce the cytokines IL-4, IL-6, IL-10 and IL-13. These Th1- and Th2-mediated 
immune responses are mutually inhibitory, and to some extent opposing (Elenkov & 
Chouosos, 1999). A strong, maybe deregulated Th1 response is often found in autoimmunity 
and there is compelling evidence for a third effector Th pathway, so-called Th17 T cells that 
secrete IL-17A and IL-17F, two cytokines not synthesized by either Th1 or Th2 CD4+ T cells 
(Saito 2010). Healthy pregnant women have a predominant TH1 response (Lit, 2007; Muñoz-
Valle et al., 2003), whereas SLE pregnancy is accompanied by a TH2 response, especially 
through IL-10, that promote antibody production by B cells. (Viallard et al., 1999). This 
change could explain protection to the fetus from maternal Th1-cell attack, but a 
predominant Th2 type immunity in recurrent abortion cases has been observed. So it is not 
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sufficient to know the Th1/Th2 relationship in order to explain the pathogenesis 
mechanisms in autoimmune diseases. Treg cells play a central role for induction of tolerance 
because they inhibit proliferation and cytokine production in both CD4+ and CD8+ T cells. 
An overstimulation of  Th1 or Th2 immunity might be harmful for successful pregnancy.  
IL-17, a proinflammatory cytokine, has been observed in peripheral blood and deciduas in 
spontaneous abortion patients; moreover, Treg and Th17 cells can be inversely regulated by 
IL-6, which blocks the development of Treg cells and induces differentiation of Th17 cells 
(Saito et al., 2010). Auto-antibodies may induce secretion of IL-6 in mesangial cells (Bobst et 
al., 2005) and enhance IL-6 concentration in serum (Arslan et al., 2004), therefore they could 
be related to pregnancy loss. 
If auto-antibodies cross the placenta, they would stimulate fetal endothelial cells to produce 
proinflammatory molecules like IL-6, so the Th1/Th2 immune balance could be modified in 
the offspring. Indeed, two transcription factors, T-bet (for Th1) and GATA-3 (for Th2), have 
been found to play an important role in the organogenesis of the immune system of the mice 
offspring during the perinatal period (Yamamoto et al., 2009). It is possible that 
autoantibodies of SLE mothers exert some modulation on the above mentioned transcription 
factors and they may induce some immune suppression on the new born child.  
4. Hormonal levels in SLE+ pregnant women 
Endocrine and immune systems work very closely to allow and maintain the development 
of gestation by means of hormones, cytokines and its receptors. These molecules can 
stimulate or suppress the activity both of them. Therefore, the regulation of autoimmnity by 
hormones or the alteration of hormone levels by immune responses happen during the 
reproductive age. The increase of progesterone and estrogens during normal pregnancy 
allow the regulation of implantation and placentation in order to avoid the rejection of the 
embryo and fetus. 
Serum levels of steroid hormones vary during pregnancy in SLE patients, depending upon 
disease activity being increased in the second trimester and decreased in the third. 
However, estradiol and progesterone serum concentrations were found significantly 
reduced in SLE patients compared with controls (Doria, et al., 2002, 2004). The increase in 
sexual hormones during normal pregnancy boosts the humoral response and leads to a 
more efficient clearance of auto-antibodies. But in SLE women there is an increment of 
circulating auto-antibodies which is associated with a decrease of serum estrogen in the 
third trimester of pregnancy. Sex hormones are considered as major regulators of the 
immune response in SLE patients (Doria et al., 2006).  
4.1 Estrogens  
Estrogens are able to modulate immune response exerting specific effects on T and B cells, 
dendritic cells (DC) and peripheral blood mononuclear cells (PBMC), enhancing IL-10, IL-2, 
and IFN-gamma production, inhibiting TNF-alpha secretion by PBMC, stimulating antibody 
production by B cells, and decreasing apoptosis of DC and macrophages (Zen et al., 2010). 
17-beta estradiol induces anti-apoptotic effects in monocyte and macrophage cell lines by 
interfering with NF-kB activities (Catelo et al., 2005). In consequence, if estrogens are 
reduced, the activity of NF-kB is augmented; therefore there will be a larger expression of 
cell adhesion molecules favoring a proinflammatory condition. Estrogen treatment induces 
an increase in the production of IL-10 and a decrease in that of TNF-alpha by PBMCs of 
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hormones or the alteration of hormone levels by immune responses happen during the 
reproductive age. The increase of progesterone and estrogens during normal pregnancy 
allow the regulation of implantation and placentation in order to avoid the rejection of the 
embryo and fetus. 
Serum levels of steroid hormones vary during pregnancy in SLE patients, depending upon 
disease activity being increased in the second trimester and decreased in the third. 
However, estradiol and progesterone serum concentrations were found significantly 
reduced in SLE patients compared with controls (Doria, et al., 2002, 2004). The increase in 
sexual hormones during normal pregnancy boosts the humoral response and leads to a 
more efficient clearance of auto-antibodies. But in SLE women there is an increment of 
circulating auto-antibodies which is associated with a decrease of serum estrogen in the 
third trimester of pregnancy. Sex hormones are considered as major regulators of the 
immune response in SLE patients (Doria et al., 2006).  
4.1 Estrogens  
Estrogens are able to modulate immune response exerting specific effects on T and B cells, 
dendritic cells (DC) and peripheral blood mononuclear cells (PBMC), enhancing IL-10, IL-2, 
and IFN-gamma production, inhibiting TNF-alpha secretion by PBMC, stimulating antibody 
production by B cells, and decreasing apoptosis of DC and macrophages (Zen et al., 2010). 
17-beta estradiol induces anti-apoptotic effects in monocyte and macrophage cell lines by 
interfering with NF-kB activities (Catelo et al., 2005). In consequence, if estrogens are 
reduced, the activity of NF-kB is augmented; therefore there will be a larger expression of 
cell adhesion molecules favoring a proinflammatory condition. Estrogen treatment induces 
an increase in the production of IL-10 and a decrease in that of TNF-alpha by PBMCs of 
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patients with SLE, but not in healthy subjects (Evans et al., 1997). Because of the TNF-alpha 
regulatory function on apoptosis, the failure to maintain the production of this cytokine 
might alter the apoptosis of activated immune cells in SLE patients exposed to high estrogen 
concentrations, as it occurs in pregnancy. 
The serum concentration of soluble adhesion molecules is higher in women with SLE than 
in normal women, but the placental values are identical (Abd-Elkareem et al., 2010, 
Lakasing et al., 2000). However, endothelial cells of  umbilical cordons of SLE mothers 
express several times less CAMs (E-Selectin, VCAM-1, ICAM-1) compared with healthy 
mothers (Rodriguez, 2008). Even if a relationship between diminished serum estrogen and 
augmented serum CAMs levels exists in SLE patients, maternal estrogen does not exert  
any deleterious effect on the fetus endothelial cells (FEC). That may be possible if FEC 
could exhibit immunotolerance or lack estrogen receptors. It is assumed that estrogen 
regulation upon the immune system uses different pathway in the fetus compared with the 
SLE mother. 
4.2 Androgens 
Sexual dimorphism has been shown in SLE diseases since women are more affected than 
men. In fact, androgens seem to act in counter part to estrogens modulating the immune 
response; because of that, they have been used as therapy on SLE patients (Gordon et al., 
2008). However, it has been shown that androgens can favor adverse effects on circulating 
lipids increasing the risk of atherosclerosis (Nutall et al., 2003). 
Some favorable effects of androgens on immunity are to inhibit Il-1b and IL-6 secretion by 
PBMC, enhance IL-2 secretion by T cells and inhibit antibody secretion by B cells. 
Testosterone also exerts pro-apoptotic effects and reduces macrophage proliferation, and 
inhibits IL-1b and IL-6 secretion by PBMC (Zen et al.,  2010). 
Testosterone and related steroid hormones have a variety of effects on the immune system. 
Dehydroepiandrosterone (DHEA), the major product of the adrenal glands in both men and 
women, whose sulphated (DHEA-S) molecule is its inactivated form, stimulates IL-2 
production (Dillon, 2005) and reduces IL-10 (Chang et al., 2004) in normal T cells, therefore 
favoring the Th1 pathway. But in SLE patients a significant finding is that serum levels of 
DHEA-S and other adrenal androgens and cortisol are decreased (Zen et al., 2010). 
Decreased adrenal production, increased conversion or conjugation to downstream 
hormones are the most likely causes of inadequately low serum levels of adrenal hormones 
in SLE (Straub 2004). It is believed that lower levels of androgen is a cause of 
proinflammatory events. In SLE pregnant women, differences in androgen levels compared 
with normal pregnant women have not been found (Doria, et al., 2002). 
4.3 Progesterone 
Progesterone is the most important hormone during pregnancy reaching its higher levels at 
the third trimester of pregnancy. All throughout the sexual cycle, progesterone modulates 
immune responses generating protection to the female tract against microorganisms. 
Progesterone can act enhancing IL-4, IL-5, IL-6, and IL-10 production, and inhibiting IFN-
gamma secretion by PBMC, stimulating antibody generation by B cells, and decreasing T 
cell proliferation. Also, it induces the secrection of a 34-kD protein, named “Progesterone-
induced blocking factor” (PIBF), which is known to regulate humoral and cell-immune 
responses in several ways (Beagley & Gockel, 2003), including the induction of a Th2-
dominant cytokine profile (Lashley et al., 2011). During pregnancy Th2 polarization occurs 
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both in the systemic circulation and at the feto-maternal interface, enhancing IL-3, IL-4, IL-5 
and IL-10 production. Thus, high progesterone levels might contribute to successful 
pregnancy, favoring feto-allograft tolerance (Zen et al., 2010).  
Disproportional changes of progesterone levels in pregnant women are associated with 
different manifestations of autoimmune pathologies since Th1-related diseases such as 
rheumatoid arthritis tend to improve, whereas Th2-related diseases may get worse (Tait 
2008). Lower production of progesterone is seen during SLE pregnancy, especially in the 
third trimester compared with normal pregnancies (Doria eta al., 2004).  
Progesterone plays a key important role at many levels including control of neuroendocrine 
responses to stress, procuring required immune balance and controlling placental and 
decidual function. A lack of progesterone can explain many unwanted consequences 
(Douglas 2010). It is possible to speculate that lack of progesterone in SLE mothers could 
cause damaging effects in the offspring’s future development. 
4.4 Prolactin  
Different to steroids hormones, prolactin is a peptide produced by the adenohypophysis but 
also by neurons, endothelium, mammary epithelium, leukocytes and thymocytes. Prolactin 
has pleiotropic effects on the immune system and it appears to stimulate both humoral and 
cell-mediated immune responses, through enhanced IL-1, IL-2, IL-12, and IFN-gamma 
secretion by PBMC. It also stimulate antibody secretion, decreases B cell apoptosis, and T 
cell proliferation (Vera-Lastra et al, 2002), but it specifically promotes the survival of the T-
cell-dependent autoreactive follicular B-cell subset, and enhances the development of 
antigen presenting cells expressing MHC class II and costimulatory molecules CD40, CD80, 
and CD86 (Matera et al., 2001). The effect of prolactin on antigen presentation and on B-T 
cells interaction results in increased response to MHC presented auto-antigens, leading to 
the loss of self tolerance. The interaction between CD40 on B cells and CD40L on T cells up-
regulates the expression of the antiapoptotic molecule Bcl-2 leading to autoreactive B cell 
rescue from negative selection which reduces tolerance to self (Peeva et al., 2003). Thus, 
hyperprolactinaemia has been found to be a risk factor for the development of 
autoimmunity by favoring Th1 immunity. 
High levels of serum prolactin have been found in a subset of SLE patients associated with 
active disease, promoting deficiency of dendritic cell functions, suggesting a lack of 
induction of T and B cell activity (Jara et al., 2008). Hyperprolactinaemia is associated with 
several autoantibodies involved in SLE such as antinuclear antibodies (ANA), anti-double 
stranded DNA (anti-dsDNA), anticardiolipin, and hypocomplementaemia (Zen et al, 2010). 
4.5 Hormone receptors 
The effects of sexual hormones are mediated through membrane receptors independent of 
their isoform or the tissue and physiological condition of the host. The relationship between 
estrogens and its receptor (ER) may play an important role in the pathogenesis of SLE. 
Results obtained from a mouse model of lupus (NZB/NZW) suggest that ER-alpha 
activation exerts a stimulatory effect on the endocrine response whereas ER-beta activation 
appears to induce a slightly immunosuppressive effect on the disease (Li & McMurray, 
2007). It has also been reported that ER-alpha mRNA expression is increased and ER-beta 
mRNA expression decreased in PBMC (Inui et al., 2007) as well as CD4+ T cells (Phiel et al., 
2005) of SLE patients. 
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both in the systemic circulation and at the feto-maternal interface, enhancing IL-3, IL-4, IL-5 
and IL-10 production. Thus, high progesterone levels might contribute to successful 
pregnancy, favoring feto-allograft tolerance (Zen et al., 2010).  
Disproportional changes of progesterone levels in pregnant women are associated with 
different manifestations of autoimmune pathologies since Th1-related diseases such as 
rheumatoid arthritis tend to improve, whereas Th2-related diseases may get worse (Tait 
2008). Lower production of progesterone is seen during SLE pregnancy, especially in the 
third trimester compared with normal pregnancies (Doria eta al., 2004).  
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cell-mediated immune responses, through enhanced IL-1, IL-2, IL-12, and IFN-gamma 
secretion by PBMC. It also stimulate antibody secretion, decreases B cell apoptosis, and T 
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cell-dependent autoreactive follicular B-cell subset, and enhances the development of 
antigen presenting cells expressing MHC class II and costimulatory molecules CD40, CD80, 
and CD86 (Matera et al., 2001). The effect of prolactin on antigen presentation and on B-T 
cells interaction results in increased response to MHC presented auto-antigens, leading to 
the loss of self tolerance. The interaction between CD40 on B cells and CD40L on T cells up-
regulates the expression of the antiapoptotic molecule Bcl-2 leading to autoreactive B cell 
rescue from negative selection which reduces tolerance to self (Peeva et al., 2003). Thus, 
hyperprolactinaemia has been found to be a risk factor for the development of 
autoimmunity by favoring Th1 immunity. 
High levels of serum prolactin have been found in a subset of SLE patients associated with 
active disease, promoting deficiency of dendritic cell functions, suggesting a lack of 
induction of T and B cell activity (Jara et al., 2008). Hyperprolactinaemia is associated with 
several autoantibodies involved in SLE such as antinuclear antibodies (ANA), anti-double 
stranded DNA (anti-dsDNA), anticardiolipin, and hypocomplementaemia (Zen et al, 2010). 
4.5 Hormone receptors 
The effects of sexual hormones are mediated through membrane receptors independent of 
their isoform or the tissue and physiological condition of the host. The relationship between 
estrogens and its receptor (ER) may play an important role in the pathogenesis of SLE. 
Results obtained from a mouse model of lupus (NZB/NZW) suggest that ER-alpha 
activation exerts a stimulatory effect on the endocrine response whereas ER-beta activation 
appears to induce a slightly immunosuppressive effect on the disease (Li & McMurray, 
2007). It has also been reported that ER-alpha mRNA expression is increased and ER-beta 
mRNA expression decreased in PBMC (Inui et al., 2007) as well as CD4+ T cells (Phiel et al., 
2005) of SLE patients. 
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The presence of estrogen receptors on the cells involved in the immune response, namely 
thymocytes, macrophages and endothelial cells is well recognized. Estrogens modulate 
cytokine production by target cells, through interference with their transcriptional activity. 
The effect of estrogens on the expression of protooncogenes and oncosuppressor genes 
involved in apoptosis might also be relevant to human autoimmunity (Cutolo et al.,, 1995). 
It is possible that different polymorphisms of the ER-alpha gene, are involved in SLE 
development and apparently they are related to sex, age at the onset of the disease, and the 
appearance of some clinically relevant symptoms, suggesting that these polymorphisms 
might contribute to SLE susceptibility (Johansson et al., 2005).  
Gonadotropin releasing hormone (GnRH) is a hypothalamic and pituitary hormone known 
to exert immune actions. GnRH administration has been associated with gender-specific 
alterations in mRNA expression of the GnRH and IL-2 receptors, after 2 weeks of treatment. 
These differences might be attributable to gender differences in response to gonadectomy. 
GnRH and GnRH receptor mRNA levels vary dynamically with the estrous cycle in 
lymphoid organs in the intact female mouse thus contributing to gender differences in the 
development and activity SLE patients (Jacobson et al., 1999). Interestingly, it has been 
recently shown that prolactin exerts a regulatory influence on GnRH through dopamine and 
LH (Hodson et al., 2010). 
5. Auto-bodies in SLE pregnant women 
Autoimmunity originates after breaking self-tolerance of the immune system, a process that 
involves many different molecules and yet poorly understood processes. It remains an open 
question whether bacterial or viral pathogens contribute to the initiation of these diseases as 
major causative agents (Borchers et al., 2010). The presence of autoantibodies has been 
mainly associated with pathologic states, probably because they were first described as a 
hallmark of autoimmune diseases. Indeed, endothelial cell autoantibodies (AECA) are often 
reported in conditions where pathologic autoantibodies bind to activated or damaged 
endothelial cells. 
5.1 Non active SLE 
Although it is increasingly recognized that autoimmunity, even in the absence of clinically 
manifest autoimmune disease, can affect every aspect of pregnancy (starting with 
fertilization) and can contribute to maternal complications and adverse fetal outcomes, 
(Cervera & Balasch, 2008) the risk of lupus flare is not as great as many people used to think 
and flares, when they do occur, are not necessarily severe. The best prevention of SLE flares 
during pregnancy is the delay of conception until a woman has had quiescent SLE for at 
least 6 months. In many situations, however, this is not possible and the continuation of 
medications for SLE helps to prevent flares. 
In the past, patients stopped all their therapy when they discovered that they were 
pregnant. This may very well have contributed to the increased risk of disease flare during 
pregnancy, especially in patients with a history of renal involvement and other forms of 
serious lupus disease. Patients should now be counseled before becoming pregnant, and in 
early pregnancy, about the use of appropriate drugs. (Gordon, 2004) 
Many women with SLE take hydroxychloroquine (HCQ) (Plaquenil) prior to pregnancy. 
This medication decreases the risk of SLE flare, improves the prognosis of SLE nephritis, 
and prevents death. (Kasitanon et al., 2006) It is also very well tolerated with arguably the 
 
Maternal SLE Influence in Fetal Development Immune and Endocrine Systems 
 
539 
best side-effect profile of any medication available to treat SLE. An expert panel, comprised 
of 29 international leaders in research and care of women with SLE, recently recommended 
the continuation of HCQ during pregnancy. (Ostensen et al., 2006) Among over  
300 pregnancies described in the literature that were exposed to HCQ for the treatment  
of autoimmune disease, no elevation of fetal anomalies was identified. When chloroquine  
is taken at supratherapeutic doses, there may be ocular or auditory damage. However,  
no such changes were seen among 133 babies exposed to HCQ in utero. (Costedoat-
Chalumeau, 2003). 
In non-pregnant SLE patients, the cessation of HCQ is associated with a 2-fold risk of SLE 
flare within the following 6 months. Among pregnant SLE patients, the risk for flare also 
increases when HCQ is discontinued. In the Hopkins Lupus Pregnancy Cohort, 38 women 
discontinued HCQ just prior to or early in pregnancy due to concerns about fetal exposure 
whereas 56 women continued HCQ throughout pregnancy (Clowse et al., 2006) Among 
those who discontinued the medication, the risk for increased lupus activity, whether 
measured by the absolute physician’s estimate of activity or the SLEDAI scale was 
significantly increased. More of these women required corticosteroid therapy at higher 
doses than those who continued HCQ treatment. Within this cohort, as in other reports, 
there was no increase in fetal abnormalities after HCQ exposure. The pregnancy outcomes 
among women who continued and discontinued HCQ were similar. This likely reflects the 
type of SLE activity that women who discontinued HCQ suffered: they did not have 
increased rates of lupus nephritis, anemia, or thrombocytopenia. Instead, women who 
discontinued HCQ had increased incidence of fatigue and joint symptoms. Though these 
symptoms are uncomfortable, they are generally not life-threatening nor require cytotoxic 
therapy. They may, however, prompt the initiation or the increase of corticosteroid therapy 
in mid-pregnancy. Again, little data is available about the use of azathioprine in inactive 
SLE pregnancy. In the Hopkins Lupus Pregnancy Cohort, 31 pregnancies were exposed to 
azathioprine. (Ostensen et al., 2006) Among the women who conceived while taking 
azathioprine and continued it through pregnancy, 2 out of 13 ended in pregnancy loss, both 
women had developed active SLE in pregnancy. Among the 10 women who maintained low 
lupus activity and azathioprine throughout pregnancy, all gave birth to live newborns at 34 
weeks or greater gestations. Based on these data, azathioprine treatment should be 
continued throughout pregnancy, especially if the woman required it prior to pregnancy to 
treat her lupus (Clowse, 2007). It is also recommended to switch women from 
mycophenolate mofetil (MMF) to azathioprine prior to conception to avoid the teratogenic 
effects of the MMF. 
5.2 Active SLE  
Mild activity SLE can be treated with low dose prednisone (under 20mg per day) as 
required. The side effects include increased risk for hypertension and diabetes, just as in a 
non-pregnant woman. There may be a 2-fold increased risk for cleft lip or palate with 
systemic corticosteroid use, though the absolute risk for this remains low (about 20 per 
10,000 babies with corticosteroid exposure) (Pradat et al. 2003). 
Nonsteroidal anti-inflammatory drugs (NSAIDs) can be used during the late part of the first 
trimester and during the second trimester. There is evidence, in a murine model, that COX 
enzymes are important for embryo implantation, which may explain the increased risk for 
early miscarriage in women taking NSAIDs around the time of conception. (Clowse, 2007). 
NSAIDs are considered fairly safe in the second trimester, though they may decrease fetal 
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best side-effect profile of any medication available to treat SLE. An expert panel, comprised 
of 29 international leaders in research and care of women with SLE, recently recommended 
the continuation of HCQ during pregnancy. (Ostensen et al., 2006) Among over  
300 pregnancies described in the literature that were exposed to HCQ for the treatment  
of autoimmune disease, no elevation of fetal anomalies was identified. When chloroquine  
is taken at supratherapeutic doses, there may be ocular or auditory damage. However,  
no such changes were seen among 133 babies exposed to HCQ in utero. (Costedoat-
Chalumeau, 2003). 
In non-pregnant SLE patients, the cessation of HCQ is associated with a 2-fold risk of SLE 
flare within the following 6 months. Among pregnant SLE patients, the risk for flare also 
increases when HCQ is discontinued. In the Hopkins Lupus Pregnancy Cohort, 38 women 
discontinued HCQ just prior to or early in pregnancy due to concerns about fetal exposure 
whereas 56 women continued HCQ throughout pregnancy (Clowse et al., 2006) Among 
those who discontinued the medication, the risk for increased lupus activity, whether 
measured by the absolute physician’s estimate of activity or the SLEDAI scale was 
significantly increased. More of these women required corticosteroid therapy at higher 
doses than those who continued HCQ treatment. Within this cohort, as in other reports, 
there was no increase in fetal abnormalities after HCQ exposure. The pregnancy outcomes 
among women who continued and discontinued HCQ were similar. This likely reflects the 
type of SLE activity that women who discontinued HCQ suffered: they did not have 
increased rates of lupus nephritis, anemia, or thrombocytopenia. Instead, women who 
discontinued HCQ had increased incidence of fatigue and joint symptoms. Though these 
symptoms are uncomfortable, they are generally not life-threatening nor require cytotoxic 
therapy. They may, however, prompt the initiation or the increase of corticosteroid therapy 
in mid-pregnancy. Again, little data is available about the use of azathioprine in inactive 
SLE pregnancy. In the Hopkins Lupus Pregnancy Cohort, 31 pregnancies were exposed to 
azathioprine. (Ostensen et al., 2006) Among the women who conceived while taking 
azathioprine and continued it through pregnancy, 2 out of 13 ended in pregnancy loss, both 
women had developed active SLE in pregnancy. Among the 10 women who maintained low 
lupus activity and azathioprine throughout pregnancy, all gave birth to live newborns at 34 
weeks or greater gestations. Based on these data, azathioprine treatment should be 
continued throughout pregnancy, especially if the woman required it prior to pregnancy to 
treat her lupus (Clowse, 2007). It is also recommended to switch women from 
mycophenolate mofetil (MMF) to azathioprine prior to conception to avoid the teratogenic 
effects of the MMF. 
5.2 Active SLE  
Mild activity SLE can be treated with low dose prednisone (under 20mg per day) as 
required. The side effects include increased risk for hypertension and diabetes, just as in a 
non-pregnant woman. There may be a 2-fold increased risk for cleft lip or palate with 
systemic corticosteroid use, though the absolute risk for this remains low (about 20 per 
10,000 babies with corticosteroid exposure) (Pradat et al. 2003). 
Nonsteroidal anti-inflammatory drugs (NSAIDs) can be used during the late part of the first 
trimester and during the second trimester. There is evidence, in a murine model, that COX 
enzymes are important for embryo implantation, which may explain the increased risk for 
early miscarriage in women taking NSAIDs around the time of conception. (Clowse, 2007). 
NSAIDs are considered fairly safe in the second trimester, though they may decrease fetal 
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renal excretion and therefore promote oligohydramnios. (Holmes and Stone, 2000). NSAIDs 
should be stopped in the third trimester for 2 reasons: they can prolong labor and may 
promote premature closure of the ductus arteriosis. (Ostensen et al., 2006). 
Moderate lupus activity can also be treated with higher doses of corticosteroids, including 
pulse-dose steroids. Only a small percentage of each dose of prednisone and prednisolone 
crosses the materno-fetal barrier. However, fluorinated glucocorticoids, such as 
dexamethasone and betamethasone, easily transfer to the fetus. These steroids can be 
helpful in treating the fetus, in particular in promoting fetal lung maturity prior to a preterm 
delivery. However, they have also been associated with lasting adverse effects on the 
offspring. Children exposed to these corticosteroids may have increased blood pressure and 
cognitive deficits. (Velíšek, 2011, Rothenberger et al., 2011) Therefore, dexamethasone and 
betamethasone should not be used to treat lupus activity during pregnancy. 
The commencement of azathioprine in mid-pregnancy for a lupus flare may be risky. There 
is little data published on the use of azathioprine in lupus pregnancy. However, in the 
Hopkins Lupus Pregnancy Cohort there was an increase in pregnancy loss among woman 
who used azathioprine to treat a moderate to severe flare. Of the 8 pregnancies treated with 
azathioprine, 5 (63%) resulted in pregnancy loss, whereas only 1 out of 9 (11%) without 
azathioprine had a misscarriage (p=0.02). (Clowse, 2007)  
Another option for the treatment of lupus in mid-pregnancy is intravenous immunoglobin 
(IVIg). IVIg can be particularly helpful in controlling hematologic and renal disease 
(Friedman et al., 2010). There are no published series of IVIg use in pregnancy for lupus 
patients, however there are multiple reports of IVIg use to prevent recurrent miscarriage. In 
these cases, the primary outcome is live birth, and there is no change in this rate with the use 
of IVIg. Little has been published on the effects of IVIg on the offspring, but cell count levels 
seem to be stable and no congenital anomalies have been reported. IVIg´s that contain 
sucrose can prompt renal insufficiency, but this has not held back the treatment of non-
pregnant women with lupus nephritis (Micheloud, 2006). Some women will develop 
headaches, rigors, or fevers with IVIg therapy, but more severe side effects are rare. 
Cyclophosphamide (Cytoxan) and mycophenolate mofetil (Cellcept) should be avoided 
during pregnancy. First trimester exposure to cyclophosphamide causes fetal abnormalities 
in a significant minority of patients. Exposure in the second and third trimesters does not 
increase the risk for fetal anomalies among women treated for breast cancer during 
pregnancy. Of the 3 SLE pregnancies with cyclophosphamide treatment during mid-
pregnancy reported in the literature, only one resulted in a live birth. (Clowse et al, 2005b). 
Cyclophosphamide should only be used when all other options are exhausted and a 
forthright discussion about the risk for pregnancy loss has been discussed with the mother. 
The data on the use of mycophenolate mofetil in pregnancy are scarce but worrisome. There 
appears to be an elevated risk for both fetal anomalies and pregnancy losses especially in 
SLE mothers. 
6. Placental barrier and auto-antibody transfer 
During pregnancy the placenta plays a very important role in the mechanism that regulates 
and maintains a suitable communication between the mother (matro-environment) and the 
fetus (micro-environment). The placental barrier, mainly constituted by syncytiotrophoblast, 
cytotrophoblast, mesenchyma and endothelium, is continuously changing while the 
gestation progresses, in such a way that the placental barrier becomes, at the third trimester, 
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a thin layer constituted by syncytiotrophoblast and chorionic-vessels endothelium. These 
morphological changes affect the traffic of cells and molecules through the placenta that 
could affect fetal development. Endothelial cells control the traffic of molecules and cells 
across the vessel wall and play an active role in hemostasis, inflammatory reactions, and 
immunity. The vascular cells dynamically respond to molecular signals, actively regulating 
many aspects of vascular homeostasis, including metabolic and cellular events, and 
executing a major role in the modulation of immune–inflammatory responses. 
6.1 Maternal auto-antibodies and its effect on the developing fetal immune system 
Immunoglobulins with the ability to bind to endothelial cell surface antigens are 
commonly known as AECA, and are often reported in conditions where potentially 
pathologic autoantibodies bind to activated or damaged endothelial cells (Salomonsson, 
2010). However, natural AECA of both the IgG and IgM classes have been described. 
These antibodies, present in the serum of healthy individuals, are strictly controlled in 
terms of antigen specificity, and their expression may be regulated by the idiotypic 
network (Vazquez-del Mercado, 2006). This control is lost in SLE (Dhar & Sokl, 2006) in 
which IgG-AECA display quantitative and qualitative modifications and exert 
proinflammatory effects on cultured endothelial cells (Munther, 2006). So far, little work 
has been done on AECA expression in pregnant healthy subjects and in pregnant  
SLE patients. 
6.2 Maternal auto-antibodies and its effect on the development of the embryonic  
and fetal heart 
Complete atrioventricular block (AVB), in 91% of affected neonates, results from neonatal 
lupus erythematosus, a disease associated with transplacental passage of maternal anti-
Ro/SSA and/or anti-La/SSB antibodies (Salomonsson, 2010). The mothers of these neonates 
are commonly diagnosed with SLE, Sjögren syndrome (SS), or other rheumatic diseases, 
although many are asymptomatic. Complete fetal AVB, which usually develops during 
gestational weeks 16 to 24, conveys a significant fetal mortality (15% to 30%) and morbidity 
rate, where two thirds on the affected offspring will require permanent pacing (Dhar & 
Sokol, 2006). It has been suggested that complete AVB may result from unresolved wound 
healing and scarring subsequent to transdifferentiation of cardiac fibroblasts into 
proliferating myofibroblasts, initiated by the specific maternal antibodies (Buyon et al., 
1996). The process that leads to AVB may rarely progress postnatally. Given the high 
recurrence in neonates of SLE mothers (18% to 25%), complete AVB could be expected to 
occur in approximately 1-3 of the every 70 newborns whose mothers have anti-SSA/Ro or 
anti-SSB/Lb antibodies (Rein AJJT, 2009). 
Membrane-associated LA protein is required for the in vivo normal maintenance of the 
inner cell mass (ICM) of the blastocyst, thus demonstrating that nullizygous disruption of 
the LA gene leads to early embryonic lethality, consistent with the observed critical defect in 
the ICM of the blastocyst observed during blastocyst outgrowth. (Park JM, 2006). One 
difficulty in identifying a pathogenic effect of an autoantibody is accounting for the 
heterogeneity of that effect. Congenital heart block (CHB) is a paradigmatic example in that 
not only is the injury seemingly rare, but the degree of injury varies along a spectrum from 
clinically inconsequential first-degree block through third-degree (complete) block and 
even, in some cases, an associated cardiomyopathy that is often fatal. Identification of a 
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necessary or essential factor is only part of the challenge in defining the pathology of CHB, 
since recurrence rates from one pregnancy to the next are 18%, not 100%, and identical twins 
are, with rare exception, discordant for the disease. Antibodies to the 52-kd SSA/Ro protein 
(Ro 52) are found in 80% of mothers whose children have CHB (Clansy RM, 2005) and it has 
been suggested that the core of the problem is that SSA/Ro or SSB/LA antigens translocate 
and then there is surface binding by maternal autoantibodies, and then through a TGF-beta 
mediated mechanism, scaring and blockade is initiated. 
7. Anomalies in newborns from SLE positive mothers 
In addition to causing pregnancy complications and adverse pregnancy outcomes, 
transplacental passage of maternal autoantibodies of the IgG isotype can result in a variety 
of neonatal diseases. Among the best known of these is the neonatal lupus syndrome (NLS), 
which can appear as cutaneous lesions resembling those of SLE (16–50%), life-threatening 
congenital complete heart blockade (CCHB, 1–2%), and hematological (~26%) and 
hepatobiliary manifestations (9–24%) (Hoftman et al. 2008). The prevalence of anti-SSA/SSB 
antibodies varies considerably in different ethnic groups. Overall, ~1–2% of women are 
thought to have anti-SSA/SSB antibodies, and estimates of the risk of them having a child 
affected by NLS range between 2% and 52% in prospective studies (Brucato, 2001). Only 1–
2% of anti-SSA/SSB antibody positive mothers will give birth to a child with CCHB. The 
large variation stems from differences in the thoroughness with which the various (and 
frequently asymptomatic) manifestations of NLS are determined and the length of follow-
up since some of the NLS symptoms, including the cutaneous lesions, are not always 
obvious at birth. The risk that a second child is affected ranges between 15% and 20%. The 
fact that not all children of women with anti-SSA/SSB antibodies develop NSL indicates 
that other factors, probably including fetal ones, play a role. NLS is almost invariably 
associated (in 95% of cases) with maternal antibodies against Ro/SSA alone or in 
conjunction with anti-La/SSB. Anti-U1-RNP (ribonucleoprotein) antibodies are associated 
exclusively with the cutaneous manifestations of NLS. All of these antibodies are found 
primarily in women with SLE. Interestingly, there are some suggestions that infants of 
mothers with SLE are more rarely affected by CCHB than those of mothers with Sjögren's 
syndrome or with undifferentiated connective tissue disease (Borchers, 2010). In contrast, 
there are indications that the presence of hypothyroidism increases the risk of CCHB, but 
not NLS overall, in infants of anti-SSA-positive mothers regardless of whether they have an 
underlying autoimmune disease or are asymptomatic. Of particular note, a recent report on 
the long-term follow-up of 49 children with NSL indicated that definitive autoimmune 
diseases were already present in 6 of 49 affected children (5 of them female) at a mean age of 
14.8 years, but in none of the 45 unaffected siblings or the 53 unrelated controls (Martin et 
at., 2002) . Similarly, it has been reported that children and adolescents diagnosed with 
autoimmune thyroid disease had been exposed to maternal thyroid peroxidase antibodies in 
utero more frequently than randomly selected control children (Svensson, et al 2006). This 
strongly suggests that, in addition to inheritance of susceptibility genes from an affected 
mother, transplacental exposure to maternal autoantibodies predisposes one to the 
development of autoimmune diseases. 
7.1 Cardiovascular 
A frequent outcome in newborns of SLE mothers is fetal intrauterine growth retardation, 
which is associated with long-term medical complications such as adult-onset hypertension. 
 
Maternal SLE Influence in Fetal Development Immune and Endocrine Systems 
 
543 
Maternal immune deregulation may play a role in the appearance of diseases such as 
myocarditis, autoimmnunity and probably atherosclerosis. Cardiac injury is presumed to be 
dependent on the transplacental passage of maternal IgG autoantibodies via Fc receptor-
bearing trophoblasts and the target antigens of the antibodies have been molecularly cloned 
and identified as three separate proteins: 52 kDa SSA=Ro and 60 kDa SSA=Ro, which share 
no sequence homology, and 48 kDa SSB=La (Tincani et al, 2010). Sera containing anti-Ro and 
anti-La antibodies can induce atrioventricular block and inhibit L-type calcium currents in 
ventricular myocytes in vitro. The developing myocardium appears to be particularly 
sensitive to the effects of these antibodies because Ro and La are localized in the surface 
blebs of apoptosing myocytes. (Tseng et al., 1999) 
The more severe condition of congenital heart blockade was bradycardia which was 
observed in 53% of the pregnancies between weeks 16 and 24, in 24% of pregnancies 
between weeks 25 and 30 weeks and in 23% of pregnancies after week 30. Congenital heart 
block may be associated with myocarditis, but clinical heart failure is fortunately 
uncommon. Lesser degrees of heart blockade are sometimes detected prior to the 
development of congenital third-degree heart blockade and may reverse with fluorinated 
steroids such as dexamethasone. Heart failure associated with myocarditis and first- and 
second-degree block may be reversible with steroids. As prednisolone does not cross the 
placenta, dexamethasone should be used. (Gordon, 2004) There is no evidence to date that 
established third-degree heart blockade can be reversed with dexamethasone, but in cases 
where there is strong suspicion that the blockade has developed within the past few days, it 
may be worth a therapeutic trial. Over half of the children with congenital heart blockade 
will require a pacemaker by the age of 1 year-old, sadly about one-third will need it within 
the first month of life. Some of the remaining children will require pacemakers by the age of 
12. Up to 20% of children with congenital heart block die in infancy (Gordon, 2004).  
In order to identify heart blockade as early as possible, when treatment may be beneficial, 
mothers with anti-Ro antibodies should have the fetal heart rate assessed weekly from the 
week 16 onwards by auscultation, and by ultrasound scans monthly, including a detailed 
scan looking for cardiac abnormalities at 20 weeks of pregnancy. An ECG should be 
performed after delivery as some neonates develop more severe degrees of blockade after 
birth. (Askanase et al., 2002). About half the cases of neonatal lupus syndrome will occur in 
children whose mothers do not have confirmed systemic connective tissue diseases; at least 
half of these children will develop Sjogren’s syndrome or mild lupus over the following 10 
years. If a mother has delivered a child with congenital heart blockade, the risk of this 
recurring in subsequent pregnancies is about one in five (Tseng & Buyon, 1997). 
7.2 Immune response 
Maternal tolerance of the fetal allograft could be the result of the integration of numerous 
mechanisms promoted by different cells present in the decidua. Decidual macrophages and 
dendritic cells, which are found in close association with T lymphocytes are the most potent 
activators of T lymphocyte responses and could play a sentinel function for the immune 
system, initiating antigen-specific T cell responses to fetal antigens. T cell cytokines 
produced in response to fetal molecules could have a role in the maintenance or in the 
failure of pregnancy. The levels of LIF, IL-4, IL-10 and macrophage colony stimulating factor 
produced by decidual T cells of women suffering from unexplained spontaneous abortion 
are lower than those of normal pregnant women indicating that these cytokines may 
contribute to the maintenance of pregnancy. T cells from the cumulus oophorus 
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surrounding the blastocyst produce LIF and IL-4. These findings suggest that cytokines 
produced by maternal T cells create a suitable microenvironment for the proper 
implantation process and further development of the placenta (Piccinni MP, 2005). 
From the early developmental stages onward, the secretory activity of placenta cells clearly 
contributes to increased local, as well as systemic levels, of cytokines and inflammatory 
molecules. Two aspects of the progression of the immune response have been thoroughly 
investigated: the highly regulated process of throphoblast invasion and blastocyst 
implantation, and the induction of preterm labor associated with infections. With the 
progression of pregnancy, the physiological role of most placental cytokines is uncertain, 
since many of them are similar to adipose tissue derived cytokines. It is possible that they 
contribute to the low grade systemic inflammation that develops during the third trimester 
of pregnancy. 
Maternal transmission of IgG antibodies to the fetus usually occurs between weeks 16 and 
32 (Tseng & Buyon 1997), but an autoimmune condition in the neonate may not be 
diagnosed until after delivery. The best-recognized condition is neonatal lupus syndrome 
due to the transmission of anti-Ro and/or anti-La antibodies to the fetus from a mother with 
lupus, primary Sjogren’s syndrome or an undifferentiated connective tissue disease. There 
are three reports of neonatal cutaneous vasculitis in infants born to mothers with cutaneous 
polyarteritis nodosa (PAN) that appeared early after delivery and resolved with treatment 
soon after birth, with no neonatal deaths. (Borrego et al., 1997). A case of hypersensitivity 
vasculitis that deteriorated in pregnancy and postpartum, and that was associated with an 
identical vasculitis rash in the newborn, has been reported, it was almost certainly 
associated with the transmission of a maternal autoantibody, although none was identified 
(Morton, 1998). Neonatal thrombocytopenia is a well recognized consequence of the 
transmission of anti-platelet antibodies from the mother to the fetus and the transmission of 
anti-phospholipid antibodies has also been reported. However, most infants born of 
thrombocytopenic mothers with SLE have normal platelet counts. IgG Coombs’ hemolytic 
antibody may also be transmitted to the fetus and can cause hemolysis in the fetus and 
newborn. Antiphospholipid antibody causes placental insufficiency, intrauterine growth 
restriction and fetal death but does not usually cause abnormalities in the infant, although 
fetal thrombosis has been detected (Tincani et al., 2003). IgG1 and IgG3 antiphospholipid 
antibodies not only affect the placental barrier but reach the fetus (Sammaritano et al., 1997) 
and induce the secretion  of TF and other inflammatory cytokines by FEC thus favouring a 
prothrombotic state. Infants do not usually develop APS from maternal antibodies, but 
exceptions do occur in women with anti-SSA/Ro or anti-SSB/La antibodies, where neonatal 
lupus development is a risk (Buyon & Clancy, 2003). In all cases of neonatal transmission of 
autoantibodies, the disease in the neonate usually resolves over 3–6 months as maternal 
antibodies are gradually destroyed in the infant. But there are many questions to be solved 
still, such as: What do these maternal antibodies do to the newborn? Do they initiate an 
early proinflammatory signaling pathway? Do they induce immune complex formations 
that eventually lead to tissue damage? Do they induce immune tolerance?  
The two main determinants of fetal outcome in patients with autoimmune diseases are the 
degree of active disease at conception and the presence of anti-phospholipid antibodies. The 
two main outcomes are fetal loss and premature delivery. The term ‘fetal loss’ includes 
spontaneous abortions under 10 weeks, miscarriages between 10 and 24 weeks, and 
stillbirths from 24 weeks onwards. Fetal loss occurs in about 20% of pregnancies in women 
with lupus (Petri, 2004). Retrospective studies have shown that active disease at conception 
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and a history of renal disease are associated with a higher risk of fetal loss, but more recent 
prospective studies do not support this conclusion and show that the main predictor of fetal 
loss is the presence of high concentrations of anti-phospholipid antibodies. (Meroni et al., 
2010). Anti-phospholipid antibodies are also associated with intrauterine growth retardation 
and pre-eclampsia  that may result in premature delivery. These complications are the result 
of uteroplacental dysfunction, but the mechanisms involved are poorly understood. Early 
pregnancy loss may result from a failure of placentation owing to the effects of anti-
phospholipid antibodies on anionic phospholipids and the co-factor B2-glycoprotein 1 on 
trophoblasts (Serdiuk, 2008). Second- and third-trimester losses are more likely to result 
from the damage to the uteroplacental vasculature since histological data reveals massive 
infarction of the decidual and placental vessels in human and experimental APS. Platelet 
deposition, prostanoids imbalance and spiral artery vasculopathy may contribute to fetal 
hypoxia which would lead to fetal death. In stillbirth, the most common predisposing factor 
to prematurity in SLE mothers, are IgG isotype antibodies (Motta et al. 2009). There is evidence 
that active SLE at conception, a history of renal disease and maternal high blood pressure 
increase the risk of a prematurity (Shah et al., 2001). Premature babies, irrespective of the 
underlying cause, may suffer from complications such as pulmonary immaturity, infection 
and feeding problems and developmental abnormalities all of which may cause neonatal 
death. To induce the rapid maturation of the lungs whose hallmark is a shortage of surfactant, 
a short course of dexamethasone is usually given over 48 hours to the mother if a premature 
delivery is considered likely because of maternal disease, poor fetal growth or signs of 
pulmonary distress. Use of antenatal dexamethasone in premature babies to promote lung 
maturity may significantly diminish the incidence of respiratory distress syndrome and 
additionally, mortality (5.7% versus 14.8%) and use of the neonatal intensive care unit (12.9% 
versus 21.1%) were reduced (Nayeri et al., 2005). Therefore, use of corticosteroids during 
gestation or perinatally could be beneficial to the fetus and SLE mother outcomes. 
The most typical feature of neonatal lupus syndrome is a photosensitive rash on the face 
and scalp, usually erythematous, annular or elliptical (Tseng & Buyon, 1997), that is often 
precipitated by exposure to sunlight in the first couple of months after delivery or following 
ultraviolet light exposure if the newborn developed neonatal jaundice. This rash may be 
accompanied by purpura caused by thrombocytopenia or by haemolytic anaemia. These 
haematological manifestations may result from the transmission of anti-platelet or anti-
erythrocyte antibodies. Other possible manifestations of neonatal lupus include 
hepatosplenomegaly and abnormal liver function tests without evidence of biliary tract 
obstruction. Neurological manifestations such as aseptic meningitis and myelopathy are 
very rare.  
7.3 Central nervous system 
The central nervous system (CNS) is susceptible to suffer damage during embryo and fetal 
development. Although in autoimmune diseases, such as SLE, antibodies react with double-
stranded DNA forming immune complex that affect several organs including the brain, 
spinal cord and nerves, the mechanisms involved are not fully understood. 
Antibodies and maternal autoantibodies that cross the placental barrier are believed to be 
responsible of almost all the fetal alterations in NLE, specially the autoantibodies against 
ribonucleoproteins SSB/La, SSA/Ro and SSA/Ro. Although the most severe and frequent 
manifestation of neonatal lupus is third-degree heart blockade, which usually begins during 
the second trimester of gestation, there are other manifestations such as rash, present in 15-
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surrounding the blastocyst produce LIF and IL-4. These findings suggest that cytokines 
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25% of children with NLE, asymptomatic elevation of liver function tests seen in 10-25% of 
cases, or some neurological manifestations like hydrocephalus, non-specific white matter 
changes and alterations of brain vessels (Silverman, 2010). 
Less evident alterations during development of CNS could be associated to behavior and 
movement. There are reports that mothers of individuals with autism have antibodies that 
react with brain proteins and when these antibodies are passively transferred to pregnant 
non-human primates or rodents the offspring has behavioral and nervous system changes. It 
is still not clear whether the antibodies found in mothers of individuals with autism actually 
play a role in the disease. More studies need to be performed to identify the proteins 
recognized by the antibodies and to determine how these could affect development, 
behavior and changes within the CNS (Libbey, 2010). Besides, the high incidence of learning 
disorders in children born to mothers with SLE may be due to the passage of antibodies, 
mainly IgGs, through the brain barrier. Given that the blood brain barrier is not fully formed 
in utero, the pathogenic antibodies in maternal circulation represent a risk factor for fetal 
brain development (Lee, 2009). 
Maternal antibodies that pass from the mother to the fetal circulation could interact with 
proteins or cell receptors to produce organ and tissue damage during gestation. In a murine 
model of lupus, NP-SLE, it has been shown that nervous system involvement can include 
seizures, stroke and other cerebrovascular events, psychosis, cognitive dysfunction, and 
notably a very high incidence of mood disorders, particularly anxiety and depression 
(Gulinello, 2011). Actually, it has been reported that the involvement of 5-HT4 receptors in 
congenital heart blockade associated to a systemic autoimmune response in the mother. 5-HT4 
receptor isoforms can be expressed in both central and peripheral organs and it is possible that 
they are important in order to maintain the normal cellular activity (Eftekhari, 2000). Also 5-
HT4 receptors have been reported to be involved in memory and learning as well as in 
gastrointestinal function, although almost nothing is known about its role in embryogenesis. 
The importance of the embryonic serotoninergic system in central nervous and cardiovascular 
functions has been largely described [Lambert, 2001; 15-20]. In early mouse embryogenesis, 
maternal serotonin (5-HT) activates different 5-HT receptors to control gene expression, 
migration and proliferation of neuronal crest and neuronal-crest derived cells (Kamel, 2007). 
When disease manifestations are not so apparent it is too hard to make a diagnostic or an 
association with a specific pathology, which is the case for SLE. The main alterations could 
be related with CNS. However, it is not possible to discard environmental factors 
modulating the interactions of maternal antibodies and autoantibodies with the treatment 
used. According to Tincani, et. al. (2006), children with complete CHB need permanent 
pacing, but apparently do not have neuropsychological problems. Nevertheless, their 
neuropsychological development shows an increased number of learning disabilities, even 
in children with normal intelligence. The need to consider fetal consequences when the SLE 
mother is being treated should always be considered thus preferentially choosing non 
teratogenic drugs, but the withdrawal of medications just because the patient is pregnant 
should be avoided to protect of SLE flares. 
8. Conclusion 
Newborns from SLE mothers can have a myriad of silent or openly clear manifestations in 
several organs, tissues and systems of the newborn, some of which are secondary to the 
transfer of maternal autoantibodies through the placenta as well as the brain barrier, that  
 




Fig. 1. Represent the two main outcomes of a pregnancy. A normal outcome, shown in the left 
of the figure, can results even in the presence of maternal autoantibodies the condition being 
that the quantity and isotype is below a threshold yet to be defined, when there is an excess 
and the mother has a clear SLE condition, the outcome is shown in the right side of the figure.  
react with several fetal proteins (glycoproteins, lipoproteins, or lipids), but there is also the 
possibility that some of the alterations might be the consequence of drugs used to treat the 
mother in order to avoid SLE flares. All these should be clearly present within the medical 
community related to the diagnosis, treatment and follow up of offsprings from SLE 
mothers, since it is highly possible that these children will manifest some of the pathologies 
associated with maternal SLE, mainly those of the immune system. 
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